PMID,Sentence,Subject,Predicate,Object
10674894,In order to explore the possibility that clonal diversity plays a biological role during disease progression we optimised methods for subclone detection and analysed the prognostic significance of clonal diversity among 75 children with B precursor-ALL.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
10674894,The majority of paediatric B precursor acute lymphoblastic leukaemias in children are derived from a single transformed haematopoietic cell with complete or partial VDJ recombination within the immunoglobulin heavy chain gene.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
10674894,In order to explore the possibility that clonal diversity plays a biological role during disease progression we optimised methods for subclone detection and analysed the prognostic significance of clonal diversity among 75 children with B precursor-ALL.,Disease Progression,PROCESS_OF,Child
10870310,"Chromosomal translocation was identified in 24 (36.4%) of the ALL patients, 17 of whom had recurrent translocations including 10 with CD10+ B-precursor ALL [4 with t(9;22), 5 with t(1;19), and 1 infant with t(8;14)(q24;q11)], one neonate with CD10- early pre-B ALL with t(4;11), three B-cell cases with t(8;14), and three T-cell cases [2 with t(11;19)(q23;p13), and 1 (11;14)(p13;q11)].",Chromosomal translocation,PROCESS_OF,Infant
10870310,"Chromosomal translocation was identified in 24 (36.4%) of the ALL patients, 17 of whom had recurrent translocations including 10 with CD10+ B-precursor ALL [4 with t(9;22), 5 with t(1;19), and 1 infant with t(8;14)(q24;q11)], one neonate with CD10- early pre-B ALL with t(4;11), three B-cell cases with t(8;14), and three T-cell cases [2 with t(11;19)(q23;p13), and 1 (11;14)(p13;q11)].","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
10870310,"Chromosomal translocation was identified in 24 (36.4%) of the ALL patients, 17 of whom had recurrent translocations including 10 with CD10+ B-precursor ALL [4 with t(9;22), 5 with t(1;19), and 1 infant with t(8;14)(q24;q11)], one neonate with CD10- early pre-B ALL with t(4;11), three B-cell cases with t(8;14), and three T-cell cases [2 with t(11;19)(q23;p13), and 1 (11;14)(p13;q11)].","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
10870310,"Chromosomal translocation was identified in 24 (36.4%) of the ALL patients, 17 of whom had recurrent translocations including 10 with CD10+ B-precursor ALL [4 with t(9;22), 5 with t(1;19), and 1 infant with t(8;14)(q24;q11)], one neonate with CD10- early pre-B ALL with t(4;11), three B-cell cases with t(8;14), and three T-cell cases [2 with t(11;19)(q23;p13), and 1 (11;14)(p13;q11)].",Precursor B-cell lymphoblastic leukemia,PROCESS_OF,"Infant, Newborn"
10870310,"Chromosomal translocation was identified in 24 (36.4%) of the ALL patients, 17 of whom had recurrent translocations including 10 with CD10+ B-precursor ALL [4 with t(9;22), 5 with t(1;19), and 1 infant with t(8;14)(q24;q11)], one neonate with CD10- early pre-B ALL with t(4;11), three B-cell cases with t(8;14), and three T-cell cases [2 with t(11;19)(q23;p13), and 1 (11;14)(p13;q11)].","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
10870310,"Chromosomal translocation was identified in 24 (36.4%) of the ALL patients, 17 of whom had recurrent translocations including 10 with CD10+ B-precursor ALL [4 with t(9;22), 5 with t(1;19), and 1 infant with t(8;14)(q24;q11)], one neonate with CD10- early pre-B ALL with t(4;11), three B-cell cases with t(8;14), and three T-cell cases [2 with t(11;19)(q23;p13), and 1 (11;14)(p13;q11)].",Chromosomal translocation,PROCESS_OF,Patients
10870481,The value of interphase fluorescence in situ hybridization for the detection of translocation t(12;21) in childhood acute lymphoblastic leukemia.,Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
10870481,The value of interphase fluorescence in situ hybridization for the detection of translocation t(12;21) in childhood acute lymphoblastic leukemia.,Fluorescent in Situ Hybridization,METHOD_OF,Detection
11331732,We report a case of lymphomatoid granulomatosis with onset after the completion of chemotherapy for childhood acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11373717,"Although age, initial white blood cell count, and central nervous system or testicular disease are all important prognostic factors, cytogenetic abnormalities have now emerged as the single most important prognostic factor for children with ALL.",Testicular Diseases,AFFECTS,Child
11373717,"Although age, initial white blood cell count, and central nervous system or testicular disease are all important prognostic factors, cytogenetic abnormalities have now emerged as the single most important prognostic factor for children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11373717,"The survival for children with acute lymphoblastic leukemia (ALL) has increased from 3% to greater than 70% in the last 30 years, with some patients achieving 95% survival.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11552712,OBJECTIVE: Acute lymphoblastic leukemia (ALL) among children may be a rare outcome of a delayed non-specific infection in situations of overall low herd immunity.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11681411,We investigated the relationships between the TPMT locus (TPMT activity and genotype) and the pharmacological response to 6-MP during maintenance therapy of 78 children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11801311,We evaluated retrospectively the cryptic t(12;21)(p13;q22) in 15 children with early B-lineage acute lymphocytic leukemia who had a normal karyotype by using the locus specific probes of TEL and AML1 genes in a dual color fluorescence in situ hybridization (FISH).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11986937,Few patients had the common cytogenetic abnormalities associated with ALL in older children and few with AML had good risk abnormalities.,"Leukemia, Lymphocytic, Acute",COEXISTS_WITH,Chromosomal translocation
11986937,Few patients had the common cytogenetic abnormalities associated with ALL in older children and few with AML had good risk abnormalities.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11986937,"Cytogenetic abnormalities involving 11q23 were found in 66% of ALL and 35% of AML cases, the commonest, t(4;11) being found only in ALL.",Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
11986937,Comparison of clinical features showed no difference in age or sex distribution between infants with ALL and AML but infants with ALL tended to have higher leucocyte counts at presentation.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Infant
11986937,Comparison of clinical features showed no difference in age or sex distribution between infants with ALL and AML but infants with ALL tended to have higher leucocyte counts at presentation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
11986937,Comparison of clinical features showed no difference in age or sex distribution between infants with ALL and AML but infants with ALL tended to have higher leucocyte counts at presentation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
11986937,Few patients had the common cytogenetic abnormalities associated with ALL in older children and few with AML had good risk abnormalities.,Chromosomal translocation,PROCESS_OF,Patients
12490758,"Treatment results in childhood ALL continue to improve, and the expected current cure rates approach 75 to 80% of all children with ALL, including T-ALL and mature B-cell ALL, the two variants that, not too long ago, had a considerably poorer prognosis compared with the common form of BpALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12490758,"Treatment results in childhood ALL continue to improve, and the expected current cure rates approach 75 to 80% of all children with ALL, including T-ALL and mature B-cell ALL, the two variants that, not too long ago, had a considerably poorer prognosis compared with the common form of BpALL.",Prognosis bad,NEG_PROCESS_OF,Child
12490758,"Treatment results in childhood ALL continue to improve, and the expected current cure rates approach 75 to 80% of all children with ALL, including T-ALL and mature B-cell ALL, the two variants that, not too long ago, had a considerably poorer prognosis compared with the common form of BpALL.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12490758,"In the United approximately 3250 cases are diagnosed annually in children and adolescents younger than 20 years, of whom 2400 have acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
12490758,"In the United approximately 3250 cases are diagnosed annually in children and adolescents younger than 20 years, of whom 2400 have acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12756018,METHODS: Bone-marrow samples from 92 children with acute lymphoblastic leukaemia were studied by high-resolution comparative genomic hybridisation (HRCGH) using dynamic standard reference intervals that enhance both specificity and sensitivity in the detection of aberrations.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12756018,BACKGROUND: Cytogenetic aberrations are of prognostic significance in childhood acute lymphoblastic leukaemias and a high detection rate could improve the biological understanding and classification of these diseases.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12756018,High-resolution comparative genomic hybridisation yields a high detection rate of chromosomal aberrations in childhood acute lymphoblastic leukaemia.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
10673523,"PURPOSE: We conducted a historic cohort study to test the hypothesis that, after adjustment for biologic factors, African-American (AA) children and Spanish surname (SS) children with newly diagnosed B-precursor acute lymphoblastic leukemia had lower survival than did comparable white children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10673523,"PURPOSE: We conducted a historic cohort study to test the hypothesis that, after adjustment for biologic factors, African-American (AA) children and Spanish surname (SS) children with newly diagnosed B-precursor acute lymphoblastic leukemia had lower survival than did comparable white children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10673751,Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
10979211,A retrospective analysis of children with acute lymphoblastic leukemia (ALL) was performed to evaluate the current status of diagnosis and treatment of ALL in Japanese children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10979211,A retrospective analysis of children with acute lymphoblastic leukemia (ALL) was performed to evaluate the current status of diagnosis and treatment of ALL in Japanese children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10979211,Clinical records of 670 children with ALL were collected and analyzed; these children had been diagnosed between 1991 and 1995 at the 53 institutions in 4 areas participating in the Japan Association of Childhood Leukemia Study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10979212,"We analyzed the expression pattern of adhesion molecules including beta 1-integrins (CD49c, CD49d, CD49e, CD49f), beta 2-integrins (CD11a, CD11b, CD11c), CD44, and CD54 in 141 children with B-cell precursor acute lymphoblastic leukemia (pre-B ALL) and in 21 children with B-cell ALL/non-Hodgkin's lymphoma (B-ALL/NHL).",Child,LOCATION_OF,CD44 gene | CD44
10979212,"We analyzed the expression pattern of adhesion molecules including beta 1-integrins (CD49c, CD49d, CD49e, CD49f), beta 2-integrins (CD11a, CD11b, CD11c), CD44, and CD54 in 141 children with B-cell precursor acute lymphoblastic leukemia (pre-B ALL) and in 21 children with B-cell ALL/non-Hodgkin's lymphoma (B-ALL/NHL).",Child,LOCATION_OF,Intercellular adhesion molecule 1 | ICAM1
10979212,"We analyzed the expression pattern of adhesion molecules including beta 1-integrins (CD49c, CD49d, CD49e, CD49f), beta 2-integrins (CD11a, CD11b, CD11c), CD44, and CD54 in 141 children with B-cell precursor acute lymphoblastic leukemia (pre-B ALL) and in 21 children with B-cell ALL/non-Hodgkin's lymphoma (B-ALL/NHL).",Child,LOCATION_OF,CD44 gene | CD44
10979212,"We analyzed the expression pattern of adhesion molecules including beta 1-integrins (CD49c, CD49d, CD49e, CD49f), beta 2-integrins (CD11a, CD11b, CD11c), CD44, and CD54 in 141 children with B-cell precursor acute lymphoblastic leukemia (pre-B ALL) and in 21 children with B-cell ALL/non-Hodgkin's lymphoma (B-ALL/NHL).",Child,LOCATION_OF,Intercellular adhesion molecule 1 | ICAM1
10979212,"We analyzed the expression pattern of adhesion molecules including beta 1-integrins (CD49c, CD49d, CD49e, CD49f), beta 2-integrins (CD11a, CD11b, CD11c), CD44, and CD54 in 141 children with B-cell precursor acute lymphoblastic leukemia (pre-B ALL) and in 21 children with B-cell ALL/non-Hodgkin's lymphoma (B-ALL/NHL).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
10979212,"We analyzed the expression pattern of adhesion molecules including beta 1-integrins (CD49c, CD49d, CD49e, CD49f), beta 2-integrins (CD11a, CD11b, CD11c), CD44, and CD54 in 141 children with B-cell precursor acute lymphoblastic leukemia (pre-B ALL) and in 21 children with B-cell ALL/non-Hodgkin's lymphoma (B-ALL/NHL).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
10981463,"The authors conducted a validation substudy within the framework of a parent case-control study on risk factors for acute lymphoblastic leukemia in children aged < or =9 years diagnosed in 1980-1993 in Quebec, Canada.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11016634,Twenty-two uniformly treated children with ALL were studied throughout induction treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11016634,Early resistance to therapy during induction in childhood acute lymphoblastic leukemia.,Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11150883,"Furthermore, we studied IGFBP-2 levels in 24 children with congenital GH deficiency (GHD), 26 with acute lymphoblastic leukemia (ALL), 75 obese children, and 60 girls with anorexia nervosa (AN) at diagnosis and during a follow-up period.",Somatotropin deficiency,PROCESS_OF,Child
11150883,"Furthermore, we studied IGFBP-2 levels in 24 children with congenital GH deficiency (GHD), 26 with acute lymphoblastic leukemia (ALL), 75 obese children, and 60 girls with anorexia nervosa (AN) at diagnosis and during a follow-up period.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11150883,"Furthermore, we studied IGFBP-2 levels in 24 children with congenital GH deficiency (GHD), 26 with acute lymphoblastic leukemia (ALL), 75 obese children, and 60 girls with anorexia nervosa (AN) at diagnosis and during a follow-up period.",Anorexia Nervosa,PROCESS_OF,Girls
11150883,"Furthermore, we studied IGFBP-2 levels in 24 children with congenital GH deficiency (GHD), 26 with acute lymphoblastic leukemia (ALL), 75 obese children, and 60 girls with anorexia nervosa (AN) at diagnosis and during a follow-up period.",Anorexia Nervosa,PROCESS_OF,Child
11150883,"Furthermore, we studied IGFBP-2 levels in 24 children with congenital GH deficiency (GHD), 26 with acute lymphoblastic leukemia (ALL), 75 obese children, and 60 girls with anorexia nervosa (AN) at diagnosis and during a follow-up period.",Obesity,PROCESS_OF,Child
11333138,The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukaemia.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11443604,Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
12060981,"Between 1981 and 1999, 890 Austrian children with acute lymphoblastic leukemia (ALL) were treated in 5 consecutive trials using protocols from the Berlin-Frankfurt-Munster (BFM) Group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12133457,METHODS: Two children with acute lymphoblastic leukemia received HLA-mismatched unrelated umbilical cord blood transplantation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12133457,METHODS: Two children with acute lymphoblastic leukemia received HLA-mismatched unrelated umbilical cord blood transplantation.,umbilical cord blood transplantation,ADMINISTERED_TO,Child
12461790,"RESULTS: Among 96 children diagnosed with ALL, and quantified for post induction residual disease, 32 were t(12;21)-positive.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12461790,"PROCEDURE: As part of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL-MRD 95 study, which includes children from Iceland, Norway, and Denmark diagnose d with ALL, patients were screened for the presence of t(12; 21) by reverse transcriptase-polymerase chain reaction (RT-PCR) at diagnosis, and their residual disease was quantified after 4 weeks of induction therapy (prednisolone, vincristine, doxorubicin, i.t. methotrexate) by a competitive, clone-specific, semi-nested PCR analysis.",Residual Tumor,PROCESS_OF,Child
12461790,"PROCEDURE: As part of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL-MRD 95 study, which includes children from Iceland, Norway, and Denmark diagnose d with ALL, patients were screened for the presence of t(12; 21) by reverse transcriptase-polymerase chain reaction (RT-PCR) at diagnosis, and their residual disease was quantified after 4 weeks of induction therapy (prednisolone, vincristine, doxorubicin, i.t. methotrexate) by a competitive, clone-specific, semi-nested PCR analysis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12461790,"PROCEDURE: As part of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL-MRD 95 study, which includes children from Iceland, Norway, and Denmark diagnose d with ALL, patients were screened for the presence of t(12; 21) by reverse transcriptase-polymerase chain reaction (RT-PCR) at diagnosis, and their residual disease was quantified after 4 weeks of induction therapy (prednisolone, vincristine, doxorubicin, i.t. methotrexate) by a competitive, clone-specific, semi-nested PCR analysis.",Polymerase chain reaction analysis,METHOD_OF,Neoadjuvant Therapy
12492580,Leukaemic blasts from 21 children with ALL were studied.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12794529,Acute lymphoblastic leukemia (ALL) in children can rarely present with severe lactic acidosis in the absence of a high white blood cell count or other complications.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10720126,"Treatment of children with acute lymphoblastic leukaemia (ALL) aims to cure all patients with as little toxicity as possible and, if possible, to restrict further intensification of chemotherapy to patients with an increased risk of relapse.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10720126,"Treatment of children with acute lymphoblastic leukaemia (ALL) aims to cure all patients with as little toxicity as possible and, if possible, to restrict further intensification of chemotherapy to patients with an increased risk of relapse.",Therapeutic procedure,TREATS,Patients
10720126,Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10720126,Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials.,Therapeutic procedure,TREATS,Child
10720126,Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
10756360,BACKGROUND AND OBJECTIVE: We previously found a high-level amplification in chromosomal region 21q22 in two children with acute lymphoblastic leukemia (ALL) using comparative genomic hybridization.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10758764,"From that number, 15 children (78.9%) were with acute lymphoblastic leukemia (ALL), 3 (15.7%) were with acute myeloic leukemia (AML) and 1 was with chronic myeloic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10758764,"From that number, 15 children (78.9%) were with acute lymphoblastic leukemia (ALL), 3 (15.7%) were with acute myeloic leukemia (AML) and 1 was with chronic myeloic leukemia.","Leukemia, Lymphocytic, Acute",ISA,Acute leukemia
10759711,The optimal treatment for relapsed ALL therefore remains uncertain.,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
10909707,The most frequent type of tumor was acute lymphocytic leukemia (22.0%).,"Leukemia, Lymphocytic, Acute",ISA,Neoplasm
11052810,"Here, we present detailed data on the expression of the interleukin 7 receptor alpha chain (IL-7Ralpha) in leukaemic cells from 210 children with acute lymphoblastic leukaemia (ALL) and describe two novel alternatively spliced transcripts of human IL-7Ralpha coding for truncated receptor proteins which are still capable of binding IL-7.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11299850,CD44v6 is considered as a marker of poor prognosis of various hematological cancers but its expression was not demonstrated in childhood acute lymphoblastic leukaemia (ALL).,Hematologic Neoplasms,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11410410,"DESIGN AND METHODS: From 1987 to 1991, a total of 632 eligible and evaluable children (age 1 to < or =16 years) with non-B-cell acute lymphoblastic leukemia (ALL), were enrolled and stratified as follows: standard risk (SR, 79 patients, 12.5%) had WBC <10,000/mm3, age > or = 3 and <7 years, and FAB L1 morphology.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
11804271,Approximately 80% of children with acute lymphoblastic leukemia (ALL) can be cured with modern therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11804271,"Herein, we review recent progress in thesefields as they relate to childhood ALL, and discuss the promise they hold to further enhance treatment of the most common cancer in children.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
11804271,Approximately 80% of children with acute lymphoblastic leukemia (ALL) can be cured with modern therapy.,Therapeutic procedure,TREATS,Child
11804271,Approximately 80% of children with acute lymphoblastic leukemia (ALL) can be cured with modern therapy.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
11987913,"In children with acute lymphoblastic leukaemia (ALL), measurements of minimal residual disease (MRD) during therapy provide crucial information about the response to treatment and the risk of relapse.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12096296,"Parents of children diagnosed with ALL must have honest information about diagnosis and treatment, as much information as possible for planning their daily lives, an opportunity to express real feelings, access to moments of personal space where feelings can be processed, and compassionate understanding of the emotional difficulties associated with this difficult life journey.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12096296,PURPOSE/OBJECTIVES: To report the perspective of parents during the initial stages of diagnosis and treatment for their children's acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
12096296,PURPOSE/OBJECTIVES: To report the perspective of parents during the initial stages of diagnosis and treatment for their children's acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12209591,"There was highly significant reduction of TREC values in children with T-cell malignancies (median 3,100 TRECs/10(6) PBMCs), whereas children with B-cell origin ALL had slightly but nonsignificantly lower TREC values compared to healthy children (medians 19,300 and 22,500 TRECs/10(6) PBMCs, respectively).",Malignant Neoplasms,PROCESS_OF,Child
12209591,"There was highly significant reduction of TREC values in children with T-cell malignancies (median 3,100 TRECs/10(6) PBMCs), whereas children with B-cell origin ALL had slightly but nonsignificantly lower TREC values compared to healthy children (medians 19,300 and 22,500 TRECs/10(6) PBMCs, respectively).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
12209591,"There was highly significant reduction of TREC values in children with T-cell malignancies (median 3,100 TRECs/10(6) PBMCs), whereas children with B-cell origin ALL had slightly but nonsignificantly lower TREC values compared to healthy children (medians 19,300 and 22,500 TRECs/10(6) PBMCs, respectively).",T-Lymphocyte,LOCATION_OF,Malignant Neoplasms
12414341,Further studies in a larger cohort of patients are needed to determine the exact role that MRD determination has in the management of T-ALL in adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
12469194,"In 30 consecutive children with ALL treated with prednisone we determined changes in the expression of Bcl-2, Bax and Bcl-xl proteins in leukemic lymphoblasts and related these to clinical features and rate of prednisone-induced apoptosis.",lymphoblast,LOCATION_OF,BAX gene | BAX
12469194,"In 30 consecutive children with ALL treated with prednisone we determined changes in the expression of Bcl-2, Bax and Bcl-xl proteins in leukemic lymphoblasts and related these to clinical features and rate of prednisone-induced apoptosis.",lymphoblast,LOCATION_OF,BCL-XL Protein
12469194,Glucocorticoid resistance is often associated with treatment failure in children with acute lymphoblastic leukaemia (ALL) but the underlying molecular mechanisms are still unclear.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12469194,Glucocorticoid resistance is often associated with treatment failure in children with acute lymphoblastic leukaemia (ALL) but the underlying molecular mechanisms are still unclear.,Glucocorticoids,TREATS,Child
12469194,Glucocorticoid resistance is often associated with treatment failure in children with acute lymphoblastic leukaemia (ALL) but the underlying molecular mechanisms are still unclear.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
12469194,"In 30 consecutive children with ALL treated with prednisone we determined changes in the expression of Bcl-2, Bax and Bcl-xl proteins in leukemic lymphoblasts and related these to clinical features and rate of prednisone-induced apoptosis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12469194,"In 30 consecutive children with ALL treated with prednisone we determined changes in the expression of Bcl-2, Bax and Bcl-xl proteins in leukemic lymphoblasts and related these to clinical features and rate of prednisone-induced apoptosis.",Prednisone,TREATS,"Leukemia, Lymphocytic, Acute"
10641030,"TEL-AML1 fusion and hyperdiploidy >50 chromosomes are associated with a good prognosis in childhood acute lymphoblastic leukemia, whereas BCR-ABL fusion and MLL rearrangements are associated with a poor prognosis.",Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
10643153,We carried out in vitro tests with a 4-day culture and a methyl-thiazol-tetrazolium assay on bone marrow samples from 209 children newly diagnosed with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10797353,PROCEDURE: All children with HR-ALL in Finland during 1990-1996 were included.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10797353,Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10906804,CONCLUSION: Malnutrition exists in a significant proportion of children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10906804,OBJECTIVE: To determine the nutritional status and the extent of skeletal muscle wasting in children with acute lymphoblastic leukemia (ALL) at the time of diagnosis and after induction chemotherapy.,Muscular Atrophy,PROCESS_OF,Child
10906804,OBJECTIVE: To determine the nutritional status and the extent of skeletal muscle wasting in children with acute lymphoblastic leukemia (ALL) at the time of diagnosis and after induction chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11054062,This might contribute to the difference in outcome between children and adults with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11054062,This might contribute to the difference in outcome between children and adults with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
11127393,An event-free survival is currently achieved in 70-80% of children diagnosed with acute lymphocytic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11145727,Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study.,Central Nervous System Prophylaxis,TREATS,"Leukemia, Lymphocytic, Acute"
11145727,Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study.,Central Nervous System Prophylaxis,TREATS,Child
11145727,Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11145841,"Thus, we analyzed bone marrow blasts from 10 children with relapsed B cell precursor ALL.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
11298592,"Twenty-six children with B-cell acute lymphoblastic leukaemia (B-ALL) or Murphy Stage III or IV B-cell non-Hodgkin's lymphoma (B-NHL) progressed or relapsed after first-line therapy with a short, intensive multiagent chemotherapy regimen [United Kingdom Childhood Cancer Study Group (UKCCSG) 9003] (n = 62) or a slightly less intensive regimen (UKCCSG 9002) (n = 112).",B-Cell Lymphomas,PROCESS_OF,Child
11298592,"Twenty-six children with B-cell acute lymphoblastic leukaemia (B-ALL) or Murphy Stage III or IV B-cell non-Hodgkin's lymphoma (B-NHL) progressed or relapsed after first-line therapy with a short, intensive multiagent chemotherapy regimen [United Kingdom Childhood Cancer Study Group (UKCCSG) 9003] (n = 62) or a slightly less intensive regimen (UKCCSG 9002) (n = 112).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
11445861,"For children with acute lymphoblastic leukemia the major morbidity burdens were in the attributes of emotion, cognition and pain.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11445861,"For children with acute lymphoblastic leukemia the major morbidity burdens were in the attributes of emotion, cognition and pain.",Child,ISA,Attribute
11445861,"For children with acute lymphoblastic leukemia the major morbidity burdens were in the attributes of emotion, cognition and pain.",Pain,PROCESS_OF,Child
11992395,"It is considered that prophylactic 18 Gy cranial irradiation plus chemotherapy for ALL in childhood can effectively prevent CNS relapse and is unlikely to produce clinically significant late effects, although it may cause slight pituitary hormone abnormality.",Late effect of,CAUSES,Endocrine System Diseases
11992395,"It is considered that prophylactic 18 Gy cranial irradiation plus chemotherapy for ALL in childhood can effectively prevent CNS relapse and is unlikely to produce clinically significant late effects, although it may cause slight pituitary hormone abnormality.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
11992395,The subjects consisted of 35 children with ALL who were treated with prophylactic 18 Gy cranial irradiation at Kanagawa Children's Medical Center between October 1981 and February 1995.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11992395,The subjects consisted of 35 children with ALL who were treated with prophylactic 18 Gy cranial irradiation at Kanagawa Children's Medical Center between October 1981 and February 1995.,Prophylactic Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute"
12098004,Resistance to glucocorticoids is nowadays one of the strongest adverse risk factors in the treatment of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,ISA,Therapeutic procedure
12098004,Resistance to glucocorticoids is nowadays one of the strongest adverse risk factors in the treatment of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12650297,"METHODS: Thirty-five children and adolescents with ALL, aged 2.4-17.4 y, were fasted for up to 16 h during MT.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
12650297,"METHODS: Thirty-five children and adolescents with ALL, aged 2.4-17.4 y, were fasted for up to 16 h during MT.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12650297,AIM: To determine the mechanisms of fasting hypoglycaemia occurring during maintenance therapy (MT) for childhood acute lymphoblastic leukaemia (ALL).,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12687755,Follow-up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
12687755,Follow-up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience.,peripheral blood,LOCATION_OF,WT1 gene | WT1
10760773,"CONCLUSIONS: These data suggest that although a cytogenetically detectable 12p aberration is a favorable risk factor for children with ALL and pseudodiploidy, it is not prognostic for the overall group of pediatric ALL patients treated with contemporary therapies of the CCG.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
10760773,"BACKGROUND: The authors have determined the prognostic significance of cytogenetically detectable 12p abnormalities, which are frequent in children with acute lymphoblastic leukemia (ALL), in a large cohort of patients treated on risk-adjusted protocols of the Children's Cancer Group (CCG).","Leukemia, Lymphocytic, Acute",PROCESS_OF,cohort
10760773,"BACKGROUND: The authors have determined the prognostic significance of cytogenetically detectable 12p abnormalities, which are frequent in children with acute lymphoblastic leukemia (ALL), in a large cohort of patients treated on risk-adjusted protocols of the Children's Cancer Group (CCG).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10760773,Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
10760773,"CONCLUSIONS: These data suggest that although a cytogenetically detectable 12p aberration is a favorable risk factor for children with ALL and pseudodiploidy, it is not prognostic for the overall group of pediatric ALL patients treated with contemporary therapies of the CCG.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10760773,"CONCLUSIONS: These data suggest that although a cytogenetically detectable 12p aberration is a favorable risk factor for children with ALL and pseudodiploidy, it is not prognostic for the overall group of pediatric ALL patients treated with contemporary therapies of the CCG.",Therapeutic procedure,TREATS,Patients
10760773,"CONCLUSIONS: These data suggest that although a cytogenetically detectable 12p aberration is a favorable risk factor for children with ALL and pseudodiploidy, it is not prognostic for the overall group of pediatric ALL patients treated with contemporary therapies of the CCG.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
10764156,"Immunofluorescence stainings for the CD10 antigen and terminal deoxynucleotidyl transferase (TdT) can be used for the detection of leukemic blasts in CD10+ precursor-B-acute lymphoblastic leukemia (precursor-B-ALL) patients, but can also provide insight into the regeneration of normal precursor-B-cells in bone marrow (BM).","Leukemia, B-Cell, Acute",PROCESS_OF,Patients
10764156,"Immunofluorescence stainings for the CD10 antigen and terminal deoxynucleotidyl transferase (TdT) can be used for the detection of leukemic blasts in CD10+ precursor-B-acute lymphoblastic leukemia (precursor-B-ALL) patients, but can also provide insight into the regeneration of normal precursor-B-cells in bone marrow (BM).",Detection,TREATS,Patients
10764156,"Immunofluorescence stainings for the CD10 antigen and terminal deoxynucleotidyl transferase (TdT) can be used for the detection of leukemic blasts in CD10+ precursor-B-acute lymphoblastic leukemia (precursor-B-ALL) patients, but can also provide insight into the regeneration of normal precursor-B-cells in bone marrow (BM).",Staining method,USES,Detection
10764156,"Immunofluorescence stainings for the CD10 antigen and terminal deoxynucleotidyl transferase (TdT) can be used for the detection of leukemic blasts in CD10+ precursor-B-acute lymphoblastic leukemia (precursor-B-ALL) patients, but can also provide insight into the regeneration of normal precursor-B-cells in bone marrow (BM).",Detection,TREATS,"Leukemia, B-Cell, Acute"
10799421,CONCLUSION: Treatment for childhood ALL with cranial irradiation and chemotherapy at a young age is clearly associated with poorer academic career.,Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
10799421,CONCLUSION: Treatment for childhood ALL with cranial irradiation and chemotherapy at a young age is clearly associated with poorer academic career.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
10877334,"METHODS: The latest SEER data (1973-1995) were analyzed for trends in childhood (age 0-14) leukemia incidence rates by histologic group (all leukemia combined, acute lymphocytic leukemia (ALL), acute mylogenous leukemia (AML), and other acute leukemia) for each SEER reporting region.","Leukemia, Lymphocytic, Acute",ISA,Acute leukemia
10877334,"METHODS: The latest SEER data (1973-1995) were analyzed for trends in childhood (age 0-14) leukemia incidence rates by histologic group (all leukemia combined, acute lymphocytic leukemia (ALL), acute mylogenous leukemia (AML), and other acute leukemia) for each SEER reporting region.","Leukemia, Lymphocytic, Acute",ISA,Acute leukemia
10914546,"We studied a total of 74 precursor B-ALL children, including 21 t(12;21)+ and 53 t(12;21)- cases.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
10914547,We conclude that moab 7.1 is a sensitive but not entirely specific marker for the identification of 11q23-associated AML and ALL by flow cytometry in children and adults.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
10914547,We conclude that moab 7.1 is a sensitive but not entirely specific marker for the identification of 11q23-associated AML and ALL by flow cytometry in children and adults.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Adult
10914547,We conclude that moab 7.1 is a sensitive but not entirely specific marker for the identification of 11q23-associated AML and ALL by flow cytometry in children and adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10914547,We conclude that moab 7.1 is a sensitive but not entirely specific marker for the identification of 11q23-associated AML and ALL by flow cytometry in children and adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
11412468,[Cytogenetic abnormalities in acute lymphoblastic leukemia].,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
11412473,[Ocular infiltration in the anterior chamber in a female infant with acute non-lymphoblastic leukemia].,Ocular infiltration,TREATS,"Leukemia, Lymphocytic, Acute"
11412473,[Ocular infiltration in the anterior chamber in a female infant with acute non-lymphoblastic leukemia].,Ocular infiltration,TREATS,Infant
11412473,[Ocular infiltration in the anterior chamber in a female infant with acute non-lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
12100141,No significant difference in expression of BCRP mRNA was measured between initial-stage and relapsed-stage ALL or between normal MNC obtained from BM and ALL patients.,Bone Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
12100141,No significant difference in expression of BCRP mRNA was measured between initial-stage and relapsed-stage ALL or between normal MNC obtained from BM and ALL patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
12100141,"Sixty-seven children (47 initial stage, 20 relapses) with ALL were analysed for BCRP gene expression by TaqMan real-time polymerase chain reaction.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12384148,RESULTS: Thirty-four of the 36 children with precursor-B ALL (94%) displayed at least one clonal Ig heavy chain (IgH) or TCR gene sequence useful as a molecular target.,Immunoglobulin Heavy Chains,PART_OF,Clone
12384148,MATERIALS AND METHODS: DNA samples from 36 children with newly diagnosed precursor-B ALL were available for molecular analysis.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12384148,In the present study we evaluated a real-time PCR-based technology for MRD quantification in children with precursor-B ALL.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12384148,OBJECTIVE: Clone specific immunoglobulin (Ig) and T-cell receptor (TCR) gene sequences can be used as molecular targets for detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
12384148,OBJECTIVE: Clone specific immunoglobulin (Ig) and T-cell receptor (TCR) gene sequences can be used as molecular targets for detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).,Detection,USES,Specific immunoglobulins
12384148,OBJECTIVE: Clone specific immunoglobulin (Ig) and T-cell receptor (TCR) gene sequences can be used as molecular targets for detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).,Specific immunoglobulins,PART_OF,Clone
12384148,RESULTS: Thirty-four of the 36 children with precursor-B ALL (94%) displayed at least one clonal Ig heavy chain (IgH) or TCR gene sequence useful as a molecular target.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12799535,"As more children with acute lymphoblastic leukemia survive into adolescence and adulthood, there is a need to address the late sequelae of current therapy and to develop more leukemia-specific treatments.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12799535,The development of effective therapy for children with acute lymphoblastic leukemia is one of the great successes of clinical hematology andoncology.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12799535,The development of effective therapy for children with acute lymphoblastic leukemia is one of the great successes of clinical hematology andoncology.,Therapeutic procedure,TREATS,Child
12799535,The development of effective therapy for children with acute lymphoblastic leukemia is one of the great successes of clinical hematology andoncology.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
10618625,Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.,"Leukemia, B-Cell, Acute",PROCESS_OF,Adolescent
10618625,Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
10618625,"BACKGROUND: Preventive cranial radiotherapy (CRT) in childhood acute lymphoblastic leukemia (ALL), although effective, may be associated with neurologic sequelae and second malignancies.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
10618625,Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.,Therapeutic procedure,TREATS,high-risk group
10877334,"METHODS: The latest SEER data (1973-1995) were analyzed for trends in childhood (age 0-14) leukemia incidence rates by histologic group (all leukemia combined, acute lymphocytic leukemia (ALL), acute mylogenous leukemia (AML), and other acute leukemia) for each SEER reporting region.","Leukemia, Lymphocytic, Acute",ISA,Acute leukemia
10877334,"METHODS: The latest SEER data (1973-1995) were analyzed for trends in childhood (age 0-14) leukemia incidence rates by histologic group (all leukemia combined, acute lymphocytic leukemia (ALL), acute mylogenous leukemia (AML), and other acute leukemia) for each SEER reporting region.","Leukemia, Lymphocytic, Acute",ISA,Acute leukemia
10914938,This indicates that the emergence of novel clonal chromosomal aberrations during remission in childhood ALL is rather common and does not by necessity predict a forthcoming relapse.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11020981,"We analyzed the prognostic significance of chromosomal findings in children with acute lymphoblastic leukemia (ALL), treated according to the Children's Cancer and Leukemia Study Group protocols between 1987 and 1993.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11122150,Vincristine-induced apoptosis in vivo in peripheral blood mononuclear cells of children with acute lymphoblastic leukaemia (ALL).,Peripheral blood mononuclear cell,PART_OF,Child
11122150,Vincristine-induced apoptosis in vivo in peripheral blood mononuclear cells of children with acute lymphoblastic leukaemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11413175,Monitoring and further investigations should be targeted at acute lymphoblastic leukaemia occurring during the childhood incidence peak (before 10 years) in children living near the La Hague site and may be other nuclear reprocessing plants.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11559948,TEL/AML1 was detected in 17.9% (12/67) B-lineage ALL at diagnosis but not in 8 T-ALL children or in 34 adults with ALL.,"Leukemia, Lymphocytic, Acute",NEG_PROCESS_OF,Child
11559948,Our data would not suggest a less aggressive treatment regimen for TEL/AML1+ ALL.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
11559948,TEL/AML1 was detected in 17.9% (12/67) B-lineage ALL at diagnosis but not in 8 T-ALL children or in 34 adults with ALL.,"Leukemia, Lymphocytic, Acute",NEG_PROCESS_OF,Adult
11559948,TEL/AML1 was detected in 17.9% (12/67) B-lineage ALL at diagnosis but not in 8 T-ALL children or in 34 adults with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11559948,TEL/AML1 was detected in 17.9% (12/67) B-lineage ALL at diagnosis but not in 8 T-ALL children or in 34 adults with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
11559948,We examined TEL/AML1 using nested reverse-transcription polymerase chain reaction (RT-PCR) and correlated TEL/AML1 with cytogenetics and immunophenotypes in 75 consecutively analyzed Chinese children with ALL in Hong Kong.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11745869,"PROCEDURE: We studied 79 children with ALL by CGH and G-banding, and explored the relationship of these findings to clinical features and outcome.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12138898,"Among 157 children with acute lymphoblastic leukemia (ALL) who experienced relapse at 54 institutes participating in the Japan Association of Childhood Leukemia Study, we analyzed the outcomes after relapse in 103 and 30 eligible cases with bone marrow (BM) and central nervous system (CNS) relapse, respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12138898,"Among 157 children with acute lymphoblastic leukemia (ALL) who experienced relapse at 54 institutes participating in the Japan Association of Childhood Leukemia Study, we analyzed the outcomes after relapse in 103 and 30 eligible cases with bone marrow (BM) and central nervous system (CNS) relapse, respectively.",Bone Marrow,PART_OF,Child
12139731,The impact of various types of intensification therapy was examined in a cohort of 3617 children aged 1-14 years with acute lymphoblastic leukaemia (ALL) enrolled in the Medical Research Council (MRC) UKALL X (1985-90) and UKALL XI (1990-97) trials.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12139731,The impact of various types of intensification therapy was examined in a cohort of 3617 children aged 1-14 years with acute lymphoblastic leukaemia (ALL) enrolled in the Medical Research Council (MRC) UKALL X (1985-90) and UKALL XI (1990-97) trials.,Therapeutic procedure,TREATS,cohort
12181040,The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12419593,Although overexpression of PRAME was less frequent than in children with AML (62%) our results suggest that PRAME could be a useful target for immunotherapy in some children with ALL.,Immunotherapy,TREATS,Child
12419593,Although overexpression of PRAME was less frequent than in children with AML (62%) our results suggest that PRAME could be a useful target for immunotherapy in some children with ALL.,Child,LOCATION_OF,PRAME
12419593,Although overexpression of PRAME was less frequent than in children with AML (62%) our results suggest that PRAME could be a useful target for immunotherapy in some children with ALL.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
12419593,Although overexpression of PRAME was less frequent than in children with AML (62%) our results suggest that PRAME could be a useful target for immunotherapy in some children with ALL.,Immunotherapy,USES,PRAME
12419593,Although overexpression of PRAME was less frequent than in children with AML (62%) our results suggest that PRAME could be a useful target for immunotherapy in some children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12419593,Although overexpression of PRAME was less frequent than in children with AML (62%) our results suggest that PRAME could be a useful target for immunotherapy in some children with ALL.,Immunotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
12487838,Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12487838,Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase.,Antithrombin III,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
12487838,Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase.,ASPARAGINASE,INTERACTS_WITH,Antithrombin III
12489505,The addition of methotrexate to treatment protocols in children with acute lymphoblastic leukemia has been found beneficial in preventing central nervous system relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12489505,The addition of methotrexate to treatment protocols in children with acute lymphoblastic leukemia has been found beneficial in preventing central nervous system relapse.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
12489505,The addition of methotrexate to treatment protocols in children with acute lymphoblastic leukemia has been found beneficial in preventing central nervous system relapse.,Treatment Protocols,TREATS,Child
12764374,Treatment failure in the children with ALL was closely related to the expression of SP observed at the beginning of treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11198935,"As the long-term event-free survival rate in children with acute lymphoblastic leukemia approaches 80%, emphasis is being placed on risk-directed therapy to prevent over- or undertreatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11340614,"Increased incidence of thyroid cancer has been noted following radiotherapy for childhood Hodgkin disease, non-Hodgkin lymphoma, neuroblastoma, Wilms tumor, acute lymphocytic leukemia and tumors of the central nervous system.",Radiation therapy,TREATS,childhood Hodgkin's lymphoma
11340614,"Increased incidence of thyroid cancer has been noted following radiotherapy for childhood Hodgkin disease, non-Hodgkin lymphoma, neuroblastoma, Wilms tumor, acute lymphocytic leukemia and tumors of the central nervous system.",Radiation therapy,TREATS,Neuroblastoma
11340614,"Increased incidence of thyroid cancer has been noted following radiotherapy for childhood Hodgkin disease, non-Hodgkin lymphoma, neuroblastoma, Wilms tumor, acute lymphocytic leukemia and tumors of the central nervous system.",Radiation therapy,TREATS,Nephroblastoma
11340614,"Increased incidence of thyroid cancer has been noted following radiotherapy for childhood Hodgkin disease, non-Hodgkin lymphoma, neuroblastoma, Wilms tumor, acute lymphocytic leukemia and tumors of the central nervous system.",Radiation therapy,TREATS,Neoplasm
11340614,"Increased incidence of thyroid cancer has been noted following radiotherapy for childhood Hodgkin disease, non-Hodgkin lymphoma, neuroblastoma, Wilms tumor, acute lymphocytic leukemia and tumors of the central nervous system.",Radiation therapy,TREATS,"Lymphoma, Non-Hodgkin's"
11340614,"Increased incidence of thyroid cancer has been noted following radiotherapy for childhood Hodgkin disease, non-Hodgkin lymphoma, neuroblastoma, Wilms tumor, acute lymphocytic leukemia and tumors of the central nervous system.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
11380466,"Collectively, our results suggest that losses of p15 and/or p16 gene expression result in elevated levels of DHFR in BP-ALL in children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11380466,"Collectively, our results suggest that losses of p15 and/or p16 gene expression result in elevated levels of DHFR in BP-ALL in children.",DHFR gene | DHFR,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
11415466,"Childhood acute lymphoblastic leukaemia (ALL) is treated by combination chemotherapy with a number of drugs, always including the enzyme L-asparaginase (ASNase).",Combination Drug Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11594517,"A total of 124 children with B-cell precursor ALL (B-pre ALL) were classified into 3 groups, the ultrahigh-risk group (UHRG) (15 patients), the high-risk group (HRG) (61 patients), or the standard-risk group (SRG) (48 patients), based on age. leukocyte count, immunophenotype, central nervous system leukemia, response to treatment, and selected chromosomal abnormalities.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
11594517,"A total of 124 children with B-cell precursor ALL (B-pre ALL) were classified into 3 groups, the ultrahigh-risk group (UHRG) (15 patients), the high-risk group (HRG) (61 patients), or the standard-risk group (SRG) (48 patients), based on age. leukocyte count, immunophenotype, central nervous system leukemia, response to treatment, and selected chromosomal abnormalities.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
11722407,"Because none of the parameters used to measure the early response to induction therapy for childhood ALL have been properly assessed as prognostic factors, we conclude that they should be considered only as candidate prognostic indicators pending more thorough studies.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11722407,Published studies of the prognostic value of the early response to induction treatment in childhood acute lymphoblastic leukaemia (ALL) were analysed.,Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11722407,Early response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological review.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11813173,"PROCEDURE: Forty-six children with ALL or T-Cell non-Hodgkins lymphoma (NHL) treated on MRC ALL 97, UKALL XI or UKCCSG 9504 NHL protocols were randomised to receive granulocyte colony-stimulating factor following either the first or the second block of intensive chemotherapy in a cross-over study to determine if the prophylactic administration of G-CSF could reduce the rate of readmission to hospital for management of febrile neutropenia.",Granulocyte Colony-Stimulating Factor,ADMINISTERED_TO,Child
11813173,CONCLUSIONS: This study shows that the prophylactic administration of G-CSF following intensification chemotherapy for childhood ALL and T-NHL produces a significant reduction in the rate of readmission to hospital for the management of febrile neutropenia.,Granulocyte Colony-Stimulating Factor | LAMC2,TREATS,Febrile neutropenia
11813173,"PROCEDURE: Forty-six children with ALL or T-Cell non-Hodgkins lymphoma (NHL) treated on MRC ALL 97, UKALL XI or UKCCSG 9504 NHL protocols were randomised to receive granulocyte colony-stimulating factor following either the first or the second block of intensive chemotherapy in a cross-over study to determine if the prophylactic administration of G-CSF could reduce the rate of readmission to hospital for management of febrile neutropenia.",Obstruction,PROCESS_OF,"Crossing Over, Genetic"
11813173,CONCLUSIONS: This study shows that the prophylactic administration of G-CSF following intensification chemotherapy for childhood ALL and T-NHL produces a significant reduction in the rate of readmission to hospital for the management of febrile neutropenia.,Pharmacotherapy,TREATS,"Lymphoma, Non-Hodgkin's"
11813173,This randomised study evaluates the role of G-CSF given after a 5-day intensification block in children with acute lymphoblastic leukaemia (ALL).,Obstruction,PROCESS_OF,Child
11813173,CONCLUSIONS: This study shows that the prophylactic administration of G-CSF following intensification chemotherapy for childhood ALL and T-NHL produces a significant reduction in the rate of readmission to hospital for the management of febrile neutropenia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11813173,This randomised study evaluates the role of G-CSF given after a 5-day intensification block in children with acute lymphoblastic leukaemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11813173,"PROCEDURE: Forty-six children with ALL or T-Cell non-Hodgkins lymphoma (NHL) treated on MRC ALL 97, UKALL XI or UKCCSG 9504 NHL protocols were randomised to receive granulocyte colony-stimulating factor following either the first or the second block of intensive chemotherapy in a cross-over study to determine if the prophylactic administration of G-CSF could reduce the rate of readmission to hospital for management of febrile neutropenia.",Granulocyte Colony-Stimulating Factor | LAMC2,TREATS,Febrile neutropenia
11813173,"PROCEDURE: Forty-six children with ALL or T-Cell non-Hodgkins lymphoma (NHL) treated on MRC ALL 97, UKALL XI or UKCCSG 9504 NHL protocols were randomised to receive granulocyte colony-stimulating factor following either the first or the second block of intensive chemotherapy in a cross-over study to determine if the prophylactic administration of G-CSF could reduce the rate of readmission to hospital for management of febrile neutropenia.",T-Cell Lymphoma,PROCESS_OF,Child
11813173,"PROCEDURE: Forty-six children with ALL or T-Cell non-Hodgkins lymphoma (NHL) treated on MRC ALL 97, UKALL XI or UKCCSG 9504 NHL protocols were randomised to receive granulocyte colony-stimulating factor following either the first or the second block of intensive chemotherapy in a cross-over study to determine if the prophylactic administration of G-CSF could reduce the rate of readmission to hospital for management of febrile neutropenia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11821358,"The risk of childhood acute lymphoblastic leukaemia (ALL) was significantly higher among children of older mothers and fathers, and significant trends with increasing mothers' (P < 0.001) and fathers' (P = 0.002) ages were found.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
12031930,Significance of real-time quantitative PCR detection of p16 gene deletions in childhood acute lymphoblastic leukemia.,Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12105771,"Using PBPC for allogeneic transplantation in childhood ALL results in faster hematopoietic recovery compared to BM, with a similar incidence of aGVHD, TRM, relapse and disease-free survival.","Transplantation, Homologous",TREATS,Patients
12105771,"Using PBPC for allogeneic transplantation in childhood ALL results in faster hematopoietic recovery compared to BM, with a similar incidence of aGVHD, TRM, relapse and disease-free survival.","Transplantation, Homologous",TREATS,"Leukemia, Lymphocytic, Acute, L1"
12105771,"Using PBPC for allogeneic transplantation in childhood ALL results in faster hematopoietic recovery compared to BM, with a similar incidence of aGVHD, TRM, relapse and disease-free survival.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
12105771,Matched-pair analysis comparing allogeneic PBPCT and BMT from HLA-identical relatives in childhood acute lymphoblastic leukemia.,Bone Marrow Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12181040,"In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12698270,METHODS: A two-compartment pharmacokinetic model was used to describe data from 23 children with ALL (aged 2-15 years).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12698270,PURPOSE: To evaluate the plasma protein binding and pharmacokinetics of prednisolone during therapeutic use in children with acute lymphoblastic leukemia (ALL) using the population approach.,Drug Kinetics,PROCESS_OF,Child
12698270,PURPOSE: To evaluate the plasma protein binding and pharmacokinetics of prednisolone during therapeutic use in children with acute lymphoblastic leukemia (ALL) using the population approach.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12698270,Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.,prednisolone,TREATS,Child
12698270,Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12698270,Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.,prednisolone,TREATS,"Leukemia, Lymphocytic, Acute"
11023499,"Sequential monitoring of MRD by the method described here provides highly significant, independent prognostic information in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11023499,"Sequential monitoring of MRD by the method described here provides highly significant, independent prognostic information in children with ALL.","Neoplasm, Residual",PROCESS_OF,Child
11023499,Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11205837,The authors prospectively analyzed P-gp using flow cytometry with monoclonal antibody JSB1 in a population-based series of 103 children with ALL treated according to intensive Nordic ALL protocols.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11426627,"From 32/109 children with B-precursor ALL screened for these abnormalities, we found evidence for del 12p, including the loss of the untranslocated TEL allele, to be the secondary event to take place in the leukaemic cells from those patients positive for these abnormalities.",Leukemic Cell,LOCATION_OF,ETV6 gene | ETV6
11426627,"From 32/109 children with B-precursor ALL screened for these abnormalities, we found evidence for del 12p, including the loss of the untranslocated TEL allele, to be the secondary event to take place in the leukaemic cells from those patients positive for these abnormalities.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11485552,"Childhood acute lymphoblastic leukaemia is treated by combination chemotherapy with a number of drugs, almost always including the enzyme L-asparaginase (ASNase).",Combination Drug Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11594517,"Thus, intensification of chemotherapy improved the EFS rate and AML-type block therapies appeared to be effective as the consolidation and reinduction therapies for B-pre ALL.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
11594517,"Thus, intensification of chemotherapy improved the EFS rate and AML-type block therapies appeared to be effective as the consolidation and reinduction therapies for B-pre ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
11723528,"OBJECTIVES: To correlate bi/oligoclonality, detected by polymerase chain reaction in Brazilian children with B-lineage acute lymphoblastic leukemia with a chance of relapse, with immunophenotype, risk group, and disease-free survival.",Polymerase Chain Reaction,USES,Immunophenotyping
11723528,"OBJECTIVES: To correlate bi/oligoclonality, detected by polymerase chain reaction in Brazilian children with B-lineage acute lymphoblastic leukemia with a chance of relapse, with immunophenotype, risk group, and disease-free survival.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11723528,"OBJECTIVES: To correlate bi/oligoclonality, detected by polymerase chain reaction in Brazilian children with B-lineage acute lymphoblastic leukemia with a chance of relapse, with immunophenotype, risk group, and disease-free survival.",BRAZILIAN,PROCESS_OF,Child
11723528,CONTEXT: The CDR-3 region of heavy-chain immunoglobulin has been used as a clonal marker in the study of minimal residual disease in children with acute lymphoblastic leukemia.,"Neoplasm, Residual",PROCESS_OF,Child
11723528,CONTEXT: The CDR-3 region of heavy-chain immunoglobulin has been used as a clonal marker in the study of minimal residual disease in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11767129,BACKGROUND AND PURPOSE: Children with acute lymphoblastic leukemia are treated with intensive chemotherapy resulting in profound immuno suppression.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11767129,BACKGROUND AND PURPOSE: Children with acute lymphoblastic leukemia are treated with intensive chemotherapy resulting in profound immuno suppression.,Pharmacotherapy,TREATS,Child
11767129,BACKGROUND AND PURPOSE: Children with acute lymphoblastic leukemia are treated with intensive chemotherapy resulting in profound immuno suppression.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
11767129,Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia.,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
11767129,Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia.,Antibacterial prophylaxis,USES,Trimethoprim-Sulfamethoxazole Combination
11773175,PURPOSE: To improve efficacy and reduce toxicity of treatment for children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,Child
11773175,PURPOSE: To improve efficacy and reduce toxicity of treatment for children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11773175,PURPOSE: To improve efficacy and reduce toxicity of treatment for children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
11952819,"Seventy uniformly treated children with acute lymphoblastic leukemia were analysed for chromosomal abnormalities with conventional G-banding, spectral karyotyping (SKY) and interphase fluorescent in situ hybridisation (FISH) using probes to detect MLL, BCR/ABL, TEL/AML1 rearrangements and INK4 locus deletions.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12183715,OBJECTIVE: To evaluate fracture rate and bone mineral density (BMD) and body composition in children with acute lymphoblastic leukemia (ALL) treated with dexamethasone-based chemotherapy.,Fracture,PROCESS_OF,Child
12183715,OBJECTIVE: To evaluate fracture rate and bone mineral density (BMD) and body composition in children with acute lymphoblastic leukemia (ALL) treated with dexamethasone-based chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12454742,Resistance to the antifolate methotrexate (MTX) can cause treatment failure in childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12454742,Resistance to the antifolate methotrexate (MTX) can cause treatment failure in childhood acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Folic Acid Antagonists
12542913,BACKGROUND: Methotrexate (MTX) followed by 6-mercaptopurine (6MP) is one of the best known combinations for the treatment of childhood acute lymphoblastic leukaemia.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12542913,BACKGROUND: Methotrexate (MTX) followed by 6-mercaptopurine (6MP) is one of the best known combinations for the treatment of childhood acute lymphoblastic leukaemia.,6-Mercaptopurine,ISA,Therapeutic procedure
12694250,"Consequently, we suggest that children with eye relapse of ALL be treated with an intensive relapse chemotherapy protocol with local ocular radiotherapy, whether the relapse occurs in isolation or in combination with relapse at another site.",Radiation therapy,TREATS,Need for isolation
12694250,"Consequently, we suggest that children with eye relapse of ALL be treated with an intensive relapse chemotherapy protocol with local ocular radiotherapy, whether the relapse occurs in isolation or in combination with relapse at another site.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
12767105,Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12767105,BACKGROUND: The goals of the current study were to examine the incidence and severity of toxicity resulting from dexamethasone and prednisone during induction therapy for children with precursor B-cell acute lymphoblastic leukemia (ALL) and to determine whether the addition of daunomycin affected toxicity.,Daunorubicin,AFFECTS,Toxic effect
12767105,BACKGROUND: The goals of the current study were to examine the incidence and severity of toxicity resulting from dexamethasone and prednisone during induction therapy for children with precursor B-cell acute lymphoblastic leukemia (ALL) and to determine whether the addition of daunomycin affected toxicity.,Neoadjuvant Therapy,TREATS,Child
12767105,BACKGROUND: The goals of the current study were to examine the incidence and severity of toxicity resulting from dexamethasone and prednisone during induction therapy for children with precursor B-cell acute lymphoblastic leukemia (ALL) and to determine whether the addition of daunomycin affected toxicity.,Prednisone,CAUSES,Toxic effect
12767105,BACKGROUND: The goals of the current study were to examine the incidence and severity of toxicity resulting from dexamethasone and prednisone during induction therapy for children with precursor B-cell acute lymphoblastic leukemia (ALL) and to determine whether the addition of daunomycin affected toxicity.,Dexamethasone,CAUSES,Toxic effect
12767105,BACKGROUND: The goals of the current study were to examine the incidence and severity of toxicity resulting from dexamethasone and prednisone during induction therapy for children with precursor B-cell acute lymphoblastic leukemia (ALL) and to determine whether the addition of daunomycin affected toxicity.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12767105,BACKGROUND: The goals of the current study were to examine the incidence and severity of toxicity resulting from dexamethasone and prednisone during induction therapy for children with precursor B-cell acute lymphoblastic leukemia (ALL) and to determine whether the addition of daunomycin affected toxicity.,Neoadjuvant Therapy,TREATS,"Leukemia, B-Cell, Acute"
10658526,"Toxicity, supportive care and costs of two chemotherapy protocols for treatment of childhood ALL in Russia: BFM 90m and MB 91.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11026819,The 3-year survival rate was 20% and the relapse-free-survival rate was 12% confirming the worse prognosis of this leukemia when treated with standard chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
11383710,"Bone marrow cells of 13 children with untreated ALL (nine common ALL, two myeloid antigen positive ALL and two early T-cell ALL) formed colonies of leukemic blast cells in primary methylcellulose cultures.",T-Lymphocyte,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
11383710,"Bone marrow cells of 13 children with untreated ALL (nine common ALL, two myeloid antigen positive ALL and two early T-cell ALL) formed colonies of leukemic blast cells in primary methylcellulose cultures.",Bone Marrow Cells,PART_OF,Child
11383710,Effect of myelopoietic and pleiotropic cytokines on colony formation by blast cells of children with acute lymphoblastic leukemia.,Blast Cell,PART_OF,Child
11383710,Effect of myelopoietic and pleiotropic cytokines on colony formation by blast cells of children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11383710,This may present a potential hazard to children with ALL while on adjuvant therapy with hematopoietic growth factors.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11383710,This may present a potential hazard to children with ALL while on adjuvant therapy with hematopoietic growth factors.,Interleukin-3,PART_OF,Child
11383710,This may present a potential hazard to children with ALL while on adjuvant therapy with hematopoietic growth factors.,Interleukin-3,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
11383710,"Bone marrow cells of 13 children with untreated ALL (nine common ALL, two myeloid antigen positive ALL and two early T-cell ALL) formed colonies of leukemic blast cells in primary methylcellulose cultures.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11452154,WBC-reduced blood transfusions and clinical outcome in children with acute lymphoid leukemia.,Blood Transfusion,TREATS,"Leukemia, Lymphocytic, Acute"
11452154,"BACKGROUND: WBC reduction offers a variety of benefits to patients requiring multiple transfusions during induction therapy for childhood acute lymphoid leukemia (ALL), including reductions in febrile transfusion reactions, HLA alloimmunization, and CMV transmission.",Transfusion - action,TREATS,Febrile transfusion reaction
11452154,"BACKGROUND: WBC reduction offers a variety of benefits to patients requiring multiple transfusions during induction therapy for childhood acute lymphoid leukemia (ALL), including reductions in febrile transfusion reactions, HLA alloimmunization, and CMV transmission.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11452154,WBC-reduced blood transfusions and clinical outcome in children with acute lymphoid leukemia.,Blood Transfusion,TREATS,Child
11452154,WBC-reduced blood transfusions and clinical outcome in children with acute lymphoid leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12070006,Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia.,Remission Induction,TREATS,"Leukemia, Lymphocytic, Acute"
12070006,Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia.,Remission Induction,TREATS,Child
12070006,Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12070008,"Thus, approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy, and these patients have an excellent treatment outcome.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
12070008,"Thus, approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy, and these patients have an excellent treatment outcome.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12070010,We analyzed GST genotypes in 710 children with ALL treated by the Children's Cancer Group.,Child,LOCATION_OF,Glutathione S-Transferase
12070010,We analyzed GST genotypes in 710 children with ALL treated by the Children's Cancer Group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12142782,"Among the children with ALL, two white and one Chinese were heterozygous for the TPMT*3A variant and showed intermediate sensitivity to 6-mercaptopurine during maintenance therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12142782,"Six hundred unrelated cord blood samples from 200 Chinese, Malay, and Indian healthy newborns were collected at the National University Hospital, Singapore; an additional 100 children with ALL were analyzed for five of the commonly reported TPMT variant alleles using polymerase chain reaction/restriction fragment length polymorphism and allele-specific polymerase chain reaction-based assays.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12142782,Thiopurine methyltransferase polymorphisms in a multiracial asian population and children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12142785,PURPOSE: To present a first descriptive serologic study on the clinical and hematologic implications of parvovirus B19 (B19) infection in children with acute lymphoblastic leukemia from the time of initial admission until discontinuation of chemotherapy.,"Parvovirus B19, Human",PROCESS_OF,Child
12142785,PURPOSE: To present a first descriptive serologic study on the clinical and hematologic implications of parvovirus B19 (B19) infection in children with acute lymphoblastic leukemia from the time of initial admission until discontinuation of chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12183715,CONCLUSIONS: Children with ALL are at risk for osteopenia because of the disease itself and the intensive chemotherapy.,"Leukemia, Lymphocytic, Acute",CAUSES,Osteopenia
12183715,CONCLUSIONS: Children with ALL are at risk for osteopenia because of the disease itself and the intensive chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12183715,CONCLUSIONS: Children with ALL are at risk for osteopenia because of the disease itself and the intensive chemotherapy.,"Leukemia, Lymphocytic, Acute",ISA,Disease
12183715,STUDY DESIGN: Children with ALL (n = 61) participated.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12387652,Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia.,Spinal Puncture,TREATS,Child
12387652,Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12387652,Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia.,Spinal Puncture,TREATS,"Leukemia, Lymphocytic, Acute"
12387652,Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia.,Blood,LOCATION_OF,Spinal Puncture
12618889,Relapse ALL samples derived from bone marrow showed increased S-phase fractions (median 9.9%) compared with initial ALL samples (median 6.9%; P<0.01).,Bone Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
12732501,Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
12732501,Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12732501,Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis.,Stem cell transplant,TREATS,Child
12732501,Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis.,Pharmacotherapy,TREATS,Child
12732501,Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis.,Stem cell transplant,compared_with,Pharmacotherapy
12732501,Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis.,Stem cell transplant,TREATS,"Leukemia, Lymphocytic, Acute"
10951359,"CONCLUSIONS: The data suggest that the treatment of children with ALL using MTX causes subclinical hypomethylation and that progressive hypomethylation in the CNS, as evidenced in the 2 patients with ALL and LE, may be responsible for the demyelination in the LE induced by MTX.",Methotrexate,CAUSES,Leukoencephalopathy
10951359,"CONCLUSIONS: The data suggest that the treatment of children with ALL using MTX causes subclinical hypomethylation and that progressive hypomethylation in the CNS, as evidenced in the 2 patients with ALL and LE, may be responsible for the demyelination in the LE induced by MTX.",Therapeutic procedure,USES,Methotrexate
10951359,"METHODS: The levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were measured in the CSF of 2 children with ALL and LE, 7 children with ALL only who were undergoing presymptomatic administration of MTX, and 18 reference children in whom diagnostic lumbar puncture was indicated for other reasons.",Cerebrospinal Fluid,PART_OF,Child
10951359,"METHODS: The levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were measured in the CSF of 2 children with ALL and LE, 7 children with ALL only who were undergoing presymptomatic administration of MTX, and 18 reference children in whom diagnostic lumbar puncture was indicated for other reasons.",Cerebrospinal Fluid,LOCATION_OF,S-Adenosylmethionine
10951359,BACKGROUND: The prognosis of patients with acute lymphoblastic leukemia (ALL) in childhood has improved with intensive chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
10951359,The SAH concentrations in the CSF were higher in the patients with ALL and LE compared with the patients with ALL only and the reference children.,Cerebrospinal Fluid,LOCATION_OF,ACSM3
10951359,"Because the mechanisms by which MTX causes this complication have not been elucidated, the authors investigated the transmethylation status of the cerebrospinal fluid (CSF) in two children with ALL and LE to investigate the pathophysiology of that disorder.",Central nervous system complication,PROCESS_OF,Child
10951359,"METHODS: The levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were measured in the CSF of 2 children with ALL and LE, 7 children with ALL only who were undergoing presymptomatic administration of MTX, and 18 reference children in whom diagnostic lumbar puncture was indicated for other reasons.",Cerebrospinal Fluid,LOCATION_OF,S-Adenosylhomocysteine
10951359,Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy.,Leukoencephalopathy,PROCESS_OF,Child
10951359,The SAH concentrations in the CSF were higher in the patients with ALL and LE compared with the patients with ALL only and the reference children.,Patients,LOCATION_OF,ACSM3
10951359,"Because the mechanisms by which MTX causes this complication have not been elucidated, the authors investigated the transmethylation status of the cerebrospinal fluid (CSF) in two children with ALL and LE to investigate the pathophysiology of that disorder.",Leukoencephalopathy,PROCESS_OF,Child
10951359,"CONCLUSIONS: The data suggest that the treatment of children with ALL using MTX causes subclinical hypomethylation and that progressive hypomethylation in the CNS, as evidenced in the 2 patients with ALL and LE, may be responsible for the demyelination in the LE induced by MTX.",Demyelination,COEXISTS_WITH,Leukoencephalopathy
10951359,"METHODS: The levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were measured in the CSF of 2 children with ALL and LE, 7 children with ALL only who were undergoing presymptomatic administration of MTX, and 18 reference children in whom diagnostic lumbar puncture was indicated for other reasons.",Leukoencephalopathy,PROCESS_OF,Child
10951359,Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10951359,The SAH concentrations in the CSF were higher in the patients with ALL and LE compared with the patients with ALL only and the reference children.,Leukoencephalopathy,PROCESS_OF,Patients
10951359,"Because the mechanisms by which MTX causes this complication have not been elucidated, the authors investigated the transmethylation status of the cerebrospinal fluid (CSF) in two children with ALL and LE to investigate the pathophysiology of that disorder.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10951359,"CONCLUSIONS: The data suggest that the treatment of children with ALL using MTX causes subclinical hypomethylation and that progressive hypomethylation in the CNS, as evidenced in the 2 patients with ALL and LE, may be responsible for the demyelination in the LE induced by MTX.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10951359,"METHODS: The levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were measured in the CSF of 2 children with ALL and LE, 7 children with ALL only who were undergoing presymptomatic administration of MTX, and 18 reference children in whom diagnostic lumbar puncture was indicated for other reasons.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10951359,The SAH concentrations in the CSF were higher in the patients with ALL and LE compared with the patients with ALL only and the reference children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
10951359,"Because the mechanisms by which MTX causes this complication have not been elucidated, the authors investigated the transmethylation status of the cerebrospinal fluid (CSF) in two children with ALL and LE to investigate the pathophysiology of that disorder.",Methotrexate,CAUSES,Central nervous system complication
10951359,"CONCLUSIONS: The data suggest that the treatment of children with ALL using MTX causes subclinical hypomethylation and that progressive hypomethylation in the CNS, as evidenced in the 2 patients with ALL and LE, may be responsible for the demyelination in the LE induced by MTX.",Leukoencephalopathy,PROCESS_OF,Patients
10951359,"METHODS: The levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were measured in the CSF of 2 children with ALL and LE, 7 children with ALL only who were undergoing presymptomatic administration of MTX, and 18 reference children in whom diagnostic lumbar puncture was indicated for other reasons.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10951359,The SAH concentrations in the CSF were higher in the patients with ALL and LE compared with the patients with ALL only and the reference children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
10951359,BACKGROUND: The prognosis of patients with acute lymphoblastic leukemia (ALL) in childhood has improved with intensive chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
10951359,"CONCLUSIONS: The data suggest that the treatment of children with ALL using MTX causes subclinical hypomethylation and that progressive hypomethylation in the CNS, as evidenced in the 2 patients with ALL and LE, may be responsible for the demyelination in the LE induced by MTX.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
10951359,"METHODS: The levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were measured in the CSF of 2 children with ALL and LE, 7 children with ALL only who were undergoing presymptomatic administration of MTX, and 18 reference children in whom diagnostic lumbar puncture was indicated for other reasons.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10951359,The SAH concentrations in the CSF were higher in the patients with ALL and LE compared with the patients with ALL only and the reference children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10951359,BACKGROUND: The prognosis of patients with acute lymphoblastic leukemia (ALL) in childhood has improved with intensive chemotherapy.,Pharmacotherapy,TREATS,Patients
11267859,This report suggests that MTX might be an overlooked drug in the treatment of childhood AML.,Methotrexate,ISA,Pharmaceutical Preparations
11267859,This report suggests that MTX might be an overlooked drug in the treatment of childhood AML.,Pharmaceutical Preparations,TREATS,pediatric acute myeloblastic leukemia
11267859,This report suggests that MTX might be an overlooked drug in the treatment of childhood AML.,Methotrexate,TREATS,pediatric acute myeloblastic leukemia
11267859,"A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia.",Methotrexate,TREATS,pediatric acute myeloblastic leukemia
11345205,"Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.",Therapeutic procedure,TREATS,Child
11345205,"Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11345205,"Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
11452154,CONCLUSION: Allogeneic WBCs in transfused blood may cause impairment of host defenses against microbial infection during induction therapy for childhood ALL.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11452936,"PROCEDURE: We tested the capacity of T-cells to regenerate in 18 ALL children in first clinical remission (median age 4.2 years) at the time of hematologic reconstitution after BFM-ALL induction therapy (treatment-free interval 22 days, median; range 12 to 52 days).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11484799,CONCLUSIONS: This study strengthens the evidence of space-time clustering around the birth date in children whom later developed ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11487261,Antibody to Haemophilus influenzae type b (Hib) polysaccharide (PRP) was measured in 42 children with acute lymphoblastic leukaemia (ALL) and 42 non-leukaemic hospital controls.,HEMOPHILUS B POLYSACCHARIDE,TREATS,"Leukemia, Lymphocytic, Acute"
11487261,Antibody to Haemophilus influenzae type b (Hib) polysaccharide (PRP) was measured in 42 children with acute lymphoblastic leukaemia (ALL) and 42 non-leukaemic hospital controls.,HEMOPHILUS B POLYSACCHARIDE,TREATS,Child
11487261,Antibody to Haemophilus influenzae type b (Hib) polysaccharide (PRP) was measured in 42 children with acute lymphoblastic leukaemia (ALL) and 42 non-leukaemic hospital controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11867505,"Among the multiple comparisons for age-, sex-, and subtype-specific subgroups, we observed an elevated risk of total ALL among children ages 11-14 at diagnosis (OR, 2.4; 95% CI, 1.1-5.0) in relation to in utero pelvimetric diagnostic X-ray exposures and a small increase in pre-B ALL for all ages combined (OR, 1.7; 95% CI, 1.1-2.7) in relation to postnatal diagnostic X-rays.",Roentgen Rays,PROCESS_OF,Precursor B-cell lymphoblastic leukemia
11867505,"Among the multiple comparisons for age-, sex-, and subtype-specific subgroups, we observed an elevated risk of total ALL among children ages 11-14 at diagnosis (OR, 2.4; 95% CI, 1.1-5.0) in relation to in utero pelvimetric diagnostic X-ray exposures and a small increase in pre-B ALL for all ages combined (OR, 1.7; 95% CI, 1.1-2.7) in relation to postnatal diagnostic X-rays.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11999562,In a long term prospective study (mean time of follow-up: 65 months) the multidrug efflux pump P-gp was examined immunocytochemically in leukemic cells of 102 protocol-treated children with de novo acute lymphoblastic leukemia (ALL) and of 37 children with relapsed ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11999562,"In conclusion we strongly advise that tests for P-gp in leukemic blasts should be conducted for every child with ALL, since this parameter selects a subgroup of patients with increased risk for leukemic relapse.",Blast Cell,LOCATION_OF,P-Glycoprotein
11999562,"In conclusion we strongly advise that tests for P-gp in leukemic blasts should be conducted for every child with ALL, since this parameter selects a subgroup of patients with increased risk for leukemic relapse.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11999562,In a long term prospective study (mean time of follow-up: 65 months) the multidrug efflux pump P-gp was examined immunocytochemically in leukemic cells of 102 protocol-treated children with de novo acute lymphoblastic leukemia (ALL) and of 37 children with relapsed ALL.,Leukemic Cell,PART_OF,Child
11999562,In a long term prospective study (mean time of follow-up: 65 months) the multidrug efflux pump P-gp was examined immunocytochemically in leukemic cells of 102 protocol-treated children with de novo acute lymphoblastic leukemia (ALL) and of 37 children with relapsed ALL.,Leukemic Cell,PART_OF,Child
11999562,In a long term prospective study (mean time of follow-up: 65 months) the multidrug efflux pump P-gp was examined immunocytochemically in leukemic cells of 102 protocol-treated children with de novo acute lymphoblastic leukemia (ALL) and of 37 children with relapsed ALL.,Leukemic Cell,LOCATION_OF,P-Glycoprotein
11999562,In a long term prospective study (mean time of follow-up: 65 months) the multidrug efflux pump P-gp was examined immunocytochemically in leukemic cells of 102 protocol-treated children with de novo acute lymphoblastic leukemia (ALL) and of 37 children with relapsed ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14647728,"RESULTS: Sixty-one children were included in this trial, 93% with acute lymphoid leukemia, and 7% with acute myeloid leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10667009,The object of this study was to evaluate the treatment outcome in children with acute lymphoblastic leukemia (ALL) in Chennai.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10952780,"In the present study, the expression of CTGF (IGFBP-rP2) in human leukaemic lymphoblasts from children with acute lymphoblastic leukaemia (ALL) was investigated.",lymphoblast,LOCATION_OF,CTGF gene | CTGF
10952780,"In the present study, the expression of CTGF (IGFBP-rP2) in human leukaemic lymphoblasts from children with acute lymphoblastic leukaemia (ALL) was investigated.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11027195,"SMRs for acute lymphatic leukaemia (ALL) among children born in high, normal and low risk areas were 1.43, 1.17 and 0.25 respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11027195,CONCLUSION: Children born in and staying at areas where the risk from ground radon has been classified as low are less likely to develop ALL than those born in areas classified as normal and high risk.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11564064,Interphase fluorescence in situ hybridization and spectral karyotyping reveals hidden genetic aberrations in children with acute lymphoblastic leukaemia and a normal banded karyotype.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11726315,"We carried out cytogenetic and FISH studies on 42 children with ALL in order to know the frequency of this translocation in our population, the incidence of TEL and/or AML1 gene alterations, and their correlation with clinical evolution and prognosis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11726315,Correlation with cytogenetic findings and prognostic value in children with acute lymphocytic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11726326,Application of a chemiluminescent methodology for detection of minimal residual disease in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11726326,Application of a chemiluminescent methodology for detection of minimal residual disease in childhood acute lymphoblastic leukemia.,Application procedure,METHOD_OF,Detection
12036851,A cohort of 8831 children diagnosed with ALL and enrolled on Children's Cancer Group therapeutic protocols between 1983 and 1995 were observed to determine the incidence of second neoplasms and associated risk factors.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12036898,This study aimed at determining the prevalence of INK4 deletions and their impact on outcome in 125 children with acute lymphoblastic leukemia (ALL) at first relapse using real-time quantitative polymerase chain reaction.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12036898,This study aimed at determining the prevalence of INK4 deletions and their impact on outcome in 125 children with acute lymphoblastic leukemia (ALL) at first relapse using real-time quantitative polymerase chain reaction.,Child,LOCATION_OF,CDKN2A gene | CDKN2A
12145681,MRD levels were analyzed in follow-up samples of 62 children with precursor-B-ALL (532 paired BM-PB samples) and 22 children with T-ALL (149 paired BM-PB samples) using real-time quantitative PCR (RQ-PCR) analysis of immunoglobulin and T cell receptor gene rearrangements with sensitivities of 10(-3) to 10(-5) (one ALL cell in 10(3) to 10(5) normal cells).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12145681,MRD levels were analyzed in follow-up samples of 62 children with precursor-B-ALL (532 paired BM-PB samples) and 22 children with T-ALL (149 paired BM-PB samples) using real-time quantitative PCR (RQ-PCR) analysis of immunoglobulin and T cell receptor gene rearrangements with sensitivities of 10(-3) to 10(-5) (one ALL cell in 10(3) to 10(5) normal cells).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12145681,Sensitive and quantitative detection of minimal residual disease (MRD) in bone marrow (BM) samples of children with acute lymphoblastic leukemia (ALL) is essential for evaluation of early treatment response.,Bone marrow specimen,LOCATION_OF,"Neoplasm, Residual"
12145681,Sensitive and quantitative detection of minimal residual disease (MRD) in bone marrow (BM) samples of children with acute lymphoblastic leukemia (ALL) is essential for evaluation of early treatment response.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12145681,Sensitive and quantitative detection of minimal residual disease (MRD) in bone marrow (BM) samples of children with acute lymphoblastic leukemia (ALL) is essential for evaluation of early treatment response.,Bone marrow specimen,PART_OF,Child
12145681,MRD levels were analyzed in follow-up samples of 62 children with precursor-B-ALL (532 paired BM-PB samples) and 22 children with T-ALL (149 paired BM-PB samples) using real-time quantitative PCR (RQ-PCR) analysis of immunoglobulin and T cell receptor gene rearrangements with sensitivities of 10(-3) to 10(-5) (one ALL cell in 10(3) to 10(5) normal cells).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12145681,MRD levels were analyzed in follow-up samples of 62 children with precursor-B-ALL (532 paired BM-PB samples) and 22 children with T-ALL (149 paired BM-PB samples) using real-time quantitative PCR (RQ-PCR) analysis of immunoglobulin and T cell receptor gene rearrangements with sensitivities of 10(-3) to 10(-5) (one ALL cell in 10(3) to 10(5) normal cells).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12145682,"We analysed the association of TNF and IL-10 polymorphisms with response to initial treatment and risk of relapse in 135 children with ALL, treated according to Berlin-Frankfurt-Munster (BFM) protocols.","Polymorphism, Genetic",PROCESS_OF,Child
12145682,"We analysed the association of TNF and IL-10 polymorphisms with response to initial treatment and risk of relapse in 135 children with ALL, treated according to Berlin-Frankfurt-Munster (BFM) protocols.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12357355,"Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92.",DELETION,PROCESS_OF,Child
12357355,"Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12661004,Prenatal origin of TEL-AML1-positive acute lymphoblastic leukemia in children born in California.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12661005,"To evaluate the frequency and extent of deletions in 284 children with ALL, we devised a real-time PCR assay for CDKN2A, CDKN2B exons 1beta and 3, and MTAP gene dosage and validated it by comparison with loss-of-heterozygosity analysis.",DELETION,PROCESS_OF,Child
12661005,"Mono-allelic deletion was observed in about 15% of cases, stressing the importance of their detection in ALL.",Detection,TREATS,"Leukemia, Lymphocytic, Acute"
12661005,"To evaluate the frequency and extent of deletions in 284 children with ALL, we devised a real-time PCR assay for CDKN2A, CDKN2B exons 1beta and 3, and MTAP gene dosage and validated it by comparison with loss-of-heterozygosity analysis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10774753,Molecular detection of TEL-AML1 transcripts as a diagnostic tool and for monitoring of minimal residual disease in B-lineage childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
10881002,DNR 100 mg/m(2) given in 4 doses of 25 mg/m(2)/week appears to be a safe dose in induction treatment of ALL.,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
10881002,Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.,Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
10995007,"In the present study, we analyzed the p53/Bax/caspase-3 pathway in a paired and an unpaired sample series of children with acute lymphoblastic leukemia (ALL) at initial diagnosis and relapse.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11069029,Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11347199,TEL/AML1 fusion gene (derived from t(12;21)(p13;q22) translocation) became recently one of the most important genetic aberrations in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11347199,TEL/AML1 fusion gene (derived from t(12;21)(p13;q22) translocation) became recently one of the most important genetic aberrations in children with ALL.,Child,LOCATION_OF,Fusion Gene
11421142,"IMPLICATIONS FOR NURSING PRACTICE: Nurses caring for children with ALL can have a significant impact on the children's overall health, from diagnosis through long-term follow-up.",Diagnosis,METHOD_OF,follow-up
11421142,"IMPLICATIONS FOR NURSING PRACTICE: Nurses caring for children with ALL can have a significant impact on the children's overall health, from diagnosis through long-term follow-up.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11455975,Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance.,Polymerase Chain Reaction,USES,prednisolone
11455975,Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance.,leukemia,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11455977,"The chimeric TEL-AML1 transcript, which has been associated with this translocation, can be detected in up to 25% of children with BpALL.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
11455977,"Lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia (BpALL) with chromosomal hyperdiploidy and with translocations affecting chromosome 12p11-13, accumulate high and low levels of methotrexate polyglutamates (MTXPGs), respectively.",Chromosomal translocation,PROCESS_OF,Child
11455977,"Lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia (BpALL) with chromosomal hyperdiploidy and with translocations affecting chromosome 12p11-13, accumulate high and low levels of methotrexate polyglutamates (MTXPGs), respectively.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
11787864,Overall and event-free survivals for acute lymphoblastic leukemia in children at a single institution in Taiwan.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11822985,"A section of this review is focused on CNS-directed treatments and the neurodevelopmental outcomes of infants diagnosed with ALL, an especially high-risk patient subset.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
12358913,"We studied the expression of HoxA9 and Meis1 by reverse transcriptase-polymerase chain reaction analysis in leukaemic cells from cases of infant acute lymphoblastic leukaemia (ALL, n = 27) and childhood ALL (n = 29).",Leukemic Cell,LOCATION_OF,MEIS1 gene | MEIS1
12358913,"We studied the expression of HoxA9 and Meis1 by reverse transcriptase-polymerase chain reaction analysis in leukaemic cells from cases of infant acute lymphoblastic leukaemia (ALL, n = 27) and childhood ALL (n = 29).",Leukemic Cell,LOCATION_OF,HOXA9 gene | HOXA9
12358913,"We studied the expression of HoxA9 and Meis1 by reverse transcriptase-polymerase chain reaction analysis in leukaemic cells from cases of infant acute lymphoblastic leukaemia (ALL, n = 27) and childhood ALL (n = 29).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
12358913,Frequent co-expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement.,MEIS1 gene | MEIS1,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
12358913,Frequent co-expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement.,HOXA9 gene | HOXA9,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
12358913,Frequent co-expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
12393277,We report the cytogenetic analysis of newly diagnosed Brazilian children with acute lymphocytic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12393277,We report the cytogenetic analysis of newly diagnosed Brazilian children with acute lymphocytic leukemia (ALL).,BRAZILIAN,PROCESS_OF,Child
12613524,Constitutively high levels of JAK3 activity may contribute to drug resistance and enhanced clonogenicity of leukemic B-cell precursors from children and infants with acute lymphoblastic leukemia (ALL).,JAK3 gene | JAK3,AFFECTS,Drug resistance
12613524,Constitutively high levels of JAK3 activity may contribute to drug resistance and enhanced clonogenicity of leukemic B-cell precursors from children and infants with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
12613524,Constitutively high levels of JAK3 activity may contribute to drug resistance and enhanced clonogenicity of leukemic B-cell precursors from children and infants with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12617867,In this context several ongoing co-operative study groups have adopted an MRD-based risk group classification to explore whether a better tailored treatment would result in further improvement in cure rates for children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12617867,In this context several ongoing co-operative study groups have adopted an MRD-based risk group classification to explore whether a better tailored treatment would result in further improvement in cure rates for children with ALL.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
12617867,"Accordingly, several retrospective studies of MRD in childhood ALL have used one of the different PCR approaches for the detection of antigen-receptor gene rearrangements.",Polymerase Chain Reaction,METHOD_OF,Detection
12617867,"Accordingly, several retrospective studies of MRD in childhood ALL have used one of the different PCR approaches for the detection of antigen-receptor gene rearrangements.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12617867,Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12617867,In this context several ongoing co-operative study groups have adopted an MRD-based risk group classification to explore whether a better tailored treatment would result in further improvement in cure rates for children with ALL.,Therapeutic procedure,TREATS,Child
10848789,"Fifty-two children presenting with ALL were studied at diagnosis and during the first 48 h of treatment for cell proliferation and apoptosis level by measurement of DNA content, and for expression of several cell proliferation regulatory proteins by means of Western blot.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10848837,A number of prospective studies have indicated the clinical utility of measuring minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia (ALL) and have highlighted the need for improved methodology for quantification of residual disease.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
10848837,Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11236947,MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11237059,We studied microsatellite markers spanning the 13q14 chromosomal region in 138 children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11237059,We studied microsatellite markers spanning the 13q14 chromosomal region in 138 children with acute lymphoblastic leukemia (ALL).,Child,LOCATION_OF,13q14
11237061,The study group comprised 38 children aged 1-15 with Philadelphia-negative B-lineage ALL who were uniformly treated and followed until relapse or for a minimum of 5 years.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11237061,Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11237068,"Sixteen children had acute lymphoblastic leukemia (ALL), three had chronic myeloid leukemia (CML) and three had acute myeloid leukemia (AML).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11237073,Multicolor spectral karyotyping identifies novel translocations in childhood acute lymphoblastic leukemia.,Chromosomal translocation,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11237073,Multicolor spectral karyotyping identifies novel translocations in childhood acute lymphoblastic leukemia.,Spectral Karyotyping,DIAGNOSES,Chromosomal translocation
11389036,"Based on previous studies showing that more than 95% of childhood B-lineage ALL express CD38, this study evaluated whether normal CD34(+)CD38(-) progenitors from children with B-lineage ALL could be isolated by flow cytometry.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11389036,Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia.,Detection,TREATS,Child
11389036,"Therefore, strategies to isolate and transplant normal HSC from children with ALL will require a more stringent definition of the normal HSC than the CD34(+)CD38(-) phenotype.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11389036,Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11389036,"CD34(+) cells from bone marrow samples from 10 children with B-lineage ALL were isolated at day 28 of treatment, when clinical remission had been attained.",Bone marrow specimen,LOCATION_OF,CD34 gene | CD34
11389036,Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia.,Detection,TREATS,"Leukemia, Lymphocytic, Acute"
11389036,"CD34(+) cells from bone marrow samples from 10 children with B-lineage ALL were isolated at day 28 of treatment, when clinical remission had been attained.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11389036,"Based on previous studies showing that more than 95% of childhood B-lineage ALL express CD38, this study evaluated whether normal CD34(+)CD38(-) progenitors from children with B-lineage ALL could be isolated by flow cytometry.",Child,LOCATION_OF,CD38
11389036,"Based on previous studies showing that more than 95% of childhood B-lineage ALL express CD38, this study evaluated whether normal CD34(+)CD38(-) progenitors from children with B-lineage ALL could be isolated by flow cytometry.","Leukemia, Lymphocytic, Acute, L1",PRODUCES,CD38
12110760,"Despite high-dose dexamethasone and methotrexate used for treatment of these children with ALL, no long-term side effects on the bone mineral status of the subjects, measured with DXA or tibial ultrasonometry, could be determined.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12110760,"Despite high-dose dexamethasone and methotrexate used for treatment of these children with ALL, no long-term side effects on the bone mineral status of the subjects, measured with DXA or tibial ultrasonometry, could be determined.",Methotrexate,TREATS,Child
12110760,"Despite high-dose dexamethasone and methotrexate used for treatment of these children with ALL, no long-term side effects on the bone mineral status of the subjects, measured with DXA or tibial ultrasonometry, could be determined.",Dexamethasone,TREATS,Child
12110760,"Despite high-dose dexamethasone and methotrexate used for treatment of these children with ALL, no long-term side effects on the bone mineral status of the subjects, measured with DXA or tibial ultrasonometry, could be determined.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
12110760,"Despite high-dose dexamethasone and methotrexate used for treatment of these children with ALL, no long-term side effects on the bone mineral status of the subjects, measured with DXA or tibial ultrasonometry, could be determined.",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
12148878,We analyzed the minimal residual disease (MRD) in 50 children with acute lymphoblastic leukemia (ALL) by amplifying the clonally rearranged T-cell receptor (TCR) gamma/delta chain and/or immunoglobulin (Ig) kappa chain gene using the allele-specific-PCR method.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12148878,We analyzed the minimal residual disease (MRD) in 50 children with acute lymphoblastic leukemia (ALL) by amplifying the clonally rearranged T-cell receptor (TCR) gamma/delta chain and/or immunoglobulin (Ig) kappa chain gene using the allele-specific-PCR method.,"Neoplasm, Residual",PROCESS_OF,Child
12148878,Minimal residual disease in early phase of chemotherapy reflects poor outcome in children with acute lymphoblastic leukemia--a retrospective study by the Children's Cancer and Leukemia Study Group in Japan.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12148878,Minimal residual disease in early phase of chemotherapy reflects poor outcome in children with acute lymphoblastic leukemia--a retrospective study by the Children's Cancer and Leukemia Study Group in Japan.,"Neoplasm, Residual",PROCESS_OF,Child
12148878,Minimal residual disease in early phase of chemotherapy reflects poor outcome in children with acute lymphoblastic leukemia--a retrospective study by the Children's Cancer and Leukemia Study Group in Japan.,Malignant Neoplasms,PROCESS_OF,Child
12189547,"Space-time clustering analyses of acute lymphoblastic leukaemia in children, by immunophenotype, were carried out using a population-based registry.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10994545,UNLABELLED: The detection of minimal residual disease (MRD) is a major prognostic factor for treatment in acute lymphoblastic leukemia (ALL) of childhood.,Detection,TREATS,"Leukemia, Lymphocytic, Acute"
11030043,"In view of the introduction of risk-adjusted therapy into the UK childhood ALL treatment trials, an interphase FISH screening programme has been developed to reveal chromosomal abnormalities with prognostic significance in childhood ALL.",Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11030043,"In view of the introduction of risk-adjusted therapy into the UK childhood ALL treatment trials, an interphase FISH screening programme has been developed to reveal chromosomal abnormalities with prognostic significance in childhood ALL.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11243399,Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions.,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11243403,6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.,Bone marrow toxicity,PROCESS_OF,Child
11243403,6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11243403,Twenty-one children with standard risk (SR) and 25 with intermediate risk (IR) acute lymphoblastic leukemia (ALL) were studied.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11311642,"Data on 13344 newly diagnosed children (0--14 years) with ALL were included in the EUROCARE study and were collected were collected by 34 population-based cancer registries (four comprising only childhood malignancies), operating in 17 countries (four in Scandinavia, two in Southern Europe, three in Eastern Europe, six in Continental Europe and two in the UK).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11311642,The aim of this study was to provide a comparative description of geographical variations and time trends in the population-based survival of European children with acute lymphoblastic leukaemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11311642,"Variation in survival of European children with acute lymphoblastic leukaemia, diagnosed in 1978--1992: the EUROCARE study.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12038876,Acute lymphoblastic leukemia: optimizing treatment strategies in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12040440,"Modern treatment strategies, consisting of intensive chemotherapy and cranial irradiation, have remarkably improved the prognosis for children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12040440,"Modern treatment strategies, consisting of intensive chemotherapy and cranial irradiation, have remarkably improved the prognosis for children with acute lymphoblastic leukemia.",Pharmacotherapy,TREATS,Child
12040440,BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
12040440,"Modern treatment strategies, consisting of intensive chemotherapy and cranial irradiation, have remarkably improved the prognosis for children with acute lymphoblastic leukemia.",Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute"
12040440,BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
12040440,"Modern treatment strategies, consisting of intensive chemotherapy and cranial irradiation, have remarkably improved the prognosis for children with acute lymphoblastic leukemia.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
12040440,BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).,Cranial Irradiation,TREATS,Patients
12040440,BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12040440,BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).,Therapeutic procedure,TREATS,Child
12040440,"Modern treatment strategies, consisting of intensive chemotherapy and cranial irradiation, have remarkably improved the prognosis for children with acute lymphoblastic leukemia.",Cranial Irradiation,TREATS,Child
12040440,BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).,Therapeutic procedure,TREATS,Child
12040444,"We now report on AML1amplification in two cases of childhood ALL, found in a series of 107 consecutive children with B-lineage ALL analyzed by fluorescence in situ hybridization (FISH).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12663634,The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12663723,We explored whether dose adjustment of MP and MTX by erythrocyte (E) levels of TGN and MTX (including polyglutamates) could improve outcome in childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12663723,We explored whether dose adjustment of MP and MTX by erythrocyte (E) levels of TGN and MTX (including polyglutamates) could improve outcome in childhood acute lymphoblastic leukemia (ALL).,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12663723,Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12663723,"PATIENTS AND METHODS: A total of 538 children with ALL were randomly assigned to have their oral MP/MTX maintenance therapy adjusted by white cell counts (WBC), E-TGN, and E-MTX (pharmacology group), or by WBC only (control group).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12663723,"PATIENTS AND METHODS: A total of 538 children with ALL were randomly assigned to have their oral MP/MTX maintenance therapy adjusted by white cell counts (WBC), E-TGN, and E-MTX (pharmacology group), or by WBC only (control group).",Cell Count,METHOD_OF,Maintenance therapy
12663723,We explored whether dose adjustment of MP and MTX by erythrocyte (E) levels of TGN and MTX (including polyglutamates) could improve outcome in childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
10735899,CONCLUSION: Early treatment intensification did not compensate for a truncated phase of maintenance chemotherapy in children with standard- or high-risk ALL.,[V]Maintenance chemotherapy,PROCESS_OF,Child
10735899,CONCLUSION: Early treatment intensification did not compensate for a truncated phase of maintenance chemotherapy in children with standard- or high-risk ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10735899,"PATIENTS AND METHODS: Three hundred forty-seven children (ages 1 to 15 years) with previously untreated acute lymphoblastic leukemia (ALL) were enrolled onto the Tokyo L92-13 study, which excluded patients with mature B-cell ALL and patients less than 1 year old.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10735899,"PATIENTS AND METHODS: Three hundred forty-seven children (ages 1 to 15 years) with previously untreated acute lymphoblastic leukemia (ALL) were enrolled onto the Tokyo L92-13 study, which excluded patients with mature B-cell ALL and patients less than 1 year old.","Leukemia, B-Cell, Acute",PROCESS_OF,Patients
10735899,"PATIENTS AND METHODS: Three hundred forty-seven children (ages 1 to 15 years) with previously untreated acute lymphoblastic leukemia (ALL) were enrolled onto the Tokyo L92-13 study, which excluded patients with mature B-cell ALL and patients less than 1 year old.","Leukemia, B-Cell, Acute",PROCESS_OF,Patients
10735900,"PATIENTS AND METHODS: Sixty-seven children with very high-risk ALL were randomized (slow early response to therapy, 55 patients; translocation t(9;22) or t(4;11), 12 patients).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10735901,"PATIENTS AND METHODS: One hundred fifty-four children with acute lymphoblastic leukemia received Escherichia coli asparaginase 10,000 IU/m(2) intramuscularly three times weekly for nine doses during multiagent induction and reinduction phases and for seven monthly doses during continuation treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10815901,"Using an enzyme-based method, we assessed Ras activation in peripheral WBCs, lymphocytes, and bone marrow cells from normal subjects and from children with T-cell ALL (T-ALL) and B-lineage ALL (B-ALL).",Acute T Cell Leukemia,PROCESS_OF,Child
10815901,"Using an enzyme-based method, we assessed Ras activation in peripheral WBCs, lymphocytes, and bone marrow cells from normal subjects and from children with T-cell ALL (T-ALL) and B-lineage ALL (B-ALL).",Peripheral,LOCATION_OF,Leukocytes
10815901,"Using an enzyme-based method, we assessed Ras activation in peripheral WBCs, lymphocytes, and bone marrow cells from normal subjects and from children with T-cell ALL (T-ALL) and B-lineage ALL (B-ALL).",Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
10815901,"Using an enzyme-based method, we assessed Ras activation in peripheral WBCs, lymphocytes, and bone marrow cells from normal subjects and from children with T-cell ALL (T-ALL) and B-lineage ALL (B-ALL).",Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
10815901,"In 9 of 18 children with T-ALL, Ras activation exceeded two SDs above the mean of the corresponding cells from normal subjects, whereas in none of 11 patients with B-ALL did Ras show increased activation; activating genetic mutations in ras occur in less than 10% of ALL patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10815901,"In 9 of 18 children with T-ALL, Ras activation exceeded two SDs above the mean of the corresponding cells from normal subjects, whereas in none of 11 patients with B-ALL did Ras show increased activation; activating genetic mutations in ras occur in less than 10% of ALL patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
10815901,"In 9 of 18 children with T-ALL, Ras activation exceeded two SDs above the mean of the corresponding cells from normal subjects, whereas in none of 11 patients with B-ALL did Ras show increased activation; activating genetic mutations in ras occur in less than 10% of ALL patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
10886214,"This study demonstrates that leukaemic cells of children with relapsed precursor-B ALL are relatively MTX resistant, but that this MTX resistance is not associated with major impairments in MTX uptake or polyglutamylation.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
10886214,"This study demonstrates that leukaemic cells of children with relapsed precursor-B ALL are relatively MTX resistant, but that this MTX resistance is not associated with major impairments in MTX uptake or polyglutamylation.",Leukemic Cell,PART_OF,Child
10886216,Detection of prognostic significant translocations in childhood acute lymphoblastic leukaemia by one-step multiplex reverse transcription polymerase chain reaction.,Chromosomal translocation,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
10886216,"In this work, we describe a new method - one-step multiplex reverse transcription polymerase chain reaction (RT-PCR) - to screen for prognostic significant translocations in childhood ALL.",Chromosomal translocation,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
10886216,"In this work, we describe a new method - one-step multiplex reverse transcription polymerase chain reaction (RT-PCR) - to screen for prognostic significant translocations in childhood ALL.",Reverse Transcriptase Polymerase Chain Reaction,DIAGNOSES,Chromosomal translocation
10997886,"During the 12-yr period 1986-1997, a total of 2054 children (< 15 yr of age) were diagnosed with acute lymphoblastic leukemia (ALL) in the five Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden).",Finland,ISA,Scandinavia
10997886,"During the 12-yr period 1986-1997, a total of 2054 children (< 15 yr of age) were diagnosed with acute lymphoblastic leukemia (ALL) in the five Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden).",Denmark,ISA,Scandinavia
10997886,"During the 12-yr period 1986-1997, a total of 2054 children (< 15 yr of age) were diagnosed with acute lymphoblastic leukemia (ALL) in the five Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10997886,"During the 12-yr period 1986-1997, a total of 2054 children (< 15 yr of age) were diagnosed with acute lymphoblastic leukemia (ALL) in the five Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden).",Sweden,ISA,Scandinavia
10997886,"During the 12-yr period 1986-1997, a total of 2054 children (< 15 yr of age) were diagnosed with acute lymphoblastic leukemia (ALL) in the five Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden).",Norway,ISA,Scandinavia
10997886,"During the 12-yr period 1986-1997, a total of 2054 children (< 15 yr of age) were diagnosed with acute lymphoblastic leukemia (ALL) in the five Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden).",Iceland,ISA,Scandinavia
11271785,"BACKGROUND/AIMS: Many regimens used in the treatment of childhood acute lymphoblastic leukaemia (ALL) include Daunorubicin or Etoposide, which act as topoisomerase poisons.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11568017,"These findings, therefore, indicate that t(4;11)-positive infant ALL is initiated later in fetal development than most B-cell precursor ALL from children younger than 3 years and that they have a shorter latency period already in utero.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
11568017,These data are compared with the 122 previously published DJ(H) sequences and were found to have a pattern similar to that of ALL in children older than 3 years at diagnosis but were unlike that in children younger than 3 years who predominantly lack N regions.,Diagnosis,TREATS,Child
11568017,These data are compared with the 122 previously published DJ(H) sequences and were found to have a pattern similar to that of ALL in children older than 3 years at diagnosis but were unlike that in children younger than 3 years who predominantly lack N regions.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11568017,Presence of N regions in the clonotypic DJ rearrangements of the immunoglobulin heavy-chain genes indicates an exquisitely short latency in t(4;11)-positive infant acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
11568017,"These findings, therefore, indicate that t(4;11)-positive infant ALL is initiated later in fetal development than most B-cell precursor ALL from children younger than 3 years and that they have a shorter latency period already in utero.",Short menstrual periods,PROCESS_OF,Child
11697624,"Fifty two children presenting with ALL were studied at diagnosis and during the first 48 hours of treatment for the level of cell proliferation by measurement of DNA content, and for expression of several cell proliferation regulatory proteins by Western blot.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11697624,"Fifty two children presenting with ALL were studied at diagnosis and during the first 48 hours of treatment for the level of cell proliferation by measurement of DNA content, and for expression of several cell proliferation regulatory proteins by Western blot.",Western Blot,METHOD_OF,Therapeutic procedure
12361242,Clearance estimates were compared to the actual clearances from Monte Carlo-simulated data and predicted clearances estimated using all available plasma concentrations in clinical data from children with acute lymphoblastic leukemia.,Child,LOCATION_OF,BCR
12361242,Clearance estimates were compared to the actual clearances from Monte Carlo-simulated data and predicted clearances estimated using all available plasma concentrations in clinical data from children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12635465,Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Munster (BFM) Group.,Acute leukemia,PROCESS_OF,Child
12635465,"Patients with lymphoblastic lymphoma (mainly with T-cell phenotypes) had an excellent prognosis with an ALL-type chemotherapy regimen (n = 49; relapse, n = 1), whereas an intensive, short-pulse therapy delivered within a 2- to 4-month period was found to be highly efficacious in children with B-cell NHL/B-ALL (n = 114; relapse, n = 6; progression, n = 5).",Therapeutic procedure,TREATS,Child
12635465,Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Munster (BFM) Group.,"Leukemia, B-Cell, Acute",ISA,"Lymphoma, Non-Hodgkin's"
12635465,Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Munster (BFM) Group.,Acute leukemia,PROCESS_OF,Adolescent
12635465,"Patients with lymphoblastic lymphoma (mainly with T-cell phenotypes) had an excellent prognosis with an ALL-type chemotherapy regimen (n = 49; relapse, n = 1), whereas an intensive, short-pulse therapy delivered within a 2- to 4-month period was found to be highly efficacious in children with B-cell NHL/B-ALL (n = 114; relapse, n = 6; progression, n = 5).",Therapeutic procedure,TREATS,"Leukemia, B-Cell, Acute"
12635465,"Patients with lymphoblastic lymphoma (mainly with T-cell phenotypes) had an excellent prognosis with an ALL-type chemotherapy regimen (n = 49; relapse, n = 1), whereas an intensive, short-pulse therapy delivered within a 2- to 4-month period was found to be highly efficacious in children with B-cell NHL/B-ALL (n = 114; relapse, n = 6; progression, n = 5).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
12635465,Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Munster (BFM) Group.,"Leukemia, B-Cell, Acute",PROCESS_OF,Adolescent
12635465,Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Munster (BFM) Group.,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Adolescent
12635465,"In the succeeding studies NHL-BFM 90 and 95, treatment stratification was additionally based on the speed of tumor response to therapy and for children with B-cell NHL/B-ALL also on the pre-therapeutic serum lactic dehydrogenase level.",Therapeutic procedure,TREATS,Child
12635465,Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Munster (BFM) Group.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12635465,Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Munster (BFM) Group.,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
12635465,"In the succeeding studies NHL-BFM 90 and 95, treatment stratification was additionally based on the speed of tumor response to therapy and for children with B-cell NHL/B-ALL also on the pre-therapeutic serum lactic dehydrogenase level.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
12635465,Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Munster (BFM) Group.,Mature B-Lymphocyte,LOCATION_OF,Acute leukemia
12635465,"In the succeeding studies NHL-BFM 90 and 95, treatment stratification was additionally based on the speed of tumor response to therapy and for children with B-cell NHL/B-ALL also on the pre-therapeutic serum lactic dehydrogenase level.",Therapeutic procedure,TREATS,"Leukemia, B-Cell, Acute"
12635465,Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Munster (BFM) Group.,Mature B-Lymphocyte,LOCATION_OF,"Leukemia, B-Cell, Acute"
12635465,"In the succeeding studies NHL-BFM 90 and 95, treatment stratification was additionally based on the speed of tumor response to therapy and for children with B-cell NHL/B-ALL also on the pre-therapeutic serum lactic dehydrogenase level.",Serum Chemistry Test for Lactate Dehydrogenase,USES,The science and art of healing
12635465,"Patients with lymphoblastic lymphoma (mainly with T-cell phenotypes) had an excellent prognosis with an ALL-type chemotherapy regimen (n = 49; relapse, n = 1), whereas an intensive, short-pulse therapy delivered within a 2- to 4-month period was found to be highly efficacious in children with B-cell NHL/B-ALL (n = 114; relapse, n = 6; progression, n = 5).",Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
12635465,Between 1986 and 2000 183 Austrian children and adolescents with non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-ALL) were enrolled in 3 consecutive studies of the Berlin-Frankfurt-Munster (BFM) Group.,"Leukemia, B-Cell, Acute",ISA,Acute leukemia
11105617,The regimen was ineffective in B-cell ALL as in acute blastic crisis of CMML and CML.,Treatment Protocols,TREATS,"Leukemia, B-Cell, Acute"
11105631,Acute lymphoblastic leukemia in a child with Wilson disease.,Hepatolenticular Degeneration,PROCESS_OF,Child
11105631,Acute lymphoblastic leukemia in a child with Wilson disease.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11105631,We report an unusual case of a child with Wilson disease who developed acute lymphoblastic leukemia in three months.,Hepatolenticular Degeneration,PROCESS_OF,Child
11105631,We report an unusual case of a child with Wilson disease who developed acute lymphoblastic leukemia in three months.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11167742,"Our study shows that (i) RT-PCR is the most effective approach for the detection of t(12;21) in childhood ALL, (ii) the association of ETV6/AML1 and chromosome 12 and/or 21, seen in 56% of our cases, further confirms existing data, (iii) overall survival of patients with t(12;21) was not better than other cytogenetics groups, and (d) MRD analysis using ETV6/AML1 fusion is specific, but not sensitive enough to avoid false negative results.",Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11167742,"Our study shows that (i) RT-PCR is the most effective approach for the detection of t(12;21) in childhood ALL, (ii) the association of ETV6/AML1 and chromosome 12 and/or 21, seen in 56% of our cases, further confirms existing data, (iii) overall survival of patients with t(12;21) was not better than other cytogenetics groups, and (d) MRD analysis using ETV6/AML1 fusion is specific, but not sensitive enough to avoid false negative results.",Reverse Transcriptase Polymerase Chain Reaction,METHOD_OF,Detection
11167742,"ETV6/AML1 fusion was found in nine out of 16 (56%) cases with a cytogenetically visible chromosome 12 abnormality, but also in nine out of 29 patients (31%) without a chromosome 12 abnormality or patients with failed cytogenetics (four out of 11 patients, 36%), making this the most common cytogenetic abnormality in childhood ALL.",Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11167743,The t(12;21)(p13;q22) translocation has been identified as the most common chromosomal abnormality in childhood acute lymphoblastic leukaemia (ALL).,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11241791,"In conclusion, the present study confirms the efficiency of the SKY technique in resolving and characterizing many complex chromosome anomalies seen in childhood B-ALLs, but it raises questions about the ability of this technique to detect cryptic rearrangements, such as the t(12;21) translocation.",Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11494125,"Since lethally irradiated mice reconstituted with SYK-deficient fetal liver-derived lymphohematopoietic progenitor cells show a block in B-cell ontogeny at the pro-B to pre-B cell transition, we examined the SYK expression profiles of primary leukemic cells from children with pro-B cell ALL.",Stem cells,PART_OF,Mus
11494125,"Since lethally irradiated mice reconstituted with SYK-deficient fetal liver-derived lymphohematopoietic progenitor cells show a block in B-cell ontogeny at the pro-B to pre-B cell transition, we examined the SYK expression profiles of primary leukemic cells from children with pro-B cell ALL.",SYK gene | SYK,PART_OF,Leukemic Cell
11494125,"Since lethally irradiated mice reconstituted with SYK-deficient fetal liver-derived lymphohematopoietic progenitor cells show a block in B-cell ontogeny at the pro-B to pre-B cell transition, we examined the SYK expression profiles of primary leukemic cells from children with pro-B cell ALL.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
11527885,BACKGROUND: We assessed adult hypothalamic-pituitary-ovarian function following treatment with chemotherapy and cranial irradiation for childhood acute lymphoblastic leukaemia.,Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11527885,BACKGROUND: We assessed adult hypothalamic-pituitary-ovarian function following treatment with chemotherapy and cranial irradiation for childhood acute lymphoblastic leukaemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11528550,"RESULTS: Children presenting with ALL and < 1000 blasts/microliter at diagnosis showed a small but significantly better outcome than prednisone good-responders with initially >/= 1000 blasts/microliter (5 year pEFS 0.86 vs. 0.81, P value 0.0064).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Methotrexate,ISA,Folic Acid Antagonists
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Methotrexate,TREATS,Disease
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Folic Acid Antagonists,ISA,Therapeutic procedure
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Folic Acid Antagonists,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Folic Acid Antagonists,TREATS,Disease
12415113,The t(1;19) translocation yields a fusion between E2A and PBX1 genes and occurs in 5% of acute lymphoblastic leukemia in children and adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12415113,The t(1;19) translocation yields a fusion between E2A and PBX1 genes and occurs in 5% of acute lymphoblastic leukemia in children and adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
12429986,"Vincristine (VCR), a microtubule interfering anti-cancer agent, plays a key role in the treatment of childhood acute lymphoblastic leukaemia (ALL).",Antineoplastic Agents,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12463833,Twenty-five parents of children with ALL and thirty-four clinicians were interviewed to identify functional requirements and to demonstrate the system's potential to improve the experience and outcomes of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12463833,Twenty-five parents of children with ALL and thirty-four clinicians were interviewed to identify functional requirements and to demonstrate the system's potential to improve the experience and outcomes of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12463833,Results from these interviews provide strong evidence that parents of children with ALL are struggling to manage the complexity of their children's care in the home.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12463833,Twenty-five parents of children with ALL and thirty-four clinicians were interviewed to identify functional requirements and to demonstrate the system's potential to improve the experience and outcomes of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Clinicians
12529671,Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.,"Neoplasm, Residual",PROCESS_OF,Child
12529671,Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.,Bone Marrow,LOCATION_OF,"Neoplasm, Residual"
12529671,Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12635465,Children with B-cell NHL and B-ALL who failed initial therapy also had a dismal prognosis (10/11 patients died).,B-Cell Lymphomas,PROCESS_OF,Child
12635465,Children with B-cell NHL and B-ALL who failed initial therapy also had a dismal prognosis (10/11 patients died).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
10696127,RESULTS: Nine children with acute lymphoblastic leukemia (ALL) of 50 (18%) patients who received pegaspargase were diagnosed to have pancreatitis.,Pancreatitis,PROCESS_OF,Patients
10696127,RESULTS: Nine children with acute lymphoblastic leukemia (ALL) of 50 (18%) patients who received pegaspargase were diagnosed to have pancreatitis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10696127,RESULTS: Nine children with acute lymphoblastic leukemia (ALL) of 50 (18%) patients who received pegaspargase were diagnosed to have pancreatitis.,pegaspargase,ADMINISTERED_TO,Patients
10961868,"Children with B-precursor ALL, in first marrow and/or extramedullary relapse were eligible.",Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
10961868,"Children with B-precursor ALL, in first marrow and/or extramedullary relapse were eligible.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11071631,These data indicate that contamination of CSF with circulating leukemic blast cells during diagnostic lumbar puncture can adversely affect the treatment outcome of children with ALL and is an indication to intensify intrathecal therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11147224,Studies of minimal residual disease in acute lymphocytic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
11281383,"The third cohort (n = 13) received CsA and six alternating cycles of alphaIFN and chemotherapy and six additional cycles of chemotherapy (vincristine, VP-16, Ara-C, prednisone) followed by G-CSF (post-transplant immune chemotherapy (PTIC)).",Vincristine,ISA,Pharmacotherapy
11571530,Prospective study on allogeneic bone marrow transplantation (allo BMT) versus chemotherapy (chemo) for very high-risk (VHR) childhood acute lymphoblastic leukaemia in first complete remission.,Allogeneic bone marrow transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11571530,Prospective study on allogeneic bone marrow transplantation (allo BMT) versus chemotherapy (chemo) for very high-risk (VHR) childhood acute lymphoblastic leukaemia in first complete remission.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11571530,Prospective study on allogeneic bone marrow transplantation (allo BMT) versus chemotherapy (chemo) for very high-risk (VHR) childhood acute lymphoblastic leukaemia in first complete remission.,Allogeneic bone marrow transplantation,compared_with,Pharmacotherapy
11876953,RESULTS: The CR rate in the ALL children is 94.1% which is significantly higher than that of adult ALL patients (67.8%).,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
11876953,RESULTS: The CR rate in the ALL children is 94.1% which is significantly higher than that of adult ALL patients (67.8%).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11877265,"Hence, we conducted a prospective, population-based MRD study in 108 sequentially recruited children with ALL uniformly treated with the ALL-Berlin-Frankfurt-Munster (ALL-BFM) 95 protocol in Austria (median follow-up of 40 months).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11877265,Detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) predicts outcome.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
11877265,Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.,Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11964308,Glucocorticoids are integral to successful treatment of childhood acute lymphoblastic leukemia (ALL) and other lymphoid malignancies.,Glucocorticoids,TREATS,Malignant lymphoid neoplasm
11964308,Glucocorticoids are integral to successful treatment of childhood acute lymphoblastic leukemia (ALL) and other lymphoid malignancies.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11964308,Glucocorticoids are integral to successful treatment of childhood acute lymphoblastic leukemia (ALL) and other lymphoid malignancies.,Glucocorticoids,ISA,Therapeutic procedure
12007502,Minimal residual disease by metaphase FISH in children with ALL: clonal cells during or after chemotherapy may not predict relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12007502,Minimal residual disease by metaphase FISH in children with ALL: clonal cells during or after chemotherapy may not predict relapse.,"Neoplasm, Residual",PROCESS_OF,Child
12007502,We studied MRD by metaphase-fluorescent in situ hybridization (FISH) in 41 children with ALL.,"Neoplasm, Residual",PROCESS_OF,Child
12007502,We studied MRD by metaphase-fluorescent in situ hybridization (FISH) in 41 children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Folic Acid Antagonists,TREATS,Disease
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Methotrexate,ISA,Folic Acid Antagonists
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Methotrexate,TREATS,Disease
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Folic Acid Antagonists,ISA,Therapeutic procedure
12114448,Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases.,Folic Acid Antagonists,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12365028,"Stratified analyses showed that maternal use of antihistamines or allergic remedies and parental use of mind-altering drugs were strongly associated with infant ALL, whereas patterns of association between childhood ALL and parental medication use did not influence markedly the immunophenotypic subgroup of ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
12512839,"At diagnosis, the leptin levels of bone marrow-derived plasma in children with ALL were found to be significantly lower than the levels of healthy control subjects (0.92 +/- 0.79 ng/mL versus 3.01 +/- 2.27 ng/mL, respectively).",Plasma,LOCATION_OF,Leptin | LEP
12512839,"At diagnosis, the leptin levels of bone marrow-derived plasma in children with ALL were found to be significantly lower than the levels of healthy control subjects (0.92 +/- 0.79 ng/mL versus 3.01 +/- 2.27 ng/mL, respectively).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12512839,"At diagnosis, the leptin levels of bone marrow-derived plasma in children with ALL were found to be significantly lower than the levels of healthy control subjects (0.92 +/- 0.79 ng/mL versus 3.01 +/- 2.27 ng/mL, respectively).",Leptin | LEP,TREATS,Child
12512839,"At diagnosis, the leptin levels of bone marrow-derived plasma in children with ALL were found to be significantly lower than the levels of healthy control subjects (0.92 +/- 0.79 ng/mL versus 3.01 +/- 2.27 ng/mL, respectively).",Leptin | LEP,TREATS,"Leukemia, Lymphocytic, Acute"
12586809,PURPOSE: A high level of minimal residual disease (MRD) after induction chemotherapy in children with acute lymphoblastic leukemia (ALL) is an indicator of relative chemotherapy resistance and a risk factor for relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12586809,PURPOSE: A high level of minimal residual disease (MRD) after induction chemotherapy in children with acute lymphoblastic leukemia (ALL) is an indicator of relative chemotherapy resistance and a risk factor for relapse.,"Neoplasm, Residual",PROCESS_OF,Child
12586809,PURPOSE: A high level of minimal residual disease (MRD) after induction chemotherapy in children with acute lymphoblastic leukemia (ALL) is an indicator of relative chemotherapy resistance and a risk factor for relapse.,Chemotherapy-Oncologic Procedure,ISA,Pharmacotherapy
12586809,Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,Child
12586809,Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12586809,Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
16118711,JAKs are abundantly expressed in primary leukemic cells from children with acute lymphoblastic leukemia (ALL) and are involved in signals regulating apoptosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10648387,Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11037860,Extramedullary relapses in children with acute lymphoblastic leukemia occur most frequently in the central nervous system and in the testis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11038037,BACKGROUND: Although reinduction rates are good for children with relapsed acute lymphoblastic leukaemia there is no consensus on whether bone marrow transplantation (BMT) is the most effective treatment to prolong second remission.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11038037,BACKGROUND: Although reinduction rates are good for children with relapsed acute lymphoblastic leukaemia there is no consensus on whether bone marrow transplantation (BMT) is the most effective treatment to prolong second remission.,Bone Marrow Transplantation,ISA,Therapeutic procedure
11070477,"PROCEDURE: Thirty-three children with ALL underwent serial cranial MRI before, during, and after therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11070477,"PROCEDURE: Thirty-three children with ALL underwent serial cranial MRI before, during, and after therapy.",Magnetic Resonance Imaging,ADMINISTERED_TO,Child
11070477,White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: correlation with neuropsychological findings.,Therapeutic procedure,TREATS,Child
11070477,White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: correlation with neuropsychological findings.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11070477,White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: correlation with neuropsychological findings.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
11148917,"Patients with T-ALL were more frequently resistant to steroids in vivo and reached remission later in comparison to precursor-B-ALL children (p = 0.019), however blasts reduction ratio was comparable in both lineages.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
11148917,"Patients with T-ALL were more frequently resistant to steroids in vivo and reached remission later in comparison to precursor-B-ALL children (p = 0.019), however blasts reduction ratio was comparable in both lineages.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
11241057,Fasting hypoglycemia is common during maintenance therapy for childhood acute lymphoblastic leukemia.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11241435,PROCEDURE: Thirty-two children with ALL were studied at the end of treatment by means of motor evoked potentials (MEPs) elicited by magnetic stimulation (MS) transcranially and peripherally and underwent a detailed neurological examination.,Stimulation procedure,METHOD_OF,Therapeutic procedure
11241435,PROCEDURE: Thirty-two children with ALL were studied at the end of treatment by means of motor evoked potentials (MEPs) elicited by magnetic stimulation (MS) transcranially and peripherally and underwent a detailed neurological examination.,Neurologic Examination,ADMINISTERED_TO,Child
11241435,PROCEDURE: Thirty-two children with ALL were studied at the end of treatment by means of motor evoked potentials (MEPs) elicited by magnetic stimulation (MS) transcranially and peripherally and underwent a detailed neurological examination.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11253952,"The detection of MRD most consistently has been associated with subsequent relapse in childhood acute lymphoblastic leukemia (ALL), t(15;17) acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) following marrow transplantation.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11496455,"The findings from this research clearly indicate the emotional pain that fathers face in their struggle to accept the diagnosis of a serious, life-threatening illness such as ALL in their child.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11699225,"The aim of this study is to evaluate, for the first time serum levels of vascular endothelial growth factor (s-VEGF), and basic fibroblast growth factor (s-b FGF) in children with acute lymphoblastic leukemia (ALL), and its relation to clinical manifestations of the disease.",Child,LOCATION_OF,"VEGF protein, human | VEGFA"
11699225,"The aim of this study is to evaluate, for the first time serum levels of vascular endothelial growth factor (s-VEGF), and basic fibroblast growth factor (s-b FGF) in children with acute lymphoblastic leukemia (ALL), and its relation to clinical manifestations of the disease.",Child,LOCATION_OF,Fibroblast Growth Factor 2
11699225,"The aim of this study is to evaluate, for the first time serum levels of vascular endothelial growth factor (s-VEGF), and basic fibroblast growth factor (s-b FGF) in children with acute lymphoblastic leukemia (ALL), and its relation to clinical manifestations of the disease.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11699225,"The aim of this study is to evaluate, for the first time serum levels of vascular endothelial growth factor (s-VEGF), and basic fibroblast growth factor (s-b FGF) in children with acute lymphoblastic leukemia (ALL), and its relation to clinical manifestations of the disease.",Fibroblast Growth Factor 2,ISA,Fibroblast Growth Factor
11699225,Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia.,Child,LOCATION_OF,Fibroblast Growth Factor 2
11699225,Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11699412,Lack of association between N-ras gene mutations and clinical prognosis in Brazilian children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11699412,Lack of association between N-ras gene mutations and clinical prognosis in Brazilian children with acute lymphoblastic leukemia.,BRAZILIAN,PROCESS_OF,Child
11699412,Our results suggest that mutations in the ras gene are infrequent in children with ALL at diagnosis and seem to be of low prognostic value.,Mutation,PROCESS_OF,Child
11699412,Our results suggest that mutations in the ras gene are infrequent in children with ALL at diagnosis and seem to be of low prognostic value.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11699412,Lack of association between N-ras gene mutations and clinical prognosis in Brazilian children with acute lymphoblastic leukemia.,NRAS Gene Mutation,PROCESS_OF,Child
11876954,There was no significant difference in CR rate between DA and HA regimens for treatment of ALL patients.,Treatment Protocols,TREATS,Patients
11876954,There was no significant difference in CR rate between DA and HA regimens for treatment of ALL patients.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
11876954,There was no significant difference in CR rate between DA and HA regimens for treatment of ALL patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
11878574,"TP53 is the most commonly mutated gene in human cancer, but TP53 mutations are present in less than 5% of children with acute lymphoblastic leukemia (ALL) at initial presentation.",Malignant Neoplasms,PROCESS_OF,Human
11878574,The authors determined the nucleotide sequence of amplified DNA from exons 5 to 8 of the TP53 gene in leukemic cells obtained from 17 children with ALL at the time of first bone marrow relapse.,Leukemic Cell,LOCATION_OF,TP53 gene | TP53
11878574,The authors determined the nucleotide sequence of amplified DNA from exons 5 to 8 of the TP53 gene in leukemic cells obtained from 17 children with ALL at the time of first bone marrow relapse.,Child,LOCATION_OF,TP53 gene | TP53
11878574,The authors determined the nucleotide sequence of amplified DNA from exons 5 to 8 of the TP53 gene in leukemic cells obtained from 17 children with ALL at the time of first bone marrow relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11878574,"TP53 is the most commonly mutated gene in human cancer, but TP53 mutations are present in less than 5% of children with acute lymphoblastic leukemia (ALL) at initial presentation.",TP53 gene | TP53,ASSOCIATED_WITH,Malignant Neoplasms
11878574,"TP53 is the most commonly mutated gene in human cancer, but TP53 mutations are present in less than 5% of children with acute lymphoblastic leukemia (ALL) at initial presentation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12116076,BACKGROUND: Antimetabolite-based continuation therapy is commonly used for childhood acute lymphoblastic leukemia (ALL) and hypoglycemia after prolonged fasting has been recently reported.,Antimetabolites,TREATS,hypoglycemia
12116076,BACKGROUND: Antimetabolite-based continuation therapy is commonly used for childhood acute lymphoblastic leukemia (ALL) and hypoglycemia after prolonged fasting has been recently reported.,Antimetabolites,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12399964,We used the cDNA array method to study the gene expression profiles of 17 children with precursor-B ALL.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12513729,The cure rate for children with acute lymphoblastic leukemia in big treatment centers in Western countries is now about 80%.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10711237,"For acute lymphoblastic leukaemia (ALL) in children, twin studies suggest that a secondary postnatal molecular event is also required.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10784391,Clinical significance of deletions of chromosome arm 6q in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group.,DELETION,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
10784391,We have compared outcome for 167 (9.0%) children with a del(6q) and 1713 (91%) children without a del(6q) treated on Children's Cancer Group (CCG) risk-adjusted treatment protocols for acute lymphoblastic leukemia (ALL).,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
11172898,We used comparative genomic hybridization (CGH) to study DNA copy number changes in 71 children with acute lymphoblastic leukemia (ALL) including 50 B-lineage and 21 T-ALLs.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11320662,"PURPOSE: In preclinical studies, thioguanine (TG) has been shown to be more potent than the standard acute lymphoblastic leukemia (ALL) maintenance agent, mercaptopurine (MP), suggesting that TG may be more efficacious than MP in the treatment of childhood ALL.",Thioguanine,compared_with,Agent
11320662,"PURPOSE: In preclinical studies, thioguanine (TG) has been shown to be more potent than the standard acute lymphoblastic leukemia (ALL) maintenance agent, mercaptopurine (MP), suggesting that TG may be more efficacious than MP in the treatment of childhood ALL.",Thioguanine,higher_than,Agent
11320662,"PURPOSE: In preclinical studies, thioguanine (TG) has been shown to be more potent than the standard acute lymphoblastic leukemia (ALL) maintenance agent, mercaptopurine (MP), suggesting that TG may be more efficacious than MP in the treatment of childhood ALL.",Thioguanine,ISA,Therapeutic procedure
11320662,"PURPOSE: In preclinical studies, thioguanine (TG) has been shown to be more potent than the standard acute lymphoblastic leukemia (ALL) maintenance agent, mercaptopurine (MP), suggesting that TG may be more efficacious than MP in the treatment of childhood ALL.",6-Mercaptopurine,ISA,Therapeutic procedure
11320662,"PURPOSE: In preclinical studies, thioguanine (TG) has been shown to be more potent than the standard acute lymphoblastic leukemia (ALL) maintenance agent, mercaptopurine (MP), suggesting that TG may be more efficacious than MP in the treatment of childhood ALL.",Thioguanine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11320662,"Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11320662,"PURPOSE: In preclinical studies, thioguanine (TG) has been shown to be more potent than the standard acute lymphoblastic leukemia (ALL) maintenance agent, mercaptopurine (MP), suggesting that TG may be more efficacious than MP in the treatment of childhood ALL.",6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11320662,"Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.",Thioguanine,TREATS,Child
11320662,"PURPOSE: In preclinical studies, thioguanine (TG) has been shown to be more potent than the standard acute lymphoblastic leukemia (ALL) maintenance agent, mercaptopurine (MP), suggesting that TG may be more efficacious than MP in the treatment of childhood ALL.",Thioguanine,higher_than,6-Mercaptopurine
11320662,"Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.",Children's Cancer Group,LOCATION_OF,Clinical Research
11320662,"PURPOSE: In preclinical studies, thioguanine (TG) has been shown to be more potent than the standard acute lymphoblastic leukemia (ALL) maintenance agent, mercaptopurine (MP), suggesting that TG may be more efficacious than MP in the treatment of childhood ALL.",Thioguanine,compared_with,6-Mercaptopurine
11320662,"Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study.",Thioguanine,TREATS,"Leukemia, Lymphocytic, Acute"
11836446,"METHODS: Reverse transcription polymerase chain reaction of Ficoll separated mononuclear cells from 142 children with ALL, 127 cord blood samples, and 55 blood samples of age matched controls were studied.",Child,LOCATION_OF,Ficoll
11836446,"METHODS: Reverse transcription polymerase chain reaction of Ficoll separated mononuclear cells from 142 children with ALL, 127 cord blood samples, and 55 blood samples of age matched controls were studied.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11836446,AIM: To characterise the expression pattern of genes of the IGF system in malignant lymphoblasts of children suffering from ALL.,lymphoblast,PART_OF,Child
11836446,AIM: To characterise the expression pattern of genes of the IGF system in malignant lymphoblasts of children suffering from ALL.,Genes,PART_OF,lymphoblast
11836446,AIM: To characterise the expression pattern of genes of the IGF system in malignant lymphoblasts of children suffering from ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11972512,"One hundred and twenty-six infants with acute lymphoblastic leukaemia (ALL) were treated on two consecutive protocols, Infant 87 (n = 40) and Infant 92 (n = 86), in an attempt to improve the poor prognosis of this disease.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
11972512,"One hundred and twenty-six infants with acute lymphoblastic leukaemia (ALL) were treated on two consecutive protocols, Infant 87 (n = 40) and Infant 92 (n = 86), in an attempt to improve the poor prognosis of this disease.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
11972513,"In this study on 27 t(4;11) infant ALL, we have used standardized primer sets for the detection of all incomplete and complete immunoglobulin (Ig) heavy chain (IGH) rearrangements, as well as for the Ig light chain kappa (IGK), T-cell receptor delta (TCRD) and gamma (TCRG) rearrangements that are most common in childhood BCP ALL.",T-Cell Receptors delta-Chain,ASSOCIATED_WITH,B-cell childhood acute lymphoblastic leukemia
11972513,"In this study on 27 t(4;11) infant ALL, we have used standardized primer sets for the detection of all incomplete and complete immunoglobulin (Ig) heavy chain (IGH) rearrangements, as well as for the Ig light chain kappa (IGK), T-cell receptor delta (TCRD) and gamma (TCRG) rearrangements that are most common in childhood BCP ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
11972513,Infant t(4;11) acute lymphoblastic leukaemia (ALL) is a rare but cytogenetically well defined subgroup of immature B-cell precursor (BCP) ALL.,"Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
11972513,Low frequency of clonotypic Ig and T-cell receptor gene rearrangements in t(4;11) infant acute lymphoblastic leukaemia and its implication for the detection of minimal residual disease.,T cell receptor gene rearrangement,DIAGNOSES,"Neoplasm, Residual"
11972513,Low frequency of clonotypic Ig and T-cell receptor gene rearrangements in t(4;11) infant acute lymphoblastic leukaemia and its implication for the detection of minimal residual disease.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
12197050,"The 10-year survival probabilities of children with acute lymphoblastic leukaemia and non-Hodgkin lymphomas were higher than those of patients aged 15-24 years: 66.7% (SE = 9.1) vs 14.3% (SE = 13.2) and 77.8% (SE = 13.9) vs 40.0% (SE = 21.9), respectively.","Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
12197050,"The 10-year survival probabilities of children with acute lymphoblastic leukaemia and non-Hodgkin lymphomas were higher than those of patients aged 15-24 years: 66.7% (SE = 9.1) vs 14.3% (SE = 13.2) and 77.8% (SE = 13.9) vs 40.0% (SE = 21.9), respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12708161,The impact of undernutrition in the outcome of treatment of children with ALL has been analyzed by several authors who have highlighted undernutrition as another relevant prognostic factor in children with acute lymphoblastic leukemia (ALL).,Therapeutic procedure,AFFECTS,Malnutrition
12708161,The impact of undernutrition in the outcome of treatment of children with ALL has been analyzed by several authors who have highlighted undernutrition as another relevant prognostic factor in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12708161,The impact of undernutrition in the outcome of treatment of children with ALL has been analyzed by several authors who have highlighted undernutrition as another relevant prognostic factor in children with acute lymphoblastic leukemia (ALL).,Malnutrition,PROCESS_OF,Child
12708161,"We here critically analyze the information of these publications referring to a total of 2,394 children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12708161,The impact of undernutrition in the outcome of treatment of children with ALL has been analyzed by several authors who have highlighted undernutrition as another relevant prognostic factor in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12708161,"Overall, data from 1,123 children with ALL worldwide support the concept of malnutrition at diagnosis being useful as a prognostic factor, whereas data from 1,271 children fail to support this concept.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12708161,A critical review of the prognostic value of the nutritional status at diagnosis in the outcome of therapy of children with acute lymphoblastic leukemia.,Diagnosis,TREATS,Child
12708161,"There are, however, some papers which have not confirmed the prognostic value of malnutrition at diagnosis in children with ALL.",Malnutrition,PROCESS_OF,Child
12708161,A critical review of the prognostic value of the nutritional status at diagnosis in the outcome of therapy of children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12708161,"There are, however, some papers which have not confirmed the prognostic value of malnutrition at diagnosis in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10896235,Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10896235,Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
11001892,"In conclusion, for the majority of children with VH-risk ALL, the first-remission transplantation has not improved EFS.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11001892,The role of bone marrow transplantation (BMT) in first remission of children with high-risk acute lymphoblastic leukemia (ALL) remains unclear.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11001892,Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11001892,Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI.,Bone Marrow Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11001892,Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI.,Bone Marrow Transplantation,compared_with,Pharmacotherapy
11187907,Methotrexate (MTX) is an important component in the treatment of childhood leukemia.,Methotrexate,TREATS,Childhood Leukemia
11187907,Methotrexate (MTX) is an important component in the treatment of childhood leukemia.,Methotrexate,ISA,Therapeutic procedure
11187912,"Four thousand, four hundred and forty eligible children of up to 18 years of age were treated in four consecutive trials between 1981 and 1995 with the treatment protocols of the Berlin-Frankfurt-Munster (BFM) study group for childhood acute lymphoblastic leukemia (ALL).",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11187913,"Since 1968, the Children's Cancer Group (CCG) has treated more than 16,000 children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11187915,"Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991.",follow-up,TREATS,Child
11187915,"Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11187919,"The overall event-free survival (EFS) at 5 and 10 years were 70.9% and 67.3% for children with B-precursor ALL, 51.0% and 50.2% for patients with T cell ALL, and 22.4% and 20.9% for infants with ALL.",Acute T Cell Leukemia,PROCESS_OF,Patients
11187919,"The overall event-free survival (EFS) at 5 and 10 years were 70.9% and 67.3% for children with B-precursor ALL, 51.0% and 50.2% for patients with T cell ALL, and 22.4% and 20.9% for infants with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11187919,"The overall event-free survival (EFS) at 5 and 10 years were 70.9% and 67.3% for children with B-precursor ALL, 51.0% and 50.2% for patients with T cell ALL, and 22.4% and 20.9% for infants with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
11187919,This paper presents the long-term results of treatment for children with acute lymphoblastic leukemia (ALL) as conducted by the Pediatric Oncology Group (POG) from 1986 to 1994.,Therapeutic procedure,TREATS,Child
11187919,This paper presents the long-term results of treatment for children with acute lymphoblastic leukemia (ALL) as conducted by the Pediatric Oncology Group (POG) from 1986 to 1994.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11187919,This paper presents the long-term results of treatment for children with acute lymphoblastic leukemia (ALL) as conducted by the Pediatric Oncology Group (POG) from 1986 to 1994.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
11187921,"The objectives were as follows: Firstly, to estimate the overall probability of event-free survival (EFS) and isolated CNS relapse in the studies for children with acute lymphoblastic leukemia (ALL) during the 1980s and 1990s.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11838420,DISCUSSION: TMP/SMX prophylaxis during induction therapy for childhood ALL seems to reduce the risk of bacteraemias and febrile illness.,Prophylactic treatment,PREVENTS,Disorder characterized by fever
11838420,"INTRODUCTION: Children with acute lymphoblastic leukaemia (ALL) are treated with intensive chemotherapy, which results in profound immunosuppression.",Pharmacotherapy,TREATS,Child
11838420,DISCUSSION: TMP/SMX prophylaxis during induction therapy for childhood ALL seems to reduce the risk of bacteraemias and febrile illness.,Prophylactic treatment,PREVENTS,Bacteremia
11838420,"INTRODUCTION: Children with acute lymphoblastic leukaemia (ALL) are treated with intensive chemotherapy, which results in profound immunosuppression.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
11838420,"MATERIAL AND METHODS: Between 1 January 1992 and 31 December 1997, 210 children were diagnosed with ALL in Denmark.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11838420,[Trimethoprim-sulfamethoxazole as antibacterial prophylaxis during induction therapy of children with acute lymphatic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11838420,This gave us the opportunity to describe the effect of TMP/SMX on bacterial infections in children with ALL during the induction therapy.,Trimethoprim-Sulfamethoxazole Combination,AFFECTS,Bacterial Infections
11838420,This gave us the opportunity to describe the effect of TMP/SMX on bacterial infections in children with ALL during the induction therapy.,Bacterial Infections,PROCESS_OF,Child
11838420,DISCUSSION: TMP/SMX prophylaxis during induction therapy for childhood ALL seems to reduce the risk of bacteraemias and febrile illness.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11838420,This gave us the opportunity to describe the effect of TMP/SMX on bacterial infections in children with ALL during the induction therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11838420,DISCUSSION: TMP/SMX prophylaxis during induction therapy for childhood ALL seems to reduce the risk of bacteraemias and febrile illness.,Prophylactic treatment,USES,Trimethoprim-Sulfamethoxazole Combination
11838420,"INTRODUCTION: Children with acute lymphoblastic leukaemia (ALL) are treated with intensive chemotherapy, which results in profound immunosuppression.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10930992,The prognostic impact of acquired chromosome abnormalities was evaluated in a population-based consecutive series of 768 children (< 15 years of age) with acute lymphoblastic leukaemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10930993,"To determine the clinical significance of apoptosis-regulating factors in acute lymphoblastic leukaemia (ALL), we investigated cell samples of children with ALL who had been included in the German ALL Berlin-Frankfurt-Munster (BFM) study using flow cytometry for constitutive expression levels of CD95 (n = 110) and Bcl-2 (n = 110).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10930993,"To determine the clinical significance of apoptosis-regulating factors in acute lymphoblastic leukaemia (ALL), we investigated cell samples of children with ALL who had been included in the German ALL Berlin-Frankfurt-Munster (BFM) study using flow cytometry for constitutive expression levels of CD95 (n = 110) and Bcl-2 (n = 110).",Cells,PART_OF,Child
10930993,"To determine the clinical significance of apoptosis-regulating factors in acute lymphoblastic leukaemia (ALL), we investigated cell samples of children with ALL who had been included in the German ALL Berlin-Frankfurt-Munster (BFM) study using flow cytometry for constitutive expression levels of CD95 (n = 110) and Bcl-2 (n = 110).",Apoptosis,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
10965000,Acute lymphoblastic leukemia (ALL) is the most common cancer in children and is among the most curable of the pediatric malignancies.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10965000,Acute lymphoblastic leukemia (ALL) is the most common cancer in children and is among the most curable of the pediatric malignancies.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
11001863,We report a patient with infant acute lymphoblastic leukemia and nonrecurrent rearrangements of chromosomes 10 and 11.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
11001863,We report a patient with infant acute lymphoblastic leukemia and nonrecurrent rearrangements of chromosomes 10 and 11.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
11001863,Cytogenetic study of a patient with infant acute lymphoblastic leukemia using GTG-banding and chromosome painting.,Chromosome Painting,USES,Banding procedure
11001863,Cytogenetic study of a patient with infant acute lymphoblastic leukemia using GTG-banding and chromosome painting.,Cytogenetic procedure,USES,Banding procedure
11001863,Cytogenetic study of a patient with infant acute lymphoblastic leukemia using GTG-banding and chromosome painting.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
11001863,Cytogenetic study of a patient with infant acute lymphoblastic leukemia using GTG-banding and chromosome painting.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
11001909,Two new recurring chromosome aberrations previously not reported in T-ALL were found: del(1)(p22) and t(8;12)(q13;p13).,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
11001909,"To further define the cytogenetic differences between B-cell lineage (B-lineage) acute lymphoblastic leukemia (ALL) and T-cell lineage ALL (T-ALL) and to determine the prognostic value of cytogenetics in childhood T-ALL, the blast cell karyotypes of 343 cases of pediatric T-ALL, the largest series reported to date, were evaluated.",Acute T Cell Leukemia,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11001909,"To further define the cytogenetic differences between B-cell lineage (B-lineage) acute lymphoblastic leukemia (ALL) and T-cell lineage ALL (T-ALL) and to determine the prognostic value of cytogenetics in childhood T-ALL, the blast cell karyotypes of 343 cases of pediatric T-ALL, the largest series reported to date, were evaluated.","Leukemia, Lymphocytic, Acute",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11001909,"To further define the cytogenetic differences between B-cell lineage (B-lineage) acute lymphoblastic leukemia (ALL) and T-cell lineage ALL (T-ALL) and to determine the prognostic value of cytogenetics in childhood T-ALL, the blast cell karyotypes of 343 cases of pediatric T-ALL, the largest series reported to date, were evaluated.",Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
11191144,"Age, sex, haemoglobin level, and white cell count at diagnosis are important prognostic factors in children with acute lymphoblastic leukemia treated with BFM-type protocol.",Berlin-Frankfort-Munster protocol,TREATS,"Leukemia, Lymphocytic, Acute"
11191144,"Age, sex, haemoglobin level, and white cell count at diagnosis are important prognostic factors in children with acute lymphoblastic leukemia treated with BFM-type protocol.",Diagnosis,TREATS,Child
11191144,"Age, sex, haemoglobin level, and white cell count at diagnosis are important prognostic factors in children with acute lymphoblastic leukemia treated with BFM-type protocol.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11502805,"Glucocorticoid treatment in childhood acute lymphoblastic leukemia increases energy intake markedly, and this effect contributes to the excess weight gain and obesity characteristic of patients being treated for acute lymphoblastic leukemia.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11502805,"Glucocorticoid treatment in childhood acute lymphoblastic leukemia increases energy intake markedly, and this effect contributes to the excess weight gain and obesity characteristic of patients being treated for acute lymphoblastic leukemia.",Glucocorticoids,ISA,Therapeutic procedure
11502805,The primary aim of the present study was to quantify the effect of dexamethasone and prednisone treatment on energy intake in children treated for childhood acute lymphoblastic leukemia.,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11502805,The primary aim of the present study was to quantify the effect of dexamethasone and prednisone treatment on energy intake in children treated for childhood acute lymphoblastic leukemia.,PREDNISONE TREATMENT,TREATS,Child
11703681,"The following diagnostic categories were analysed: 0-14 years--all cancers, leukaemias, acute lymphoblastic leukaemias, central nervous system tumours, all other solid tumours; 1-6 years--leukaemias, acute lymphoblastic leukaemias.","Leukemia, Lymphocytic, Acute",ISA,leukemia
11703681,"The following diagnostic categories were analysed: 0-14 years--all cancers, leukaemias, acute lymphoblastic leukaemias, central nervous system tumours, all other solid tumours; 1-6 years--leukaemias, acute lymphoblastic leukaemias.",leukemia,ISA,Malignant Neoplasms
11929760,Asparaginase is an enzyme used in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in children.,ASPARAGINASE | ASPG,TREATS,Large Cell Lymphoblastic Lymphoma
11929760,Asparaginase is an enzyme used in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in children.,ASPARAGINASE | ASPG,ISA,Enzymes
11929760,The European Organisation for Research and Treatment of Cancer-Children's Leukemia Group (EORTC-CLG) 58881 trial randomized 700 children with acute lymphoblastic leukemia or lymphoblastic lymphoma to either E coli- or Erwinia-asparaginase at the same dosage of 10 000 IU/m(2) twice weekly to compare toxicity and efficacy.,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
11929760,Asparaginase is an enzyme used in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in children.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
11929760,The European Organisation for Research and Treatment of Cancer-Children's Leukemia Group (EORTC-CLG) 58881 trial randomized 700 children with acute lymphoblastic leukemia or lymphoblastic lymphoma to either E coli- or Erwinia-asparaginase at the same dosage of 10 000 IU/m(2) twice weekly to compare toxicity and efficacy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11929760,Asparaginase is an enzyme used in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in children.,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
11929760,Asparaginase is an enzyme used in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11929760,Asparaginase is an enzyme used in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in children.,Enzymes,TREATS,Large Cell Lymphoblastic Lymphoma
11929760,Asparaginase is an enzyme used in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in children.,Enzymes,TREATS,"Leukemia, Lymphocytic, Acute"
11929791,High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia.,Blood specimen,PART_OF,Child
11929791,High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12015077,[Immunophenotyping of eighty six children with acute lymphoblastic leukemia by three-color flow cytometry].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12015077,[Immunophenotyping of eighty six children with acute lymphoblastic leukemia by three-color flow cytometry].,Flow Cytometry,METHOD_OF,Immunophenotyping
12673688,"A major finding of our study is that hay fever, neurodermatitis and contact eczema are underrepresented within the group of children with ALL, with respective odds ratios (OR) of 0.45 (95% confidence interval [CI] 0.31-0.66) for hay fever, of 0.49 (CI 0.34-0.71) for neurodermatitis and of 0.62 (CI 0.39-0.99) for eczema, respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12744734,The immunophenotypic subtype of B-ALL in adolescents was similar to that in the adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
12819636,"Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, but remarkable progress in methods of chemotherapy has increased the cure rate to 80%.","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
12819636,"Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, but remarkable progress in methods of chemotherapy has increased the cure rate to 80%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11230471,CONCLUSION: No advantage was observed for IR ALL children treated with BFM-based intensive chemotherapy who received protracted E chrysanthemi HD ASP during reinduction and the early continuation phase.,ASPARAGINASE | ASIP | ASPA | C3 | ATG5 | A1CF | ROPN1L | ASPM,ADMINISTERED_TO,Child
11230471,CONCLUSION: No advantage was observed for IR ALL children treated with BFM-based intensive chemotherapy who received protracted E chrysanthemi HD ASP during reinduction and the early continuation phase.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11468150,"It is speculated that, in some patients, combination chemotherapy for childhood ALL may fail to eliminate a fetal preleukemic clone with TEL-AML1 and that a second, independent transformation event within this clone after treatment gives rise to a new leukemia masquerading as relapse.",ETV6 gene | ETV6,PART_OF,Clone
11468150,"It is speculated that, in some patients, combination chemotherapy for childhood ALL may fail to eliminate a fetal preleukemic clone with TEL-AML1 and that a second, independent transformation event within this clone after treatment gives rise to a new leukemia masquerading as relapse.",Combination Drug Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11468150,"It is speculated that, in some patients, combination chemotherapy for childhood ALL may fail to eliminate a fetal preleukemic clone with TEL-AML1 and that a second, independent transformation event within this clone after treatment gives rise to a new leukemia masquerading as relapse.",Clone,PART_OF,Dysmyelopoietic Syndromes
11841456,Seventy percent of children with acute lymphoblastic leukaemia (ALL) who may benefit from bone marrow transplant (BMT) lack a human leucocyte antigen (HLA)-matched related donor (MRD).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11841456,"These results suggest that MUD BMT is a valuable therapy for children with ALL in whom BMT is indicated, and underscore the importance of efforts aimed at expediting unrelated donor searches for patients lacking a MRD.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11841456,"These results suggest that MUD BMT is a valuable therapy for children with ALL in whom BMT is indicated, and underscore the importance of efforts aimed at expediting unrelated donor searches for patients lacking a MRD.",Bone Marrow Transplantation,TREATS,Child
11841456,"These results suggest that MUD BMT is a valuable therapy for children with ALL in whom BMT is indicated, and underscore the importance of efforts aimed at expediting unrelated donor searches for patients lacking a MRD.",Bone Marrow Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
11841456,We reviewed the course of 62 children with ALL who received fully matched marrow allografts at our institution between 1990 and 1998: 36 with MRDs and 26 with MUDs.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11841456,We reviewed the course of 62 children with ALL who received fully matched marrow allografts at our institution between 1990 and 1998: 36 with MRDs and 26 with MUDs.,Allografting,ADMINISTERED_TO,Child
11841456,We reviewed the course of 62 children with ALL who received fully matched marrow allografts at our institution between 1990 and 1998: 36 with MRDs and 26 with MUDs.,"Neoplasm, Residual",PROCESS_OF,Child
11908926,"Whereas the relationship between the clinical pharmacology, and potentially important pharmacodynamic effects such as asparagine depletion, has been well characterized for therapy with L-asparaginase, similar studies have yet to be performed for the other drugs that form the mainstay of remission induction therapy for childhood ALL.",Therapeutic procedure,USES,ASPARAGINASE
11908926,"Remission induction therapy with vincristine, a corticosteroid, L-asparaginase and an anthracycline has been the mainstay of the initial phase of treatment for childhood acute lymphoblastic leukaemia (ALL) for the past 25 years.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11908926,"Remission induction therapy with vincristine, a corticosteroid, L-asparaginase and an anthracycline has been the mainstay of the initial phase of treatment for childhood acute lymphoblastic leukaemia (ALL) for the past 25 years.",Remission Induction Therapy,USES,Vincristine
11908926,"Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.",Remission Induction Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11908926,"Where these have been studied, interindividual differences in the clinical and cellular pharmacology of anticancer agents have been shown to be important determinants of the long-term disease-free survival for children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11908926,"Therefore, further studies are required to investigate the relative importance of the clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines in the speed and depth of response to remission induction therapy for childhood ALL.",Remission Induction Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11908926,"Whereas the relationship between the clinical pharmacology, and potentially important pharmacodynamic effects such as asparagine depletion, has been well characterized for therapy with L-asparaginase, similar studies have yet to be performed for the other drugs that form the mainstay of remission induction therapy for childhood ALL.",Remission Induction Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11908927,A potentially important example of this may be served by the success of antimetabolite-based intrathecal chemotherapy for CNS-directed treatment of childhood ALL.,Antimetabolites,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11908928,Further studies will be needed to determine the importance of pharmacokinetic variability during continuing therapy as a determinant of outcome for children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11908928,"In this review, the pharmacological determinants of the sensitivity of human leukaemia cell lines and lymphoblasts derived from children with ALL will be discussed.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12199776,"It focuses on trials that began before 1988, making use of the register of trials developed for a systematic review of treatments for acute lymphoblastic leukaemia in children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12199776,"It focuses on trials that began before 1988, making use of the register of trials developed for a systematic review of treatments for acute lymphoblastic leukaemia in children.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
12199807,Is there a relationship between in vitro drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia?,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12199807,Is there a relationship between in vitro drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia?,Polymerase Chain Reaction,DIAGNOSES,"Neoplasm, Residual"
12437645,"Minimal residual disease (MRD) was investigated in 52 children with acute lymphoblastic leukaemia (ALL), using antigen receptor gene rearrangements and reverse transcription polymerase chain reaction for fusion transcripts as molecular targets.","Neoplasm, Residual",PROCESS_OF,Child
12437645,"Minimal residual disease (MRD) was investigated in 52 children with acute lymphoblastic leukaemia (ALL), using antigen receptor gene rearrangements and reverse transcription polymerase chain reaction for fusion transcripts as molecular targets.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12439601,Methotrexate (MTX) is one of the most widely used drugs for the treatment of childhood acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12439601,Methotrexate (MTX) is one of the most widely used drugs for the treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Pharmaceutical Preparations
12439601,Methotrexate (MTX) is one of the most widely used drugs for the treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12745901,"Parents reported overall more promotion than prevention; however, mothers of children with tumours of the CNS reported more prevention-focus than mothers of children with ALL.",Neoplasm,PROCESS_OF,Child
12745901,"Parents reported overall more promotion than prevention; however, mothers of children with tumours of the CNS reported more prevention-focus than mothers of children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21765697,Pediatricians at Ochsner Clinic and Alton Ochsner Medical Foundation have treated children with acute lymphoblastic leukemia for the past 17 years with excellent results.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10791859,IQ decrements following cranial radiation therapy (CRT) for acute lymphoblastic leukemia (ALL) are most apparent years after treatment.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
10791859,IQ decrements following cranial radiation therapy (CRT) for acute lymphoblastic leukemia (ALL) are most apparent years after treatment.,Radiation therapy,ISA,Therapeutic procedure
10901326,Data collected by the National Cancer Institute-Children's Cancer Group were utilized to explore various metrics of magnetic field levels and risk of acute lymphoblastic leukemia (ALL) in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11186134,"In children with acute lymphoblastic leukaemia (ALL) treated according to protocols of the Berlin-Frankfurt-Munster (BFM) study group, the initial response to prednisone is the strongest predictor of therapy outcome.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11579464,Chromosome 21 abnormalities with AML1 amplification in acute lymphoblastic leukemia.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
11672578,Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11844835,"PURPOSE: Investigation of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) using molecular markers has proven superior to other standard criteria (age, sex, and WBC) in distinguishing patients at high, intermediate, and low risk of relapse.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12201083,Only one-third of the medicines are available for chemotherapy for the treatment of acute lymphoblastic leukaemia in children (UKALL 97 modified 99 protocol).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12201083,Only one-third of the medicines are available for chemotherapy for the treatment of acute lymphoblastic leukaemia in children (UKALL 97 modified 99 protocol).,Pharmacotherapy,USES,Pharmaceutical Preparations
12201083,Only one-third of the medicines are available for chemotherapy for the treatment of acute lymphoblastic leukaemia in children (UKALL 97 modified 99 protocol).,Pharmacotherapy,METHOD_OF,Therapeutic procedure
12406084,"To our knowledge, this is the first report on the evaluation of minimal residual disease (MRD) in childhood Ph+ ALL prospectively enrolled in an intensive, Berlin-Frankfurt-Munster (BFM)-type treatment protocol.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12406084,"We have prospectively monitored, by reverse transcription polymerase chain reaction (RT-PCR) during follow-up, the presence of the BCR/ABL fusion transcript in Ph+ ALL children diagnosed in the Italian multicentre Associazione Italiana Ematologia Oncologia Pediatrica ALL-AIEOP-95 therapy protocol.",reverse transcription polymerase chain reaction,PROCESS_OF,Child
12406084,"We have prospectively monitored, by reverse transcription polymerase chain reaction (RT-PCR) during follow-up, the presence of the BCR/ABL fusion transcript in Ph+ ALL children diagnosed in the Italian multicentre Associazione Italiana Ematologia Oncologia Pediatrica ALL-AIEOP-95 therapy protocol.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12406084,Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12803106,"Among a number of various multi-drug resistance mechanisms, differences between adults and children with ALL have been found only for higher P-glycoprotein expression and possibly more often p53 gene mutations in adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
12803106,"In adults, in spite of adopting treatment protocols based on therapy for childhood ALL, the disease is still curable in 30-40% of patients only.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12803106,"Among a number of various multi-drug resistance mechanisms, differences between adults and children with ALL have been found only for higher P-glycoprotein expression and possibly more often p53 gene mutations in adults.",Mutation,PROCESS_OF,Adult
12803106,"Among a number of various multi-drug resistance mechanisms, differences between adults and children with ALL have been found only for higher P-glycoprotein expression and possibly more often p53 gene mutations in adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12807155,INTERPRETATION & CONCLUSION: This is probably the first report to show that leukaemic blasts of bcr-abl positive children with ALL are about four-fold resistant to prednisolone as compared to blasts from bcr-abl negative children.,Blast Cell,PART_OF,Child
12807155,INTERPRETATION & CONCLUSION: This is probably the first report to show that leukaemic blasts of bcr-abl positive children with ALL are about four-fold resistant to prednisolone as compared to blasts from bcr-abl negative children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12807155,We studied the association between the presence of bcr-abl fusion gene and in vitro prednisolone resistance in children with B-lineage acute lymphoblastic leukaemia at diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12807155,INTERPRETATION & CONCLUSION: This is probably the first report to show that leukaemic blasts of bcr-abl positive children with ALL are about four-fold resistant to prednisolone as compared to blasts from bcr-abl negative children.,Child,LOCATION_OF,prednisolone
12807155,We studied the association between the presence of bcr-abl fusion gene and in vitro prednisolone resistance in children with B-lineage acute lymphoblastic leukaemia at diagnosis.,prednisolone,TREATS,"Leukemia, Lymphocytic, Acute"
12807155,INTERPRETATION & CONCLUSION: This is probably the first report to show that leukaemic blasts of bcr-abl positive children with ALL are about four-fold resistant to prednisolone as compared to blasts from bcr-abl negative children.,BCR negative,PROCESS_OF,Child
12807155,"BACKGROUND & OBJECTIVES: Although the outcome of children with acute lymphoblastic leukaemia (ALL) has improved dramatically over the last decade, some children still fare poorly and relapses are seen.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12807155,INTERPRETATION & CONCLUSION: This is probably the first report to show that leukaemic blasts of bcr-abl positive children with ALL are about four-fold resistant to prednisolone as compared to blasts from bcr-abl negative children.,BCR positive,PROCESS_OF,Child
12807155,The median LD50 for prednisolone differed significantly between the bcr-abl positive and negative groups of children with acute lymphoblastic leukaemia (P<0.005).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12807155,"METHODS: A total of 23 children (aged 1-16 yr, median age: 12 yr) with B-lineage acute lymphoblastic leukaemia at diagnosis were included in the study.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12807155,We studied the association between the presence of bcr-abl fusion gene and in vitro prednisolone resistance in children with B-lineage acute lymphoblastic leukaemia at diagnosis.,prednisolone,TREATS,Child
12823343,"The measurement of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia offers the promise of individualized, risk-stratified treatment, but an optimal protocol needs establishing.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12823350,These observations support the hypothesis that loss of ETV6 expression is a critical secondary event for leukaemogenesis in ETV6-CBFA2 ALL.,Leukemogenesis,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
12823350,These observations support the hypothesis that loss of ETV6 expression is a critical secondary event for leukaemogenesis in ETV6-CBFA2 ALL.,ETV6 gene | ETV6,TREATS,Leukemogenesis
10628395,Children with acute lymphoblastic leukemia (ALL) who are treated with chemotherapy have remissions in more than 95% of the cases.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10628395,Children with acute lymphoblastic leukemia (ALL) who are treated with chemotherapy have remissions in more than 95% of the cases.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
10657870,RESULTS: One hundred twenty-four children (age <15 years) developed non-Burkitt ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10706859,Overall survival of patients with p15 methylation was notably shortened among 38 adults with AML and 12 adults with ALL.,CDKN2B gene | CDKN2B,PART_OF,Patients
10706859,Overall survival of patients with p15 methylation was notably shortened among 38 adults with AML and 12 adults with ALL.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Adult
10706859,Overall survival of patients with p15 methylation was notably shortened among 38 adults with AML and 12 adults with ALL.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Adult
10706859,Overall survival of patients with p15 methylation was notably shortened among 38 adults with AML and 12 adults with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
10706859,Overall survival of patients with p15 methylation was notably shortened among 38 adults with AML and 12 adults with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
10791859,Participants with ALL treated only with chemotherapy showed similar working memory and processing speed as matched controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Participant
10791859,Participants with ALL treated only with chemotherapy showed similar working memory and processing speed as matched controls.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
11268324,STATE OF ART: Modern first-line treatment protocols for childhood ALL have contributed to curing an ever larger number of patients but this strategy could be responsible for creating a more resistant leukemic clone at the time of systemic or extramedullary relapse.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11268324,In this review the authors point out the contribution of current strategy in the setting of children with ALL who experience a first relapse and should be offered optimal treatment in order to obtain the best disease-free survival (DFS).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11268333,"EVIDENCE AND INFORMATION SOURCE: Data covered by Medline and produced by the authors involved in ongoing international studies cover a vast ""scenario"" of children with very high risk ALL who underwent allogeneic BMT.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11268333,"EVIDENCE AND INFORMATION SOURCE: Data covered by Medline and produced by the authors involved in ongoing international studies cover a vast ""scenario"" of children with very high risk ALL who underwent allogeneic BMT.",Allogeneic bone marrow transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
11325820,The aim of the present study was to elucidate the potential role of the gene mutated in NBS (NBS1) in the pathogenesis and disease progression of childhood acute lymphoblastic leukemia (ALL).,NBS1 gene | NBN | NLRP2,ASSOCIATED_WITH,Disease Progression
11325820,The aim of the present study was to elucidate the potential role of the gene mutated in NBS (NBS1) in the pathogenesis and disease progression of childhood acute lymphoblastic leukemia (ALL).,NBS1 gene | NBN | NLRP2,ASSOCIATED_WITH,Pathogenesis
11325820,The aim of the present study was to elucidate the potential role of the gene mutated in NBS (NBS1) in the pathogenesis and disease progression of childhood acute lymphoblastic leukemia (ALL).,NBS1 gene | NBN | NLRP2,ASSOCIATED_WITH,Nijmegen Breakage Syndrome
11325820,The aim of the present study was to elucidate the potential role of the gene mutated in NBS (NBS1) in the pathogenesis and disease progression of childhood acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
11675066,Molecular monitoring by quantitative PCR techniques of residual leukaemia cells during the first phases of treatment can predict outcome in children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11675066,Molecular monitoring by quantitative PCR techniques of residual leukaemia cells during the first phases of treatment can predict outcome in children with acute lymphoblastic leukaemia.,Therapeutic procedure,TREATS,Child
11675066,Molecular monitoring by quantitative PCR techniques of residual leukaemia cells during the first phases of treatment can predict outcome in children with acute lymphoblastic leukaemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
12091331,"We attribute this improvement to the replacement of 6 alternating blocks of non-cross-resistant drugs with an 8-drug reinduction regimen (Berlin-Frankfurt-Muenster [BFM] protocol II), repeated twice, in the context of a standard BFM-type intensive chemotherapy for high-risk ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
12168056,The purpose of this investigation was to evaluate the expression profile of proteins involved in children with newly diagnosed acute lymphoblastic leukemia (ALL) children who are developing relapses.,Child,LOCATION_OF,Proteins
12168056,The purpose of this investigation was to evaluate the expression profile of proteins involved in children with newly diagnosed acute lymphoblastic leukemia (ALL) children who are developing relapses.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12168056,Protein expression profile of newly diagnosed acute lymphoblastic leukemia in children developing relapses.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12818116,CONCLUSIONS: 1) The chemotherapy and radiotherapy contribute to growth retardation in the first year of treatment in both groups 2) It seems that prophylactic cranial irradiation in children with ALL with total doses 12 and 18 Gy does not contribute to retardation of growth velocity after cancer treatment 3) Endocrine follow-up should be introduced in order to detect and treat complications as early as possible.,Radiation therapy,PREDISPOSES,Growth retardation
12818116,CONCLUSIONS: 1) The chemotherapy and radiotherapy contribute to growth retardation in the first year of treatment in both groups 2) It seems that prophylactic cranial irradiation in children with ALL with total doses 12 and 18 Gy does not contribute to retardation of growth velocity after cancer treatment 3) Endocrine follow-up should be introduced in order to detect and treat complications as early as possible.,Pharmacotherapy,PREDISPOSES,Growth retardation
12818116,CONCLUSIONS: 1) The chemotherapy and radiotherapy contribute to growth retardation in the first year of treatment in both groups 2) It seems that prophylactic cranial irradiation in children with ALL with total doses 12 and 18 Gy does not contribute to retardation of growth velocity after cancer treatment 3) Endocrine follow-up should be introduced in order to detect and treat complications as early as possible.,Prophylactic Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute"
12818116,CONCLUSIONS: 1) The chemotherapy and radiotherapy contribute to growth retardation in the first year of treatment in both groups 2) It seems that prophylactic cranial irradiation in children with ALL with total doses 12 and 18 Gy does not contribute to retardation of growth velocity after cancer treatment 3) Endocrine follow-up should be introduced in order to detect and treat complications as early as possible.,follow-up,TREATS,Complication
12818116,CONCLUSIONS: 1) The chemotherapy and radiotherapy contribute to growth retardation in the first year of treatment in both groups 2) It seems that prophylactic cranial irradiation in children with ALL with total doses 12 and 18 Gy does not contribute to retardation of growth velocity after cancer treatment 3) Endocrine follow-up should be introduced in order to detect and treat complications as early as possible.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12818116,CONCLUSIONS: 1) The chemotherapy and radiotherapy contribute to growth retardation in the first year of treatment in both groups 2) It seems that prophylactic cranial irradiation in children with ALL with total doses 12 and 18 Gy does not contribute to retardation of growth velocity after cancer treatment 3) Endocrine follow-up should be introduced in order to detect and treat complications as early as possible.,Prophylactic Cranial Irradiation,TREATS,Child
12825213,Impaired adrenal function after glucocorticoid therapy in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12825213,The purpose of this study was to assess the incidence of adrenal insufficiency and the time for children with ALL to recover after treatment with the glucorticoids prednisolone or dexamethasone.,Dexamethasone,PART_OF,Child
12825213,CONCLUSIONS: Adrenal insufficiency occurs and may persist for several months in children with ALL after treatment with high doses of prednisolone or dexamethasone.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12825213,Impaired adrenal function after glucocorticoid therapy in children with acute lymphoblastic leukemia.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute"
12825213,The purpose of this study was to assess the incidence of adrenal insufficiency and the time for children with ALL to recover after treatment with the glucorticoids prednisolone or dexamethasone.,prednisolone,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
12825213,CONCLUSIONS: Adrenal insufficiency occurs and may persist for several months in children with ALL after treatment with high doses of prednisolone or dexamethasone.,Adrenal gland hypofunction,PROCESS_OF,Child
12825213,The purpose of this study was to assess the incidence of adrenal insufficiency and the time for children with ALL to recover after treatment with the glucorticoids prednisolone or dexamethasone.,Dexamethasone,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
12825213,BACKGROUND: Glucocorticoids are commonly used in the treatment of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12825213,"PROCEDURE: Seventeen children, 2-15 years, with ALL were studied after receiving prednisolone (60 mg/m(2)/day, n = 10) for 5 weeks during remission induction therapy or dexamethasone (10 mg/m(2)/day, n = 7) for 3 weeks during reinduction therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12825213,BACKGROUND: Glucocorticoids are commonly used in the treatment of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,ISA,Therapeutic procedure
12825213,The purpose of this study was to assess the incidence of adrenal insufficiency and the time for children with ALL to recover after treatment with the glucorticoids prednisolone or dexamethasone.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12825213,Impaired adrenal function after glucocorticoid therapy in children with acute lymphoblastic leukemia.,GLUCOCORTICOID THERAPY,TREATS,Child
12825213,The purpose of this study was to assess the incidence of adrenal insufficiency and the time for children with ALL to recover after treatment with the glucorticoids prednisolone or dexamethasone.,prednisolone,PART_OF,Child
10755411,"Among children with ALL, however, the relative risk of death allowing for period of diagnosis, age and white blood count was 1.25 for those of South Asian ethnic origin compared with Whites (P = 0.057).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10755411,"Among children with ALL, however, the relative risk of death allowing for period of diagnosis, age and white blood count was 1.25 for those of South Asian ethnic origin compared with Whites (P = 0.057).",South Asian,ISA,Ethnic group
10830464,"Some attempts have been made to reduce the costs incurred in the therapy of leukaemia, but no studies are available regarding costs of the entire treatment in children with acute lymphocytic leukaemia (ALL).",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
10830464,The complete treatment of a child with ALL came to a total of US $103250.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10830464,The complete treatment of a child with ALL came to a total of US $103250.,Therapeutic procedure,USES,Compleat
10830464,We analysed all the direct costs of treatment of 11 children with ALL diagnosed and treated in Kuopio University Hospital.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
10830464,"Some attempts have been made to reduce the costs incurred in the therapy of leukaemia, but no studies are available regarding costs of the entire treatment in children with acute lymphocytic leukaemia (ALL).",Therapeutic procedure,TREATS,Child
10830464,"Some attempts have been made to reduce the costs incurred in the therapy of leukaemia, but no studies are available regarding costs of the entire treatment in children with acute lymphocytic leukaemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11181667,Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11292328,We examined a median of 0.165 microg (from 1.0-2.0x10(4)cells) genomic DNA from archived peripheral blood smears collected 8-16 months prior to clinical relapse in eight children with ALL for evidence of MRD.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11292328,Submicroscopic evidence of persistent minimal residual disease (MRD) in first remission bone marrow samples from children with acute lymphoblastic leukaemia (ALL) indicates a high risk of clinical relapse.,Bone marrow specimen,LOCATION_OF,"Neoplasm, Residual"
11292328,Submicroscopic evidence of persistent minimal residual disease (MRD) in first remission bone marrow samples from children with acute lymphoblastic leukaemia (ALL) indicates a high risk of clinical relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11293291,Parotid mucoepidermoid carcinoma following chemotherapy for childhood acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11293291,The authors report a case of secondary parotid mucoepidermoid carcinoma after chemotherapy for childhood acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
11325643,Rapid detection of clonality in patients with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
11325643,Rapid detection of clonality in patients with acute lymphoblastic leukemia.,Detection,TREATS,"Leukemia, Lymphocytic, Acute"
11325643,"DESIGN AND METHODS: We applied a semi-automated electrophoretic technique (PhastSystem , Amersham Pharmacia Biotech) and compared it with standard homo-heteroduplex analysis in 21 cases of childhood acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
11325643,Rapid detection of clonality in patients with acute lymphoblastic leukemia.,Detection,TREATS,Patients
11328290,PEG-ASNase is a useful alternative to the native ASNases in children with relapsed ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11328290,PEG-ASNase is a useful alternative to the native ASNases in children with relapsed ALL.,ASPARAGINASE,TREATS,Child
11328290,Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11328290,PEG-ASNase is a useful alternative to the native ASNases in children with relapsed ALL.,pegaspargase,ISA,ASPARAGINASE
11328290,Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.,Oncaspar,ISA,pegaspargase
11328290,PEG-ASNase is a useful alternative to the native ASNases in children with relapsed ALL.,pegaspargase,TREATS,Child
11328290,Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.,Oncaspar,TREATS,Child
11328290,PEG-ASNase is a useful alternative to the native ASNases in children with relapsed ALL.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
11328290,Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.,pegaspargase,TREATS,"Leukemia, Lymphocytic, Acute"
11328290,"Therefore, PEG-ASNase (Oncaspar), a polyethylene glycol conjugate of the native Escherichia coli-ASNase, was introduced into the Berlin-Frankfurt-Munster (BFM) 96 treatment protocol for relapsed ALL under drug monitoring conditions.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
11328290,"Therefore, PEG-ASNase (Oncaspar), a polyethylene glycol conjugate of the native Escherichia coli-ASNase, was introduced into the Berlin-Frankfurt-Munster (BFM) 96 treatment protocol for relapsed ALL under drug monitoring conditions.",Oncaspar,ISA,pegaspargase
11328290,Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.,pegaspargase,TREATS,Child
12091359,"In conclusion, our data support the hypothesis that the leukemia in TEL/AML1-positive childhood ALL originates in a CD19+ lymphoid progenitor.","Leukemia, Lymphocytic, Acute",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12091359,"CD34+CD19- cells from the bone marrow of 9 children with TEL/AML1-positive ALL were purified by flow sorting and subjected to reverse transcriptase-polymerase chain reaction (RT-PCR), fluorescence in situ hybridization, and methylcellulose cultures.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12091359,"CD34+CD19- cells from the bone marrow of 9 children with TEL/AML1-positive ALL were purified by flow sorting and subjected to reverse transcriptase-polymerase chain reaction (RT-PCR), fluorescence in situ hybridization, and methylcellulose cultures.",Bone Marrow,PART_OF,Child
12376977,"White children with ALL had better 5-year survival rates than Black children with ALL (71% vs. 58%, P < 0.0001), and 5-year survival was poorest among black males.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12376977,"White children with ALL had better 5-year survival rates than Black children with ALL (71% vs. 58%, P < 0.0001), and 5-year survival was poorest among black males.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12827651,144 Turkish children with acute lymphoblastic leukemia (ALL) and 33 with acute nonlymphoblastic leukemia (ANLL) were studied and compared with 185 healthy pediatric controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12827651,144 Turkish children with acute lymphoblastic leukemia (ALL) and 33 with acute nonlymphoblastic leukemia (ANLL) were studied and compared with 185 healthy pediatric controls.,"Nonlymphocytic Leukemia, Acute",PROCESS_OF,Child
10830464,"However, since 80% of children with ALL are long-term survivors, the cost must be regarded as a good investment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11048511,The level of minimal residual disease is an important prognostic factor in childhood acute lymphoblastic leukaemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
11166827,"A statistically significant correlation (P 0.027) with MMP-2 positivity and appearance of extramedullary infiltrates was found in adult ALL, suggesting that the gelatinase activity could be related with increased extravasation of the leukemic cells in ALL.",Infiltration,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
11166827,"A statistically significant correlation (P 0.027) with MMP-2 positivity and appearance of extramedullary infiltrates was found in adult ALL, suggesting that the gelatinase activity could be related with increased extravasation of the leukemic cells in ALL.",Extravasation,ASSOCIATED_WITH,Gelatinases
11166827,"A statistically significant correlation (P 0.027) with MMP-2 positivity and appearance of extramedullary infiltrates was found in adult ALL, suggesting that the gelatinase activity could be related with increased extravasation of the leukemic cells in ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
11255727,Bone marrow slides from 26 children with leukemia (18 acute lymphoblastic leukemia [ALL] and 8 acute myeloid leukemia [AML]) and 4 children with neuroblastoma were studied.,"Leukemia, Lymphocytic, Acute",ISA,leukemia
11255727,Bone marrow slides from 26 children with leukemia (18 acute lymphoblastic leukemia [ALL] and 8 acute myeloid leukemia [AML]) and 4 children with neuroblastoma were studied.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
11255727,Bone marrow slides from 26 children with leukemia (18 acute lymphoblastic leukemia [ALL] and 8 acute myeloid leukemia [AML]) and 4 children with neuroblastoma were studied.,leukemia,PROCESS_OF,Child
11255727,Bone marrow slides from 26 children with leukemia (18 acute lymphoblastic leukemia [ALL] and 8 acute myeloid leukemia [AML]) and 4 children with neuroblastoma were studied.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11255727,Bone marrow slides from 26 children with leukemia (18 acute lymphoblastic leukemia [ALL] and 8 acute myeloid leukemia [AML]) and 4 children with neuroblastoma were studied.,leukemia,PROCESS_OF,Child
11255727,Bone marrow slides from 26 children with leukemia (18 acute lymphoblastic leukemia [ALL] and 8 acute myeloid leukemia [AML]) and 4 children with neuroblastoma were studied.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11255727,Bone marrow slides from 26 children with leukemia (18 acute lymphoblastic leukemia [ALL] and 8 acute myeloid leukemia [AML]) and 4 children with neuroblastoma were studied.,Neuroblastoma,PROCESS_OF,Child
11255727,Bone marrow slides from 26 children with leukemia (18 acute lymphoblastic leukemia [ALL] and 8 acute myeloid leukemia [AML]) and 4 children with neuroblastoma were studied.,Neuroblastoma,PROCESS_OF,Child
11255727,Bone marrow slides from 26 children with leukemia (18 acute lymphoblastic leukemia [ALL] and 8 acute myeloid leukemia [AML]) and 4 children with neuroblastoma were studied.,"Leukemia, Myelocytic, Acute",ISA,leukemia
11255727,Bone marrow slides from 26 children with leukemia (18 acute lymphoblastic leukemia [ALL] and 8 acute myeloid leukemia [AML]) and 4 children with neuroblastoma were studied.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
11936734,Encephalitis and myocarditis in a child with acute lymphoblastic leukemia: role of coxsackievirus B5?,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11936734,Encephalitis and myocarditis in a child with acute lymphoblastic leukemia: role of coxsackievirus B5?,Myocarditis,PROCESS_OF,Child
11936734,Encephalitis and myocarditis in a child with acute lymphoblastic leukemia: role of coxsackievirus B5?,Encephalitis,PROCESS_OF,Child
11937268,OBJECTIVE: Hyperdiploidy of 51-65 chromosomes is associated with a good prognosis in childhood B-lineage acute lymphoblastic leukemia (ALL).,Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12021625,The authors assayed the TPMT activity in red blood cells from 122 patients treated with azathioprine or 6-mercaptopurine (83 adults with inflammatory bowel disease and 39 children with acute lymphoblastic leukemia) and in 290 untreated controls (219 adult blood donors and 71 children).,Inflammatory Bowel Diseases,PROCESS_OF,Adult
12021625,The authors assayed the TPMT activity in red blood cells from 122 patients treated with azathioprine or 6-mercaptopurine (83 adults with inflammatory bowel disease and 39 children with acute lymphoblastic leukemia) and in 290 untreated controls (219 adult blood donors and 71 children).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12021625,The authors assayed the TPMT activity in red blood cells from 122 patients treated with azathioprine or 6-mercaptopurine (83 adults with inflammatory bowel disease and 39 children with acute lymphoblastic leukemia) and in 290 untreated controls (219 adult blood donors and 71 children).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
12021625,The authors assayed the TPMT activity in red blood cells from 122 patients treated with azathioprine or 6-mercaptopurine (83 adults with inflammatory bowel disease and 39 children with acute lymphoblastic leukemia) and in 290 untreated controls (219 adult blood donors and 71 children).,Encounter due to blood donor,PROCESS_OF,Adult
12021625,The authors assayed the TPMT activity in red blood cells from 122 patients treated with azathioprine or 6-mercaptopurine (83 adults with inflammatory bowel disease and 39 children with acute lymphoblastic leukemia) and in 290 untreated controls (219 adult blood donors and 71 children).,Azathioprine,TREATS,Patients
12021625,The authors assayed the TPMT activity in red blood cells from 122 patients treated with azathioprine or 6-mercaptopurine (83 adults with inflammatory bowel disease and 39 children with acute lymphoblastic leukemia) and in 290 untreated controls (219 adult blood donors and 71 children).,6-Mercaptopurine,TREATS,Patients
12021625,The authors assayed the TPMT activity in red blood cells from 122 patients treated with azathioprine or 6-mercaptopurine (83 adults with inflammatory bowel disease and 39 children with acute lymphoblastic leukemia) and in 290 untreated controls (219 adult blood donors and 71 children).,Inflammatory Bowel Diseases,PROCESS_OF,Child
12057554,"METHODS: We reviewed data on 497 children and young adults who had ALL with various 11q23 abnormalities, including the translocations t(4;11), t(9;11), and t(11;19).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12057554,INTERPRETATION: The prognosis of acute lymphoblastic leukaemia with an 11q23 abnormality is particularly dismal in infants.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
12057554,"METHODS: We reviewed data on 497 children and young adults who had ALL with various 11q23 abnormalities, including the translocations t(4;11), t(9;11), and t(11;19).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
12094263,Several studies have shown that quantitative detection of minimal residual disease (MRD) predicts clinical outcome in childhood acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12094263,T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
12094263,T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis.,Polymerase chain reaction analysis,DIAGNOSES,"Neoplasm, Residual"
12094263,Seventeen children with precursor-B-ALL and 15 children with T-ALL were included in this study.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12094263,Seventeen children with precursor-B-ALL and 15 children with T-ALL were included in this study.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12094263,Seventeen children with precursor-B-ALL and 15 children with T-ALL were included in this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12094263,Seventeen children with precursor-B-ALL and 15 children with T-ALL were included in this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12127556,Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,B-cell childhood acute lymphoblastic leukemia
12127556,Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.,CDKN2A gene | CDKN2A,ASSOCIATED_WITH,"Neoplasm, Residual"
12393405,Increased frequency of mannose-binding lectin insufficiency among children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12412390,Allogeneic bone marrow transplantation versus chemotherapy in childhood very high risk acute lymphoblastic leukemia in first complete remission: a controversial issue.,Allogeneic bone marrow transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12412390,Allogeneic bone marrow transplantation versus chemotherapy in childhood very high risk acute lymphoblastic leukemia in first complete remission: a controversial issue.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12412390,Allogeneic bone marrow transplantation versus chemotherapy in childhood very high risk acute lymphoblastic leukemia in first complete remission: a controversial issue.,Allogeneic bone marrow transplantation,compared_with,Pharmacotherapy
11895912,"Our study included 320 children with ALL, of which 68 relapsed or died because of this disease within 5 years of follow-up.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11896119,"PATIENTS AND METHODS: In a randomized study, children with high-risk acute lymphoblastic leukemia received doxorubicin 360 mg/m(2) in 30-mg/m(2) doses every 3 weeks either by bolus (within 1 hour, n = 57) or by continuous infusion (over 48 hours, n = 64).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11982900,Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: A retrospective study by the JACLS.,Hemostatic function,PROCESS_OF,Child
11982900,METHODS: A multicenter retrospective survey on the incidence of hemostatic complications and the frequency of prophylactic replacement of plasma-derived products among children with ALL who under went ASP therapy was conducted.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11982900,Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: A retrospective study by the JACLS.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11982900,METHODS: A multicenter retrospective survey on the incidence of hemostatic complications and the frequency of prophylactic replacement of plasma-derived products among children with ALL who under went ASP therapy was conducted.,Therapeutic procedure,USES,ASPARAGINASE
11982900,METHODS: A multicenter retrospective survey on the incidence of hemostatic complications and the frequency of prophylactic replacement of plasma-derived products among children with ALL who under went ASP therapy was conducted.,Complication,PROCESS_OF,Hemostatic function
11982900,METHODS: A multicenter retrospective survey on the incidence of hemostatic complications and the frequency of prophylactic replacement of plasma-derived products among children with ALL who under went ASP therapy was conducted.,ASPARAGINASE,ISA,Therapeutic procedure
11982900,BACKGROUND: Thromboembolic and bleeding events are serious complications associated with the administration of L-asparaginase (ASP) during the induction phase in children with acute lymphoblastic leukemia (ALL).,Complication,PROCESS_OF,Child
11982900,BACKGROUND: Thromboembolic and bleeding events are serious complications associated with the administration of L-asparaginase (ASP) during the induction phase in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
11982900,METHODS: A multicenter retrospective survey on the incidence of hemostatic complications and the frequency of prophylactic replacement of plasma-derived products among children with ALL who under went ASP therapy was conducted.,Complication,PROCESS_OF,Child
12094263,Seventeen children with precursor-B-ALL and 15 children with T-ALL were included in this study.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12094263,Seventeen children with precursor-B-ALL and 15 children with T-ALL were included in this study.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
12094263,Seventeen children with precursor-B-ALL and 15 children with T-ALL were included in this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12094263,Seventeen children with precursor-B-ALL and 15 children with T-ALL were included in this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12094264,"Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry.",Detection,TREATS,"Leukemia, Myelocytic, Acute"
12094264,"Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
12094264,"Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry.",Detection,TREATS,Child
12411325,Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of childhood acute lymphoblastic leukemia (ALL).,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12411325,Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Chemotherapy-Oncologic Procedure
12411325,Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12481884,Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.,pegaspargase,TREATS,"Lymphoma, Non-Hodgkin's"
12481884,Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.,pegaspargase,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12481884,Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.,Therapeutic procedure,USES,pegaspargase
12481884,Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.,pegaspargase,ISA,Therapeutic procedure
12555248,Human polyomavirus DNA is not detected in Guthrie cards (dried blood spots) from children who developed acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12555248,Human polyomavirus DNA is not detected in Guthrie cards (dried blood spots) from children who developed acute lymphoblastic leukemia.,DNA,PART_OF,Polyomavirus
12555248,Human polyomavirus DNA is not detected in Guthrie cards (dried blood spots) from children who developed acute lymphoblastic leukemia.,Blood,LOCATION_OF,Exanthema
12555248,CONCLUSIONS: JCV or BKV were not found in any of the dried blood spots of children who later developed ALL or in the healthy controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12555248,"The human polyomavirus JC virus (JCV) has been discussed as a candidate virus, but its presence has not been demonstrated in leukemia cells from children with ALL.",Leukemic Cell,LOCATION_OF,Virus
12555248,"The human polyomavirus JC virus (JCV) has been discussed as a candidate virus, but its presence has not been demonstrated in leukemia cells from children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12555248,"The human polyomavirus JC virus (JCV) has been discussed as a candidate virus, but its presence has not been demonstrated in leukemia cells from children with ALL.",JC Virus,ISA,Virus
12605417,Treatment of acute lymphoblastic leukemia in Hong Kong children: HKALL 93 study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12682627,"This study illustrates the marked clinical heterogeneity among and within subgroups of infants or older children with ALL and specific 11q23 abnormalities, and identifies patients at particularly high risk of failure who may benefit from innovative therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12682627,"This study illustrates the marked clinical heterogeneity among and within subgroups of infants or older children with ALL and specific 11q23 abnormalities, and identifies patients at particularly high risk of failure who may benefit from innovative therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
12682627,"This study illustrates the marked clinical heterogeneity among and within subgroups of infants or older children with ALL and specific 11q23 abnormalities, and identifies patients at particularly high risk of failure who may benefit from innovative therapy.",Innovative Therapies,TREATS,Patients
15828306,[The prognostic significance of P-glycoprotein in children with acute lymphoblastic leukemia and neuroblastoma].,Child,LOCATION_OF,P-Glycoprotein
15828306,[The prognostic significance of P-glycoprotein in children with acute lymphoblastic leukemia and neuroblastoma].,Neuroblastoma,PROCESS_OF,Child
15828306,[The prognostic significance of P-glycoprotein in children with acute lymphoblastic leukemia and neuroblastoma].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16709928,"Therefore, we investigated whether OPAL1 expression was of prognostic importance in 2 independent cohorts of children with ALL treated on Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)-92/97 (n = 180) and St Jude Total 13 protocols (n = 257).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16709928,New prognostic factors may result in better risk classification and improved treatment of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16709928,"Therefore, we investigated whether OPAL1 expression was of prognostic importance in 2 independent cohorts of children with ALL treated on Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)-92/97 (n = 180) and St Jude Total 13 protocols (n = 257).",cohort,LOCATION_OF,WBP1L
12829593,High hyperdiploidy (HeH) (51 to 65 chromosomes) is found in one third of children with acute lymphoblastic leukemia and is associated with a good prognosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12829594,"High hyperdiploidy, common in childhood acute lymphoblastic leukemia (ALL) with a favorable prognosis, is characterized by specific trisomies.",Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12829594,"High hyperdiploidy, common in childhood acute lymphoblastic leukemia (ALL) with a favorable prognosis, is characterized by specific trisomies.",Trisomy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12843002,The German cooperative study group for childhood acute lymphoblastic leukemia (COALL-92) was designed to examine the clinical effectiveness of thioguanine (TG) versus mercaptopurine (MP) in maintenance treatment of childhood acute lymphoblastic leukemia (ALL) in a randomized multicenter trial.,Thioguanine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12843002,The German cooperative study group for childhood acute lymphoblastic leukemia (COALL-92) was designed to examine the clinical effectiveness of thioguanine (TG) versus mercaptopurine (MP) in maintenance treatment of childhood acute lymphoblastic leukemia (ALL) in a randomized multicenter trial.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12843002,The German cooperative study group for childhood acute lymphoblastic leukemia (COALL-92) was designed to examine the clinical effectiveness of thioguanine (TG) versus mercaptopurine (MP) in maintenance treatment of childhood acute lymphoblastic leukemia (ALL) in a randomized multicenter trial.,Thioguanine,compared_with,6-Mercaptopurine
12843002,"Therefore, MP should remain the preferred drug for maintenance treatment of ALL, unless other studies demonstrate superiority of TG in larger trials or selected patient groups.",6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
12843002,"Therefore, MP should remain the preferred drug for maintenance treatment of ALL, unless other studies demonstrate superiority of TG in larger trials or selected patient groups.",6-Mercaptopurine,ISA,Pharmaceutical Preparations
14578205,"Furthermore, PARC serum levels were significantly increased in children with T-ALL and prepreB-ALL compared to control serum samples, whereas serum levels in AML and preB-ALL patients were not significantly different from controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14578205,"Furthermore, PARC serum levels were significantly increased in children with T-ALL and prepreB-ALL compared to control serum samples, whereas serum levels in AML and preB-ALL patients were not significantly different from controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
14578205,"Furthermore, PARC serum levels were significantly increased in children with T-ALL and prepreB-ALL compared to control serum samples, whereas serum levels in AML and preB-ALL patients were not significantly different from controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14578205,"Furthermore, PARC serum levels were significantly increased in children with T-ALL and prepreB-ALL compared to control serum samples, whereas serum levels in AML and preB-ALL patients were not significantly different from controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
14630074,Gene expression profiles of 10 children with acute lymphoblastic leukemia (ALL) were detected using cDNA arrays.,Child,USES,cDNA Microarray device
14630074,Gene expression profiles of 10 children with acute lymphoblastic leukemia (ALL) were detected using cDNA arrays.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14764536,Continuous xenografts from 10 children with acute lymphoblastic leukemia (ALL) were established in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.,Xenograft procedure,TREATS,SCID Mice
14764536,Continuous xenografts from 10 children with acute lymphoblastic leukemia (ALL) were established in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14990973,"We sought to define the frequency and spectrum, and possible prognostic importance, of N- and K-RAS mutations in children with ALL treated with contemporary therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14990973,"We sought to define the frequency and spectrum, and possible prognostic importance, of N- and K-RAS mutations in children with ALL treated with contemporary therapy.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
16517536,Guthrie cards were obtained from 48 children with ALL and 46 healthy children and were analyzed for the presence of CMV DNA by a real-time TaqMan PCR.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16517536,The authors investigated the presence of prenatal CMV infection in children who later developed ALL.,Cytomegalovirus Infections,PROCESS_OF,Child
16517536,The authors investigated the presence of prenatal CMV infection in children who later developed ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16517536,The authors investigated the presence of prenatal CMV infection in children who later developed ALL.,Cytomegalovirus Infections,PROCESS_OF,prenatal
16517536,No CMV DNA in Guthrie cards from children who later developed ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16517536,"CMV DNA was not detected in Guthrie cards from the children with ALL, from the control healthy children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16892892,"From 1981 to 1986, children with acute lymphoblastic leukemia (ALL) and initial WBC above 50,000/mm3, achieved significantly worse treatment results than children with lower WBC: over 6-year disease-free survival were respectively 33% and 60%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16892892,"From 1981 to 1986, children with acute lymphoblastic leukemia (ALL) and initial WBC above 50,000/mm3, achieved significantly worse treatment results than children with lower WBC: over 6-year disease-free survival were respectively 33% and 60%.",Leukocytes,PART_OF,Child
16892892,"[Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].",Leukocytosis,PROCESS_OF,Child
16892892,"[Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16892892,The analysis of treatment results achieved shows the improvement of the prognosis in children with ALL and initial WBC above 50 000/mm3 in comparison with patients treated before 1987.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17350480,The purpose of this study was to define and classify the frequency and type of chromosomal abnormalities among newly diagnosed children with ALL and compare the results with those reported from other geographical regions of the world.,Chromosome abnormality,PROCESS_OF,Child
17350480,"RESULTS: Among Omani children examined with ALL, 47 (81%) patients yielded results, with 26 (55.3%) showing an abnormal karyotype [10 (21.3%) pseudodiploid, 2 (4.3%) hypodiploid and 14 (29.7%) hyperdiploidy] and 21 (44.6%) had normal diploidy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17350480,The purpose of this study was to define and classify the frequency and type of chromosomal abnormalities among newly diagnosed children with ALL and compare the results with those reported from other geographical regions of the world.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17350480,BACKGROUND: Chromosomal abnormalities have important diagnostic and prognostic significance in acute lymphoblastic leukemia (ALL).,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
17390373,Our finding of a reciprocal relationship between allergy and ALL in children is compatible with the hypothesis that a dysregulated immune response is a critical determinant of childhood ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17390373,Our finding of a reciprocal relationship between allergy and ALL in children is compatible with the hypothesis that a dysregulated immune response is a critical determinant of childhood ALL.,Hypersensitivity,PROCESS_OF,Child
12930910,"In 23 consecutive children with ALL, a bone biopsy was taken from the crista iliaca posterior under ketamine anesthesia, together with the diagnostic marrow aspiration, before any treatment was given.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12930910,"In 23 consecutive children with ALL, a bone biopsy was taken from the crista iliaca posterior under ketamine anesthesia, together with the diagnostic marrow aspiration, before any treatment was given.",Iliac crest structure,LOCATION_OF,Biopsy
15044926,"Cytogenetic descriptions were available for 249 of 326 children with Ph+ ALL, diagnosed and treated by 10 different study groups/large single institutions from 1986 to 1996.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15292925,"To investigate if children who later developed acute lymphoblastic leukaemia (ALL) were prenatally infected with HHV-6 and/or EBV, Guthrie cards taken at birth were analysed by PCR.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15292925,"To investigate if children who later developed acute lymphoblastic leukaemia (ALL) were prenatally infected with HHV-6 and/or EBV, Guthrie cards taken at birth were analysed by PCR.","Herpesvirus 6, Human",PROCESS_OF,Child
15755280,Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.,Flow Cytometry,DIAGNOSES,"Neoplasm, Residual"
15755280,Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15755280,Minimal (i.e. submicroscopic) residual disease (MRD) predicts outcome in childhood acute lymphoblastic leukaemia (ALL).,Residual Tumor,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15755280,Minimal (i.e. submicroscopic) residual disease (MRD) predicts outcome in childhood acute lymphoblastic leukaemia (ALL).,"Neoplasm, Residual",ISA,Residual Tumor
15755280,Minimal (i.e. submicroscopic) residual disease (MRD) predicts outcome in childhood acute lymphoblastic leukaemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15755280,Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.,Polymerase Chain Reaction,DIAGNOSES,"Neoplasm, Residual"
16435384,"PROCEDURES: We genotyped polymorphisms of X-ray repair cross-complimenting group 1 (XRCC1) codon 194 (Arg to Trp), 280 (Arg to His) and 399 (Arg to Gln), and xeroderma pigmentosum group D (XPD) codon 312 (Asp to Asn) and 715 (Lys to Gln) in 108 children with ALL and 317 healthy controls using PCR-RFLP method.",Child,LOCATION_OF,Asparagine
16435384,"PROCEDURES: We genotyped polymorphisms of X-ray repair cross-complimenting group 1 (XRCC1) codon 194 (Arg to Trp), 280 (Arg to His) and 399 (Arg to Gln), and xeroderma pigmentosum group D (XPD) codon 312 (Asp to Asn) and 715 (Lys to Gln) in 108 children with ALL and 317 healthy controls using PCR-RFLP method.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16791263,"PRF1 A91V frequency was significantly increased in children with BCR-ABL positive ALL (24 vs 8.5%; P=0.0048); however, this observation includes a relatively small number of cases and needs further exploration.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16791263,"To investigate the role of A91V in ALL, we genotyped 2272 children with de novo ALL registered on the Pediatric Oncology Group ALL Classification study P9900 and 655 normal controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17456722,The biologic processes regulated by the genes we identified appear to be key determinants of the early cytoreductive response to remission induction therapy and subsequent clinical outcome in childhood ALL.,Remission Induction Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17456722,The biologic processes regulated by the genes we identified appear to be key determinants of the early cytoreductive response to remission induction therapy and subsequent clinical outcome in childhood ALL.,Genes,AFFECTS,"Biological function, NOS"
17532236,"Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood and is treated with chemotherapy alone or, in particular subgroups, with additional radiation therapy and/or stem cell transplantation.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
17532236,"Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood and is treated with chemotherapy alone or, in particular subgroups, with additional radiation therapy and/or stem cell transplantation.","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
17532236,"Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood and is treated with chemotherapy alone or, in particular subgroups, with additional radiation therapy and/or stem cell transplantation.",Pharmacotherapy,TREATS,Malignant Neoplasms
17805035,"METHODS: Alendronate (Fosamax), an inhibitor of osteoclastic bone resorption, was administered for at least 6 months to 15 children with ALL during maintenance chemotherapy, after the diagnosis of osteopenia/osteoporosis by dual energy x-ray absorptiometry.",Fosamax,ISA,Alendronate
17805035,CONCLUSIONS: This preliminary experience suggests a potential value in the use of alendronate for the treatment of osteopenia/osteoporosis in children with ALL and points to the need for a randomized controlled trial of this intervention.,Osteoporosis,PROCESS_OF,Child
17805035,"METHODS: Alendronate (Fosamax), an inhibitor of osteoclastic bone resorption, was administered for at least 6 months to 15 children with ALL during maintenance chemotherapy, after the diagnosis of osteopenia/osteoporosis by dual energy x-ray absorptiometry.",Fosamax,INHIBITS,Osteoclastic resorption
17805035,CONCLUSIONS: This preliminary experience suggests a potential value in the use of alendronate for the treatment of osteopenia/osteoporosis in children with ALL and points to the need for a randomized controlled trial of this intervention.,Alendronate,TREATS,Osteoporosis
17805035,"BACKGROUND: Osteopenia is a common consequence of the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents, due predominantly to glucocorticosteroid therapy.",Therapeutic procedure,CAUSES,Osteopenia
17805035,CONCLUSIONS: This preliminary experience suggests a potential value in the use of alendronate for the treatment of osteopenia/osteoporosis in children with ALL and points to the need for a randomized controlled trial of this intervention.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17805035,"BACKGROUND: Osteopenia is a common consequence of the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents, due predominantly to glucocorticosteroid therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
17805035,"METHODS: Alendronate (Fosamax), an inhibitor of osteoclastic bone resorption, was administered for at least 6 months to 15 children with ALL during maintenance chemotherapy, after the diagnosis of osteopenia/osteoporosis by dual energy x-ray absorptiometry.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17805035,"BACKGROUND: Osteopenia is a common consequence of the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents, due predominantly to glucocorticosteroid therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17805035,"METHODS: Alendronate (Fosamax), an inhibitor of osteoclastic bone resorption, was administered for at least 6 months to 15 children with ALL during maintenance chemotherapy, after the diagnosis of osteopenia/osteoporosis by dual energy x-ray absorptiometry.",Alendronate,INHIBITS,Osteoclastic resorption
17805035,"METHODS: Alendronate (Fosamax), an inhibitor of osteoclastic bone resorption, was administered for at least 6 months to 15 children with ALL during maintenance chemotherapy, after the diagnosis of osteopenia/osteoporosis by dual energy x-ray absorptiometry.",Dual-Energy X-Ray Absorptiometry,DIAGNOSES,Osteoporosis
17805038,We describe the outcome of children with B-precursor acute lymphoblastic leukemia registered on Pediatric Oncology Group 8602 who switched to Erwinia asparaginase (ASP) due to an allergy to the Escherichia coli product.,Escherichia coli,PRODUCES,Erwinia asparaginase
17805038,We describe the outcome of children with B-precursor acute lymphoblastic leukemia registered on Pediatric Oncology Group 8602 who switched to Erwinia asparaginase (ASP) due to an allergy to the Escherichia coli product.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17943971,"During 1995-2004, 209 children/adolescents were diagnosed with acute lymphoblastic or myeloid leukemia (ALL, AML) in Southern Sweden, of which 177 (85%), comprising 128 B-lineage ALL, 34 AML, and 15 T-cell ALL, could be analyzed for internal tandem duplications (ITD) and activating point mutations in the second tyrosine kinase domain (ATKD) of FLT3.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
17943971,"During 1995-2004, 209 children/adolescents were diagnosed with acute lymphoblastic or myeloid leukemia (ALL, AML) in Southern Sweden, of which 177 (85%), comprising 128 B-lineage ALL, 34 AML, and 15 T-cell ALL, could be analyzed for internal tandem duplications (ITD) and activating point mutations in the second tyrosine kinase domain (ATKD) of FLT3.",BCR,PART_OF,T-Lymphocyte
18079617,"Recently, the selective inhibitor of BCR-ABL kinase, imatinib, showed significant efficacy in the treatment of Ph+ALL, and imatinib-combined chemotherapy for Ph+ALL is expected to improve the prognosis of this disease.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
18079617,"In the past few decades, the results of treatment for childhood acute lymphoblastic leukemia (ALL) have achieved about 80% long-term disease-free survival (DFS).",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18079617,"In the past few decades, the results of treatment for childhood acute lymphoblastic leukemia (ALL) have achieved about 80% long-term disease-free survival (DFS).","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
18240908,"Here, we provide an overview of pharmacogenetics studies carried out in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia, attempting to find the associations between treatment responses and polymorphisms in the genes whose products are needed for metabolism, and effects of drugs used in the treatment of leukemia.",Therapeutic procedure,ADMINISTERED_TO,Child
18240908,"Here, we provide an overview of pharmacogenetics studies carried out in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia, attempting to find the associations between treatment responses and polymorphisms in the genes whose products are needed for metabolism, and effects of drugs used in the treatment of leukemia.",Therapeutic procedure,ADMINISTERED_TO,Adult
18240908,"Here, we provide an overview of pharmacogenetics studies carried out in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia, attempting to find the associations between treatment responses and polymorphisms in the genes whose products are needed for metabolism, and effects of drugs used in the treatment of leukemia.",Genes,INTERACTS_WITH,Pharmaceutical Preparations
18240908,"Here, we provide an overview of pharmacogenetics studies carried out in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia, attempting to find the associations between treatment responses and polymorphisms in the genes whose products are needed for metabolism, and effects of drugs used in the treatment of leukemia.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
18240908,"Here, we provide an overview of pharmacogenetics studies carried out in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia, attempting to find the associations between treatment responses and polymorphisms in the genes whose products are needed for metabolism, and effects of drugs used in the treatment of leukemia.","Leukemia, Myelocytic, Acute",PROCESS_OF,Adult
18240908,"Here, we provide an overview of pharmacogenetics studies carried out in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia, attempting to find the associations between treatment responses and polymorphisms in the genes whose products are needed for metabolism, and effects of drugs used in the treatment of leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18240908,"Here, we provide an overview of pharmacogenetics studies carried out in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia, attempting to find the associations between treatment responses and polymorphisms in the genes whose products are needed for metabolism, and effects of drugs used in the treatment of leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
14966833,CONCLUSION: B19 DNA was not found in any of the Guthrie cards from children who later developed ALL or in the healthy controls.,DNA,PART_OF,EVA1C
14966833,Human parvovirus B19 DNA is not detected in Guthrie cards from children who have developed acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14966833,CONCLUSION: B19 DNA was not found in any of the Guthrie cards from children who later developed ALL or in the healthy controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15390276,"PROCEDURE: We studied 15 children with acute lymphoblastic leukemia (ALL) receiving dapsone for PCP prophylaxis to determine the frequency of methemoglobinemia, and correlate its occurrence with cytochrome b5 reductase (Cb5R) enzyme levels.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15390276,"PROCEDURE: We studied 15 children with acute lymphoblastic leukemia (ALL) receiving dapsone for PCP prophylaxis to determine the frequency of methemoglobinemia, and correlate its occurrence with cytochrome b5 reductase (Cb5R) enzyme levels.",PCP PROPHYLAXIS,USES,Dapsone
15390276,"PROCEDURE: We studied 15 children with acute lymphoblastic leukemia (ALL) receiving dapsone for PCP prophylaxis to determine the frequency of methemoglobinemia, and correlate its occurrence with cytochrome b5 reductase (Cb5R) enzyme levels.",CYTOCHROME B5 REDUCTASE,PART_OF,Child
15390276,"PROCEDURE: We studied 15 children with acute lymphoblastic leukemia (ALL) receiving dapsone for PCP prophylaxis to determine the frequency of methemoglobinemia, and correlate its occurrence with cytochrome b5 reductase (Cb5R) enzyme levels.",CYTOCHROME B5 REDUCTASE,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
15390276,Children with ALL tend to be symptomatic at low levels of metHb and may have delayed detection of methemoglobinemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16212682,Visuomotor control in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16435384,The frequency of the XRCC1 haplotype B (194Trp-280Arg-399Arg) was significantly lower in children with ALL when compared to controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16484698,METHODS: Eighty-four parents of children diagnosed with acute lymphoblastic leukemia or acute myeloid leukemia who were enrolled onto a pediatric leukemia RCT at one of six US children's hospitals participated.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
16484698,METHODS: Eighty-four parents of children diagnosed with acute lymphoblastic leukemia or acute myeloid leukemia who were enrolled onto a pediatric leukemia RCT at one of six US children's hospitals participated.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16521130,"PROCEDURE: In our prospective study, MRD before and after HSCT was monitored using quantitative real-time PCR in a cohort of 36 children with ALL consecutively transplanted in our center between VIII/2000 and VII/2004.","Neoplasm, Residual",PROCESS_OF,cohort
16521130,"PROCEDURE: In our prospective study, MRD before and after HSCT was monitored using quantitative real-time PCR in a cohort of 36 children with ALL consecutively transplanted in our center between VIII/2000 and VII/2004.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16521130,Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.,Prognosis bad,PROCESS_OF,Child
16521130,Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16610629,Children with acute lymphoblastic leukemia (ALL) and deletions of glutathione-S-transferase M1 (GSTMI) and glutathione-S-transferase T1 (GSTT1) have better event-free survival and lower rates of relapses than those with GSTM1 and/or GSTT1.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16610629,Children with acute lymphoblastic leukemia (ALL) and deletions of glutathione-S-transferase M1 (GSTMI) and glutathione-S-transferase T1 (GSTT1) have better event-free survival and lower rates of relapses than those with GSTM1 and/or GSTT1.,DELETION,PROCESS_OF,Child
16610629,Children with acute lymphoblastic leukemia (ALL) and deletions of glutathione-S-transferase M1 (GSTMI) and glutathione-S-transferase T1 (GSTT1) have better event-free survival and lower rates of relapses than those with GSTM1 and/or GSTT1.,GSTM1 gene | GSTM1,PART_OF,Child
16610629,Children with acute lymphoblastic leukemia (ALL) and deletions of glutathione-S-transferase M1 (GSTMI) and glutathione-S-transferase T1 (GSTT1) have better event-free survival and lower rates of relapses than those with GSTM1 and/or GSTT1.,GSTM1 gene | GSTM1,ASSOCIATED_WITH,DELETION
16610629,Children with acute lymphoblastic leukemia (ALL) and deletions of glutathione-S-transferase M1 (GSTMI) and glutathione-S-transferase T1 (GSTT1) have better event-free survival and lower rates of relapses than those with GSTM1 and/or GSTT1.,GSTM1 gene | GSTM1,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
16610629,[Genetic polymorphism of glutathione-S-transferase M1 and T1 in children with acute lymphoblastic leukemia].,"Polymorphism, Genetic",PROCESS_OF,Child
16610629,[Genetic polymorphism of glutathione-S-transferase M1 and T1 in children with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16856155,"BACKGROUND: Although mercaptopurine (MP) is conventionally used to treat childhood acute lymphoblastic leukemia (ALL), thioguanine (TG) is a more potent thiopurine in vitro and, when administered orally to patients, achieves cytotoxic drug concentrations in the cerebrospinal fluid (CSF).",Thioguanine,ISA,thiopurine
16856155,"BACKGROUND: Although mercaptopurine (MP) is conventionally used to treat childhood acute lymphoblastic leukemia (ALL), thioguanine (TG) is a more potent thiopurine in vitro and, when administered orally to patients, achieves cytotoxic drug concentrations in the cerebrospinal fluid (CSF).",Thioguanine,ADMINISTERED_TO,Patients
16856155,Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).,Treatment Protocols,TREATS,Child
16856155,Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16856155,"BACKGROUND: Although mercaptopurine (MP) is conventionally used to treat childhood acute lymphoblastic leukemia (ALL), thioguanine (TG) is a more potent thiopurine in vitro and, when administered orally to patients, achieves cytotoxic drug concentrations in the cerebrospinal fluid (CSF).",thiopurine,ADMINISTERED_TO,Patients
16856155,Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
16856155,"BACKGROUND: Although mercaptopurine (MP) is conventionally used to treat childhood acute lymphoblastic leukemia (ALL), thioguanine (TG) is a more potent thiopurine in vitro and, when administered orally to patients, achieves cytotoxic drug concentrations in the cerebrospinal fluid (CSF).",6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16856155,"BACKGROUND: Although mercaptopurine (MP) is conventionally used to treat childhood acute lymphoblastic leukemia (ALL), thioguanine (TG) is a more potent thiopurine in vitro and, when administered orally to patients, achieves cytotoxic drug concentrations in the cerebrospinal fluid (CSF).",Cerebrospinal Fluid,LOCATION_OF,Thioguanine
17061283,Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,Child
17061283,Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17061283,Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
17061283,Most children diagnosed today with acute lymphoblastic leukemia (ALL) will be cured.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17921849,PATIENTS AND METHODS: A total of 121 children with acute lymphoblastic leukemia on HDMTX therapy were enrolled into this study.,Therapeutic procedure,USES,Methotrexate
17921849,PATIENTS AND METHODS: A total of 121 children with acute lymphoblastic leukemia on HDMTX therapy were enrolled into this study.,Methotrexate,ISA,Therapeutic procedure
17921849,OBJECTIVES: The aim of this study was to observe the morbidity of elimination delay in Chinese children with acute lymphoblastic leukemia during high-dose methotrexate (HDMTX) therapy and the toxicities.,Toxic effect,PROCESS_OF,Child
17921849,OBJECTIVES: The aim of this study was to observe the morbidity of elimination delay in Chinese children with acute lymphoblastic leukemia during high-dose methotrexate (HDMTX) therapy and the toxicities.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17921849,OBJECTIVES: The aim of this study was to observe the morbidity of elimination delay in Chinese children with acute lymphoblastic leukemia during high-dose methotrexate (HDMTX) therapy and the toxicities.,Therapeutic procedure,USES,Methotrexate
17921849,OBJECTIVES: The aim of this study was to observe the morbidity of elimination delay in Chinese children with acute lymphoblastic leukemia during high-dose methotrexate (HDMTX) therapy and the toxicities.,Methotrexate,ISA,Therapeutic procedure
17921849,PATIENTS AND METHODS: A total of 121 children with acute lymphoblastic leukemia on HDMTX therapy were enrolled into this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17921849,Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17952026,"Second malignancies are a significant concern for survivors of childhood acute lymphoblastic leukemia (ALL), in particular patients who have been treated with cranial irradiation.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
17952026,"Second malignancies are a significant concern for survivors of childhood acute lymphoblastic leukemia (ALL), in particular patients who have been treated with cranial irradiation.",Cranial Irradiation,TREATS,Patients
17952026,"Second malignancies are a significant concern for survivors of childhood acute lymphoblastic leukemia (ALL), in particular patients who have been treated with cranial irradiation.",Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12870051,OBJECTIVE: To determine probable alterations in the p16 gene in children with acute lymphoblastic leukemias using the polymerase chain reaction (PCR) and direct DNA sequencing and also to analyze event-free survival (EFS).,Child,LOCATION_OF,CDKN2A gene | CDKN2A
12870051,OBJECTIVE: To determine probable alterations in the p16 gene in children with acute lymphoblastic leukemias using the polymerase chain reaction (PCR) and direct DNA sequencing and also to analyze event-free survival (EFS).,Child,LOCATION_OF,DNA Sequence
12870051,OBJECTIVE: To determine probable alterations in the p16 gene in children with acute lymphoblastic leukemias using the polymerase chain reaction (PCR) and direct DNA sequencing and also to analyze event-free survival (EFS).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12870051,"Alterations in this gene have been reported for various neoplasia types, including acute lymphoblastic leukemias (ALL), especially T-cell acute lymphoblastic leukemias (ALL).",Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
12870051,"The Kaplan-Meyer survival curves and the log-rank test showed no significant differences in 5-year EFS between children with normal or altered p16, or between patients with B-ALL carrying normal or altered p16 gene.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
12870051,Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias.,DELETION,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12870051,"The Kaplan-Meyer survival curves and the log-rank test showed no significant differences in 5-year EFS between children with normal or altered p16, or between patients with B-ALL carrying normal or altered p16 gene.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12870051,PARTICIPANTS: Fifty-six children with ALL (mean age 4 years).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14660309,"Between 2001 and 2002, 20 children with acute lymphoblastic leukemia at the Dr.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14698648,This concluding section of the series will evaluate the role of host environment in the development of thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL).,Thromboembolism,AFFECTS,Child
14698648,This concluding section of the series will evaluate the role of host environment in the development of thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14698648,Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14698648,Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment.,Thrombosis,PROCESS_OF,Child
14698648,The few studies conducted so far in children with ALL have reported wide variability in the prevalence of prothrombotic defects and its impact on the risk of TE.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15562558,"This study was designed to assess the predictive value of an MTT (3-[4,5-dimethylthiazol-2,5-diphenyl] tetrazolium bromide) in vitro assay for the evaluation of leukemic cell resistance/sensitivity to cytotoxic drugs, and to compare these results with clinical and laboratory parameters in cases of childhood acute lymphoblastic leukemia (ALL).The chemoresistance of leukemic cells was ascertained by means of an MTT assay in 32 previously untreated children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15562558,"This study was designed to assess the predictive value of an MTT (3-[4,5-dimethylthiazol-2,5-diphenyl] tetrazolium bromide) in vitro assay for the evaluation of leukemic cell resistance/sensitivity to cytotoxic drugs, and to compare these results with clinical and laboratory parameters in cases of childhood acute lymphoblastic leukemia (ALL).The chemoresistance of leukemic cells was ascertained by means of an MTT assay in 32 previously untreated children with ALL.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
15562558,"This study was designed to assess the predictive value of an MTT (3-[4,5-dimethylthiazol-2,5-diphenyl] tetrazolium bromide) in vitro assay for the evaluation of leukemic cell resistance/sensitivity to cytotoxic drugs, and to compare these results with clinical and laboratory parameters in cases of childhood acute lymphoblastic leukemia (ALL).The chemoresistance of leukemic cells was ascertained by means of an MTT assay in 32 previously untreated children with ALL.",monooxyethylene trimethylolpropane tristearate,INTERACTS_WITH,Cytotoxic agent
16324833,An important problem in the treatment of children with acute lymphoblastic leukaemia (ALL) is pre-existent or acquired resistance to structurally and functionally unrelated chemotherapeutic compounds.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16324833,An important problem in the treatment of children with acute lymphoblastic leukaemia (ALL) is pre-existent or acquired resistance to structurally and functionally unrelated chemotherapeutic compounds.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16324833,An important problem in the treatment of children with acute lymphoblastic leukaemia (ALL) is pre-existent or acquired resistance to structurally and functionally unrelated chemotherapeutic compounds.,Pharmacotherapy,TREATS,Child
16421910,BACKGROUND: Adolescents with acute lymphoblastic leukaemia (ALL) have languished in the shadow of success of the outcome of therapy in childhood ALL.,"Leukemia, Lymphocytic, Acute",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
16456858,"Children with acute lymphoblastic leukemia (ALL) can experience a decrease in their white blood count (WBC) prior to chemotherapy, a phenomenon commonly attributed to the administration of allopurinol and hydration.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16511054,Bacterial L-asparaginases have been used as therapeutic agents in the treatment of acute childhood lymphoblastic leukaemia for over 30 y.,Therapeutic agent (substance),TREATS,"Leukemia, Lymphocytic, Acute"
16511054,Bacterial L-asparaginases have been used as therapeutic agents in the treatment of acute childhood lymphoblastic leukaemia for over 30 y.,ASPARAGINASE,ISA,Therapeutic agent (substance)
16511054,Bacterial L-asparaginases have been used as therapeutic agents in the treatment of acute childhood lymphoblastic leukaemia for over 30 y.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
16627760,"To identify genes associated with this response, we analyzed gene expression of diagnostic lymphoblasts from 189 children with ALL and compared the findings with minimal residual disease (MRD) levels on days 19 and 46 of remission induction treatment.",Child,LOCATION_OF,Genes
16627760,"To identify genes associated with this response, we analyzed gene expression of diagnostic lymphoblasts from 189 children with ALL and compared the findings with minimal residual disease (MRD) levels on days 19 and 46 of remission induction treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16627760,Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
16627760,Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.,Genes,PREDISPOSES,"Neoplasm, Residual"
16818274,"RESULTS: Bi-allelic and mono-allelic inactivation were found in, respectively, 38 (17%) and 31 (14%) of 227 children with B-lineage ALL enrolled in EORTC trials.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17922427,METHODS: Samples of bone marrow or peripheral blood were collected from 95 newly diagnosed ALL children and the TEL-AML1 fusion gene was detected using nested reverse transcription-polymerase chain reaction (RT-PCR).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14985880,"Imaging findings of recurrent acute lymphoblastic leukemia in children and young adults, with emphasis on MRI.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
14985880,"Imaging findings of recurrent acute lymphoblastic leukemia in children and young adults, with emphasis on MRI.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15009002,"Therefore a prospective study was undertaken to evaluate serial changes in percentage bone mineral content (BMC), adiposity and serum leptin concentrations during 2 years of treatment of children with ALL with chemotherapy but without cranial irradiation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15009002,"Therefore a prospective study was undertaken to evaluate serial changes in percentage bone mineral content (BMC), adiposity and serum leptin concentrations during 2 years of treatment of children with ALL with chemotherapy but without cranial irradiation.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15009002,"Therefore a prospective study was undertaken to evaluate serial changes in percentage bone mineral content (BMC), adiposity and serum leptin concentrations during 2 years of treatment of children with ALL with chemotherapy but without cranial irradiation.",Pharmacotherapy,TREATS,Child
15010194,Platelet aggregation in children with acute lymphoblastic leukemia during induction of remission therapy.,Platelet aggregation,PROCESS_OF,Child
15010194,Platelet aggregation in children with acute lymphoblastic leukemia during induction of remission therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15024455,Validation of a multiplex RT-PCR assay for screening significant oncogene fusion transcripts in children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15024967,"These are acquired rapidly, and possibly in utero also, in infant acute lymphoblastic leukemia (ALL) but post-natally for most childhood ALL and acute myeloblastic leukemia (AML).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
15024971,"In this context, several ongoing cooperative study groups have adopted a MRD-based risk group classification to explore whether a better tailored treatment would result in further improvement in cure rates for children with ALL.",Therapeutic procedure,TREATS,Child
15024971,"In this context, several ongoing cooperative study groups have adopted a MRD-based risk group classification to explore whether a better tailored treatment would result in further improvement in cure rates for children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15024971,"In this context, several ongoing cooperative study groups have adopted a MRD-based risk group classification to explore whether a better tailored treatment would result in further improvement in cure rates for children with ALL.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
15049013,PROCEDURE: Human sera were obtained from 68 children with primary B-lineage ALL at diagnosis and 46 healthy children (control).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15049013,PROCEDURE: Human sera were obtained from 68 children with primary B-lineage ALL at diagnosis and 46 healthy children (control).,Serum,PART_OF,Human
15494605,"METHODS: Overall, 1905 children (aged 0-14 years) with acute lymphoblastic leukemia (ALL) and 299 children with acute myeloid leukemia (AML) diagnosed between January 1, 1984, and December 31, 1999, were identified in the Nordic Society of Paediatric Haematology and Oncology acute leukemia database.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15494605,"METHODS: Overall, 1905 children (aged 0-14 years) with acute lymphoblastic leukemia (ALL) and 299 children with acute myeloid leukemia (AML) diagnosed between January 1, 1984, and December 31, 1999, were identified in the Nordic Society of Paediatric Haematology and Oncology acute leukemia database.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15494605,"METHODS: Overall, 1905 children (aged 0-14 years) with acute lymphoblastic leukemia (ALL) and 299 children with acute myeloid leukemia (AML) diagnosed between January 1, 1984, and December 31, 1999, were identified in the Nordic Society of Paediatric Haematology and Oncology acute leukemia database.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
15494605,"METHODS: Overall, 1905 children (aged 0-14 years) with acute lymphoblastic leukemia (ALL) and 299 children with acute myeloid leukemia (AML) diagnosed between January 1, 1984, and December 31, 1999, were identified in the Nordic Society of Paediatric Haematology and Oncology acute leukemia database.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
15494605,"However, children with ALL did not weigh more at birth than their siblings.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15583359,"Children with high-risk ALL received the most MTX, especially during the most intensive phase of treatment (consolidation).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15583359,"Children with high-risk ALL received the most MTX, especially during the most intensive phase of treatment (consolidation).",Methotrexate,ADMINISTERED_TO,Child
15617994,"Since vincristine plays a key role in the treatment of childhood acute lymphoblastic leukaemia (ALL), it is worthwhile to explore if efficacy can be improved by individual dose adjustment.",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15983429,Long-term outcome of ph-negative acute lymphoblastic leukaemia in adults: a single centre experience.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
16354839,"Global expression profiles of a consecutive series of 121 childhood acute leukemias (87 B lineage acute lymphoblastic leukemias, 11 T cell acute lymphoblastic leukemias, and 23 acute myeloid leukemias), six normal bone marrows, and 10 normal hematopoietic subpopulations of different lineages and maturations were ascertained by using 27K cDNA microarrays.",Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
17605825,The mothers of 97 children with ALL and of 303 controls were asked about vitamin and mineral supplements taken during pregnancy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17724682,METHODS: Health records of children aged </=18 years who were diagnosed with ALL between 1998 and 2004 were reviewed.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17724682,Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17889709,A series of 92 Chinese children newly diagnosed with acute lymphoblastic leukemia (ALL) were examined for the ETV6-RUNX1 (previously TEL-AML1) fusion gene by using a nested reverse transcriptase-polymerase chain reaction.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17889714,It does not occur with other primary chromosomal abnormalities in acute ALL.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
14647408,"The analysis of 201 children treated with methotrexate for childhood acute lymphoblastic leukemia (ALL) showed that patients with either the MTHFR T677A1298 haplotype or MTHFD1 A1958 variant had a lower probability of event-free survival (EFS) in univariate analysis (hazard ratio (HR)=2.2, 95% confidence interval (CI), 1.0-4.7 and 2.8, 95% CI, 1.1-7.3, respectively).",Methotrexate,TREATS,Child
14647408,"The analysis of 201 children treated with methotrexate for childhood acute lymphoblastic leukemia (ALL) showed that patients with either the MTHFR T677A1298 haplotype or MTHFD1 A1958 variant had a lower probability of event-free survival (EFS) in univariate analysis (hazard ratio (HR)=2.2, 95% confidence interval (CI), 1.0-4.7 and 2.8, 95% CI, 1.1-7.3, respectively).",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
14704033,"Microarray-based identification of several translocations has been performed in acute lymphoblastic leukemia (ALL), leading to the discovery of t(1;19), t(12;21), and 11q23 translocations, and in acute myeloid leukemia (AML), finding t(8;21), inv(16), and t(15;17).",Chromosomal translocation,COEXISTS_WITH,"Leukemia, Myelocytic, Acute"
14704033,"Microarray-based identification of several translocations has been performed in acute lymphoblastic leukemia (ALL), leading to the discovery of t(1;19), t(12;21), and 11q23 translocations, and in acute myeloid leukemia (AML), finding t(8;21), inv(16), and t(15;17).",Chromosomal translocation,COEXISTS_WITH,"Leukemia, Myelocytic, Acute"
14704033,"Microarray-based identification of several translocations has been performed in acute lymphoblastic leukemia (ALL), leading to the discovery of t(1;19), t(12;21), and 11q23 translocations, and in acute myeloid leukemia (AML), finding t(8;21), inv(16), and t(15;17).",Chromosomal translocation,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
14704033,"Microarray-based identification of several translocations has been performed in acute lymphoblastic leukemia (ALL), leading to the discovery of t(1;19), t(12;21), and 11q23 translocations, and in acute myeloid leukemia (AML), finding t(8;21), inv(16), and t(15;17).",Chromosomal translocation,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
15833833,Here we describe the use of oligonucleotide microarrays to characterize single nucleotide polymorphisms (SNPs) in lymphoblasts isolated from children with acute lymphoblastic leukemia for the pan-genomic mapping of LOH with a resolution of 100 to 200 kb.,lymphoblast,LOCATION_OF,Single Nucleotide Polymorphism
15833833,Here we describe the use of oligonucleotide microarrays to characterize single nucleotide polymorphisms (SNPs) in lymphoblasts isolated from children with acute lymphoblastic leukemia for the pan-genomic mapping of LOH with a resolution of 100 to 200 kb.,Child,LOCATION_OF,Single Nucleotide Polymorphism
15833833,Here we describe the use of oligonucleotide microarrays to characterize single nucleotide polymorphisms (SNPs) in lymphoblasts isolated from children with acute lymphoblastic leukemia for the pan-genomic mapping of LOH with a resolution of 100 to 200 kb.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15908976,The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.,Acute graft-versus-host disease,PROCESS_OF,Child
15908976,The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
15908976,The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15908976,The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.,Cyclosporine,AFFECTS,Acute graft-versus-host disease
15908976,The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.,Acute graft-versus-host disease,PROCESS_OF,Adolescent
15982341,"A common profile for children with ALL with an ETV6-RUNX1 fusion, amplification or deletion of ETV6, amplification of RUNX1 or hyperdiploidy with an additional chromosome 21 was identified.",Hyperploidy,PROCESS_OF,Child
15982341,"A common profile for children with ALL with an ETV6-RUNX1 fusion, amplification or deletion of ETV6, amplification of RUNX1 or hyperdiploidy with an additional chromosome 21 was identified.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15982341,"A common profile for children with ALL with an ETV6-RUNX1 fusion, amplification or deletion of ETV6, amplification of RUNX1 or hyperdiploidy with an additional chromosome 21 was identified.","Chromosomes, Human, Pair 21",PART_OF,Child
15982341,"A common profile for children with ALL with an ETV6-RUNX1 fusion, amplification or deletion of ETV6, amplification of RUNX1 or hyperdiploidy with an additional chromosome 21 was identified.",DELETION,PROCESS_OF,Child
16019535,"Methylenetetrahydrofolate reductase (MTHFR) polymorphisms have been associated not only with the risk for acute lymphoblastic leukemia (ALL) in adults and children, but also with increased methotrexate toxicity.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16019535,"Methylenetetrahydrofolate reductase (MTHFR) polymorphisms have been associated not only with the risk for acute lymphoblastic leukemia (ALL) in adults and children, but also with increased methotrexate toxicity.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
16019535,"Methylenetetrahydrofolate reductase (MTHFR) polymorphisms have been associated not only with the risk for acute lymphoblastic leukemia (ALL) in adults and children, but also with increased methotrexate toxicity.",Oxidoreductase,NEG_PREDISPOSES,"Leukemia, Lymphocytic, Acute"
16020115,Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment.,bone metabolism,PROCESS_OF,Child
16020115,The aim of this study was to evaluate abnormalities in bone mass and mineral homeostasis in children with ALL after induction therapy (during consolidation treatment).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16020115,"The data demonstrate that bone metabolism in children with ALL during consolidation therapy is disturbed, resulting in a reduced BMD and z-score with respect to healthy controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16020115,Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16020115,"The data demonstrate that bone metabolism in children with ALL during consolidation therapy is disturbed, resulting in a reduced BMD and z-score with respect to healthy controls.",bone metabolism,PROCESS_OF,Child
16020115,Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment.,Chemotherapy-Oncologic Procedure,ISA,Therapeutic procedure
16020115,"In addition, children with ALL had reduced lumbar BMDs (z-score -0.817) in comparison to healthy controls (z-score -0.353) (p = .04).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16020115,"Among the 20 children with ALL (12 boys and 8 girls), 12 presented z-scores < 1 SD (normal) and 8 were osteopenic (z-score between 1 and 2.5 SD).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16020115,"Lumbar spine (L2-L4) bone mineral density (BMD, g/cm(2)) was measured by dual energy X-ray absorptiometry in 20 children with ALL, a median of 25.9 months postdiagnosis and results were expressed as z-scores relative to healthy Caucasian children (controls).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16020115,The aim of this study was to evaluate abnormalities in bone mass and mineral homeostasis in children with ALL after induction therapy (during consolidation treatment).,Homeostasis,PROCESS_OF,Child
16326407,"In the present study the authors evaluated the status of spinal bone mineral density (BMD) using dual-energy X-ray absorptiometry in a group of 31 children with acute lymphoblastic leukemia, treated by ALL-BFM protocols without irradiation, at different phases of their treatment.",Dual-Energy X-Ray Absorptiometry,ADMINISTERED_TO,Author
16326407,"In the present study the authors evaluated the status of spinal bone mineral density (BMD) using dual-energy X-ray absorptiometry in a group of 31 children with acute lymphoblastic leukemia, treated by ALL-BFM protocols without irradiation, at different phases of their treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16326407,"In the present study the authors evaluated the status of spinal bone mineral density (BMD) using dual-energy X-ray absorptiometry in a group of 31 children with acute lymphoblastic leukemia, treated by ALL-BFM protocols without irradiation, at different phases of their treatment.",Berlin-Frankfort-Munster protocol,TREATS,"Leukemia, Lymphocytic, Acute"
16928306,"The results showed that (1) among 119 children with B-ALL, 22 (18.5%) were TEL-AML1 positive and classified as L2 morphological subtype.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17313277,"The purpose of this study was to determine the effects of an intrahospital, short-duration (8 weeks) exercise training program on muscle strength and endurance and functional mobility of children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17641854,The expression of SODD and phospho-NF-kappaB-p65 proteins in bone marrow cells was detected by immunohistochemistry in 25 children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17641854,The expression of SODD and phospho-NF-kappaB-p65 proteins in bone marrow cells was detected by immunohistochemistry in 25 children with ALL.,Bone Marrow Cells,LOCATION_OF,synaptotagmin I | RELA | SYT1 | GORASP1 | WNK1
17641854,The expression of SODD and phospho-NF-kappaB-p65 proteins in bone marrow cells was detected by immunohistochemistry in 25 children with ALL.,Child,LOCATION_OF,synaptotagmin I | RELA | SYT1 | GORASP1 | WNK1
17724682,CONCLUSIONS: Clinical and laboratory features at the time of presentation identified a group of children with ALL at low risk for TLS that may benefit from a risk-stratified approach directed at reduced TLS monitoring and prophylaxis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12816874,"In this study the expression of the MRP2, MRP3, MRP4, MRP5, and SMRP genes was measured using TaqMan real-time polymerase chain reaction (PCR) in 103 children with previously untreated acute lymphoblastic leukemia (ALL) (precursor B-cell ALL [B-ALL], n = 71; T-cell ALL [T-ALL], n = 32).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
12816874,"In this study the expression of the MRP2, MRP3, MRP4, MRP5, and SMRP genes was measured using TaqMan real-time polymerase chain reaction (PCR) in 103 children with previously untreated acute lymphoblastic leukemia (ALL) (precursor B-cell ALL [B-ALL], n = 71; T-cell ALL [T-ALL], n = 32).",multidrug resistance-associated protein 3,PART_OF,ABCC2 | KLHL1 | SYCE1L
12816874,"In this study the expression of the MRP2, MRP3, MRP4, MRP5, and SMRP genes was measured using TaqMan real-time polymerase chain reaction (PCR) in 103 children with previously untreated acute lymphoblastic leukemia (ALL) (precursor B-cell ALL [B-ALL], n = 71; T-cell ALL [T-ALL], n = 32).",Child,LOCATION_OF,ABCC4
12816874,"In this study the expression of the MRP2, MRP3, MRP4, MRP5, and SMRP genes was measured using TaqMan real-time polymerase chain reaction (PCR) in 103 children with previously untreated acute lymphoblastic leukemia (ALL) (precursor B-cell ALL [B-ALL], n = 71; T-cell ALL [T-ALL], n = 32).",Child,LOCATION_OF,ABCC5 | MSLN
12816874,"In this study the expression of the MRP2, MRP3, MRP4, MRP5, and SMRP genes was measured using TaqMan real-time polymerase chain reaction (PCR) in 103 children with previously untreated acute lymphoblastic leukemia (ALL) (precursor B-cell ALL [B-ALL], n = 71; T-cell ALL [T-ALL], n = 32).",Child,LOCATION_OF,ABCC5
12816874,"In this study the expression of the MRP2, MRP3, MRP4, MRP5, and SMRP genes was measured using TaqMan real-time polymerase chain reaction (PCR) in 103 children with previously untreated acute lymphoblastic leukemia (ALL) (precursor B-cell ALL [B-ALL], n = 71; T-cell ALL [T-ALL], n = 32).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12816874,"In this study the expression of the MRP2, MRP3, MRP4, MRP5, and SMRP genes was measured using TaqMan real-time polymerase chain reaction (PCR) in 103 children with previously untreated acute lymphoblastic leukemia (ALL) (precursor B-cell ALL [B-ALL], n = 71; T-cell ALL [T-ALL], n = 32).","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
12920041,Resistance of leukemic cells to chemotherapeutic agents is associated with an unfavorable outcome in pediatric acute lymphoblastic leukemia (ALL).,Antineoplastic Agents,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12920041,"To investigate the underlying mechanisms of cellular drug resistance, the activation of various apoptotic parameters in leukemic cells from 50 children with ALL was studied after in vitro exposure with 4 important drugs in ALL therapy (prednisolone, vincristine, l-asparaginase, and daunorubicin).",ASPARAGINASE,ISA,Therapeutic procedure
12920041,"To investigate the underlying mechanisms of cellular drug resistance, the activation of various apoptotic parameters in leukemic cells from 50 children with ALL was studied after in vitro exposure with 4 important drugs in ALL therapy (prednisolone, vincristine, l-asparaginase, and daunorubicin).",Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute"
12920041,"To investigate the underlying mechanisms of cellular drug resistance, the activation of various apoptotic parameters in leukemic cells from 50 children with ALL was studied after in vitro exposure with 4 important drugs in ALL therapy (prednisolone, vincristine, l-asparaginase, and daunorubicin).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12920041,"To investigate the underlying mechanisms of cellular drug resistance, the activation of various apoptotic parameters in leukemic cells from 50 children with ALL was studied after in vitro exposure with 4 important drugs in ALL therapy (prednisolone, vincristine, l-asparaginase, and daunorubicin).",Vincristine,ISA,Therapeutic procedure
12920041,"To investigate the underlying mechanisms of cellular drug resistance, the activation of various apoptotic parameters in leukemic cells from 50 children with ALL was studied after in vitro exposure with 4 important drugs in ALL therapy (prednisolone, vincristine, l-asparaginase, and daunorubicin).",prednisolone,ISA,Therapeutic procedure
12920041,"To investigate the underlying mechanisms of cellular drug resistance, the activation of various apoptotic parameters in leukemic cells from 50 children with ALL was studied after in vitro exposure with 4 important drugs in ALL therapy (prednisolone, vincristine, l-asparaginase, and daunorubicin).",Daunorubicin,ISA,Therapeutic procedure
12946997,Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.,Immunoglobulins,PART_OF,Clone
12946997,Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.,T cell receptor gene rearrangement,METHOD_OF,Detection
12946997,"We analyzed the sequences of Ig and TCR gene rearrangements obtained at presentation and relapse in 41 children with ALL to study clonal stability, which has important implications for monitoring MRD, during the course of the disease.","Leukemia, Lymphocytic, Acute",AFFECTS,"Neoplasm, Residual"
12946997,Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.,Sequence Analysis,METHOD_OF,Detection
12946997,"We analyzed the sequences of Ig and TCR gene rearrangements obtained at presentation and relapse in 41 children with ALL to study clonal stability, which has important implications for monitoring MRD, during the course of the disease.",Immunoglobulins,TREATS,Child
12946997,Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.,Diagnosis,TREATS,Pathogenesis
12946997,"We analyzed the sequences of Ig and TCR gene rearrangements obtained at presentation and relapse in 41 children with ALL to study clonal stability, which has important implications for monitoring MRD, during the course of the disease.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12946997,Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12946997,"We analyzed the sequences of Ig and TCR gene rearrangements obtained at presentation and relapse in 41 children with ALL to study clonal stability, which has important implications for monitoring MRD, during the course of the disease.",Immunoglobulins,TREATS,"Leukemia, Lymphocytic, Acute"
12946997,Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.,Immunoglobulins,TREATS,Child
12946997,Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements provide clonal markers useful for diagnosis and measurement of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
12946997,Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.,Immunoglobulins,TREATS,"Leukemia, Lymphocytic, Acute"
12946997,Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements provide clonal markers useful for diagnosis and measurement of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).,Diagnosis,USES,Immunoglobulins
14616997,Early relapse was more common in children with T-ALL and those with unfavourable cytogenetics.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14616997,We have reviewed the outcome after relapse in a cohort of 505 children with acute lymphoblastic leukaemia (ALL) seen at a single institution.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14675406,Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172).,Pharmacotherapy,ADMINISTERED_TO,Child
14675406,Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
14675406,The Medical Research Council UKALL XI trial recruited 2090 children with ALL between 1990 and 1997.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14675406,Concern about late adverse effects of cranial radiotherapy (XRT) has led to alternative approaches to eliminate leukaemia from the central nervous system (CNS) in childhood acute lymphoblastic leukaemia (ALL).,leukemia,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
14675406,Concern about late adverse effects of cranial radiotherapy (XRT) has led to alternative approaches to eliminate leukaemia from the central nervous system (CNS) in childhood acute lymphoblastic leukaemia (ALL).,Radiation therapy,TREATS,leukemia
15125607,Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
15125609,"Specific chromosome abnormalities are associated with prognosis in childhood acute lymphoblastic leukemia (ALL); however, chromosome abnormalities have not been evaluated for prognostic value in pediatric Burkitt and Burkitt-like lymphomas.",Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15770663,"An enhanced linkage-specific 9-O-acetylated sialic acid (9-O-AcSA) on peripheral blood mononuclear cells (PBMC) of children with acute lymphoblastic leukaemia, ALL (PBMC(ALL), 9-O-AcSA+ cells) was demonstrated by using a lectin, Achatinin-H, whose lectinogenic epitope was 9-O-AcSAalpha2-6GalNAc.",Peripheral blood mononuclear cell,PART_OF,Child
15770663,"An enhanced linkage-specific 9-O-acetylated sialic acid (9-O-AcSA) on peripheral blood mononuclear cells (PBMC) of children with acute lymphoblastic leukaemia, ALL (PBMC(ALL), 9-O-AcSA+ cells) was demonstrated by using a lectin, Achatinin-H, whose lectinogenic epitope was 9-O-AcSAalpha2-6GalNAc.",achatinin(H),ISA,Lectin
15770663,"An enhanced linkage-specific 9-O-acetylated sialic acid (9-O-AcSA) on peripheral blood mononuclear cells (PBMC) of children with acute lymphoblastic leukaemia, ALL (PBMC(ALL), 9-O-AcSA+ cells) was demonstrated by using a lectin, Achatinin-H, whose lectinogenic epitope was 9-O-AcSAalpha2-6GalNAc.",Peripheral blood mononuclear cell,LOCATION_OF,N-Acetylneuraminic Acid
15770663,"An enhanced linkage-specific 9-O-acetylated sialic acid (9-O-AcSA) on peripheral blood mononuclear cells (PBMC) of children with acute lymphoblastic leukaemia, ALL (PBMC(ALL), 9-O-AcSA+ cells) was demonstrated by using a lectin, Achatinin-H, whose lectinogenic epitope was 9-O-AcSAalpha2-6GalNAc.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16184475,"Associations were assessed using odds ratios (OR) calculated by time of exposure (birth, diagnosis), diagnostic group (all cancers, leukaemia, acute lymphoblastic leukaemia (ALL), central nervous system tumours, other cancers), level of occupational social contact (high, medium, low), urban-rural status at diagnosis and occupational title.","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
16184475,"Associations were assessed using odds ratios (OR) calculated by time of exposure (birth, diagnosis), diagnostic group (all cancers, leukaemia, acute lymphoblastic leukaemia (ALL), central nervous system tumours, other cancers), level of occupational social contact (high, medium, low), urban-rural status at diagnosis and occupational title.","Leukemia, Lymphocytic, Acute",ISA,leukemia
16184475,"Associations were assessed using odds ratios (OR) calculated by time of exposure (birth, diagnosis), diagnostic group (all cancers, leukaemia, acute lymphoblastic leukaemia (ALL), central nervous system tumours, other cancers), level of occupational social contact (high, medium, low), urban-rural status at diagnosis and occupational title.",leukemia,ISA,Malignant Neoplasms
17442849,"Pediatric Oncology Group (POG) protocol 9201 enrolled children with lesser-risk B-lineage acute lymphoblastic leukemia (ALL) defined by age (1-9), white blood cell count (WBC) less than 50 x 10(9)/L (50,000/microL), DNA findings of trisomies 4 and 10 (or DNA index > 1.16), and lack of overt central nervous system (CNS) leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17442849,This indicates the great majority of children with lesser-risk B-lineage ALL are curable without agents with substantial late effects.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17442849,This indicates the great majority of children with lesser-risk B-lineage ALL are curable without agents with substantial late effects.,Late effect of,NEG_PROCESS_OF,Child
17641854,It was concluded that SODD may be closely related to the clinical classification and prognosis of ALL in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12835723,"Through inhibition of purine de novo synthesis and enhancement of the bioavailability, HDM may increase the incorporation into DNA of 6-thioguanine nucleotides, the cytotoxic metabolites of 6 MP.A total of 26 children diagnosed 3/1996-4/2001 with ALL received five courses of HDM (5 g/m(2)/24 h with leucovorin rescue) at 8 weeks intervals during their first year of maintenance therapy with oral methotrexate (20 mg/m(2)/week) and 6MP (75 mg/m(2)/day).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12835723,Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia.,Methotrexate,TREATS,Childhood Leukemia
12835723,"Through inhibition of purine de novo synthesis and enhancement of the bioavailability, HDM may increase the incorporation into DNA of 6-thioguanine nucleotides, the cytotoxic metabolites of 6 MP.A total of 26 children diagnosed 3/1996-4/2001 with ALL received five courses of HDM (5 g/m(2)/24 h with leucovorin rescue) at 8 weeks intervals during their first year of maintenance therapy with oral methotrexate (20 mg/m(2)/week) and 6MP (75 mg/m(2)/day).",Maintenance therapy,USES,Methotrexate
12835723,"Through inhibition of purine de novo synthesis and enhancement of the bioavailability, HDM may increase the incorporation into DNA of 6-thioguanine nucleotides, the cytotoxic metabolites of 6 MP.A total of 26 children diagnosed 3/1996-4/2001 with ALL received five courses of HDM (5 g/m(2)/24 h with leucovorin rescue) at 8 weeks intervals during their first year of maintenance therapy with oral methotrexate (20 mg/m(2)/week) and 6MP (75 mg/m(2)/day).",Maintenance therapy,USES,6-Mercaptopurine
12947061,Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
12947061,"CONCLUSION: Drug resistance profiles identify patients at higher risk of early treatment failures and may, therefore, be used to improve risk-group stratification of children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12947061,"PURPOSE: To confirm the prognostic value of a drug resistance profile combining prednisolone, vincristine, and l-asparaginase (PVA) cytotoxicity in an independent group of children with acute lymphoblastic leukemia (ALL) treated with a different protocol and analyzed at longer follow-up compared with our previous study of patients treated according to the Dutch Childhood Leukemia Study Group (DCLSG) ALL VII/VIII protocol.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12947061,Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.,ASPARAGINASE,TREATS,Child
12947061,Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15051768,We sought to determine if changes in BMD are common long-term sequelae in children with ALL.,Sequela of disorder,PROCESS_OF,Child
15051768,We sought to determine if changes in BMD are common long-term sequelae in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15160965,Acute renal failure due to leukemic cell infiltration followed by relapse at multiple extramedullary sites in a child with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15160965,Acute renal failure due to leukemic cell infiltration followed by relapse at multiple extramedullary sites in a child with acute lymphoblastic leukemia.,"Kidney Failure, Acute",PROCESS_OF,Child
15160965,Acute renal failure due to leukemic cell infiltration followed by relapse at multiple extramedullary sites in a child with acute lymphoblastic leukemia.,Cells,LOCATION_OF,Leukemic Infiltration
15160965,"On the basis of previous reports and the experience of this patient, intensive treatment may be needed in ALL children with renal involvement.",Therapeutic procedure,TREATS,Child
15160965,"On the basis of previous reports and the experience of this patient, intensive treatment may be needed in ALL children with renal involvement.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
15160965,"On the basis of previous reports and the experience of this patient, intensive treatment may be needed in ALL children with renal involvement.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15160965,Acute renal failure due to leukemic cell infiltration followed by relapse at multiple extramedullary sites in a child with acute lymphoblastic leukemia.,Leukemic Infiltration,CAUSES,"Kidney Failure, Acute"
15193447,The ETV6/RUNX1 rearrangement (also known as TEL/AML1) was evaluated in 39 children with B-precursor acute lymphoblastic leukemia (ALL) who had a normal karyotype or lack of mitoses.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15371983,Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia.,ABCB1 gene | ABCB1,INTERACTS_WITH,Vincristine
15371983,Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia.,Vincristine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15462611,"CONCLUSION: A reduction in survival probability in children with ALL was associated with homozygosity for G allele of the NR3C1BclI RFLP polymorphism, particularly in certain patient subgroups.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15462611,"METHODS: Towards this aim we analyzed the CYP3A4-290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs.",Child,LOCATION_OF,NR3C1 gene | NR3C1
15462611,"METHODS: Towards this aim we analyzed the CYP3A4-290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15462611,"METHODS: Towards this aim we analyzed the CYP3A4-290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs.",Adrenal Cortex Hormones,ISA,Pharmaceutical Preparations
15532875,"On the database of children with Acute Lymphoblastic Leukaemia (ALL) collected by the Childhood Cancer Registry of Piedmont (CCRP) in 1979-1991, we have estimated an alternative time-dimensional index to estimate both patients' life expectancy of patient and number of years gained to death.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15899912,"To elucidate causes of apoptotic defects, we studied the protein expression of Apaf-1, procaspases-2, -3, -6, -7, -8, -10, and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) in cells from children with acute lymphoblastic leukemia (ALL; n = 43) and acute myeloid leukemia (AML; n = 10).",Cells,LOCATION_OF,Polymerase
15899912,"To elucidate causes of apoptotic defects, we studied the protein expression of Apaf-1, procaspases-2, -3, -6, -7, -8, -10, and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) in cells from children with acute lymphoblastic leukemia (ALL; n = 43) and acute myeloid leukemia (AML; n = 10).",Child,LOCATION_OF,procaspase-2
15899912,"To elucidate causes of apoptotic defects, we studied the protein expression of Apaf-1, procaspases-2, -3, -6, -7, -8, -10, and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) in cells from children with acute lymphoblastic leukemia (ALL; n = 43) and acute myeloid leukemia (AML; n = 10).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16445826,Here we review the current acquaintance with the biology of infant ALL and describe how this knowledge may lead to innovative therapeutic approaches.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
16445826,Towards targeted therapy for infant acute lymphoblastic leukaemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
16445826,Towards targeted therapy for infant acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
16822902,Outcome for children with childhood acute lymphoblastic leukemia (ALL) who relapse is poor.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
17434155,"The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17512587,"However, we observed an association between 677TT variant and survival in a subset of ALL patients homogenously treated with MTX-based maintenance (p=0.02).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
17512587,"However, we observed an association between 677TT variant and survival in a subset of ALL patients homogenously treated with MTX-based maintenance (p=0.02).",Methotrexate,TREATS,Patients
17512587,"However, we observed an association between 677TT variant and survival in a subset of ALL patients homogenously treated with MTX-based maintenance (p=0.02).",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
14603332,"Here, we present gene expression data of 34 adult acute lymphoblastic leukemia (ALL) patients (Affymetrix U133A microarrays).","Leukemia, Lymphocytic, Acute, L2",ISA,"Leukemia, Lymphocytic, Acute"
15012841,ALL participants treated with CRT (n = 13) demonstrated an increased cost in response time with invalid spatial orienting cues and inefficient shifts of attention across hierarchical levels.,Radiation therapy,TREATS,Participant
15012841,ALL participants treated with CRT (n = 13) demonstrated an increased cost in response time with invalid spatial orienting cues and inefficient shifts of attention across hierarchical levels.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
15012841,ALL participants treated with CRT (n = 13) demonstrated an increased cost in response time with invalid spatial orienting cues and inefficient shifts of attention across hierarchical levels.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Participant
15162063,It was demonstrated that ETV6/RUNX1 gene fusion was a frequent event (0.59-1.84/100 cells) in peripheral blood lymphocytes from normal individuals and the ALL patients who underwent chemotherapy showed significantly (P = 0.0043) increased frequencies (0.62-3.96/100 cells) of the rearrangement when compared with the control groups (patients at diagnosis and healthy subjects).,Pharmacotherapy,TREATS,Individual
15162063,It was demonstrated that ETV6/RUNX1 gene fusion was a frequent event (0.59-1.84/100 cells) in peripheral blood lymphocytes from normal individuals and the ALL patients who underwent chemotherapy showed significantly (P = 0.0043) increased frequencies (0.62-3.96/100 cells) of the rearrangement when compared with the control groups (patients at diagnosis and healthy subjects).,Pharmacotherapy,TREATS,Patients
15162063,It was demonstrated that ETV6/RUNX1 gene fusion was a frequent event (0.59-1.84/100 cells) in peripheral blood lymphocytes from normal individuals and the ALL patients who underwent chemotherapy showed significantly (P = 0.0043) increased frequencies (0.62-3.96/100 cells) of the rearrangement when compared with the control groups (patients at diagnosis and healthy subjects).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
15162063,It was demonstrated that ETV6/RUNX1 gene fusion was a frequent event (0.59-1.84/100 cells) in peripheral blood lymphocytes from normal individuals and the ALL patients who underwent chemotherapy showed significantly (P = 0.0043) increased frequencies (0.62-3.96/100 cells) of the rearrangement when compared with the control groups (patients at diagnosis and healthy subjects).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15217836,The t(12;21) (p13;q22) translocation resulting in ETV6/RUNX1 (previously named TEL/AML1) gene fusion is present in about 25% of children with precursor B-lineage acute lymphoblastic leukemia (B-ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15251979,Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15538405,"Hence, we investigated this in 30 children with B-cell precursor ALL consecutively enrolled in the AIEOP-BFM ALL 2000 protocol.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
15596292,"In this pilot study, through the use of PCR and RFLP, further confirmed by DNA sequencing, we have shown an increased risk of ALL among children with XRCC1 codons 194 and 399 variant genotypes.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15596292,"In this pilot study, through the use of PCR and RFLP, further confirmed by DNA sequencing, we have shown an increased risk of ALL among children with XRCC1 codons 194 and 399 variant genotypes.",DNA Sequence,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
15681483,Several approaches for the detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) have shown the importance of determining the level of MRD precisely.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15681483,Consensus JH gene probes with conjugated 3'-minor groove binder for monitoring minimal residual disease in acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
15681483,Consensus JH gene probes with conjugated 3'-minor groove binder for monitoring minimal residual disease in acute lymphoblastic leukemia.,Binder,TREATS,"Neoplasm, Residual"
15837616,The goal is now to integrate these and other findings using gene expression technology into the care of children with the most common pediatric malignancy.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
15837616,Building better therapy for children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,Child
15837616,Building better therapy for children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15837616,Building better therapy for children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
15837626,"Acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy in over 75% of children, but the cause of treatment failure in the remaining patients is unknown.",Combination Drug Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
15911988,"Acute lymphoblastic leukemia (ALL) is predominantly a disease of the bone marrow that disseminates to multiple organ sites throughout the body and, without aggressive treatment, eventually results in multiorgan failure and death.",Bone Marrow,LOCATION_OF,Disease
15911988,"Acute lymphoblastic leukemia (ALL) is predominantly a disease of the bone marrow that disseminates to multiple organ sites throughout the body and, without aggressive treatment, eventually results in multiorgan failure and death.",Therapeutic procedure,CAUSES,Multiple Organ Failure
15911988,"Acute lymphoblastic leukemia (ALL) is predominantly a disease of the bone marrow that disseminates to multiple organ sites throughout the body and, without aggressive treatment, eventually results in multiorgan failure and death.","Leukemia, Lymphocytic, Acute",ISA,Disease
15911988,"Acute lymphoblastic leukemia (ALL) is predominantly a disease of the bone marrow that disseminates to multiple organ sites throughout the body and, without aggressive treatment, eventually results in multiorgan failure and death.",Bone Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
15946500,[Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15946502,[Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].,Methotrexate,ISA,Therapeutic procedure
15946502,[Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15946502,[Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15946502,[Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].,Therapeutic procedure,USES,Methotrexate
16528607,"Because of its relatively high prevalence, most of the work done in pediatric oncogenetics has been focused on leukemias, particularly acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",ISA,leukemia
16751110,Samples from 49 consecutive pediatric patients with B cell precursor acute lymphocytic leukemia (BCP ALL) were analyzed by semiquantitative RT-PCR.,"Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
16751110,Samples from 49 consecutive pediatric patients with B cell precursor acute lymphocytic leukemia (BCP ALL) were analyzed by semiquantitative RT-PCR.,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
17011029,"In conclusion, the present data indicate that an anti-angiogenic response is observed in some ALL children, but its physiopathological importance remains to be established.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17011029,"At diagnosis, the plasma levels of the anti-angiogenic factor endostatin were significantly higher in 33 children with ALL than in controls (median values 17.7 and 7.6 ng/ml, respectively, p=0.0192) but no relationship was observed with plasma bFGF or VEGF levels.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17011029,"At diagnosis, the plasma levels of the anti-angiogenic factor endostatin were significantly higher in 33 children with ALL than in controls (median values 17.7 and 7.6 ng/ml, respectively, p=0.0192) but no relationship was observed with plasma bFGF or VEGF levels.",Endostatins,TREATS,Child
17011029,"At diagnosis, the plasma levels of the anti-angiogenic factor endostatin were significantly higher in 33 children with ALL than in controls (median values 17.7 and 7.6 ng/ml, respectively, p=0.0192) but no relationship was observed with plasma bFGF or VEGF levels.",Endostatins,TREATS,"Leukemia, Lymphocytic, Acute"
17011029,"At diagnosis, the plasma levels of the anti-angiogenic factor endostatin were significantly higher in 33 children with ALL than in controls (median values 17.7 and 7.6 ng/ml, respectively, p=0.0192) but no relationship was observed with plasma bFGF or VEGF levels.",Plasma,LOCATION_OF,Fibroblast Growth Factor 2
17356293,"Incidence of obesity does not appear to be increased after treatment of acute lymphoblastic leukemia in Brazilian children: role of leptin, insulin, and IGF-1.",Leptin | LEP,TREATS,"Leukemia, Lymphocytic, Acute"
17356293,"Incidence of obesity does not appear to be increased after treatment of acute lymphoblastic leukemia in Brazilian children: role of leptin, insulin, and IGF-1.",Insulin-Like Growth Factor I,TREATS,"Leukemia, Lymphocytic, Acute"
17356293,"Incidence of obesity does not appear to be increased after treatment of acute lymphoblastic leukemia in Brazilian children: role of leptin, insulin, and IGF-1.",Insulin,TREATS,"Leukemia, Lymphocytic, Acute"
17356293,"Incidence of obesity does not appear to be increased after treatment of acute lymphoblastic leukemia in Brazilian children: role of leptin, insulin, and IGF-1.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17356293,"Incidence of obesity does not appear to be increased after treatment of acute lymphoblastic leukemia in Brazilian children: role of leptin, insulin, and IGF-1.",BRAZILIAN,PROCESS_OF,Child
12910697,"RESULTS: hTERT gene was expressed in K562 cell line, acute lymphoblastic leukemia children (23/30), acute myeloid leukemia children (7/10), and healthy subject (1/10).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12910697,"RESULTS: hTERT gene was expressed in K562 cell line, acute lymphoblastic leukemia children (23/30), acute myeloid leukemia children (7/10), and healthy subject (1/10).","TERT protein, human | TERT",PART_OF,Cell Line
12910697,"RESULTS: hTERT gene was expressed in K562 cell line, acute lymphoblastic leukemia children (23/30), acute myeloid leukemia children (7/10), and healthy subject (1/10).","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
15012841,ALL participants treated only with chemotherapy (n = 8) showed performance similar to the non-ALL comparison group.,Pharmacotherapy,TREATS,Participant
15012841,ALL participants treated only with chemotherapy (n = 8) showed performance similar to the non-ALL comparison group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Participant
15012841,ALL participants treated only with chemotherapy (n = 8) showed performance similar to the non-ALL comparison group.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15127413,Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia.,Radiation therapy,TREATS,Woman
15127413,Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia.,Fertility,PROCESS_OF,Woman
15127413,"CONCLUSION: This study provides evidence for fertility deficits after treatment for ALL with CRT, and, in addition, for the first time, suggests that girls treated around the time of menarche are especially at risk.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
15127413,Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15704223,Differential mRNA expression of glucocorticoid receptor alpha and beta is associated with glucocorticoid sensitivity of acute lymphoblastic leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15704223,Differential mRNA expression of glucocorticoid receptor alpha and beta is associated with glucocorticoid sensitivity of acute lymphoblastic leukemia in children.,glucocorticoid receptor alpha,INTERACTS_WITH,Glucocorticoids
15763652,"Mothers' whose children developed common B-cell precursor acute lymphoblastic leukaemia (ALL) were more likely to have had a previous molar pregnancy (OR=5.2, 95%CI=1.9-14.7).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
15763652,"Mothers' whose children developed common B-cell precursor acute lymphoblastic leukaemia (ALL) were more likely to have had a previous molar pregnancy (OR=5.2, 95%CI=1.9-14.7).",Hydatidiform Mole,PROCESS_OF,Mothers
15782402,"PROCEDURES: Of the 407 children with ALL diagnosed between 1984 and 1996, 117 suffered from a relapse before December 1999.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15782402,"CONCLUSIONS: In children with ALL and a first relapse, the time of relapse and the treatment after relapse were found to be independent prognostic factors.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16258093,"PURPOSE: We studied the frequency, causes, and predictors of adverse events in children with acute lymphoblastic leukemia (ALL) who had completed treatment on contemporary clinical protocols between 1984 and 1999.",Adverse event,PROCESS_OF,Child
16258093,"PURPOSE: We studied the frequency, causes, and predictors of adverse events in children with acute lymphoblastic leukemia (ALL) who had completed treatment on contemporary clinical protocols between 1984 and 1999.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16490598,Comparison of these and previously published cases demonstrates that the translocation predominately occurs in children and young adults with precursor B-ALL and is typically characterized by low CD10 expression and high CD33 expression.,Neprilysin | MME,compared_with,CD33
16490598,Comparison of these and previously published cases demonstrates that the translocation predominately occurs in children and young adults with precursor B-ALL and is typically characterized by low CD10 expression and high CD33 expression.,"Leukemia, B-Cell, Acute",PROCESS_OF,Young adult
16490598,Comparison of these and previously published cases demonstrates that the translocation predominately occurs in children and young adults with precursor B-ALL and is typically characterized by low CD10 expression and high CD33 expression.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
16594471,[Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].,Adrenal Cortex Hormones,TREATS,"Leukemia, Lymphocytic, Acute"
16594471,"In conclusion, response to glucocorticosteroids employed in the initial treatment of children with ALL, should be included in the stratification into prognostic groups.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16594471,[Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].,Adrenal Cortex Hormones,TREATS,Child
16594471,[Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16651440,"Therefore, such an antibody, either naked or conjugated to radioactive isotopes or cytotoxic agents, may prove useful in the therapy of infant ALL as well as childhood and adult ALL patients whose blasts typically express FLT3.","Leukemia, Lymphocytic, Acute, L2",PRODUCES,FLT3 gene | FLT3
16651440,"Therefore, such an antibody, either naked or conjugated to radioactive isotopes or cytotoxic agents, may prove useful in the therapy of infant ALL as well as childhood and adult ALL patients whose blasts typically express FLT3.","Leukemia, Lymphocytic, Acute",PRODUCES,FLT3 gene | FLT3
16651440,"Therefore, such an antibody, either naked or conjugated to radioactive isotopes or cytotoxic agents, may prove useful in the therapy of infant ALL as well as childhood and adult ALL patients whose blasts typically express FLT3.",Antibodies,INTERACTS_WITH,Cytotoxic agent
16651440,"Therefore, such an antibody, either naked or conjugated to radioactive isotopes or cytotoxic agents, may prove useful in the therapy of infant ALL as well as childhood and adult ALL patients whose blasts typically express FLT3.",Antibodies,INTERACTS_WITH,Radioisotopes
16651440,"Therefore, such an antibody, either naked or conjugated to radioactive isotopes or cytotoxic agents, may prove useful in the therapy of infant ALL as well as childhood and adult ALL patients whose blasts typically express FLT3.","Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
16651440,"Therefore, such an antibody, either naked or conjugated to radioactive isotopes or cytotoxic agents, may prove useful in the therapy of infant ALL as well as childhood and adult ALL patients whose blasts typically express FLT3.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17006263,"Acute lymphoblastic leukemia (ALL), the most common malignancy in children, constitutes 25% of all pediatric cancer.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17006263,Obesity and survival in a cohort of predominantly Hispanic children with acute lymphoblastic leukemia.,Obesity,PROCESS_OF,cohort
17006263,Obesity and survival in a cohort of predominantly Hispanic children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17146715,"These Neu5,9Ac(2)-GPs are also capable of inducing disease-specific anti-Neu5,9Ac(2)-GPs antibodies in ALL children.",9-amino-20-camptothecin,TREATS,"Leukemia, Lymphocytic, Acute"
17146715,"These Neu5,9Ac(2)-GPs are also capable of inducing disease-specific anti-Neu5,9Ac(2)-GPs antibodies in ALL children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17146715,"Exploiting the selective affinity of Achatinin-H towards 9-O-acetylneuraminic acid(alpha2-6)GalNAc, we have demonstrated the presence of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on hematopoietic cells of children suffering from acute lymphoblastic leukemia (ALL), indicative of defective sialylation associated with this disease.",Cells,PART_OF,Child
17146715,"Exploiting the selective affinity of Achatinin-H towards 9-O-acetylneuraminic acid(alpha2-6)GalNAc, we have demonstrated the presence of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on hematopoietic cells of children suffering from acute lymphoblastic leukemia (ALL), indicative of defective sialylation associated with this disease.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17146715,"Exploiting the selective affinity of Achatinin-H towards 9-O-acetylneuraminic acid(alpha2-6)GalNAc, we have demonstrated the presence of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on hematopoietic cells of children suffering from acute lymphoblastic leukemia (ALL), indicative of defective sialylation associated with this disease.",achatinin(H),COEXISTS_WITH,Sialoglycoproteins
17146715,"These Neu5,9Ac(2)-GPs are also capable of inducing disease-specific anti-Neu5,9Ac(2)-GPs antibodies in ALL children.",9-amino-20-camptothecin,TREATS,Child
17514734,BACKGROUND: Asparaginase (ASNase) is an essential component of most treatment protocols for childhood acute lymphoblastic leukemia (ALL).,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17522113,CONCLUSIONS: Treatment with intrathecal and infusional chemotherapy for childhood ALL may be associated with skill deficits comparable to those seen in individuals with cerebellar-frontal abnormalities.,Cerebellar Diseases,PROCESS_OF,Individual
17522113,"Children with ALL were at least 5 years from diagnosis, treated with intrathecal chemotherapy (methotrexate in all, hydrocortisone and cytarabine in 20/22), but not radiation therapy, and free from recurrence of disease.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17522113,"Children with ALL were at least 5 years from diagnosis, treated with intrathecal chemotherapy (methotrexate in all, hydrocortisone and cytarabine in 20/22), but not radiation therapy, and free from recurrence of disease.",Intrathecal Chemotherapy,TREATS,Child
17522113,"Children with ALL were at least 5 years from diagnosis, treated with intrathecal chemotherapy (methotrexate in all, hydrocortisone and cytarabine in 20/22), but not radiation therapy, and free from recurrence of disease.",Intrathecal Chemotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
17522113,CONCLUSIONS: Treatment with intrathecal and infusional chemotherapy for childhood ALL may be associated with skill deficits comparable to those seen in individuals with cerebellar-frontal abnormalities.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17522113,CONCLUSIONS: Treatment with intrathecal and infusional chemotherapy for childhood ALL may be associated with skill deficits comparable to those seen in individuals with cerebellar-frontal abnormalities.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15093578,"Although the sample was small, there was no demonstrable effect of chemotherapy on nutritional status in this Cuban paediatric population, in contrast to that reported in children with ALL in other developing countries.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15093578,"Although the sample was small, there was no demonstrable effect of chemotherapy on nutritional status in this Cuban paediatric population, in contrast to that reported in children with ALL in other developing countries.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15093578,"Although the sample was small, there was no demonstrable effect of chemotherapy on nutritional status in this Cuban paediatric population, in contrast to that reported in children with ALL in other developing countries.",Pharmacotherapy,TREATS,Child
15161898,OBJECTIVE: To assess the effect of a multidisciplinary team approach and protocol-based therapy on the event-free survival of children with ALL in an area with limited resources.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15161898,We reviewed medical records of the outcomes of 375 children with ALL diagnosed between 1980 and 2002.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15569732,"We evaluated diffusion-weighted (DW) and conventional MR images in children with ALL and acute MTX-induced neurotoxicity, with clinical correlation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15569732,"BACKGROUND AND PURPOSE: Acute lymphocytic leukemia (ALL) is a common malignancy of childhood treated with methotrexate (MTX), which is associated with acute neurotoxicity.",Methotrexate,TREATS,Malignant Neoplasms
15569732,"BACKGROUND AND PURPOSE: Acute lymphocytic leukemia (ALL) is a common malignancy of childhood treated with methotrexate (MTX), which is associated with acute neurotoxicity.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
15569732,"BACKGROUND AND PURPOSE: Acute lymphocytic leukemia (ALL) is a common malignancy of childhood treated with methotrexate (MTX), which is associated with acute neurotoxicity.","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
15837978,Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.,Doxorubicin,ISA,Therapeutic procedure
15837978,Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.,Doxorubicin,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15837978,Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.,Therapeutic procedure,USES,Doxorubicin
15981231,"The GSTM1 null genotype was significantly increased in children with ALL (OR 1.7; 95% CI, 1.0, 2.7).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15981231,"CYP 1A1, CYP 3A4*1B, CYP 3A5*3, CYP 3A5*6, GSTM1, and GSTT1 polymorphisms were genotyped by using PCR-RFLP in 107 children with ALL and 320 healthy controls.",Child,LOCATION_OF,GSTT1 gene | GSTT1
15981231,"CYP 1A1, CYP 3A4*1B, CYP 3A5*3, CYP 3A5*6, GSTM1, and GSTT1 polymorphisms were genotyped by using PCR-RFLP in 107 children with ALL and 320 healthy controls.",Child,LOCATION_OF,GSTM1 gene | GSTM1
15981231,"CYP 1A1, CYP 3A4*1B, CYP 3A5*3, CYP 3A5*6, GSTM1, and GSTT1 polymorphisms were genotyped by using PCR-RFLP in 107 children with ALL and 320 healthy controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16112299,"We compared this strategy with intensified chemotherapy protocols, with the aim to improve the outcome of children with very-high-risk acute lymphoblastic leukaemia in first complete remission.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16112299,Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.,"Transplantation, Homologous",TREATS,"Leukemia, Lymphocytic, Acute, L1"
16112299,Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16112299,Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.,Pharmacotherapy,compared_with,"Transplantation, Homologous"
16189266,The same trend was observed in a validation group of 92 children with ALL treated on a different protocol at St Jude (P = .051).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16189266,"We used microarrays to investigate, in 190 children with ALL at initial diagnosis, whether 70 key apoptosis genes were differentially expressed between leukemic subgroups defined by lineage, genetic subtype, in vitro drug resistance, and clinical outcome.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16189266,"We used microarrays to investigate, in 190 children with ALL at initial diagnosis, whether 70 key apoptosis genes were differentially expressed between leukemic subgroups defined by lineage, genetic subtype, in vitro drug resistance, and clinical outcome.",Child,PRODUCES,Subgroup
16258093,"CONCLUSION: Further treatment refinements for children with ALL should aim not only to decrease the leukemic relapse rate, but also to reduce the risk of development of second malignancies.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16529012,[Osteonecroses of the bilateral tali during maintenance therapy in a child with acute lymphoblastic leukemia].,Bone necrosis,PROCESS_OF,Child
16529012,[Osteonecroses of the bilateral tali during maintenance therapy in a child with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17607584,SUBJECTS AND METHODS: This work was conducted on 63 ALL children (40 males and 23 females) with age range 4.5 months-16 years (mean = 7.76 years).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17607584,OBJECTIVE: To evaluate children with acute lymphoblastic leukemia (ALL) showing resistance to immediate induction chemotherapy in relation to conventional and advanced cytogenetic analysis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17610809,"RESULTS: Four randomised controlled trials (RCTs) met the inclusion criteria of the review, each considering a different cardioprotective intervention; all trials included children with acute lymphoblastic leukaemia, and one also included children with non-Hodgkin's lymphoma.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17610809,"RESULTS: Four randomised controlled trials (RCTs) met the inclusion criteria of the review, each considering a different cardioprotective intervention; all trials included children with acute lymphoblastic leukaemia, and one also included children with non-Hodgkin's lymphoma.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17610809,"RESULTS: Four randomised controlled trials (RCTs) met the inclusion criteria of the review, each considering a different cardioprotective intervention; all trials included children with acute lymphoblastic leukaemia, and one also included children with non-Hodgkin's lymphoma.","Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
17610809,"RESULTS: Four randomised controlled trials (RCTs) met the inclusion criteria of the review, each considering a different cardioprotective intervention; all trials included children with acute lymphoblastic leukaemia, and one also included children with non-Hodgkin's lymphoma.","Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
12839283,"METHODS: A total of 98 children, aged 1.3-17.3 y, with acute lymphoblastic leukaemia (ALL) were studied on day 1 of induction therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14687622,T cell receptor gamma (TCRG) gene rearrangements in Brazilian children with acute lymphoblastic leukemia: analysis and implications for the study of minimal residual disease.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14687622,T cell receptor gamma (TCRG) gene rearrangements in Brazilian children with acute lymphoblastic leukemia: analysis and implications for the study of minimal residual disease.,BRAZILIAN,PROCESS_OF,Child
15615261,"Twenty-eight children (13 boys, 15 girls) with ALL aged 3-14 years (median 7 years) and treated according to the ALL-BFM 90/95 protocol were studied during maintenance for ALL.",Berlin-Frankfort-Munster protocol,TREATS,"Leukemia, Lymphocytic, Acute"
15615261,"Twenty-eight children (13 boys, 15 girls) with ALL aged 3-14 years (median 7 years) and treated according to the ALL-BFM 90/95 protocol were studied during maintenance for ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15615261,The suppression of lymphopoiesis and immune competence during the maintenance phase in children with acute lymphoblastic leukemia (ALL) and the occurrence of infectious complications remain an unexplored area.,Lymphopoiesis,PROCESS_OF,Child
15615261,The suppression of lymphopoiesis and immune competence during the maintenance phase in children with acute lymphoblastic leukemia (ALL) and the occurrence of infectious complications remain an unexplored area.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15615261,Decrease of CD4+ and B-lymphocyte populations is not associated with severe infectious complications in children with acute lymphoblastic leukemia during maintenance.,"Complication, infection",PROCESS_OF,Child
15615261,Decrease of CD4+ and B-lymphocyte populations is not associated with severe infectious complications in children with acute lymphoblastic leukemia during maintenance.,CD4 gene | CD4,NEG_ASSOCIATED_WITH,"Complication, infection"
15615261,Decrease of CD4+ and B-lymphocyte populations is not associated with severe infectious complications in children with acute lymphoblastic leukemia during maintenance.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15630450,"We measured in vivo MTXPG accumulation in leukemia cells from 101 children with acute lymphoblastic leukemia (ALL) and established that B-lineage ALL with either TEL-AML1 or E2A-PBX1 gene fusion, or T-lineage ALL, accumulates significantly lower MTXPG compared with B-lineage ALL without these genetic abnormalities or compared with hyperdiploid (fewer than 50 chromosomes) ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15630450,"We measured in vivo MTXPG accumulation in leukemia cells from 101 children with acute lymphoblastic leukemia (ALL) and established that B-lineage ALL with either TEL-AML1 or E2A-PBX1 gene fusion, or T-lineage ALL, accumulates significantly lower MTXPG compared with B-lineage ALL without these genetic abnormalities or compared with hyperdiploid (fewer than 50 chromosomes) ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15630450,"We measured in vivo MTXPG accumulation in leukemia cells from 101 children with acute lymphoblastic leukemia (ALL) and established that B-lineage ALL with either TEL-AML1 or E2A-PBX1 gene fusion, or T-lineage ALL, accumulates significantly lower MTXPG compared with B-lineage ALL without these genetic abnormalities or compared with hyperdiploid (fewer than 50 chromosomes) ALL.",TCF3 gene | TCF3 | TCF7L1,PART_OF,"Leukemia, Lymphocytic, Acute"
15630450,"We measured in vivo MTXPG accumulation in leukemia cells from 101 children with acute lymphoblastic leukemia (ALL) and established that B-lineage ALL with either TEL-AML1 or E2A-PBX1 gene fusion, or T-lineage ALL, accumulates significantly lower MTXPG compared with B-lineage ALL without these genetic abnormalities or compared with hyperdiploid (fewer than 50 chromosomes) ALL.",ETV6 gene | ETV6,PART_OF,"Leukemia, Lymphocytic, Acute"
15651075,"The goal of the current study was to investigate possible correlations between gene expression patterns of C/CR in leukemic cells, clinical features, and outcome in children with acute lymphoblastic leukemia (ALL) at first disease recurrence.",Leukemic Cell,LOCATION_OF,"Receptors, Cytokine"
15651075,"The goal of the current study was to investigate possible correlations between gene expression patterns of C/CR in leukemic cells, clinical features, and outcome in children with acute lymphoblastic leukemia (ALL) at first disease recurrence.",Child,LOCATION_OF,"Receptors, Cytokine"
15651075,"The goal of the current study was to investigate possible correlations between gene expression patterns of C/CR in leukemic cells, clinical features, and outcome in children with acute lymphoblastic leukemia (ALL) at first disease recurrence.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15687344,"Serum levels of IGF-I, IGF-II, IGF binding protein (IGFBP)-1, IGFBP-2, and IGFBP-3 were measured in 162 children with acute lymphoblastic leukemia treated by the Berlin Frankfurt Munster Study Group.",Child,LOCATION_OF,Insulin-Like Growth Factor Binding Protein 3
15687344,"Serum levels of IGF-I, IGF-II, IGF binding protein (IGFBP)-1, IGFBP-2, and IGFBP-3 were measured in 162 children with acute lymphoblastic leukemia treated by the Berlin Frankfurt Munster Study Group.",Child,LOCATION_OF,"IGFBP2 protein, human | IGFBP2"
15687344,"Serum levels of IGF-I, IGF-II, IGF binding protein (IGFBP)-1, IGFBP-2, and IGFBP-3 were measured in 162 children with acute lymphoblastic leukemia treated by the Berlin Frankfurt Munster Study Group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15687344,"Despite remarkable advances in the clinical outcome of most children with acute lymphoblastic leukemia, a substantial number of patients ultimately relapse or suffer from side effects of treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15687344,"Despite remarkable advances in the clinical outcome of most children with acute lymphoblastic leukemia, a substantial number of patients ultimately relapse or suffer from side effects of treatment.",Adverse effects,PROCESS_OF,Patients
16020107,Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome.,Down Syndrome,PROCESS_OF,Child
16020107,Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16249212,CONCLUSIONS: These analyses show an improvement over the time period of diagnosis of life expectancy for children with ALL.,Diagnosis,TREATS,Child
16249212,CONCLUSIONS: These analyses show an improvement over the time period of diagnosis of life expectancy for children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16333308,The antimetabolite mercaptopurine (MP) is widely used to treat childhood acute lymphoblastic leukaemia (ALL).,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16333308,The antimetabolite mercaptopurine (MP) is widely used to treat childhood acute lymphoblastic leukaemia (ALL).,6-Mercaptopurine,ISA,Antimetabolites
16651289,RESULTS: The majority (75%) of children with ALL did not have blasts in the peripheral blood at the time of evaluation by pediatric rheumatologists.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17148505,The relevance of this phenomenon in clinical samples is unknown but is extremely pertinent in childhood acute lymphoblastic leukaemia (ALL) in which children are exposed for prolonged periods to both MTX and thiopurines such that a single amplification event involving both the DHFR and the MSH3 genes may cause chemotherapeutic resistance to both agents.,thiopurine,INTERACTS_WITH,MSH3 gene | MSH3
17148505,The relevance of this phenomenon in clinical samples is unknown but is extremely pertinent in childhood acute lymphoblastic leukaemia (ALL) in which children are exposed for prolonged periods to both MTX and thiopurines such that a single amplification event involving both the DHFR and the MSH3 genes may cause chemotherapeutic resistance to both agents.,Methotrexate,INTERACTS_WITH,DHFR gene | DHFR
17148505,The relevance of this phenomenon in clinical samples is unknown but is extremely pertinent in childhood acute lymphoblastic leukaemia (ALL) in which children are exposed for prolonged periods to both MTX and thiopurines such that a single amplification event involving both the DHFR and the MSH3 genes may cause chemotherapeutic resistance to both agents.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
17148505,The relevance of this phenomenon in clinical samples is unknown but is extremely pertinent in childhood acute lymphoblastic leukaemia (ALL) in which children are exposed for prolonged periods to both MTX and thiopurines such that a single amplification event involving both the DHFR and the MSH3 genes may cause chemotherapeutic resistance to both agents.,Methotrexate,INTERACTS_WITH,MSH3 gene | MSH3
17148505,The relevance of this phenomenon in clinical samples is unknown but is extremely pertinent in childhood acute lymphoblastic leukaemia (ALL) in which children are exposed for prolonged periods to both MTX and thiopurines such that a single amplification event involving both the DHFR and the MSH3 genes may cause chemotherapeutic resistance to both agents.,thiopurine,INTERACTS_WITH,DHFR gene | DHFR
17223475,Control patients were given conventional mercaptopurine and methotrexate chemotherapy only.,Pharmacotherapy,ADMINISTERED_TO,Patients
17223475,Control patients were given conventional mercaptopurine and methotrexate chemotherapy only.,6-Mercaptopurine,ADMINISTERED_TO,Patients
17223475,Control patients were given conventional mercaptopurine and methotrexate chemotherapy only.,Methotrexate,ISA,Pharmacotherapy
17223475,Control patients were given conventional mercaptopurine and methotrexate chemotherapy only.,Methotrexate,ADMINISTERED_TO,Patients
17223475,Control patients were given conventional mercaptopurine and methotrexate chemotherapy only.,Pharmacotherapy,USES,Methotrexate
17223475,"METHODS: 3109 children, diagnosed with ALL and intermediate-risk features, were enrolled by eight participating organisations in eleven countries.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17332311,Excess transmission of the NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in families of children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17577046,Transplantation in childhood very high risk acute lymphoblastic leukemia in first complete remission: where are we now?,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18045317,Methotrexate (MTX) is a key drug in the chemotherapy for childhood acute lymphocytic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18045317,Methotrexate (MTX) is a key drug in the chemotherapy for childhood acute lymphocytic leukemia (ALL).,Methotrexate,ISA,Pharmaceutical Preparations
14982869,"Mutations were observed in 23 of 317 B-cell precursor ALL cases, but not among 44 children with T-lineage ALL.",Mutation,NEG_PROCESS_OF,Child
14982869,"Mutations were observed in 23 of 317 B-cell precursor ALL cases, but not among 44 children with T-lineage ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15017909,"Today, about 70% children suffering from acute lymphoblastic leukemia and about 55% children with acute mycloid leukemia could be cured.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15017909,"Today, about 70% children suffering from acute lymphoblastic leukemia and about 55% children with acute mycloid leukemia could be cured.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15017909,"Today, about 70% children suffering from acute lymphoblastic leukemia and about 55% children with acute mycloid leukemia could be cured.",Acute leukemia,PROCESS_OF,Child
15017909,"Today, about 70% children suffering from acute lymphoblastic leukemia and about 55% children with acute mycloid leukemia could be cured.",Acute leukemia,PROCESS_OF,Child
15197782,Differential expression of 9-O-acetylated sialoglycoconjugates on leukemic blasts: a potential tool for long-term monitoring of children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15806539,"METHODS: In a multi-center study, we compared attentional function in 36 children at least 1 year after finishing treatment with chemotherapy only for ALL, with a cancer control group consisting of 39 Wilms tumor patients and with 110 healthy children.",Nephroblastoma,PROCESS_OF,Patients
15806539,"METHODS: In a multi-center study, we compared attentional function in 36 children at least 1 year after finishing treatment with chemotherapy only for ALL, with a cancer control group consisting of 39 Wilms tumor patients and with 110 healthy children.",Malignant Neoplasms,PROCESS_OF,Control Groups
15806539,"BACKGROUND: Central nervous system (CNS) directed chemotherapy is replacing prophylactic cranial irradiation in treatment protocols for childhood acute lymphoblastic leukemia (ALL), mainly to reduce long-term neuropsychological sequelae.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15806539,"METHODS: In a multi-center study, we compared attentional function in 36 children at least 1 year after finishing treatment with chemotherapy only for ALL, with a cancer control group consisting of 39 Wilms tumor patients and with 110 healthy children.",Therapeutic procedure,compared_with,Pharmacotherapy
15806539,"METHODS: In a multi-center study, we compared attentional function in 36 children at least 1 year after finishing treatment with chemotherapy only for ALL, with a cancer control group consisting of 39 Wilms tumor patients and with 110 healthy children.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15918215,Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15918215,CONCLUSIONS: ALL survivors treated with chemotherapy have specific information processing difficulties.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15918215,CONCLUSIONS: ALL survivors treated with chemotherapy have specific information processing difficulties.,Pharmacotherapy,TREATS,Survivors
15918215,CONCLUSIONS: ALL survivors treated with chemotherapy have specific information processing difficulties.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
16115950,"In conclusion, polymorphisms but not somatic mutations in the GR gene coding region occur in leukemic blasts of children with ALL.",Blast Cell,PART_OF,Child
16115950,"In conclusion, polymorphisms but not somatic mutations in the GR gene coding region occur in leukemic blasts of children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16293608,"For comparisons, expression profiles were generated from an adult patient with ALL, peripheral blood lymphocytes from GC-exposed healthy donors, GC-sensitive and -resistant ALL cell lines, and mouse thymocytes treated with GCs in vivo and in vitro.",thymocyte,PART_OF,House mice
16293608,"For comparisons, expression profiles were generated from an adult patient with ALL, peripheral blood lymphocytes from GC-exposed healthy donors, GC-sensitive and -resistant ALL cell lines, and mouse thymocytes treated with GCs in vivo and in vitro.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
16293608,Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16293608,"For comparisons, expression profiles were generated from an adult patient with ALL, peripheral blood lymphocytes from GC-exposed healthy donors, GC-sensitive and -resistant ALL cell lines, and mouse thymocytes treated with GCs in vivo and in vitro.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
16293608,"For comparisons, expression profiles were generated from an adult patient with ALL, peripheral blood lymphocytes from GC-exposed healthy donors, GC-sensitive and -resistant ALL cell lines, and mouse thymocytes treated with GCs in vivo and in vitro.",Glucocorticoids,TREATS,Patients
16709515,Isolated renal relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) in children with acute lymphoblastic leukemia (ALL) is a rare condition.,Hematopoietic Stem Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
16709515,Isolated renal relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) in children with acute lymphoblastic leukemia (ALL) is a rare condition.,Hematopoietic Stem Cell Transplantation,TREATS,Child
16709515,Isolated renal relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) in children with acute lymphoblastic leukemia (ALL) is a rare condition.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16710032,Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group.,Spinal Puncture,TREATS,Child
16710032,Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16710032,Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group.,Spinal Puncture,TREATS,"Leukemia, Lymphocytic, Acute"
16710032,PURPOSE: To determine the significance of blasts in the CSF without pleiocytosis and a traumatic lumbar puncture in children with acute lymphoblastic leukemia (ALL).,Spinal Puncture,TREATS,Child
16710032,PURPOSE: To determine the significance of blasts in the CSF without pleiocytosis and a traumatic lumbar puncture in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16710032,PURPOSE: To determine the significance of blasts in the CSF without pleiocytosis and a traumatic lumbar puncture in children with acute lymphoblastic leukemia (ALL).,Spinal Puncture,TREATS,"Leukemia, Lymphocytic, Acute"
16755223,PURPOSE OF REVIEW: The cure rate in children with acute lymphoblastic leukemia now exceeds almost 80% in most treatment protocols in industrialized countries.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17008858,"Treatment for acute lymphoblastic leukemia in children is associated with papillary carcinoma of thyroid, but not with thyroid disfunction.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17008858,"Treatment for acute lymphoblastic leukemia in children is associated with papillary carcinoma of thyroid, but not with thyroid disfunction.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
17008858,"AIM: The treatment of acute lymphoblastic leukemia (ALL) in children may cause sequelae, some appearing only at long-term follow-up.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17224657,"This is not surprising given that leukemia is the most common cancer affecting children, accounting for 25-35% of childhood malignancies worldwide with acute lymphoblastic leukemia comprising 80% of leukemia cases.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17224657,"This is not surprising given that leukemia is the most common cancer affecting children, accounting for 25-35% of childhood malignancies worldwide with acute lymphoblastic leukemia comprising 80% of leukemia cases.",leukemia,ISA,Malignant Neoplasms
17224657,"RECENT FINDINGS: The majority of recent findings concern the pharmacogenetics of key components of acute lymphoblastic leukemia treatment, 6-mercaptopurine and methotrexate.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
17224657,"RECENT FINDINGS: The majority of recent findings concern the pharmacogenetics of key components of acute lymphoblastic leukemia treatment, 6-mercaptopurine and methotrexate.",6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
15338196,Anemia is a prominent feature in children with acute lymphoblastic leukemia (ALL).,Anemia,PROCESS_OF,Child
15338196,Anemia is a prominent feature in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15674422,RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia.,Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15730719,"Group A is normal control (n = 15), group B MTX control (n = 20), group C IL-11 pretreatment group before MTX injection (n = 20), group D (n = 20) the high dose IL-11 group (475 microg.kg(-1).d(-1)) after MTX injection, group E (n = 20) the low dose IL-11 group (150 microg.kg(-1).d(-1)) after MTX injection.",Methotrexate,ISA,Injection procedure
15730719,"Rats were killed at day 1, 3, 5, 7 after MTX injection.",Injection procedure,USES,Methotrexate
15730719,"Group A is normal control (n = 15), group B MTX control (n = 20), group C IL-11 pretreatment group before MTX injection (n = 20), group D (n = 20) the high dose IL-11 group (475 microg.kg(-1).d(-1)) after MTX injection, group E (n = 20) the low dose IL-11 group (150 microg.kg(-1).d(-1)) after MTX injection.",Methotrexate,ISA,Injection procedure
15730719,"Rats were killed at day 1, 3, 5, 7 after MTX injection.",Methotrexate,ISA,Injection procedure
15730719,"Group A is normal control (n = 15), group B MTX control (n = 20), group C IL-11 pretreatment group before MTX injection (n = 20), group D (n = 20) the high dose IL-11 group (475 microg.kg(-1).d(-1)) after MTX injection, group E (n = 20) the low dose IL-11 group (150 microg.kg(-1).d(-1)) after MTX injection.",Injection procedure,USES,Methotrexate
15730719,"Group A is normal control (n = 15), group B MTX control (n = 20), group C IL-11 pretreatment group before MTX injection (n = 20), group D (n = 20) the high dose IL-11 group (475 microg.kg(-1).d(-1)) after MTX injection, group E (n = 20) the low dose IL-11 group (150 microg.kg(-1).d(-1)) after MTX injection.",Injection procedure,USES,Methotrexate
15730719,"Group A is normal control (n = 15), group B MTX control (n = 20), group C IL-11 pretreatment group before MTX injection (n = 20), group D (n = 20) the high dose IL-11 group (475 microg.kg(-1).d(-1)) after MTX injection, group E (n = 20) the low dose IL-11 group (150 microg.kg(-1).d(-1)) after MTX injection.",Injection procedure,USES,Methotrexate
15730719,"Group A is normal control (n = 15), group B MTX control (n = 20), group C IL-11 pretreatment group before MTX injection (n = 20), group D (n = 20) the high dose IL-11 group (475 microg.kg(-1).d(-1)) after MTX injection, group E (n = 20) the low dose IL-11 group (150 microg.kg(-1).d(-1)) after MTX injection.",Methotrexate,ISA,Injection procedure
15806539,These sequelae stress the importance of reducing doses of neurotoxic chemotherapy as much as possible in the design of future treatment protocols for ALL.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
15806539,"RESULTS: After chemotherapy, attentional deficits were detected in patients with ALL, but not in Wilms tumor patients.",Pharmacotherapy,TREATS,Patients
15806539,"RESULTS: After chemotherapy, attentional deficits were detected in patients with ALL, but not in Wilms tumor patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
15806539,"RESULTS: After chemotherapy, attentional deficits were detected in patients with ALL, but not in Wilms tumor patients.",Nephroblastoma,PROCESS_OF,Patients
15806539,"RESULTS: After chemotherapy, attentional deficits were detected in patients with ALL, but not in Wilms tumor patients.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15952999,Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.,prednisolone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15952999,"The use of 6.5 mg/m(2) dexamethasone throughout treatment for ALL led to a significant decrease in the risk of relapse for all risk-groups of patients and, despite the increased toxicity, should now be regarded as part of standard therapy for childhood ALL.",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
15952999,Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15952999,Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.,Dexamethasone,compared_with,prednisolone
15952999,"The use of 6.5 mg/m(2) dexamethasone throughout treatment for ALL led to a significant decrease in the risk of relapse for all risk-groups of patients and, despite the increased toxicity, should now be regarded as part of standard therapy for childhood ALL.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15953000,Continuation chemotherapy is a key component of the treatment of childhood acute lymphoblastic leukaemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15953000,Continuation chemotherapy is a key component of the treatment of childhood acute lymphoblastic leukaemia.,Pharmacotherapy,ISA,Therapeutic procedure
16137060,[Clinical study on mitoxantrone contained regimen for treatment of newly diagnosed childhood acute lymphoblastic leukemia].,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16154840,BACKGROUND AND OBJECTIVES: It is often difficult to obtain good karyotypes of cells from children with acute lymphoblastic leukemia (ALL) because of poor morphology and spreading.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16154841,The aim of this study was to evaluate the efficacy of treatment reduction in a subset of children with ALL at minimal risk of failure.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16494620,Searching for cryptic chromosomal aberrations in high hyperdiploid childhood acute lymphoblastic leukaemias.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
16955505,Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16955505,Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
17080335,"BACKGROUND: Contemporary risk adapted treatment protocols for childhood acute lymphoblastic leukemia (ALL) rely on accurate risk assessment strategies for disease re-occurrence by incorporating clinical parameters as well as immunological, molecular and cytogenetic features of the blasts at initial manifestation.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17826085,"We conclude that the findings based on clinical data, combined with the markers of infectious exposure, confirm the observation that immune dysregulation among children who develop ALL is detectable from an early age.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17923868,"Positive interactions between this index and rural residence associated with an increased risk of childhood ALL and common ALL (c-ALL) were observed (interaction P-value=0.02 for both, using tertiles of contact months; interaction P-value=0.05 and 0.02 for ALL and c-ALL, respectively, using continuous contact months); such findings were not observed when job durations were ignored.",Common acute lymphoblastic leukemia,ISA,"Leukemia, Lymphocytic, Acute"
17923868,"Positive interactions between this index and rural residence associated with an increased risk of childhood ALL and common ALL (c-ALL) were observed (interaction P-value=0.02 for both, using tertiles of contact months; interaction P-value=0.05 and 0.02 for ALL and c-ALL, respectively, using continuous contact months); such findings were not observed when job durations were ignored.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
17923868,"To study the possible relation between parental social contact through occupation, a marker for a child's risk of infection, and childhood acute lymphoblastic leukaemia (ALL), the parents of 294 children with ALL aged 0-14.9 years and 376 matched controls were interviewed about their jobs after their child's birth up to the age of 3 years.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14728596,Forty seven children affected with acute lymphoblastic leukemia (ALL) were cytogenetically investigated at diagnosis and all through different stages of the disease (remission and relapse).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15659698,Acute lymphoblastic leukemia (ALL) with Bcr-Abl translocation is one of the most difficult to treat and deadly diseases in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15659698,Acute lymphoblastic leukemia (ALL) with Bcr-Abl translocation is one of the most difficult to treat and deadly diseases in children.,Disease,PROCESS_OF,Child
15738600,"RESULTS: the higher frequency of A-G transition in the GSTP1 gene was identified in the group of children with ALL in comparison to healthy controls (OR=3.13, 95%CI=1.4-7).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15738600,In the group of children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15877734,"Summary Interphase fluorescence in situ hybridization (iFISH) was used independently to reveal chromosomal abnormalities of prognostic importance in a large, consecutive series of children (n = 2367) with acute lymphoblastic leukaemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15877734,Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15877734,This study highlights the importance of iFISH as a complementary tool to cytogenetics in routine screening for significant chromosomal abnormalities in ALL.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
15877734,"Summary Interphase fluorescence in situ hybridization (iFISH) was used independently to reveal chromosomal abnormalities of prognostic importance in a large, consecutive series of children (n = 2367) with acute lymphoblastic leukaemia (ALL).",Fluorescent in Situ Hybridization,DIAGNOSES,Chromosome abnormality
16154856,"In a cohort of 54 children with ALL, a lower expression of the glucocorticoid receptor (GR), but not the relative expression levels of the GR-alpha, GR-beta and GR-P isoforms, was associated with in vitro prednisolone resistance.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16154856,"In a cohort of 54 children with ALL, a lower expression of the glucocorticoid receptor (GR), but not the relative expression levels of the GR-alpha, GR-beta and GR-P isoforms, was associated with in vitro prednisolone resistance.",prednisolone,COEXISTS_WITH,glucocorticoid receptor beta
16190149,"METHODS: The study included all newly diagnosed, statewide cases of childhood lymphoma and acute lymphoblastic leukemia in 1988-1994 among children aged <15 years.",Childhood Lymphoma,PROCESS_OF,Child
16190149,"METHODS: The study included all newly diagnosed, statewide cases of childhood lymphoma and acute lymphoblastic leukemia in 1988-1994 among children aged <15 years.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16200556,"BACKGROUND: The study objective was to compare a hospital-based and a home-based chemotherapy program for children with acute lymphoblastic leukemia (ALL) in relation to Quality of Life (QOL), safety, caregiver burden, and costs.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16200556,PROCEDURE: A randomized cross-over trial (RCT) design with repeated measures was conducted with 23 children with ALL who attended the oncology outpatient clinic of a metropolitan university affiliated tertiary level pediatric hospital and who also received home visits from a community health services care provider in central Canada.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16302217,"BACKGROUND: L-asparaginase is a crucial drug in childhood acute lymphoblastic leukemia (ALL) induction therapy, but much debate remains regarding the optimal formulation and dosage.",ASPARAGINASE,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
16302217,"BACKGROUND: L-asparaginase is a crucial drug in childhood acute lymphoblastic leukemia (ALL) induction therapy, but much debate remains regarding the optimal formulation and dosage.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
16302217,"BACKGROUND: L-asparaginase is a crucial drug in childhood acute lymphoblastic leukemia (ALL) induction therapy, but much debate remains regarding the optimal formulation and dosage.",ASPARAGINASE,ISA,Pharmaceutical Preparations
16411094,"A white blood cell count greater than 50,000 x 10(6) cells/l was associated with decreased survival in children with acute lymphocytic leukemia and acute non-lymphocytic leukemia.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
16411094,"A white blood cell count greater than 50,000 x 10(6) cells/l was associated with decreased survival in children with acute lymphocytic leukemia and acute non-lymphocytic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16575474,Resistance to glucocorticoids remains one of the main obstacles in therapy of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16575474,Resistance to glucocorticoids remains one of the main obstacles in therapy of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,ISA,Therapeutic procedure
17116485,"Specific chromosomal abnormalities are associated with prognosis in childhood acute lymphoblastic leukemia, but chromosome abnormalities have not been evaluated for prognostic value in pediatric ALCL.",Chromosome abnormality,COEXISTS_WITH,Childhood Anaplastic Large Cell Lymphoma
17116485,"Specific chromosomal abnormalities are associated with prognosis in childhood acute lymphoblastic leukemia, but chromosome abnormalities have not been evaluated for prognostic value in pediatric ALCL.",Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
17175373,"Specific chromosome abnormalities are associated with prognosis in childhood acute lymphoblastic leukemia, but have not been evaluated for prognostic value in pediatric LBL.",Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
17175380,"Using interphase multipoint FISH (mp-FISH), which was developed by our group, with 42 chromosome 3-specific probes, we detected clonal chromosome 3 aberrations in 4 T-cell ALL (T-ALL) cases.",Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
17401007,"PURPOSE: We evaluated the long-term effects of treatment on the body mass index (BMI) of children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma who received one of three CNS-directed therapies: intrathecal methotrexate with intravenous high-dose methotrexate (1 g/m2), intrathecal methotrexate with 18 Gy cranial radiation, or intrathecal methotrexate with 24 Gy cranial radiation.",Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
17401007,"PURPOSE: We evaluated the long-term effects of treatment on the body mass index (BMI) of children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma who received one of three CNS-directed therapies: intrathecal methotrexate with intravenous high-dose methotrexate (1 g/m2), intrathecal methotrexate with 18 Gy cranial radiation, or intrathecal methotrexate with 24 Gy cranial radiation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17401007,"PURPOSE: We evaluated the long-term effects of treatment on the body mass index (BMI) of children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma who received one of three CNS-directed therapies: intrathecal methotrexate with intravenous high-dose methotrexate (1 g/m2), intrathecal methotrexate with 18 Gy cranial radiation, or intrathecal methotrexate with 24 Gy cranial radiation.",Therapeutic procedure,USES,Methotrexate
17401264,OBJECTIVE: To evaluate children with acute lymphoblastic leukemia (ALL) showing resistance to immediate induction chemotherapy in relation to conventional and advanced cytogenetic analysis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17401264,METHODS: This work was conducted on 63 ALL children (40 males and 23 females) with age range 4.5 months-16 years (mean = 7.76 years).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12917300,CONCLUSIONS: Children with acute lymphoblastic leukemia who did not receive radiation therapy and who have attained 10 or more years of event-free survival can expect a normal long-term survival.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12917300,CONCLUSIONS: Children with acute lymphoblastic leukemia who did not receive radiation therapy and who have attained 10 or more years of event-free survival can expect a normal long-term survival.,Radiation therapy,NEG_ADMINISTERED_TO,Child
14724653,Significantly higher expression of AsnS was found in untreated leukaemic cells from children with TEL/AML1[+] ALL (n=20) in comparison with the group of age-matched children with ALL bearing no known fusion gene (n=25; P=0.0043).,Leukemic Cell,LOCATION_OF,ASNS gene | ASNS
14724653,Significantly higher expression of AsnS was found in untreated leukaemic cells from children with TEL/AML1[+] ALL (n=20) in comparison with the group of age-matched children with ALL bearing no known fusion gene (n=25; P=0.0043).,RUNX1 gene | RUNX1,PART_OF,Child
14724653,Significantly higher expression of AsnS was found in untreated leukaemic cells from children with TEL/AML1[+] ALL (n=20) in comparison with the group of age-matched children with ALL bearing no known fusion gene (n=25; P=0.0043).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14724653,Significantly higher expression of AsnS was found in untreated leukaemic cells from children with TEL/AML1[+] ALL (n=20) in comparison with the group of age-matched children with ALL bearing no known fusion gene (n=25; P=0.0043).,RUNX1 gene | RUNX1,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
14981525,Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15059065,"To evaluate whether C3435T MDR1 polymorphism is associated with the occurrence and outcome of ALL, 113 children with ALL (median age 5.1 yr) and 175 healthy individuals of Polish Caucasian origin were studied by polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) assay.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15504922,"BACKGROUND: A comprehensive review was made of the literature on the health-related quality of life (HRQL) and economic outcomes of children with acute lymphoblastic leukemia (ALL), the most common of all cancers in childhood.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15504922,"In the near future, further work to generate evidence of validity for available HRQL measures for use in children with ALL will be a high priority.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15770827,Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome.,Down Syndrome,PROCESS_OF,Child
15770827,Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15942938,"High hyperdiploidy (>50 chromosomes) in childhood acute lymphoblastic leukemia (ALL) is characterized by nonrandom multiple trisomies and tetrasomies involving in particular chromosomes X, 4, 6, 8, 10, 14, 17, 18, and 21.",Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15942938,"High hyperdiploidy (>50 chromosomes) in childhood acute lymphoblastic leukemia (ALL) is characterized by nonrandom multiple trisomies and tetrasomies involving in particular chromosomes X, 4, 6, 8, 10, 14, 17, 18, and 21.",X Chromosome,LOCATION_OF,Trisomy
15942938,These data strongly suggest that hyperdiploidy in childhood ALL generally arises by a simultaneous gain of all additional chromosomes in a single abnormal mitosis.,Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
16191084,"PATIENTS AND METHODS: During 1991-2000, 132 children with ALL were diagnosed in our Unit.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16302217,"Early response to treatment as measured by MRD is a direct reflection of leukemic cell kill and is a significant prognosticator of eventual outcome, making it a good surrogate marker to evaluate the efficacy of induction drugs in childhood ALL.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
16302217,We utilized MRD to compare the efficacy of Erwinia-asparaginase (Erwinia-asp) and E. coli-asparaginase (E. coli-asp) during induction therapy for childhood ALL.,Erwinia asparaginase,compared_with,ASPARAGINASE | ASPG
16302217,We utilized MRD to compare the efficacy of Erwinia-asparaginase (Erwinia-asp) and E. coli-asparaginase (E. coli-asp) during induction therapy for childhood ALL.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16338493,"RESULTS: The expression of the membrane bound CD27, as well as membrane bound CD70, on CD19(+) cells in the BM was significantly increased in ALL children compared to the expression found in the controls.",Cells,PART_OF,Bone Marrow
16338493,"This study addresses the expression of CD27 and its ligand, CD70, in children with acute lymphoblastic leukemia (ALL) and the possible role of this receptor-ligand pair in the pathogenesis of ALL.",CD70,PART_OF,Child
16338493,"RESULTS: The expression of the membrane bound CD27, as well as membrane bound CD70, on CD19(+) cells in the BM was significantly increased in ALL children compared to the expression found in the controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16338493,"This study addresses the expression of CD27 and its ligand, CD70, in children with acute lymphoblastic leukemia (ALL) and the possible role of this receptor-ligand pair in the pathogenesis of ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16338493,PATIENTS AND METHODS: Expression of CD27 and CD70 was evaluated with three-color flow cytometry in blood and bone marrow (BM) samples in children with ALL and controls.,Bone marrow specimen,LOCATION_OF,CD27
16338493,"This study addresses the expression of CD27 and its ligand, CD70, in children with acute lymphoblastic leukemia (ALL) and the possible role of this receptor-ligand pair in the pathogenesis of ALL.","Leukemia, Lymphocytic, Acute",AFFECTS,Pathogenesis
16338493,PATIENTS AND METHODS: Expression of CD27 and CD70 was evaluated with three-color flow cytometry in blood and bone marrow (BM) samples in children with ALL and controls.,Bone marrow specimen,LOCATION_OF,CD70
16338493,"This study addresses the expression of CD27 and its ligand, CD70, in children with acute lymphoblastic leukemia (ALL) and the possible role of this receptor-ligand pair in the pathogenesis of ALL.",CD70,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
16338493,PATIENTS AND METHODS: Expression of CD27 and CD70 was evaluated with three-color flow cytometry in blood and bone marrow (BM) samples in children with ALL and controls.,Blood,LOCATION_OF,CD70
16338493,PATIENTS AND METHODS: Expression of CD27 and CD70 was evaluated with three-color flow cytometry in blood and bone marrow (BM) samples in children with ALL and controls.,Blood,LOCATION_OF,CD27
16338493,PATIENTS AND METHODS: Expression of CD27 and CD70 was evaluated with three-color flow cytometry in blood and bone marrow (BM) samples in children with ALL and controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16786762,This review is focused on genetic and functional polymorphism of enzymes that have or may have the influence on metabolism of drugs included in treatment protocol for ALL in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16786762,This review is focused on genetic and functional polymorphism of enzymes that have or may have the influence on metabolism of drugs included in treatment protocol for ALL in children.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
16786762,"However, as many as 30% of patients suffer from relapse and majority of children with ALL is profoundly affected by toxicity of anticancer drugs.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17441477,[Complications in the central nervous system during chemotherapy for childhood acute lymphoblastic leukemia: JACLS ALL-02 study].,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17652222,"RESULTS: Controlled for age and race, ALL survivors treated with CRT had higher levels of abdominal and visceral fat, body fat percentage, metabolic risk (insulin resistance and dyslipidemia), and leptin but lower lean mass and IGF-I levels than non-CRT survivors (P </= 0.05 for each).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
17652222,"RESULTS: Controlled for age and race, ALL survivors treated with CRT had higher levels of abdominal and visceral fat, body fat percentage, metabolic risk (insulin resistance and dyslipidemia), and leptin but lower lean mass and IGF-I levels than non-CRT survivors (P </= 0.05 for each).",Leptin | LEP,TREATS,Survivors
17652222,"RESULTS: Controlled for age and race, ALL survivors treated with CRT had higher levels of abdominal and visceral fat, body fat percentage, metabolic risk (insulin resistance and dyslipidemia), and leptin but lower lean mass and IGF-I levels than non-CRT survivors (P </= 0.05 for each).",Radiation therapy,TREATS,Survivors
17652222,"RESULTS: Controlled for age and race, ALL survivors treated with CRT had higher levels of abdominal and visceral fat, body fat percentage, metabolic risk (insulin resistance and dyslipidemia), and leptin but lower lean mass and IGF-I levels than non-CRT survivors (P </= 0.05 for each).",Leptin | LEP,TREATS,"Leukemia, Lymphocytic, Acute"
17652222,"RESULTS: Controlled for age and race, ALL survivors treated with CRT had higher levels of abdominal and visceral fat, body fat percentage, metabolic risk (insulin resistance and dyslipidemia), and leptin but lower lean mass and IGF-I levels than non-CRT survivors (P </= 0.05 for each).",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
15472198,"A group of 44 ALL survivors (23 males, median age 25 yr, range 19-32 yr at the time of study) treated with CRT (median 24 Gy, 18-30 Gy) at a median age of 5 yr (1-18 yr) and chemotherapy were investigated for prevalence of GH deficiency and cardiovascular risk factors.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15472198,"In conclusion, at a median 17 yr after treatment with CRT and chemotherapy in former childhood ALL patients, a significant increase in cardiovascular risk factors was recorded.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
15472198,"In the only previously reported study on cardiovascular risk after childhood ALL, obesity and dyslipidemia were recorded in a small subgroup treated with CRT, compared with patients treated with chemotherapy.",Pharmacotherapy,TREATS,Dyslipidemias
15472198,"In the only previously reported study on cardiovascular risk after childhood ALL, obesity and dyslipidemia were recorded in a small subgroup treated with CRT, compared with patients treated with chemotherapy.",Radiation therapy,compared_with,Pharmacotherapy
15472198,"In conclusion, at a median 17 yr after treatment with CRT and chemotherapy in former childhood ALL patients, a significant increase in cardiovascular risk factors was recorded.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15472198,"In the only previously reported study on cardiovascular risk after childhood ALL, obesity and dyslipidemia were recorded in a small subgroup treated with CRT, compared with patients treated with chemotherapy.",Pharmacotherapy,TREATS,Obesity
15472198,"A group of 44 ALL survivors (23 males, median age 25 yr, range 19-32 yr at the time of study) treated with CRT (median 24 Gy, 18-30 Gy) at a median age of 5 yr (1-18 yr) and chemotherapy were investigated for prevalence of GH deficiency and cardiovascular risk factors.",Radiation therapy,TREATS,Survivors
15472198,"In conclusion, at a median 17 yr after treatment with CRT and chemotherapy in former childhood ALL patients, a significant increase in cardiovascular risk factors was recorded.",Therapeutic procedure,TREATS,"Risk factor, cardiovascular"
15472198,"In the only previously reported study on cardiovascular risk after childhood ALL, obesity and dyslipidemia were recorded in a small subgroup treated with CRT, compared with patients treated with chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15472198,"A group of 44 ALL survivors (23 males, median age 25 yr, range 19-32 yr at the time of study) treated with CRT (median 24 Gy, 18-30 Gy) at a median age of 5 yr (1-18 yr) and chemotherapy were investigated for prevalence of GH deficiency and cardiovascular risk factors.",Pharmacotherapy,TREATS,Survivors
15472198,"In conclusion, at a median 17 yr after treatment with CRT and chemotherapy in former childhood ALL patients, a significant increase in cardiovascular risk factors was recorded.",Radiation therapy,TREATS,Patients
15472198,"In the only previously reported study on cardiovascular risk after childhood ALL, obesity and dyslipidemia were recorded in a small subgroup treated with CRT, compared with patients treated with chemotherapy.",Radiation therapy,TREATS,Dyslipidemias
15472198,"A group of 44 ALL survivors (23 males, median age 25 yr, range 19-32 yr at the time of study) treated with CRT (median 24 Gy, 18-30 Gy) at a median age of 5 yr (1-18 yr) and chemotherapy were investigated for prevalence of GH deficiency and cardiovascular risk factors.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
15472198,"In conclusion, at a median 17 yr after treatment with CRT and chemotherapy in former childhood ALL patients, a significant increase in cardiovascular risk factors was recorded.",Pharmacotherapy,TREATS,Patients
15472198,"In the only previously reported study on cardiovascular risk after childhood ALL, obesity and dyslipidemia were recorded in a small subgroup treated with CRT, compared with patients treated with chemotherapy.",Radiation therapy,TREATS,Obesity
15472198,"A group of 44 ALL survivors (23 males, median age 25 yr, range 19-32 yr at the time of study) treated with CRT (median 24 Gy, 18-30 Gy) at a median age of 5 yr (1-18 yr) and chemotherapy were investigated for prevalence of GH deficiency and cardiovascular risk factors.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
15472198,"In conclusion, at a median 17 yr after treatment with CRT and chemotherapy in former childhood ALL patients, a significant increase in cardiovascular risk factors was recorded.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15472198,"In the only previously reported study on cardiovascular risk after childhood ALL, obesity and dyslipidemia were recorded in a small subgroup treated with CRT, compared with patients treated with chemotherapy.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15700246,Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15700246,Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia.,Hyperglycemia,PROCESS_OF,Child
15929135,CONCLUSIONS: We conclude that CBT can effectively treat ALL in children with high risk features and following relapse.,Transplanted tissue,PART_OF,Blood
15929135,CONCLUSIONS: We conclude that CBT can effectively treat ALL in children with high risk features and following relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16034921,Clinical trials have attempted to evaluate the use of colony-stimulating factors (CSF) as additional therapy to prevent febrile neutropenia in children with ALL.,Therapeutic procedure,PREVENTS,Febrile neutropenia
16034921,SELECTION CRITERIA: We looked for randomised controlled trials (RCTs) comparing CSF with placebo or no treatment as primary or secondary prophylaxis to prevent febrile neutropenia in children with ALL.,Clinical Trials,USES,Placebos
16034921,Clinical trials have attempted to evaluate the use of colony-stimulating factors (CSF) as additional therapy to prevent febrile neutropenia in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16034921,"In spite of these results, CSF did not influence the length of episodes of neutropenia (WMD = -1.11; 95% CI -3.55 to 1.32; p = 0.4) or delays in chemotherapy courses (Rate Ratio=0.77; 95%CI 0.49 to 1,23; p=0.28) . AUTHORS' CONCLUSIONS: Children with ALL treated with CSF benefit from shorter hospitalisation and fewer infections.",Infection,PROCESS_OF,Child
16034921,"In spite of these results, CSF did not influence the length of episodes of neutropenia (WMD = -1.11; 95% CI -3.55 to 1.32; p = 0.4) or delays in chemotherapy courses (Rate Ratio=0.77; 95%CI 0.49 to 1,23; p=0.28) . AUTHORS' CONCLUSIONS: Children with ALL treated with CSF benefit from shorter hospitalisation and fewer infections.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16034921,SELECTION CRITERIA: We looked for randomised controlled trials (RCTs) comparing CSF with placebo or no treatment as primary or secondary prophylaxis to prevent febrile neutropenia in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16034921,SELECTION CRITERIA: We looked for randomised controlled trials (RCTs) comparing CSF with placebo or no treatment as primary or secondary prophylaxis to prevent febrile neutropenia in children with ALL.,Febrile neutropenia,PROCESS_OF,Child
16034921,Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia.,Prophylactic treatment,USES,Colony-Stimulating Factors
16034921,"In spite of these results, CSF did not influence the length of episodes of neutropenia (WMD = -1.11; 95% CI -3.55 to 1.32; p = 0.4) or delays in chemotherapy courses (Rate Ratio=0.77; 95%CI 0.49 to 1,23; p=0.28) . AUTHORS' CONCLUSIONS: Children with ALL treated with CSF benefit from shorter hospitalisation and fewer infections.",Colony-Stimulating Factors,TREATS,"Leukemia, Lymphocytic, Acute"
16034921,"OBJECTIVES: To evaluate the safety and effectiveness of the addition of G-CSF or GM-CSF to myelosuppressive chemotherapy in children with ALL, in an effort to prevent the development of febrile neutropenia.",Pharmacotherapy,TREATS,Child
16034921,SELECTION CRITERIA: We looked for randomised controlled trials (RCTs) comparing CSF with placebo or no treatment as primary or secondary prophylaxis to prevent febrile neutropenia in children with ALL.,Colony-Stimulating Factors,compared_with,Placebos
16034921,Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia.,Febrile neutropenia,PROCESS_OF,Child
16034921,"In spite of these results, CSF did not influence the length of episodes of neutropenia (WMD = -1.11; 95% CI -3.55 to 1.32; p = 0.4) or delays in chemotherapy courses (Rate Ratio=0.77; 95%CI 0.49 to 1,23; p=0.28) . AUTHORS' CONCLUSIONS: Children with ALL treated with CSF benefit from shorter hospitalisation and fewer infections.",Colony-Stimulating Factors,TREATS,Infection
16034921,"OBJECTIVES: To evaluate the safety and effectiveness of the addition of G-CSF or GM-CSF to myelosuppressive chemotherapy in children with ALL, in an effort to prevent the development of febrile neutropenia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16034921,SELECTION CRITERIA: We looked for randomised controlled trials (RCTs) comparing CSF with placebo or no treatment as primary or secondary prophylaxis to prevent febrile neutropenia in children with ALL.,Prophylactic treatment,PREVENTS,Febrile neutropenia
16034921,Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia.,Therapeutic procedure,CAUSES,Febrile neutropenia
16034921,"In spite of these results, CSF did not influence the length of episodes of neutropenia (WMD = -1.11; 95% CI -3.55 to 1.32; p = 0.4) or delays in chemotherapy courses (Rate Ratio=0.77; 95%CI 0.49 to 1,23; p=0.28) . AUTHORS' CONCLUSIONS: Children with ALL treated with CSF benefit from shorter hospitalisation and fewer infections.",Hospitalization,TREATS,Child
16034921,"OBJECTIVES: To evaluate the safety and effectiveness of the addition of G-CSF or GM-CSF to myelosuppressive chemotherapy in children with ALL, in an effort to prevent the development of febrile neutropenia.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16034921,SELECTION CRITERIA: We looked for randomised controlled trials (RCTs) comparing CSF with placebo or no treatment as primary or secondary prophylaxis to prevent febrile neutropenia in children with ALL.,Therapeutic procedure,PREVENTS,Febrile neutropenia
16034921,Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16034921,"In spite of these results, CSF did not influence the length of episodes of neutropenia (WMD = -1.11; 95% CI -3.55 to 1.32; p = 0.4) or delays in chemotherapy courses (Rate Ratio=0.77; 95%CI 0.49 to 1,23; p=0.28) . AUTHORS' CONCLUSIONS: Children with ALL treated with CSF benefit from shorter hospitalisation and fewer infections.",Hospitalization,TREATS,Infection
16034921,Clinical trials have attempted to evaluate the use of colony-stimulating factors (CSF) as additional therapy to prevent febrile neutropenia in children with ALL.,Febrile neutropenia,PROCESS_OF,Child
16034921,SELECTION CRITERIA: We looked for randomised controlled trials (RCTs) comparing CSF with placebo or no treatment as primary or secondary prophylaxis to prevent febrile neutropenia in children with ALL.,Placebos,PREVENTS,Febrile neutropenia
16192600,Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16329562,An RT-PCR assay detected the t(4;11) translocation in two infants with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
16329562,Heterogeneous t(4;11) fusion transcripts in two infants with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
16988997,We examined the association between magnetic field (MF) exposure and the presence of prognostic risk factors among 482 children diagnosed with acute lymphoblastic leukemia (ALL) between 1996 and 2001.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17442991,High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia.,Bone necrosis,PROCESS_OF,Child
17442991,High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17548680,"Inspired by a recent U.S. study showing poorer survival among children with acute lymphoblastic leukemia (ALL) exposed to magnetic fields above 0.3 microT, we examine this relationship in a German cohort of childhood leukemia cases derived from previous population-based case-control studies conducted between 1992 and 2001.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12847317,"At diagnosis, clonal chromosomal abnormalities are found in the bone marrow blasts in more than two thirds of children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12882586,The erythrocyte concentration of mercaptopurine has a prognostic value in the treatment of childhood acute lymphoblastic leukemia.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
14559953,OBJECTIVE: To compare the clinical outcomes of therapy for black and white children with ALL treated at a single institution.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14559953,OBJECTIVE: To compare the clinical outcomes of therapy for black and white children with ALL treated at a single institution.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
14559953,Results of therapy for acute lymphoblastic leukemia in black and white children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14559953,Results of therapy for acute lymphoblastic leukemia in black and white children.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
14559953,OBJECTIVE: To compare the clinical outcomes of therapy for black and white children with ALL treated at a single institution.,Therapeutic procedure,TREATS,Child
15202168,"In a conclusion, for children with acute lymphoblastic leukemia and an isolated CNS relapse, with delayed definitive craniospinal irradiation allowing more intensive systemic and intrathecal chemotherapy results in better overall survival than has been previously reported.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15236274,INTRODUCTION: Mercaptopurine is an important antimetabolite for treatment of childhood acute lymphoblastic leukemia (ALL).,Antimetabolites,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15236274,INTRODUCTION: Mercaptopurine is an important antimetabolite for treatment of childhood acute lymphoblastic leukemia (ALL).,6-Mercaptopurine,ISA,Antimetabolites
15236274,INTRODUCTION: Mercaptopurine is an important antimetabolite for treatment of childhood acute lymphoblastic leukemia (ALL).,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15236274,A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15236274,A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).,thiopurine,TREATS,Child
15236274,A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).,Pediatric Oncology Group,LOCATION_OF,Clinical Research
15236274,A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).,thiopurine,TREATS,"Leukemia, Lymphocytic, Acute"
15514916,Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95.,Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15543007,"OBJECTIVES: Immunity to diphtheria toxoid (D), tetanus toxoid (T), and Haemophilus influenzae type b (Hib) is affected in children with acute lymphoblastic leukemia (ALL).",Immunity,AFFECTS,Child
15543007,"OBJECTIVES: Immunity to diphtheria toxoid (D), tetanus toxoid (T), and Haemophilus influenzae type b (Hib) is affected in children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15577295,METHODS: Seven hundred and eighty nine children (< 15 years old) diagnosed with ALL in the province of Quebec between 1980 and 2000 were recruited for study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15773318,A 12 year-old girl was treated with prophylatic cranial irradiation for acute lymphoblastic leukaemia (ALL).,Cranial Irradiation,TREATS,Girls
15773318,A 12 year-old girl was treated with prophylatic cranial irradiation for acute lymphoblastic leukaemia (ALL).,Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute"
16192600,"CONCLUSION: In this subset of patients, selected with criteria not including monitoring of minimal residual disease, application of extended HD-l-ASP may improve prognosis, compensating reduced leukemia control that results from adoption of a reduced-intensity BFM-backbone for treatment of children with SR ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16192600,"PURPOSE: Between September 1991 and May 1997, within the International Berlin-Frankfurt-Muenster Study Group (I-BFM-SG), a randomized study was performed aimed at assessing the efficacy of prolonged use of high-dose l-asparaginase (HD-l-ASP) during continuation therapy in children with standard risk (SR) acute lymphoblastic leukemia (ALL), treated with a reduced BFM-type chemotherapy.",Therapeutic procedure,TREATS,Child
16192600,"PURPOSE: Between September 1991 and May 1997, within the International Berlin-Frankfurt-Muenster Study Group (I-BFM-SG), a randomized study was performed aimed at assessing the efficacy of prolonged use of high-dose l-asparaginase (HD-l-ASP) during continuation therapy in children with standard risk (SR) acute lymphoblastic leukemia (ALL), treated with a reduced BFM-type chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16192600,"PURPOSE: Between September 1991 and May 1997, within the International Berlin-Frankfurt-Muenster Study Group (I-BFM-SG), a randomized study was performed aimed at assessing the efficacy of prolonged use of high-dose l-asparaginase (HD-l-ASP) during continuation therapy in children with standard risk (SR) acute lymphoblastic leukemia (ALL), treated with a reduced BFM-type chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16192600,"PURPOSE: Between September 1991 and May 1997, within the International Berlin-Frankfurt-Muenster Study Group (I-BFM-SG), a randomized study was performed aimed at assessing the efficacy of prolonged use of high-dose l-asparaginase (HD-l-ASP) during continuation therapy in children with standard risk (SR) acute lymphoblastic leukemia (ALL), treated with a reduced BFM-type chemotherapy.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
16192600,"CONCLUSION: In this subset of patients, selected with criteria not including monitoring of minimal residual disease, application of extended HD-l-ASP may improve prognosis, compensating reduced leukemia control that results from adoption of a reduced-intensity BFM-backbone for treatment of children with SR ALL.",Application procedure,TREATS,Child
16192600,"CONCLUSION: In this subset of patients, selected with criteria not including monitoring of minimal residual disease, application of extended HD-l-ASP may improve prognosis, compensating reduced leukemia control that results from adoption of a reduced-intensity BFM-backbone for treatment of children with SR ALL.",ASPARAGINASE,DISRUPTS,Vertebral column
16193392,"Survivors of childhood ALL treated with high-dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation-induced meningioma.",Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16193392,"Survivors of childhood ALL treated with high-dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation-induced meningioma.",Organ,LOCATION_OF,Radiation Injuries
16193392,"Survivors of childhood ALL treated with high-dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation-induced meningioma.",Pituitary Gland,LOCATION_OF,Radiation Injuries
16193392,"Survivors of childhood ALL treated with high-dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation-induced meningioma.","Lens, Crystalline",LOCATION_OF,Radiation Injuries
16537719,Cytogenetics of Hispanic and White children with acute lymphoblastic leukemia in California.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16537719,Cytogenetics of Hispanic and White children with acute lymphoblastic leukemia in California.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Hispanics
16945940,"CONCLUSIONS: The comprehensive nature of the data, coupled with complete case-ascertainment and representative population-based controls suggests that SES in the UK is not a determinant of ALL in children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16945940,BACKGROUND: It is widely believed that children of high socioeconomic status (SES) are more likely than those of low SES to develop acute lymphoblastic leukaemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17129225,"Seven of 21 children with B-lineage ALL had multiple PAX5 variants, while 14 children and healthy controls showed full-length (FL) and one variant PAX5.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17702568,Dexamethasone in the maintenance phase of acute lymphoblastic leukaemia treatment: is the risk of lethal infections too high?,Therapeutic procedure,PREDISPOSES,Infection
17702568,Dexamethasone in the maintenance phase of acute lymphoblastic leukaemia treatment: is the risk of lethal infections too high?,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
14504110,HOX11L2/t(5;14) positivity was more frequent in acute lymphoblastic leukemia (ALL) with cortical T immunophenotype and in children aged between 6 and 9 years.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14559953,"CONCLUSION: With equal access to effective antileukemic therapy, black and white children with ALL can expect the same high rate of cure.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14559954,"CONCLUSIONS: Black, Hispanic, and American Indian/Alaskan Native children with ALL have worse survival than white and Asian/Pacific Islander children, even in the contemporary treatment era.","Leukemia, Lymphocytic, Acute",PROCESS_OF,African race
14559954,"CONCLUSIONS: Black, Hispanic, and American Indian/Alaskan Native children with ALL have worse survival than white and Asian/Pacific Islander children, even in the contemporary treatment era.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14559954,"CONCLUSIONS: Black, Hispanic, and American Indian/Alaskan Native children with ALL have worse survival than white and Asian/Pacific Islander children, even in the contemporary treatment era.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14559954,"CONTEXT: The role of race/ethnicity in survival of children with acute lymphoblastic leukemia (ALL) is unclear, with some studies reporting poorer survival among minority children and others reporting equivalent survival across race/ethnicity in the modern, risk-stratified treatment era.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14559954,"CONCLUSIONS: Black, Hispanic, and American Indian/Alaskan Native children with ALL have worse survival than white and Asian/Pacific Islander children, even in the contemporary treatment era.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Hispanics
14738574,Only 34 (31%) of the children were diagnosed with acute lymphoblastic leukaemia (ALL) compared with 54 (49%) children with acute myeloid leukaemia (AML).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14738574,Only 34 (31%) of the children were diagnosed with acute lymphoblastic leukaemia (ALL) compared with 54 (49%) children with acute myeloid leukaemia (AML).,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
15921375,In this study we investigated the significance of novel translocations and inversions of 6q in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).,Chromosomal translocation,COEXISTS_WITH,"Leukemia, Myelocytic, Acute"
15921375,In this study we investigated the significance of novel translocations and inversions of 6q in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).,Chromosomal translocation,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
15921391,We screened 100 children with acute lymphoblastic leukemia (ALL) to assess the incidence of single amino acid change A91V in perforin.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15921391,We screened 100 children with acute lymphoblastic leukemia (ALL) to assess the incidence of single amino acid change A91V in perforin.,Amino Acids,COEXISTS_WITH,perforin
15921391,We screened 100 children with acute lymphoblastic leukemia (ALL) to assess the incidence of single amino acid change A91V in perforin.,Amino Acids,PART_OF,Unmarried person
15995009,"In the present study, 1-year longitudinal changes in BMD, body composition, and bone metabolism were evaluated in children with ALL during the first 3 years after completion of therapy without cranial irradiation.",bone metabolism,PROCESS_OF,Child
15995009,"In the present study, 1-year longitudinal changes in BMD, body composition, and bone metabolism were evaluated in children with ALL during the first 3 years after completion of therapy without cranial irradiation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16059922,"The major morphological subtypes of leukemia, acute lymphoblastic leukemia (ALL), and acute myeloblastic leukemia (AML), are characterized by chromosomal translocations involving over 200 genes including mixed lineage leukemia (MLL), TEL, and AML1.","Leukemia, Lymphocytic, Acute",ISA,leukemia
16059922,"The major morphological subtypes of leukemia, acute lymphoblastic leukemia (ALL), and acute myeloblastic leukemia (AML), are characterized by chromosomal translocations involving over 200 genes including mixed lineage leukemia (MLL), TEL, and AML1.","Leukemia, Myelocytic, Acute",ISA,leukemia
16059922,"The major morphological subtypes of leukemia, acute lymphoblastic leukemia (ALL), and acute myeloblastic leukemia (AML), are characterized by chromosomal translocations involving over 200 genes including mixed lineage leukemia (MLL), TEL, and AML1.",Chromosomal translocation,COEXISTS_WITH,"Leukemia, Myelocytic, Acute"
16059922,"The major morphological subtypes of leukemia, acute lymphoblastic leukemia (ALL), and acute myeloblastic leukemia (AML), are characterized by chromosomal translocations involving over 200 genes including mixed lineage leukemia (MLL), TEL, and AML1.",Chromosomal translocation,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
16083543,The present study was designed to establish a flow cytometric method for detecting MRD in children with B-ALL and evaluate its clinical prognostic value.,"Neoplasm, Residual",PROCESS_OF,Child
16083543,The present study was designed to establish a flow cytometric method for detecting MRD in children with B-ALL and evaluate its clinical prognostic value.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
16083543,OBJECTIVE: Flow cytometry may be used to detect minimal residual disease (MRD) in acute lymphoblastic leukemia because leukemic cells often display aberrant phenotypes when compared to normal cells.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
16083543,OBJECTIVE: Flow cytometry may be used to detect minimal residual disease (MRD) in acute lymphoblastic leukemia because leukemic cells often display aberrant phenotypes when compared to normal cells.,Flow Cytometry,DIAGNOSES,"Neoplasm, Residual"
16083545,OBJECTIVE: To analyze the main reason of failure in treatment and compliance to protocol in children with acute lymphoblastic leukemia (ALL) at a single institute which is located at the most developed city of China.,Therapeutic procedure,TREATS,Child
16083545,OBJECTIVE: To analyze the main reason of failure in treatment and compliance to protocol in children with acute lymphoblastic leukemia (ALL) at a single institute which is located at the most developed city of China.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16083545,OBJECTIVE: To analyze the main reason of failure in treatment and compliance to protocol in children with acute lymphoblastic leukemia (ALL) at a single institute which is located at the most developed city of China.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
16266899,Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.,Polymerase Chain Reaction,DIAGNOSES,"Neoplasm, Residual"
16266899,Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16386788,"Therefore, we have analyzed 83 children with acute B-lineage ALL (67 de novo patients and 19 relapses) by PCR analysis for clonal IgH, incomplete TCRD (Vdelta2-Ddelta3 and Ddelta2-Ddelta3) and TCRG rearrangements.",IGH@ gene cluster | IGH,PART_OF,Clone
16386788,"Therefore, we have analyzed 83 children with acute B-lineage ALL (67 de novo patients and 19 relapses) by PCR analysis for clonal IgH, incomplete TCRD (Vdelta2-Ddelta3 and Ddelta2-Ddelta3) and TCRG rearrangements.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16412348,"OBJECTIVE: With more precise diagnostic criteria and risk classifications, more effective therapy administered in clinical trials, and better supportive care, the outcome of children with acute lymphoblastic leukemia (ALL) has been improved dramatically.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17015055,The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.,Venoocclusive disease,ASSOCIATED_WITH,"Polymorphism, Genetic"
17015055,The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.,Liver,LOCATION_OF,Venoocclusive disease
17015055,The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17015055,OBJECTIVE: Thiopurine metabolism was investigated in children with acute lymphoblastic leukemia treated in the United Kingdom Medical Research Council trial ALL97.,thiopurine,TREATS,Child
17015055,OBJECTIVE: Thiopurine metabolism was investigated in children with acute lymphoblastic leukemia treated in the United Kingdom Medical Research Council trial ALL97.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17015055,OBJECTIVE: Thiopurine metabolism was investigated in children with acute lymphoblastic leukemia treated in the United Kingdom Medical Research Council trial ALL97.,thiopurine,TREATS,"Leukemia, Lymphocytic, Acute"
17546641,Granular ALL occurs approximately 2 to 7% in childhood populations but is extremely rare in adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
14510941,"To investigate this possibility, we conducted a case-control study on 287 children with ALL and 320 healthy controls both of French-Canadian origin.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14510948,Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
14510948,Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.,thiopurine,ADMINISTERED_TO,Patients
14510948,Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.,Venoocclusive disease,PROCESS_OF,Patients
14510948,The case records of 99 consecutive children with acute lymphoblastic leukaemia who received either 6-thioguanine (6-TG) or 6-mercaptopurine (6-MP) as maintenance therapy for at least 1 year were reviewed for hepatic veno-occlusive disease (VOD).,Maintenance therapy,TREATS,Hepatic Veno-Occlusive Disease
14510948,The case records of 99 consecutive children with acute lymphoblastic leukaemia who received either 6-thioguanine (6-TG) or 6-mercaptopurine (6-MP) as maintenance therapy for at least 1 year were reviewed for hepatic veno-occlusive disease (VOD).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14510948,The case records of 99 consecutive children with acute lymphoblastic leukaemia who received either 6-thioguanine (6-TG) or 6-mercaptopurine (6-MP) as maintenance therapy for at least 1 year were reviewed for hepatic veno-occlusive disease (VOD).,Thioguanine,ADMINISTERED_TO,Child
14752789,Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14752789,Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation.,Neuraxis,LOCATION_OF,Radiation therapy
15380339,"Our results suggest the potential of spectral imaging as a new method for the distinction of lymphocytes from lymphoblasts in cases that with the light microscope, the morphologic differences are not visible in the bone marrow smears at diagnosis or the follow up of the children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15380339,"Our results suggest the potential of spectral imaging as a new method for the distinction of lymphocytes from lymphoblasts in cases that with the light microscope, the morphologic differences are not visible in the bone marrow smears at diagnosis or the follow up of the children with ALL.",Bone Marrow,NEG_LOCATION_OF,"Microscopes, Light"
15382273,"RESULTS: In children with ALL, CYP1A1 m1 polymorphism was evident in 42.4% of subjects and CYP1A1 m2 in 37.3%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15382273,"Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15473876,The proportion of children with CH who reached AR by 37 months and by 49 months of age were compared with healthy children and children with acute lymphoblastic leukaemia (ALL) described in the literature.,Cretinism,PROCESS_OF,Child
15473876,The proportion of children with CH who reached AR by 37 months and by 49 months of age were compared with healthy children and children with acute lymphoblastic leukaemia (ALL) described in the literature.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15473876,The proportion of children with CH who reached AR by 37 months and by 49 months of age were compared with healthy children and children with acute lymphoblastic leukaemia (ALL) described in the literature.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15473876,The proportion of children with CH who reached AR by 37 months and by 49 months of age were compared with healthy children and children with acute lymphoblastic leukaemia (ALL) described in the literature.,Cretinism,PROCESS_OF,Child
16136167,"POG 8101 demonstrated that the induction rate associated with the 3+7+7 combination of daunorubicin, Ara-C, and 6-thioguanine (DAT) was greater than that associated with an induction regimen used to treat acute lymphoblastic leukemia (82 vs 61%; P=0.02).",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
16158972,"BACKGROUND: Glucocorticoids are the most important group of drugs used in the treatment of childhood acute lymphoblastic leukemia (ALL), however, resistance to this group remains the main obstacle in curing the disease.",Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16158972,"BACKGROUND: Glucocorticoids are the most important group of drugs used in the treatment of childhood acute lymphoblastic leukemia (ALL), however, resistance to this group remains the main obstacle in curing the disease.",Glucocorticoids,ISA,Pharmaceutical Preparations
16158972,"BACKGROUND: Glucocorticoids are the most important group of drugs used in the treatment of childhood acute lymphoblastic leukemia (ALL), however, resistance to this group remains the main obstacle in curing the disease.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16158972,PATIENTS AND METHODS: Leukemic samples from 60 children with ALL were tested by the M7T assay for glucocorticoid resistance.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16226335,"METHODS: We report six children with ALL, who presented with splenomegaly after a median (range) treatment duration of 12 (6-22) months.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16226335,"METHODS: We report six children with ALL, who presented with splenomegaly after a median (range) treatment duration of 12 (6-22) months.",Splenomegaly,PROCESS_OF,Child
16226335,BACKGROUND/AIMS: The United Kingdom (UK) acute lymphoblastic leukaemia (ALL) 97/99 clinical trial compared 6-mercaptopurine (6MP) with 6-thioguanine (6TG) as maintenance therapy for childhood ALL.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16226335,BACKGROUND/AIMS: The United Kingdom (UK) acute lymphoblastic leukaemia (ALL) 97/99 clinical trial compared 6-mercaptopurine (6MP) with 6-thioguanine (6TG) as maintenance therapy for childhood ALL.,6-Mercaptopurine,compared_with,Thioguanine
16226335,Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia.,Chronic liver disease NOS,PROCESS_OF,Child
16226335,Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16307022,MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia.,MLL GENE REARRANGEMENTS | KMT2A,NEG_INTERACTS_WITH,Ara-C
16307022,MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
16875937,"In 620 children with ALL diagnosed between 1988 and 1999, the leukemic cells were near-triploid (DNA index, 1.50-1.73) in 4 and near-tetraploid (DNA index, 1.79-2.28) in 14.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17254469,"[Clinical analysis of short period chemotherapy in childhood acute B-cell lymphoblastic leukemia, standard-risk type].",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17254469,"[Clinical analysis of short period chemotherapy in childhood acute B-cell lymphoblastic leukemia, standard-risk type].",B-Lymphocytes,LOCATION_OF,"Leukemia, Lymphocytic, Acute, L1"
19308508,Acute lymphoblastic leukemia in children: correlation of musculoskeletal manifestations and immunophenotypes.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19308508,"CONCLUSIONS: MSM occur mostly in children with BCP ALL who present with less involvement of extramedullary organs, low peripheral blood blasts and white blood cells counts.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
12850377,Acute lymphoblastic leukemia (ALL) is associated with recurrent chromosomal abnormalities.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
12850377,"The fusion was found among 19.6% of the 57 ALL children, additional changes being identified by conventional cytogenetics in 80% of the cases.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12850377,No TEL-AML1 fusion was observed in the 26 ALL adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
14633779,The outcome for children with acute lymphoblastic leukemia (ALL) has improved dramatically with current therapy resulting in an event free survival exceeding 75% for most patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15170885,"PROCEDURE: Thirty children with high-risk non-B acute lymphoblastic leukemia (ALL) treated according to the national protocol (PINDA 92) based on ALL BFM 90, were randomized to receive consolidation with four doses of either 1 or 2 g/m(2) MTX as a 24-hr infusion, at 2-week intervals (group M1 and M2, respectively).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15170885,High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.,Therapeutic procedure,USES,Methotrexate
15170885,High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15170885,High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.,Methotrexate,ISA,Therapeutic procedure
15204659,There is scant research available about how fathers cope with their children receiving difficult treatment protocols for diseases such as childhood acute lymphoblastic leukemia (ALL).,Treatment Protocols,ADMINISTERED_TO,Child
15204659,There is scant research available about how fathers cope with their children receiving difficult treatment protocols for diseases such as childhood acute lymphoblastic leukemia (ALL).,Treatment Protocols,TREATS,Disease
15204659,There is scant research available about how fathers cope with their children receiving difficult treatment protocols for diseases such as childhood acute lymphoblastic leukemia (ALL).,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15204659,There is scant research available about how fathers cope with their children receiving difficult treatment protocols for diseases such as childhood acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute, L1",ISA,Disease
15579181,"SUBJECTS AND DESIGN: Eleven patients with GHD (median age 29 years), previously given prophylactic CRT for ALL, and 11 sex-, age- and body mass index (BMI)-matched controls were investigated with bioimpedance analysis (BIA) and analysis of serum leptin, serum free fatty acids (FFA) and serum insulin.",Serum,LOCATION_OF,Leptin | LEP
15579181,"SUBJECTS AND DESIGN: Eleven patients with GHD (median age 29 years), previously given prophylactic CRT for ALL, and 11 sex-, age- and body mass index (BMI)-matched controls were investigated with bioimpedance analysis (BIA) and analysis of serum leptin, serum free fatty acids (FFA) and serum insulin.",Leptin | LEP,ADMINISTERED_TO,Patients
15579181,"SUBJECTS AND DESIGN: Eleven patients with GHD (median age 29 years), previously given prophylactic CRT for ALL, and 11 sex-, age- and body mass index (BMI)-matched controls were investigated with bioimpedance analysis (BIA) and analysis of serum leptin, serum free fatty acids (FFA) and serum insulin.",Insulin,ADMINISTERED_TO,Patients
15579181,"SUBJECTS AND DESIGN: Eleven patients with GHD (median age 29 years), previously given prophylactic CRT for ALL, and 11 sex-, age- and body mass index (BMI)-matched controls were investigated with bioimpedance analysis (BIA) and analysis of serum leptin, serum free fatty acids (FFA) and serum insulin.","Fatty Acids, Nonesterified",ADMINISTERED_TO,Patients
15579181,"SUBJECTS AND DESIGN: Eleven patients with GHD (median age 29 years), previously given prophylactic CRT for ALL, and 11 sex-, age- and body mass index (BMI)-matched controls were investigated with bioimpedance analysis (BIA) and analysis of serum leptin, serum free fatty acids (FFA) and serum insulin.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
15579181,"SUBJECTS AND DESIGN: Eleven patients with GHD (median age 29 years), previously given prophylactic CRT for ALL, and 11 sex-, age- and body mass index (BMI)-matched controls were investigated with bioimpedance analysis (BIA) and analysis of serum leptin, serum free fatty acids (FFA) and serum insulin.",Serum,LOCATION_OF,Insulin
15921627,OBJECTIVE: To investigate the changes in the activity of Escherichia coli asparaginase (L-asp) and the concentration of asparagines (ASN) in the plasma of the acute lymphoblastic leukemia (ALL) children receiving L-asp containing chemotherapeutic protocol to explore more reasonable usage of L-asp in the treatment of childhood ALL.,ASPARAGINASE | ASIP | ASPA | C3 | ATG5 | A1CF | ROPN1L | ASPM,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15921627,"METHODS: L-asp containing hemotherapy regimen of VDLP was used, in which L-asp (10,000 U/m(2)) was administered intravenously every other day for 10 doses in 15 children with ALL.",ASPARAGINASE | ASIP | ASPA | C3 | ATG5 | A1CF | ROPN1L | ASPM,TREATS,"Leukemia, Lymphocytic, Acute"
15921627,OBJECTIVE: To investigate the changes in the activity of Escherichia coli asparaginase (L-asp) and the concentration of asparagines (ASN) in the plasma of the acute lymphoblastic leukemia (ALL) children receiving L-asp containing chemotherapeutic protocol to explore more reasonable usage of L-asp in the treatment of childhood ALL.,Plasma,PART_OF,Child
15921627,OBJECTIVE: To investigate the changes in the activity of Escherichia coli asparaginase (L-asp) and the concentration of asparagines (ASN) in the plasma of the acute lymphoblastic leukemia (ALL) children receiving L-asp containing chemotherapeutic protocol to explore more reasonable usage of L-asp in the treatment of childhood ALL.,Plasma,LOCATION_OF,Asparagine
15921627,OBJECTIVE: To investigate the changes in the activity of Escherichia coli asparaginase (L-asp) and the concentration of asparagines (ASN) in the plasma of the acute lymphoblastic leukemia (ALL) children receiving L-asp containing chemotherapeutic protocol to explore more reasonable usage of L-asp in the treatment of childhood ALL.,ASPARAGINASE | ASIP | ASPA | C3 | ATG5 | A1CF | ROPN1L | ASPM,ADMINISTERED_TO,Child
15921627,OBJECTIVE: To investigate the changes in the activity of Escherichia coli asparaginase (L-asp) and the concentration of asparagines (ASN) in the plasma of the acute lymphoblastic leukemia (ALL) children receiving L-asp containing chemotherapeutic protocol to explore more reasonable usage of L-asp in the treatment of childhood ALL.,Escherichia coli asparaginase | ASPG,ISA,ASPARAGINASE | ASIP | ASPA | C3 | ATG5 | A1CF | ROPN1L | ASPM
15921627,"METHODS: L-asp containing hemotherapy regimen of VDLP was used, in which L-asp (10,000 U/m(2)) was administered intravenously every other day for 10 doses in 15 children with ALL.",ASPARAGINASE | ASIP | ASPA | C3 | ATG5 | A1CF | ROPN1L | ASPM,TREATS,Child
15921627,OBJECTIVE: To investigate the changes in the activity of Escherichia coli asparaginase (L-asp) and the concentration of asparagines (ASN) in the plasma of the acute lymphoblastic leukemia (ALL) children receiving L-asp containing chemotherapeutic protocol to explore more reasonable usage of L-asp in the treatment of childhood ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15921627,"METHODS: L-asp containing hemotherapy regimen of VDLP was used, in which L-asp (10,000 U/m(2)) was administered intravenously every other day for 10 doses in 15 children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15921627,[Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16152606,"In addition, the substitution 643C>T (R215W) has also been found in excess among children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16358301,Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML.,Methotrexate,TREATS,pediatric acute myeloblastic leukemia
16980228,"Because of its relatively high prevalence, most of the work done in pediatric oncogenetics has been focused on leukemias, particularly acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",ISA,leukemia
17164697,These results justify performing TPMT genotyping before initiating thiopurine therapy in all children with ALL to minimize consequent toxicity.,Therapeutic procedure,USES,thiopurine
17164697,These results justify performing TPMT genotyping before initiating thiopurine therapy in all children with ALL to minimize consequent toxicity.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
17164697,These results justify performing TPMT genotyping before initiating thiopurine therapy in all children with ALL to minimize consequent toxicity.,Therapeutic procedure,TREATS,Child
17164697,Blood samples from 100 healthy adults and 100 children with ALL were analyzed for common mutations in the TPMT gene using polymerase chain reaction-based assays.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17164697,These results justify performing TPMT genotyping before initiating thiopurine therapy in all children with ALL to minimize consequent toxicity.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17164697,These results justify performing TPMT genotyping before initiating thiopurine therapy in all children with ALL to minimize consequent toxicity.,Genotype determination,USES,TPMT gene | TPMT
17164697,These results justify performing TPMT genotyping before initiating thiopurine therapy in all children with ALL to minimize consequent toxicity.,thiopurine,ISA,Therapeutic procedure
17164697,These results justify performing TPMT genotyping before initiating thiopurine therapy in all children with ALL to minimize consequent toxicity.,thiopurine,TREATS,Child
17291319,METHODS: This study was longitudinal and involved a cross section of 32 mothers of children recently diagnosed with acute lymphoblastic leukaemia (ALL) currently participating in the Medical Research Council ALL-97 randomized control trial.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17291319,'Building a new normality': mothers' experiences of caring for a child with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17503007,"Thus, two findings from this post-hoc analysis are worthy of note: (1) the use of birthweight-for-gestation age categories within birthweight sub-groups potentially identified new high-risk groups among firstborns for ALL tumors and among all children for CNS tumors; and (2) although the magnitudes of risk estimators for ALL were comparable in the traditional high-birthweight group and in the LGA, the same children were not jointly classified in the same newborn categories indicating two potentially different subsets of children at risk.",Pregnancy,PROCESS_OF,Human Age Group
17503007,"Thus, two findings from this post-hoc analysis are worthy of note: (1) the use of birthweight-for-gestation age categories within birthweight sub-groups potentially identified new high-risk groups among firstborns for ALL tumors and among all children for CNS tumors; and (2) although the magnitudes of risk estimators for ALL were comparable in the traditional high-birthweight group and in the LGA, the same children were not jointly classified in the same newborn categories indicating two potentially different subsets of children at risk.","Leukemia, Lymphocytic, Acute",ISA,Neoplasm
17503007,"Thus, two findings from this post-hoc analysis are worthy of note: (1) the use of birthweight-for-gestation age categories within birthweight sub-groups potentially identified new high-risk groups among firstborns for ALL tumors and among all children for CNS tumors; and (2) although the magnitudes of risk estimators for ALL were comparable in the traditional high-birthweight group and in the LGA, the same children were not jointly classified in the same newborn categories indicating two potentially different subsets of children at risk.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17503007,"Thus, two findings from this post-hoc analysis are worthy of note: (1) the use of birthweight-for-gestation age categories within birthweight sub-groups potentially identified new high-risk groups among firstborns for ALL tumors and among all children for CNS tumors; and (2) although the magnitudes of risk estimators for ALL were comparable in the traditional high-birthweight group and in the LGA, the same children were not jointly classified in the same newborn categories indicating two potentially different subsets of children at risk.",Neoplasm,PROCESS_OF,Child
12886242,Early reduction of leukaemic cells by chemotherapy is a strong predictor for treatment outcome in childhood acute lymphoblastic leukaemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15172754,"However, although chromosome 13 aberrations are a nonrandom event in childhood acute lymphoblastic leukemia (ALL), their biological and clinical associations are limited.",Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15952191,"METHODS: From 1997 to 2002, 158 children ages birth-18 years with DS and acute leukemia (n = 61 children with acute myeloid leukemia [AML] and n = 97 children with ALL) were enrolled through the Children's Oncology Group in North America.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15952191,"METHODS: From 1997 to 2002, 158 children ages birth-18 years with DS and acute leukemia (n = 61 children with acute myeloid leukemia [AML] and n = 97 children with ALL) were enrolled through the Children's Oncology Group in North America.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
15952191,"METHODS: From 1997 to 2002, 158 children ages birth-18 years with DS and acute leukemia (n = 61 children with acute myeloid leukemia [AML] and n = 97 children with ALL) were enrolled through the Children's Oncology Group in North America.",Acute leukemia,PROCESS_OF,Child
15952191,"METHODS: From 1997 to 2002, 158 children ages birth-18 years with DS and acute leukemia (n = 61 children with acute myeloid leukemia [AML] and n = 97 children with ALL) were enrolled through the Children's Oncology Group in North America.",Down Syndrome,PROCESS_OF,Child
16369923,Chemotherapy-related growth failure is a significant problem in children with acute lymphoblastic leukemia (ALL) and other childhood cancers.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16369923,We report the two survivors of childhood ALL treated with chemotherapy without CR who required GH replacement due to absence of catch-up growth.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16369923,Growth hormone deficiency after chemotherapy for acute lymphoblastic leukemia in children who have not received cranial radiation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16369923,"Among the 235 ALL survivors treated with chemotherapy without CR, 2 were diagnosed with growth failure and GHD.",Pharmacotherapy,TREATS,Survivors
16369923,Growth hormone deficiency after chemotherapy for acute lymphoblastic leukemia in children who have not received cranial radiation.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16369923,"Among the 235 ALL survivors treated with chemotherapy without CR, 2 were diagnosed with growth failure and GHD.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
16369923,"Among the 235 ALL survivors treated with chemotherapy without CR, 2 were diagnosed with growth failure and GHD.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16369923,Chemotherapy-related growth failure is a significant problem in children with acute lymphoblastic leukemia (ALL) and other childhood cancers.,Growth failure,PROCESS_OF,Child
16369923,Chemotherapy-related growth failure is a significant problem in children with acute lymphoblastic leukemia (ALL) and other childhood cancers.,Malignant Childhood Neoplasm,PROCESS_OF,Child
16522695,"CONTEXT: Survivors of childhood-onset (CO) acute lymphoblastic leukemia (ALL) treated with prophylactic cranial radiotherapy often exhibit GH deficiency (GHD), which is associated with increased prevalence of cardiovascular risk factors and cardiac dysfunction.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16585211,Metabolism to more biologically active polyglutamate forms is also potentiated for MTX and other antifolates.,Methotrexate,ISA,Folic Acid Antagonists
16585211,Metabolism to more biologically active polyglutamate forms is also potentiated for MTX and other antifolates.,Folic Acid Antagonists,ISA,Methotrexate
17054463,"No relationship was found between dose of CRT, time since treatment of ALL or gender and neuropsychological performance.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
17054463,"OBJECTIVE: Cranial radiotherapy (CRT) was, until recently, important for achieving long-term survival in acute lymphoblastic leukaemia (ALL).",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
17054463,"CONCLUSIONS: This study showed that adults treated with CRT for CO ALL had GHD and significantly impaired neuropsychological performance, although self-reported quality of life was not affected.",Radiation therapy,TREATS,Adult
17054463,"CONCLUSIONS: This study showed that adults treated with CRT for CO ALL had GHD and significantly impaired neuropsychological performance, although self-reported quality of life was not affected.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17124053,"Children with B-cell precursor ALL who have a late CNS relapse (after an initial remission of 18 months or more) and did not receive cranial irradiation have an excellent outcome after retrieval therapy, with a 5-year event-free survival (EFS) rate approaching that in newly diagnosed patients.",Cranial Irradiation,NEG_ADMINISTERED_TO,Child
17124053,"CNS control is a less urgent concern in adults with ALL, in whom systemic relapse remains the major problem.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
17124053,"Children with B-cell precursor ALL who have a late CNS relapse (after an initial remission of 18 months or more) and did not receive cranial irradiation have an excellent outcome after retrieval therapy, with a 5-year event-free survival (EFS) rate approaching that in newly diagnosed patients.",Therapeutic procedure,TREATS,Patients
17124053,"Children with B-cell precursor ALL who have a late CNS relapse (after an initial remission of 18 months or more) and did not receive cranial irradiation have an excellent outcome after retrieval therapy, with a 5-year event-free survival (EFS) rate approaching that in newly diagnosed patients.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
17445885,Our results indicate that RQ-PCR measurements of WT1 may be of limited value for monitoring MRD in childhood ALL.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
17445885,Our results indicate that RQ-PCR measurements of WT1 may be of limited value for monitoring MRD in childhood ALL.,WT1 gene | WT1,TREATS,"Neoplasm, Residual"
17445885,Minimal residual disease (MRD) in 56 children with acute lymphoblastic leukemia (ALL) was quantified simultaneously by flow cytometry and by RQ-PCR of WT1 transcripts.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17445885,Minimal residual disease (MRD) in 56 children with acute lymphoblastic leukemia (ALL) was quantified simultaneously by flow cytometry and by RQ-PCR of WT1 transcripts.,"Neoplasm, Residual",PROCESS_OF,Child
17551551,Four of 6 infants with acute lymphoblastic leukemia and all 4 with mature B-cell leukemia are alive.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17551551,Four of 6 infants with acute lymphoblastic leukemia and all 4 with mature B-cell leukemia are alive.,Chronic Lymphocytic Leukemia,PROCESS_OF,Infant
17617792,The frequencies of these variants were investigated among 106 children with ALL in Turkish population.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Turkish population
17617792,The frequencies of these variants were investigated among 106 children with ALL in Turkish population.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17662616,"PURPOSE: Children with acute lymphoblastic leukemia (ALL), the most common pediatric malignancy, have a 5-year survival rate of better than 80%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17662616,"PURPOSE: Children with acute lymphoblastic leukemia (ALL), the most common pediatric malignancy, have a 5-year survival rate of better than 80%.","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
14634180,"Odds ratios were calculated for 31 ""occupational groups"" by parent, diagnostic group (leukaemia, acute lymphoblastic leukaemia (ALL), central nervous system tumours, and other cancers) and time of exposure (periconception, birth, and diagnosis).",leukemia,ISA,Malignant Neoplasms
14634180,"Specific examination of periconceptual chemical exposures showed small but statistically significant increased risks for leukaemia and ALL among children whose fathers were exposed to exhaust fumes, driving, and/or inhaled particulate hydrocarbons.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14634180,"Odds ratios were calculated for 31 ""occupational groups"" by parent, diagnostic group (leukaemia, acute lymphoblastic leukaemia (ALL), central nervous system tumours, and other cancers) and time of exposure (periconception, birth, and diagnosis).",Malignant Neoplasms,ISA,Central Nervous System Neoplasms
14634180,"Specific examination of periconceptual chemical exposures showed small but statistically significant increased risks for leukaemia and ALL among children whose fathers were exposed to exhaust fumes, driving, and/or inhaled particulate hydrocarbons.",leukemia,PROCESS_OF,Child
14634180,"Odds ratios were calculated for 31 ""occupational groups"" by parent, diagnostic group (leukaemia, acute lymphoblastic leukaemia (ALL), central nervous system tumours, and other cancers) and time of exposure (periconception, birth, and diagnosis).",Malignant Neoplasms,ISA,"Leukemia, Lymphocytic, Acute"
14634180,"Odds ratios were calculated for 31 ""occupational groups"" by parent, diagnostic group (leukaemia, acute lymphoblastic leukaemia (ALL), central nervous system tumours, and other cancers) and time of exposure (periconception, birth, and diagnosis).",Central Nervous System Neoplasms,ISA,Malignant Neoplasms
14634180,"Odds ratios were calculated for 31 ""occupational groups"" by parent, diagnostic group (leukaemia, acute lymphoblastic leukaemia (ALL), central nervous system tumours, and other cancers) and time of exposure (periconception, birth, and diagnosis).",Malignant Neoplasms,ISA,leukemia
14634180,"Odds ratios were calculated for 31 ""occupational groups"" by parent, diagnostic group (leukaemia, acute lymphoblastic leukaemia (ALL), central nervous system tumours, and other cancers) and time of exposure (periconception, birth, and diagnosis).","Leukemia, Lymphocytic, Acute",ISA,leukemia
14634180,"Odds ratios were calculated for 31 ""occupational groups"" by parent, diagnostic group (leukaemia, acute lymphoblastic leukaemia (ALL), central nervous system tumours, and other cancers) and time of exposure (periconception, birth, and diagnosis).","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
14634180,"Odds ratios were calculated for 31 ""occupational groups"" by parent, diagnostic group (leukaemia, acute lymphoblastic leukaemia (ALL), central nervous system tumours, and other cancers) and time of exposure (periconception, birth, and diagnosis).",leukemia,ISA,"Leukemia, Lymphocytic, Acute"
14710221,"A case-control study was conducted from 1995 to 1998 in France, and included 473 incident cases of acute leukaemia (AL) (408 acute lymphoblastic leukaemia (ALL), 65 acute myeloid leukaemia (AML) age-, sex- and region-matched with 567 population-based controls.","Leukemia, Lymphocytic, Acute",ISA,Acute leukemia
15190007,"Exploiting the selective affinity of Achatinin-H toward N-acetyl-9-O-acetylneuraminic acid-alpha2-6-GalNAc, we have demonstrated the presence of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on lymphoblasts of 70 children with acute lymphoblastic leukemia (ALL) and on leukemic cell lines by fluorimetric HPLC and flow cytometric analysis.",achatinin(H),COEXISTS_WITH,Sialoglycoproteins
15190007,"Exploiting the selective affinity of Achatinin-H toward N-acetyl-9-O-acetylneuraminic acid-alpha2-6-GalNAc, we have demonstrated the presence of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on lymphoblasts of 70 children with acute lymphoblastic leukemia (ALL) and on leukemic cell lines by fluorimetric HPLC and flow cytometric analysis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15190007,"Exploiting the selective affinity of Achatinin-H toward N-acetyl-9-O-acetylneuraminic acid-alpha2-6-GalNAc, we have demonstrated the presence of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on lymphoblasts of 70 children with acute lymphoblastic leukemia (ALL) and on leukemic cell lines by fluorimetric HPLC and flow cytometric analysis.",lymphoblast,PART_OF,Child
15190007,"Exploiting the selective affinity of Achatinin-H toward N-acetyl-9-O-acetylneuraminic acid-alpha2-6-GalNAc, we have demonstrated the presence of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on lymphoblasts of 70 children with acute lymphoblastic leukemia (ALL) and on leukemic cell lines by fluorimetric HPLC and flow cytometric analysis.",Cell Line,PART_OF,Child
15347448,[Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].,"Neoplasm, Residual",COEXISTS_WITH,B-cell childhood acute lymphoblastic leukemia
15553044,Physicians should be aware of this rare complication during maintenance treatment with weekly low dose MTX for acute lymphoblastic leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15553044,Physicians should be aware of this rare complication during maintenance treatment with weekly low dose MTX for acute lymphoblastic leukemia in children.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
15553044,[Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].,"Pneumonitis, Interstitial",PROCESS_OF,Child
15553044,[Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15737564,"Hypermethylation of the p15INK4B gene was more frequent in cases with T-cell origin ALL (46.2%), but similar among children with B-cell origin ALL (13.0%) and AML (18.8%).",Hypermethylation,PROCESS_OF,Child
15737564,"Hypermethylation of the p15INK4B gene was more frequent in cases with T-cell origin ALL (46.2%), but similar among children with B-cell origin ALL (13.0%) and AML (18.8%).",Acute T Cell Leukemia,PROCESS_OF,Hypermethylation
15737564,"Hypermethylation of the p15INK4B gene was more frequent in cases with T-cell origin ALL (46.2%), but similar among children with B-cell origin ALL (13.0%) and AML (18.8%).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
16288492,L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16288492,L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16288492,"CONCLUSIONS: To the authors' knowledge, the current study is the first published report of an obesity-associated chemotherapy dose modification in pediatric patients with ALL, the most common childhood malignancy.",Pharmacotherapy,TREATS,Patients
16288492,"CONCLUSIONS: To the authors' knowledge, the current study is the first published report of an obesity-associated chemotherapy dose modification in pediatric patients with ALL, the most common childhood malignancy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
16288492,"CONCLUSIONS: To the authors' knowledge, the current study is the first published report of an obesity-associated chemotherapy dose modification in pediatric patients with ALL, the most common childhood malignancy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16288492,L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Child
16679918,"In this study, we examined the gene expression of interleukin (IL)-8, CXCR3, and CXCR4 in leukemic cells from 100 children with relapsed B-cell progenitors (BCP) acute lymphoblastic leukemia (ALL), using quantitative real-time polymerase chain reaction (RT-PCR).",Leukemic Cell,LOCATION_OF,CXCR4 gene | CXCR4
16679918,"In this study, we examined the gene expression of interleukin (IL)-8, CXCR3, and CXCR4 in leukemic cells from 100 children with relapsed B-cell progenitors (BCP) acute lymphoblastic leukemia (ALL), using quantitative real-time polymerase chain reaction (RT-PCR).",Leukemic Cell,LOCATION_OF,Chemokine (C-X-C Motif) Receptor 3 | CXCR3
16679918,"In this study, we examined the gene expression of interleukin (IL)-8, CXCR3, and CXCR4 in leukemic cells from 100 children with relapsed B-cell progenitors (BCP) acute lymphoblastic leukemia (ALL), using quantitative real-time polymerase chain reaction (RT-PCR).",Child,LOCATION_OF,CXCR4 gene | CXCR4
16679918,"In this study, we examined the gene expression of interleukin (IL)-8, CXCR3, and CXCR4 in leukemic cells from 100 children with relapsed B-cell progenitors (BCP) acute lymphoblastic leukemia (ALL), using quantitative real-time polymerase chain reaction (RT-PCR).",Child,LOCATION_OF,Chemokine (C-X-C Motif) Receptor 3 | CXCR3
16679918,"In this study, we examined the gene expression of interleukin (IL)-8, CXCR3, and CXCR4 in leukemic cells from 100 children with relapsed B-cell progenitors (BCP) acute lymphoblastic leukemia (ALL), using quantitative real-time polymerase chain reaction (RT-PCR).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
16679935,High hyperdiploid acute lymphoblastic leukemia in children is related to a good outcome.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16679943,We report for the first time a child with acute lymphoblastic leukemia who developed immune thrombocytopenic purpura due to mumps during the maintenance phase of acute lymphoblastic leukemia treatment.,Mumps,CAUSES,Immune thrombocytopenic purpura
16679943,Immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia and mumps.,Mumps,PROCESS_OF,Child
16679943,Immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia and mumps.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16679943,Immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia and mumps.,Immune thrombocytopenic purpura,PROCESS_OF,Child
16679943,We report for the first time a child with acute lymphoblastic leukemia who developed immune thrombocytopenic purpura due to mumps during the maintenance phase of acute lymphoblastic leukemia treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16679943,We report for the first time a child with acute lymphoblastic leukemia who developed immune thrombocytopenic purpura due to mumps during the maintenance phase of acute lymphoblastic leukemia treatment.,Immune thrombocytopenic purpura,PROCESS_OF,Child
16912588,"The correlation between age and karyotype was studied in 1425, 0 to 14.9 years old children who were diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
16912588,"The correlation between age and karyotype was studied in 1425, 0 to 14.9 years old children who were diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17483708,"CONCLUSIONS: Young survivors of childhood ALL, especially those treated with cranial irradiation, are at risk for obesity, dyslipidemia, insulin resistance, hypertension, and the full DS early after the completion of therapy.",Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17720883,"In summary, we show marked heterogeneity of submicroscopic BM involvement at first AIEM relapse diagnosis in children with ALL, and demonstrate its possible prognostic relevance.",Bone Marrow Involvement,PROCESS_OF,Child
17720883,"In summary, we show marked heterogeneity of submicroscopic BM involvement at first AIEM relapse diagnosis in children with ALL, and demonstrate its possible prognostic relevance.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14758108,"However, few studies have specifically investigated the influence of nutrition and socioeconomic factors on the prognosis of children with acute lymphoblastic leukemia, and the results are conflicting.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15152267,We analyzed the gene expression at the time of diagnosis for 45 Danish children with ALL.,Diagnosis,TREATS,Child
15152267,We analyzed the gene expression at the time of diagnosis for 45 Danish children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15347448,CONCLUSION: The study showed that the above approach with RQ-PCR was applicable to clinical detection of MRD in childhood ALL.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15347448,CONCLUSION: The study showed that the above approach with RQ-PCR was applicable to clinical detection of MRD in childhood ALL.,Polymerase Chain Reaction,DIAGNOSES,"Neoplasm, Residual"
15347448,OBJECTIVE: The study was aimed to investigate the feasibility and clinical significance of quantitative detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) by real-time quantitative polymerase chain reaction (RQ-PCR).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15347448,OBJECTIVE: The study was aimed to investigate the feasibility and clinical significance of quantitative detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) by real-time quantitative polymerase chain reaction (RQ-PCR).,Polymerase Chain Reaction,DIAGNOSES,"Neoplasm, Residual"
16041314,"A non-total body irradiation-containing preparative regimen was studied in young children (<4 years old) undergoing unrelated donor cord blood transplantation as part of the Cord Blood Transplantation trial for the treatment of acute lymphoblastic leukemia (n = 14), acute myeloid leukemia (n = 13), undifferentiated leukemia (n = 1), juvenile myelomonocytic leukemia (n = 2), and myelodysplastic syndromes (n = 2).",Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
16041314,"A non-total body irradiation-containing preparative regimen was studied in young children (<4 years old) undergoing unrelated donor cord blood transplantation as part of the Cord Blood Transplantation trial for the treatment of acute lymphoblastic leukemia (n = 14), acute myeloid leukemia (n = 13), undifferentiated leukemia (n = 1), juvenile myelomonocytic leukemia (n = 2), and myelodysplastic syndromes (n = 2).",Treatment Protocols,TREATS,Child
16307416,"Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16307416,Adolescents with pB-ALL had a significantly higher proportion of prednisone poor-responders.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
16307416,"The proportion of T-ALL as compared to precursor B-cell ALL (pB-ALL) was lower in younger children, due to an incidence peak of pB-ALL in toddlers and at pre-school age compared to a constant incidence of T-ALL.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
16307416,"The proportion of T-ALL as compared to precursor B-cell ALL (pB-ALL) was lower in younger children, due to an incidence peak of pB-ALL in toddlers and at pre-school age compared to a constant incidence of T-ALL.","Leukemia, Lymphocytic, Acute",OCCURS_IN,Toddler
16307416,"The proportion of T-ALL as compared to precursor B-cell ALL (pB-ALL) was lower in younger children, due to an incidence peak of pB-ALL in toddlers and at pre-school age compared to a constant incidence of T-ALL.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
16307416,"Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
16404744,METHODS: Bone marrow samples from 313 children with B-precursor ALL and 130 children with de novo AML were studied at diagnosis.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
16404744,METHODS: Bone marrow samples from 313 children with B-precursor ALL and 130 children with de novo AML were studied at diagnosis.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
16404744,METHODS: Bone marrow samples from 313 children with B-precursor ALL and 130 children with de novo AML were studied at diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16404744,METHODS: Bone marrow samples from 313 children with B-precursor ALL and 130 children with de novo AML were studied at diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16526056,"METHODS: Bone marrow blasts from 49 children with leukemia, 37 acute lymphoblastic leukemia (ALL), and 12 acute myeloid leukemia (AML) were studied.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16526056,"METHODS: Bone marrow blasts from 49 children with leukemia, 37 acute lymphoblastic leukemia (ALL), and 12 acute myeloid leukemia (AML) were studied.",leukemia,PROCESS_OF,Child
16526056,"METHODS: Bone marrow blasts from 49 children with leukemia, 37 acute lymphoblastic leukemia (ALL), and 12 acute myeloid leukemia (AML) were studied.","Leukemia, Myelocytic, Acute",ISA,leukemia
16526056,"METHODS: Bone marrow blasts from 49 children with leukemia, 37 acute lymphoblastic leukemia (ALL), and 12 acute myeloid leukemia (AML) were studied.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
16526056,"METHODS: Bone marrow blasts from 49 children with leukemia, 37 acute lymphoblastic leukemia (ALL), and 12 acute myeloid leukemia (AML) were studied.","Leukemia, Lymphocytic, Acute",ISA,leukemia
16584581,Individual difference of PAX5 mRNA expression levels in children with B-ALL was great.,Child,LOCATION_OF,paired box 5 protein (B-cell lineage specific activator) | PAX5
16584581,Individual difference of PAX5 mRNA expression levels in children with B-ALL was great.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
16801167,"UNLABELLED: Infant acute lymphoid leukaemia (IALL) represents a distinct subset with an extremely poor response to therapy, despite major progress in the treatment of childhood leukaemia.",Therapeutic procedure,TREATS,Childhood Leukemia
16801167,"UNLABELLED: Infant acute lymphoid leukaemia (IALL) represents a distinct subset with an extremely poor response to therapy, despite major progress in the treatment of childhood leukaemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
16801167,"We reviewed the clinical characteristics of the disease, the results of several recent international clinical trials, and our experience with 16 infants with acute lymphoid leukaemia diagnosed and treated at our institution.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
16801167,"We reviewed the clinical characteristics of the disease, the results of several recent international clinical trials, and our experience with 16 infants with acute lymphoid leukaemia diagnosed and treated at our institution.",Health care facility,LOCATION_OF,Clinical Trials
16875573,The LOH on 6q16.3 may be a prognostic index of children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16875573,"OBJECTIVE: To locate the cluster region of loss of heterozygosity (LOH) in children with acute lymphoblastic leukemia (ALL), and explore the new tumor suppressor gene.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17218380,Glucocorticoids are keystone drugs in the treatment of childhood acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17218380,Glucocorticoids are keystone drugs in the treatment of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,ISA,Pharmaceutical Preparations
17218380,Glucocorticoids are keystone drugs in the treatment of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17409534,"Although the frequency of variant T allele in a Japanese population is not so high as compared to Caucasians, determination of C452T polymorphism of GGH may be useful for monitoring of efficacy and side-effects of MTX for treatment of diseases such as rheumatoid arthritis or childhood acute leukemia.",Rheumatoid Arthritis,ISA,Disease
17409534,"Although the frequency of variant T allele in a Japanese population is not so high as compared to Caucasians, determination of C452T polymorphism of GGH may be useful for monitoring of efficacy and side-effects of MTX for treatment of diseases such as rheumatoid arthritis or childhood acute leukemia.",Methotrexate,TREATS,Disease
17409534,"Although the frequency of variant T allele in a Japanese population is not so high as compared to Caucasians, determination of C452T polymorphism of GGH may be useful for monitoring of efficacy and side-effects of MTX for treatment of diseases such as rheumatoid arthritis or childhood acute leukemia.",Childhood Leukemia,ISA,Disease
17409534,"Although the frequency of variant T allele in a Japanese population is not so high as compared to Caucasians, determination of C452T polymorphism of GGH may be useful for monitoring of efficacy and side-effects of MTX for treatment of diseases such as rheumatoid arthritis or childhood acute leukemia.",Methotrexate,TREATS,Childhood Leukemia
17409534,"Although the frequency of variant T allele in a Japanese population is not so high as compared to Caucasians, determination of C452T polymorphism of GGH may be useful for monitoring of efficacy and side-effects of MTX for treatment of diseases such as rheumatoid arthritis or childhood acute leukemia.",Methotrexate,TREATS,Rheumatoid Arthritis
14515443,[Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14515443,[Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].,Berlin-Frankfort-Munster protocol,TREATS,"Leukemia, Lymphocytic, Acute"
14515443,The authors report the treatment outcome in children with ALL cured according to ALL-BFM 90 Study protocol in the Czech Republic during the first half of nineties.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14515443,"BACKGROUND: Prognosis of children with acute lymphoblastic leukaemia (ALL)--the most common cancer in childhood, has improved remarkably over the last 40 years.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15068830,The risk of ALL was not increased in children with a family history of cancers other than hematopoietic cancers.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15068830,Family history of hematopoietic and other cancers in children with acute lymphoblastic leukemia.,Malignant Neoplasms,PROCESS_OF,Child
15068830,Family history of hematopoietic and other cancers in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15599932,BACKGROUND: The authors studied the clinical outcome of 106 children with acute lymphoblastic leukemia (ALL) who developed a bone marrow recurrence as the first adverse event after contemporary intensified therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15744348,Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG.,6-Mercaptopurine,TREATS,"Lymphoma, Non-Hodgkin's"
15744348,Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15759037,Resistance to glucocorticoids (GC) is an important adverse risk factor in the treatment of acute lymphoblastic leukemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
15759037,Resistance to glucocorticoids (GC) is an important adverse risk factor in the treatment of acute lymphoblastic leukemia (ALL).,Glucocorticoids,ISA,Therapeutic procedure
16001813,[Primitive neuroectodermal tumor arising 8 years after chemotherapy and radiotherapy for acute lymphoblastic leukemia: case report].,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16001813,We report a case of primitive neuroectodermal tumor (PNET) arising 8 years after chemotherapy and radiotherapy for acute lymphoblastic leukemia.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
16001813,We report a case of primitive neuroectodermal tumor (PNET) arising 8 years after chemotherapy and radiotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16001813,[Primitive neuroectodermal tumor arising 8 years after chemotherapy and radiotherapy for acute lymphoblastic leukemia: case report].,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
16354258,"We describe atypical pyoderma gangrenosum in association with acute lymphoblastic leukemia in a 2-year-old child, an occurrence not reported before.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16404744,METHODS: Bone marrow samples from 313 children with B-precursor ALL and 130 children with de novo AML were studied at diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16404744,METHODS: Bone marrow samples from 313 children with B-precursor ALL and 130 children with de novo AML were studied at diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16404744,METHODS: Bone marrow samples from 313 children with B-precursor ALL and 130 children with de novo AML were studied at diagnosis.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
16404744,METHODS: Bone marrow samples from 313 children with B-precursor ALL and 130 children with de novo AML were studied at diagnosis.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
16879394,METHODS AND RESULTS: Bone marrow samples were taken from 120 children diagnosed with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17169794,"Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17169794,"CCG-134P evaluated the addition of intensified systemic and intrathecal therapy to VHD-MTX in 128 patients with high-risk acute lymphoblastic leukemia (ALL) and demonstrated reduced CNS relapse compared to the CCG-191P trial, but equivalent survival.",Methotrexate,TREATS,Patients
17169794,"CCG-134P evaluated the addition of intensified systemic and intrathecal therapy to VHD-MTX in 128 patients with high-risk acute lymphoblastic leukemia (ALL) and demonstrated reduced CNS relapse compared to the CCG-191P trial, but equivalent survival.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
17169794,"CCG-134P evaluated the addition of intensified systemic and intrathecal therapy to VHD-MTX in 128 patients with high-risk acute lymphoblastic leukemia (ALL) and demonstrated reduced CNS relapse compared to the CCG-191P trial, but equivalent survival.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
17696749,"Polymorphisms of GSTP1 at codon 105 residue forms GSTP1 active site for binding of hydrophobic electrophiles, and the Ile-Val substitution affect substrate specific catalytic activity of this enzyme and may associate with susceptibility to malignant human disease, especially acute lymphoblastic leukemia (ALL), which is the most common leukemia in children younger than 15 years old.",GSTP1 gene | GSTP1,AFFECTS,enzyme activity
17696749,"Polymorphisms of GSTP1 at codon 105 residue forms GSTP1 active site for binding of hydrophobic electrophiles, and the Ile-Val substitution affect substrate specific catalytic activity of this enzyme and may associate with susceptibility to malignant human disease, especially acute lymphoblastic leukemia (ALL), which is the most common leukemia in children younger than 15 years old.",Malignant disease,PROCESS_OF,Human
17696749,"Polymorphisms of GSTP1 at codon 105 residue forms GSTP1 active site for binding of hydrophobic electrophiles, and the Ile-Val substitution affect substrate specific catalytic activity of this enzyme and may associate with susceptibility to malignant human disease, especially acute lymphoblastic leukemia (ALL), which is the most common leukemia in children younger than 15 years old.","Leukemia, Lymphocytic, Acute",ISA,leukemia
17696749,"Polymorphisms of GSTP1 at codon 105 residue forms GSTP1 active site for binding of hydrophobic electrophiles, and the Ile-Val substitution affect substrate specific catalytic activity of this enzyme and may associate with susceptibility to malignant human disease, especially acute lymphoblastic leukemia (ALL), which is the most common leukemia in children younger than 15 years old.","Leukemia, Lymphocytic, Acute",ISA,Malignant disease
17696749,"Polymorphisms of GSTP1 at codon 105 residue forms GSTP1 active site for binding of hydrophobic electrophiles, and the Ile-Val substitution affect substrate specific catalytic activity of this enzyme and may associate with susceptibility to malignant human disease, especially acute lymphoblastic leukemia (ALL), which is the most common leukemia in children younger than 15 years old.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Human
17696749,"Polymorphisms of GSTP1 at codon 105 residue forms GSTP1 active site for binding of hydrophobic electrophiles, and the Ile-Val substitution affect substrate specific catalytic activity of this enzyme and may associate with susceptibility to malignant human disease, especially acute lymphoblastic leukemia (ALL), which is the most common leukemia in children younger than 15 years old.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18024642,Therapy protocols designed to treat children with acute lymphoblastic leukemia (ALL) have proven highly efficacious for treating children with LBL and are associated with event-free survival (EFS) rates up to 80%.,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
18024642,Therapy protocols designed to treat children with acute lymphoblastic leukemia (ALL) have proven highly efficacious for treating children with LBL and are associated with event-free survival (EFS) rates up to 80%.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14515443,CONCLUSIONS: The treatment outcome of children with ALL improved significantly (p = 0.0045) compared to the previous study ALL-BFM 83 (EFS 62%).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14990071,"CONCLUSION: t(12;21) was the most common chromosomal translocation in childhood ALL, but not all of them could be detected by CCA.",Chromosomal translocation,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
14990071,"CONCLUSION: t(12;21) was the most common chromosomal translocation in childhood ALL, but not all of them could be detected by CCA.",Cytogenetic Analysis,USES,R-Banding
14999294,"Monosomy 7 or deletions of 7q are associated with many myeloid disorders; however, the significance of such abnormalities in childhood acute lymphoblastic leukemia (ALL) is unknown.",Disease,COEXISTS_WITH,Monosomy 7
14999294,"Monosomy 7 or deletions of 7q are associated with many myeloid disorders; however, the significance of such abnormalities in childhood acute lymphoblastic leukemia (ALL) is unknown.",Disease,COEXISTS_WITH,DELETION
14999294,Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group.,Monosomy 7,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
14999294,"Among 1880 children with ALL, 75 (4%) had losses involving chromosome 7, 16 (21%) with monosomy 7, 41 (55%) with losses of 7p (del(7p)), 16 (21%) with losses of 7q (del(7q)), and two (3%) with losses involving both arms.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14999294,Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group.,DELETION,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
14999294,"Among 1880 children with ALL, 75 (4%) had losses involving chromosome 7, 16 (21%) with monosomy 7, 41 (55%) with losses of 7p (del(7p)), 16 (21%) with losses of 7q (del(7q)), and two (3%) with losses involving both arms.",Monosomy 7,PROCESS_OF,Child
14999294,"Monosomy 7 or deletions of 7q are associated with many myeloid disorders; however, the significance of such abnormalities in childhood acute lymphoblastic leukemia (ALL) is unknown.",Monosomy 7,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
14999294,"Monosomy 7 or deletions of 7q are associated with many myeloid disorders; however, the significance of such abnormalities in childhood acute lymphoblastic leukemia (ALL) is unknown.",DELETION,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15014526,"Among 96 children with relapsed ALL, diagnostic BM aspirates with high VEGF mRNA levels were associated with a significantly lower probability of event-free survival at 3 years (0.31+/-0.08 vs 0.65+/-0.07, P=0.003).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15014526,"Among 96 children with relapsed ALL, diagnostic BM aspirates with high VEGF mRNA levels were associated with a significantly lower probability of event-free survival at 3 years (0.31+/-0.08 vs 0.65+/-0.07, P=0.003).","VEGF protein, human | VEGFA",PART_OF,Bone Marrow
15029212,Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.,Flow Cytometry,DIAGNOSES,"Neoplasm, Residual"
15029212,Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.,Polymerase Chain Reaction,DIAGNOSES,"Neoplasm, Residual"
15029212,Minimal residual disease (MRD) is an independent prognostic factor in childhood acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15029212,Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15547738,The aim of this retrospective study was to evaluate in 85 children with ALL the impact of the MDR1 product of the mdr-1 gene on the achievement of complete remission (CR) and outcome.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15547738,The aim of this retrospective study was to evaluate in 85 children with ALL the impact of the MDR1 product of the mdr-1 gene on the achievement of complete remission (CR) and outcome.,ABCB1 gene | ABCB1,INTERACTS_WITH,ABCB1
16123993,"In addition, we observed a general tendency towards lower values in all three parameters studied, associated with the MTHFR 677CC genotype, which was more evident in the transition from the induction to the consolidation phase, indicating that MTHFR genotyping may be of prognostic value in the early phase of treatment for childhood ALL, in our population.",Genotype determination,USES,Oxidoreductase
16123993,"BACKGROUND: As of late, a number of studies have focused on the association of the gene for methyletetrahydrofolate reductase (MTHFR) with risk for acute lymphoblastic leukemia (ALL) in children and in adults, as well as with response to chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16123993,"BACKGROUND: As of late, a number of studies have focused on the association of the gene for methyletetrahydrofolate reductase (MTHFR) with risk for acute lymphoblastic leukemia (ALL) in children and in adults, as well as with response to chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
16123993,"BACKGROUND: As of late, a number of studies have focused on the association of the gene for methyletetrahydrofolate reductase (MTHFR) with risk for acute lymphoblastic leukemia (ALL) in children and in adults, as well as with response to chemotherapy.",Oxidoreductase,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
16123993,"In addition, we observed a general tendency towards lower values in all three parameters studied, associated with the MTHFR 677CC genotype, which was more evident in the transition from the induction to the consolidation phase, indicating that MTHFR genotyping may be of prognostic value in the early phase of treatment for childhood ALL, in our population.",Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17190987,"However, ALL patients who undergo this treatment are at risk of developing secondary neoplasms related to treatment, which has become an increasingly recognized problem.",Pharmacotherapy,TREATS,Patients
17190987,"However, ALL patients who undergo this treatment are at risk of developing secondary neoplasms related to treatment, which has become an increasingly recognized problem.",Prophylactic Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute"
17190987,"However, ALL patients who undergo this treatment are at risk of developing secondary neoplasms related to treatment, which has become an increasingly recognized problem.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
17190987,"However, ALL patients who undergo this treatment are at risk of developing secondary neoplasms related to treatment, which has become an increasingly recognized problem.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
17190987,Radiation-induced meningioma following prophylactic radiotherapy for acute lymphoblastic leukemia in childhood.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
17556067,Chromosome anomalies have been shown to have prognostic significance in children with acute lymphoblastic leukemia (ALL).,Chromosome abnormality,PROCESS_OF,Child
17556067,Chromosome anomalies have been shown to have prognostic significance in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17658395,"We initiated an international study to investigate the effects of a new hybrid treatment protocol with elements designed to treat both acute lymphoblastic leukaemia and acute myeloid leukaemia, and to identify any prognostic factors for outcome in infants.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
17658395,"BACKGROUND: Acute lymphoblastic leukaemia in infants younger than 1 year is rare, and infants with the disease have worse outcomes than do older children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17658395,"BACKGROUND: Acute lymphoblastic leukaemia in infants younger than 1 year is rare, and infants with the disease have worse outcomes than do older children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17658395,"BACKGROUND: Acute lymphoblastic leukaemia in infants younger than 1 year is rare, and infants with the disease have worse outcomes than do older children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17658395,"We initiated an international study to investigate the effects of a new hybrid treatment protocol with elements designed to treat both acute lymphoblastic leukaemia and acute myeloid leukaemia, and to identify any prognostic factors for outcome in infants.",Treatment Protocols,TREATS,"Leukemia, Myelocytic, Acute"
20425369,Acute lymphoblastic leukemia (ALL) is the most common cancer in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20425369,Acute lymphoblastic leukemia (ALL) is the most common cancer in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
12854915,We have analyzed the clinical significance of the plasma level of tumor necrosis-alpha (TNF-alpha) detection in childhood acute lymphoblastic leukemia (ALL) at diagnosis.,Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
14656893,To understand the mechanisms behind the dissemination of T-cell ALL (T-ALL) cells this study investigated the homing receptor expression on the blast cells of 11 pediatric T-ALL patients at diagnosis.,Blast Cell,PART_OF,Patients
14656893,To understand the mechanisms behind the dissemination of T-cell ALL (T-ALL) cells this study investigated the homing receptor expression on the blast cells of 11 pediatric T-ALL patients at diagnosis.,Blast Cell,LOCATION_OF,Acute T Cell Leukemia
14656893,To understand the mechanisms behind the dissemination of T-cell ALL (T-ALL) cells this study investigated the homing receptor expression on the blast cells of 11 pediatric T-ALL patients at diagnosis.,Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
14670928,"Each kindred subsequently had a second affected child; one developed Wilms tumor followed by a medulloblastoma, and the other developed T-lineage acute lymphoblastic leukemia.",medulloblastoma,PROCESS_OF,Child
14670928,"Each kindred subsequently had a second affected child; one developed Wilms tumor followed by a medulloblastoma, and the other developed T-lineage acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15179003,The extent of reduction in the level of minimal residual disease (MRD) during the first phase of therapy can be exploited for improved risk classification of children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15179003,Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15179011,"In acute lymphoblastic leukemia (ALL), the MRD based evaluation of initial response to front-line therapy emerged as a highly relevant diagnostic tool, particularly in childhood ALL, where MRD has been shown to be an independent prognostic factor allowing a precise risk group classification.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15280635,"OBJECTIVE: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and the second most common cause of mortality in children aged 1-14 years.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
15701979,Fatal adenovirus hepatitis during standard chemotherapy for childhood acute lymphoblastic leukemia.,Hepatitis,PROCESS_OF,Adenoviruses
15701979,The authors have observed fatal adenovirus hepatitis in three children receiving first-line chemotherapy for acute lymphoblastic leukemia (ALL).,Hepatitis,PROCESS_OF,Author
15701979,The authors have observed fatal adenovirus hepatitis in three children receiving first-line chemotherapy for acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15701979,The authors have observed fatal adenovirus hepatitis in three children receiving first-line chemotherapy for acute lymphoblastic leukemia (ALL).,Hepatitis,PROCESS_OF,Child
15701979,The authors have observed fatal adenovirus hepatitis in three children receiving first-line chemotherapy for acute lymphoblastic leukemia (ALL).,Pharmacotherapy,ADMINISTERED_TO,Child
15701979,"Although rare, adenovirus infection should be considered in the differential diagnosis of acute hepatitis in children receiving standard chemotherapy for ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15701979,The authors have observed fatal adenovirus hepatitis in three children receiving first-line chemotherapy for acute lymphoblastic leukemia (ALL).,Hepatitis,PROCESS_OF,Adenoviruses
15701979,"Although rare, adenovirus infection should be considered in the differential diagnosis of acute hepatitis in children receiving standard chemotherapy for ALL.",Acute hepatitis,PROCESS_OF,Child
15701979,Fatal adenovirus hepatitis during standard chemotherapy for childhood acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15701979,"Although rare, adenovirus infection should be considered in the differential diagnosis of acute hepatitis in children receiving standard chemotherapy for ALL.",Pharmacotherapy,ADMINISTERED_TO,Child
17091764,Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia.,Therapeutic procedure,USES,ASPARAGINASE | ASPG
17091764,Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia.,Glutamine,COEXISTS_WITH,Purines
17091764,Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia.,ASPARAGINASE | ASPG,ISA,Therapeutic procedure
17091764,Asparaginase is a key component of the chemotherapy protocols used in the treatment of acute lymphoblastic leukemia (ALL).,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
17091764,Asparaginase is a key component of the chemotherapy protocols used in the treatment of acute lymphoblastic leukemia (ALL).,ASPARAGINASE | ASPG,ISA,Chemotherapy-Oncologic Procedure
17091764,Asparaginase is a key component of the chemotherapy protocols used in the treatment of acute lymphoblastic leukemia (ALL).,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
17091764,Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17091764,Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia.,Glutamine,COEXISTS_WITH,Pyrimidine
17190987,"CONCLUSION: Long-term survivors who received radiotherapy for ALL in childhood are at risk for late complications, including radiation-induced meningioma.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
17190987,"CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).",Methotrexate,ISA,Pharmacotherapy
17190987,"CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Boys
17190987,"CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).",Methotrexate,TREATS,Boys
17190987,"CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).",Pharmacotherapy,TREATS,Boys
17190987,"CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
17190987,"CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).",Vincristine,ISA,Pharmacotherapy
17190987,"CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).",6-Mercaptopurine,ISA,Pharmacotherapy
17190987,"CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).",Vincristine,TREATS,Boys
17190987,"CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).",6-Mercaptopurine,TREATS,Boys
17190987,"CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).",prednisolone,ISA,Pharmacotherapy
17190987,"CONCLUSION: Long-term survivors who received radiotherapy for ALL in childhood are at risk for late complications, including radiation-induced meningioma.",Radiation therapy,ADMINISTERED_TO,Long-Term Survivors
17190987,"CASE DESCRIPTION: A 3-year-old boy with ALL was successfully treated with chemotherapy (vincristine, prednisolone, mercaptopurine and methotrexate) and prophylactic cranial irradiation (total 18 Gy).",prednisolone,TREATS,Boys
17333344,The antifolate methotrexate has been rationally-designed nearly 60 years ago to potently block the folate-dependent enzyme dihydrofolate reductase (DHFR) thereby achieving temporary remissions in childhood acute leukemia.,Methotrexate,AUGMENTS,Childhood Leukemia
17333344,The antifolate methotrexate has been rationally-designed nearly 60 years ago to potently block the folate-dependent enzyme dihydrofolate reductase (DHFR) thereby achieving temporary remissions in childhood acute leukemia.,Methotrexate,ISA,Folic Acid Antagonists
17762501,"In this study, we used flow cytometry to determine the frequency of the immunologic types of acute lymphoblastic leukemia (ALL) in Moroccan children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20425348,Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
12966372,CONCLUSIONS: Folic acid fortification was associated with a 60% reduction in neuroblastoma but was not associated with any change in the rate of infant acute lymphoblastic leukemia or hepatoblastoma.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
12966372,"In contrast, there was no significant change in the rate of infant acute lymphoblastic leukemia (incidence rate ratio, 0.97; 95% confidence interval, 0.41-2.27) or hepatoblastoma (incidence rate ratio, 0.81; 95% confidence interval, 0.35-1.89).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
14649479,Approximately 80% of children and adolsecents with acute lymphoblastic leukemia (ALL) can be cured.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14959846,"The application of modern molecular cytogenetic techniques including a broad set of fluorescence in situ hybridisation (FISH) methods and recent developments in comparative genomic hybridisation to DNA microarrays, together with molecular methods such as Southern blotting and RT-PCR has greatly improved the detection rate of genetic changes in ALL.",Cytogenetic Analysis,METHOD_OF,Fluorescent in Situ Hybridization
14959846,"The application of modern molecular cytogenetic techniques including a broad set of fluorescence in situ hybridisation (FISH) methods and recent developments in comparative genomic hybridisation to DNA microarrays, together with molecular methods such as Southern blotting and RT-PCR has greatly improved the detection rate of genetic changes in ALL.",Detection,TREATS,"Leukemia, Lymphocytic, Acute"
15010366,We analyzed 381 IgH sequences identified at presentation in 317 children with B-lineage ALL and assessed the V(H)D(H)J(H) gene utilization profiles.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15010366,"Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis.",Pathogenesis,PROCESS_OF,Child
15010366,"Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15010366,We analyzed 381 IgH sequences identified at presentation in 317 children with B-lineage ALL and assessed the V(H)D(H)J(H) gene utilization profiles.,Child,LOCATION_OF,IGH@ gene cluster
15247135,Parental exposure to medications and hydrocarbons and ras mutations in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.,Pharmaceutical Preparations,TREATS,Child
15247135,Parental exposure to medications and hydrocarbons and ras mutations in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15247135,Parental exposure to medications and hydrocarbons and ras mutations in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute"
15548999,Further knowledge of and insight into the role of host genetic polymorphisms will improve the results by integrating pharmacodynamic and pharmacogenomic studies in individualizing therapy for children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,Child
15548999,Further knowledge of and insight into the role of host genetic polymorphisms will improve the results by integrating pharmacodynamic and pharmacogenomic studies in individualizing therapy for children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15548999,Further knowledge of and insight into the role of host genetic polymorphisms will improve the results by integrating pharmacodynamic and pharmacogenomic studies in individualizing therapy for children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
15548999,PURPOSE OF REVIEW: The outcome in children with acute lymphoblastic leukemia has improved significantly over the past four decades.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15651967,Adolescents with ALL have a better prognosis if treated with paediatric rather than adult protocols.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
15651967,"Greater awareness of the late effects of chemotherapy has led to changes in the treatment protocols for ALL, with improvement in neurocognitive outcomes and reduced rates of second malignancies.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
17003366,Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17003380,"From 11 779 children (age, 1 to 21.99 years) with newly diagnosed B-precursor ALL consecutively enrolled by the CCG (December 1988 to August 1995, n=4986) and POG (January 1986 to November 1999, n=6793), we retrospectively analyzed 6238 patients (CCG, 1182; POG, 5056) with informative cytogenetic data.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17138821,Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.,Central nervous system lymphoma,PROCESS_OF,Adolescent
17138821,Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.,Central nervous system lymphoma,PROCESS_OF,Child
17138821,Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
17138821,Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17138821,"Children 21 years old or younger with newly diagnosed B-cell non-Hodgkin lymphoma/B-cell acute lymphoblastic leukemia (B-NHL/B-ALL) with higher risk factors (bone marrow [BM] with or without CNS involvement) were randomized to standard intensity French-American-British/Lymphoma Malignancy B (FAB/LMB) therapy or reduced intensity (reduced cytarabine plus etoposide and deletion of 3 maintenance courses M2, M3, M4).","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
17268512,"As compared to childhood precursor-B-ALL, Ig/TCR rearrangements in infant ALL were less frequent and more oligoclonal.",B-cell childhood acute lymphoblastic leukemia,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
17268512,"As compared to childhood precursor-B-ALL, Ig/TCR rearrangements in infant ALL were less frequent and more oligoclonal.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17268512,Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.,[M]Compound leukemia,PROCESS_OF,Gene Rearrangement
17268512,Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17762501,"The overall 5-year survival rate of ALL was 38%, whereas patients with B-ALL showed better survival than children with T-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
17762501,"The overall 5-year survival rate of ALL was 38%, whereas patients with B-ALL showed better survival than children with T-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18021709,"Because of its relatively higher prevalence, most of the work done in pediatric oncogenetics has been focused on leukemias, particularly acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",ISA,leukemia
14678808,"To reduce the incidence of TE and its impact on overall outcome as well as on the quality of life in children undergoing treatment for ALL, further studies to define the epidemiology of TE in relation to the biology of ALL and chemotherapy protocols are urgently needed.",Chemotherapy-Oncologic Procedure,TREATS,Child
14678808,Epidemiology of thrombosis in children with acute lymphoblastic leukemia.,Thrombosis,PROCESS_OF,Child
14678808,"To reduce the incidence of TE and its impact on overall outcome as well as on the quality of life in children undergoing treatment for ALL, further studies to define the epidemiology of TE in relation to the biology of ALL and chemotherapy protocols are urgently needed.",Therapeutic procedure,TREATS,Child
14678808,The first part will review the available information regarding epidemiology of TE in children with ALL.,Thromboembolism,PROCESS_OF,Child
14678808,Epidemiology of thrombosis in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14678808,"To reduce the incidence of TE and its impact on overall outcome as well as on the quality of life in children undergoing treatment for ALL, further studies to define the epidemiology of TE in relation to the biology of ALL and chemotherapy protocols are urgently needed.",Thromboembolism,PROCESS_OF,Child
14678808,The first part will review the available information regarding epidemiology of TE in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14678808,Thrombosis in children with acute lymphoblastic leukemia: part I.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14678808,"To reduce the incidence of TE and its impact on overall outcome as well as on the quality of life in children undergoing treatment for ALL, further studies to define the epidemiology of TE in relation to the biology of ALL and chemotherapy protocols are urgently needed.",Chemotherapy-Oncologic Procedure,TREATS,Thromboembolism
14678808,"The purpose of this review is to evaluate the current knowledge of TE in association with ALL in children, especially in relation with the treatment protocols and genetic background.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14678808,Thrombosis in children with acute lymphoblastic leukemia: part I.,Thrombosis,PROCESS_OF,Child
14678808,"To reduce the incidence of TE and its impact on overall outcome as well as on the quality of life in children undergoing treatment for ALL, further studies to define the epidemiology of TE in relation to the biology of ALL and chemotherapy protocols are urgently needed.",Therapeutic procedure,TREATS,Thromboembolism
14678808,"To reduce the incidence of TE and its impact on overall outcome as well as on the quality of life in children undergoing treatment for ALL, further studies to define the epidemiology of TE in relation to the biology of ALL and chemotherapy protocols are urgently needed.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
14678808,"In addition, older children and patients with high risk ALL may be at higher risk for developing TE.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
14678808,"To reduce the incidence of TE and its impact on overall outcome as well as on the quality of life in children undergoing treatment for ALL, further studies to define the epidemiology of TE in relation to the biology of ALL and chemotherapy protocols are urgently needed.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
14678808,"In addition, older children and patients with high risk ALL may be at higher risk for developing TE.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14963341,Normal karyotype was found in 44% whereas pseudodiploidy in 25% of children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14963341,The probability of event-free survival (EFS) in the group of children with ALL and genetic abnormalities of favourable prognosis was 96% whereas in the group of children with unfavourable prognosis it was 55%.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14963341,"Among 63 children with acute lymphoblastic leukaemia (ALL) and 13 with de novo acute myeloblastic leukaemia (AML), hyperdiploidy was found in 25% and hypodiploidy in 6% of patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14963341,"Among 63 children with acute lymphoblastic leukaemia (ALL) and 13 with de novo acute myeloblastic leukaemia (AML), hyperdiploidy was found in 25% and hypodiploidy in 6% of patients.",Hyperploidy,PROCESS_OF,Child
14963341,"Among 63 children with acute lymphoblastic leukaemia (ALL) and 13 with de novo acute myeloblastic leukaemia (AML), hyperdiploidy was found in 25% and hypodiploidy in 6% of patients.",Hypoploidy,PROCESS_OF,Child
14963341,"Among 63 children with acute lymphoblastic leukaemia (ALL) and 13 with de novo acute myeloblastic leukaemia (AML), hyperdiploidy was found in 25% and hypodiploidy in 6% of patients.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
14963341,The probability of event-free survival (EFS) in the group of children with ALL and genetic abnormalities of favourable prognosis was 96% whereas in the group of children with unfavourable prognosis it was 55%.,Molecular Abnormality,PROCESS_OF,Child
15315337,GSTM1 and GSTT1 genotypes in genomic DNA from 67 children with ALL and 146 healthy controls were analyzed by using the multiplex polymerase chain reaction (PCR).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15315337,GSTM1 and GSTT1 genotypes in genomic DNA from 67 children with ALL and 146 healthy controls were analyzed by using the multiplex polymerase chain reaction (PCR).,GSTT1 gene | GSTT1,COEXISTS_WITH,DNA
15315337,GSTM1 and GSTT1 genotypes in genomic DNA from 67 children with ALL and 146 healthy controls were analyzed by using the multiplex polymerase chain reaction (PCR).,GSTM1 gene | GSTM1,COEXISTS_WITH,DNA
15315337,Genetic polymorphisms analysis of glutathione S-transferase M1 and T1 in children with acute lymphoblastic leukemia.,Child,LOCATION_OF,GSTM1 gene | GSTM1
15315337,Genetic polymorphisms analysis of glutathione S-transferase M1 and T1 in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15315337,"The frequencies of GSTM1, M1-T1 null genotypes in ALL children were significantly higher than in the healthy controls (76.12% versus 52.74%, OR=2.856, P<0.001; 50.74% versus 24.66%, OR=3.148, P<0.001, respectively).",Child,LOCATION_OF,GSTM1 gene | GSTM1
15315337,"The frequencies of GSTM1, M1-T1 null genotypes in ALL children were significantly higher than in the healthy controls (76.12% versus 52.74%, OR=2.856, P<0.001; 50.74% versus 24.66%, OR=3.148, P<0.001, respectively).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16533526,"In the present study, we investigated the prevalence of mutations in PTPN11, RAS and FLT3 in samples from 95 Japanese children with ALL.",Child,LOCATION_OF,FLT3 gene | FLT3
16533526,"In the present study, we investigated the prevalence of mutations in PTPN11, RAS and FLT3 in samples from 95 Japanese children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16533526,"These data suggest that PTPN11 mutation may play an important role for leukemogenesis in a proportion of children with ALL, particularly B precursor ALL.",PTPN11 gene | PTPN11,AFFECTS,Leukemogenesis
16533526,"Recently, PTPN11 mutations have been reported in children with acute lymphoblastic leukemia (ALL).",Child,LOCATION_OF,PTPN11 gene | PTPN11
16533526,"These data suggest that PTPN11 mutation may play an important role for leukemogenesis in a proportion of children with ALL, particularly B precursor ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16533526,"Recently, PTPN11 mutations have been reported in children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16533526,We observed exon 3 and 8 missense mutations of PTPN11 in 6 children with B precursor ALL.,"Mutation, Missense",PROCESS_OF,Child
16533526,We observed exon 3 and 8 missense mutations of PTPN11 in 6 children with B precursor ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16533526,"In the present study, we investigated the prevalence of mutations in PTPN11, RAS and FLT3 in samples from 95 Japanese children with ALL.",Child,LOCATION_OF,PTPN11 gene | PTPN11
17268512,"The immature Ig/TCR pattern in infant ALL correlated with young age at diagnosis, CD10 negativity and predominantly with the presence and the type of MLL translocation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17301806,Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
17301806,Standardized MRD techniques form the basis for stratification of patients into the risk groups in new treatment protocols mainly in childhood ALL.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17301806,Standardized MRD techniques form the basis for stratification of patients into the risk groups in new treatment protocols mainly in childhood ALL.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Adult
17488489,Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17488489,Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia.,Disease,PROCESS_OF,Streptococcus pneumoniae
17488489,Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia.,Disease,PROCESS_OF,Child
12857551,"We, therefore, performed a PCR-study on bone marrow samples from 49 children with precursor B-ALL at first and second relapse.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
12857552,Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12857552,"The incidence and main risk factors for symptomatic ON have been investigated in a large group of children treated with high-dose steroids, prednisone and dexamethasone for childhood acute lymphoblastic leukemia (ALL).",Dexamethasone,TREATS,Bone necrosis
12857552,"INTERPRETATION AND CONCLUSIONS: Symptomatic ON occurred in only 1.1% of patients treated with BFM-type, intensive chemotherapy for childhood ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12857552,"The incidence and main risk factors for symptomatic ON have been investigated in a large group of children treated with high-dose steroids, prednisone and dexamethasone for childhood acute lymphoblastic leukemia (ALL).",Steroids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12857552,"The incidence and main risk factors for symptomatic ON have been investigated in a large group of children treated with high-dose steroids, prednisone and dexamethasone for childhood acute lymphoblastic leukemia (ALL).",Prednisone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12857552,"The incidence and main risk factors for symptomatic ON have been investigated in a large group of children treated with high-dose steroids, prednisone and dexamethasone for childhood acute lymphoblastic leukemia (ALL).",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
12857552,"The incidence and main risk factors for symptomatic ON have been investigated in a large group of children treated with high-dose steroids, prednisone and dexamethasone for childhood acute lymphoblastic leukemia (ALL).",Steroids,TREATS,Bone necrosis
12857552,"The incidence and main risk factors for symptomatic ON have been investigated in a large group of children treated with high-dose steroids, prednisone and dexamethasone for childhood acute lymphoblastic leukemia (ALL).",Prednisone,TREATS,Bone necrosis
14968727,Molecular monitoring of minimal residual disease in childhood acute lymphoblastic leukaemia using antigen receptor gene rearrangements is highly feasible for disease stratification and prognostication.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15247354,"METHODS: To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes, we randomly assigned 101 children with ALL to receive doxorubicin alone (30 mg per square meter of body-surface area every three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediately by doxorubicin.",Dexrazoxane,PREVENTS,Injury
15247354,The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.,Dexrazoxane,AFFECTS,myocardium; injury
15247354,BACKGROUND: Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells.,Pharmacotherapy,TREATS,Child
15247354,"CONCLUSIONS: Dexrazoxane prevents or reduces cardiac injury, as reflected by elevations in troponin T, that is associated with the use of doxorubicin for childhood ALL without compromising the antileukemic efficacy of doxorubicin.",Dexrazoxane,PREVENTS,Injury
15247354,"CONCLUSIONS: Dexrazoxane prevents or reduces cardiac injury, as reflected by elevations in troponin T, that is associated with the use of doxorubicin for childhood ALL without compromising the antileukemic efficacy of doxorubicin.",Doxorubicin,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15247354,The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.,myocardium; injury,PROCESS_OF,Child
15247354,BACKGROUND: Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15247354,"METHODS: To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes, we randomly assigned 101 children with ALL to receive doxorubicin alone (30 mg per square meter of body-surface area every three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediately by doxorubicin.","Myocytes, Cardiac",LOCATION_OF,Injury
15247354,The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15247354,BACKGROUND: Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells.,Pharmacotherapy,USES,Doxorubicin
15247354,"METHODS: To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes, we randomly assigned 101 children with ALL to receive doxorubicin alone (30 mg per square meter of body-surface area every three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediately by doxorubicin.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15247354,BACKGROUND: Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15247354,"METHODS: To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes, we randomly assigned 101 children with ALL to receive doxorubicin alone (30 mg per square meter of body-surface area every three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediately by doxorubicin.",Doxorubicin,ADMINISTERED_TO,Child
15247354,BACKGROUND: Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells.,Doxorubicin,ISA,Pharmacotherapy
15247354,"METHODS: To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes, we randomly assigned 101 children with ALL to receive doxorubicin alone (30 mg per square meter of body-surface area every three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediately by doxorubicin.",Dexrazoxane,ADMINISTERED_TO,Child
15247354,BACKGROUND: Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells.,Doxorubicin,TREATS,Child
15849205,"When children with non-ALL malignancies were taken as the reference group, a significant protective effect for ALL was seen only for formal day care (odds ratio = 0.69, 0.51 to 0.93; P = 0.02).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15849205,"PARTICIPANTS: 6305 children (aged 2-14 years) without cancer; 3140 children with cancer (diagnosed 1991-6), of whom 1286 had acute lymphoblastic leukaemia (ALL).",Malignant Neoplasms,PROCESS_OF,Child
15849205,"PARTICIPANTS: 6305 children (aged 2-14 years) without cancer; 3140 children with cancer (diagnosed 1991-6), of whom 1286 had acute lymphoblastic leukaemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15849205,"When children with non-ALL malignancies were taken as the reference group, a significant protective effect for ALL was seen only for formal day care (odds ratio = 0.69, 0.51 to 0.93; P = 0.02).",Malignant Neoplasms,PROCESS_OF,Child
15849205,"When children with non-ALL malignancies were taken as the reference group, a significant protective effect for ALL was seen only for formal day care (odds ratio = 0.69, 0.51 to 0.93; P = 0.02).",Myeloid Leukemia,ISA,Malignant Neoplasms
15849205,"When children with non-ALL malignancies were taken as the reference group, a significant protective effect for ALL was seen only for formal day care (odds ratio = 0.69, 0.51 to 0.93; P = 0.02).",Myeloid Leukemia,PROCESS_OF,Child
15849205,"When children with non-ALL malignancies were taken as the reference group, a significant protective effect for ALL was seen only for formal day care (odds ratio = 0.69, 0.51 to 0.93; P = 0.02).","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
16131575,The utility of the growth hormone (GH) releasing hormone-arginine test for diagnosing GH deficiency in adults with childhood acute lymphoblastic leukemia treated with cranial irradiation.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Adult
16131575,The utility of the growth hormone (GH) releasing hormone-arginine test for diagnosing GH deficiency in adults with childhood acute lymphoblastic leukemia treated with cranial irradiation.,Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16131575,The utility of the growth hormone (GH) releasing hormone-arginine test for diagnosing GH deficiency in adults with childhood acute lymphoblastic leukemia treated with cranial irradiation.,Growth hormone releasing hormone test,USES,Arginine
16131575,The utility of the growth hormone (GH) releasing hormone-arginine test for diagnosing GH deficiency in adults with childhood acute lymphoblastic leukemia treated with cranial irradiation.,Somatotropin deficiency,PROCESS_OF,Adult
17488489,"This study combined data from a nation-wide surveillance for IPD and the German childhood cancer registry, and showed that children with ALL carry a more than 10-fold higher risk for IPD than the general paediatric population.",Disease,PROCESS_OF,Streptococcus pneumoniae
17488489,"This study combined data from a nation-wide surveillance for IPD and the German childhood cancer registry, and showed that children with ALL carry a more than 10-fold higher risk for IPD than the general paediatric population.",Disease,PROCESS_OF,Streptococcus pneumoniae
17488489,"There are no current data available on the risk of IPD in children with acute lymphoblastic leukaemia (ALL), the most common type of childhood malignancy.",Disease,PROCESS_OF,Child
17488489,"As a substantial proportion of IPD occurs during maintenance chemotherapy, children with ALL may represent candidates for the evaluation of prophylactic interventions including vaccination.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17488489,"There are no current data available on the risk of IPD in children with acute lymphoblastic leukaemia (ALL), the most common type of childhood malignancy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17488489,"As a substantial proportion of IPD occurs during maintenance chemotherapy, children with ALL may represent candidates for the evaluation of prophylactic interventions including vaccination.",Disease,COEXISTS_WITH,[V]Maintenance chemotherapy
17488489,"There are no current data available on the risk of IPD in children with acute lymphoblastic leukaemia (ALL), the most common type of childhood malignancy.",Disease,PROCESS_OF,Streptococcus pneumoniae
17488489,"As a substantial proportion of IPD occurs during maintenance chemotherapy, children with ALL may represent candidates for the evaluation of prophylactic interventions including vaccination.",Disease,PROCESS_OF,Streptococcus pneumoniae
17488489,"This study combined data from a nation-wide surveillance for IPD and the German childhood cancer registry, and showed that children with ALL carry a more than 10-fold higher risk for IPD than the general paediatric population.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17558696,The study was performed on 34 children with ALL and 39 healthy children as a control group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17558696,The aim of the study is to characterize markers of apoptosis in children with acute lymphoblastic leukemia (ALL) in relation to treatment outcome of the disease.,Apoptosis,PROCESS_OF,Child
17558696,The aim of the study is to characterize markers of apoptosis in children with acute lymphoblastic leukemia (ALL) in relation to treatment outcome of the disease.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17875533,"We prospectively studied 49 children (26 boys and 23 girls) with acute lymphoblastic leukemia (ALL) (median age, 5.5 years; range, 15 months to 12.5 years) who were treated with the BFM95 chemotherapy protocol.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17875533,"We prospectively studied 49 children (26 boys and 23 girls) with acute lymphoblastic leukemia (ALL) (median age, 5.5 years; range, 15 months to 12.5 years) who were treated with the BFM95 chemotherapy protocol.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
14607754,Initial in vivo resistance to glucocorticoid (GC) treatment in childhood ALL (prednisone-poor response) is associated with a dramatically shorter event-free survival than that found in GC-sensitive patients (prednisone-good responders).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
14607754,Initial in vivo resistance to glucocorticoid (GC) treatment in childhood ALL (prednisone-poor response) is associated with a dramatically shorter event-free survival than that found in GC-sensitive patients (prednisone-good responders).,Glucocorticoids,ISA,Therapeutic procedure
15111780,"Plasma lipids and lipoproteins were measured at diagnosis, prior to the administration of induction treatment, and every 2 months for the first 12 months of the maintenance phase of chemotherapy in 64 patients with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
15111780,"Plasma lipids and lipoproteins were measured at diagnosis, prior to the administration of induction treatment, and every 2 months for the first 12 months of the maintenance phase of chemotherapy in 64 patients with ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15111780,"Plasma lipids and lipoproteins were measured at diagnosis, prior to the administration of induction treatment, and every 2 months for the first 12 months of the maintenance phase of chemotherapy in 64 patients with ALL.",Pharmacotherapy,TREATS,Patients
15784872,"CONTEXT: Early response to multiagent chemotherapy, including mercaptopurine, as measured by minimal residual disease is an important prognostic factor for children with acute lymphoblastic leukemia (ALL).","Neoplasm, Residual",AFFECTS,Child
15784872,"CONTEXT: Early response to multiagent chemotherapy, including mercaptopurine, as measured by minimal residual disease is an important prognostic factor for children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15951600,"We report 6 children, aged 4.5- 16 years, with acute lymphoblastic leukaemia with back pain, exacerbated by walking as the first symptom of disease.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16804111,"In conclusion, the overall thrombotic risk in ALL children was significant, and the subgroup analysis was able to identify high-risk individuals, a finding that will hopefully guide future prospective studies aimed at decreasing this risk.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16804111,The risk of thrombosis in children with acute lymphoblastic leukemia (ALL) reportedly ranges between 1% and 37%.,Thrombosis,PROCESS_OF,Child
16804111,The risk of thrombosis in children with acute lymphoblastic leukemia (ALL) reportedly ranges between 1% and 37%.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16990760,"We explored the relationship between time to relapse and different exposure variables (serum methotrexate (S-MTX) 23, 36 and 42 h after start of administration, MTX elimination time and leucovorin (LV) dose) during high-dose MTX (HDM) treatment of 445 children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17267033,Quantification of MK gene by real-time PCR offers particular promise as a prognostic marker and a marker for minimal residual disease in children with B-precursor ALL.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
17267033,Quantification of MK gene by real-time PCR offers particular promise as a prognostic marker and a marker for minimal residual disease in children with B-precursor ALL.,"Neoplasm, Residual",PROCESS_OF,Child
17267033,Quantification of MK gene by real-time PCR offers particular promise as a prognostic marker and a marker for minimal residual disease in children with B-precursor ALL.,"MDK protein, human | MDK",TREATS,"Neoplasm, Residual"
17301519,The JPLSG/ALL committee was started in 2005 for discussing the ongoing need for cooperative clinical study in Japan and the possibility of nelarabine-containing regimen for T-ALL.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
17301519,"For the purpose of finding the standard treatment, JPLSG protocols have been started for three distinct and rare types of ALL, including mature B-ALL, infant ALL and Ph+ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17454190,The study was conducted on 63 ALL children (40 males and 23 females) with age range 4.5 months-16 years (mean = 7.76 years).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17454190,The objective of the work was to evaluate children with acute lymphoblastic leukemia (ALL) showing resistance to immediate induction chemotherapy in relation to conventional and advanced cytogenetic analysis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17454638,Gene-gene interactions in the folate metabolic pathway influence the risk for acute lymphoblastic leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17804520,"In addition, benign abnormalities of the blood count and blood film, which may manifest at any age, population-based and cancer-based registries and clinical trials suggest there is a approximately 12-fold increased risk of acute lymphoblastic leukaemia in the age group of 5-30 years that rises to approximately 40-fold in children younger than 5 years, and that there is a approximately 150-fold increased risk of acute myeloid leukaemia in children younger than 5 years.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
17804520,"In addition, benign abnormalities of the blood count and blood film, which may manifest at any age, population-based and cancer-based registries and clinical trials suggest there is a approximately 12-fold increased risk of acute lymphoblastic leukaemia in the age group of 5-30 years that rises to approximately 40-fold in children younger than 5 years, and that there is a approximately 150-fold increased risk of acute myeloid leukaemia in children younger than 5 years.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17876329,Adenovirus DNA is detected at increased frequency in Guthrie cards from children who develop acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17956600,We report an analysis of gene expression in 60 children with B-lineage ALL using Agilent whole genome oligo-chips (44K-G4112A) and/or real time RT-PCR.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
17956600,We report an analysis of gene expression in 60 children with B-lineage ALL using Agilent whole genome oligo-chips (44K-G4112A) and/or real time RT-PCR.,Gene Expression,PROCESS_OF,Child
17963265,"Although treatment intensity and outcome were not comparable, with improvements in survival it is important to evaluate the rate and the type of second neoplasms in adults with ALL.",Neoplasm,PROCESS_OF,Adult
17963265,"Although treatment intensity and outcome were not comparable, with improvements in survival it is important to evaluate the rate and the type of second neoplasms in adults with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
18021563,RESULTS: Cytogenetic analysis was successful in 112 of 124 children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18021563,The aim of the present study was to assess the demography of cytogenetic abnormalities in childhood ALL.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
18067025,Characterization of high-hyperdiploidy in childhood acute lymphoblastic leukemia with gain of a single chromosome 21.,Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
14607754,Initial in vivo resistance to glucocorticoid (GC) treatment in childhood ALL (prednisone-poor response) is associated with a dramatically shorter event-free survival than that found in GC-sensitive patients (prednisone-good responders).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
14607754,Initial in vivo resistance to glucocorticoid (GC) treatment in childhood ALL (prednisone-poor response) is associated with a dramatically shorter event-free survival than that found in GC-sensitive patients (prednisone-good responders).,Glucocorticoids,ISA,Therapeutic procedure
15111780,"Plasma lipids and lipoproteins were measured at diagnosis, prior to the administration of induction treatment, and every 2 months for the first 12 months of the maintenance phase of chemotherapy in 64 patients with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
15111780,"Plasma lipids and lipoproteins were measured at diagnosis, prior to the administration of induction treatment, and every 2 months for the first 12 months of the maintenance phase of chemotherapy in 64 patients with ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
15111780,"Plasma lipids and lipoproteins were measured at diagnosis, prior to the administration of induction treatment, and every 2 months for the first 12 months of the maintenance phase of chemotherapy in 64 patients with ALL.",Pharmacotherapy,TREATS,Patients
15784872,"CONTEXT: Early response to multiagent chemotherapy, including mercaptopurine, as measured by minimal residual disease is an important prognostic factor for children with acute lymphoblastic leukemia (ALL).","Neoplasm, Residual",AFFECTS,Child
15784872,"CONTEXT: Early response to multiagent chemotherapy, including mercaptopurine, as measured by minimal residual disease is an important prognostic factor for children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15951600,"We report 6 children, aged 4.5- 16 years, with acute lymphoblastic leukaemia with back pain, exacerbated by walking as the first symptom of disease.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16804111,"In conclusion, the overall thrombotic risk in ALL children was significant, and the subgroup analysis was able to identify high-risk individuals, a finding that will hopefully guide future prospective studies aimed at decreasing this risk.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16804111,The risk of thrombosis in children with acute lymphoblastic leukemia (ALL) reportedly ranges between 1% and 37%.,Thrombosis,PROCESS_OF,Child
16804111,The risk of thrombosis in children with acute lymphoblastic leukemia (ALL) reportedly ranges between 1% and 37%.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16990760,"We explored the relationship between time to relapse and different exposure variables (serum methotrexate (S-MTX) 23, 36 and 42 h after start of administration, MTX elimination time and leucovorin (LV) dose) during high-dose MTX (HDM) treatment of 445 children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17267033,Quantification of MK gene by real-time PCR offers particular promise as a prognostic marker and a marker for minimal residual disease in children with B-precursor ALL.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
17267033,Quantification of MK gene by real-time PCR offers particular promise as a prognostic marker and a marker for minimal residual disease in children with B-precursor ALL.,"Neoplasm, Residual",PROCESS_OF,Child
17267033,Quantification of MK gene by real-time PCR offers particular promise as a prognostic marker and a marker for minimal residual disease in children with B-precursor ALL.,"MDK protein, human | MDK",TREATS,"Neoplasm, Residual"
17301519,The JPLSG/ALL committee was started in 2005 for discussing the ongoing need for cooperative clinical study in Japan and the possibility of nelarabine-containing regimen for T-ALL.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
17301519,"For the purpose of finding the standard treatment, JPLSG protocols have been started for three distinct and rare types of ALL, including mature B-ALL, infant ALL and Ph+ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17454190,The study was conducted on 63 ALL children (40 males and 23 females) with age range 4.5 months-16 years (mean = 7.76 years).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17454190,The objective of the work was to evaluate children with acute lymphoblastic leukemia (ALL) showing resistance to immediate induction chemotherapy in relation to conventional and advanced cytogenetic analysis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17454638,Gene-gene interactions in the folate metabolic pathway influence the risk for acute lymphoblastic leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17804520,"In addition, benign abnormalities of the blood count and blood film, which may manifest at any age, population-based and cancer-based registries and clinical trials suggest there is a approximately 12-fold increased risk of acute lymphoblastic leukaemia in the age group of 5-30 years that rises to approximately 40-fold in children younger than 5 years, and that there is a approximately 150-fold increased risk of acute myeloid leukaemia in children younger than 5 years.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
17804520,"In addition, benign abnormalities of the blood count and blood film, which may manifest at any age, population-based and cancer-based registries and clinical trials suggest there is a approximately 12-fold increased risk of acute lymphoblastic leukaemia in the age group of 5-30 years that rises to approximately 40-fold in children younger than 5 years, and that there is a approximately 150-fold increased risk of acute myeloid leukaemia in children younger than 5 years.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17876329,Adenovirus DNA is detected at increased frequency in Guthrie cards from children who develop acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17956600,We report an analysis of gene expression in 60 children with B-lineage ALL using Agilent whole genome oligo-chips (44K-G4112A) and/or real time RT-PCR.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
17956600,We report an analysis of gene expression in 60 children with B-lineage ALL using Agilent whole genome oligo-chips (44K-G4112A) and/or real time RT-PCR.,Gene Expression,PROCESS_OF,Child
17963265,"Although treatment intensity and outcome were not comparable, with improvements in survival it is important to evaluate the rate and the type of second neoplasms in adults with ALL.",Neoplasm,PROCESS_OF,Adult
17963265,"Although treatment intensity and outcome were not comparable, with improvements in survival it is important to evaluate the rate and the type of second neoplasms in adults with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
18021563,RESULTS: Cytogenetic analysis was successful in 112 of 124 children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18021563,The aim of the present study was to assess the demography of cytogenetic abnormalities in childhood ALL.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
18067025,Characterization of high-hyperdiploidy in childhood acute lymphoblastic leukemia with gain of a single chromosome 21.,Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
14766125,Acute lymphoblastic leukaemia (ALL) is a disease diagnosed in children as well as adults.,"Leukemia, Lymphocytic, Acute",ISA,Disease
14766125,Acute lymphoblastic leukaemia (ALL) is a disease diagnosed in children as well as adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14766125,Acute lymphoblastic leukaemia (ALL) is a disease diagnosed in children as well as adults.,Disease,PROCESS_OF,Child
15355694,CONCLUSIONS: Multiplex RT-PCR combined with chromosome analysis can enhance the detection rate of genetic abnormalities in childhood ALL.,Reverse Transcriptase Polymerase Chain Reaction,USES,Chromosome analysis
15355694,CONCLUSIONS: Multiplex RT-PCR combined with chromosome analysis can enhance the detection rate of genetic abnormalities in childhood ALL.,Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15386768,"In this study 55 parents of children (36 boys and 19 girls, mean age = 7.33 years) newly diagnosed with acute lymphoblastic leukaemia (ALL) were interviewed about (i) the child's reactions and behaviour following diagnosis, (ii) their views about what to tell their child and (iii) factors influencing parents' communication with the child.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15518596,REVIEW SUMMARY: Children with acute lymphoblastic leukemia previously treated with cranial irradiation are at risk for cognitive decline.,Cranial Irradiation,TREATS,Child
15518596,REVIEW SUMMARY: Children with acute lymphoblastic leukemia previously treated with cranial irradiation are at risk for cognitive decline.,Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute"
15518596,REVIEW SUMMARY: Children with acute lymphoblastic leukemia previously treated with cranial irradiation are at risk for cognitive decline.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15937026,"Details of 299 children (0-14 years) with acute lymphoblastic leukemia and 1,551 children with diabetes diagnosed between 1986 and 1998 were extracted from two registers in Yorkshire, United Kingdom.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15937026,"Details of 299 children (0-14 years) with acute lymphoblastic leukemia and 1,551 children with diabetes diagnosed between 1986 and 1998 were extracted from two registers in Yorkshire, United Kingdom.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15937026,"Details of 299 children (0-14 years) with acute lymphoblastic leukemia and 1,551 children with diabetes diagnosed between 1986 and 1998 were extracted from two registers in Yorkshire, United Kingdom.",Diabetes,PROCESS_OF,Child
15937026,"Details of 299 children (0-14 years) with acute lymphoblastic leukemia and 1,551 children with diabetes diagnosed between 1986 and 1998 were extracted from two registers in Yorkshire, United Kingdom.",Diabetes,PROCESS_OF,Child
16474265,CONCLUSIONS: The results provide support to the association between parental occupational exposures and ALL in their children.,Occupational Exposure,PROCESS_OF,Child
16474265,CONCLUSIONS: The results provide support to the association between parental occupational exposures and ALL in their children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16474265,"Our case-control study included 224 children, 112 diagnosed with ALL and 112 matched controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16885052,A flow cytometric approach to minimal residual disease (MRD) monitoring useful in childhood B-lineage acute lymphoblastic leukemia (ALL) is discussed here in the context of ALL in adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
16885052,A flow cytometric approach to minimal residual disease (MRD) monitoring useful in childhood B-lineage acute lymphoblastic leukemia (ALL) is discussed here in the context of ALL in adults.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
16921038,CONCLUSION: Treatment strategies for young children with ALL that avoid CRT are associated with good long-term neurocognitive outcomes.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
16921038,CONCLUSION: Treatment strategies for young children with ALL that avoid CRT are associated with good long-term neurocognitive outcomes.,Therapeutic procedure,TREATS,Child
16921038,PATIENTS AND METHODS: Seventy nine of 120 eligible children diagnosed with high-risk ALL between the ages of 1.0 and 4.9 years participated in this retrospective cohort study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16921038,Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16921038,CONCLUSION: Treatment strategies for young children with ALL that avoid CRT are associated with good long-term neurocognitive outcomes.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17179108,CONCLUSION: SCT in CR1 is superior to treatment with chemotherapy alone for childhood HR-T-ALL.,"Receptors, Complement 3b | CR1",higher_than,Stem cell transplant
17179108,CONCLUSION: SCT in CR1 is superior to treatment with chemotherapy alone for childhood HR-T-ALL.,"Receptors, Complement 3b | CR1",compared_with,Stem cell transplant
17179108,T-cell ALL (T-ALL) patients with poor in vivo response to initial treatment represented the largest homogeneous subgroup within VHR patients.,Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
17179108,CONCLUSION: SCT in CR1 is superior to treatment with chemotherapy alone for childhood HR-T-ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17179108,PURPOSE: The role of hematopoietic stem-cell transplantation (SCT) in first complete remission (CR1) for children with very high-risk (VHR) acute lymphoblastic leukemia (ALL) is still under critical discussion.,Hematopoietic Stem Cell Transplantation,TREATS,Child
17179108,CONCLUSION: SCT in CR1 is superior to treatment with chemotherapy alone for childhood HR-T-ALL.,"Receptors, Complement 3b | CR1",higher_than,Therapeutic procedure
17179108,PURPOSE: The role of hematopoietic stem-cell transplantation (SCT) in first complete remission (CR1) for children with very high-risk (VHR) acute lymphoblastic leukemia (ALL) is still under critical discussion.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17179108,CONCLUSION: SCT in CR1 is superior to treatment with chemotherapy alone for childhood HR-T-ALL.,"Receptors, Complement 3b | CR1",compared_with,Therapeutic procedure
17179108,PURPOSE: The role of hematopoietic stem-cell transplantation (SCT) in first complete remission (CR1) for children with very high-risk (VHR) acute lymphoblastic leukemia (ALL) is still under critical discussion.,Hematopoietic Stem Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
17179108,CONCLUSION: SCT in CR1 is superior to treatment with chemotherapy alone for childhood HR-T-ALL.,Stem cell transplant,ISA,Therapeutic procedure
17454638,"We analysed common genetic polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS), methionine synthase (MS) and methionine synthase reductase (MTRR) in 68 children with ALL and 258 healthy controls to investigate their influence on the risk for ALL.","Polymorphism, Genetic",PROCESS_OF,Child
17454638,"We analysed common genetic polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS), methionine synthase (MS) and methionine synthase reductase (MTRR) in 68 children with ALL and 258 healthy controls to investigate their influence on the risk for ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17525906,CONCLUSIONS: We conclude that in children with ALL a 24-h infusion of DNR has the same in vivo cytotoxicity for leukemic cells as a 1-h infusion.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17525906,CONCLUSIONS: We conclude that in children with ALL a 24-h infusion of DNR has the same in vivo cytotoxicity for leukemic cells as a 1-h infusion.,cytotoxicity,PROCESS_OF,Child
17623090,The aim of this study was to investigate the AMP activated protein kinase (AMPK) as a potential target in childhood acute lymphoblastic leukemia (ALL) subtypes characterized by non-random translocation signature profiles.,PROTEIN KINASE,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
17623090,The aim of this study was to investigate the AMP activated protein kinase (AMPK) as a potential target in childhood acute lymphoblastic leukemia (ALL) subtypes characterized by non-random translocation signature profiles.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
15285454,SETTING: Registry records of the paediatric cancer units at Tygerberg and Red Cross War Memorial Children's hospitals where all children with ALL in the WC were initially treated.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15684603,Molecular parameters involved in the prediction of response of childhood acute lymphoblastic leukemia (ALL) are still unclear.,response,PREDISPOSES,"Leukemia, Lymphocytic, Acute, L1"
15684603,Molecular parameters involved in the prediction of response of childhood acute lymphoblastic leukemia (ALL) are still unclear.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
15991223,A semi-quantitative expression analysis of both AML1-a and AML1-total was performed by RT-PCR in 19 children with acute lymphoblastic leukemia (ALL) at diagnosis.,Child,LOCATION_OF,RUNX1 gene | RUNX1
15991223,A semi-quantitative expression analysis of both AML1-a and AML1-total was performed by RT-PCR in 19 children with acute lymphoblastic leukemia (ALL) at diagnosis.,Child,LOCATION_OF,RUNX1 gene | RUNX1
15991223,A semi-quantitative expression analysis of both AML1-a and AML1-total was performed by RT-PCR in 19 children with acute lymphoblastic leukemia (ALL) at diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16552836,This finding encourages further investigation of baicalin in its role as a potential candidate for chemotherapeutic agents in T-ALL.,Antineoplastic Agents,TREATS,"Leukemia, Lymphocytic, Acute"
16848106,We conclude that children's BMDs are reduced after completion of chemotherapy for ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16848106,"Children with ALL had reduced lumbar BMDs (z score -0.99) in comparison to healthy controls (z score -0.14) (p=0.011), which is indicative of relative osteopenia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16848106,"Bone mineral density (g/cm2) of lumbar spine was measured by dual energy X-ray absorptiometry (Norland bone densitometer) in 18 children with ALL and a median of 34 months' post-diagnosis with no history of relapse, secondary malignancy, or transplantation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17255265,They validate our previous studies of hRFC transcriptional regulation in pediatric ALL and provide further compelling evidence for the critical role for methotrexate in the successful treatment of this disease.,Transcriptional Regulation,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
17255265,They validate our previous studies of hRFC transcriptional regulation in pediatric ALL and provide further compelling evidence for the critical role for methotrexate in the successful treatment of this disease.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17523695,"Although these approaches have been successful in dramatically improving outcomes, approximately 20% of children with ALL still relapse and many of these children do not have an identifiable adverse risk factor at presentation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17525899,Most of the available information in this area originates mainly from retrospective and some prospective observational cohort studies conducted in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17697613,[Induction chemotherapy in childhood acute lymphoblastic leukemia: the association between the intensity of therapy and cure].,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17697614,"CONCLUSIONS: ALL Protocol 2005 had the same efficacy as ALL-XH-99 Protocol had in the induction therapy in treating children with ALL, but it was safer than ALL-XH-99.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17697614,"CONCLUSIONS: ALL Protocol 2005 had the same efficacy as ALL-XH-99 Protocol had in the induction therapy in treating children with ALL, but it was safer than ALL-XH-99.",Neoadjuvant Therapy,TREATS,Child
17697614,"OBJECTIVE: To improve the treatment outcome of children with acute lymphoblastic leukemia (ALL), and to evaluate the efficacy and safety of a modified induction chemotherapy between the two protocols used to treat children with ALL in Shanghai Children's Medical Center.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
17697614,"CONCLUSIONS: ALL Protocol 2005 had the same efficacy as ALL-XH-99 Protocol had in the induction therapy in treating children with ALL, but it was safer than ALL-XH-99.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
17697614,[Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia].,Pharmacotherapy,TREATS,Child
17697614,"1st, 2006, 311 patients with newly diagnosed childhood ALL, who underwent induction chemotherapy for over 10 days, were eligible for analysis.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
17697614,[Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17697614,"1st, 2006, 311 patients with newly diagnosed childhood ALL, who underwent induction chemotherapy for over 10 days, were eligible for analysis.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17697614,[Evaluation of a modified induction chemotherapy in children with acute lymphoblastic leukemia].,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
17697614,"OBJECTIVE: To improve the treatment outcome of children with acute lymphoblastic leukemia (ALL), and to evaluate the efficacy and safety of a modified induction chemotherapy between the two protocols used to treat children with ALL in Shanghai Children's Medical Center.",Pharmacotherapy,TREATS,Child
17697614,"OBJECTIVE: To improve the treatment outcome of children with acute lymphoblastic leukemia (ALL), and to evaluate the efficacy and safety of a modified induction chemotherapy between the two protocols used to treat children with ALL in Shanghai Children's Medical Center.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17697614,"OBJECTIVE: To improve the treatment outcome of children with acute lymphoblastic leukemia (ALL), and to evaluate the efficacy and safety of a modified induction chemotherapy between the two protocols used to treat children with ALL in Shanghai Children's Medical Center.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17697615,[High mobility group box 1 is increased in children with acute lymphocytic leukemia and stimulates the release of tumor necrosis factor-alpha in leukemic cell].,Child,LOCATION_OF,HMGB1 gene | HMGB1
17697615,[High mobility group box 1 is increased in children with acute lymphocytic leukemia and stimulates the release of tumor necrosis factor-alpha in leukemic cell].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17697615,[High mobility group box 1 is increased in children with acute lymphocytic leukemia and stimulates the release of tumor necrosis factor-alpha in leukemic cell].,Leukemic Cell,LOCATION_OF,Tumor Necrosis Factor-alpha
12860036,Incomplete T-cell-receptor delta (TCR-delta) rearrangements are widely used for detection of minimal residual disease in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
14642920,Who should be treating adolescents and young adults with acute lymphoblastic leukaemia?,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
14642920,"In this article, I present some of the current challenges in the treatment of ALL in adolescents and young adults and propose strategies to improve outcome in these patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
14642920,Who should be treating adolescents and young adults with acute lymphoblastic leukaemia?,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
14642920,"In this article, I present some of the current challenges in the treatment of ALL in adolescents and young adults and propose strategies to improve outcome in these patients.",Therapeutic procedure,TREATS,Patients
14642920,"In this article, I present some of the current challenges in the treatment of ALL in adolescents and young adults and propose strategies to improve outcome in these patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
15183902,"We performed HLA-mismatched stem cell transplantations with megadoses of purified positively selected mobilized peripheral blood CD34+ progenitor cells (PBPC) from adult donors in 27 children with acute lymphoblastic leukemia (ALL) in first (CR1 n = 7), second (CR2 n = 10), or third (CR3 n = 4) complete remission, and in refractory state (NR n = 6).",Stem cell transplant,TREATS,"Leukemia, Lymphocytic, Acute"
15183902,Haploidentical transplantation in childhood acute lymphoblastic leukemia (ALL) is a promising option for children lacking a suitable donor.,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15183902,Haploidentical transplantation for acute lymphoblastic leukemia in childhood.,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
15183902,"We performed HLA-mismatched stem cell transplantations with megadoses of purified positively selected mobilized peripheral blood CD34+ progenitor cells (PBPC) from adult donors in 27 children with acute lymphoblastic leukemia (ALL) in first (CR1 n = 7), second (CR2 n = 10), or third (CR3 n = 4) complete remission, and in refractory state (NR n = 6).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15183902,"We performed HLA-mismatched stem cell transplantations with megadoses of purified positively selected mobilized peripheral blood CD34+ progenitor cells (PBPC) from adult donors in 27 children with acute lymphoblastic leukemia (ALL) in first (CR1 n = 7), second (CR2 n = 10), or third (CR3 n = 4) complete remission, and in refractory state (NR n = 6).",Stem cell transplant,TREATS,Child
15285454,This contrast may indicate significant underdiagnosis of ALL in coloured children over the period in question.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15285454,"Of 246 children with ALL diagnosed in the period 1983 - 1999, 144 were male and 102 female.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15285454,SUBJECTS: All white and coloured children aged 0 - 12 years diagnosed as having ALL from 1983 - 1999.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15285454,SUBJECTS: All white and coloured children aged 0 - 12 years diagnosed as having ALL from 1983 - 1999.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Caucasoid Race
15749670,"There is now urgent need to incorporate MRD data into clinical studies, properly designed to address treatment questions, in order to explore whether a better tailored treatment would result in further improvement in cure rates for children with ALL.",Therapeutic procedure,TREATS,Child
15749670,"There is now urgent need to incorporate MRD data into clinical studies, properly designed to address treatment questions, in order to explore whether a better tailored treatment would result in further improvement in cure rates for children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15749670,"There is now urgent need to incorporate MRD data into clinical studies, properly designed to address treatment questions, in order to explore whether a better tailored treatment would result in further improvement in cure rates for children with ALL.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
15749670,"Several retrospective studies have demonstrated the strong association between MRD and risk of relapse in childhood acute lymphoid leukemia (ALL), irrespective of the methodology used.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
16010438,Clonal T-cell receptor gamma (TCR-gamma) rearrangements are frequently used for detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
16010441,"The Fas-sensitive leukemia cell line, MML-1, was established from a child with B-precursor acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16207592,"To examine the genotypic frequency of CCND1 polymorphism, we performed a case-control study in a Chinese population of 183 children with ALL and 190 healthy controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16952844,Acute lymphoblastic leukemia (ALL) is the most common subtype and infants with ALL have a greatly increased risk of treatment failure.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17095619,Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17442692,"METHODS: A review of literature is provided on the mechanism of and cognitive toxicities for children and adolescents treated for acute lymphoblastic leukemia (ALL) and malignant brain tumors (BT) as well as the pharmacotherapy of stimulant medications, with a specific review of literature on the efficacy and safety of the stimulants for children with ALL and BT.",Stimulant,ISA,Pharmaceutical Preparations
17442692,"METHODS: A review of literature is provided on the mechanism of and cognitive toxicities for children and adolescents treated for acute lymphoblastic leukemia (ALL) and malignant brain tumors (BT) as well as the pharmacotherapy of stimulant medications, with a specific review of literature on the efficacy and safety of the stimulants for children with ALL and BT.",Stimulant,TREATS,Child
17442692,"METHODS: A review of literature is provided on the mechanism of and cognitive toxicities for children and adolescents treated for acute lymphoblastic leukemia (ALL) and malignant brain tumors (BT) as well as the pharmacotherapy of stimulant medications, with a specific review of literature on the efficacy and safety of the stimulants for children with ALL and BT.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17442692,"METHODS: A review of literature is provided on the mechanism of and cognitive toxicities for children and adolescents treated for acute lymphoblastic leukemia (ALL) and malignant brain tumors (BT) as well as the pharmacotherapy of stimulant medications, with a specific review of literature on the efficacy and safety of the stimulants for children with ALL and BT.",Stimulant,TREATS,"Leukemia, Lymphocytic, Acute"
18221103,Intensified treatments with multi-drug regimens are responsible for the continuously increasing survival of children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18221103,Intensified treatments with multi-drug regimens are responsible for the continuously increasing survival of children with acute lymphoblastic leukaemia.,Treatment Protocols,USES,Pharmaceutical Preparations
18221103,"A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: recommendations of the ""Coagulation Defects"" AIEOP Working Group.",Thromboembolic event,PROCESS_OF,Child
18221103,"A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: recommendations of the ""Coagulation Defects"" AIEOP Working Group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18221103,"Guidelines for the treatment of thrombosis in childhood only became available recently, but they do not include specific clinical subsets such as children with acute lymphoblastic leukaemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14999936,[FISH detected 11q23 microdeletion and translocation at the long arm of chromosome 11 in a child with normal karyotypic acute lymphoblastic leukemia].,Long upper limb,PROCESS_OF,Child
14999936,[FISH detected 11q23 microdeletion and translocation at the long arm of chromosome 11 in a child with normal karyotypic acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15295608,Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15356653,Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15356660,"Finally, we compared the reported twins with an additional 31 children with ALL by using the microarray technology.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15690069,"We analyzed causes of death, other than resistant disease or relapse, in 875 children with acute lymphoblastic leukemia (ALL) and 229 with acute myeloid leukemia (AML), treated on three different Dutch Childhood Oncology Group (DCOG) ALL and three AML protocols.",Disease,PROCESS_OF,Child
15690069,"We analyzed causes of death, other than resistant disease or relapse, in 875 children with acute lymphoblastic leukemia (ALL) and 229 with acute myeloid leukemia (AML), treated on three different Dutch Childhood Oncology Group (DCOG) ALL and three AML protocols.",lymphoblast,LOCATION_OF,"Leukemia, Myelocytic, Acute"
15690069,"We analyzed causes of death, other than resistant disease or relapse, in 875 children with acute lymphoblastic leukemia (ALL) and 229 with acute myeloid leukemia (AML), treated on three different Dutch Childhood Oncology Group (DCOG) ALL and three AML protocols.",lymphoblast,LOCATION_OF,"Leukemia, Myelocytic, Acute"
15690069,"We analyzed causes of death, other than resistant disease or relapse, in 875 children with acute lymphoblastic leukemia (ALL) and 229 with acute myeloid leukemia (AML), treated on three different Dutch Childhood Oncology Group (DCOG) ALL and three AML protocols.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15744345,This study characterized the additional chromosomal abnormalities (ACA) associated with 11q23 rearrangements in 450 infants and children with acute lymphoblastic leukemia (ALL) and examined the impact of these ACA on survival.,Chromosome abnormality,PROCESS_OF,Child
15744345,This study characterized the additional chromosomal abnormalities (ACA) associated with 11q23 rearrangements in 450 infants and children with acute lymphoblastic leukemia (ALL) and examined the impact of these ACA on survival.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
15744345,This study characterized the additional chromosomal abnormalities (ACA) associated with 11q23 rearrangements in 450 infants and children with acute lymphoblastic leukemia (ALL) and examined the impact of these ACA on survival.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15744345,No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities.,Chromosome abnormality,NEG_AFFECTS,Child
15744345,No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15744345,This study characterized the additional chromosomal abnormalities (ACA) associated with 11q23 rearrangements in 450 infants and children with acute lymphoblastic leukemia (ALL) and examined the impact of these ACA on survival.,Chromosome abnormality,PROCESS_OF,Infant
16496289,"We report two children with precursor B ALL who had marked hypercalcemia (15.8 and 16.6 mg/dl, respectively) and disseminated osteolysis.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
16496289,"We report two children with precursor B ALL who had marked hypercalcemia (15.8 and 16.6 mg/dl, respectively) and disseminated osteolysis.",Osteolysis,PROCESS_OF,Child
16496289,"We report two children with precursor B ALL who had marked hypercalcemia (15.8 and 16.6 mg/dl, respectively) and disseminated osteolysis.",Hypercalcemia,PROCESS_OF,Child
16496289,PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia.,Bone Resorption,PROCESS_OF,Child
16496289,PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
16568441,Teacher-rated behavior and mathematics performance was correlated with attention function in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16568441,Teacher-rated behavior and mathematics performance was correlated with attention function in children with ALL.,Performance,PROCESS_OF,Child
16568441,Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor.,Pharmacotherapy,TREATS,Nephroblastoma
16568441,"School performance was poorer in children with ALL attending primary school compared with same-age peers; however, the rate of utilization of special education services was low.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16568441,Behavioral and educational limitations after chemotherapy for childhood acute lymphoblastic leukemia or Wilms tumor.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16568441,RESULTS: A moderately increased risk of behavioral and educational problems was found in children with ALL but not in children with Wilms tumor.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16568441,RESULTS: A moderately increased risk of behavioral and educational problems was found in children with ALL but not in children with Wilms tumor.,Nephroblastoma,PROCESS_OF,Child
16568441,Careful follow-up of children with ALL treated with chemotherapy only is warranted.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16568441,Sixty-four children were at least 1 year from finishing treatment with chemotherapy for ALL (n = 28) or a Wilms tumor (n = 36).,Pharmacotherapy,TREATS,Nephroblastoma
16568441,Careful follow-up of children with ALL treated with chemotherapy only is warranted.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16568441,Sixty-four children were at least 1 year from finishing treatment with chemotherapy for ALL (n = 28) or a Wilms tumor (n = 36).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16568441,Teacher-rated behavior and mathematics performance was correlated with attention function in children with ALL.,teacher behavior,PROCESS_OF,Child
16568441,"In this study, children with ALL received central nervous system directed chemotherapy without cranial irradiation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17302647,"Emotional, socio-economic and perhaps cultural differences between the groups of mothers were exemplified by the willingness of mothers of children with ALL to participate in epidemiological interviews earlier in their child's treatment course and to provide greater access to maternal reproductive history records compared with mothers of children with brain tumours.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17302647,"Emotional, socio-economic and perhaps cultural differences between the groups of mothers were exemplified by the willingness of mothers of children with ALL to participate in epidemiological interviews earlier in their child's treatment course and to provide greater access to maternal reproductive history records compared with mothers of children with brain tumours.",Brain Neoplasms,PROCESS_OF,Child
17302647,"Two focus group sessions with mothers of children with acute lymphoblastic leukaemia (ALL) and two with mothers of children with brain tumours were conducted to explore: the optimal time of day, method of administration, and location for the interview; the availability of alternative data sources; the interval between paediatric cancer diagnosis and epidemiological interview; and other features which may affect maternal interview responses.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17302647,"Two focus group sessions with mothers of children with acute lymphoblastic leukaemia (ALL) and two with mothers of children with brain tumours were conducted to explore: the optimal time of day, method of administration, and location for the interview; the availability of alternative data sources; the interval between paediatric cancer diagnosis and epidemiological interview; and other features which may affect maternal interview responses.",Brain Neoplasms,PROCESS_OF,Child
18221103,"We believe it would be possible to propose reasoned appropriate recommendations for treating thrombosis in children with acute lymphoblastic leukaemia, looking forward for the effects of recent patents.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18221103,"We believe it would be possible to propose reasoned appropriate recommendations for treating thrombosis in children with acute lymphoblastic leukaemia, looking forward for the effects of recent patents.",Thrombosis,PROCESS_OF,Child
14770434,"BACKGROUND: Although the majority of children with acute lymphoblastic leukemia (ALL) are cured with combination chemotherapy containing methotrexate (MTX), drug resistance contributes to treatment failure for a substantial fraction of patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15547931,"RESULTS: A total of 178 children, representing 8% of all children with ALL, had an initial leukocyte count >200 x 10(9)/L; 67 patients had a leukocyte count >400 x 10(9)/L.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15661262,"In this study, 107 children with acute lymphoblastic leukemia (ALL) were analysed for the presence of hyperdiploidy by cytogenetics and interphase fluorescence in situ hybridisation (I-FISH).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15661262,Prognostic value of structural chromosomal rearrangements and small cell clones with high hyperdiploidy in children with acute lymphoblastic leukemia.,Hyperploidy,PROCESS_OF,Child
15661262,Prognostic value of structural chromosomal rearrangements and small cell clones with high hyperdiploidy in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15716990,This study shows that the incidence of deletions from the der(9) in childhood ALL is at least as high as that reported for CML.,DELETION,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15744345,This study characterized the additional chromosomal abnormalities (ACA) associated with 11q23 rearrangements in 450 infants and children with acute lymphoblastic leukemia (ALL) and examined the impact of these ACA on survival.,Chromosome abnormality,PROCESS_OF,Infant
15744345,This study characterized the additional chromosomal abnormalities (ACA) associated with 11q23 rearrangements in 450 infants and children with acute lymphoblastic leukemia (ALL) and examined the impact of these ACA on survival.,Chromosome abnormality,PROCESS_OF,Child
15744345,This study characterized the additional chromosomal abnormalities (ACA) associated with 11q23 rearrangements in 450 infants and children with acute lymphoblastic leukemia (ALL) and examined the impact of these ACA on survival.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
15744345,This study characterized the additional chromosomal abnormalities (ACA) associated with 11q23 rearrangements in 450 infants and children with acute lymphoblastic leukemia (ALL) and examined the impact of these ACA on survival.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15823699,"Since treatment with zinc and other identified deficient nutrients, particularly magnesium, did not appear injurious in ALL and they appear to be highly beneficial, controlled clinical studies of zinc (3.18 mg/kg body weight/day) with magnesium (8.0 mg/kg body weight/day) as adjuvants to chemotherapy in the treatment of childhood ALL are suggested.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15823699,"Since treatment with zinc and other identified deficient nutrients, particularly magnesium, did not appear injurious in ALL and they appear to be highly beneficial, controlled clinical studies of zinc (3.18 mg/kg body weight/day) with magnesium (8.0 mg/kg body weight/day) as adjuvants to chemotherapy in the treatment of childhood ALL are suggested.",Magnesium,INTERACTS_WITH,Zinc
15823699,"Since treatment with zinc and other identified deficient nutrients, particularly magnesium, did not appear injurious in ALL and they appear to be highly beneficial, controlled clinical studies of zinc (3.18 mg/kg body weight/day) with magnesium (8.0 mg/kg body weight/day) as adjuvants to chemotherapy in the treatment of childhood ALL are suggested.",Therapeutic procedure,USES,Zinc
15823699,Identical results also occurred in 13 other children with ALL whose parents chose to treat with zinc adjuvant.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16048425,"RESULTS: The children and youth who had ALL had poorer balance than the comparison subjects (BOTMP = 10.55 and 16.30, respectively) and lower CSAPPA scores (57.72 and 63.72, respectively) and HUI scores (0.86 and 0.97, respectively).",Poor balance,PROCESS_OF,Child
16048425,"This cross-sectional, descriptive study compared the balance skills of children and youth who have had ALL with those of comparable subjects and explored associations with demographics, therapy, physical activity, and health-related quality of life (HRQL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Youth
16048425,"This cross-sectional, descriptive study compared the balance skills of children and youth who have had ALL with those of comparable subjects and explored associations with demographics, therapy, physical activity, and health-related quality of life (HRQL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16048425,Proficiency of balance in children and youth who have had acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Youth
16048425,"RESULTS: The children and youth who had ALL had poorer balance than the comparison subjects (BOTMP = 10.55 and 16.30, respectively) and lower CSAPPA scores (57.72 and 63.72, respectively) and HUI scores (0.86 and 0.97, respectively).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Youth
16048425,Proficiency of balance in children and youth who have had acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16048425,"RESULTS: The children and youth who had ALL had poorer balance than the comparison subjects (BOTMP = 10.55 and 16.30, respectively) and lower CSAPPA scores (57.72 and 63.72, respectively) and HUI scores (0.86 and 0.97, respectively).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16048425,"RESULTS: The children and youth who had ALL had poorer balance than the comparison subjects (BOTMP = 10.55 and 16.30, respectively) and lower CSAPPA scores (57.72 and 63.72, respectively) and HUI scores (0.86 and 0.97, respectively).",Poor balance,PROCESS_OF,Youth
16849280,Increased expression of multidrug resistance gene (MDR1) at relapse in a child with acute lymphoblastic leukemia.,Child,LOCATION_OF,Multidrug Resistance Gene
16849280,Increased expression of multidrug resistance gene (MDR1) at relapse in a child with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16849280,This is the first report on increased mRNA expression at relapse in a paired sample of a child with ALL in our region.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17096875,"To evaluate the significance of FCM in minimal residual disease (MRD) detection, the immunophenotyping and leukemia-associated immunophenotypes (LAIP) of leukemia cells from 273 adult and 142 childhood patients with B lineage acute lymphoblastic leukemia (B-ALL) were detected by four to six antibody combinations of 4-color CD45/SSC gating multiparametric flow cytometry (FCM).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
17096875,"To evaluate the significance of FCM in minimal residual disease (MRD) detection, the immunophenotyping and leukemia-associated immunophenotypes (LAIP) of leukemia cells from 273 adult and 142 childhood patients with B lineage acute lymphoblastic leukemia (B-ALL) were detected by four to six antibody combinations of 4-color CD45/SSC gating multiparametric flow cytometry (FCM).",Immunophenotyping,DIAGNOSES,"Neoplasm, Residual"
17096875,"To evaluate the significance of FCM in minimal residual disease (MRD) detection, the immunophenotyping and leukemia-associated immunophenotypes (LAIP) of leukemia cells from 273 adult and 142 childhood patients with B lineage acute lymphoblastic leukemia (B-ALL) were detected by four to six antibody combinations of 4-color CD45/SSC gating multiparametric flow cytometry (FCM).",Immunophenotyping,DIAGNOSES,"Neoplasm, Residual"
17096875,"To evaluate the significance of FCM in minimal residual disease (MRD) detection, the immunophenotyping and leukemia-associated immunophenotypes (LAIP) of leukemia cells from 273 adult and 142 childhood patients with B lineage acute lymphoblastic leukemia (B-ALL) were detected by four to six antibody combinations of 4-color CD45/SSC gating multiparametric flow cytometry (FCM).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
17330098,"Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17405151,BACKGROUND: At present about 80% of children with acute lymphoblastic leukemia (ALL) will be cured following treatment with multi-drug chemotherapy.,Pharmacotherapy,USES,Pharmaceutical Preparations
17405151,BACKGROUND: At present about 80% of children with acute lymphoblastic leukemia (ALL) will be cured following treatment with multi-drug chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17405151,PROCEDURE: Evaluation of cardiac function in a cohort of 63 long-term survivors in first continuous remission following treatment of ALL with multi-drug chemotherapy including anthracyclines was performed using standard M-mode echocardiography and tissue doppler imaging (TDI).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
17405151,PROCEDURE: Evaluation of cardiac function in a cohort of 63 long-term survivors in first continuous remission following treatment of ALL with multi-drug chemotherapy including anthracyclines was performed using standard M-mode echocardiography and tissue doppler imaging (TDI).,Cardiac function,PROCESS_OF,cohort
17405151,PROCEDURE: Evaluation of cardiac function in a cohort of 63 long-term survivors in first continuous remission following treatment of ALL with multi-drug chemotherapy including anthracyclines was performed using standard M-mode echocardiography and tissue doppler imaging (TDI).,"Echocardiography, M-Mode",ADMINISTERED_TO,Long-Term Survivors
17405151,PROCEDURE: Evaluation of cardiac function in a cohort of 63 long-term survivors in first continuous remission following treatment of ALL with multi-drug chemotherapy including anthracyclines was performed using standard M-mode echocardiography and tissue doppler imaging (TDI).,Pharmacotherapy,USES,Pharmaceutical Preparations
17633097,"In a literature review of mucoepidermoid carcinoma following ALL, 11 out of 14 cases received radiation therapy for the initial treatment of ALL, but 3 cases had no radiation therapy.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
17633097,[Mucoepidermoid carcinoma of the parotid gland as a secondary malignancy developed ten years after chemotherapy for childhood acute lymphoblastic leukemia].,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17633097,[Mucoepidermoid carcinoma of the parotid gland as a secondary malignancy developed ten years after chemotherapy for childhood acute lymphoblastic leukemia].,Mucoepidermoid Carcinoma,PART_OF,Parotid Gland
18225736,"In 2006 the GFAOP began assessment of two new treatment protocols, i.e., one for acute lymphoblastic leukemia and the other for Hodgkin's disease.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
18225736,"In 2006 the GFAOP began assessment of two new treatment protocols, i.e., one for acute lymphoblastic leukemia and the other for Hodgkin's disease.",Treatment Protocols,TREATS,Hodgkin Disease
14574999,"The detection of very low numbers of leukemic cells persisting after treatment, i.e. the monitoring of minimal residual disease (MRD) is of significant clinical value for children with acute lymphoblastic leukemia (ALL).",Internal-External Locus of Control Scale,DIAGNOSES,"Neoplasm, Residual"
14574999,"The detection of very low numbers of leukemic cells persisting after treatment, i.e. the monitoring of minimal residual disease (MRD) is of significant clinical value for children with acute lymphoblastic leukemia (ALL).",Detection,TREATS,Child
14574999,"The detection of very low numbers of leukemic cells persisting after treatment, i.e. the monitoring of minimal residual disease (MRD) is of significant clinical value for children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14574999,"The detection of very low numbers of leukemic cells persisting after treatment, i.e. the monitoring of minimal residual disease (MRD) is of significant clinical value for children with acute lymphoblastic leukemia (ALL).",Detection,TREATS,"Leukemia, Lymphocytic, Acute"
14574999,[Minimal residual disease in childhood acute lymphoblastic leukemia: diagnosis of the 21 century].,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
15360802,"OBJECTIVES: To assess the acceptability to clinicians of a web-based decision support system designed to assist with dosage adjustments during maintenance therapy for childhood Acute Lymphoblastic Leukaemia (ALL), and to evaluate the potential impact of the system on decision-making and dosage calculations.",Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15360802,"A quantitative and qualitative evaluation of LISA, a decision support system for chemotherapy dosing in childhood acute lymphoblastic leukaemia.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
15750445,Steroid withdrawal morbidity in ALL children during induction is a frequent and clinically relevant complaint.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15750445,"Children with acute lymphoblastic leukemia (ALL) receive as part of induction therapy a 4-week course of high-dose glucocorticoid, which is either abruptly discontinued or shortly tapered.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15750448,"The clinical and diagnostic findings and the factors influencing the neurologic and radiologic outcome of symptomatic ischemic stroke were evaluated in a group of 2,318 children with acute lymphoblastic leukemia (ALL) treated according to the AIEOP (Italian Association of Pediatric Hematology and Oncology) study protocols.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15860861,This study aimed to determine the expression of a splicing-derived variant of interleukin (IL) -10 in leukemic cells and its clinical relevance in children with acute lymphoblastic leukemia (ALL) at first relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15860861,This study aimed to determine the expression of a splicing-derived variant of interleukin (IL) -10 in leukemic cells and its clinical relevance in children with acute lymphoblastic leukemia (ALL) at first relapse.,Interleukin-10,PART_OF,Leukemic Cell
16101646,Mothers' attitudes to the randomized controlled trial (RCT): the case of acute lymphoblastic leukaemia (ALL) in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16103439,These results offer indirect yet strong support for the infectious disease hypothesis in the etiology of ALL in non-Hispanic White children and highlight an important ethnic difference.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16103439,"In addition, self-reported ear infection during infancy was associated with a significantly reduced risk of c-ALL (OR, 0.32; 95% CI, 0.14-0.74) in non-Hispanic White children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16103439,"A role for infectious agents has been proposed in the etiology of childhood acute lymphoblastic leukemia (ALL), particularly for common ALL (c-ALL; ALL diagnosed in children ages 2-5 years and expressing CD10 and CD19 surface antigens).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16103439,"A role for infectious agents has been proposed in the etiology of childhood acute lymphoblastic leukemia (ALL), particularly for common ALL (c-ALL; ALL diagnosed in children ages 2-5 years and expressing CD10 and CD19 surface antigens).",Common acute lymphoblastic leukemia,ISA,"Leukemia, Lymphocytic, Acute"
16103440,"Because leukemia clone-specific chromosomal abnormalities are present at birth in children who later develop leukemia, it has been hypothesized that maternal factors, including nutrition during pregnancy, might affect the risk of acute lymphoblastic leukemia (ALL) among young children.",Chromosome abnormality,AFFECTS,Mothers
16103440,"Because leukemia clone-specific chromosomal abnormalities are present at birth in children who later develop leukemia, it has been hypothesized that maternal factors, including nutrition during pregnancy, might affect the risk of acute lymphoblastic leukemia (ALL) among young children.",Birth,PROCESS_OF,Child
16103440,Children (n=131) with ALL were gender and age matched to control children (n=131) hospitalized for minor conditions between 1999 and 2003.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16103440,Maternal diet and acute lymphoblastic leukemia in young children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16103440,We have evaluated this hypothesis in a nationwide case-control study of ALL among children ages 12 to 59 months in Greece.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16103440,"Because leukemia clone-specific chromosomal abnormalities are present at birth in children who later develop leukemia, it has been hypothesized that maternal factors, including nutrition during pregnancy, might affect the risk of acute lymphoblastic leukemia (ALL) among young children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16103440,"Because leukemia clone-specific chromosomal abnormalities are present at birth in children who later develop leukemia, it has been hypothesized that maternal factors, including nutrition during pregnancy, might affect the risk of acute lymphoblastic leukemia (ALL) among young children.",Question of pregnancy,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
16103440,"Because leukemia clone-specific chromosomal abnormalities are present at birth in children who later develop leukemia, it has been hypothesized that maternal factors, including nutrition during pregnancy, might affect the risk of acute lymphoblastic leukemia (ALL) among young children.",leukemia,PROCESS_OF,Child
17182983,"Children diagnosed with ALL had significantly more clinically diagnosed infectious episodes in infancy than did controls; the average number of episodes was 3.6 (95% confidence interval (CI): 3.3, 3.9) versus 3.1 (95% CI: 2.9, 3.2).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17596539,The treatment of newly diagnosed acute lymphocytic leukemia (ALL) in adults remains unsatisfactory.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
17596539,How I treat acute lymphocytic leukemia in adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
12931229,Twin children with hyperdiploid ALL have not hitherto been reported.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
12931229,High hyperdiploidy is the most common genetic abnormality in childhood acute lymphoblastic leukemia (ALL).,Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12931229,High hyperdiploidy is the most common genetic abnormality in childhood acute lymphoblastic leukemia (ALL).,Hyperploidy,ISA,Molecular Abnormality
12972956,This study shows that children with acute lymphoblastic leukaemia (ALL) who are homozygous for the CCND1 A variant have a lower probability of event-free survival (P = 0.006) compared to carriers of the G variant.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
14645357,Development of immunoglobulin variable heavy chain gene consensus probes with conjugated 3' minor groove binder groups for monitoring minimal residual disease in childhood acute lymphoblastic leukaemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
14645357,Development of immunoglobulin variable heavy chain gene consensus probes with conjugated 3' minor groove binder groups for monitoring minimal residual disease in childhood acute lymphoblastic leukaemia.,Binder,TREATS,"Neoplasm, Residual"
15899736,High-dose intravenous methotrexate is an important component of many effective chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Chemotherapy-Oncologic Procedure
15899736,High-dose intravenous methotrexate is an important component of many effective chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL).,Methotrexate,AFFECTS,"Leukemia, Lymphocytic, Acute, L1"
15899736,The evidence favoring administration of intravenous methotrexate for children with ALL is critically reviewed.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
15899736,High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use?,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
15899736,The implied superiority of intravenous methotrexate mainly stems from studies that used identical leucovorin rescue with low-dose methotrexate or from studies of upfront window therapy in untreated children with ALL in which single standard doses of oral methotrexate were compared with high-dose intravenous methotrexate with leucovorin rescue.,Methotrexate,compared_with,Methotrexate
15899736,The implied superiority of intravenous methotrexate mainly stems from studies that used identical leucovorin rescue with low-dose methotrexate or from studies of upfront window therapy in untreated children with ALL in which single standard doses of oral methotrexate were compared with high-dose intravenous methotrexate with leucovorin rescue.,Therapeutic procedure,TREATS,Child
15899736,The implied superiority of intravenous methotrexate mainly stems from studies that used identical leucovorin rescue with low-dose methotrexate or from studies of upfront window therapy in untreated children with ALL in which single standard doses of oral methotrexate were compared with high-dose intravenous methotrexate with leucovorin rescue.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15899736,The implied superiority of intravenous methotrexate mainly stems from studies that used identical leucovorin rescue with low-dose methotrexate or from studies of upfront window therapy in untreated children with ALL in which single standard doses of oral methotrexate were compared with high-dose intravenous methotrexate with leucovorin rescue.,Leukovorin rescue,USES,Methotrexate
15899736,The evidence favoring administration of intravenous methotrexate for children with ALL is critically reviewed.,Methotrexate,TREATS,Child
15899736,The implied superiority of intravenous methotrexate mainly stems from studies that used identical leucovorin rescue with low-dose methotrexate or from studies of upfront window therapy in untreated children with ALL in which single standard doses of oral methotrexate were compared with high-dose intravenous methotrexate with leucovorin rescue.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
15899736,The evidence favoring administration of intravenous methotrexate for children with ALL is critically reviewed.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16173962,"In conclusion, 3% of children with ALL died of TRD, with bacterial infections as the most common cause of death.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16173962,"In conclusion, 3% of children with ALL died of TRD, with bacterial infections as the most common cause of death.",Bacterial Infections,PROCESS_OF,Child
16184615,METHODS: We compared diagnostic and relapse bone marrow specimens in 42 children with precursor B-ALL studied with the two-tube panel CD19-APC/CD45-PerCP/CD10-PE/CD20-FITC and CD19-APC/CD45-PerCP/CD9-PE/CD34-FITC.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16434366,T-ALL was significantly more resistant to cladribine than B-cell precursor ALL.,"Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
16520989,"Since ALL is a disease of the bone marrow, a hypoxic tissue compartment, and it has been reported that there is an antagonistic effect of hypoxia on many chemotherapeutic agents, our purpose was to observe whether hypoxia is able to inhibit the effect of 4-HPR for ALL cell lines and to investigate its mechanisms of antagonism to 4-HPR.",Bone Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
16520989,"Since ALL is a disease of the bone marrow, a hypoxic tissue compartment, and it has been reported that there is an antagonistic effect of hypoxia on many chemotherapeutic agents, our purpose was to observe whether hypoxia is able to inhibit the effect of 4-HPR for ALL cell lines and to investigate its mechanisms of antagonism to 4-HPR.",Bone Marrow,LOCATION_OF,Disease
16520989,"Since ALL is a disease of the bone marrow, a hypoxic tissue compartment, and it has been reported that there is an antagonistic effect of hypoxia on many chemotherapeutic agents, our purpose was to observe whether hypoxia is able to inhibit the effect of 4-HPR for ALL cell lines and to investigate its mechanisms of antagonism to 4-HPR.",Antineoplastic Agents,INTERACTS_WITH,Fenretinide
16520989,"Since ALL is a disease of the bone marrow, a hypoxic tissue compartment, and it has been reported that there is an antagonistic effect of hypoxia on many chemotherapeutic agents, our purpose was to observe whether hypoxia is able to inhibit the effect of 4-HPR for ALL cell lines and to investigate its mechanisms of antagonism to 4-HPR.",antagonists,AFFECTS,Hypoxia
16520989,"Since ALL is a disease of the bone marrow, a hypoxic tissue compartment, and it has been reported that there is an antagonistic effect of hypoxia on many chemotherapeutic agents, our purpose was to observe whether hypoxia is able to inhibit the effect of 4-HPR for ALL cell lines and to investigate its mechanisms of antagonism to 4-HPR.","Leukemia, Lymphocytic, Acute",ISA,Disease
16541142,The response to initial glucocorticoid therapy in childhood acute lymphoblastic leukaemia (ALL) reliably predicts the response to multiagent chemotherapy.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16732932,"CONCLUSION: Low dose L-Asp has definite efficacy for childhood ALL, while avoids serious side effects from standard dose L-Asp.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16732932,OBJECTIVE: To investigate the safety and therapeutic effect of low dose (1000 U/m(2)) L-asparaginase (L-Asp) in the treatment of children with acute lymphoblastic leukemia (ALL).,ASPARAGINASE,TREATS,Child
16732932,OBJECTIVE: To investigate the safety and therapeutic effect of low dose (1000 U/m(2)) L-asparaginase (L-Asp) in the treatment of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16732932,OBJECTIVE: To investigate the safety and therapeutic effect of low dose (1000 U/m(2)) L-asparaginase (L-Asp) in the treatment of children with acute lymphoblastic leukemia (ALL).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
16732969,OBJECTIVE: To assess the prognostic value of minimal residual disease (MRD) in childhood B-cell acute lymphoblastic leukemia (ALL) after induction chemotherapy.,"Neoplasm, Residual",COEXISTS_WITH,B-cell childhood acute lymphoblastic leukemia
16732969,[Prognostic value of minimal residual disease in childhood B-cell acute lymphoblastic leukemia].,"Neoplasm, Residual",COEXISTS_WITH,B-cell childhood acute lymphoblastic leukemia
16923565,Blood samples of 135 children with ALL and 142 matched controls were analysed.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16923565,Blood samples of 135 children with ALL and 142 matched controls were analysed.,Blood specimen,PART_OF,Child
15152368,"The aim of our study was to estimate serum levels of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia (ALL) after cessation of chemotherapy.",Child,LOCATION_OF,Interleukin-10
15152368,"The aim of our study was to estimate serum levels of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia (ALL) after cessation of chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15152368,"Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy.",Child,LOCATION_OF,Tumor Necrosis Factor-alpha | TNF
15152368,"Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy.",Child,LOCATION_OF,Interleukin-10
15152368,"Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15152368,The study involved 150 children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15152368,"The aim of our study was to estimate serum levels of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia (ALL) after cessation of chemotherapy.",Child,LOCATION_OF,Tumor Necrosis Factor-alpha | TNF
15325594,"RESULTS: The varicella vaccine has been extensively studied in susceptible children with acute lymphoblastic leukaemia in remission, but studies involving individuals with other immunodeficiency disorders are scarce.","Vaccines, Attenuated",TREATS,"Leukemia, Lymphocytic, Acute"
15325594,"RESULTS: The varicella vaccine has been extensively studied in susceptible children with acute lymphoblastic leukaemia in remission, but studies involving individuals with other immunodeficiency disorders are scarce.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
15325594,"RESULTS: The varicella vaccine has been extensively studied in susceptible children with acute lymphoblastic leukaemia in remission, but studies involving individuals with other immunodeficiency disorders are scarce.","Vaccines, Attenuated",TREATS,Child
15325594,"RESULTS: The varicella vaccine has been extensively studied in susceptible children with acute lymphoblastic leukaemia in remission, but studies involving individuals with other immunodeficiency disorders are scarce.",Immunologic Deficiency Syndromes,PROCESS_OF,Individual
16167060,The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype.,Drug resistance,AFFECTS,Child
16167060,"The association between five coding ATM alterations in T-ALL, their germline presence, white blood cell count and unfavourable outcome may point to a role for ATM in the development of T-ALL in these children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16167060,"The association between five coding ATM alterations in T-ALL, their germline presence, white blood cell count and unfavourable outcome may point to a role for ATM in the development of T-ALL in these children.",Mutate,AFFECTS,"Leukemia, Lymphocytic, Acute"
16167060,Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL) that are linked to drug resistance and clinical outcome.,ATM gene | ATM,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
16167060,Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL) that are linked to drug resistance and clinical outcome.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
16167060,The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16341043,"WT1, thus, will not be a useful marker for MRD detection in childhood ALL, however, it does represent a potential independent risk factor in childhood ALL.",Detection,USES,WT1 gene | WT1
16341043,"WT1, thus, will not be a useful marker for MRD detection in childhood ALL, however, it does represent a potential independent risk factor in childhood ALL.",Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
16494622,"METHODS: In a population-based cohort of 137 children with ALL treated at a single pediatric hematology-oncology center with an almost identical chemotherapy regimen, we studied the relationship between polymorphisms in the MBL gene (MBL2) and the MBL2 promoter and the risk of infections during the first 50 d of induction therapy.",Neoadjuvant Therapy,PREDISPOSES,Infection
16494622,"METHODS: In a population-based cohort of 137 children with ALL treated at a single pediatric hematology-oncology center with an almost identical chemotherapy regimen, we studied the relationship between polymorphisms in the MBL gene (MBL2) and the MBL2 promoter and the risk of infections during the first 50 d of induction therapy.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
16494622,"CONCLUSIONS: MBL deficiency did not influence the frequency of infections in children receiving induction chemotherapy for ALL, not even in the youngest children (<2.5 yr) whom we found to have the highest risk for infections.",Pharmacotherapy,ADMINISTERED_TO,Child
16494622,"CONCLUSIONS: MBL deficiency did not influence the frequency of infections in children receiving induction chemotherapy for ALL, not even in the youngest children (<2.5 yr) whom we found to have the highest risk for infections.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
16494622,"CONCLUSIONS: MBL deficiency did not influence the frequency of infections in children receiving induction chemotherapy for ALL, not even in the youngest children (<2.5 yr) whom we found to have the highest risk for infections.",Infection,PROCESS_OF,Child
16494622,"CONCLUSIONS: MBL deficiency did not influence the frequency of infections in children receiving induction chemotherapy for ALL, not even in the youngest children (<2.5 yr) whom we found to have the highest risk for infections.",Mannose Binding Lectin,NEG_ASSOCIATED_WITH,Infection
16494622,"METHODS: In a population-based cohort of 137 children with ALL treated at a single pediatric hematology-oncology center with an almost identical chemotherapy regimen, we studied the relationship between polymorphisms in the MBL gene (MBL2) and the MBL2 promoter and the risk of infections during the first 50 d of induction therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16496405,"We analyzed 312 case children (0-15 years old) newly diagnosed with acute lymphoblastic leukemia (ALL) or acute myelocytic leukemia (AML) in 1999-2001 (2.3 years) and 603 controls matched for gender, age and residential area.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
16496405,"We analyzed 312 case children (0-15 years old) newly diagnosed with acute lymphoblastic leukemia (ALL) or acute myelocytic leukemia (AML) in 1999-2001 (2.3 years) and 603 controls matched for gender, age and residential area.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16761017,Mixed lineage leukemia (MLL) rearrangements occur in 80% of infants and 5% of older children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16923354,METHODS: The cellular activity of asparagine synthetase was detected by HPLC-FLD and Protein measurement in 28 ALL children (7 cases of T-ALL and 21 cases of B-lymphoid lineage ALL) before chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
16923354,METHODS: The cellular activity of asparagine synthetase was detected by HPLC-FLD and Protein measurement in 28 ALL children (7 cases of T-ALL and 21 cases of B-lymphoid lineage ALL) before chemotherapy.,Child,LOCATION_OF,ASNS gene | ASNS
16956497,"RESULTS: Between 1984 and 2004, 232 children were diagnosed with ALL and treated according to the different versions of the BFM protocols (BFM83, BFM86, BFM90 and BFM95) at the Hospital Nino Jesus, Madrid, Spain.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17180579,Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma.,Methotrexate,TREATS,Lymphoma
17180579,Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17180579,Methotrexate is administered in high doses to treat childhood acute lymphoblastic leukemia and malignant lymphoma.,Methotrexate,TREATS,Lymphoma
17180579,Methotrexate is administered in high doses to treat childhood acute lymphoblastic leukemia and malignant lymphoma.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17261500,Survival outcome after the first central nervous system relapse in children with acute lymphoblastic leukemia: a retrospective analysis of 79 patients in a joint program involving the experience of three Japanese study groups.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17926333,"CONCLUSIONS: Dexamethasone treatment during continuation therapy for childhood ALL significantly and adversely altered sleep and fatigue, confirming that sleep and fatigue are behavioral responses to dexamethasone.",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17926333,"CONCLUSIONS: Dexamethasone treatment during continuation therapy for childhood ALL significantly and adversely altered sleep and fatigue, confirming that sleep and fatigue are behavioral responses to dexamethasone.",Dexamethasone,TREATS,Fatigue
17926333,"CONCLUSIONS: Dexamethasone treatment during continuation therapy for childhood ALL significantly and adversely altered sleep and fatigue, confirming that sleep and fatigue are behavioral responses to dexamethasone.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17926333,"CONCLUSIONS: Dexamethasone treatment during continuation therapy for childhood ALL significantly and adversely altered sleep and fatigue, confirming that sleep and fatigue are behavioral responses to dexamethasone.",Dexamethasone,TREATS,Fatigue
17926333,"CONCLUSIONS: Dexamethasone treatment during continuation therapy for childhood ALL significantly and adversely altered sleep and fatigue, confirming that sleep and fatigue are behavioral responses to dexamethasone.",Therapeutic procedure,TREATS,Fatigue
17926333,BACKGROUND: Dexamethasone improves the cure rate of childhood acute lymphoblastic leukemia (ALL) but causes physical and behavioral adverse events.,Dexamethasone,TREATS,Adverse event
17926333,"CONCLUSIONS: Dexamethasone treatment during continuation therapy for childhood ALL significantly and adversely altered sleep and fatigue, confirming that sleep and fatigue are behavioral responses to dexamethasone.",Therapeutic procedure,TREATS,Fatigue
17926333,BACKGROUND: Dexamethasone improves the cure rate of childhood acute lymphoblastic leukemia (ALL) but causes physical and behavioral adverse events.,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17926333,"CONCLUSIONS: Dexamethasone treatment during continuation therapy for childhood ALL significantly and adversely altered sleep and fatigue, confirming that sleep and fatigue are behavioral responses to dexamethasone.",Therapeutic procedure,USES,Dexamethasone
17926333,"CONCLUSIONS: Dexamethasone treatment during continuation therapy for childhood ALL significantly and adversely altered sleep and fatigue, confirming that sleep and fatigue are behavioral responses to dexamethasone.",Dexamethasone,ISA,Therapeutic procedure
18094715,We retrospectively evaluated reticulin fiber density (RFD) in 166 diagnostic bone marrow (BM) biopsies and 62 biopsies obtained at treatment day 29 from children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18094715,We retrospectively evaluated reticulin fiber density (RFD) in 166 diagnostic bone marrow (BM) biopsies and 62 biopsies obtained at treatment day 29 from children with acute lymphoblastic leukemia (ALL).,Child,LOCATION_OF,Reticulin
18181181,Genetic lesions in a preleukemic aplasia phase in a child with acute lymphoblastic leukemia.,Genital lesion,PROCESS_OF,Child
18181181,Genetic lesions in a preleukemic aplasia phase in a child with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18413892,Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time.,"Transplantation, Homologous",TREATS,"Leukemia, Lymphocytic, Acute, L1"
18413892,The advantage of allogeneic transplant from compatible related donors versus chemotherapy in children with very-high-risk acute lymphoblastic leukemia in first complete remission was previously demonstrated in an international prospective trial.,Transplanted organ and tissue status,PROCESS_OF,Child
18413892,The advantage of allogeneic transplant from compatible related donors versus chemotherapy in children with very-high-risk acute lymphoblastic leukemia in first complete remission was previously demonstrated in an international prospective trial.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18615507,Vincristine pharmacokinetics in children with Down syndrome.,Vincristine,TREATS,Child
18615507,Vincristine pharmacokinetics in children with Down syndrome.,Down Syndrome,PROCESS_OF,Child
18615507,Vincristine pharmacokinetics in children with Down syndrome.,Vincristine,TREATS,Down Syndrome
19210218,"We evaluated spine health in 186 newly diagnosed children (median age, 5.3 yr; 108 boys) with ALL (precursor B cell: N = 167; T cell: N = 19) who were enrolled in a national bone health research program.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19210218,Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19210218,Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program.,Spinal Fractures,PROCESS_OF,Child
19470474,Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease consisting of distinct clinical and biological subtypes that are characterized by specific chromosomal abnormalities or gene mutations.,Chromosome abnormality,COEXISTS_WITH,Disease
19470474,Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease consisting of distinct clinical and biological subtypes that are characterized by specific chromosomal abnormalities or gene mutations.,"Leukemia, Lymphocytic, Acute, L1",ISA,Disease
19470474,Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease consisting of distinct clinical and biological subtypes that are characterized by specific chromosomal abnormalities or gene mutations.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
19593802,"Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19593802,"Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children.",BRAZILIAN,PROCESS_OF,Child
20378168,High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20378168,"Prognosis for children with acute lymphoblastic leukemia (ALL) has considerably improved, yet relapse still occurs in a significant proportion of patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20589650,PROCEDURE: Adult survivors of ALL and Wilms tumor treated with radiotherapy and chemotherapy (RT + CT) or treated with chemotherapy alone (CT) were compared with sibling controls.,Survivors,INTERACTS_WITH,sibling
20589650,PROCEDURE: Adult survivors of ALL and Wilms tumor treated with radiotherapy and chemotherapy (RT + CT) or treated with chemotherapy alone (CT) were compared with sibling controls.,Pharmacotherapy,TREATS,Nephroblastoma
20589650,PROCEDURE: Adult survivors of ALL and Wilms tumor treated with radiotherapy and chemotherapy (RT + CT) or treated with chemotherapy alone (CT) were compared with sibling controls.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
20589650,Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy.,Radiation therapy,TREATS,Nephroblastoma
20589650,Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy.,Cardiovascular Diseases,PROCESS_OF,Long-Term Survivors
20589650,Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
20615069,Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.,Hyperammonemia,PROCESS_OF,Child
20615069,"The standard treatment protocol for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) in childhood includes intravenous therapy with asparaginase (Asp), which may cause hyperammonemia.",ASPARAGINASE,PART_OF,"Leukemia, Lymphocytic, Acute"
20615069,Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
20615069,"The standard treatment protocol for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) in childhood includes intravenous therapy with asparaginase (Asp), which may cause hyperammonemia.",Treatment Protocols,TREATS,"Lymphoma, Non-Hodgkin's"
20615069,Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20615069,"The standard treatment protocol for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) in childhood includes intravenous therapy with asparaginase (Asp), which may cause hyperammonemia.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
20615069,Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.,Therapeutic procedure,USES,ASPARAGINASE
20615069,Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.,ASPARAGINASE,ISA,Therapeutic procedure
20615069,Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.,ASPARAGINASE,CAUSES,Hyperammonemia
20615069,Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.,Therapeutic procedure,CAUSES,Hyperammonemia
20615069,"The standard treatment protocol for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) in childhood includes intravenous therapy with asparaginase (Asp), which may cause hyperammonemia.",ASPARAGINASE,PART_OF,"Lymphoma, Non-Hodgkin's"
21396490,Early response to 7 days of prednisolone (PRED) treatment is one of the important prognostic factors in predicting eventual outcome in childhood acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21396490,Early response to 7 days of prednisolone (PRED) treatment is one of the important prognostic factors in predicting eventual outcome in childhood acute lymphoblastic leukemia (ALL).,Therapeutic procedure,USES,prednisolone
21396490,Early response to 7 days of prednisolone (PRED) treatment is one of the important prognostic factors in predicting eventual outcome in childhood acute lymphoblastic leukemia (ALL).,prednisolone,ISA,Therapeutic procedure
21396490,Early response to 7 days of prednisolone (PRED) treatment is one of the important prognostic factors in predicting eventual outcome in childhood acute lymphoblastic leukemia (ALL).,prednisolone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21396490,Early response to 7 days of prednisolone (PRED) treatment is one of the important prognostic factors in predicting eventual outcome in childhood acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
21487112,New markers for minimal residual disease detection in acute lymphoblastic leukemia.,Detection,TREATS,"Leukemia, Lymphocytic, Acute"
21487112,"To identify new markers for minimal residual disease (MRD) detection in acute lymphoblastic leukemia (ALL), we compared genome-wide gene expression of lymphoblasts from 270 patients with newly diagnosed childhood ALL to that of normal CD19+CD10+ B-cell progenitors (n = 4).","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
21487112,"To identify new markers for minimal residual disease (MRD) detection in acute lymphoblastic leukemia (ALL), we compared genome-wide gene expression of lymphoblasts from 270 patients with newly diagnosed childhood ALL to that of normal CD19+CD10+ B-cell progenitors (n = 4).",Detection,TREATS,"Leukemia, Lymphocytic, Acute"
21843409,"METHODS: For this case-control study, cases were children younger than 15 years who were newly diagnosed with ALL between January 2000 and March 2005 at 1 of 6 Colombian hospitals.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21946195,Education given to parents of children newly diagnosed with acute lymphoblastic leukemia: a narrative review.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18258511,Approximately 67% of the children diagnosed with ALL in Spain during this period were enrolled in these trials.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18615507,We studied vincristine pharmacokinetics on treatment day one in six children with DS and compared to 92 non-DS children.,Down Syndrome,PROCESS_OF,Child
18615507,We studied vincristine pharmacokinetics on treatment day one in six children with DS and compared to 92 non-DS children.,Vincristine,TREATS,Child
18615507,We studied vincristine pharmacokinetics on treatment day one in six children with DS and compared to 92 non-DS children.,Vincristine,TREATS,Down Syndrome
18615507,"Thus, we found no rationale for dose reduction of vincristine in DS children from a strictly pharmacokinetic point of view.",Vincristine,TREATS,Child
18615507,"Thus, we found no rationale for dose reduction of vincristine in DS children from a strictly pharmacokinetic point of view.",Vincristine,TREATS,Down Syndrome
18615507,"Thus, we found no rationale for dose reduction of vincristine in DS children from a strictly pharmacokinetic point of view.",Down Syndrome,PROCESS_OF,Child
18711187,Five of seven patients with T-cell ALL (T-ALL) failed to achieve CR2.,Acute T Cell Leukemia,PROCESS_OF,Patients
18711187,Five of seven patients with T-cell ALL (T-ALL) failed to achieve CR2.,Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
18800262,We reviewed our 20-year experience with infant acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
18800262,Infant acute lymphoblastic leukemia: a 20-year children's hospital experience.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19061007,"INTRODUCTION: Methotrexate, a folate antagonist, is a mainstay treatment for childhood acute lymphoblastic leukemia.",Folic Acid Antagonists,ISA,Therapeutic procedure
19061007,"INTRODUCTION: Methotrexate, a folate antagonist, is a mainstay treatment for childhood acute lymphoblastic leukemia.",Folic Acid Antagonists,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19061007,"INTRODUCTION: Methotrexate, a folate antagonist, is a mainstay treatment for childhood acute lymphoblastic leukemia.",Methotrexate,ISA,Folic Acid Antagonists
19061007,"INTRODUCTION: Methotrexate, a folate antagonist, is a mainstay treatment for childhood acute lymphoblastic leukemia.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19148140,DPB1(*)0601 is significantly over-transmitted (76.9%) from parents to children with BCP ALL (OR; CI: 4.7; 1.01-22.2).,parent,LOCATION_OF,HLA-DPB1
19148140,DPB1(*)0601 is significantly over-transmitted (76.9%) from parents to children with BCP ALL (OR; CI: 4.7; 1.01-22.2).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
19158828,We analysed and compared MRD levels quantified by BCR/ABL transcript detection and by the standard Ig/TCR-based method in 218 bone marrow specimens from 17 children with BCR/ABL-positive ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19158828,We analysed and compared MRD levels quantified by BCR/ABL transcript detection and by the standard Ig/TCR-based method in 218 bone marrow specimens from 17 children with BCR/ABL-positive ALL.,Bone marrow specimen,LOCATION_OF,T-Cell Receptor
19158828,We analysed and compared MRD levels quantified by BCR/ABL transcript detection and by the standard Ig/TCR-based method in 218 bone marrow specimens from 17 children with BCR/ABL-positive ALL.,Child,LOCATION_OF,T-Cell Receptor
19839053,"The Australian Study of Causes of Acute Lymphoblastic Leukemia in Children (Aus-ALL) was designed to test the hypothesis, raised by a previous Western Australian study, that maternal folic acid supplementation during pregnancy might reduce the risk of childhood acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19839053,"The Australian Study of Causes of Acute Lymphoblastic Leukemia in Children (Aus-ALL) was designed to test the hypothesis, raised by a previous Western Australian study, that maternal folic acid supplementation during pregnancy might reduce the risk of childhood acute lymphoblastic leukemia (ALL).",Folic acid supplementation,PREVENTS,"Leukemia, Lymphocytic, Acute, L1"
19923983,"Methotrexate is a key drug in acute lymphoblastic leukemia (ALL) treatment; it inhibits DNA replication by blocking the conversion of 5,10 methylene tetrahydrofolate to 5-methylene tetrahydrofolate by methylene tetrahydrofolate reductase (MTHFR).",Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute"
19923983,MTHFR TT genotype is significantly associated with increased mucosal and hepatic toxicity during methotrexate therapy as well as increased relapse rate in childhood ALL.,Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
19923983,"Methotrexate is a key drug in acute lymphoblastic leukemia (ALL) treatment; it inhibits DNA replication by blocking the conversion of 5,10 methylene tetrahydrofolate to 5-methylene tetrahydrofolate by methylene tetrahydrofolate reductase (MTHFR).",Methotrexate,ISA,Pharmaceutical Preparations
19923983,MTHFR TT genotype is significantly associated with increased mucosal and hepatic toxicity during methotrexate therapy as well as increased relapse rate in childhood ALL.,Hepatic,LOCATION_OF,Toxic effect
19923983,"Methotrexate is a key drug in acute lymphoblastic leukemia (ALL) treatment; it inhibits DNA replication by blocking the conversion of 5,10 methylene tetrahydrofolate to 5-methylene tetrahydrofolate by methylene tetrahydrofolate reductase (MTHFR).",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
19923983,MTHFR TT genotype is significantly associated with increased mucosal and hepatic toxicity during methotrexate therapy as well as increased relapse rate in childhood ALL.,Therapeutic procedure,USES,Methotrexate
19923983,Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.,Child,LOCATION_OF,MTHFR gene | MTHFR
19923983,MTHFR TT genotype is significantly associated with increased mucosal and hepatic toxicity during methotrexate therapy as well as increased relapse rate in childhood ALL.,Methotrexate,ISA,Therapeutic procedure
19923983,Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19923983,The present study aimed to assess the prevalence of MTHFR polymorphisms C677>T and A1298>C in Egyptian children with ALL and the relation to the frequency of drug-induced complications and relapse rate.,Child,LOCATION_OF,Methylenetetrahydrofolate reductase (NADPH)
19923983,The present study aimed to assess the prevalence of MTHFR polymorphisms C677>T and A1298>C in Egyptian children with ALL and the relation to the frequency of drug-induced complications and relapse rate.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19923983,"Because of the relatively high prevalence of the TT genotype in the studied Egyptian children with ALL, MTHFR gene polymorphisms should be studied in large multicenter studies; and dosage modification of methotrexate in the ALL treatment protocols should be considered based on the MTHFR gene pattern.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19965625,We determined the methylation levels of 1320 CpG sites in regulatory regions of 416 genes in cells from 401 children diagnosed with ALL.,"Regulatory Sequences, Nucleic Acid",PART_OF,Genes
19965625,We determined the methylation levels of 1320 CpG sites in regulatory regions of 416 genes in cells from 401 children diagnosed with ALL.,Cells,LOCATION_OF,Genes
19965625,We determined the methylation levels of 1320 CpG sites in regulatory regions of 416 genes in cells from 401 children diagnosed with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21531684,"PURPOSE/OBJECTIVES: To clarify the concept of adherence to daily oral chemotherapy in children with acute lymphoblastic leukemia (ALL), to examine its implications for clinical practice, and to provide a foundation for further research and knowledge development.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21531684,"PURPOSE/OBJECTIVES: To clarify the concept of adherence to daily oral chemotherapy in children with acute lymphoblastic leukemia (ALL), to examine its implications for clinical practice, and to provide a foundation for further research and knowledge development.",Oral chemotherapy,TREATS,Child
21531684,"PURPOSE/OBJECTIVES: To clarify the concept of adherence to daily oral chemotherapy in children with acute lymphoblastic leukemia (ALL), to examine its implications for clinical practice, and to provide a foundation for further research and knowledge development.",Oral chemotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
21531684,"IMPLICATIONS FOR NURSING: Nurses should recognize the importance of clear communication of medication instructions, reinforcement of adherence-related behaviors, and assistance with common issues such as pill-swallowing skills and reminder systems in caring for children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18194100,Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy.,Erythema Infectiosum,PROCESS_OF,Child
18194100,"CONCLUSIONS: Children with ALL who were infected with parvovirus B19 became cytopenic, leading to reduced treatment intensity and to complications during treatment.","Leukemia, Lymphocytic, Acute",PART_OF,"Parvovirus B19, Human"
18194100,"RESULTS: Among the 117 children with ALL, 18 (15%) were found to be parvovirus B19 DNA positive.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18194100,METHODS: Consecutive bone marrow samples were collected from 117 children with ALL and were analyzed for parvovirus B19 DNA by polymerase chain reaction.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18194100,"We evaluated the complications of parvovirus B19 infection, including delays in the scheduled course of chemotherapy, in children with acute lymphoblastic leukemia (ALL).",Erythema Infectiosum,PROCESS_OF,Child
18194100,"We evaluated the complications of parvovirus B19 infection, including delays in the scheduled course of chemotherapy, in children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18194100,Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18194100,"CONCLUSIONS: Children with ALL who were infected with parvovirus B19 became cytopenic, leading to reduced treatment intensity and to complications during treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19437898,PATIENTS AND METHODS: We studied 60 children with acute lymphoblastic leukemia at a mean age of 5 +/- 0.5 years between February 2002 and October 2007.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19594068,"OUTLINE OF CASES: From 2002 until January 2008, 32 children with ALL were diagnosed and treated at the Children's Hospital in Nis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19594068,[Neurotoxicity during induction treatment of childhood acute lymphoblastic leukaemia--two case reports].,Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19760767,"CONCLUSIONS: Thus, FC with preset uniform gating at day 15 predicts PCR-detectable MRD in B precursor ALL.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
19760767,"CONCLUSIONS: Thus, FC with preset uniform gating at day 15 predicts PCR-detectable MRD in B precursor ALL.",Flow Cytometry,DIAGNOSES,"Neoplasm, Residual"
19813250,"BACKGROUND: Children with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) after induction therapy (induction failure: IF) have a poor prognosis; however, there have been few prospective studies in patients with IF.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19813250,"BACKGROUND: Children with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) after induction therapy (induction failure: IF) have a poor prognosis; however, there have been few prospective studies in patients with IF.",Prognosis bad,PROCESS_OF,Child
19941740,METHODS: MDM-2 expression by flow cytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of 46 ALL children (at initial diagnosis) and control group.,Bone Marrow,PART_OF,Child
19941740,METHODS: MDM-2 expression by flow cytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of 46 ALL children (at initial diagnosis) and control group.,Polymerase Chain Reaction,METHOD_OF,Flow Cytometry
19941740,METHODS: MDM-2 expression by flow cytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of 46 ALL children (at initial diagnosis) and control group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19941740,AIM: Determination of frequency and prognostic significance of murine double minute protein-2 (MDM-2) over expression and its association with p53 status in children with acute lymphoblastic leukemia (ALL).,TP53 gene | TP53,PART_OF,Child
19941740,METHODS: MDM-2 expression by flow cytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of 46 ALL children (at initial diagnosis) and control group.,peripheral blood,PART_OF,Control Groups
19941740,AIM: Determination of frequency and prognostic significance of murine double minute protein-2 (MDM-2) over expression and its association with p53 status in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19941740,METHODS: MDM-2 expression by flow cytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of 46 ALL children (at initial diagnosis) and control group.,peripheral blood,PART_OF,Child
19941740,AIM: Determination of frequency and prognostic significance of murine double minute protein-2 (MDM-2) over expression and its association with p53 status in children with acute lymphoblastic leukemia (ALL).,TP53 gene | TP53,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
19941740,METHODS: MDM-2 expression by flow cytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of 46 ALL children (at initial diagnosis) and control group.,Bone Marrow,PART_OF,Control Groups
20435142,We previously defined a list of GC-regulated genes by expression profiling in children with acute lymphoblastic leukemia (ALL) during systemic GC monotherapy and in experimental systems of GC-induced apoptosis.,Child,LOCATION_OF,GC gene | GC
20435142,We previously defined a list of GC-regulated genes by expression profiling in children with acute lymphoblastic leukemia (ALL) during systemic GC monotherapy and in experimental systems of GC-induced apoptosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20535816,Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20535816,Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.,"Neoplasm, Residual",COEXISTS_WITH,leukemia
20535816,The ALL2000 study was performed to evaluate the efficacy of augmented chemotherapy based on MRD-restratification in childhood ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20734402,We describe a patient diagnosed with haemolytic uraemic syndrome (HUS) during long-term maintenance therapy for childhood acute lymphoblastic leukaemia (ALL).,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20734402,We describe a patient diagnosed with haemolytic uraemic syndrome (HUS) during long-term maintenance therapy for childhood acute lymphoblastic leukaemia (ALL).,Hemolytic-Uremic Syndrome,PROCESS_OF,Patients
20843128,Through a case-control study 300 children aged 1-18 years with confirmed ALL were selected from all referral teaching centers for cancer.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20979094,"The 5-year event-free survival (EFS) in infant ALL and AML showed no difference (18% vs. 12%, respectively).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
20979094,"Acute lymphoblastic leukemia (ALL) was diagnosed in 23 infants, acute myeloid leukemia (AML) in 21 (including TMD in 4), and juvenile myelomonocytic leukemia (JMML) in 1.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
21239764,Minimal residual disease in acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
18445843,PURPOSE: To prospectively determine the prognostic significance of the TEL-AML1 fusion in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18554450,OBJECTIVE: To study the prognostic factors for events-free survival (EFS) in children with acute non-mature B-lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18554462,"METHODS: MRD testing was performed in 124 children with B-cell ALL, who were newly diagnosed and enrolled in the ALL-XH-99 treatment protocol from September 2001 to April 2005MRD was determined by 4-color flow cytometry in the different time points during the treatment period.",Flow Cytometry,METHOD_OF,Treatment Protocols
18554462,CONCLUSIONS: The MRD level in the whole course of therapy is an important outcome indicator in childhood B cell ALL.,"Neoplasm, Residual",COEXISTS_WITH,B-cell childhood acute lymphoblastic leukemia
18554462,"METHODS: MRD testing was performed in 124 children with B-cell ALL, who were newly diagnosed and enrolled in the ALL-XH-99 treatment protocol from September 2001 to April 2005MRD was determined by 4-color flow cytometry in the different time points during the treatment period.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
18940822,"In this review, the previously reported day-care results have been described, showing that in non-Hispanic White children, children in the highest category of total child-hours of exposure had a reduced risk of acute lymphoblastic leukaemia (ALL), particularly common B-cell precursor ALL (c-ALL), compared with children without such exposures, with evidence of a dose-response effect.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
18940822,"In this review, the previously reported day-care results have been described, showing that in non-Hispanic White children, children in the highest category of total child-hours of exposure had a reduced risk of acute lymphoblastic leukaemia (ALL), particularly common B-cell precursor ALL (c-ALL), compared with children without such exposures, with evidence of a dose-response effect.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
19298590,Aminopterin (AMT) has been suggested to provide clinical advantages over MTX and other antifolates.,Methotrexate,ISA,Folic Acid Antagonists
19298590,Aminopterin (AMT) has been suggested to provide clinical advantages over MTX and other antifolates.,Folic Acid Antagonists,ISA,Methotrexate
19298590,"Due to the development of neurological toxicity and resistance to methotrexate (MTX), other antifolates have been evaluated for its potential replacement in the treatment of childhood acute lymphoblastic leukaemia (ALL).",Folic Acid Antagonists,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19785064,"As ALL is still among the leading causes of death from disease in children aged one to 15 years, further improvement of childhood ALL therapy is urgently needed.","Leukemia, Lymphocytic, Acute",ISA,Disease
19785064,"As ALL is still among the leading causes of death from disease in children aged one to 15 years, further improvement of childhood ALL therapy is urgently needed.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19785064,"Childhood acute lymphoblastic leukemia (ALL) is the classic example for a drug-responsive malignancy, and contemporary risk-directed therapies cure more than 80% of children with ALL in industrialized countries.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19785064,"Childhood acute lymphoblastic leukemia (ALL) is the classic example for a drug-responsive malignancy, and contemporary risk-directed therapies cure more than 80% of children with ALL in industrialized countries.","Leukemia, Lymphocytic, Acute, L1",ISA,Malignant Neoplasms
19785064,"As ALL is still among the leading causes of death from disease in children aged one to 15 years, further improvement of childhood ALL therapy is urgently needed.",Disease,PROCESS_OF,Child
20113840,"Here, we describe clinical and molecular cytogenetic findings in a child with ALL who had a near-triploid complex karyotype, with loss and gain of chromosomes, including extra copies of the same derivative chromosomes.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20113840,"High hyperdiploidy with modal chromosome numbers between 50 and 65 is common in childhood acute lymphoblastic leukemia (ALL), occurring in 25-30% of the cases.",Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20113840,Molecular cytogenetic studies characterize a near-triploid complex karyotype in a child with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20712542,"DESIGN, SETTING AND PARTICIPANTS: Population-based study of all Australian children (aged 0-14 years), adolescents (15-19 years) and young adults (20-29 years) diagnosed with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) between 1982 and 2004, with follow-up to 2006.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
20712542,"DESIGN, SETTING AND PARTICIPANTS: Population-based study of all Australian children (aged 0-14 years), adolescents (15-19 years) and young adults (20-29 years) diagnosed with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) between 1982 and 2004, with follow-up to 2006.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
20712542,"DESIGN, SETTING AND PARTICIPANTS: Population-based study of all Australian children (aged 0-14 years), adolescents (15-19 years) and young adults (20-29 years) diagnosed with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) between 1982 and 2004, with follow-up to 2006.",AUSTRALIAN,PROCESS_OF,Child
20979094,The only independent predictor of an adverse prognosis among infants diagnosed with ALL was high presenting white count >= 100 * 10(9)/l (P = 0.05).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
21271777,A protocol including agents used for acute myeloid leukemia combined with those for ALL is seemingly effective for treatment of MNKPL.,"Leukemia, Lymphocytic, Acute",COEXISTS_WITH,"Leukemia, Myelocytic, Acute"
21271777,A protocol including agents used for acute myeloid leukemia combined with those for ALL is seemingly effective for treatment of MNKPL.,Agent,TREATS,"Leukemia, Myelocytic, Acute"
21586621,CONCLUSIONS: Our study suggests that polymorphisms in CYP1A1 may contribute to the increased risk of ALL in Hispanic children due to both their impact on leukemia susceptibility and the increased prevalence of the at-risk alleles in the Hispanic population.,CYP1A1 gene | CYP1A1,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
21586621,"Surveillance Epidemiology and End Results (SEER) registry reports that Hispanic children have the highest incidence of ALL, however, it is unclear if this is due to genetic factors, unique environmental exposures, or both.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21586621,Polymorphisms in CYP1A1 and ethnic-specific susceptibility to acute lymphoblastic leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21586621,CONCLUSIONS: Our study suggests that polymorphisms in CYP1A1 may contribute to the increased risk of ALL in Hispanic children due to both their impact on leukemia susceptibility and the increased prevalence of the at-risk alleles in the Hispanic population.,leukemia,PROCESS_OF,Hispanics
21586621,CONCLUSIONS: Our study suggests that polymorphisms in CYP1A1 may contribute to the increased risk of ALL in Hispanic children due to both their impact on leukemia susceptibility and the increased prevalence of the at-risk alleles in the Hispanic population.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21701407,We report follow-up data in a cohort of 10 children with acute lymphoblastic leukaemia and 6-TG-related hepatotoxicity described initially in 2006.,Hepatotoxicity,PROCESS_OF,Child
21701407,We report follow-up data in a cohort of 10 children with acute lymphoblastic leukaemia and 6-TG-related hepatotoxicity described initially in 2006.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18802149,PATIENTS AND METHODS: Gene expression profiles were generated from bone marrow blasts at initial diagnosis from a cohort of 99 children with National Cancer Institute-defined high-risk ALL who were treated uniformly on the Children's Oncology Group (COG) 1961 study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18802149,PURPOSE: To identify children with acute lymphoblastic leukemia (ALL) at initial diagnosis who are at risk for inferior response to therapy by using molecular signatures.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19017727,Systematic enrollment of children and adolescents with acute lymphoblastic leukaemia (ALL) into clinical trials has allowed the establishment of prognostic parameters derived from initial diagnostic findings.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19017727,"Some problems that are related to the specificity of the parameters used for risk assessment were not overcome: high tumour load by white blood cell count (WBC), age and (rare) cytogenetic subtypes (e.g. t9;22) may characterise a significant proportion of children and adolescents with high-risk ALL.",White Blood Cell Count procedure,METHOD_OF,Tumor Burden
19017727,"Some problems that are related to the specificity of the parameters used for risk assessment were not overcome: high tumour load by white blood cell count (WBC), age and (rare) cytogenetic subtypes (e.g. t9;22) may characterise a significant proportion of children and adolescents with high-risk ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
19017727,"Some problems that are related to the specificity of the parameters used for risk assessment were not overcome: high tumour load by white blood cell count (WBC), age and (rare) cytogenetic subtypes (e.g. t9;22) may characterise a significant proportion of children and adolescents with high-risk ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19224761,This study indicates that the duration and intensity of 6MP/MTX maintenance therapy of childhood ALL may influence the risk of SMNs in childhood ALL.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19224761,"Among 1614 children with acute lymphoblastic leukemia (ALL) treated with the Nordic Society for Paediatric Haematology and Oncology (NOPHO) ALL-92 protocol, 20 patients developed a second malignant neoplasm (SMN) with a cumulative risk of 1.6% at 12 years from the diagnosis of ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19224761,"Among 1614 children with acute lymphoblastic leukemia (ALL) treated with the Nordic Society for Paediatric Haematology and Oncology (NOPHO) ALL-92 protocol, 20 patients developed a second malignant neoplasm (SMN) with a cumulative risk of 1.6% at 12 years from the diagnosis of ALL.",Second Primary Cancers,PROCESS_OF,Patients
19285277,Acute lymphoblastic leukaemia (ALL) is the most common malignancy associated with venous thromboembolism (VTE) in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19285277,Acute lymphoblastic leukaemia (ALL) is the most common malignancy associated with venous thromboembolism (VTE) in children.,Thromboembolism,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
19285277,Acute lymphoblastic leukaemia (ALL) is the most common malignancy associated with venous thromboembolism (VTE) in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
19317599,"To determine the influence of the MDR1 C3435T polymorphism on the development of childhood acute lymphoblastic leukemia (ALL), we studied 107 children with ALL and 111 healthy subjects.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19317599,MDR1 C3435T polymorphism in Mexican children with acute lymphoblastic leukemia and in healthy individuals.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Individual
19317599,MDR1 C3435T polymorphism in Mexican children with acute lymphoblastic leukemia and in healthy individuals.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19785064,Results from recent pharmacogenomic investigations in children with ALL hold promise to improve ALL therapy in the near future; and can serve as a model to improve drug therapy in other malignancies as well.,Pharmacotherapy,TREATS,Malignant Neoplasms
19785064,Results from recent pharmacogenomic investigations in children with ALL hold promise to improve ALL therapy in the near future; and can serve as a model to improve drug therapy in other malignancies as well.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19850641,"Acute lymphoblastic leukaemia (ALL) survivors treated with cranial irradiation had an increased risk of developing the metabolic syndrome compared with ALL survivors not treated with cranial irradiation (23% versus 7%, P = 0.011), probably determined by higher prevalence of overweight and hypertension.",Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute"
19850641,"Acute lymphoblastic leukaemia (ALL) survivors treated with cranial irradiation had an increased risk of developing the metabolic syndrome compared with ALL survivors not treated with cranial irradiation (23% versus 7%, P = 0.011), probably determined by higher prevalence of overweight and hypertension.",Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute"
19850641,"Acute lymphoblastic leukaemia (ALL) survivors treated with cranial irradiation had an increased risk of developing the metabolic syndrome compared with ALL survivors not treated with cranial irradiation (23% versus 7%, P = 0.011), probably determined by higher prevalence of overweight and hypertension.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
19850641,"Acute lymphoblastic leukaemia (ALL) survivors treated with cranial irradiation had an increased risk of developing the metabolic syndrome compared with ALL survivors not treated with cranial irradiation (23% versus 7%, P = 0.011), probably determined by higher prevalence of overweight and hypertension.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
19850641,"Acute lymphoblastic leukaemia (ALL) survivors treated with cranial irradiation had an increased risk of developing the metabolic syndrome compared with ALL survivors not treated with cranial irradiation (23% versus 7%, P = 0.011), probably determined by higher prevalence of overweight and hypertension.",Cranial Irradiation,TREATS,Survivors
19850641,"Acute lymphoblastic leukaemia (ALL) survivors treated with cranial irradiation had an increased risk of developing the metabolic syndrome compared with ALL survivors not treated with cranial irradiation (23% versus 7%, P = 0.011), probably determined by higher prevalence of overweight and hypertension.",Cranial Irradiation,TREATS,Survivors
19850641,"Acute lymphoblastic leukaemia (ALL) survivors treated with cranial irradiation had an increased risk of developing the metabolic syndrome compared with ALL survivors not treated with cranial irradiation (23% versus 7%, P = 0.011), probably determined by higher prevalence of overweight and hypertension.",Cranial Irradiation,compared_with,Cranial Irradiation
20067466,"Glucocorticoids play a crucial role in the treatment of childhood acute lymphoblastic leukemia, therefore we hypothesized that GSTM1 plays important roles in glucocorticoid-induced apoptotic pathways.",Glutathione Transferase mu,AFFECTS,Apoptosis
20067466,"Glucocorticoids play a crucial role in the treatment of childhood acute lymphoblastic leukemia, therefore we hypothesized that GSTM1 plays important roles in glucocorticoid-induced apoptotic pathways.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20460642,"Although childhood acute lymphoblastic leukemia is the most common pediatric cancer, its etiology remains poorly understood.","Leukemia, Lymphocytic, Acute, L1",ISA,Malignant Childhood Neoplasm
20669630,"In rich countries, the overall survival rate among children with acute lymphoblastic leukaemia now reaches 85 to 90%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20669632,[Towards cure for all children with acute lymphoblastic leukemia?].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20701601,"Here we review the current diagnostic criteria of genetic abnormalities in precursor B-ALL (BCP-ALL), including the relevant technical approaches and the application of the most appropriate methods for the detection of each abnormality.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
20701601,"Here we review the current diagnostic criteria of genetic abnormalities in precursor B-ALL (BCP-ALL), including the relevant technical approaches and the application of the most appropriate methods for the detection of each abnormality.",Application procedure,METHOD_OF,Detection
21574100,Activation of NF-KB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: relation to other prognostic factors.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21574100,Activation of NF-KB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: relation to other prognostic factors.,Therapeutic procedure,USES,Prednisone
21574100,Activation of NF-KB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: relation to other prognostic factors.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
21574100,Activation of NF-KB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: relation to other prognostic factors.,Prednisone,ISA,Therapeutic procedure
21574100,Activation of NF-KB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: relation to other prognostic factors.,Prednisone,TREATS,Child
21574100,Increased activation of NF-KB may be responsible for treatment failure in children with acute lymphoblastic leukaemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21574100,Activation of NF-KB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: relation to other prognostic factors.,Therapeutic procedure,TREATS,Child
18194413,OBJECTIVE: To determine the incidence of post-thrombotic syndrome (PTS) in (i) children with ALL diagnosed with asymptomatic DVT using radiographic testing and (ii) an unselected group of ALL survivors.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
18194413,BACKGROUND: Deep vein thrombosis (DVT) is a complication of treatment of acute lymphoblastic leukemia (ALL) in children but little is known about the long-term outcomes of these DVT.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18194413,Group I comprised children in the Prophylactic Antithrombin Replacement in Kids with ALL treated with L-Asparaginase (PARKAA) study diagnosed with DVT by radiographic tests.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Offspring
18194413,Group I comprised children in the Prophylactic Antithrombin Replacement in Kids with ALL treated with L-Asparaginase (PARKAA) study diagnosed with DVT by radiographic tests.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
18194413,Group I comprised children in the Prophylactic Antithrombin Replacement in Kids with ALL treated with L-Asparaginase (PARKAA) study diagnosed with DVT by radiographic tests.,Deep Vein Thrombosis,PROCESS_OF,Offspring
18194413,OBJECTIVE: To determine the incidence of post-thrombotic syndrome (PTS) in (i) children with ALL diagnosed with asymptomatic DVT using radiographic testing and (ii) an unselected group of ALL survivors.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18194413,OBJECTIVE: To determine the incidence of post-thrombotic syndrome (PTS) in (i) children with ALL diagnosed with asymptomatic DVT using radiographic testing and (ii) an unselected group of ALL survivors.,Deep Vein Thrombosis,PROCESS_OF,Child
18376281,B-cell precursor ALL was the major contributor to peak age; T lineage ALL showed a peak among 1 and 3 years of age.,"Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
18376281,"The frequency of B-cell precursor ALL was 76.1%, whereas T lineage ALL showed a frequency of 23.6%.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
18768390,"In an independent cohort of children with ALL, reduced expression of MSH6 was associated with resistance to mercaptopurine and prednisone, thereby providing a plausible mechanism by which this acquired deletion contributes to drug resistance at relapse.",Prednisone,AFFECTS,Drug resistance
18768390,"In an independent cohort of children with ALL, reduced expression of MSH6 was associated with resistance to mercaptopurine and prednisone, thereby providing a plausible mechanism by which this acquired deletion contributes to drug resistance at relapse.",6-Mercaptopurine,AFFECTS,Drug resistance
18768390,"In an independent cohort of children with ALL, reduced expression of MSH6 was associated with resistance to mercaptopurine and prednisone, thereby providing a plausible mechanism by which this acquired deletion contributes to drug resistance at relapse.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19206004,The present study provides an informative profile of the expression of miRNAs in pre-B-ALL using two independent and quantitative methods: miRNA chip and qRT-PCR of mature miRNA from 40 newly diagnosed pre-B-ALL children.,MicroRNAs,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
19206004,The present study provides an informative profile of the expression of miRNAs in pre-B-ALL using two independent and quantitative methods: miRNA chip and qRT-PCR of mature miRNA from 40 newly diagnosed pre-B-ALL children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19322206,"A standardized, sensitive and universal method for minimal residual disease (MRD) detection in acute myeloid leukemia (AML) is still pending.",Detection,TREATS,"Leukemia, Myelocytic, Acute"
19478700,MATERIAL/METHODS: The study comprised 43 children with de novo ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19676052,"Importantly, XIAP inhibitors sensitize primary leukemic blasts from children with ALL for MegaFasL-induced apoptosis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21067287,Previous epidemiologic studies showed four times increased risk of acute lymphoblastic leukemia (ALL) in children of women with multiple sclerosis (MS).,Multiple Sclerosis,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
21067287,Previous epidemiologic studies showed four times increased risk of acute lymphoblastic leukemia (ALL) in children of women with multiple sclerosis (MS).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21152005,Methotrexate (MTX) is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Therapeutic procedure
21152005,Methotrexate (MTX) is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21574100,The association of higher activation of NF-KB with an elevated initial WBC count suggests that activation of NF-KB may be responsible for treatment failure in children with ALL.,White blood cell count increased,PROCESS_OF,Child
21574100,The association of higher activation of NF-KB with an elevated initial WBC count suggests that activation of NF-KB may be responsible for treatment failure in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21574100,The study comprised 55 children with de novo ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21738539,"However, it is classified as a high or very high risk, and only 20-30% of Philadelphia chromosome-positive (Ph+) children with ALL are cured with chemotherapy alone.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
21738539,"Because Ph+ ALL is rare in children, the question of whether HSCT could be a dispensable part of their therapy may not be answered for some time.",Hematopoietic Stem Cell Transplantation,ISA,Therapeutic procedure
21738539,Reports on the use of second-generation TKIs in children with Ph+ ALL are limited.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21738539,Recent data suggest that chemotherapy plus tyrosine kinase inhibitors (TKIs) may be the initial treatment of choice for Ph+ ALL in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21738539,Recent data suggest that chemotherapy plus tyrosine kinase inhibitors (TKIs) may be the initial treatment of choice for Ph+ ALL in children.,Protein-tyrosine kinase inhibitor,TREATS,"Leukemia, Lymphocytic, Acute"
21738539,An international multicenter study is needed to answer the question of whether imatinib plus chemotherapy could replace sibling allogeneic HSCT in children with Ph+ ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21738539,An international multicenter study is needed to answer the question of whether imatinib plus chemotherapy could replace sibling allogeneic HSCT in children with Ph+ ALL.,Hematopoietic Stem Cell Transplantation,TREATS,Child
21738539,"However, it is classified as a high or very high risk, and only 20-30% of Philadelphia chromosome-positive (Ph+) children with ALL are cured with chemotherapy alone.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21738539,An international multicenter study is needed to answer the question of whether imatinib plus chemotherapy could replace sibling allogeneic HSCT in children with Ph+ ALL.,Hematopoietic Stem Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
21738539,"However, it is classified as a high or very high risk, and only 20-30% of Philadelphia chromosome-positive (Ph+) children with ALL are cured with chemotherapy alone.",Pharmacotherapy,TREATS,Child
21738539,"Because Ph+ ALL is rare in children, the question of whether HSCT could be a dispensable part of their therapy may not be answered for some time.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18071690,MR features of isolated uterine relapse in an adolescent with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
18376281,We conclude that the age peak for children with ALL in MC is within the ranges reported for developed countries and that B-cell precursor ALL is the main contributor to these peak.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18376281,We conclude that the age peak for children with ALL in MC is within the ranges reported for developed countries and that B-cell precursor ALL is the main contributor to these peak.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
18989157,"RESULTS: Parents in the complicated cancer category showed significantly heightened disease-related fear, anxiety, depression, loss of control, late effects-related uncertainty, and poorer self-esteem compared with parents of children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18989157,Parental distress in that category (n=144) was compared with distress after acute lymphoblastic leukemia (n=177) in the child.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19147312,Dental maturity assessment in children with acute lymphoblastic leukemia after cancer therapy.,Assessment procedure,TREATS,Child
19147312,Dental maturity assessment in children with acute lymphoblastic leukemia after cancer therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20113651,"METHODS: nm23-H(1) expression was measured by semiquantitative RT-PCR in children with ALL (newly diagnosed, n = 40; remission, n = 32; relapse, n = 16; refractory, n = 3).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20113651,A higher expression of nm23-H(1) in children with T-ALL may be contributed to a low remission rate and a poor prognosis.,Prognosis bad,PROCESS_OF,Child
20113651,OBJECTIVE: To study the expression of nm23-H(1) gene in children with acute lymphoblastic leukemia (ALL) and the relationship between nm23-H(1) expression and immunophenotype.,Child,LOCATION_OF,Genes
20113651,A higher expression of nm23-H(1) in children with T-ALL may be contributed to a low remission rate and a poor prognosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20113651,OBJECTIVE: To study the expression of nm23-H(1) gene in children with acute lymphoblastic leukemia (ALL) and the relationship between nm23-H(1) expression and immunophenotype.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20113651,"Newly diagnosed, relapsed and refractory ALL children have higher nm23-H(1) expression.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20113651,Both the positive rate and expression of nm23-H(1) in children with T-lineage ALL were higher than in children with B-lineage ALL (p<0.05).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20113651,Both the positive rate and expression of nm23-H(1) in children with T-lineage ALL were higher than in children with B-lineage ALL (p<0.05).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20113651,The three children with refractory ALL had higher nm23-H(1) expression.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20364408,"Although we did not observe the differences in single nucleotide polymorphisms (SNPs) in MUTYH and XRCC1 genes between control group and children with ALL, we have shown that the combined genotypes of examined genes can modulate the risk of childhood ALL in Polish population.",XRCC1 gene | XRCC1,PREDISPOSES,"Leukemia, Lymphocytic, Acute, L1"
20364408,"Although we did not observe the differences in single nucleotide polymorphisms (SNPs) in MUTYH and XRCC1 genes between control group and children with ALL, we have shown that the combined genotypes of examined genes can modulate the risk of childhood ALL in Polish population.",MUTYH,PREDISPOSES,"Leukemia, Lymphocytic, Acute, L1"
20364408,"Although we did not observe the differences in single nucleotide polymorphisms (SNPs) in MUTYH and XRCC1 genes between control group and children with ALL, we have shown that the combined genotypes of examined genes can modulate the risk of childhood ALL in Polish population.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Control Groups
20364408,"Although we did not observe the differences in single nucleotide polymorphisms (SNPs) in MUTYH and XRCC1 genes between control group and children with ALL, we have shown that the combined genotypes of examined genes can modulate the risk of childhood ALL in Polish population.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20364408,"Although we did not observe the differences in single nucleotide polymorphisms (SNPs) in MUTYH and XRCC1 genes between control group and children with ALL, we have shown that the combined genotypes of examined genes can modulate the risk of childhood ALL in Polish population.",Single Nucleotide Polymorphism,COEXISTS_WITH,MUTYH
20364408,"Although we did not observe the differences in single nucleotide polymorphisms (SNPs) in MUTYH and XRCC1 genes between control group and children with ALL, we have shown that the combined genotypes of examined genes can modulate the risk of childhood ALL in Polish population.",Single Nucleotide Polymorphism,COEXISTS_WITH,XRCC1 gene | XRCC1
20364408,We have demonstrated that the OGG1 Cys/Cys genotype increases the risk of ALL (OR 5.36) whereas the Ser/Ser genotype variant strongly reduces the risk of this cancer among Polish children (OR 0.45).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20364408,"Although we did not observe the differences in single nucleotide polymorphisms (SNPs) in MUTYH and XRCC1 genes between control group and children with ALL, we have shown that the combined genotypes of examined genes can modulate the risk of childhood ALL in Polish population.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Polish population
20364408,We have demonstrated that the OGG1 Cys/Cys genotype increases the risk of ALL (OR 5.36) whereas the Ser/Ser genotype variant strongly reduces the risk of this cancer among Polish children (OR 0.45).,cysteinylcysteine,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
21116279,MLL-rearranged acute lymphoblastic leukemia (ALL) in infants (<1 year) is the most aggressive type of childhood leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
21116279,Our data suggests that inhibitors of methylation have a potential beyond re-expression of hypermethylated protein-coding genes in t(4;11)-positive infant ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
21116279,We identified 11 miRNAs that were downregulated in t(4;11)-positive infant ALL as a consequence of CpG hypermethylation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
21116279,We recently showed that t(4;11)-positive infant ALL is also characterized by pronounced promoter CpG hypermethylation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
21258308,Most frequent causes of malignant lymphadenopathy were acute lymphoblastic leukemia in 11 children (55 %) and acute myeloid leukemia in two (10%) children.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
21258308,Most frequent causes of malignant lymphadenopathy were acute lymphoblastic leukemia in 11 children (55 %) and acute myeloid leukemia in two (10%) children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18416598,"BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be cured in approximately 80% of patients.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
18416598,"BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be cured in approximately 80% of patients.","Leukemia, Lymphocytic, Acute, L1",ISA,Malignant Neoplasms
18416598,"CONCLUSIONS: Together, these data provide new insights into the genomic basis of MTX resistance and interpatient differences in MTX response, pointing to new strategies to overcome MTX resistance in childhood ALL.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18416598,This finding was validated in an independent cohort of children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18416598,"Nevertheless, drug resistance is the major cause of treatment failure in children with ALL.",Drug resistance,PROCESS_OF,Child
18416598,"Nevertheless, drug resistance is the major cause of treatment failure in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18639340,Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
18639340,In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
18990928,"In Montreal, Canada, children with acute lymphoblastic leukemia did not have drinking-water arsenic more frequently either prenatal or postnatal, and British children with cancer did not have early exposure to environmental sources of airborne arsenic.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18990928,"In Montreal, Canada, children with acute lymphoblastic leukemia did not have drinking-water arsenic more frequently either prenatal or postnatal, and British children with cancer did not have early exposure to environmental sources of airborne arsenic.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18990928,"In Montreal, Canada, children with acute lymphoblastic leukemia did not have drinking-water arsenic more frequently either prenatal or postnatal, and British children with cancer did not have early exposure to environmental sources of airborne arsenic.",Malignant Neoplasms,PROCESS_OF,Child
18990928,"In Montreal, Canada, children with acute lymphoblastic leukemia did not have drinking-water arsenic more frequently either prenatal or postnatal, and British children with cancer did not have early exposure to environmental sources of airborne arsenic.",Malignant Neoplasms,PROCESS_OF,Child
20364408,"In conclusion, we suggest that polymorphisms of BER genes may be used as an important predictive factor for acute lymphoblastic leukemia in children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20364408,"In conclusion, we suggest that polymorphisms of BER genes may be used as an important predictive factor for acute lymphoblastic leukemia in children.",Base Excision Repair,AFFECTS,"Leukemia, Lymphocytic, Acute"
20717757,"Although the vast majority of children with acute lymphocytic leukemia attain remission with modern therapies, an unacceptably high number will suffer a disease relapse.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20834190,Determination of intronic 19-bp deletion polymorphisms of DHFR may be useful for monitoring the efficacy and side effects of MTX for the treatment of diseases such as rheumatoid arthritis and childhood acute leukemia in the Japanese population because the frequency of the deletion allele is higher.,Childhood Leukemia,PROCESS_OF,Japanese Population
20834190,Determination of intronic 19-bp deletion polymorphisms of DHFR may be useful for monitoring the efficacy and side effects of MTX for the treatment of diseases such as rheumatoid arthritis and childhood acute leukemia in the Japanese population because the frequency of the deletion allele is higher.,Rheumatoid Arthritis,PROCESS_OF,Japanese Population
20834190,Determination of intronic 19-bp deletion polymorphisms of DHFR may be useful for monitoring the efficacy and side effects of MTX for the treatment of diseases such as rheumatoid arthritis and childhood acute leukemia in the Japanese population because the frequency of the deletion allele is higher.,Methotrexate,TREATS,Disease
20834190,Determination of intronic 19-bp deletion polymorphisms of DHFR may be useful for monitoring the efficacy and side effects of MTX for the treatment of diseases such as rheumatoid arthritis and childhood acute leukemia in the Japanese population because the frequency of the deletion allele is higher.,Methotrexate,TREATS,Childhood Leukemia
20834190,Determination of intronic 19-bp deletion polymorphisms of DHFR may be useful for monitoring the efficacy and side effects of MTX for the treatment of diseases such as rheumatoid arthritis and childhood acute leukemia in the Japanese population because the frequency of the deletion allele is higher.,Childhood Leukemia,ISA,Disease
20834190,Determination of intronic 19-bp deletion polymorphisms of DHFR may be useful for monitoring the efficacy and side effects of MTX for the treatment of diseases such as rheumatoid arthritis and childhood acute leukemia in the Japanese population because the frequency of the deletion allele is higher.,Methotrexate,TREATS,Rheumatoid Arthritis
20834190,Determination of intronic 19-bp deletion polymorphisms of DHFR may be useful for monitoring the efficacy and side effects of MTX for the treatment of diseases such as rheumatoid arthritis and childhood acute leukemia in the Japanese population because the frequency of the deletion allele is higher.,Rheumatoid Arthritis,ISA,Disease
20845994,Acute lymphoblastic leukemia is the most common form of cancer in children.,Malignant Neoplasms,PROCESS_OF,Child
20845994,Acute lymphoblastic leukemia is the most common form of cancer in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
20845994,Acute lymphoblastic leukemia is the most common form of cancer in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21067050,Objective was to see the bone marrow remission pattern at the end of induction therapy in paediatric ALL patients in our setup.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
21067050,Objective was to see the bone marrow remission pattern at the end of induction therapy in paediatric ALL patients in our setup.,Neoadjuvant Therapy,TREATS,Patients
21067050,Objective was to see the bone marrow remission pattern at the end of induction therapy in paediatric ALL patients in our setup.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21342615,[Serum levels of insulin-like growth factor-1 and growth factor binding protein-3 in children with acute lymphocytic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21342615,METHODS: Serum samples were obtained from 36 children with ALL before treatment and 6 months after complete remission.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21342615,OBJECTIVE: To study serum levels and clinical significance of insulin-like growth factor-1 (IGF-1) and growth factor binding protein 3 (IGFBP-3) in children with acute lymphocytic leukemia (ALL).,Child,LOCATION_OF,Binding protein 3
21342615,OBJECTIVE: To study serum levels and clinical significance of insulin-like growth factor-1 (IGF-1) and growth factor binding protein 3 (IGFBP-3) in children with acute lymphocytic leukemia (ALL).,Child,LOCATION_OF,Insulin-Like Growth Factor I
21342615,OBJECTIVE: To study serum levels and clinical significance of insulin-like growth factor-1 (IGF-1) and growth factor binding protein 3 (IGFBP-3) in children with acute lymphocytic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21342615,"CONCLUSIONS: Serum levels of IGF-1 and IGFBP-3 are reduced in children with ALL, but increase significantly after complete remission, suggesting that IGF-1 and IGFBP-3 might serve as useful markers for the diagnosis and evaluation of therapeutic effects of childhood ALL.",Child,LOCATION_OF,Insulin-Like Growth Factor Binding Protein 3
21342615,[Serum levels of insulin-like growth factor-1 and growth factor binding protein-3 in children with acute lymphocytic leukemia].,Child,LOCATION_OF,Binding protein 3
21342615,"CONCLUSIONS: Serum levels of IGF-1 and IGFBP-3 are reduced in children with ALL, but increase significantly after complete remission, suggesting that IGF-1 and IGFBP-3 might serve as useful markers for the diagnosis and evaluation of therapeutic effects of childhood ALL.",Child,LOCATION_OF,Insulin-Like Growth Factor I
21342615,[Serum levels of insulin-like growth factor-1 and growth factor binding protein-3 in children with acute lymphocytic leukemia].,Child,LOCATION_OF,Insulin-Like Growth Factor I
21342615,"CONCLUSIONS: Serum levels of IGF-1 and IGFBP-3 are reduced in children with ALL, but increase significantly after complete remission, suggesting that IGF-1 and IGFBP-3 might serve as useful markers for the diagnosis and evaluation of therapeutic effects of childhood ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21368672,"For the treatment of children with acute lymphoblastic leukemia (ALL), Dutch pediatric oncologists use the Dutch Childhood Oncology Group ALL 10 protocol.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21368672,Erroneous exchange of asparaginase forms in the treatment of acute lymphoblastic leukemia.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
21399528,L-Asparaginase and steroids-associated hypertriglyceridemia successfully treated with plasmapheresis in a child with acute lymphoblastic leukemia.,Plasmapheresis,TREATS,"Leukemia, Lymphocytic, Acute"
21399528,L-Asparaginase and steroids-associated hypertriglyceridemia successfully treated with plasmapheresis in a child with acute lymphoblastic leukemia.,Plasmapheresis,TREATS,Hypertriglyceridemia
21399528,L-Asparaginase and steroids-associated hypertriglyceridemia successfully treated with plasmapheresis in a child with acute lymphoblastic leukemia.,Plasmapheresis,TREATS,Child
21399528,L-Asparaginase and steroids-associated hypertriglyceridemia successfully treated with plasmapheresis in a child with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19117694,"METHODS AND MATERIALS: For this study, 17 patients (6 medulloblastoma, 5 ALL treated with high-dose methotrexate (MTX) (4 x 5 g/m(2)) and 6 with low-dose MTX (3 x 2 g/m(2))) and 17 age-matched controls participated.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
19212332,"We retrospectively analyzed the incidence, pattern and causes of death and its risk factors for 896 children with ALL enrolled into five Austrian (A) Berlin-Frankfurt-Munster (BFM) trials between 1981 and 1999.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19212332,Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Munster study group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19288940,"METHOD: This retrospective review included all newly diagnosed children with acute lymphoblastic Leukaemia less than 15 years of age registered from April 1999 to December 2004 at oncology unit of National Institute of Child Health and Children Cancer Hospital, Karachi.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19288940,"METHOD: This retrospective review included all newly diagnosed children with acute lymphoblastic Leukaemia less than 15 years of age registered from April 1999 to December 2004 at oncology unit of National Institute of Child Health and Children Cancer Hospital, Karachi.",Child,ISA,Health
19377076,"Minimal residual disease detection, used for clinical management of children with acute lymphoblastic leukemia, can be performed by molecular analysis of antigen-receptor gene rearrangements or by flow cytometric analysis of aberrant immunophenotypes.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19377076,"Minimal residual disease detection, used for clinical management of children with acute lymphoblastic leukemia, can be performed by molecular analysis of antigen-receptor gene rearrangements or by flow cytometric analysis of aberrant immunophenotypes.",Molecular Analysis,METHOD_OF,Detection
19377076,Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
19377076,Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.,Flow Cytometry,DIAGNOSES,"Neoplasm, Residual"
19483156,BACKGROUND: Minimal residual disease is an important independent prognostic factor in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
19483156,A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19483156,"CONCLUSIONS: This simplified strategy for detection of minimal residual disease was feasible, reproducible, cheaper and simpler when compared with other methods, and allowed powerful discrimination between children with acute lymphoblastic leukemia with a good and poor outcome.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19483156,DESIGN AND METHODS: We analyzed 229 consecutive children with acute lymphoblastic leukemia treated according to the GBTLI-99 protocol at three different Brazilian centers.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19515727,They were investigated for association with treatment responses in 275 children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19652598,Hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
19652598,Hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia.,Hematopoietic Stem Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
19652598,Hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia.,Hematopoietic Stem Cell Transplantation,TREATS,Adult
19909482,Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children.,Malignant Neoplasms,PROCESS_OF,Child
19909482,Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
19909482,Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20304809,"Thus, low levels of MRD (0.001%-< 0.01%) at the end of remission induction therapy have prognostic significance in childhood ALL, suggesting that patients with this finding should be monitored closely for adverse events.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20304809,"We examined the clinical significance of levels below the usual threshold value for MRD positivity (0.01%) in 455 children with B-lineage ALL, using polymerase chain reaction amplification of antigen-receptor genes capable of detecting at least 1 leukemic cell per 100 000 normal mononucleated cells (0.001%).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20304809,"We examined the clinical significance of levels below the usual threshold value for MRD positivity (0.01%) in 455 children with B-lineage ALL, using polymerase chain reaction amplification of antigen-receptor genes capable of detecting at least 1 leukemic cell per 100 000 normal mononucleated cells (0.001%).",Leukemic Cell,LOCATION_OF,"Receptors, Antigen"
20304809,Minimal residual disease (MRD) at the end of remission-induction therapy predicts relapse in acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
20304809,Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20335220,"A total of 500 children with acute lymphoblastic leukemia treated according to the common Nordic treatment protocols were included, and we found that the RFC AA variant was associated with a 50% better chance of staying in remission compared with GG or GA variants (P = .046).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20335220,"A total of 500 children with acute lymphoblastic leukemia treated according to the common Nordic treatment protocols were included, and we found that the RFC AA variant was associated with a 50% better chance of staying in remission compared with GG or GA variants (P = .046).",Nordic,LOCATION_OF,Treatment Protocols
21067050,CONCLUSION: ALL in children is curable with effective chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21613255,Our results show that harboring activating KIR genes is associated with reduced risk for developing B-ALL in these children.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
21613255,Our results show that harboring activating KIR genes is associated with reduced risk for developing B-ALL in these children.,GEM | KIR3DL1,PREDISPOSES,"Leukemia, B-Cell, Acute"
18239620,Detection of minimal residual disease (MRD) is the most sensitive method to evaluate treatment response and one of the strongest predictors of outcome in childhood acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
18484470,Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon).,Transplantation,TREATS,Transplanted organ and tissue status
18484470,Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon).,Transplanted organ and tissue status,PROCESS_OF,Child
18484470,Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon).,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
18484470,Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon).,Hematopoietic Stem Cell Transplantation,TREATS,Transplanted organ and tissue status
18484470,Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon).,Hematopoietic Stem Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18484470,Allogeneic hemopoietic stem cell transplantation for childhood acute lymphoblastic leukemia in second complete remission-similar outcomes after matched related and unrelated donor transplant: a study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon).,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18484473,"A prospective, randomized clinical trial was conducted to compare the efficacy of piperacillin/tazobactam and amikacin combination with carbapenem monotherapy for the empirical treatment of febrile neutropenic episodes of children with acute lymphoblastic leukemia or acute myeloblastic leukemia.",piperacillin-tazobactam combination product,compared_with,Amikacin
18484473,"A prospective, randomized clinical trial was conducted to compare the efficacy of piperacillin/tazobactam and amikacin combination with carbapenem monotherapy for the empirical treatment of febrile neutropenic episodes of children with acute lymphoblastic leukemia or acute myeloblastic leukemia.",piperacillin-tazobactam combination product,TREATS,Febrile neutropenia
18484473,"A prospective, randomized clinical trial was conducted to compare the efficacy of piperacillin/tazobactam and amikacin combination with carbapenem monotherapy for the empirical treatment of febrile neutropenic episodes of children with acute lymphoblastic leukemia or acute myeloblastic leukemia.",Amikacin,TREATS,Febrile neutropenia
18484473,"A prospective, randomized clinical trial was conducted to compare the efficacy of piperacillin/tazobactam and amikacin combination with carbapenem monotherapy for the empirical treatment of febrile neutropenic episodes of children with acute lymphoblastic leukemia or acute myeloblastic leukemia.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
18484473,"A prospective, randomized clinical trial was conducted to compare the efficacy of piperacillin/tazobactam and amikacin combination with carbapenem monotherapy for the empirical treatment of febrile neutropenic episodes of children with acute lymphoblastic leukemia or acute myeloblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19339772,Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia.,Prednisone,TREATS,"Leukemia, Lymphocytic, Acute"
19339772,"METHODS: In the present prospective trial, 15 children with acute lymphoblastic leukemia and hyperleukocytosis (range 101-838 x 10(9)/l) were treated with intravenous low-dose prednisone continuous infusion (6 mg/m(2)/24 h).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19339772,"METHODS: In the present prospective trial, 15 children with acute lymphoblastic leukemia and hyperleukocytosis (range 101-838 x 10(9)/l) were treated with intravenous low-dose prednisone continuous infusion (6 mg/m(2)/24 h).",Prednisone,TREATS,Child
19339772,"METHODS: In the present prospective trial, 15 children with acute lymphoblastic leukemia and hyperleukocytosis (range 101-838 x 10(9)/l) were treated with intravenous low-dose prednisone continuous infusion (6 mg/m(2)/24 h).",Prednisone,TREATS,"Leukemia, Lymphocytic, Acute"
19339772,Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia.,Prednisone,TREATS,Child
19339772,Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia.,Prednisone,PREVENTS,Tumor Lysis Syndrome
19339772,Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19825451,"However, cure rates for adults and adolescents and young adults (AYA) with ALL remain relatively low, at only 40% to 50%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
19825451,"However, cure rates for adults and adolescents and young adults (AYA) with ALL remain relatively low, at only 40% to 50%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
19825451,Acute lymphoblastic leukemia in adolescents and young adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
19825451,Acute lymphoblastic leukemia in adolescents and young adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
20426520,The authors here present a family with pR337P mutation in TP53 gene who had a child with acute lymphoblastic leukemia (ALL) and associated adrenocortical carcinoma as a case 1 and his cousin with brain tumor as a case 2.,Adrenocortical carcinoma,PROCESS_OF,Child
20426520,The authors here present a family with pR337P mutation in TP53 gene who had a child with acute lymphoblastic leukemia (ALL) and associated adrenocortical carcinoma as a case 1 and his cousin with brain tumor as a case 2.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20426520,The authors here present a family with pR337P mutation in TP53 gene who had a child with acute lymphoblastic leukemia (ALL) and associated adrenocortical carcinoma as a case 1 and his cousin with brain tumor as a case 2.,Brain Neoplasms,PROCESS_OF,Cousin
20426951,[Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20426951,[Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].,"Neoplasm, Residual",PROCESS_OF,Child
20620600,A group of 89 children with acute lymphoblastic leukemia was studied by means of CGH using bone marrow obtained from all consecutive pediatric patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20620604,"Further studies for the detection of a FUS-ERG chimeric transcript were conducted, and an unusual type of FUS-ERG rearrangement was discovered, which has been reported in only three patients including a 1-year-old infant with ALL.",Detection,TREATS,Patients
20620604,"Further studies for the detection of a FUS-ERG chimeric transcript were conducted, and an unusual type of FUS-ERG rearrangement was discovered, which has been reported in only three patients including a 1-year-old infant with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
20824655,"In this study, we investigated 10 polymorphisms in 6 genes (GSTM1-present/null, GSTT1-present/null, GSTP1 1578A > G, NQO1 609C > T, MTHFR 677C > T, MTHFR 1298A > C, MTHFD1 1958G > A, 3'-TYMS 1494 6bp-deletion/insertion, 5'-TYMS 28bp-tandem repeats, and SLC19A1 80G > A) in a cohort of 185 Javanese children with ALL and 177 healthy controls.","Polymorphism, Genetic",PROCESS_OF,cohort
20824655,"In this study, we investigated 10 polymorphisms in 6 genes (GSTM1-present/null, GSTT1-present/null, GSTP1 1578A > G, NQO1 609C > T, MTHFR 677C > T, MTHFR 1298A > C, MTHFD1 1958G > A, 3'-TYMS 1494 6bp-deletion/insertion, 5'-TYMS 28bp-tandem repeats, and SLC19A1 80G > A) in a cohort of 185 Javanese children with ALL and 177 healthy controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20824655,Xenobiotic and folate pathway gene polymorphisms and risk of childhood acute lymphoblastic leukaemia in Javanese children.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
20889538,"METHODS: This case-control study included children aged 0-14 years diagnosed with acute lymphoid leukaemia (ALL, n = 711) or acute myeloid leukaemia (AML, n = 116) from 1995 to 2008.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
20889538,"METHODS: This case-control study included children aged 0-14 years diagnosed with acute lymphoid leukaemia (ALL, n = 711) or acute myeloid leukaemia (AML, n = 116) from 1995 to 2008.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21740479,IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
21740479,IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan.,Prognosis bad,PROCESS_OF,Child
21918440,"One of the major concerns in hematologic malignancies is childhood acute lymphoblastic leukemia, in which the leukemogenic role of extended etoposide/teniposide treatment, concomitant intensive antimetabolite and asparaginase, granulocyte colony-stimulating factor (G-CSF) and prophylactic cranial radiotherapy use have been established.","Leukemia, Lymphocytic, Acute, L1",AFFECTS,leukemia
21918440,"One of the major concerns in hematologic malignancies is childhood acute lymphoblastic leukemia, in which the leukemogenic role of extended etoposide/teniposide treatment, concomitant intensive antimetabolite and asparaginase, granulocyte colony-stimulating factor (G-CSF) and prophylactic cranial radiotherapy use have been established.","Leukemia, Lymphocytic, Acute, L1",ISA,Hematologic Neoplasms
21918440,"One of the major concerns in hematologic malignancies is childhood acute lymphoblastic leukemia, in which the leukemogenic role of extended etoposide/teniposide treatment, concomitant intensive antimetabolite and asparaginase, granulocyte colony-stimulating factor (G-CSF) and prophylactic cranial radiotherapy use have been established.",Teniposide,ISA,Therapeutic procedure
21956467,AIM: The objective of this study was to investigate expression of drug resistance associated genes in CD34+ and CD34- leukemic subpopulations in childhood acute lymphoblastic leukemia (ALL).,CD34 gene | CD34,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
21956467,AIM: The objective of this study was to investigate expression of drug resistance associated genes in CD34+ and CD34- leukemic subpopulations in childhood acute lymphoblastic leukemia (ALL).,CD34 gene | CD34,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
21956467,AIM: The objective of this study was to investigate expression of drug resistance associated genes in CD34+ and CD34- leukemic subpopulations in childhood acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
21981741,"This study was designed to describe children and youth (age <20 years) diagnosed with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL) in Alberta, Canada, during 22 fiscal years.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21981741,"During 22 years, 525, 117, 257, and 111 children (total = 1010) were diagnosed with ALL, AML, HL, and NHL, respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21981741,"This study was designed to describe children and youth (age <20 years) diagnosed with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL) in Alberta, Canada, during 22 fiscal years.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Youth
18484482,Urolithiasis in an acute lymphoblastic leukemia child during induction chemotherapy.,Urolithiasis,PROCESS_OF,Child
18484482,Urolithiasis in an acute lymphoblastic leukemia child during induction chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18949677,We report two children with ALL who developed HL while receiving maintenance CT.,Hodgkin Disease,PROCESS_OF,Child
18949677,Hodgkin lymphoma as second malignancy during continuing chemotherapy for childhood acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18949677,We report two children with ALL who developed HL while receiving maintenance CT.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19741605,Asparaginase (ASP) is used routinely in frontline clinical trials for the treatment of childhood acute lymphoblastic leukemia (ALL).,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20309661,"To investigate the seroprevalence of Herpes Simplex Viruses (HSV1 and HSV2), Ebstein-Barr Virus (EBV) and Hepatitis B Virus (HBV) in children with acute lymphoblastic leukemia (ALL) in southern Iran.",Virus,PROCESS_OF,Child
20309661,"To investigate the seroprevalence of Herpes Simplex Viruses (HSV1 and HSV2), Ebstein-Barr Virus (EBV) and Hepatitis B Virus (HBV) in children with acute lymphoblastic leukemia (ALL) in southern Iran.",Hepatitis B Virus,PROCESS_OF,Child
20309661,"To investigate the seroprevalence of Herpes Simplex Viruses (HSV1 and HSV2), Ebstein-Barr Virus (EBV) and Hepatitis B Virus (HBV) in children with acute lymphoblastic leukemia (ALL) in southern Iran.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20309661,"Seroprevalence of human herpes simplex, hepatitis B and epstein-barr viruses in children with acute lymphoblastic leukemia in southern iran.","Herpesvirus 4, Human",PROCESS_OF,Child
20309661,"Seroprevalence of human herpes simplex, hepatitis B and epstein-barr viruses in children with acute lymphoblastic leukemia in southern iran.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20510681,"We examined the association among functional polymorphisms in these two angiogenesis related genes: VEGF (-2578C>A, -1154G>A, and -634G>C) and NOS3 (-786T>C, intron 4 b>a, and Glu298Asp) with prognosis of childhood acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
20824725,Current treatment protocols include E. coli asparaginase or PEG-asparaginase for first-line treatment of ALL.,pegaspargase | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
20824725,Asparaginases are a cornerstone of treatment protocols for acute lymphoblastic leukemia (ALL) and are used for remission induction and intensification treatment in all pediatric regimens and in the majority of adult treatment protocols.,Remission Induction,USES,ASPARAGINASE | ASPG
20824725,Current treatment protocols include E. coli asparaginase or PEG-asparaginase for first-line treatment of ALL.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
20824725,Asparaginases are a cornerstone of treatment protocols for acute lymphoblastic leukemia (ALL) and are used for remission induction and intensification treatment in all pediatric regimens and in the majority of adult treatment protocols.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
20824725,Current treatment protocols include E. coli asparaginase or PEG-asparaginase for first-line treatment of ALL.,ASPARAGINASE | ASPG,PART_OF,Escherichia coli
20824725,L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.,Therapeutic procedure,USES,ASPARAGINASE | ASPG
20824725,Extensive clinical data have shown that intensive asparaginase treatment improves clinical outcomes in childhood ALL.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20824725,L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
20824725,Extensive clinical data have shown that intensive asparaginase treatment improves clinical outcomes in childhood ALL.,ASPARAGINASE | ASPG,ISA,Therapeutic procedure
20824725,Extensive clinical data have shown that intensive asparaginase treatment improves clinical outcomes in childhood ALL.,Therapeutic procedure,USES,ASPARAGINASE | ASPG
20824725,L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.,ASPARAGINASE | ASPG,ISA,Therapeutic procedure
20824725,Extensive clinical data have shown that intensive asparaginase treatment improves clinical outcomes in childhood ALL.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20824725,Asparaginases are a cornerstone of treatment protocols for acute lymphoblastic leukemia (ALL) and are used for remission induction and intensification treatment in all pediatric regimens and in the majority of adult treatment protocols.,Therapeutic procedure,USES,ASPARAGINASE | ASPG
21290342,This study is aimed to evaluate changes in MDM2 and p53 expression in peripheral blood mononuclear cells collected from children with ALL prior to and after 6 and 12 h of prednisone administration in relation to early treatment response.,MDM2 gene | MDM2,PART_OF,Peripheral blood mononuclear cell
21290342,This study is aimed to evaluate changes in MDM2 and p53 expression in peripheral blood mononuclear cells collected from children with ALL prior to and after 6 and 12 h of prednisone administration in relation to early treatment response.,TP53 gene | TP53,PART_OF,Peripheral blood mononuclear cell
21290342,Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.,MDM2 gene | MDM2,PART_OF,Leukemic Cell
21290342,Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.,TP53 gene | TP53,PART_OF,Leukemic Cell
21290342,Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21290342,Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.,Therapeutic procedure,USES,Prednisone
21290342,This study is aimed to evaluate changes in MDM2 and p53 expression in peripheral blood mononuclear cells collected from children with ALL prior to and after 6 and 12 h of prednisone administration in relation to early treatment response.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21290342,Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.,Prednisone,ISA,Therapeutic procedure
21331151,This is the first proof-of-concept study to measure mtDNA copy numbers in MD/PRD-positive CSF specimens from children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21331151,UNLABELLED: This feasibility study was designed to assess the ability to measure mitochondrial DNA (mtDNA) in cerebrospinal fluid (CSF) cells that contributed to minimal disease/persistent or residual disease (MD/PRD) from children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21331151,Mitochondrial DNA in residual leukemia cells in cerebrospinal fluid in children with acute lymphoblastic leukemia.,Cerebrospinal Fluid,LOCATION_OF,"DNA, Mitochondrial"
21331151,Mitochondrial DNA in residual leukemia cells in cerebrospinal fluid in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21418106,"The aim of this study was to investigate the role of a single-nucleotide polymorphism (CYP3A5*3 6986A>G), which renders low enzyme activity, in the risk of developing ALL and in the outcome for children with ALL.",Single Nucleotide Polymorphism,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
21418106,"The aim of this study was to investigate the role of a single-nucleotide polymorphism (CYP3A5*3 6986A>G), which renders low enzyme activity, in the risk of developing ALL and in the outcome for children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21886397,Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia in a child.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21915123,"METHODS: In an Australian case-control study of ALL in children aged < 15 years, parents were asked about tasks they undertook in each job.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21915123,BACKGROUND: Earlier studies have reported moderate increases in the risk of acute lymphoblastic leukaemia (ALL) among children whose mothers have been occupationally exposed to extremely low frequency (ELF) electromagnetic fields.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18493991,A child with acute pre-B cell lymphoblastic leukemia underwent haploidentical bone marrow transplantation (BMT) after first relapse.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
18493991,A child with acute pre-B cell lymphoblastic leukemia underwent haploidentical bone marrow transplantation (BMT) after first relapse.,Bone Marrow Transplantation,TREATS,"Leukemia, B-Cell, Acute"
18523991,"CONCLUSION: Hyperglycemia, especially when overt, may be a previously unrecognized risk factor of infectious complications in children with ALL during the first year of treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18523991,We hypothesized that children with ALL who become hyperglycemic during induction chemotherapy have an increased risk for infection during their first year of treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18523991,BACKGROUND: Children with acute lymphocytic leukemia (ALL) are at high risk for developing hyperglycemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18523991,"CONCLUSION: Hyperglycemia, especially when overt, may be a previously unrecognized risk factor of infectious complications in children with ALL during the first year of treatment.","Complication, infection",PROCESS_OF,Child
18523991,"CONCLUSION: Hyperglycemia, especially when overt, may be a previously unrecognized risk factor of infectious complications in children with ALL during the first year of treatment.",Hyperglycemia,PREDISPOSES,"Complication, infection"
18829111,"In children with acute lymphoblastic leukemia (ALL), leukemic cells express several members of the VEGF family and the three VEGF receptors which, via an autocrine loop are responsible for secretion of MMP-2/-9.",Child,INTERACTS_WITH,member
18829111,"In children with acute lymphoblastic leukemia (ALL), leukemic cells express several members of the VEGF family and the three VEGF receptors which, via an autocrine loop are responsible for secretion of MMP-2/-9.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18829111,"In children with acute lymphoblastic leukemia (ALL), leukemic cells express several members of the VEGF family and the three VEGF receptors which, via an autocrine loop are responsible for secretion of MMP-2/-9.",Vascular Endothelial Growth Factor Receptor,CAUSES,Exocytosis
18829111,"In children with acute lymphoblastic leukemia (ALL), leukemic cells express several members of the VEGF family and the three VEGF receptors which, via an autocrine loop are responsible for secretion of MMP-2/-9.",VEGFA,CAUSES,Exocytosis
18947485,"METHODS: WAVE1 mRNA and protein expression in bone marrow mononuclear cells (BMMCs) was measured by RT-PCR and Western blotting respectively in 4 children with ALL relapse, 15 children with ALL in complete remission (CR) and 40 children with newly diagnosed ALL.",Bone Marrow Cells,LOCATION_OF,WASF1
18947485,"METHODS: WAVE1 mRNA and protein expression in bone marrow mononuclear cells (BMMCs) was measured by RT-PCR and Western blotting respectively in 4 children with ALL relapse, 15 children with ALL in complete remission (CR) and 40 children with newly diagnosed ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18947485,"METHODS: WAVE1 mRNA and protein expression in bone marrow mononuclear cells (BMMCs) was measured by RT-PCR and Western blotting respectively in 4 children with ALL relapse, 15 children with ALL in complete remission (CR) and 40 children with newly diagnosed ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18947485,CONCLUSIONS: The WAVE1 expression increased in children with ALL.,Child,LOCATION_OF,WASF1
18947485,WAVE1 may be related to the development of ALL and may be severed as a marker for the evaluation of the severity of ALL in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18947485,CONCLUSIONS: The WAVE1 expression increased in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18947485,"METHODS: WAVE1 mRNA and protein expression in bone marrow mononuclear cells (BMMCs) was measured by RT-PCR and Western blotting respectively in 4 children with ALL relapse, 15 children with ALL in complete remission (CR) and 40 children with newly diagnosed ALL.","Blotting, Western",DIAGNOSES,"Leukemia, Lymphocytic, Acute"
19564743,Treatment of children with acute lymphoblastic leukemia (ALL) is based on P-glycoprotein (P-gp)-dependent cytostatics.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20309661,"With the results of this study, we could not exclude a connection between these viral infections and later leukemogenesis in childhood ALL, although nor latent infection nor congenital infection cannot be excluded by this method.",Leukemogenesis,COEXISTS_WITH,Congenital infectious disease
20309661,"With the results of this study, we could not exclude a connection between these viral infections and later leukemogenesis in childhood ALL, although nor latent infection nor congenital infection cannot be excluded by this method.",Leukemogenesis,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20309661,"With the results of this study, we could not exclude a connection between these viral infections and later leukemogenesis in childhood ALL, although nor latent infection nor congenital infection cannot be excluded by this method.",Virus Diseases,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20309661,"With the results of this study, we could not exclude a connection between these viral infections and later leukemogenesis in childhood ALL, although nor latent infection nor congenital infection cannot be excluded by this method.",Virus Diseases,COEXISTS_WITH,Latent Infection
20309661,"With the results of this study, we could not exclude a connection between these viral infections and later leukemogenesis in childhood ALL, although nor latent infection nor congenital infection cannot be excluded by this method.",Virus Diseases,COEXISTS_WITH,Congenital infectious disease
20309661,"With the results of this study, we could not exclude a connection between these viral infections and later leukemogenesis in childhood ALL, although nor latent infection nor congenital infection cannot be excluded by this method.",Leukemogenesis,COEXISTS_WITH,Latent Infection
20442364,"We reviewed data from 2811 children with ALL enrolled in Children's Oncology Group P9900, which included prospective testing for the major cytogenetic lesions in childhood ALL: ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, and MLL translocations and trisomies of chromosomes 4 and 10.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20442364,"We reviewed data from 2811 children with ALL enrolled in Children's Oncology Group P9900, which included prospective testing for the major cytogenetic lesions in childhood ALL: ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, and MLL translocations and trisomies of chromosomes 4 and 10.","Chromosomes, Human, Pair 4",LOCATION_OF,Trisomy
20442364,"We reviewed data from 2811 children with ALL enrolled in Children's Oncology Group P9900, which included prospective testing for the major cytogenetic lesions in childhood ALL: ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, and MLL translocations and trisomies of chromosomes 4 and 10.","Chromosomes, Human, Pair 4",LOCATION_OF,"Leukemia, Lymphocytic, Acute, L1"
20442364,"Five-year event-free (EFS) and overall survival (OS) were inferior in children with DS-ALL: 69.9% +/- 8.6% versus 78.1% +/- 1.2% (P = .078), and 85.8% +/- 6.5% versus 90.0% +/- 0.9% (P = .033).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20442364,"Children with DS-ALL had lower rates of the favorable cytogenetic lesions ETV6-RUNX1 (2.5% vs 24%, P < .001) and trisomies 4 and 10 (7.7% vs 24%, P < .001).",Trisomy 4,PROCESS_OF,Child
20442364,"Children with DS-ALL had lower rates of the favorable cytogenetic lesions ETV6-RUNX1 (2.5% vs 24%, P < .001) and trisomies 4 and 10 (7.7% vs 24%, P < .001).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20957630,"The analyses were categorized into the following groups: all childhood cancer, leukemias, acute lymphocytic leukemia, lymphomas, brain and central nervous system (CNS) cancers and remaining cancers (excluding leukemia, lymphoma and CNS tumors).",leukemia,ISA,"Leukemia, Lymphocytic, Acute"
20957630,"The analyses were categorized into the following groups: all childhood cancer, leukemias, acute lymphocytic leukemia, lymphomas, brain and central nervous system (CNS) cancers and remaining cancers (excluding leukemia, lymphoma and CNS tumors).",leukemia,ISA,Malignant Neoplasms
20957630,"The analyses were categorized into the following groups: all childhood cancer, leukemias, acute lymphocytic leukemia, lymphomas, brain and central nervous system (CNS) cancers and remaining cancers (excluding leukemia, lymphoma and CNS tumors).",Central Nervous System Neoplasms,ISA,Malignant neoplasm of central nervous system
20957630,"The analyses were categorized into the following groups: all childhood cancer, leukemias, acute lymphocytic leukemia, lymphomas, brain and central nervous system (CNS) cancers and remaining cancers (excluding leukemia, lymphoma and CNS tumors).",Central Nervous System Neoplasms,ISA,Malignant Neoplasms
20957630,"The analyses were categorized into the following groups: all childhood cancer, leukemias, acute lymphocytic leukemia, lymphomas, brain and central nervous system (CNS) cancers and remaining cancers (excluding leukemia, lymphoma and CNS tumors).",Lymphoma,ISA,leukemia
20957630,"The analyses were categorized into the following groups: all childhood cancer, leukemias, acute lymphocytic leukemia, lymphomas, brain and central nervous system (CNS) cancers and remaining cancers (excluding leukemia, lymphoma and CNS tumors).",Lymphoma,ISA,Malignant Neoplasms
20957630,"The analyses were categorized into the following groups: all childhood cancer, leukemias, acute lymphocytic leukemia, lymphomas, brain and central nervous system (CNS) cancers and remaining cancers (excluding leukemia, lymphoma and CNS tumors).",leukemia,ISA,Lymphoma
21298773,This study was performed to assess the THP-induced cardiotoxicity for children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21298773,Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia.,Cardiotoxicity,PROCESS_OF,Child
21298773,Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21360658,CONCLUSION: Treatment protocols developed by major cooperative groups and institutions to treat childhood ALL was successfully adapted and suggest that such an approach may be useful in other low- and middle-income countries.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21360658,"RESULTS: Over a 7-year period, 300 children with ALL were treated.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21509929,L-asparaginase for treatment of childhood acute lymphoblastic leukemia: what have we learned?,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18283545,Similar results were observed for children diagnosed with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18989886,This emphasizes the importance of improving supportive care in developing countries for children with high-risk ALL who receive very intensive chemotherapy.,Supportive care,TREATS,Child
18989886,This emphasizes the importance of improving supportive care in developing countries for children with high-risk ALL who receive very intensive chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18989886,This emphasizes the importance of improving supportive care in developing countries for children with high-risk ALL who receive very intensive chemotherapy.,Supportive care,TREATS,"Leukemia, Lymphocytic, Acute"
19488866,"Contemporary protocols ensure high-remission rate and long-term free survival in children with acute lymphoblastic leukemia (ALL), but small percentage of patients is still incurable.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19998443,This study describes the cytogenetics of 33 children with ETV6-RUNX1 positive acute lymphoblastic leukemia (ALL) who had been in continuous complete remission for a minimum of 8.8 years [median event-free survival (EFS) 10.9 years].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20484480,"OBJECTIVE: Our objective was to evaluate GH therapy on CV risk, cardiac function, physical activity, and quality of life in ALL patients treated with cranial radiotherapy (18-24 Gy) and chemotherapy (anthracycline dose 120 mg/m2).",Pharmacotherapy,TREATS,Patients
20484480,"OBJECTIVE: Our objective was to evaluate GH therapy on CV risk, cardiac function, physical activity, and quality of life in ALL patients treated with cranial radiotherapy (18-24 Gy) and chemotherapy (anthracycline dose 120 mg/m2).",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
20484480,"OBJECTIVE: Our objective was to evaluate GH therapy on CV risk, cardiac function, physical activity, and quality of life in ALL patients treated with cranial radiotherapy (18-24 Gy) and chemotherapy (anthracycline dose 120 mg/m2).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
20484480,"OBJECTIVE: Our objective was to evaluate GH therapy on CV risk, cardiac function, physical activity, and quality of life in ALL patients treated with cranial radiotherapy (18-24 Gy) and chemotherapy (anthracycline dose 120 mg/m2).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
20484480,"OBJECTIVE: Our objective was to evaluate GH therapy on CV risk, cardiac function, physical activity, and quality of life in ALL patients treated with cranial radiotherapy (18-24 Gy) and chemotherapy (anthracycline dose 120 mg/m2).",Cardiac function,PROCESS_OF,Patients
20484480,"OBJECTIVE: Our objective was to evaluate GH therapy on CV risk, cardiac function, physical activity, and quality of life in ALL patients treated with cranial radiotherapy (18-24 Gy) and chemotherapy (anthracycline dose 120 mg/m2).",Radiation therapy,TREATS,Patients
20890066,RESULTS: Ninety-four children with ALL (n=90) and LL (n=4) were analyzed.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20890066,PATIENTS AND METHODS: We included children diagnosed with ALL and lymphoblastic lymphoma (LL) stage III and IV.,Lymphoma stage III,PROCESS_OF,Child
20890066,PATIENTS AND METHODS: We included children diagnosed with ALL and lymphoblastic lymphoma (LL) stage III and IV.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20890066,RESULTS: Ninety-four children with ALL (n=90) and LL (n=4) were analyzed.,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
21092265,"PFKFB2 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-2), a kinase controlling glucose metabolism, was identified by us previously as a GC response gene in expression profiling analyses performed in children with ALL during initial systemic GC mono-therapy.",Child,LOCATION_OF,GC gene | GC
21092265,"PFKFB2 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-2), a kinase controlling glucose metabolism, was identified by us previously as a GC response gene in expression profiling analyses performed in children with ALL during initial systemic GC mono-therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21092265,"RESULTS: Expression analyses in additional ALL children, non-leukemic individuals and leukemic cell lines confirmed frequent PFKFB2 induction by GC in most systems sensitive to GC-induced apoptosis, particularly T-ALL cells.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21337680,BACKGROUND: We report on the treatment of children and adolescents with acute lymphoblastic leukemia (ALL) in first relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21337680,Outcome after first relapse in children with acute lymphoblastic leukemia: a report based on the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21360659,BACKGROUND: It is common practice to hold anthracycline induction chemotherapy in children with high-risk acute lymphoblastic leukemia (HR-ALL) until an echocardiogram is performed and interpreted.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
21360659,We reviewed the initial echocardiograms in a cohort of children with HR-ALL to determine the incidence of contraindications for anthracycline treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21360659,Clinical impact of the baseline echocardiogram in children with high-risk acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21360659,It is unclear whether withholding therapy in HR-ALL children is justified by echocardiogram findings.,Therapeutic procedure,TREATS,Child
21360659,It is unclear whether withholding therapy in HR-ALL children is justified by echocardiogram findings.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
21360659,It is unclear whether withholding therapy in HR-ALL children is justified by echocardiogram findings.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21360659,BACKGROUND: It is common practice to hold anthracycline induction chemotherapy in children with high-risk acute lymphoblastic leukemia (HR-ALL) until an echocardiogram is performed and interpreted.,Pharmacotherapy,TREATS,Child
21360659,BACKGROUND: It is common practice to hold anthracycline induction chemotherapy in children with high-risk acute lymphoblastic leukemia (HR-ALL) until an echocardiogram is performed and interpreted.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21671359,CONCLUSIONS: The number of blood products transfused to children with ALL appears to be significantly associated with lower survival rates.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21671359,Is the number of blood products transfused associated with lower survival in children with acute lymphoblastic leukemia?,Blood product,TREATS,Child
21671359,Children with ALL are immunosuppressed by both the disease and its therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21671359,Is the number of blood products transfused associated with lower survival in children with acute lymphoblastic leukemia?,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21671359,Is the number of blood products transfused associated with lower survival in children with acute lymphoblastic leukemia?,Blood product,TREATS,"Leukemia, Lymphocytic, Acute"
18565891,"PURPOSE: We aimed to identify relapse predictors in children with a B-cell precursor acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iAMP21), a novel genetic entity associated with poor outcome.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
18565891,Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
19016726,Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.,Detection,TREATS,Patients
19016726,Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.,Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19016726,Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
19034904,We also characterized disease features and outcome according to the presence of TPMT SNPs in children with acute lymphoblastic leukemia (ALL).,Child,LOCATION_OF,Single Nucleotide Polymorphism
19034904,We also characterized disease features and outcome according to the presence of TPMT SNPs in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19531816,[Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19531816,Treatment results for children with acute lymphoblastic leukaemia in Olsztyn Province are similar to the results in the Polish Paediatric Leukaemia/Lymphoma Study Group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19531816,Treatment results for children with acute lymphoblastic leukaemia in Olsztyn Province are similar to the results in the Polish Paediatric Leukaemia/Lymphoma Study Group.,Therapeutic procedure,TREATS,Child
19531816,Treatment results for children with acute lymphoblastic leukaemia in Olsztyn Province are similar to the results in the Polish Paediatric Leukaemia/Lymphoma Study Group.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
19531830,"The highest incidence is among children with acute lymphoblastic leukaemia, followed by those with lymphoma and solid tumours.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19586938,"This notion is supported by a large body of data among chronic myeloid leukemia patients, but minimal residual disease detection and monitoring is increasingly applied to other types of leukemia, and is starting to be a factor in decision-making for some therapeutic trials in childhood acute lymphoblastic leukemia.",leukemia,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
19586938,"This notion is supported by a large body of data among chronic myeloid leukemia patients, but minimal residual disease detection and monitoring is increasingly applied to other types of leukemia, and is starting to be a factor in decision-making for some therapeutic trials in childhood acute lymphoblastic leukemia.","Myeloid Leukemia, Chronic",PROCESS_OF,Patients
20197772,Adenovirus DNA in Guthrie cards from children who develop acute lymphoblastic leukaemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20197772,METHODS: Guthrie cards from 243 children who later developed ALL and from 486 matched controls were collected and analysed by nested polymerase chain reaction for the presence of adenovirus DNA.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20197772,"BACKGROUND: In search of a proposed viral aetiology of childhood acute lymphoblastic leukaemia (ALL), the common species C adenoviruses were analysed in Guthrie cards.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
20713965,"t(12;21)(p13;q22)[ETV6-RUNX1] is the most common chromosomal translocation in childhood acute lymphoblastic leukemia, and it can often be backtracked to Guthrie cards supporting prenatal initiation and high levels of circulating t(12;21)-positive cells at birth.",Chromosomal translocation,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20961616,Leukemic cells from 230 children with newly diagnosed B-cell precursor ALL were tested for in vitro drug resistance to a panel of anti-cancer drugs.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
21051085,Chemotherapy for childhood acute lymphoblastic leukemia may cause severe immune damage.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21051085,Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: impact on lymphocyte compartment composition.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21297632,"Interrogating genome-wide germline SNP genotypes in an unselected large cohort of children with ALL, we observed that the component of genomic variation that co-segregated with Native American ancestry was associated with risk of relapse (P = 0.0029) even after adjusting for known prognostic factors (P = 0.017).",cohort,LOCATION_OF,Single Nucleotide Polymorphism
21297632,"Interrogating genome-wide germline SNP genotypes in an unselected large cohort of children with ALL, we observed that the component of genomic variation that co-segregated with Native American ancestry was associated with risk of relapse (P = 0.0029) even after adjusting for known prognostic factors (P = 0.017).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21652620,Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.,Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21998807,Acute Lymphoblastic Leukemia (ALL) is the most prevalent hematological malignant tumor during childhood.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
22122053,Acute lymphoblastic leukemia (ALL) is the most common cancer in children in the modern world.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22122053,Acute lymphoblastic leukemia (ALL) is the most common cancer in children in the modern world.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
22122053,"Recent efforts in characterizing the genetic contribution to this disease through uncovering gene mutations, deletions and structural variation by genome-scale methods have only accounted for a modest proportion of children with ALL.",DELETION,AFFECTS,"Leukemia, Lymphocytic, Acute"
22122053,"Recent efforts in characterizing the genetic contribution to this disease through uncovering gene mutations, deletions and structural variation by genome-scale methods have only accounted for a modest proportion of children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17986648,"The microtubule-depolymerizing drug, vincristine, is effective in the treatment of acute lymphoblastic leukemia (ALL).",Vincristine,ISA,Therapeutic procedure
17986648,"The microtubule-depolymerizing drug, vincristine, is effective in the treatment of acute lymphoblastic leukemia (ALL).",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
17986648,"The microtubule-depolymerizing drug, vincristine, is effective in the treatment of acute lymphoblastic leukemia (ALL).",Vincristine,ISA,Pharmaceutical Preparations
18491104,Survivors of childhood ALL who underwent cranial irradiation during childhood had smaller WM volumes and reduced GM concentration within the caudate nucleus and thalamus.,Entire caudate nucleus,LOCATION_OF,Reduced concentration
18491104,Survivors of childhood ALL who underwent cranial irradiation during childhood had smaller WM volumes and reduced GM concentration within the caudate nucleus and thalamus.,Entire caudate nucleus,LOCATION_OF,"Leukemia, Lymphocytic, Acute, L1"
18491104,Survivors of childhood ALL who underwent cranial irradiation during childhood had smaller WM volumes and reduced GM concentration within the caudate nucleus and thalamus.,Thalamic structure,LOCATION_OF,Reduced concentration
18491104,Survivors of childhood ALL who underwent cranial irradiation during childhood had smaller WM volumes and reduced GM concentration within the caudate nucleus and thalamus.,Cranial Irradiation,TREATS,Reduced concentration
18491104,Survivors of childhood ALL who underwent cranial irradiation during childhood had smaller WM volumes and reduced GM concentration within the caudate nucleus and thalamus.,Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18491104,Survivors of childhood ALL who underwent cranial irradiation during childhood had smaller WM volumes and reduced GM concentration within the caudate nucleus and thalamus.,Thalamic structure,LOCATION_OF,"Leukemia, Lymphocytic, Acute, L1"
19353239,These results support a role of specific genetic polymorphisms on lethal infections during induction chemotherapy of ALL treatment.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
19621425,"The aim of our study was to evaluate the association between polymorphisms of genes encoding for proteins involved in the pharmacokinetics/pharmacodynamics of these drugs and the occurrence of side effects, in particular infections, in a small population of ALL children.",Adverse effects,OCCURS_IN,Infection
19621425,"The aim of our study was to evaluate the association between polymorphisms of genes encoding for proteins involved in the pharmacokinetics/pharmacodynamics of these drugs and the occurrence of side effects, in particular infections, in a small population of ALL children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19621425,"BACKGROUND: Glucocorticoids (GCs) play a fundamental role in the treatment of pediatric acute lymphoblastic leukemia (ALL), but therapy with these agents often results in a number of severe side effects.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19621425,"The aim of our study was to evaluate the association between polymorphisms of genes encoding for proteins involved in the pharmacokinetics/pharmacodynamics of these drugs and the occurrence of side effects, in particular infections, in a small population of ALL children.",Proteins,INTERACTS_WITH,Genes
19672973,Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.,Hypersensitivity,PROCESS_OF,Child
19672973,Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19672973,Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.,ASPARAGINASE | ASPG,PART_OF,Escherichia coli
19774638,Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19813253,The purpose of this study was to evaluate if birth weight (BW) corrected-for-gestational age is a better predictor than BW alone for occurrence of ALL and other malignancies in children.,Malignant Neoplasms,PROCESS_OF,Child
19813253,The purpose of this study was to evaluate if birth weight (BW) corrected-for-gestational age is a better predictor than BW alone for occurrence of ALL and other malignancies in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
19813253,The purpose of this study was to evaluate if birth weight (BW) corrected-for-gestational age is a better predictor than BW alone for occurrence of ALL and other malignancies in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19813253,The purpose of this study was to evaluate if birth weight (BW) corrected-for-gestational age is a better predictor than BW alone for occurrence of ALL and other malignancies in children.,Malignant Neoplasms,ISA,"Leukemia, Lymphocytic, Acute"
19813253,The purpose of this study was to evaluate if birth weight (BW) corrected-for-gestational age is a better predictor than BW alone for occurrence of ALL and other malignancies in children.,Malignant Neoplasms,PROCESS_OF,Child
19813253,The purpose of this study was to evaluate if birth weight (BW) corrected-for-gestational age is a better predictor than BW alone for occurrence of ALL and other malignancies in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20561032,B-cell precursor (BCP) ALL was diagnosed in 26 children.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
20957179,"We examined if family characteristics, particularly maternal and paternal age and number of older siblings, were risk factors for childhood acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
21223250,One hundred and seventy-one children newly diagnosed with ALL between 2004 and 2007 and treated according to the Dutch Childhood Oncology Group ALL 10 protocol were prospectively followed during the 2-year treatment course.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21223250,Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity*.,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21223250,Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity*.,Chemotherapy-Oncologic Procedure,ISA,Therapeutic procedure
21645570,Transmission of HLA-DP variants from parents to children with B-cell precursor acute lymphoblastic leukemia: log-linear analysis using the case-parent design.,parent,LOCATION_OF,HLA-DPA1 | HLA-DPB1
21645570,Transmission of HLA-DP variants from parents to children with B-cell precursor acute lymphoblastic leukemia: log-linear analysis using the case-parent design.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
21652620,BACKGROUND: Vincristine is one of the cornerstones of the treatment of children with acute lymphoblastic leukaemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21652620,"Therefore, we advise avoidance of the combination of azole and vincristine treatments in patients with ALL.",Vincristine,TREATS,Patients
21652620,BACKGROUND: Vincristine is one of the cornerstones of the treatment of children with acute lymphoblastic leukaemia (ALL).,Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
21652620,"Therefore, we advise avoidance of the combination of azole and vincristine treatments in patients with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
21652620,BACKGROUND: Vincristine is one of the cornerstones of the treatment of children with acute lymphoblastic leukaemia (ALL).,Vincristine,ISA,Therapeutic procedure
21652620,"Therefore, we advise avoidance of the combination of azole and vincristine treatments in patients with ALL.",Therapeutic procedure,USES,Vincristine
21652620,"Therefore, we advise avoidance of the combination of azole and vincristine treatments in patients with ALL.",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
21652620,"Therefore, we advise avoidance of the combination of azole and vincristine treatments in patients with ALL.",Vincristine,ISA,Therapeutic procedure
21652620,BACKGROUND: Vincristine is one of the cornerstones of the treatment of children with acute lymphoblastic leukaemia (ALL).,Vincristine,TREATS,Child
21781499,OBJECTIVE: To study the clinical significance of sequentially monitoring minimal residual disease (MRD) in childhood B-cell acute lymphoblastic leukemia (B-ALL).,"Neoplasm, Residual",COEXISTS_WITH,B-cell childhood acute lymphoblastic leukemia
21781499,[Clinical significance of sequential monitoring minimal residual disease in childhood B-cell acute lymphoblastic leukemia].,"Neoplasm, Residual",COEXISTS_WITH,B-cell childhood acute lymphoblastic leukemia
22135543,"Given the importance of genetic factors in leukaemogenesis and the usefulness of screening the whole genome, SNPA analysis has been utilised in many studies to characterise genetic aberrations in childhood acute lymphoblastic leukaemia.",Leukemogenesis,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
19000557,OBJECTIVE: Oral mucositis is a major toxicity in the high-dose methotrexate (HD-MTX) treatment for children with acute lymphoblastic leukemia (ALL).,METHOTREXATE TREATMENT,TREATS,Child
19000557,OBJECTIVE: Oral mucositis is a major toxicity in the high-dose methotrexate (HD-MTX) treatment for children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19000557,OBJECTIVE: Oral mucositis is a major toxicity in the high-dose methotrexate (HD-MTX) treatment for children with acute lymphoblastic leukemia (ALL).,METHOTREXATE TREATMENT,TREATS,"Leukemia, Lymphocytic, Acute"
19035175,[Study of the correlation between the expression level of asparagine synthetase and the outcome of children with acute lymphocytic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19035175,CONCLUSION: High expression of AS is associated with a poor outcome in ALL children.,Child,LOCATION_OF,Aspartate-Ammonia Ligase
19035175,CONCLUSION: High expression of AS is associated with a poor outcome in ALL children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19035175,METHODS: AS mRNA level in leukemic cells from 53 newly diagnosed ALL children was measured by real time fluorescent quantitative PCR method.,Leukemic Cell,LOCATION_OF,Aspartate-Ammonia Ligase
19035175,METHODS: AS mRNA level in leukemic cells from 53 newly diagnosed ALL children was measured by real time fluorescent quantitative PCR method.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19061221,Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19061221,Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
19061221,Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature.,Pharmacotherapy,TREATS,Child
19374803,CONCLUSIONS: MRD targets were identified using tandem application of flow cytometry and PCR in almost of children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19374803,This study aimed to identify MRD targets by tandem application of both techniques in children with ALL.,"Neoplasm, Residual",PROCESS_OF,Child
19374803,OBJECTIVE: Minimal residual disease (MRD) is one of the most important prognostic factors in childhood acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
19374803,This study aimed to identify MRD targets by tandem application of both techniques in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19621425,CONCLUSIONS: GST-M1 genotype may influence the severity of infections in ALL children during GC administration.,Infection,PROCESS_OF,Child
19621425,CONCLUSIONS: GST-M1 genotype may influence the severity of infections in ALL children during GC administration.,glutathione S-transferase M1,ASSOCIATED_WITH,Infection
19621425,CONCLUSIONS: GST-M1 genotype may influence the severity of infections in ALL children during GC administration.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19672972,"PROCEDURE: The levels of mRNA expression of the drug resistance genes ABCB1, ABCC1, ABCC3, ABCG2, and LRP/MVP were analyzed by quantitative real-time PCR using the median values as cut-off points, in consecutive samples from 140 children with ALL at diagnosis.",Drug resistance,PROCESS_OF,CONSECUTIVE SAMPLE
19672972,"PROCEDURE: The levels of mRNA expression of the drug resistance genes ABCB1, ABCC1, ABCC3, ABCG2, and LRP/MVP were analyzed by quantitative real-time PCR using the median values as cut-off points, in consecutive samples from 140 children with ALL at diagnosis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19672972,"The objective of the present study was to assess the expression profile of the genes related to MDR: ABCB1, ABCC1, ABCC3, ABCG2, and LRP/MVP in terms of the clinical and biological variable and the survival of children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20826236,Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20826236,To our knowledge it is the first report of an acute lymphoblastic leukaemia of T-type in a child with BWS.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20826236,To our knowledge it is the first report of an acute lymphoblastic leukaemia of T-type in a child with BWS.,Beckwith-Wiedemann Syndrome,PROCESS_OF,Child
21395650,METHODS: Sixty-six children with ALL treated according to EORTC 58951 protocol were included in this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21699468,A rare complication of intrathecal methotrexate in a child with acute lymphoblastic leukemia.,Complication,PROCESS_OF,Child
21699468,A rare complication of intrathecal methotrexate in a child with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21699468,Methotrexate (MTX) is an essential component of chemotherapy for childhood acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21699468,Methotrexate (MTX) is an essential component of chemotherapy for childhood acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Pharmacotherapy
21699468,Methotrexate (MTX) is an essential component of chemotherapy for childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21923652,"This retrospective analysis evaluated the therapy outcome of 38 children with Ataxia teleangiectasia or Nijmegen-breakage syndrome with acute lymphoblastic leukaemia (ALL, n = 9), Non-Hodgkin lymphoma (NHL, n = 28) and Hodgkin lymphoma (HL, n = 1).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19055668,"Most importantly, the advent of imatinib mesylate has changed the outlook for adults with Ph-positive ALL.",Imatinib mesylate,TREATS,"Leukemia, Lymphocytic, Acute"
19055668,The cure rate of acute lymphoblastic leukaemia (ALL) in adults remains unsatisfactory.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
19055668,Optimal management of adults with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
19055668,"Most importantly, the advent of imatinib mesylate has changed the outlook for adults with Ph-positive ALL.",Imatinib mesylate,TREATS,Adult
19055668,"Most importantly, the advent of imatinib mesylate has changed the outlook for adults with Ph-positive ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
19077160,"In order to analyse a population-based cohort with uniform treatment of initial disease, we examined the outcome of children suffering from relapsed ALL in Austria for the past 20 years and the validity of the currently used prognostic factors (e.g. time to and site of relapse, immunophenotype).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19767099,"Therefore, we have analysed alternative splicing of hMLH1 in a cohort of children with ALL.",Alternative Splicing,PROCESS_OF,cohort
19767099,"Therefore, we have analysed alternative splicing of hMLH1 in a cohort of children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19895569,"Overall, clonal IG/TCR rearrangements were detected in 97% (236/244) of B-cell precursor ALL (BCP ALL) and 94% (33/35) of T-ALL.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
20658612,"PROCEDURE: Among 433 Taiwanese children with ALL diagnosed at our hospitals between 1997 and 2007, the ETV6-RUNX1 fusion was found in 15.8%, and hyperdiploidy (>50 chromosomes) in 14.1% of the patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20658612,Frequencies of ETV6-RUNX1 fusion and hyperdiploidy in pediatric acute lymphoblastic leukemia are lower in far east than west.,Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20658612,"These frequencies were lower than those reported in the West, leading us to conduct a meta-analysis of ETV6-RUNX1 fusion and hyperdiploidy frequencies in childhood ALL based on published reports.",Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20658613,PROCEDURE: All children diagnosed with ALL at BC Children's Hospital between 2001 and 2006 were included.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21077814,"OBJECTIVES: To compare survival among the subgroup of children with acute lymphoblastic leukaemia (ALL) who were treated at Princess Margaret Hospital for Children (PMH) in Perth, Western Australia, over 25 years under 15 consecutive protocols of the Children's Cancer Group (CCG) with survival for the entire cohort of children in multiple centres treated under CCG protocols in that period; and to highlight the benefits of membership of a large cooperative research group conducting multicentre randomised controlled trials.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21077814,"OBJECTIVES: To compare survival among the subgroup of children with acute lymphoblastic leukaemia (ALL) who were treated at Princess Margaret Hospital for Children (PMH) in Perth, Western Australia, over 25 years under 15 consecutive protocols of the Children's Cancer Group (CCG) with survival for the entire cohort of children in multiple centres treated under CCG protocols in that period; and to highlight the benefits of membership of a large cooperative research group conducting multicentre randomised controlled trials.",Child,USES,Subgroup
21077814,"OBJECTIVES: To compare survival among the subgroup of children with acute lymphoblastic leukaemia (ALL) who were treated at Princess Margaret Hospital for Children (PMH) in Perth, Western Australia, over 25 years under 15 consecutive protocols of the Children's Cancer Group (CCG) with survival for the entire cohort of children in multiple centres treated under CCG protocols in that period; and to highlight the benefits of membership of a large cooperative research group conducting multicentre randomised controlled trials.",cohort,USES,Subgroup
21344760,"The study was designed to assess the long-term treatment results in children with ALL and the initial leukocytosis over 50 000/mm3 with the use of the modified ""New York"" protocols.",long-term care,TREATS,Child
21344760,"The implementation of modified ""New York"" protocols has improved the treatment results in children with ALL and initial leukocytosis over 50 000/mm3 compared to previous results.",New York protocol,TREATS,"Leukemia, Lymphocytic, Acute"
21344760,"[Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified ""New York"" protocols (1987-2003)].",Leukocytosis,PROCESS_OF,Child
21344760,The implementation of the New York protocol in 1987 and New York I in 1997 has improved the treatment results in children with ALL and initial leukocytosis over 50 000/mm3.,New York protocol,TREATS,Child
21344760,"[Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified ""New York"" protocols (1987-2003)].","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21344760,The implementation of the New York protocol in 1987 and New York I in 1997 has improved the treatment results in children with ALL and initial leukocytosis over 50 000/mm3.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21344760,The implementation of the New York protocol in 1987 and New York I in 1997 has improved the treatment results in children with ALL and initial leukocytosis over 50 000/mm3.,New York protocol,TREATS,"Leukemia, Lymphocytic, Acute"
21344760,"We present the treatment results of 340 children with ALL treated in nine centers of Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG) according to three consecutive versions of modified ""New York"" protocol (group I, II, and III) between 1987 and 2003.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21344760,"The implementation of modified ""New York"" protocols has improved the treatment results in children with ALL and initial leukocytosis over 50 000/mm3 compared to previous results.",New York protocol,TREATS,Child
21344760,"The study was designed to assess the long-term treatment results in children with ALL and the initial leukocytosis over 50 000/mm3 with the use of the modified ""New York"" protocols.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21344760,"The implementation of modified ""New York"" protocols has improved the treatment results in children with ALL and initial leukocytosis over 50 000/mm3 compared to previous results.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21344762,Objective was to assess changes in expression of cell antigens during induction treatment of ALL.,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
21344762,Objective was to assess changes in expression of cell antigens during induction treatment of ALL.,Antigens,PART_OF,Cells
21344762,Up to now there are single publications about immunophenotypic changes during treatment of ALL in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21344762,"Leukemias are the most common malignancy in children, and acute lymphoblastic leukemia (ALL) accounts for 85% of all childhood leukemias.",leukemia,ISA,"Leukemia, Lymphocytic, Acute"
21344762,[Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].,Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21344762,"Leukemias are the most common malignancy in children, and acute lymphoblastic leukemia (ALL) accounts for 85% of all childhood leukemias.",leukemia,ISA,Malignant Neoplasms
17905612,"The treatment of MLL-rearranged ALL in children involves increased intensification of chemotherapy, and infants with ALL are treated with an intensive regimen of ALL- and AML-like chemotherapy, with the proportion of MLL-rearranged cases being responsible for the poor outcome in this age group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17905612,"The treatment of MLL-rearranged ALL in children involves increased intensification of chemotherapy, and infants with ALL are treated with an intensive regimen of ALL- and AML-like chemotherapy, with the proportion of MLL-rearranged cases being responsible for the poor outcome in this age group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17905612,"The treatment of MLL-rearranged ALL in children involves increased intensification of chemotherapy, and infants with ALL are treated with an intensive regimen of ALL- and AML-like chemotherapy, with the proportion of MLL-rearranged cases being responsible for the poor outcome in this age group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
17905612,"The treatment of MLL-rearranged ALL in children involves increased intensification of chemotherapy, and infants with ALL are treated with an intensive regimen of ALL- and AML-like chemotherapy, with the proportion of MLL-rearranged cases being responsible for the poor outcome in this age group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17905612,"The majority of MLL gene rearrangements are associated with infant ALL, and their presence predicts a poor prognosis which worsens with earlier age of presentation.","Leukemia, Lymphocytic, Acute",AFFECTS,Gene Rearrangement
17905612,"The majority of MLL gene rearrangements are associated with infant ALL, and their presence predicts a poor prognosis which worsens with earlier age of presentation.",[M]Compound leukemia,PROCESS_OF,Gene Rearrangement
17905612,"The majority of MLL gene rearrangements are associated with infant ALL, and their presence predicts a poor prognosis which worsens with earlier age of presentation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19747876,BACKGROUND: A population-based cohort of children aged 1-18 years with acute lymphoblastic leukaemia (ALL) was treated with a dexamethasone-based protocol (Dutch Childhood Oncology Group [DCOG] ALL-9).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19747876,Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19875970,"BACKGROUND: Chromosomal abnormalities, such as t(9;22)(q34;q11) (ABL/BCR), t(12;21)(p13;q22) (TEL/AML1), and t(11q23) (MLL) are independent prognostic indicators in childhood acute lymphoblastic leukemia resulting in risk adapted therapy.",Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20121577,"The authors make a number of recommendations aimed at assisting parents to deal with the impact of the administration of corticosteroids in continuation therapy, including increasing the awareness on the part of health care providers of the side-effects of these drugs and their impact on the child with ALL and their family; provision of information to families on the effects of corticosteroid use; and, ensuring that professional counseling assistance is available when required.",Adrenal Cortex Hormones,AUGMENTS,Awareness
20121577,This is concerning in light of the many serious challenges corticosteroid use poses to families of children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20121577,"To date, scant information on the serious emotional side-effects of corticosteroid administration for children with ALL during the continuation period is available.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20121577,"The authors make a number of recommendations aimed at assisting parents to deal with the impact of the administration of corticosteroids in continuation therapy, including increasing the awareness on the part of health care providers of the side-effects of these drugs and their impact on the child with ALL and their family; provision of information to families on the effects of corticosteroid use; and, ensuring that professional counseling assistance is available when required.",Author,INTERACTS_WITH,Child
20121577,"The authors make a number of recommendations aimed at assisting parents to deal with the impact of the administration of corticosteroids in continuation therapy, including increasing the awareness on the part of health care providers of the side-effects of these drugs and their impact on the child with ALL and their family; provision of information to families on the effects of corticosteroid use; and, ensuring that professional counseling assistance is available when required.",Author,INTERACTS_WITH,Family
20121577,"The authors make a number of recommendations aimed at assisting parents to deal with the impact of the administration of corticosteroids in continuation therapy, including increasing the awareness on the part of health care providers of the side-effects of these drugs and their impact on the child with ALL and their family; provision of information to families on the effects of corticosteroid use; and, ensuring that professional counseling assistance is available when required.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Family
20121577,"The authors make a number of recommendations aimed at assisting parents to deal with the impact of the administration of corticosteroids in continuation therapy, including increasing the awareness on the part of health care providers of the side-effects of these drugs and their impact on the child with ALL and their family; provision of information to families on the effects of corticosteroid use; and, ensuring that professional counseling assistance is available when required.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20193149,"METHODS: This study included 88 children with ALL below the age of 18 years during the period from October 1, 2004 to June 30, 2007.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20409752,BACKGROUND: Chromosomal abnormalities in childhood acute lymphoblastic leukaemia are well established disease markers and indicators of outcomes.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21401806,"Furthermore, we found a decreased risk for high risk ALL (adjusted OR = 0.60, 95% CI = 0.40-0.88, P = 0.005), low risk ALL (adjusted OR = 0.68, 95% CI = 0.47-0.99, P = 0.042), and B-phenotype ALL (adjusted OR = 0.63, 95% CI = 0.46-0.86, P = 0.003) among children with the Ser/Ser and Ser/Cys genotypes.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21401806,"To determine whether this polymorphism is associated with risk of childhood acute lymphoblastic leukemia (ALL) in Chinese children, we genotyped the hOGG1 Ser326Cys polymorphism (rs1052133) in a case-control study including 415 cases and 511 controls.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
21653647,IMPACT: The current analysis shows that children with ALL may have a dysregulated immune function present at birth.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21653647,It is unknown whether prenatal immune development may differ in children who develop the disease.,Prenatal development,PROCESS_OF,Child
21653647,It is unknown whether prenatal immune development may differ in children who develop the disease.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
21653647,Profound deficit of IL10 at birth in children who develop childhood acute lymphoblastic leukemia.,Birth,PROCESS_OF,Child
21653647,Profound deficit of IL10 at birth in children who develop childhood acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
21866372,"METHODS: In an Australian case-control study of ALL in children aged <15 years, parents were asked about tasks they undertook in each job using a set of job-specific modules (JSMs).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21868007,CONCLUSION(S): Treatment of childhood ALL with 0-10 g/m(2) of cyclophosphamide and cranial irradiation does not affect fertility or semen quality but may impair long-term Leydig cell function.,Therapeutic procedure,NEG_AFFECTS,Fertility
21868007,CONCLUSION(S): Treatment of childhood ALL with 0-10 g/m(2) of cyclophosphamide and cranial irradiation does not affect fertility or semen quality but may impair long-term Leydig cell function.,Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21868007,CONCLUSION(S): Treatment of childhood ALL with 0-10 g/m(2) of cyclophosphamide and cranial irradiation does not affect fertility or semen quality but may impair long-term Leydig cell function.,Cyclophosphamide,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18458567,We investigated preliminarily whether methylenetetrahydrofolate reductase (MTHFR) 677C/T or reduced folate carrier 1 (RFC1) 80G/A polymorphisms were associated with toxicities during maintenance chemotherapy with mercaptopurine (6MP) and methotrexate (MTX) in children with acute lymphoblastic leukemia or lymphoblastic lymphoma.,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
18458567,We investigated preliminarily whether methylenetetrahydrofolate reductase (MTHFR) 677C/T or reduced folate carrier 1 (RFC1) 80G/A polymorphisms were associated with toxicities during maintenance chemotherapy with mercaptopurine (6MP) and methotrexate (MTX) in children with acute lymphoblastic leukemia or lymphoblastic lymphoma.,[V]Maintenance chemotherapy,PROCESS_OF,Child
18458567,We investigated preliminarily whether methylenetetrahydrofolate reductase (MTHFR) 677C/T or reduced folate carrier 1 (RFC1) 80G/A polymorphisms were associated with toxicities during maintenance chemotherapy with mercaptopurine (6MP) and methotrexate (MTX) in children with acute lymphoblastic leukemia or lymphoblastic lymphoma.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18609485,"In both the AML and ALL groups, there was a higher frequency of leukemic relapses in the bone marrow and/or central nervous system in patients with specific lesions (63.1%) compared to patients with nonspecific lesions (42%), and in patients without orbital or ocular lesions (29.2%) (p<0.05).",Lesion,PROCESS_OF,Patients
18609485,"In both the AML and ALL groups, there was a higher frequency of leukemic relapses in the bone marrow and/or central nervous system in patients with specific lesions (63.1%) compared to patients with nonspecific lesions (42%), and in patients without orbital or ocular lesions (29.2%) (p<0.05).",Bone Marrow,LOCATION_OF,"Leukemia, Myelocytic, Acute"
18609485,"In both the AML and ALL groups, there was a higher frequency of leukemic relapses in the bone marrow and/or central nervous system in patients with specific lesions (63.1%) compared to patients with nonspecific lesions (42%), and in patients without orbital or ocular lesions (29.2%) (p<0.05).",Eye,LOCATION_OF,Lesion
18609485,"In both the AML and ALL groups, there was a higher frequency of leukemic relapses in the bone marrow and/or central nervous system in patients with specific lesions (63.1%) compared to patients with nonspecific lesions (42%), and in patients without orbital or ocular lesions (29.2%) (p<0.05).",Bone Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
18609485,"In both the AML and ALL groups, there was a higher frequency of leukemic relapses in the bone marrow and/or central nervous system in patients with specific lesions (63.1%) compared to patients with nonspecific lesions (42%), and in patients without orbital or ocular lesions (29.2%) (p<0.05).",Lesion,PROCESS_OF,Patients
18609485,"In both the AML and ALL groups, there was a higher frequency of leukemic relapses in the bone marrow and/or central nervous system in patients with specific lesions (63.1%) compared to patients with nonspecific lesions (42%), and in patients without orbital or ocular lesions (29.2%) (p<0.05).",Lesion,PROCESS_OF,Patients
18609485,"In both the AML and ALL groups, there was a higher frequency of leukemic relapses in the bone marrow and/or central nervous system in patients with specific lesions (63.1%) compared to patients with nonspecific lesions (42%), and in patients without orbital or ocular lesions (29.2%) (p<0.05).",Lesion,PROCESS_OF,Patients
18609485,"In both the AML and ALL groups, there was a higher frequency of leukemic relapses in the bone marrow and/or central nervous system in patients with specific lesions (63.1%) compared to patients with nonspecific lesions (42%), and in patients without orbital or ocular lesions (29.2%) (p<0.05).",Lesion,PROCESS_OF,Patients
19176037,"METHODS: Two hundred and twenty-five children with ALL (from Jan 2003 to Dec 2006) were divided into high-(HR) and standard-risk (SR) groups according to cytomorphology, immunology, cytogenetics and molecular biology (MICM) finding.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19176037,OBJECTIVE: To retrospectively analyze the outcomes in newly diagnosed children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19176037,CONCLUSION: (1) Early intensive therapy with mid-dose Ara-C and HD-MTX significantly improves the outcome of HR children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19177822,OBJECTIVES: To establish if individually tailored doses of MP can reduce myelotoxicity in ALL patients carrying mutations in the TPMT gene.To establish if variable number of tandem repeats (VNTR) genotype influences the treatment effects of MP.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
19177822,[Importance of genotyping of thiopurine S-methyltransferase in children with acute lymphoblastic leukaemia during maintenance therapy].,Child,LOCATION_OF,TPMT gene | TPMT
19177822,[Importance of genotyping of thiopurine S-methyltransferase in children with acute lymphoblastic leukaemia during maintenance therapy].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19177822,OBJECTIVES: To establish if individually tailored doses of MP can reduce myelotoxicity in ALL patients carrying mutations in the TPMT gene.To establish if variable number of tandem repeats (VNTR) genotype influences the treatment effects of MP.,6-Mercaptopurine,TREATS,Patients
19177822,OBJECTIVES: To establish if individually tailored doses of MP can reduce myelotoxicity in ALL patients carrying mutations in the TPMT gene.To establish if variable number of tandem repeats (VNTR) genotype influences the treatment effects of MP.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
19196656,Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia.,Vincristine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19196656,Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19196656,Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia.,RAD 001,ISA,everolimus
19196656,Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia.,Therapeutic procedure,USES,Vincristine
19196656,Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia.,Vincristine,ISA,Therapeutic procedure
19459201,CONCLUSIONS: The risk of thyroid dysfunction and thyroid cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy.,Radiation therapy,TREATS,Thyroid dysfunction
19459201,CONCLUSIONS: The risk of thyroid dysfunction and thyroid cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19459201,CONCLUSIONS: The risk of thyroid dysfunction and thyroid cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy.,Radiation therapy,TREATS,Malignant neoplasm of thyroid
19459201,CONCLUSIONS: The risk of thyroid dysfunction and thyroid cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Survivors
19459201,CONCLUSIONS: The risk of thyroid dysfunction and thyroid cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy.,Thyroid dysfunction,PROCESS_OF,Survivors
19459201,CONCLUSIONS: The risk of thyroid dysfunction and thyroid cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy.,Malignant neoplasm of thyroid,PROCESS_OF,Survivors
19459201,CONCLUSIONS: The risk of thyroid dysfunction and thyroid cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy.,Radiation therapy,TREATS,Survivors
19648786,Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19648786,135 children with B-lineage ALL and a white blood count > or =50 x 10/L and 98 children with T-lineage ALL were included.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19648786,Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.,6-Mercaptopurine,higher_than,Maintenance therapy
19648786,135 children with B-lineage ALL and a white blood count > or =50 x 10/L and 98 children with T-lineage ALL were included.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Caucasoid Race
19648786,Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.,6-Mercaptopurine,compared_with,Maintenance therapy
19648786,135 children with B-lineage ALL and a white blood count > or =50 x 10/L and 98 children with T-lineage ALL were included.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19648786,135 children with B-lineage ALL and a white blood count > or =50 x 10/L and 98 children with T-lineage ALL were included.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19648786,The importance of maintenance therapy for higher risk childhood acute lymphoblastic leukemia (ALL) is uncertain.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19648786,Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19954663,"OBJECTIVE: To report a case of T cell acute lymphoblastic leukemia (ALL) with t(1;19)(q23;pl3) and E2A-PBX1 fusion gene, which is a characteristic translocation of childhood B cell ALL (B-ALL).",B-cell childhood acute lymphoblastic leukemia,ISA,"Leukemia, Lymphocytic, Acute"
20141435,"Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia.",Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20367265,The rare cases of acute lymphoblastic leukemia (ALL) in children presenting with extensive bone involvement may represent an exaggerated form of some aspects of the normal tumor-bone interactions.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20409752,METHODS: We analysed cytogenetic data from 1725 children with B-cell precursor acute lymphoblastic leukaemia who were included in the UK Medical Research Council ALL97/99 study and followed up for a median time of 8.2 years.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
21686579,Isochromosomes are rare chromosomal abnormalities in childhood ALL and the effect of i(9q) is not well established.,Isochromosomes,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21686579,Isochromosomes are rare chromosomal abnormalities in childhood ALL and the effect of i(9q) is not well established.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21686579,Isochromosomes are rare chromosomal abnormalities in childhood ALL and the effect of i(9q) is not well established.,Isochromosomes,ISA,Chromosome abnormality
21747090,"PURPOSE: In the clinical management of children with relapsed acute lymphoblastic leukemia (ALL), treatment resistance remains a major challenge.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18368069,Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18368069,Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia.,Adverse effects,PROCESS_OF,"Polymorphism, Genetic"
18496130,Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.,Hypertensive disease,PROCESS_OF,Child
18496130,Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18537965,Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18537965,Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia.,Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
18537965,Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia.,Vincristine,TREATS,Child
18569638,Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18580955,L-asparaginase is an effective drug for treatment of children with acute lymphoblastic leukemia (ALL).,ASPARAGINASE,ISA,Pharmaceutical Preparations
18580955,L-asparaginase is an effective drug for treatment of children with acute lymphoblastic leukemia (ALL).,ASPARAGINASE,TREATS,Child
18580955,L-asparaginase is an effective drug for treatment of children with acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,Child
18580955,L-asparaginase is an effective drug for treatment of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18580955,L-asparaginase is an effective drug for treatment of children with acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute"
18610829,"In the present work the frequencies of xenobiotic-metabolizing gene polymorphisms in 332 children with the diagnosis acute lymphoblastic leukemia (ALL), 71 children with the diagnosis acute myeloblastic leukemia (AML) and 490 healthy donors have been determined using allele-specific hybridization on the biochip.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18610829,"In the present work the frequencies of xenobiotic-metabolizing gene polymorphisms in 332 children with the diagnosis acute lymphoblastic leukemia (ALL), 71 children with the diagnosis acute myeloblastic leukemia (AML) and 490 healthy donors have been determined using allele-specific hybridization on the biochip.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
18610829,"In the present work the frequencies of xenobiotic-metabolizing gene polymorphisms in 332 children with the diagnosis acute lymphoblastic leukemia (ALL), 71 children with the diagnosis acute myeloblastic leukemia (AML) and 490 healthy donors have been determined using allele-specific hybridization on the biochip.",gene polymorphism,PROCESS_OF,Child
19648786,135 children with B-lineage ALL and a white blood count > or =50 x 10/L and 98 children with T-lineage ALL were included.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Caucasoid Race
19648786,135 children with B-lineage ALL and a white blood count > or =50 x 10/L and 98 children with T-lineage ALL were included.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19648786,135 children with B-lineage ALL and a white blood count > or =50 x 10/L and 98 children with T-lineage ALL were included.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19648786,These results indicate that oral MTX/6MP maintenance therapy administered after the first year of remission can improve the cure rates of children with T-lineage or with higher risk B-lineage ALL.,Maintenance therapy,TREATS,Child
19648786,These results indicate that oral MTX/6MP maintenance therapy administered after the first year of remission can improve the cure rates of children with T-lineage or with higher risk B-lineage ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19648786,These results indicate that oral MTX/6MP maintenance therapy administered after the first year of remission can improve the cure rates of children with T-lineage or with higher risk B-lineage ALL.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute"
19648786,135 children with B-lineage ALL and a white blood count > or =50 x 10/L and 98 children with T-lineage ALL were included.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19648791,Most of the children presenting with acute lymphoblastic leukemia and hypercalcemia tend to be in older age groups and have an absence of blasts in the peripheral blood film.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19648791,Most of the children presenting with acute lymphoblastic leukemia and hypercalcemia tend to be in older age groups and have an absence of blasts in the peripheral blood film.,Hypercalcemia,PROCESS_OF,Child
19860612,Random determination of serum MTX levels should be given consideration for monitoring long-term compliance with maintenance therapy in children with ALL.,Maintenance therapy,TREATS,Child
19860612,Random determination of serum MTX levels should be given consideration for monitoring long-term compliance with maintenance therapy in children with ALL.,Serum methotrexate measurement,USES,Maintenance therapy
19860612,Random determination of serum MTX levels should be given consideration for monitoring long-term compliance with maintenance therapy in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19860612,Random determination of serum MTX levels should be given consideration for monitoring long-term compliance with maintenance therapy in children with ALL.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute"
19860612,We determined the compliance status of children with ALL treated at a University Hospital.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19860612,Random serum methotrexate determinations for assessing compliance with maintenance therapy for childhood acute lymphoblastic leukemia.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20067563,The presence of a dicentric chromosome dic(9;20) has been reported to have an unfavourable prognosis in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).,Child,LOCATION_OF,SLC25A10
20067563,The presence of a dicentric chromosome dic(9;20) has been reported to have an unfavourable prognosis in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
21045397,Age and leukemia phenotype emerged as the important prognostic factors in pediatric ALL in our patients.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
21045397,Age and leukemia phenotype emerged as the important prognostic factors in pediatric ALL in our patients.,leukemia,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21045397,"MATERIALS AND METHODS: Children diagnosed with ALL were evaluated over a period of 17 years (January 1, 1989 to December 31, 2006).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21269562,Our study included 50 newly diagnosed children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21387541,Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.,METHOTREXATE TOXICITY,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21387541,Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.,SLCO1B1 gene | SLCO1B1,PREDISPOSES,METHOTREXATE TOXICITY
21584934,Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after low-risk relapse.,Peripheral Stem Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21584934,Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after low-risk relapse.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21584934,Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after low-risk relapse.,Peripheral Stem Cell Transplantation,compared_with,Pharmacotherapy
19100367,"Progress in the treatment of acute lymphoblastic leukemia (ALL) in children has been remarkable, from a disease being lethal four decades ago to current cure rates exceeding 80%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19100367,"Progress in the treatment of acute lymphoblastic leukemia (ALL) in children has been remarkable, from a disease being lethal four decades ago to current cure rates exceeding 80%.","Leukemia, Lymphocytic, Acute",ISA,Disease
19486196,"Acute lymphoblastic leukemia (ALL) is commonest in children, and acute myeloid leukemia (AML) is more frequent in adults.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
19486196,"Acute lymphoblastic leukemia (ALL) is commonest in children, and acute myeloid leukemia (AML) is more frequent in adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19688832,Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19688832,"CONCLUSIONS: Successful treatment of higher risk childhood ALL was associated with obesity, independent of cranial irradiation.",Obesity,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
19688832,BACKGROUND: This retrospective analysis defined and described patterns and predictors of weight change during treatment in children with acute lymphocytic leukemia (ALL) with high-risk features who received treatment on Children's Cancer Group protocol CCG 1961.,Body Weight Changes,PROCESS_OF,Child
19688832,BACKGROUND: This retrospective analysis defined and described patterns and predictors of weight change during treatment in children with acute lymphocytic leukemia (ALL) with high-risk features who received treatment on Children's Cancer Group protocol CCG 1961.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19711434,"BACKGROUND: Our original studies reported an association between the iron-metabolism gene HFE and risk of childhood acute lymphoblastic leukemia (ALL), and a birth weight association in ALL.","Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
19860612,Random determination of serum MTX levels should be given consideration for monitoring long-term compliance with maintenance therapy in children with ALL.,Serum methotrexate measurement,USES,Maintenance therapy
19860612,Random determination of serum MTX levels should be given consideration for monitoring long-term compliance with maintenance therapy in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19860612,Random determination of serum MTX levels should be given consideration for monitoring long-term compliance with maintenance therapy in children with ALL.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute"
19860612,Random determination of serum MTX levels should be given consideration for monitoring long-term compliance with maintenance therapy in children with ALL.,Maintenance therapy,TREATS,Child
20209620,Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
20209620,Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.,Central Nervous System Prophylaxis,TREATS,Adult
20209620,Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.,Therapeutic procedure,TREATS,Adult
20209620,Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.,Central Nervous System Prophylaxis,TREATS,"Leukemia, Lymphocytic, Acute"
20209620,Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
20668473,"In conclusion, flowcytometric MRD detection is possible in children with AML.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
20668473,"In conclusion, flowcytometric MRD detection is possible in children with AML.",Detection,TREATS,"Leukemia, Myelocytic, Acute"
20668473,"In conclusion, flowcytometric MRD detection is possible in children with AML.",Detection,TREATS,Child
20693762,[Treatment strategy for childhood and adolescent acute lymphoblastic leukemia in first remission].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
20855458,Thiopurine drugs such as 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used to treat acute lymphoblastic leukemia of childhood.,Thioguanine,TREATS,"Leukemia, Lymphocytic, Acute"
20855458,Thiopurine drugs such as 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used to treat acute lymphoblastic leukemia of childhood.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
20855458,Thiopurine drugs such as 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used to treat acute lymphoblastic leukemia of childhood.,thiopurine,ISA,Pharmaceutical Preparations
20855458,Thiopurine drugs such as 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used to treat acute lymphoblastic leukemia of childhood.,6-Mercaptopurine,ISA,Pharmaceutical Preparations
20970323,Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
20970323,Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21423043,The rapidity of response to induction therapy is emerging as an important prognostic factor in children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).,Neoadjuvant Therapy,TREATS,Child
21423043,The rapidity of response to induction therapy is emerging as an important prognostic factor in children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
21423043,The rapidity of response to induction therapy is emerging as an important prognostic factor in children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21423043,The rapidity of response to induction therapy is emerging as an important prognostic factor in children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).,Neoadjuvant Therapy,TREATS,"Leukemia, Myelocytic, Acute"
21423043,The rapidity of response to induction therapy is emerging as an important prognostic factor in children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
21497906,"CONCLUSION: Our data suggest that there did not appear to be any prognostic value of BclI, ER22/23EK, and N363S polymorphisms for predicting relapse in this population of 100 Iranian children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21497906,"No statistically significant association between BclI, N363S, and ER22/23EK polymorphisms and risk of relapse in children with ALL was observed (P = 0.104 [BclI], not calculated for the last 2 polymorphisms [N363S and ER22/23EK]).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21497906,"RESULTS: One hundred children with ALL, consisting of 65 males and 35 females, were recruited into this study.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21497906,"OBJECTIVE: The aim of this study was to evaluate the possible association between 3 prominent glucocorticoid receptor gene polymorphisms-BclI, N363S, and ER22/23EK-and the risk of relapse in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21497906,"METHODS: We conducted a case-control study on 100 children with ALL, aged 0 to 15 years, including 50 nonrelapsed (control) and 50 relapsed (case) subjects.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18243305,To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A polymorphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the breast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192 control patients.,Child,LOCATION_OF,"ABCG2 protein, human | ABCG2"
18243305,To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A polymorphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the breast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192 control patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
18243305,To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A polymorphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the breast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192 control patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18243305,To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A polymorphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the breast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192 control patients.,disease characteristic,ASSOCIATED_WITH,ABCB1 gene | ABCB1
18243305,To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A polymorphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the breast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192 control patients.,Patients,LOCATION_OF,"ABCG2 protein, human | ABCG2"
19100368,"While the goal of effective therapy for the majority of children with ALL has been achieved, significant numbers of patients still die due to recurrent disease or the toxicity of treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19100372,Minimal residual disease in acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
20145275,"RESULTS: The incidences of MPAL were 28/582 and 4/107 for children treated with acute lymphoblastic leukemia and acute myeloid leukemia regimens, respectively.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
20145275,"RESULTS: The incidences of MPAL were 28/582 and 4/107 for children treated with acute lymphoblastic leukemia and acute myeloid leukemia regimens, respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20229709,"MATERIAL AND METHODS: The study group consisted of 66 children with ALL treated at the Department of Pediatric, Hematology and Oncology in Zabrze.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20724951,L-asparaginase (L-ASNase) has been an essential component of multiagent chemotherapy for acute lymphoblastic leukemia in childhood for over 3 decades.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
20724951,L-asparaginase (L-ASNase) has been an essential component of multiagent chemotherapy for acute lymphoblastic leukemia in childhood for over 3 decades.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
20724951,L-asparaginase (L-ASNase) has been an essential component of multiagent chemotherapy for acute lymphoblastic leukemia in childhood for over 3 decades.,ASPARAGINASE,ISA,Pharmacotherapy
21436736,The mixed lineage leukemia (MLL)-AF4 fusion/t(4;11) is mostly found in acute lymphoblastic leukemia (ALL) and MLL-AF9 fusion/t(9;11) in acute myeloid leukemia (AML).,"Leukemia, Lymphocytic, Acute",COEXISTS_WITH,"Leukemia, Myelocytic, Acute"
21606961,MicroRNAs (miRNAs) relevant to acute lymphoblastic leukemia (ALL) in children are hypothesized to be largely unknown as most miRNAs have been identified in non-leukemic tissues.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21646917,"We examined 24 adults who received 18 Gy CRT and chemotherapy for treatment of ALL between ages 2 and 15 years (median, 5.5).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
21792038,The mRNA expression of Ikaros was detected in 88 children with previously untreated ALL by nested reverse transcription-polymerase chain reaction (RT-PCR).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21792038,The mRNA expression of Ikaros was detected in 88 children with previously untreated ALL by nested reverse transcription-polymerase chain reaction (RT-PCR).,mRNA Expression,PROCESS_OF,Child
21792039,"Unlike previous studies, we found that the expression of MyAg in children with T-ALL and B-ALL was comparable, and the percentage of patients with a high WBC count (>50*109/L) and CD34 positivity in MyAg+ was higher than that in MyAg- ALL types, but no differences were found with regard to other clinical features.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21792039,"OBJECTIVE: In this study, we investigated the immunophenotypic subtype profiles of 207 Chinese children with acute lymphoblastic leukemia (ALL) and its association with cytogenetics and clinical features.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21792039,"Unlike previous studies, we found that the expression of MyAg in children with T-ALL and B-ALL was comparable, and the percentage of patients with a high WBC count (>50*109/L) and CD34 positivity in MyAg+ was higher than that in MyAg- ALL types, but no differences were found with regard to other clinical features.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21792039,"Unlike previous studies, we found that the expression of MyAg in children with T-ALL and B-ALL was comparable, and the percentage of patients with a high WBC count (>50*109/L) and CD34 positivity in MyAg+ was higher than that in MyAg- ALL types, but no differences were found with regard to other clinical features.",Antigens,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
21792039,"Unlike previous studies, we found that the expression of MyAg in children with T-ALL and B-ALL was comparable, and the percentage of patients with a high WBC count (>50*109/L) and CD34 positivity in MyAg+ was higher than that in MyAg- ALL types, but no differences were found with regard to other clinical features.",Antigens,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
21792039,"RESULTS: Of the 207 children with ALL, 11.6% were identified as T-ALL and 88.4% as B-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21792039,CONCLUSIONS: Our results indicate that the distribution of ALL in Chinese children was similar to the general distribution pattern in other countries.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21792039,METHODS: A total of 207 children with ALL were immunophenotyped by 4-color flow cytometry using a panel of monoclonal antibodies.,Flow Cytometry,USES,Monoclonal Antibodies
21792039,"Unlike previous studies, we found that the expression of MyAg in children with T-ALL and B-ALL was comparable, and the percentage of patients with a high WBC count (>50*109/L) and CD34 positivity in MyAg+ was higher than that in MyAg- ALL types, but no differences were found with regard to other clinical features.",Antigens,PART_OF,Child
21792039,METHODS: A total of 207 children with ALL were immunophenotyped by 4-color flow cytometry using a panel of monoclonal antibodies.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22039382,The results of this study showed the positive effects of administering self-care on the quality of life of children suffering from acute lymphocytic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22039382,"Consequently, the present study was conducted in 2007-2008 about the effects of self-care on the lives of children suffering from acute lymphocytic leukemia, referring to treatment centers in Isfahan City.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22039382,The Effect of self-care on the lives of children suffering from acute lymphocytic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18253115,"In this population-based study of acute lymphoblastic leukaemia (ALL) diagnosed among children aged under 15 years in England and Wales during 1986-1995, we analysed incidence at census ward level in relation to a range of variables from the 1991 census, which could be relevant to theories of infectious aetiology.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18458336,Our findings provide insights into the leukemogenic process and may be clinically important in adult and adolescent ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
18458336,Our findings provide insights into the leukemogenic process and may be clinically important in adult and adolescent ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
18458336,"Importantly, the pattern of deletions resembled that recently reported in pediatric ALL, suggesting that adult, adolescent, and childhood cases may be more similar on the genetic level than previously thought.",DELETION,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
18458336,We present here a genome-wide map of abnormalities found in diagnostic samples from 45 adults and adolescents with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
18458336,Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease.,Disease,PROCESS_OF,Adolescent
18458336,Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease.,Disease,PROCESS_OF,Adult
18458336,Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
19109731,We evaluated major cytogenetic abnormalities associated with childhood acute lymphoblastic leukemia (ALL) through both fluorescent in situ hybridization and conventional chromosomal analysis for 132 ALL patients diagnosed at St Mary's Hospital in Korea.,Hospitals,LOCATION_OF,Fluorescent in Situ Hybridization
19109731,We evaluated major cytogenetic abnormalities associated with childhood acute lymphoblastic leukemia (ALL) through both fluorescent in situ hybridization and conventional chromosomal analysis for 132 ALL patients diagnosed at St Mary's Hospital in Korea.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
19109731,"We believe that the data provided will aid in comparative studies of the treatment outcomes, as well as the type and incidence of chromosomal abnormalities associated with childhood ALL in various Asian nations and Western countries.","Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,Chromosome abnormality
19109731,We evaluated major cytogenetic abnormalities associated with childhood acute lymphoblastic leukemia (ALL) through both fluorescent in situ hybridization and conventional chromosomal analysis for 132 ALL patients diagnosed at St Mary's Hospital in Korea.,"Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,Chromosome abnormality
19109731,We evaluated major cytogenetic abnormalities associated with childhood acute lymphoblastic leukemia (ALL) through both fluorescent in situ hybridization and conventional chromosomal analysis for 132 ALL patients diagnosed at St Mary's Hospital in Korea.,Hospitals,LOCATION_OF,Chromosomal analysis
19138562,"However, hierarchical clustering showed that many of these genetically unclassified cases clustered with BCR-ABL1-positive cases: 30 (19%) of 154 children with precursor B-ALL in the COALL cohort and 14 (15%) of 92 children with precursor B-ALL in the DCOG cohort had this BCR-ABL1-like disease.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
19138562,We aimed to use a genome-wide study to improve prognostic classification of ALL in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19138562,BACKGROUND: Genetic subtypes of acute lymphoblastic leukaemia (ALL) are used to determine risk and treatment in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19138562,"However, hierarchical clustering showed that many of these genetically unclassified cases clustered with BCR-ABL1-positive cases: 30 (19%) of 154 children with precursor B-ALL in the COALL cohort and 14 (15%) of 92 children with precursor B-ALL in the DCOG cohort had this BCR-ABL1-like disease.","Leukemia, B-Cell, Acute",PROCESS_OF,cohort
19138562,"However, hierarchical clustering showed that many of these genetically unclassified cases clustered with BCR-ABL1-positive cases: 30 (19%) of 154 children with precursor B-ALL in the COALL cohort and 14 (15%) of 92 children with precursor B-ALL in the DCOG cohort had this BCR-ABL1-like disease.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
19138562,"However, hierarchical clustering showed that many of these genetically unclassified cases clustered with BCR-ABL1-positive cases: 30 (19%) of 154 children with precursor B-ALL in the COALL cohort and 14 (15%) of 92 children with precursor B-ALL in the DCOG cohort had this BCR-ABL1-like disease.","Leukemia, B-Cell, Acute",PROCESS_OF,cohort
19213989,Quantitative computed tomography was performed to determine bone mineral density (BMD) at initial presentation and following 6-months of therapy in children with acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,Child
19213989,Quantitative computed tomography was performed to determine bone mineral density (BMD) at initial presentation and following 6-months of therapy in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19213989,Quantitative computed tomography was performed to determine bone mineral density (BMD) at initial presentation and following 6-months of therapy in children with acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
19213989,"To conclude, there was a significant reduction of BMD in children with ALL following 6- months of treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19956952,METHODS: We studied these metabolites in 229 blood samples from 18 children with ALL (N = 16) or NHL (N = 2) on 6MP/Methotrexate maintenance therapy.,Blood specimen,LOCATION_OF,Metabolites
19956952,METHODS: We studied these metabolites in 229 blood samples from 18 children with ALL (N = 16) or NHL (N = 2) on 6MP/Methotrexate maintenance therapy.,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
19956952,METHODS: We studied these metabolites in 229 blood samples from 18 children with ALL (N = 16) or NHL (N = 2) on 6MP/Methotrexate maintenance therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21527934,DEX in induction therapy for children with ALL is more efficacious than PRED.,Neoadjuvant Therapy,TREATS,Child
21527934,DEX in induction therapy for children with ALL is more efficacious than PRED.,Prednisone,TREATS,Child
21527934,DEX in induction therapy for children with ALL is more efficacious than PRED.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
21527934,DEX in induction therapy for children with ALL is more efficacious than PRED.,Prednisone,TREATS,"Leukemia, Lymphocytic, Acute"
21527934,DEX in induction therapy for children with ALL is more efficacious than PRED.,Neoadjuvant Therapy,higher_than,Prednisone
21527934,We searched biomedical literature databases and conference proceedings for randomized controlled trials comparing DEX and PRED during induction therapy for childhood ALL.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21527934,DEX in induction therapy for children with ALL is more efficacious than PRED.,Neoadjuvant Therapy,compared_with,Prednisone
21527934,We searched biomedical literature databases and conference proceedings for randomized controlled trials comparing DEX and PRED during induction therapy for childhood ALL.,Dexamethasone,compared_with,Prednisone
21527934,DEX in induction therapy for children with ALL is more efficacious than PRED.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21546902,Minimal residual disease (MRD) quantified after induction treatment of childhood acute lymphoblastic leukemia (ALL) predicts risk of relapse.,Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21792040,This study explores the adrenal function in 96 children with ALL treated according to common protocols.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18409021,"The study analysed 121 cases of children, aged under 5 years, who were diagnosed with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18409021,Maximal rates were seen in children born in February and August in the simple harmonic regression model for all children diagnosed with ALL.,Child,USES,Study models
18409021,Maximal rates were seen in children born in February and August in the simple harmonic regression model for all children diagnosed with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18570650,BACKGROUND: To reduce the risk of brain damage children with acute lymphoblastic leukaemia (ALL) are nowadays mainly treated with intrathecal chemotherapy (ITC) instead of central nervous system (CNS) radiation therapy (CRT) to prevent CNS relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18570650,BACKGROUND: To reduce the risk of brain damage children with acute lymphoblastic leukaemia (ALL) are nowadays mainly treated with intrathecal chemotherapy (ITC) instead of central nervous system (CNS) radiation therapy (CRT) to prevent CNS relapse.,Intrathecal Chemotherapy,TREATS,Child
18570650,"As growth hormone deficiency (GHD) or impaired growth hormone secretion are frequently found in ALL patients treated with cranial radiation therapy and/or chemotherapy, we hypothesized that GH therapy may reduce cognitive deficits in these patients.",COGNITIVE DEFICIT,PROCESS_OF,Survivors
18570650,BACKGROUND: To reduce the risk of brain damage children with acute lymphoblastic leukaemia (ALL) are nowadays mainly treated with intrathecal chemotherapy (ITC) instead of central nervous system (CNS) radiation therapy (CRT) to prevent CNS relapse.,Intrathecal Chemotherapy,TREATS,Brain Injuries
18570650,"As growth hormone deficiency (GHD) or impaired growth hormone secretion are frequently found in ALL patients treated with cranial radiation therapy and/or chemotherapy, we hypothesized that GH therapy may reduce cognitive deficits in these patients.",Therapeutic procedure,PREVENTS,COGNITIVE DEFICIT
18570650,BACKGROUND: To reduce the risk of brain damage children with acute lymphoblastic leukaemia (ALL) are nowadays mainly treated with intrathecal chemotherapy (ITC) instead of central nervous system (CNS) radiation therapy (CRT) to prevent CNS relapse.,Intrathecal Chemotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
18570650,"As growth hormone deficiency (GHD) or impaired growth hormone secretion are frequently found in ALL patients treated with cranial radiation therapy and/or chemotherapy, we hypothesized that GH therapy may reduce cognitive deficits in these patients.",growth hormone secretion,PROCESS_OF,Patients
18570650,"As growth hormone deficiency (GHD) or impaired growth hormone secretion are frequently found in ALL patients treated with cranial radiation therapy and/or chemotherapy, we hypothesized that GH therapy may reduce cognitive deficits in these patients.",Radiation therapy,TREATS,Patients
18570650,BACKGROUND: To reduce the risk of brain damage children with acute lymphoblastic leukaemia (ALL) are nowadays mainly treated with intrathecal chemotherapy (ITC) instead of central nervous system (CNS) radiation therapy (CRT) to prevent CNS relapse.,Brain Injuries,PROCESS_OF,Child
18570650,"As growth hormone deficiency (GHD) or impaired growth hormone secretion are frequently found in ALL patients treated with cranial radiation therapy and/or chemotherapy, we hypothesized that GH therapy may reduce cognitive deficits in these patients.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
18570650,"As growth hormone deficiency (GHD) or impaired growth hormone secretion are frequently found in ALL patients treated with cranial radiation therapy and/or chemotherapy, we hypothesized that GH therapy may reduce cognitive deficits in these patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
19346877,"PURPOSE: To assess (1) the effect of a home-based nutrition and exercise intervention program on cardiovascular fitness, strength, and flexibility in children with ALL during maintenance therapy and (2) the feasibility of conducting and evaluating a home-based exercise and nutrition program in this patient population.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19346877,"PURPOSE: To assess (1) the effect of a home-based nutrition and exercise intervention program on cardiovascular fitness, strength, and flexibility in children with ALL during maintenance therapy and (2) the feasibility of conducting and evaluating a home-based exercise and nutrition program in this patient population.",Fitness,TREATS,Child
19346877,Further investigation involving larger populations of children with ALL is warranted.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19573409,"METHODS: Among the 327 B-ALL children enrolled in our study, 289 cases were identified with at least one antigen combination as MRD marker.",Antigens,PREDISPOSES,"Neoplasm, Residual"
19573409,"METHODS: Among the 327 B-ALL children enrolled in our study, 289 cases were identified with at least one antigen combination as MRD marker.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19764592,[Immunoglobulin genes and T-cell receptors as molecular markers in children with acute lymphoblastic leukaemia].,Child,LOCATION_OF,"Genes, Immunoglobulin"
19764592,[Immunoglobulin genes and T-cell receptors as molecular markers in children with acute lymphoblastic leukaemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19764592,"METHODS: Forty-one children with ALL were enrolled in the study group, with initial diagnosis of IgH and TCR gene rearrangements by polimerase chain reaction (PCR).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19764592,[Immunoglobulin genes and T-cell receptors as molecular markers in children with acute lymphoblastic leukaemia].,Child,LOCATION_OF,T-Cell Receptor
19966411,Bacterial L-asparaginases have been used in the treatment of childhood acute lymphoblastic leukaemia for over 30 years.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20033410,"METHODS: To clarify the pharmacokinetic interactions between these two antimetabolites, we serially measured RBC 6-TGN and MTX polyglutamates (MTXPG) levels following repeated courses of HDMTX (5 g/m(2) over 24 h) with daily oral 6-MP (25 mg/m(2)) during interval therapy in 20 children with ALL.",Therapeutic procedure,TREATS,Child
20033410,"METHODS: To clarify the pharmacokinetic interactions between these two antimetabolites, we serially measured RBC 6-TGN and MTX polyglutamates (MTXPG) levels following repeated courses of HDMTX (5 g/m(2) over 24 h) with daily oral 6-MP (25 mg/m(2)) during interval therapy in 20 children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20033410,"METHODS: To clarify the pharmacokinetic interactions between these two antimetabolites, we serially measured RBC 6-TGN and MTX polyglutamates (MTXPG) levels following repeated courses of HDMTX (5 g/m(2) over 24 h) with daily oral 6-MP (25 mg/m(2)) during interval therapy in 20 children with ALL.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
20306673,The MDM-2 expression by flowcytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of ALL children (at initial diagnosis) and also of control group.,peripheral blood,LOCATION_OF,TP53 gene | TP53
20306673,The MDM-2 expression by flowcytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of ALL children (at initial diagnosis) and also of control group.,Bone Marrow,LOCATION_OF,TP53 gene | TP53
20306673,"The ALL children were treated by the modified BFM 76179 protocol of therapy, 29 patients (63%) achieved complete remission, while 17 patients (37%) were subsequently failed to achieve complete remission or relapsed within 6 months of achieving complete remission (CR).",Berlin-Frankfort-Munster protocol,TREATS,Child
20306673,The MDM-2 expression by flowcytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of ALL children (at initial diagnosis) and also of control group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20306673,"The ALL children were treated by the modified BFM 76179 protocol of therapy, 29 patients (63%) achieved complete remission, while 17 patients (37%) were subsequently failed to achieve complete remission or relapsed within 6 months of achieving complete remission (CR).",Berlin-Frankfort-Munster protocol,TREATS,"Leukemia, Lymphocytic, Acute"
20306673,"This work was conducted on 46 children with ALL (31 males and 15 females) with age range 2-18 years, 18 children with matched age and sex were enrolled in the study as a control group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20306673,"The ALL children were treated by the modified BFM 76179 protocol of therapy, 29 patients (63%) achieved complete remission, while 17 patients (37%) were subsequently failed to achieve complete remission or relapsed within 6 months of achieving complete remission (CR).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20306673,The MDM-2 expression by flowcytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of ALL children (at initial diagnosis) and also of control group.,peripheral blood,PART_OF,Child
20306673,The MDM-2 expression by flowcytometry and p53 gene status by PCR were determined in peripheral blood or bone marrow of ALL children (at initial diagnosis) and also of control group.,Bone Marrow,PART_OF,Child
20425458,Most children with ALL have been able to achieve a complete remission (CR) with an induction rate of about 98% and a 5-year estimated event-free survival rate (EFS) rate of about 80%.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20582937,"PROCEDURE: This is a Phase I study of escalating doses bortezomib administered days 1, 4, 8, and 11, added to 4-drug induction chemotherapy with vincristine, dexamethasone, pegylated L-asparaginase, and doxorubicin (VXLD) in children with relapsed ALL.",Vincristine,STIMULATES,Pharmaceutical Preparations
20582937,"PROCEDURE: This is a Phase I study of escalating doses bortezomib administered days 1, 4, 8, and 11, added to 4-drug induction chemotherapy with vincristine, dexamethasone, pegylated L-asparaginase, and doxorubicin (VXLD) in children with relapsed ALL.",Doxorubicin,STIMULATES,Pharmaceutical Preparations
20582937,"PROCEDURE: This is a Phase I study of escalating doses bortezomib administered days 1, 4, 8, and 11, added to 4-drug induction chemotherapy with vincristine, dexamethasone, pegylated L-asparaginase, and doxorubicin (VXLD) in children with relapsed ALL.",Dexamethasone,STIMULATES,Pharmaceutical Preparations
20582937,"PROCEDURE: This is a Phase I study of escalating doses bortezomib administered days 1, 4, 8, and 11, added to 4-drug induction chemotherapy with vincristine, dexamethasone, pegylated L-asparaginase, and doxorubicin (VXLD) in children with relapsed ALL.",ASPARAGINASE,STIMULATES,Pharmaceutical Preparations
20582937,"PROCEDURE: This is a Phase I study of escalating doses bortezomib administered days 1, 4, 8, and 11, added to 4-drug induction chemotherapy with vincristine, dexamethasone, pegylated L-asparaginase, and doxorubicin (VXLD) in children with relapsed ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21072045,Asparaginase is an important component for treatment of childhood acute lymphoblastic leukemia (ALL).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21072045,Asparaginase is an important component for treatment of childhood acute lymphoblastic leukemia (ALL).,ASPARAGINASE,ISA,Therapeutic procedure
21182165,"The purpose of this study was to monitor the expression of pro- and anti-apoptotic proteins CD(95) , Bcl-2, as well as copper and zinc levels in the peripheral blood of children with acute lymphocytic leukemia (ALL) prior to and 6 months after the beginning of chemotherapy.",peripheral blood,PART_OF,Child
21182165,"The purpose of this study was to monitor the expression of pro- and anti-apoptotic proteins CD(95) , Bcl-2, as well as copper and zinc levels in the peripheral blood of children with acute lymphocytic leukemia (ALL) prior to and 6 months after the beginning of chemotherapy.",peripheral blood,LOCATION_OF,Copper
21182165,"The purpose of this study was to monitor the expression of pro- and anti-apoptotic proteins CD(95) , Bcl-2, as well as copper and zinc levels in the peripheral blood of children with acute lymphocytic leukemia (ALL) prior to and 6 months after the beginning of chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21631924,The ALL therapy was conducted according to modified Berlin-Frankfurt-Munster (BFM; n = 69) regimen or New York (n = 13) regimen.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
22162740,Acute lymphoblastic leukaemia and acute myeloblastic leukaemia are the most common malignancies diagnosed in children.,"Leukemia, Myelocytic, Acute",ISA,Malignant Neoplasms
22162740,Acute lymphoblastic leukaemia and acute myeloblastic leukaemia are the most common malignancies diagnosed in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
22162740,Acute lymphoblastic leukaemia and acute myeloblastic leukaemia are the most common malignancies diagnosed in children.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
22162740,Acute lymphoblastic leukaemia and acute myeloblastic leukaemia are the most common malignancies diagnosed in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18426524,"During the period 1997-2002, we enrolled 158 children with DS aged 0-18 years that were diagnosed with acute lymphoblastic leukaemia (ALL) (n = 97) or acute myeloid leukaemia (AML) (n = 61) at participating Children's Oncology Group institutions.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
18426524,"During the period 1997-2002, we enrolled 158 children with DS aged 0-18 years that were diagnosed with acute lymphoblastic leukaemia (ALL) (n = 97) or acute myeloid leukaemia (AML) (n = 61) at participating Children's Oncology Group institutions.",Down Syndrome,PROCESS_OF,Child
18426524,"During the period 1997-2002, we enrolled 158 children with DS aged 0-18 years that were diagnosed with acute lymphoblastic leukaemia (ALL) (n = 97) or acute myeloid leukaemia (AML) (n = 61) at participating Children's Oncology Group institutions.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18818707,New therapeutic strategies are urgently needed for children with relapsed ALL and efforts should focus on discovering the biological pathways that mediate drug resistance.,"Leukemia, Lymphocytic, Acute",AFFECTS,Drug resistance
18818707,New therapeutic strategies are urgently needed for children with relapsed ALL and efforts should focus on discovering the biological pathways that mediate drug resistance.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19036151,Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19036151,Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study.,Dexamethasone,TREATS,Child
19036151,Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study.,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
19036151,BACKGROUND: Glucocorticoids are important in the treatment of childhood acute lymphoblastic leukaemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19036151,BACKGROUND: Glucocorticoids are important in the treatment of childhood acute lymphoblastic leukaemia (ALL).,Glucocorticoids,ISA,Therapeutic procedure
19127567,"Over the past several decades partnerships (""twinning"") between HIC and LIC pediatric oncology programs have led to major improvements in outcome for children with ALL in some LICs, often by developing time and resource intensive relationships that allow LIC centers to treat children with regimens similar or identical to those used in HICs.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19127567,Cure rates for children with acute lymphoblastic leukemia (ALL) are 80-85% in high-income countries (HICs) in North America and Western Europe.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19127567,Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: A proposal.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19127567,Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: A proposal.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19148952,Early childhood infections may protect against acute lymphoid leukemia (ALL) in children with and without DS.,Down Syndrome,PROCESS_OF,Child
19148952,Early childhood infections may protect against acute lymphoid leukemia (ALL) in children with and without DS.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19444126,"French National Registry of Childhood Haematological Malignancies data and population counts by type of leukaemia (AL, acute lymphoblastic leukaemia, acute myeloblastic leukaemia), time period (1990-2004, 1990-1994, 1995-1999 and 2000-2004), sex, and age group (0-14, 0-4, 5-9 and 10-14 years of age) were considered.","Leukemia, Lymphocytic, Acute",ISA,Acute leukemia
19444126,"French National Registry of Childhood Haematological Malignancies data and population counts by type of leukaemia (AL, acute lymphoblastic leukaemia, acute myeloblastic leukaemia), time period (1990-2004, 1990-1994, 1995-1999 and 2000-2004), sex, and age group (0-14, 0-4, 5-9 and 10-14 years of age) were considered.",Acute leukemia,ISA,leukemia
20200450,"In vivo resistance to first-line chemotherapy, including to glucocorticoids, is a strong predictor of poor outcome in children with acute lymphoblastic leukemia (ALL).",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
20200450,"In vivo resistance to first-line chemotherapy, including to glucocorticoids, is a strong predictor of poor outcome in children with acute lymphoblastic leukemia (ALL).",Glucocorticoids,TREATS,Child
20200450,"In vivo resistance to first-line chemotherapy, including to glucocorticoids, is a strong predictor of poor outcome in children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20378752,Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
21150180,Thrombomodulin and von Willebrand factor: relation to endothelial dysfunction and disease outcome in children with acute lymphoblastic leukemia.,Endothelial dysfunction,PROCESS_OF,Child
21150180,Thrombomodulin and von Willebrand factor: relation to endothelial dysfunction and disease outcome in children with acute lymphoblastic leukemia.,Disease Outcome,PROCESS_OF,Child
21150180,"In children with ALL, there was a significant increase in thrombomodulin (TM) and von Willebrand factor (vWF) levels during the acute phase of the disease and during treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21150180,Thrombomodulin and von Willebrand factor: relation to endothelial dysfunction and disease outcome in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21150180,"Fifty-two children with ALL, 19 children with ALL 1-10 years after the completion of therapy, and 28 healthy children were studied.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21150180,The aim of this study was to determine the levels of markers of endothelial activation in children with ALL and to assess their potential prognostic value.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21150180,"The severe endothelial dysfunction in children with acute lymphoblastic leukemia (ALL) can result from the disease itself, from treatment, or from other conditions (e.g. sepsis).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21150180,"The severe endothelial dysfunction in children with acute lymphoblastic leukemia (ALL) can result from the disease itself, from treatment, or from other conditions (e.g. sepsis).",Endothelial dysfunction,PROCESS_OF,Child
21326239,"BACKGROUND: As most children with acute lymphoblastic leukaemia (ALL) achieve long-term survival, minimising late effects of treatment is a priority.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21649543,We analyzed the CDR3 region of 80 children with B-cell acute lymphoblastic leukemia (B-ALL) using the ImMunoGeneTics Information System and JOINSOLVER.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
18162384,[HHV-6 infection and acute lymphoblastic leukemia in a child].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18311775,"In vivo response to initial therapy, as assessed by determination of minimal residual disease (MRD) after 5 and 12 weeks of treatment, has evolved as a strong prognostic factor in children with acute lymphoblastic leukemia (ALL) treated according to the BFM regime.","Neoplasm, Residual",PROCESS_OF,Child
18311775,"In vivo response to initial therapy, as assessed by determination of minimal residual disease (MRD) after 5 and 12 weeks of treatment, has evolved as a strong prognostic factor in children with acute lymphoblastic leukemia (ALL) treated according to the BFM regime.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18648353,"This Practice Point commentary discusses the recent findings of the Children's Cancer Group CCG-1961 study, which enrolled 2,078 children and adolescents with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
18648353,"This Practice Point commentary discusses the recent findings of the Children's Cancer Group CCG-1961 study, which enrolled 2,078 children and adolescents with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18677580,"Previous studies had established an over-expression of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on lymphoblasts of childhood acute lymphoblastic leukaemia (ALL).",lymphoblast,LOCATION_OF,Sialoglycoproteins
18677580,"Previous studies had established an over-expression of 9-O-acetylated sialoglycoproteins (Neu5,9Ac(2)-GPs) on lymphoblasts of childhood acute lymphoblastic leukaemia (ALL).","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
18824710,"Compared with CCSS siblings, ALL survivors who were treated with cranial radiation therapy (CRT) had a significantly greater increase in BMI (women, 0.41 units/yr, 95% CI, 0.37 to 0.45 units; men, 0.29 units/yr; 95% CI, 0.26 to 0.32 units).",Radiation therapy,TREATS,Survivors
18824710,"Compared with CCSS siblings, ALL survivors who were treated with cranial radiation therapy (CRT) had a significantly greater increase in BMI (women, 0.41 units/yr, 95% CI, 0.37 to 0.45 units; men, 0.29 units/yr; 95% CI, 0.26 to 0.32 units).",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
18824710,"Compared with CCSS siblings, ALL survivors who were treated with cranial radiation therapy (CRT) had a significantly greater increase in BMI (women, 0.41 units/yr, 95% CI, 0.37 to 0.45 units; men, 0.29 units/yr; 95% CI, 0.26 to 0.32 units).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
18989891,Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18989891,Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
19036151,The present study was performed to assess the effect of dexamethasone on QoL during treatment for ALL according to this protocol.,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
19036706,"Importantly, XIAP inhibitors kill leukemic blasts from children with ALL ex vivo and cooperate with TRAIL to induce apoptosis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19423428,"Our procedure was applied to a significant cohort of Brazilian children with ALL, the majority of the cases treated in the last decade in the two main University Hospitals of Rio de Janeiro.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19423428,"Our procedure was applied to a significant cohort of Brazilian children with ALL, the majority of the cases treated in the last decade in the two main University Hospitals of Rio de Janeiro.",BRAZILIAN,PROCESS_OF,Child
19679573,DESIGN: The medical records of 283 children with ALL diagnosed before (1997-2002; n = 164) and after (2004-2006; n = 119) the introduction of the education programme were reviewed.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19890789,"PATIENTS AND METHODS: Medical history and clinical findings of 189 children and adolescents, diagnosed with ALL between 1/1995 and 7/2004, were analyzed retrospectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
19890789,"PATIENTS AND METHODS: Medical history and clinical findings of 189 children and adolescents, diagnosed with ALL between 1/1995 and 7/2004, were analyzed retrospectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",Steroid therapy,TREATS,"Leukemia, Lymphocytic, Acute"
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",prednisolone,TREATS,"Leukemia, Lymphocytic, Acute"
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",prednisolone,TREATS,Patients
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",prednisolone,TREATS,Large Cell Lymphoblastic Lymphoma
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",prednisolone,TREATS,"Leukemia, Lymphocytic, Acute"
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",prednisolone,TREATS,Patients
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",Dexamethasone,TREATS,Large Cell Lymphoblastic Lymphoma
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",Steroid therapy,compared_with,prednisolone
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",Dexamethasone,TREATS,Patients
20815080,"[2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.",Steroid therapy,TREATS,Patients
21098271,High hyperdiploid acute lymphoblastic leukemia (ALL) is one of the most common malignancies in children.,Malignant Neoplasms,PROCESS_OF,Child
21098271,High hyperdiploid acute lymphoblastic leukemia (ALL) is one of the most common malignancies in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
21098271,High hyperdiploid acute lymphoblastic leukemia (ALL) is one of the most common malignancies in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21280034,"We examined the relationship between three measures of early life exposure to infections-daycare attendance, birth order and common childhood infections in infancy-with the risk of ALL in non-Hispanic white and Hispanic children, two ethnicities that show sociodemographic differences.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21280034,"We examined the relationship between three measures of early life exposure to infections-daycare attendance, birth order and common childhood infections in infancy-with the risk of ALL in non-Hispanic white and Hispanic children, two ethnicities that show sociodemographic differences.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Caucasoid Race
21280034,"We examined the relationship between three measures of early life exposure to infections-daycare attendance, birth order and common childhood infections in infancy-with the risk of ALL in non-Hispanic white and Hispanic children, two ethnicities that show sociodemographic differences.",Infection,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
21280034,"When the three measures were evaluated separately, daycare attendance by the age of 6 months (odds ratio [OR] for each thousand child-hours of exposure = 0.90, 95% confidence interval [CI]: 0.82-1.00) and birth order (OR for having an older sibling = 0.68, 95% CI: 0.50-0.92) were associated with a reduced risk of ALL among non-Hispanic white children but not Hispanic children, whereas ear infection before age 6 months was protective in both ethnic groups.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21394895,"PROCEDURE: From January 1996 to November 2002, 429 eligible children with ALL were enrolled in a protocol with BFM-based back-bone, followed by a randomized continuation phase in standard (SRG) and intermediate (IRG) risk groups.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21719599,"The study is registered at http://www.clinicaltrials.gov; ""Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia,"" protocol identification #NCT00430118 for BFM and #NCT00613457 for AIEOP.",Combination Drug Therapy,TREATS,Patients
21719599,"The study is registered at http://www.clinicaltrials.gov; ""Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia,"" protocol identification #NCT00430118 for BFM and #NCT00613457 for AIEOP.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
21719599,"The study is registered at http://www.clinicaltrials.gov; ""Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia,"" protocol identification #NCT00430118 for BFM and #NCT00613457 for AIEOP.",Combination Drug Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
21969893,"The commonest types of leukaemia were acute lymphoblastic leukaemia (ALL), then acute myeloid leukaemia (AML) and finally chronic myeloid leukaemia (CML).","Leukemia, Lymphocytic, Acute",ISA,leukemia
18388178,"The Children's Oncology Group studied the prognostic impact of MRD measured by flow cytometry in the peripheral blood at day 8, and in end-induction (day 29) and end-consolidation marrows in 2143 children with precursor B-cell ALL (B-ALL).","Neoplasm, Residual",PROCESS_OF,Child
18388178,"The Children's Oncology Group studied the prognostic impact of MRD measured by flow cytometry in the peripheral blood at day 8, and in end-induction (day 29) and end-consolidation marrows in 2143 children with precursor B-cell ALL (B-ALL).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
18388178,"The Children's Oncology Group studied the prognostic impact of MRD measured by flow cytometry in the peripheral blood at day 8, and in end-induction (day 29) and end-consolidation marrows in 2143 children with precursor B-cell ALL (B-ALL).","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
18388178,"Minimal residual disease (MRD) is an important predictor of relapse in acute lymphoblastic leukemia (ALL), but its relationship to other prognostic variables has not been fully assessed.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
18388178,Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
18388178,Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.,Children's Oncology Group,LOCATION_OF,Clinical Research
18575824,A decrease in BCL-2 protein and apoptotic DNA fragmentation was detected in the studied cell lines and primary blast cells of two children with acute lymphoblastic leukemia.,Blast Cell,PART_OF,Child
18575824,A decrease in BCL-2 protein and apoptotic DNA fragmentation was detected in the studied cell lines and primary blast cells of two children with acute lymphoblastic leukemia.,Cell Line,PART_OF,Child
18575824,A decrease in BCL-2 protein and apoptotic DNA fragmentation was detected in the studied cell lines and primary blast cells of two children with acute lymphoblastic leukemia.,Blast Cell,LOCATION_OF,BCL-2 Protein
18575824,A decrease in BCL-2 protein and apoptotic DNA fragmentation was detected in the studied cell lines and primary blast cells of two children with acute lymphoblastic leukemia.,Cell Line,LOCATION_OF,BCL-2 Protein
18575824,A decrease in BCL-2 protein and apoptotic DNA fragmentation was detected in the studied cell lines and primary blast cells of two children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18824710,The rate of BMI increase was not significantly increased for ALL survivors who were treated with chemotherapy alone.,Pharmacotherapy,TREATS,Survivors
18824710,The rate of BMI increase was not significantly increased for ALL survivors who were treated with chemotherapy alone.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
18824710,The rate of BMI increase was not significantly increased for ALL survivors who were treated with chemotherapy alone.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
18824710,"CONCLUSION: CRT used in the treatment of childhood ALL is associated with a greater rate of increasing BMI, particularly among women treated with CRT during the first decade of life.",Radiation therapy,TREATS,Woman
18824710,"CONCLUSION: CRT used in the treatment of childhood ALL is associated with a greater rate of increasing BMI, particularly among women treated with CRT during the first decade of life.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19500099,Detection of minimal residual disease (MRD) after induction and consolidation therapy is highly predictive of outcome for childhood acute lymphoblastic leukaemia (ALL) and is used to identify patients at high risk of relapse in several current clinical trials.,Consolidation Therapy,PRECEDES,Detection
19500099,Detection of minimal residual disease (MRD) after induction and consolidation therapy is highly predictive of outcome for childhood acute lymphoblastic leukaemia (ALL) and is used to identify patients at high risk of relapse in several current clinical trials.,Induction,PRECEDES,Detection
19500099,Detection of minimal residual disease (MRD) after induction and consolidation therapy is highly predictive of outcome for childhood acute lymphoblastic leukaemia (ALL) and is used to identify patients at high risk of relapse in several current clinical trials.,Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19500099,Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20014183,"CONCLUSIONS: In children with ALL and liver toxicity, MT was associated with a trend toward significant reductions in liver toxicity.",Liver,LOCATION_OF,Toxic effect
20014183,"CONCLUSIONS: In children with ALL and liver toxicity, MT was associated with a trend toward significant reductions in liver toxicity.",Liver,LOCATION_OF,Toxic effect
20014183,"METHODS: In a double-blind study, children with acute lymphoblastic leukemia (ALL) and hepatic toxicity were randomized to MT or placebo orally for 28 days.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20014183,"METHODS: In a double-blind study, children with acute lymphoblastic leukemia (ALL) and hepatic toxicity were randomized to MT or placebo orally for 28 days.",Hepatic,LOCATION_OF,Toxic effect
20014183,MT did not antagonize the effects of chemotherapy agents used for the treatment of ALL.,Antineoplastic Agents,TREATS,"Leukemia, Lymphocytic, Acute"
20014183,"CONCLUSIONS: In children with ALL and liver toxicity, MT was associated with a trend toward significant reductions in liver toxicity.",Toxic effect,PROCESS_OF,Child
20014183,"CONCLUSIONS: In children with ALL and liver toxicity, MT was associated with a trend toward significant reductions in liver toxicity.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20572038,METHODS: Ninety-seven children with ALL received risk-directed therapy based on presenting clinical and biological factors.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20572038,METHODS: Ninety-seven children with ALL received risk-directed therapy based on presenting clinical and biological factors.,Therapeutic procedure,ADMINISTERED_TO,Child
20572038,METHODS: Ninety-seven children with ALL received risk-directed therapy based on presenting clinical and biological factors.,Biological Factors,ADMINISTERED_TO,Child
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.","Leukemia, Myelocytic, Acute",ISA,leukemia
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.","Leukemia, Myelocytic, Acute",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.","Leukemia, Lymphocytic, Acute",ISA,leukemia
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.","Leukemia, Lymphocytic, Acute",COEXISTS_WITH,"Leukemia, Myelocytic, Acute"
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.",leukemia,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.",leukemia,COEXISTS_WITH,"Leukemia, Myelocytic, Acute"
21178703,Serum creatinine concentration provides a surrogate measure of LBM in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21178703,Eleven children with acute lymphoblastic leukemia were assessed at 7 time points (6-mo intervals) from diagnosis to 1 year after the completion of therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21509569,"PURPOSE: The objectives of this study were (1) to develop a population pharmacokinetic model of high-dose methotrexate (HD-MTX) in children with acute lymphoblastic leukaemia (ALL) and malignant lymphoma (ML) in order to investigate the influence of common polymorphisms in SLC19A1, MTHFR and ABCB1 on plasma levels of MTX and (2) to estimate MTX exposure in individual patients to study the association of genetic variability in the folate metabolic pathway with MTX toxicity.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
21509569,"PURPOSE: The objectives of this study were (1) to develop a population pharmacokinetic model of high-dose methotrexate (HD-MTX) in children with acute lymphoblastic leukaemia (ALL) and malignant lymphoma (ML) in order to investigate the influence of common polymorphisms in SLC19A1, MTHFR and ABCB1 on plasma levels of MTX and (2) to estimate MTX exposure in individual patients to study the association of genetic variability in the folate metabolic pathway with MTX toxicity.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21509569,Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.,Methotrexate,AFFECTS,"Polymorphism, Genetic"
21509569,"PURPOSE: The objectives of this study were (1) to develop a population pharmacokinetic model of high-dose methotrexate (HD-MTX) in children with acute lymphoblastic leukaemia (ALL) and malignant lymphoma (ML) in order to investigate the influence of common polymorphisms in SLC19A1, MTHFR and ABCB1 on plasma levels of MTX and (2) to estimate MTX exposure in individual patients to study the association of genetic variability in the folate metabolic pathway with MTX toxicity.",Plasma,LOCATION_OF,MTHFR gene | MTHFR
21509569,Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.,Toxic effect,COEXISTS_WITH,Lymphoma
21509569,"PURPOSE: The objectives of this study were (1) to develop a population pharmacokinetic model of high-dose methotrexate (HD-MTX) in children with acute lymphoblastic leukaemia (ALL) and malignant lymphoma (ML) in order to investigate the influence of common polymorphisms in SLC19A1, MTHFR and ABCB1 on plasma levels of MTX and (2) to estimate MTX exposure in individual patients to study the association of genetic variability in the folate metabolic pathway with MTX toxicity.",Plasma,LOCATION_OF,ABCB1 gene | ABCB1
21509569,Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.,Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21509569,"PURPOSE: The objectives of this study were (1) to develop a population pharmacokinetic model of high-dose methotrexate (HD-MTX) in children with acute lymphoblastic leukaemia (ALL) and malignant lymphoma (ML) in order to investigate the influence of common polymorphisms in SLC19A1, MTHFR and ABCB1 on plasma levels of MTX and (2) to estimate MTX exposure in individual patients to study the association of genetic variability in the folate metabolic pathway with MTX toxicity.",Plasma,LOCATION_OF,SLC19A1
21509569,METHODS: The study population comprised 64 children with ALL/ML (age 1.6-16.8 years) who had received a total of 252 MTX courses (2-4 per patient).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21509569,"PURPOSE: The objectives of this study were (1) to develop a population pharmacokinetic model of high-dose methotrexate (HD-MTX) in children with acute lymphoblastic leukaemia (ALL) and malignant lymphoma (ML) in order to investigate the influence of common polymorphisms in SLC19A1, MTHFR and ABCB1 on plasma levels of MTX and (2) to estimate MTX exposure in individual patients to study the association of genetic variability in the folate metabolic pathway with MTX toxicity.",Methotrexate,TREATS,Child
21509569,"PURPOSE: The objectives of this study were (1) to develop a population pharmacokinetic model of high-dose methotrexate (HD-MTX) in children with acute lymphoblastic leukaemia (ALL) and malignant lymphoma (ML) in order to investigate the influence of common polymorphisms in SLC19A1, MTHFR and ABCB1 on plasma levels of MTX and (2) to estimate MTX exposure in individual patients to study the association of genetic variability in the folate metabolic pathway with MTX toxicity.",Methotrexate,TREATS,Patients
21509569,"PURPOSE: The objectives of this study were (1) to develop a population pharmacokinetic model of high-dose methotrexate (HD-MTX) in children with acute lymphoblastic leukaemia (ALL) and malignant lymphoma (ML) in order to investigate the influence of common polymorphisms in SLC19A1, MTHFR and ABCB1 on plasma levels of MTX and (2) to estimate MTX exposure in individual patients to study the association of genetic variability in the folate metabolic pathway with MTX toxicity.",Methotrexate,TREATS,Lymphoma
21509569,"PURPOSE: The objectives of this study were (1) to develop a population pharmacokinetic model of high-dose methotrexate (HD-MTX) in children with acute lymphoblastic leukaemia (ALL) and malignant lymphoma (ML) in order to investigate the influence of common polymorphisms in SLC19A1, MTHFR and ABCB1 on plasma levels of MTX and (2) to estimate MTX exposure in individual patients to study the association of genetic variability in the folate metabolic pathway with MTX toxicity.",Lymphoma,PROCESS_OF,Child
18096764,These polymorphisms were investigated for association with treatment response in 277 children with ALL.,Single Nucleotide Polymorphism,PROCESS_OF,Child
18096764,These polymorphisms were investigated for association with treatment response in 277 children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18368070,"Until 1990, the survival of children with acute lymphoblastic leukaemia (ALL) in Russia was below 10%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18661511,"METHODS: Between 2000 and 2007, 104 pediatric patients with ALL or LBL were treated at the authors' affiliated hospitals with intensive regimens that included Escherichia coli-derived L-asparaginase.",Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Patients
18661511,BACKGROUND: L-asparaginase is a key drug in the treatment of childhood acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).,ASPARAGINASE,ISA,Pharmaceutical Preparations
18661511,"METHODS: Between 2000 and 2007, 104 pediatric patients with ALL or LBL were treated at the authors' affiliated hospitals with intensive regimens that included Escherichia coli-derived L-asparaginase.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
18661511,BACKGROUND: L-asparaginase is a key drug in the treatment of childhood acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).,ASPARAGINASE,TREATS,Large Cell Lymphoblastic Lymphoma
18661511,"METHODS: Between 2000 and 2007, 104 pediatric patients with ALL or LBL were treated at the authors' affiliated hospitals with intensive regimens that included Escherichia coli-derived L-asparaginase.",Treatment Protocols,TREATS,Patients
18661511,BACKGROUND: L-asparaginase is a key drug in the treatment of childhood acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18661511,"METHODS: Between 2000 and 2007, 104 pediatric patients with ALL or LBL were treated at the authors' affiliated hospitals with intensive regimens that included Escherichia coli-derived L-asparaginase.",Treatment Protocols,TREATS,Large Cell Lymphoblastic Lymphoma
18661511,"METHODS: Between 2000 and 2007, 104 pediatric patients with ALL or LBL were treated at the authors' affiliated hospitals with intensive regimens that included Escherichia coli-derived L-asparaginase.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
18661511,BACKGROUND: L-asparaginase is a key drug in the treatment of childhood acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).,Pharmaceutical Preparations,TREATS,Large Cell Lymphoblastic Lymphoma
18661511,BACKGROUND: L-asparaginase is a key drug in the treatment of childhood acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18698082,"Retrospectively, we evaluated the available coagulation parameters at diagnosis and during induction treatment of 161 acute lymphoblastic leukemia patients: 24 with symptomatic osteonecrosis (median age: 13.8 years, range 4.0-17.2) and 137 without osteonecrosis (median age: 4.9 years, range 1.0-16.7).",Induction,TREATS,"Leukemia, Lymphocytic, Acute"
18698082,"Retrospectively, we evaluated the available coagulation parameters at diagnosis and during induction treatment of 161 acute lymphoblastic leukemia patients: 24 with symptomatic osteonecrosis (median age: 13.8 years, range 4.0-17.2) and 137 without osteonecrosis (median age: 4.9 years, range 1.0-16.7).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
18698082,"Retrospectively, we evaluated the available coagulation parameters at diagnosis and during induction treatment of 161 acute lymphoblastic leukemia patients: 24 with symptomatic osteonecrosis (median age: 13.8 years, range 4.0-17.2) and 137 without osteonecrosis (median age: 4.9 years, range 1.0-16.7).",Induction,TREATS,Patients
19099730,Good long-term outcomes of the childhood T-ALL could be achieved as the B lineage ALL had been treated with HD-AraC regimen.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19099730,Good long-term outcomes of the childhood T-ALL could be achieved as the B lineage ALL had been treated with HD-AraC regimen.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
19099804,[Efficacy and prognosis analysis in 188 children with acute lymphoblastic leukemia of China].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19816207,We screened 28 children with T-lineage acute lymphoblastic leukemia at diagnosis by reverse transcription polymerase chain reaction for major and minor break point regions of bcr-abl fusion gene.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19951974,"Using a cohort of 48 children with B-lineage acute lymphoblastic leukemia (ALL), we sought the newly proposed candidate-LSC population, CD34(+)CD38(low)CD19(+), at presentation and in end of induction bone marrow samples.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20212252,Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20212252,Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
20212252,Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.","Leukemia, Myelocytic, Acute",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.","Leukemia, Lymphocytic, Acute",ISA,leukemia
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.","Leukemia, Lymphocytic, Acute",COEXISTS_WITH,"Leukemia, Myelocytic, Acute"
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.",leukemia,COEXISTS_WITH,"Leukemia, Myelocytic, Acute"
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.",leukemia,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
21169835,"In contrast, genomic profiling of acute myeloid leukemia (AML) has thus far yielded fewer insights, but ongoing resequencing of leukemia genomes is uncovering novel mutations in both ALL and AML.","Leukemia, Myelocytic, Acute",ISA,leukemia
21344616,Multivariate analysis of the relation between immune dysfunction and treatment intensity in children with acute lymphoblastic leukemia.,Immune System Diseases,PROCESS_OF,Child
21344616,Multivariate analysis of the relation between immune dysfunction and treatment intensity in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21366654,Our objective was to retrospectively evaluate the pharmacokinetics and plasma levels of high-dose methotrexate as it relates to event-free survival (EFS) in children with ALL.,Drug Kinetics,PROCESS_OF,Child
21366654,Our objective was to retrospectively evaluate the pharmacokinetics and plasma levels of high-dose methotrexate as it relates to event-free survival (EFS) in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21366654,High-dose methotrexate is a common component of many chemotherapeutic protocols for childhood with ALL.,Methotrexate,ISA,Chemotherapy-Oncologic Procedure
21366654,"WHAT IS KNOWN AND OBJECTIVE: In industrialized countries, acute lymphoblastic leukaemia (ALL) is the most frequent cancer in children aged less than 15 years.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21366654,Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21366654,WHAT IS NEW AND CONCLUSION: Serum concentrations and pharmacokinetic parameters of MTX are not associated with outcome in ALL.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
21867623,[Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance].,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
21867623,[Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance].,Detection,TREATS,Child
21867623,[Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance].,Detection,TREATS,"Leukemia, Myelocytic, Acute"
18184841,"CONCLUSION: These findings are consistent with previous literature describing the long-term cognitive, academic, and imaging findings of survivors of ALL and suggest that right frontal white matter is particularly vulnerable to disruption following intensive chemotherapy for ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
18398226,Methotrexate-induced alterations in beta-oxidation correlate with cognitive abilities in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18521602,Response to initial glucocorticoid (GC) treatment is a strong prognostic factor in childhood acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18521602,Response to initial glucocorticoid (GC) treatment is a strong prognostic factor in childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,ISA,Therapeutic procedure
18521602,Response to initial glucocorticoid (GC) treatment is a strong prognostic factor in childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18688848,CONCLUSION: This report examines a cohort of children with ALL treated with a BFM protocol in India with adequate follow up and demonstrates the need for cost effective improvements.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18688848,CONCLUSION: This report examines a cohort of children with ALL treated with a BFM protocol in India with adequate follow up and demonstrates the need for cost effective improvements.,Berlin-Frankfort-Munster protocol,TREATS,"Leukemia, Lymphocytic, Acute"
18688848,PROCEDURE: Three hundred and seven children (1-14 years) with acute lymphoblastic leukemia (ALL) were treated with a modified BFM protocol 76/79 between 1985 and 2003.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18688848,Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18688848,Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.,Berlin-Frankfort-Munster protocol,ADMINISTERED_TO,Child
19713226,"BACKGROUND: The t(9;22) and t(4;11) chromosomal translocations, which generate the BCR-ABL and MLL-AF4 fusion genes, define high-risk subtypes of acute lymphoblastic leukemia in adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
20034668,The study was aimed to explore the value of minimal residual disease (MRD) for risk stratification in childhood precursor-B-acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,B-cell childhood acute lymphoblastic leukemia
20034668,Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20212252,Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20212252,Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
20212252,Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
20212252,"PURPOSE To describe event-free survival (EFS) and toxicities in children with low-risk acute lymphoblastic leukemia (ALL) assigned to receive either continuous 6-mercaptopurine (6-MP) and weekly methotrexate (MTX) or intermittent 6-MP with intermediate-dose MTX, as maintenance treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20212252,"PURPOSE To describe event-free survival (EFS) and toxicities in children with low-risk acute lymphoblastic leukemia (ALL) assigned to receive either continuous 6-mercaptopurine (6-MP) and weekly methotrexate (MTX) or intermittent 6-MP with intermediate-dose MTX, as maintenance treatment.",Toxic effect,PROCESS_OF,Child
21129267,"This study was purposed to detect the minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) by using real time quantitative PCR (RQ-PCR) . The Ig and TCR gene rearrangements were amplified by using 18 primer sets in B-ALL, 8 primer sets in T-ALL; the ALL-MRD levels were quantified by using RQ-PCR with SYBR green dye staining and clone specific Ig/TCR gene rearrangements as molecular markers.",Polymerase Chain Reaction,DIAGNOSES,"Leukemia, Lymphocytic, Acute"
21129267,"This study was purposed to detect the minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) by using real time quantitative PCR (RQ-PCR) . The Ig and TCR gene rearrangements were amplified by using 18 primer sets in B-ALL, 8 primer sets in T-ALL; the ALL-MRD levels were quantified by using RQ-PCR with SYBR green dye staining and clone specific Ig/TCR gene rearrangements as molecular markers.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21129267,[Detection of minimal residual disease in childhood acute lymphoblastic leukemia by using real-time quantitative PCR].,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21129267,"It is concluded that Ig/TCR gene rearrangements can be used as a marker to detect MRD in childhood ALL; the technique of QR-PCR with SYBR green dye staining is reliable, relatively sensitive and easy performable method which can be used in routine detection for childhood ALL.",Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21129267,"It is concluded that Ig/TCR gene rearrangements can be used as a marker to detect MRD in childhood ALL; the technique of QR-PCR with SYBR green dye staining is reliable, relatively sensitive and easy performable method which can be used in routine detection for childhood ALL.",Polymerase Chain Reaction,USES,Detection
21129267,"It is concluded that Ig/TCR gene rearrangements can be used as a marker to detect MRD in childhood ALL; the technique of QR-PCR with SYBR green dye staining is reliable, relatively sensitive and easy performable method which can be used in routine detection for childhood ALL.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21246704,Western Australian children with acute lymphoblastic leukemia are taller at diagnosis than unaffected children of the same age and sex.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21246704,Western Australian children with acute lymphoblastic leukemia are taller at diagnosis than unaffected children of the same age and sex.,AUSTRALIAN,PROCESS_OF,Child
21261497,The Japan Association of Childhood Leukemia Study (JACLS) NHL-98 is a multicenter study designed to evaluate treatment outcomes in Japanese children with B-cell non-Hodgkin lymphoma (B-NHL) and mature B-cell acute lymphoblastic leukemia (B-ALL).,B-Cell Lymphomas,PROCESS_OF,Child
21261497,The Japan Association of Childhood Leukemia Study (JACLS) NHL-98 is a multicenter study designed to evaluate treatment outcomes in Japanese children with B-cell non-Hodgkin lymphoma (B-NHL) and mature B-cell acute lymphoblastic leukemia (B-ALL).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
21261497,"Patients in groups B, C, and D received consolidation phases with high-dose methotrexate (HDMTX) followed by other multi-agent chemotherapy.",Methotrexate,ISA,Pharmacotherapy
21261497,The Japan Association of Childhood Leukemia Study (JACLS) NHL-98 is a multicenter study designed to evaluate treatment outcomes in Japanese children with B-cell non-Hodgkin lymphoma (B-NHL) and mature B-cell acute lymphoblastic leukemia (B-ALL).,Child,LOCATION_OF,TNFRSF6B gene | TNFRSF6B
21497902,"In a cohort of 86 children with BCP-ALL, we found increased expression of drebrin in TEL/AML1(pos) ALL.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
21497902,"In a cohort of 86 children with BCP-ALL, we found increased expression of drebrin in TEL/AML1(pos) ALL.",drebrin,PRODUCES,RUNX1 gene | RUNX1
21617562,Parvovirus B19-associated hemophagocytic lymphohistiocytosis in a child with precursor B-cell acute lymphoblastic leukemia under maintenance chemotherapy.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
21617562,Parvovirus B19-associated hemophagocytic lymphohistiocytosis in a child with precursor B-cell acute lymphoblastic leukemia under maintenance chemotherapy.,"Lymphohistiocytosis, Hemophagocytic",PROCESS_OF,Child
18398738,"Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor acute lymphoblastic leukemia lacking adverse or favorable genetics.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
18398738,These findings may assist in the process of refining prognostic groups for children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18398738,"Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor acute lymphoblastic leukemia lacking adverse or favorable genetics.",Child,LOCATION_OF,CD44
18665825,Eighty three children diagnosed with ALL (n = 63) and ANLL (n = 20) were included in this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18665825,Eighty three children diagnosed with ALL (n = 63) and ANLL (n = 20) were included in this study.,"Nonlymphocytic Leukemia, Acute",PROCESS_OF,Child
19064980,"PATIENTS AND METHODS: Between March 1999 and July 2005, 91 children with relapsed ALL treated according to the ALL-REZ BFM 96 or 2002 protocols and receiving stem-cell transplantation in >or= second remission were enrolled.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19064980,PURPOSE: Minimal residual disease (MRD) before allogeneic stem-cell transplantation was shown to predict outcome in children with relapsed acute lymphoblastic leukemia (ALL) in retrospective analysis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19064980,PURPOSE: Minimal residual disease (MRD) before allogeneic stem-cell transplantation was shown to predict outcome in children with relapsed acute lymphoblastic leukemia (ALL) in retrospective analysis.,"Neoplasm, Residual",PROCESS_OF,Child
19661822,Steroid-induced glaucoma in children with acute lymphoblastic leukemia: a possible complication.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19661822,Steroid-induced glaucoma in children with acute lymphoblastic leukemia: a possible complication.,Glaucoma,PROCESS_OF,Child
19884541,"PURPOSE: For the majority of children with acute lymphoblastic leukemia (ALL), CNS prophylaxis consists of either intrathecal (IT) methotrexate or triple IT therapy (ie, methotrexate with both cytarabine and hydrocortisone).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19884541,Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.,Methotrexate,compared_with,Therapeutic procedure
19884541,Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19884541,Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20033054,"Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
20033054,"Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification.",Treatment Protocols,TREATS,Patients
20033054,"Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification.",Assessment procedure,COEXISTS_WITH,Treatment Protocols
20033054,"Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
20072153,"The antifolate methotrexate (MTX), a universal component of ALL therapies, is metabolized by folylpoly-gamma-glutamate synthetase (FPGS) into long-chain polyglutamates (MTX-PG(3-7)), resulting in enhanced cytotoxicity from prolonged inhibition of dihydrofolate reductase (DHFR) and thymidylate synthetase (TS).",Methotrexate,ISA,Folic Acid Antagonists
20072153,"Children with acute lymphoblastic leukemia (ALL) diagnosed with resistant phenotypes, and those who relapse, have a dismal prognosis for cure.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20072153,"The antifolate methotrexate (MTX), a universal component of ALL therapies, is metabolized by folylpoly-gamma-glutamate synthetase (FPGS) into long-chain polyglutamates (MTX-PG(3-7)), resulting in enhanced cytotoxicity from prolonged inhibition of dihydrofolate reductase (DHFR) and thymidylate synthetase (TS).",Folylpolyglutamate synthase,INHIBITS,Dihydrofolate Reductase | DHFR
20072153,"The antifolate methotrexate (MTX), a universal component of ALL therapies, is metabolized by folylpoly-gamma-glutamate synthetase (FPGS) into long-chain polyglutamates (MTX-PG(3-7)), resulting in enhanced cytotoxicity from prolonged inhibition of dihydrofolate reductase (DHFR) and thymidylate synthetase (TS).",Thymidylate Synthase | TYMS,INHIBITS,Dihydrofolate Reductase | DHFR
20072153,"The antifolate methotrexate (MTX), a universal component of ALL therapies, is metabolized by folylpoly-gamma-glutamate synthetase (FPGS) into long-chain polyglutamates (MTX-PG(3-7)), resulting in enhanced cytotoxicity from prolonged inhibition of dihydrofolate reductase (DHFR) and thymidylate synthetase (TS).",polyglutamates,CAUSES,cytotoxicity
20072153,"The antifolate methotrexate (MTX), a universal component of ALL therapies, is metabolized by folylpoly-gamma-glutamate synthetase (FPGS) into long-chain polyglutamates (MTX-PG(3-7)), resulting in enhanced cytotoxicity from prolonged inhibition of dihydrofolate reductase (DHFR) and thymidylate synthetase (TS).",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
21193696,"While intensification of therapy has improved event-free survival (EFS) and survival in newly diagnosed children with acute lymphoblastic leukemia (ALL), postrelapse outcomes remain poor.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
21193696,"While intensification of therapy has improved event-free survival (EFS) and survival in newly diagnosed children with acute lymphoblastic leukemia (ALL), postrelapse outcomes remain poor.",Therapeutic procedure,TREATS,Child
21193696,"While intensification of therapy has improved event-free survival (EFS) and survival in newly diagnosed children with acute lymphoblastic leukemia (ALL), postrelapse outcomes remain poor.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21206717,Acute lymphoblastic leukemia (ALL) is the most common form of leukemia in childhood and accounts for 85% of cases.,"Leukemia, Lymphocytic, Acute",ISA,leukemia
21246704,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the commonest childhood malignancy in Australian children.,AUSTRALIAN,PROCESS_OF,Child
21246704,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the commonest childhood malignancy in Australian children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
21246704,CONCLUSIONS: Our results suggest that children diagnosed with ALL in Western Australia are slightly taller than their counterparts in the general population.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21246704,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the commonest childhood malignancy in Australian children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21246704,METHODS: Records of children diagnosed with ALL between January 1984 and June 2008 were accessed.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21246704,The aim of this study was to determine whether children diagnosed with ALL in Western Australia were taller at the time of diagnosis than children of the same age and sex in the general population.,Diagnosis,TREATS,General Population
21246704,The aim of this study was to determine whether children diagnosed with ALL in Western Australia were taller at the time of diagnosis than children of the same age and sex in the general population.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21246704,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the commonest childhood malignancy in Australian children.,Malignant Neoplasms,PROCESS_OF,Child
21611110,"A review of the research investigating the relationship of treatment regimens for ALL to specific late effect deficits, underlying mechanisms, and possible remediation is warranted to support continued studies.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
21906358,Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia.,Antimetabolites,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21906358,Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia.,Therapeutic procedure,USES,Antimetabolites
21906358,Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia.,Antimetabolites,ISA,Therapeutic procedure
19106127,"In the present study, urinary Ni and 8-OHdG were examined in 116 children with acute leukaemia (94 acute lymphoid leukaemia [ALL] and 22 acute myeloid leukaemia [AML]) and 51 healthy child controls.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
19106127,"In the present study, urinary Ni and 8-OHdG were examined in 116 children with acute leukaemia (94 acute lymphoid leukaemia [ALL] and 22 acute myeloid leukaemia [AML]) and 51 healthy child controls.","Leukemia, Lymphocytic, Acute",ISA,Acute leukemia
19106127,"In the present study, urinary Ni and 8-OHdG were examined in 116 children with acute leukaemia (94 acute lymphoid leukaemia [ALL] and 22 acute myeloid leukaemia [AML]) and 51 healthy child controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19106127,"In the present study, urinary Ni and 8-OHdG were examined in 116 children with acute leukaemia (94 acute lymphoid leukaemia [ALL] and 22 acute myeloid leukaemia [AML]) and 51 healthy child controls.",Acute leukemia,PROCESS_OF,Child
19106127,"In the present study, urinary Ni and 8-OHdG were examined in 116 children with acute leukaemia (94 acute lymphoid leukaemia [ALL] and 22 acute myeloid leukaemia [AML]) and 51 healthy child controls.","Leukemia, Myelocytic, Acute",ISA,Acute leukemia
19526524,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common and curable malignant pediatric disease in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19526524,"We analyzed the costs of 45 newly diagnosed children with ALL from May 2005 to June 2006; 20 were classified into low-risk group, 25 into medium-risk group, and all had completed the ALL-2005 protocol treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19526524,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common and curable malignant pediatric disease in children.,Malignant disease,PROCESS_OF,Child
20072153,The synergism exhibited by the combination of MTX and SAHA warrants clinical testing in ALL patients.,suberoylanilide hydroxamic acid,TREATS,"Leukemia, Lymphocytic, Acute"
20072153,The synergism exhibited by the combination of MTX and SAHA warrants clinical testing in ALL patients.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
20072153,The synergism exhibited by the combination of MTX and SAHA warrants clinical testing in ALL patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
20072153,The synergism exhibited by the combination of MTX and SAHA warrants clinical testing in ALL patients.,suberoylanilide hydroxamic acid,TREATS,Patients
20072153,The synergism exhibited by the combination of MTX and SAHA warrants clinical testing in ALL patients.,Methotrexate,TREATS,Patients
20448374,BACKGROUND: Relapse of disease is documented in 15-20% of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20850381,Dexrazoxane reduces cardiac damage during treatment with doxorubicin in children with acute lymphoblastic leukaemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20850381,Dexrazoxane reduces cardiac damage during treatment with doxorubicin in children with acute lymphoblastic leukaemia (ALL).,Doxorubicin,TREATS,"Leukemia, Lymphocytic, Acute"
20850381,INTERPRETATION: Dexrazoxane provides long-term cardioprotection without compromising oncological efficacy in doxorubicin-treated children with high-risk ALL.,Dexrazoxane,NEG_TREATS,Child
20850381,"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20850381,INTERPRETATION: Dexrazoxane provides long-term cardioprotection without compromising oncological efficacy in doxorubicin-treated children with high-risk ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20850381,"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.",Dexrazoxane,TREATS,Child
20850381,INTERPRETATION: Dexrazoxane provides long-term cardioprotection without compromising oncological efficacy in doxorubicin-treated children with high-risk ALL.,Dexrazoxane,NEG_TREATS,"Leukemia, Lymphocytic, Acute"
20850381,"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.",Dexrazoxane,TREATS,"Leukemia, Lymphocytic, Acute"
20850381,"METHODS: Between January, 1996, and September, 2000, children with high-risk ALL were enrolled from nine centres in the USA, Canada, and Puerto Rico.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20850381,Dexrazoxane reduces cardiac damage during treatment with doxorubicin in children with acute lymphoblastic leukaemia (ALL).,Doxorubicin,TREATS,Child
21258838,This report is the first to document minimal change nephrotic syndrome occurring during induction chemotherapy for childhood acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21258838,Nephrotic syndrome developing during induction chemotherapy for childhood acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21493871,"We sought to determine the potential role of genetic variants within the topoisomerase IIalpha gene (TOP2A), within the mixed lineage leukemia gene (MLL) and two of its translocation partners, cyclin AMP response element-binding protein gene (CREBBP) and E1A binding protein gene (EP300) in the increased sensitivity of Hispanic children with ALL to topo II inhibitors.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21493871,"Moreover, a higher incidence for therapy-related acute myeloid leukemia with 11q23 translocations after treatment with topoisomerase II (topo II) inhibitors has been observed in Hispanic children with ALL.",Chromosomal translocation,PROCESS_OF,Child
21493871,"Moreover, a higher incidence for therapy-related acute myeloid leukemia with 11q23 translocations after treatment with topoisomerase II (topo II) inhibitors has been observed in Hispanic children with ALL.",Therapeutic procedure,USES,Topoisomerase-II Inhibitor
21493871,"Moreover, a higher incidence for therapy-related acute myeloid leukemia with 11q23 translocations after treatment with topoisomerase II (topo II) inhibitors has been observed in Hispanic children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21493871,METHODS: Fifty-two tagged single nucleotide polymorphisms (SNP) covering the four genes were genotyped in 241 samples (66 children with ALL and 175 age matched controls) of self-identified Hispanic origin.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21493871,"We sought to determine the potential role of genetic variants within the topoisomerase IIalpha gene (TOP2A), within the mixed lineage leukemia gene (MLL) and two of its translocation partners, cyclin AMP response element-binding protein gene (CREBBP) and E1A binding protein gene (EP300) in the increased sensitivity of Hispanic children with ALL to topo II inhibitors.",CREBBP gene | CREBBP,INTERACTS_WITH,Topoisomerase-II Inhibitor
21493871,"We sought to determine the potential role of genetic variants within the topoisomerase IIalpha gene (TOP2A), within the mixed lineage leukemia gene (MLL) and two of its translocation partners, cyclin AMP response element-binding protein gene (CREBBP) and E1A binding protein gene (EP300) in the increased sensitivity of Hispanic children with ALL to topo II inhibitors.",Adenovirus E1A Proteins,INTERACTS_WITH,Topoisomerase-II Inhibitor
21596436,"We conclude, that MRD quantified by RQ-PCR in children with ALL treated with ALL-MB protocols is feasible and independently associated with outcome.","Neoplasm, Residual",PROCESS_OF,Child
21596436,"We conclude, that MRD quantified by RQ-PCR in children with ALL treated with ALL-MB protocols is feasible and independently associated with outcome.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21611938,Magnetic resonance imaging screening of cerebral thromboembolic events in children with acute lymphoblastic leukemia: a pilot study.,Screening procedure,USES,Magnetic Resonance Imaging
21611938,The aim of this study was to assess the incidence of asymptomatic cerebral thromboembolic events in children with acute lymphoblastic leukemia (ALL) screened by magnetic resonance imaging and magnetic resonance venography.,Venography - procedure,DIAGNOSES,"Leukemia, Lymphocytic, Acute"
21611938,The aim of this study was to assess the incidence of asymptomatic cerebral thromboembolic events in children with acute lymphoblastic leukemia (ALL) screened by magnetic resonance imaging and magnetic resonance venography.,Magnetic Resonance Imaging,DIAGNOSES,"Leukemia, Lymphocytic, Acute"
21611938,The majority of thromboembolic events are cerebral thromboses and deep venous thromboses; many asymptomatic deep venous thromboses are detected in children with acute lymphoblastic leukemia by instrumental screening.,Deep Vein Thrombosis,PROCESS_OF,Child
21611938,The majority of thromboembolic events are cerebral thromboses and deep venous thromboses; many asymptomatic deep venous thromboses are detected in children with acute lymphoblastic leukemia by instrumental screening.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21611938,"METHODS: 46 children with acute lymphoblastic leukemia, during the induction phase of the AIEOP ALL 2000 protocol, were stratified into 2 groups.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21611938,Magnetic resonance imaging screening of cerebral thromboembolic events in children with acute lymphoblastic leukemia: a pilot study.,Thromboembolic event,PROCESS_OF,Child
21611938,The aim of this study was to assess the incidence of asymptomatic cerebral thromboembolic events in children with acute lymphoblastic leukemia (ALL) screened by magnetic resonance imaging and magnetic resonance venography.,Thromboembolic event,OCCURS_IN,Child
21611938,Magnetic resonance imaging screening of cerebral thromboembolic events in children with acute lymphoblastic leukemia: a pilot study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21611938,The aim of this study was to assess the incidence of asymptomatic cerebral thromboembolic events in children with acute lymphoblastic leukemia (ALL) screened by magnetic resonance imaging and magnetic resonance venography.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18241334,"Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18241334,"Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study.","Neoplasm, Residual",PROCESS_OF,Child
18241334,"Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study.",Sialoglycoproteins,TREATS,"Neoplasm, Residual"
18318429,"Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
18318429,"BACKGROUND: The authors evaluated the response rate, toxicity, and pharmacokinetics of topotecan given before standard induction therapy for childhood acute lymphoblastic leukemia (ALL) in first relapse.",Neoadjuvant Therapy,ADMINISTERED_TO,Author
18318429,"Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
18318429,"Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.",Vincristine,TREATS,Patients
18318429,"Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.",Dexamethasone,TREATS,Patients
18318429,"Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.",ASPARAGINASE,TREATS,Patients
18318429,"Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
18318429,"Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
18318429,"BACKGROUND: The authors evaluated the response rate, toxicity, and pharmacokinetics of topotecan given before standard induction therapy for childhood acute lymphoblastic leukemia (ALL) in first relapse.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19149913,"[Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China].","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19149918,RESULTS: Blood GYPC expression in newly diagnosed ALL children was significantly higher than that in the control group (p<0.01) and the CR group (p<0.01).,Control Groups,LOCATION_OF,GYPC
19149918,RESULTS: Blood GYPC expression in newly diagnosed ALL children was significantly higher than that in the control group (p<0.01) and the CR group (p<0.01).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19149918,RESULTS: Blood GYPC expression in newly diagnosed ALL children was significantly higher than that in the control group (p<0.01) and the CR group (p<0.01).,GYPC,PART_OF,Blood
19149918,METHODS: Thirty-eight newly diagnosed ALL children were enrolled.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19149918,"Of the 38 newly diagnosed ALL children, the patients with positive TRIP3 expression showed higher remission rate than those with negative TRIP3 (p<0.05).",ZNHIT3,PART_OF,Patients
19149918,OBJECTIVE: To study the relationship of GYPC and TRIP3 gene expression and the prognosis of acute lymphoblastic leukemia (ALL) in children in order to explore the molecular biological mechanisms of recurrence and remission of ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19149918,"Of the 38 newly diagnosed ALL children, the patients with positive TRIP3 expression showed higher remission rate than those with negative TRIP3 (p<0.05).",ZNHIT3,PART_OF,Patients
19149918,"Of the 38 newly diagnosed ALL children, the patients with positive TRIP3 expression showed higher remission rate than those with negative TRIP3 (p<0.05).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19849934,E2A-PBX1 fusion gene was expressed in 3.9% of children with B-cell ALL.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
20155409,Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia.,Mesenchymal Stem Cells,PART_OF,Child
20155409,Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20704789,[Biological characteristics of T-lineage acute lymphoblastic leukemia in 23 children].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20704789,METHODS: Immunophenotyping was performed by three-color flow cytometry analysis using CD45 /SSC gating in 23 children with newly diagnosed T-ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,APC gene | APC,COEXISTS_WITH,"Receptors, Complement 3d | CR2 | TDGF1P2"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,HRK gene | HRK,COEXISTS_WITH,"Receptors, Complement 3b | CR1"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,DPP8,COEXISTS_WITH,"Receptors, Complement 3d | CR2 | TDGF1P2"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,PTGDR | TFDP1 | REEP5,compared_with,Treatment Protocols
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,Refractory Disease,PROCESS_OF,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,Stem cell transplant,TREATS,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,TFDP3,COEXISTS_WITH,"Receptors, Complement 3d | CR2 | TDGF1P2"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,Stem cell transplant,TREATS,"Leukemia, Myelocytic, Acute"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,PTGDR | TFDP1 | REEP5,COEXISTS_WITH,"Receptors, Complement 3b | CR1"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,APC gene | APC,COEXISTS_WITH,"Receptors, Complement 3b | CR1"
21218018,Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Child
21218018,Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21218018,PURPOSE: Our study attempted to determine the prognostic significance of minimal residual disease (MRD) detected by a simplified flow cytometric assay during induction chemotherapy in children with B-cell acute lymphoblastic leukemia (B-ALL).,Pharmacotherapy,TREATS,Child
21218018,Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
21218018,PURPOSE: Our study attempted to determine the prognostic significance of minimal residual disease (MRD) detected by a simplified flow cytometric assay during induction chemotherapy in children with B-cell acute lymphoblastic leukemia (B-ALL).,Assay,DIAGNOSES,"Neoplasm, Residual"
21218018,PURPOSE: Our study attempted to determine the prognostic significance of minimal residual disease (MRD) detected by a simplified flow cytometric assay during induction chemotherapy in children with B-cell acute lymphoblastic leukemia (B-ALL).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
21218018,PURPOSE: Our study attempted to determine the prognostic significance of minimal residual disease (MRD) detected by a simplified flow cytometric assay during induction chemotherapy in children with B-cell acute lymphoblastic leukemia (B-ALL).,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
21218018,Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia.,Assay,DIAGNOSES,"Neoplasm, Residual"
21611938,CONCLUSIONS: Our study does not seem to suggest a screening for asymptomatic cerebral thromboembolic events in children with ALL during the induction phase.,Thromboembolic event,PROCESS_OF,Child
21611938,CONCLUSIONS: Our study does not seem to suggest a screening for asymptomatic cerebral thromboembolic events in children with ALL during the induction phase.,Screening procedure,TREATS,Thromboembolic event
21611938,CONCLUSIONS: Our study does not seem to suggest a screening for asymptomatic cerebral thromboembolic events in children with ALL during the induction phase.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17278117,Fatal adenovirus hepatitis during maintenance therapy for childhood acute lymphoblastic leukemia.,Hepatitis,PROCESS_OF,Adenoviruses
17278117,Fatal adenovirus hepatitis during maintenance therapy for childhood acute lymphoblastic leukemia.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17455314,BACKGROUND: To evaluate the treatment results of central nervous system preventive therapy (CNSP) with triple intrathecal therapy (TIT) alone in children with acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,Child
17455314,BACKGROUND: To evaluate the treatment results of central nervous system preventive therapy (CNSP) with triple intrathecal therapy (TIT) alone in children with acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
17455314,BACKGROUND: To evaluate the treatment results of central nervous system preventive therapy (CNSP) with triple intrathecal therapy (TIT) alone in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17455314,Triple intrathecal therapy without cranial irradiation for central nervous system preventive therapy in childhood acute lymphoblastic leukemia.,Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
17668867,BACKGROUND: To determine the response rate and toxicity of docetaxel when administered as a 60 mg/m(2) dose by 1 hr intravenous (IV) infusion weekly x 3 weeks in children with relapsed acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).,Toxic effect,PROCESS_OF,Child
17668867,BACKGROUND: To determine the response rate and toxicity of docetaxel when administered as a 60 mg/m(2) dose by 1 hr intravenous (IV) infusion weekly x 3 weeks in children with relapsed acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
17668867,BACKGROUND: To determine the response rate and toxicity of docetaxel when administered as a 60 mg/m(2) dose by 1 hr intravenous (IV) infusion weekly x 3 weeks in children with relapsed acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17668867,CONCLUSIONS: Docetaxel was not effective therapy for children with relapsed ALL at the dose and schedule tested.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17668867,CONCLUSIONS: Docetaxel was not effective therapy for children with relapsed ALL at the dose and schedule tested.,docetaxel,NEG_TREATS,Child
17668867,CONCLUSIONS: Docetaxel was not effective therapy for children with relapsed ALL at the dose and schedule tested.,docetaxel,NEG_TREATS,"Leukemia, Lymphocytic, Acute"
17668867,CONCLUSIONS: Docetaxel was not effective therapy for children with relapsed ALL at the dose and schedule tested.,docetaxel,ISA,Therapeutic procedure
17828747,"In this study, adrenal function and signs and symptoms of adrenal insufficiency were prospectively assessed in children with acute lymphoblastic leukemia (ALL) after induction treatment including high-dose prednisone (PDN) or dexamethasone (DXM).",Adrenal gland hypofunction,PROCESS_OF,Child
17828747,"In this study, adrenal function and signs and symptoms of adrenal insufficiency were prospectively assessed in children with acute lymphoblastic leukemia (ALL) after induction treatment including high-dose prednisone (PDN) or dexamethasone (DXM).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17828747,CONCLUSIONS: High-dose glucocorticoid therapy in ALL children may cause prolonged adrenal suppression and related clinical symptoms.,GLUCOCORTICOID THERAPY,TREATS,Child
17828747,CONCLUSIONS: High-dose glucocorticoid therapy in ALL children may cause prolonged adrenal suppression and related clinical symptoms.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute"
17828747,CONCLUSIONS: High-dose glucocorticoid therapy in ALL children may cause prolonged adrenal suppression and related clinical symptoms.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
17828747,"PROCEDURES: Sixty-four children with ALL, treated according to the AIEOP ALL 2000 Study protocol, underwent low dose ACTH (LD-ACTH) stimulation 24 hr after the last tapered steroid dose.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18298855,Cases included 560 children with ALL and 87 with acute myeloid leukemia (AML) diagnoses from 28 days to 14 years.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19773675,Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19773675,CONCLUSIONS: About 20% of children with acute lymphoblastic leukemia have a microbiologically documented infection during induction.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19773675,BACKGROUND: The primary objective was to describe microbiologically documented infections during induction therapy for acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
19809787,"We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.",Erythrocyte Transfusion,TREATS,Iron deficiency
19809787,"We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.",Glomerulonephritis,PROCESS_OF,Patients
19809787,"We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.",Neutropenia,CAUSES,Ulcerative Colitis
19809787,"We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.",Therapeutic procedure,USES,ASPARAGINASE
19809787,"We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.",ASPARAGINASE,ISA,Therapeutic procedure
19809787,"We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.",Reversible posterior leukoencephalopathy syndrome,PROCESS_OF,Patients
19809787,"We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
19809787,"We presented nine patients with RPLS who had primary diagnoses such as acute post-streptococcal glomerulonephritis, idiopathic hypertension, the performing of intravenous immunoglobulin for infection with crescentic glomerulonephritis, erythrocyte transfusion for severe iron deficiency, L: -asparaginase treatment for acute lymphoblastic leukemia and performing of granulocyte-colony stimulating factor for ulcerative colitis due to neutropenia.",Granulocyte Colony-Stimulating Factor,TREATS,Ulcerative Colitis
20670164,The objective of this study was to identify novel pharmacogenetic determinants of treatment-related hepatotoxicity during the maintenance phase in children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).,Hepatotoxicity,PROCESS_OF,Child
20670164,The objective of this study was to identify novel pharmacogenetic determinants of treatment-related hepatotoxicity during the maintenance phase in children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).,Large Cell Lymphoblastic Lymphoma,PROCESS_OF,Child
20670164,The objective of this study was to identify novel pharmacogenetic determinants of treatment-related hepatotoxicity during the maintenance phase in children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20813012,Modifications to the treatment of acute lymphoblastic leukaemia (ALL) in children have led to a dramatic increase in survival in the past 40 years.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,Refractory Disease,PROCESS_OF,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,PTGDR | TFDP1 | REEP5,compared_with,Treatment Protocols
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,Stem cell transplant,TREATS,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,TFDP3,COEXISTS_WITH,"Receptors, Complement 3d | CR2 | TDGF1P2"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,PTGDR | TFDP1 | REEP5,COEXISTS_WITH,"Receptors, Complement 3b | CR1"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,Stem cell transplant,TREATS,"Leukemia, Myelocytic, Acute"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,APC gene | APC,COEXISTS_WITH,"Receptors, Complement 3b | CR1"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,APC gene | APC,COEXISTS_WITH,"Receptors, Complement 3d | CR2 | TDGF1P2"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Adult
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,DPP8,COEXISTS_WITH,"Receptors, Complement 3d | CR2 | TDGF1P2"
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21138675,Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.,HRK gene | HRK,COEXISTS_WITH,"Receptors, Complement 3b | CR1"
21618420,Therefore a retrospective cost-effectiveness analysis of ALL treatment with chemotherapy only according to the two most recent Dutch Childhood Oncology Group treatment protocols was performed.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
21618420,Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: the influence of new medication and diagnostic technology.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18022899,Treatments given were subdivided between group T (regimens for T NHL or acute lymphoblastic leukaemia) or group B (regimens for B NHL).,Treatment Protocols,TREATS,"Lymphoma, Non-Hodgkin's"
18022899,Treatments given were subdivided between group T (regimens for T NHL or acute lymphoblastic leukaemia) or group B (regimens for B NHL).,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
18022899,Treatments given were subdivided between group T (regimens for T NHL or acute lymphoblastic leukaemia) or group B (regimens for B NHL).,Treatment Protocols,TREATS,"Lymphoma, Non-Hodgkin's"
18022899,Treatments given were subdivided between group T (regimens for T NHL or acute lymphoblastic leukaemia) or group B (regimens for B NHL).,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
18022899,Treatments given were subdivided between group T (regimens for T NHL or acute lymphoblastic leukaemia) or group B (regimens for B NHL).,Treatment Protocols,TREATS,"Lymphoma, Non-Hodgkin's"
18022899,Treatments given were subdivided between group T (regimens for T NHL or acute lymphoblastic leukaemia) or group B (regimens for B NHL).,Treatment Protocols,TREATS,"Lymphoma, Non-Hodgkin's"
18519521,Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.,prednisolone,TREATS,Child
18519521,Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18519521,Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.,Peripheral,LOCATION_OF,Blast Cell
18519521,Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.,Therapeutic procedure,USES,prednisolone
18519521,"CONCLUSIONS: Children with Day8NoBlasts constituted one third of all the cases with childhood acute lymphoblastic leukemia with an excellent outcome, and should be candidates for curative management with less intensive treatment.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
18519521,Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.,prednisolone,ISA,Therapeutic procedure
18519521,"DESIGN AND METHODS: Seven hundred and fifty-four children diagnosed with acute lymphoblastic leukemia, consecutively enrolled from 1999 to 2003 in the TCCSG L99-15 study, were eligible for analysis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18519521,Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.,prednisolone,TREATS,"Leukemia, Lymphocytic, Acute"
18519521,We evaluated the significance of the complete clearance of peripheral leukemic blasts on survival in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18987654,"Of 601 children with acute lymphoblastic leukemia (ALL) who were treated by the NOPHO ALL-92 protocol, 117 had TPMT genotype determined, whereas for 484 patients only erythrocyte TPMT activity was available.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18987654,"These data suggest that children with ALL and TPMT wild type might have their cure rate improved, if the pharmacokinetics/-dynamics of TPMT low-activity patients could be mimicked without a concurrent excessive risk of second cancers.",Thiopurine S-Methyltransferase,NEG_PREDISPOSES,Second Primary Cancers
18987654,"These data suggest that children with ALL and TPMT wild type might have their cure rate improved, if the pharmacokinetics/-dynamics of TPMT low-activity patients could be mimicked without a concurrent excessive risk of second cancers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19509471,l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19509471,l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL).,ASPARAGINASE,ISA,Therapeutic procedure
19778845,Infants with mixed-lineage leukemia (MLL)-rearranged ALL comprise a very poor-risk group wherein further intensification of chemotherapy causes significant toxicity.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19778845,"Although most children with acute lymphoblastic leukemia (ALL) are cured, certain subsets have a high risk of relapse.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19917844,"PURPOSE: Children with acute lymphoblastic leukemia (ALL) are often cured, but the therapies they receive may be neurotoxic.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20502353,This descriptive study was designed to determine the pattern of deaths in children with ALL treated at a single center and identify the problem areas in management.,Death (finding),PROCESS_OF,Child
20502353,This descriptive study was designed to determine the pattern of deaths in children with ALL treated at a single center and identify the problem areas in management.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20632326,BACKGROUND: Minimal residual disease (MRD) is a powerful prognostic indicator in childhood acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
20930648,Multiplex RT-PCR assay is an efficient and sensitive diagnostic tool that may improve the ability to accurately and rapidly risk-stratify children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20930648,Multiplex reverse transcription-polymerase chain reaction as diagnostic molecular screening of 4 common fusion chimeric genes in Taiwanese children with acute lymphoblastic leukemia.,reverse transcription polymerase chain reaction,PROCESS_OF,Child
20930648,Multiplex reverse transcription-polymerase chain reaction as diagnostic molecular screening of 4 common fusion chimeric genes in Taiwanese children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20930649,Data of 142 children with ALL who were treated with a modified BFM 95 protocol between 1997 and 2007 were evaluated.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20930649,Data of 142 children with ALL who were treated with a modified BFM 95 protocol between 1997 and 2007 were evaluated.,Berlin-Frankfort-Munster protocol,TREATS,"Leukemia, Lymphocytic, Acute"
21372841,Mercaptopurine has been used in continuing treatment of childhood acute lymphoblastic leukaemia since the mid 1950s.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21415851,"Although up to 13 chemotherapeutic agents are used in the treatment of this cancer, it remains a model disease for exploring the impact of genetic variation due to well-characterized cytogenetics, drug response pathways and precise monitoring of minimal residual disease.",Antineoplastic Agents,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21415851,"Although up to 13 chemotherapeutic agents are used in the treatment of this cancer, it remains a model disease for exploring the impact of genetic variation due to well-characterized cytogenetics, drug response pathways and precise monitoring of minimal residual disease.",Malignant Neoplasms,ISA,Disease
21415851,"Although up to 13 chemotherapeutic agents are used in the treatment of this cancer, it remains a model disease for exploring the impact of genetic variation due to well-characterized cytogenetics, drug response pathways and precise monitoring of minimal residual disease.",drug response,AFFECTS,Variation (Genetics)
21618420,CONCLUSION: Treatment of childhood ALL with chemotherapy only is well within accepted ranges of cost-effectiveness.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18512312,CONCLUSION: The effectiveness of PEG-Asp and L-asparaginase for treatment of pediatric ALL is similar and no difference in adverse effect.,pegaspargase,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18512312,CONCLUSION: The effectiveness of PEG-Asp and L-asparaginase for treatment of pediatric ALL is similar and no difference in adverse effect.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18512312,[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].,pegaspargase,TREATS,"Leukemia, Lymphocytic, Acute, L1"
18512312,[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19212336,"Concurrent treatment with methotrexate (MTX) and antiepileptic drugs, such as phenobarbital (PB), reduces the efficacy of MTX chemotherapy in childhood acute lymphoblastic leukemia (ALL).",Therapeutic procedure,USES,Methotrexate
19212336,Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity.,Antiepileptic Agents,DISRUPTS,reduced folate carrier activity
19212336,"Concurrent treatment with methotrexate (MTX) and antiepileptic drugs, such as phenobarbital (PB), reduces the efficacy of MTX chemotherapy in childhood acute lymphoblastic leukemia (ALL).",Therapeutic procedure,USES,Antiepileptic Agents
19212336,"In conclusion, we identified for the first time the molecular mechanism of this clinically relevant drug resistance in patients with ALL concurrently receiving MTX chemotherapy and antiepileptic drugs.",Drug resistance,PROCESS_OF,Patients
19212336,Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity.,Methotrexate,ISA,Pharmacotherapy
19212336,"Concurrent treatment with methotrexate (MTX) and antiepileptic drugs, such as phenobarbital (PB), reduces the efficacy of MTX chemotherapy in childhood acute lymphoblastic leukemia (ALL).",Therapeutic procedure,USES,Phenobarbital
19212336,"In conclusion, we identified for the first time the molecular mechanism of this clinically relevant drug resistance in patients with ALL concurrently receiving MTX chemotherapy and antiepileptic drugs.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
19212336,Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity.,Pharmacotherapy,USES,Methotrexate
19212336,"Concurrent treatment with methotrexate (MTX) and antiepileptic drugs, such as phenobarbital (PB), reduces the efficacy of MTX chemotherapy in childhood acute lymphoblastic leukemia (ALL).",Phenobarbital,ISA,Antiepileptic Agents
19212336,"In conclusion, we identified for the first time the molecular mechanism of this clinically relevant drug resistance in patients with ALL concurrently receiving MTX chemotherapy and antiepileptic drugs.",Methotrexate,ISA,Pharmacotherapy
19212336,"Concurrent treatment with methotrexate (MTX) and antiepileptic drugs, such as phenobarbital (PB), reduces the efficacy of MTX chemotherapy in childhood acute lymphoblastic leukemia (ALL).",Methotrexate,ISA,Pharmacotherapy
19212336,"In conclusion, we identified for the first time the molecular mechanism of this clinically relevant drug resistance in patients with ALL concurrently receiving MTX chemotherapy and antiepileptic drugs.",Pharmacotherapy,USES,Methotrexate
19212336,"Concurrent treatment with methotrexate (MTX) and antiepileptic drugs, such as phenobarbital (PB), reduces the efficacy of MTX chemotherapy in childhood acute lymphoblastic leukemia (ALL).",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19212336,"Concurrent treatment with methotrexate (MTX) and antiepileptic drugs, such as phenobarbital (PB), reduces the efficacy of MTX chemotherapy in childhood acute lymphoblastic leukemia (ALL).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19212336,"Concurrent treatment with methotrexate (MTX) and antiepileptic drugs, such as phenobarbital (PB), reduces the efficacy of MTX chemotherapy in childhood acute lymphoblastic leukemia (ALL).",Pharmacotherapy,USES,Methotrexate
19212338,These data indicate that MRD diagnostics has added value for recognition of risk groups in infant ALL and that MRD diagnostics can be used for treatment intervention in infant ALL as well.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19212338,Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19212338,We therefore evaluated the prognostic significance of MRD in infant ALL.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
19212338,We therefore evaluated the prognostic significance of MRD in infant ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19212338,Several studies in children and adults with ALL have shown that minimal residual disease (MRD) status is a strong and independent prognostic factor.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19212338,"Acute lymphoblastic leukemia (ALL) in infants younger than 1 year is a rare but relatively homogeneous disease ( approximately 80% MLL gene rearranged, approximately 70% CD10-negative) when compared with childhood and adult ALL.","Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Infant
19212338,Several studies in children and adults with ALL have shown that minimal residual disease (MRD) status is a strong and independent prognostic factor.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
19212338,"Acute lymphoblastic leukemia (ALL) in infants younger than 1 year is a rare but relatively homogeneous disease ( approximately 80% MLL gene rearranged, approximately 70% CD10-negative) when compared with childhood and adult ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19212338,These data indicate that MRD diagnostics has added value for recognition of risk groups in infant ALL and that MRD diagnostics can be used for treatment intervention in infant ALL as well.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19212338,Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.,"Neoplasm, Residual",PROCESS_OF,Infant
20930649,This report examines children with ALL treated with a modified ALL-BFM 95 protocol in a tertiary care center in Turkey with adequate follow up and demonstrates the need for improvements especially for patients with unfavorable risk group and strategies to reduce deaths from infection in CR to keep pace with cure rates in developed countries.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20930649,This report examines children with ALL treated with a modified ALL-BFM 95 protocol in a tertiary care center in Turkey with adequate follow up and demonstrates the need for improvements especially for patients with unfavorable risk group and strategies to reduce deaths from infection in CR to keep pace with cure rates in developed countries.,Berlin-Frankfort-Munster protocol,TREATS,"Leukemia, Lymphocytic, Acute"
20930649,This report examines children with ALL treated with a modified ALL-BFM 95 protocol in a tertiary care center in Turkey with adequate follow up and demonstrates the need for improvements especially for patients with unfavorable risk group and strategies to reduce deaths from infection in CR to keep pace with cure rates in developed countries.,follow-up,TREATS,Patients
21159109,Pharmacokinetics of high-dose etoposide administered in combination with fractionated total-body irradiation as conditioning for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia.,Drug Kinetics,PROCESS_OF,Child
21159109,Pharmacokinetics of high-dose etoposide administered in combination with fractionated total-body irradiation as conditioning for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia.,Whole-Body Irradiation,METHOD_OF,Hematopoietic Stem Cell Transplantation
21159109,Pharmacokinetics of high-dose etoposide administered in combination with fractionated total-body irradiation as conditioning for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21846410,"The overall SAAIR was 57.6 per million children (95% CI, 46.9-68.3); acute lymphoblastic leukemia (ALL) was the most frequent type of leukemia, constituting 85.1% of the cases (SAAIR: 49.5 per million), followed by acute myeloblastic leukemia at 12.3% (SAAIR: 6.9 per million), and chronic myeloid leukemia at 1.7% (SAAIR: 0.9 per million).","Leukemia, Lymphocytic, Acute",ISA,leukemia
20010621,"Over the era encompassed by these four trials, there has been a major improvement in both event-free and overall survival for children in the United Kingdom with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20010622,"Analysis of 2668 children with acute lymphoblastic leukemia (ALL) treated in two successive Nordic clinical trials (Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000) showed that 75% of all patients are cured by first-line therapy, and 83% are long-term survivors.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20010622,"Analysis of 2668 children with acute lymphoblastic leukemia (ALL) treated in two successive Nordic clinical trials (Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000) showed that 75% of all patients are cured by first-line therapy, and 83% are long-term survivors.",Therapeutic procedure,TREATS,Patients
20010622,"Analysis of 2668 children with acute lymphoblastic leukemia (ALL) treated in two successive Nordic clinical trials (Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000) showed that 75% of all patients are cured by first-line therapy, and 83% are long-term survivors.",Nordic,LOCATION_OF,Clinical Trials
20010625,"The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed re-intensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients.",Induction,TREATS,Patients
20010625,"The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed re-intensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
20010625,"The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed re-intensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
20010625,"The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed re-intensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
20010625,"The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed re-intensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients.",Therapeutic procedure,TREATS,Patients
20016528,The Dutch Childhood Oncology Group (DCOG) has used two treatment strategies for children with acute lymphoblastic leukemia (ALL) based on Pinkel's St Jude Total Therapy or the Berlin-Frankfurt-Munster (BFM) backbone.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20016528,The Dutch Childhood Oncology Group (DCOG) has used two treatment strategies for children with acute lymphoblastic leukemia (ALL) based on Pinkel's St Jude Total Therapy or the Berlin-Frankfurt-Munster (BFM) backbone.,Therapeutic procedure,TREATS,Child
20016528,The Dutch Childhood Oncology Group (DCOG) has used two treatment strategies for children with acute lymphoblastic leukemia (ALL) based on Pinkel's St Jude Total Therapy or the Berlin-Frankfurt-Munster (BFM) backbone.,Therapeutic procedure,TREATS,Commotio retinae
20016528,We conclude that the chemotherapy-only approach in children with ALL in Total Therapy-based strategies and BFM-backbone treatment does not jeopardize survival and preserves cognitive functioning.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20016528,The Dutch Childhood Oncology Group (DCOG) has used two treatment strategies for children with acute lymphoblastic leukemia (ALL) based on Pinkel's St Jude Total Therapy or the Berlin-Frankfurt-Munster (BFM) backbone.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
20016528,We conclude that the chemotherapy-only approach in children with ALL in Total Therapy-based strategies and BFM-backbone treatment does not jeopardize survival and preserves cognitive functioning.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute"
20016528,We conclude that the chemotherapy-only approach in children with ALL in Total Therapy-based strategies and BFM-backbone treatment does not jeopardize survival and preserves cognitive functioning.,Maintenance therapy,TREATS,Child
20016528,Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20016528,The Dutch Childhood Oncology Group (DCOG) has used two treatment strategies for children with acute lymphoblastic leukemia (ALL) based on Pinkel's St Jude Total Therapy or the Berlin-Frankfurt-Munster (BFM) backbone.,Therapeutic procedure,ADMINISTERED_TO,Oncology Group
20016528,The Dutch Childhood Oncology Group (DCOG) has used two treatment strategies for children with acute lymphoblastic leukemia (ALL) based on Pinkel's St Jude Total Therapy or the Berlin-Frankfurt-Munster (BFM) backbone.,Commotio retinae,PROCESS_OF,Child
20016529,"Despite the success of contemporary treatment protocols in childhood acute lymphoblastic leukaemia (ALL), relapse within the central nervous system (CNS) remains a challenge.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20016529,"Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20016536,The introduction of minimal residual disease monitoring and evaluation of common randomized questions by AIEOP and BFM groups in the protocol AIEOP-BFM-ALL 2000 are expected to further ameliorate treatment of children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20016536,The introduction of minimal residual disease monitoring and evaluation of common randomized questions by AIEOP and BFM groups in the protocol AIEOP-BFM-ALL 2000 are expected to further ameliorate treatment of children with ALL.,Introduction procedure,TREATS,Child
20016538,"The long-term outcome of 1390 children with acute lymphoblastic leukemia (ALL), treated in two successive clinical trials (Taiwan Pediatric Oncology Group (TPOG)-ALL-97 and TPOG-ALL-2002) between 1997 and 2007, is reported.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20016539,"Thus, cure can become a reality for about 70% of children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20207611,The authors describe a case of an intraventricular meningioma occurring 23 years after cranial irradiation for childhood acute lymphoblastic leukemia.,Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21520007,Forty children with ALL [median age 11 (8.5-15.4) years] and 42 healthy children [median age 11 (8.9- 15) years] served as controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21520007,Our objective was to assess the mental health and health-related quality of life (HRQOL) in children and their parents after renal transplantation (TX) compared to healthy controls and children with acute lymphoblastic leukemia (ALL) and to identify possible health status variables associated with impaired mental health and HRQOL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21520007,Our objective was to assess the mental health and health-related quality of life (HRQOL) in children and their parents after renal transplantation (TX) compared to healthy controls and children with acute lymphoblastic leukemia (ALL) and to identify possible health status variables associated with impaired mental health and HRQOL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21729553,"The results showed that 11.6% out of 207 children with ALL were identified as T-ALL, 88.4% as B-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21729553,207 children with ALL were immunophenotyped by four color flow cytometry using a panel of monoclonal antibodies.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21729553,207 children with ALL were immunophenotyped by four color flow cytometry using a panel of monoclonal antibodies.,Flow Cytometry,USES,Monoclonal Antibodies
21729608,[Study of relationship between plasmacytoid dendritic cells and minimal residual disease in childhood acute lymphoblastic leukemia].,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12050732,CD44v6 is considered as a marker of poor prognosis of various hematological cancers but its expression was not demonstrated in childhood acute lymphoblastic leukemia (ALL).,Hematologic Neoplasms,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
12578666,The purpose of this investigation was to study the myeloid antigen expression and its relationship with clinical and biological features in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
18089849,High-dose methotrexate (MTX) has been extensively used for treatment of acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
18089849,High-dose methotrexate (MTX) has been extensively used for treatment of acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Therapeutic procedure
19553647,BACKGROUND: Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse.,Prophylactic Cranial Irradiation,ISA,Therapeutic procedure
19553647,BACKGROUND: Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse.,Prophylactic Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute"
19553647,BACKGROUND: Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19553647,BACKGROUND: Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse.,Prophylactic Cranial Irradiation,TREATS,Child
19707206,Population was divided in children with AL and with acute lymphoblastic leukaemia (ALL) and also in children < or = 6 and >6 years old.,Acute leukemia,PROCESS_OF,Child
19707206,Population was divided in children with AL and with acute lymphoblastic leukaemia (ALL) and also in children < or = 6 and >6 years old.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19710397,"DS children with acute lymphoblastic leukemia frequently experience higher levels of treatment-related toxicity and inferior event-free survival rates, as compared with non-DS children.",Toxic effect,PROCESS_OF,Child
19710397,"DS children with acute lymphoblastic leukemia frequently experience higher levels of treatment-related toxicity and inferior event-free survival rates, as compared with non-DS children.",Down Syndrome,PROCESS_OF,Child
19710397,"DS children with acute lymphoblastic leukemia frequently experience higher levels of treatment-related toxicity and inferior event-free survival rates, as compared with non-DS children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20013659,"Individually, the 194Trp, 280His, and 399Gln alleles were not associated with significantly increased risk for ALL in these Mexican children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20033052,"We report the long-term results of Tokyo Children's Cancer Study Group's studies L84-11, L89-12, L92-13, and L95-14 for 1846 children with acute lymphoblastic leukemia, which were conducted between 1984 and 1999.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20138060,An adaptive model predictive control (MPC) strategy is presented in which maintenance therapy for childhood ALL is personalized using routine patient measurements of red blood cell mean corpuscular volume as a surrogate for the active drug metabolite concentration.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21172127,"METHODS: Methylation-specific polymerase chain reaction (MS-PCR) was used to detect the methylation status of ID4 promoter region in 18 children with newly-diagnosed ALL (2 cases of T-ALL, 13 cases of B-ALL and 3 cases of T/B-ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21172127,"The complete methylation rate of ID4 gene promoter region in children with T-ALL, B-ALL and T/B-ALL (50%, 85% and 100% respectively) was significantly higher than that in the control group (18%; P<0.05).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Control Groups
21172127,"The complete methylation rate of ID4 gene promoter region in children with T-ALL, B-ALL and T/B-ALL (50%, 85% and 100% respectively) was significantly higher than that in the control group (18%; P<0.05).",Child,LOCATION_OF,ID4 gene | ID4
21172127,"The complete methylation rate of ID4 gene promoter region in children with T-ALL, B-ALL and T/B-ALL (50%, 85% and 100% respectively) was significantly higher than that in the control group (18%; P<0.05).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21172127,"RESULTS: The complete methylation rate of ID4 gene promoter region (15/18, 83%) was significantly higher than the partial methylation rate (3/18, 17%) in the 18 ALL children (P<0.05).",Child,LOCATION_OF,ID4 gene | ID4
21172127,"RESULTS: The complete methylation rate of ID4 gene promoter region (15/18, 83%) was significantly higher than the partial methylation rate (3/18, 17%) in the 18 ALL children (P<0.05).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21172127,"METHODS: Methylation-specific polymerase chain reaction (MS-PCR) was used to detect the methylation status of ID4 promoter region in 18 children with newly-diagnosed ALL (2 cases of T-ALL, 13 cases of B-ALL and 3 cases of T/B-ALL).",Child,LOCATION_OF,ID4
21172127,"The complete methylation rate of ID4 gene promoter region in children with T-ALL, B-ALL and T/B-ALL (50%, 85% and 100% respectively) was significantly higher than that in the control group (18%; P<0.05).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Control Groups
22558532,l-Asparaginase (E.C. 3.5.1.1) is used as a therapeutic agent in the treatment of acute childhood lymphoblastic leukemia.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
22870143,We aimed to improve relapse prediction in children with ALL through evaluation of the early chemosensitivity of normal and malignant cells and to determine the relationship between such chemosensitivity and risk of relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",Dexamethasone,TREATS,Patients
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",prednisolone,TREATS,"Leukemia, Lymphocytic, Acute"
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",prednisolone,TREATS,Patients
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",Glucocorticoids,TREATS,Patients
23388033,"For example, modification of treatment protocols for childhood acute lymphoblastic leukemia have led to incremental but steady improvements in long-term overall survival to nearly 90% using combinations of upwards of six drugs.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23610732,"This is particularly true for ALL in older children, adolescents, and adults, in whom treatment outcomes are markedly inferior to those of young children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
23610732,"This is particularly true for ALL in older children, adolescents, and adults, in whom treatment outcomes are markedly inferior to those of young children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23610732,"This is particularly true for ALL in older children, adolescents, and adults, in whom treatment outcomes are markedly inferior to those of young children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
18678946,The L-asparaginases from Escherichia coli and Erwinia chrysanthemi are effective drugs that have been used in the treatment of acute childhood lymphoblastic leukaemia for over 30 years.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
18678946,The L-asparaginases from Escherichia coli and Erwinia chrysanthemi are effective drugs that have been used in the treatment of acute childhood lymphoblastic leukaemia for over 30 years.,Pectobacterium chrysanthemi,LOCATION_OF,ASPARAGINASE
18678946,The L-asparaginases from Escherichia coli and Erwinia chrysanthemi are effective drugs that have been used in the treatment of acute childhood lymphoblastic leukaemia for over 30 years.,Escherichia coli,LOCATION_OF,ASPARAGINASE
18678946,The L-asparaginases from Escherichia coli and Erwinia chrysanthemi are effective drugs that have been used in the treatment of acute childhood lymphoblastic leukaemia for over 30 years.,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute"
18678946,The L-asparaginases from Escherichia coli and Erwinia chrysanthemi are effective drugs that have been used in the treatment of acute childhood lymphoblastic leukaemia for over 30 years.,ASPARAGINASE,ISA,Pharmaceutical Preparations
19546477,A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia.,Prednisone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19546477,A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia.,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
19684603,"These ARID5B SNPs also distinguished B-hyperdiploid ALL from other subtypes in an independent validation cohort (n = 124 children with ALL; P = 0.003 and P = 0.0008, OR 2.45 and 2.86, respectively) and were associated with methotrexate accumulation and gene expression pattern in leukemic lymphoblasts.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19684603,"These ARID5B SNPs also distinguished B-hyperdiploid ALL from other subtypes in an independent validation cohort (n = 124 children with ALL; P = 0.003 and P = 0.0008, OR 2.45 and 2.86, respectively) and were associated with methotrexate accumulation and gene expression pattern in leukemic lymphoblasts.","Leukemia, Lymphocytic, Acute",PROCESS_OF,cohort
19855078,"MLL translocations t(4;11) and t(11;19) characterized extensively hypermethylated leukemias, whereas t(9;11)-positive infant ALL and infant ALL carrying wild-type MLL genes epigenetically resembled normal bone marrow.",MLL gene | KMT2A,PART_OF,"Leukemia, Lymphocytic, Acute"
19855078,"MLL translocations t(4;11) and t(11;19) characterized extensively hypermethylated leukemias, whereas t(9;11)-positive infant ALL and infant ALL carrying wild-type MLL genes epigenetically resembled normal bone marrow.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19855078,"MLL translocations t(4;11) and t(11;19) characterized extensively hypermethylated leukemias, whereas t(9;11)-positive infant ALL and infant ALL carrying wild-type MLL genes epigenetically resembled normal bone marrow.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19855078,Distinct promoter CpG island methylation patterns separated different genetic subtypes of MLL-rearranged ALL in infants.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19855078,"Therefore, inhibition of aberrant DNA methylation may be an important novel therapeutic strategy for MLL-rearranged ALL in infants.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19855078,"To test this hypothesis, we used differential methylation hybridization to explore the DNA methylation patterns underlying MLL-rearranged ALL in infants.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
19855078,"Therefore, inhibition of aberrant DNA methylation may be an important novel therapeutic strategy for MLL-rearranged ALL in infants.",Aberrant DNA Methylation,AFFECTS,"Leukemia, Lymphocytic, Acute"
19855078,"MLL translocations t(4;11) and t(11;19) characterized extensively hypermethylated leukemias, whereas t(9;11)-positive infant ALL and infant ALL carrying wild-type MLL genes epigenetically resembled normal bone marrow.",MLL gene | KMT2A,PART_OF,"Leukemia, Lymphocytic, Acute"
20027391,"An association may exist between exposure to low frequency magnetic fields and acute lymphoblastic leukemia in children, but this association is weak, preventing the observation of consistency in the findings.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20027391,Magnetic fields and acute lymphoblastic leukemia in children: a systematic review of case-control studies.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20030914,[A comparative cytogenetic analysis in large scale between adult and childhood patients with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
20030914,[A comparative cytogenetic analysis in large scale between adult and childhood patients with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
20044045,"MATERIALS AND METHODS: Forty-four newly diagnosed ALL children underwent bone measurement by QUS parameters BTT (Bone Transmission Time) and AD-SoS (Amplitude-Dependent Speed of Sound), mainly reliant on bone density and cortical thickness, respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20101025,"No evidence of an association with MTHFR 677 was observed for ALL or AML, either in children or their mothers.","Leukemia, Myelocytic, Acute",PROCESS_OF,Mothers
20101025,"No evidence of an association with MTHFR 677 was observed for ALL or AML, either in children or their mothers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Mothers
20101025,"No evidence of an association with MTHFR 677 was observed for ALL or AML, either in children or their mothers.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
20101025,"No evidence of an association with MTHFR 677 was observed for ALL or AML, either in children or their mothers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20215554,EXPERIMENTAL DESIGN: Lymphoblasts from children with B-lineage ALL were assessed for CD22 expression by flow cytometry and for BL22 sensitivity by in vitro cytotoxicity assay.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20215554,EXPERIMENTAL DESIGN: Lymphoblasts from children with B-lineage ALL were assessed for CD22 expression by flow cytometry and for BL22 sensitivity by in vitro cytotoxicity assay.,lymphoblast,PRODUCES,CD22 gene | CD22
20215554,EXPERIMENTAL DESIGN: Lymphoblasts from children with B-lineage ALL were assessed for CD22 expression by flow cytometry and for BL22 sensitivity by in vitro cytotoxicity assay.,Cytotoxicity assay,METHOD_OF,Flow Cytometry
20215554,"PURPOSE: Although most children with B-lineage acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma are cured, new agents are needed to overcome drug resistance and reduce toxicities of chemotherapy.","Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
20215554,"PURPOSE: Although most children with B-lineage acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma are cured, new agents are needed to overcome drug resistance and reduce toxicities of chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21072044,The oncogenic fusion protein E2A-HLF is a chimeric transcription factor that arises from the t(17;19) translocation in childhood B-cell acute lymphoblastic leukemias (B-precursor ALL) and is associated with very poor outcome.,TRANSCRIPTION FACTOR,ASSOCIATED_WITH,B-cell childhood acute lymphoblastic leukemia
21072044,The oncogenic fusion protein E2A-HLF is a chimeric transcription factor that arises from the t(17;19) translocation in childhood B-cell acute lymphoblastic leukemias (B-precursor ALL) and is associated with very poor outcome.,B-cell childhood acute lymphoblastic leukemia,ISA,"Leukemia, B-Cell, Acute"
21241277,Interphase fluorescent in situ hybridization (FISH) was applied on diagnostic BM smears from 519 children with acute lymphoblastic leukaemia (ALL) in order to establish the frequency and prognostic importance of 9p21 deletion in children enrolled in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) - 2000 treatment protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21241277,Interphase fluorescent in situ hybridization (FISH) was applied on diagnostic BM smears from 519 children with acute lymphoblastic leukaemia (ALL) in order to establish the frequency and prognostic importance of 9p21 deletion in children enrolled in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) - 2000 treatment protocol.,Child,LOCATION_OF,9p21
21246408,Allogeneic hematopoietic stem-cell transplantation is the treatment of choice for many children with relapsed ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21246408,Allogeneic hematopoietic stem-cell transplantation is the treatment of choice for many children with relapsed ALL.,Hematopoietic Stem Cell Transplantation,ISA,Therapeutic procedure
21246408,Allogeneic hematopoietic stem-cell transplantation is the treatment of choice for many children with relapsed ALL.,Hematopoietic Stem Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
21246408,Relapse of acute lymphoblastic leukemia in children in the context of microarray analyses.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21246408,Allogeneic hematopoietic stem-cell transplantation is the treatment of choice for many children with relapsed ALL.,Hematopoietic Stem Cell Transplantation,TREATS,Child
21298738,PROCEDURE: Children with B-ALL diagnosed between 1988 and 1999 were enrolled in the AIEOP-8805 protocol.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
18690355,Alterations in haemostasis are frequently observed in children with acute lymphoblastic leukemia (ALL).,Hemostatic function,PROCESS_OF,Child
18690355,Alterations in haemostasis are frequently observed in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
19726791,Fifty-one parents of children with acute lymphoblastic leukemia in a tertiary care hospital in Indonesia were interviewed about their perception of side effects and their impact on treatment noncompliance and daily activities.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20049174,"In this study, Forty-one out of fifty-seven Tunisian children with B-lineage acute lymphoblastic leukemia (B-ALL), and without cytogenetically detectable recurrent abnormalities at the time of the diagnosis, were evaluated by fluorescence in situ hybridization (FISH) for the t(12;21).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20154213,Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.,"Leukemia, B-Cell, Acute",PROCESS_OF,Adolescent
20154213,Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
20154213,Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.,Therapeutic procedure,TREATS,Adolescent
20154213,Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.,Therapeutic procedure,TREATS,"Leukemia, B-Cell, Acute"
20154213,Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.,Therapeutic procedure,TREATS,Child
20223597,"Although the majority of children with acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy, the challenge remains to salvage patients with resistant disease and to reduce treatment related toxicity.",Combination Drug Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
20223597,"Although the majority of children with acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy, the challenge remains to salvage patients with resistant disease and to reduce treatment related toxicity.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20223597,"Although the majority of children with acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy, the challenge remains to salvage patients with resistant disease and to reduce treatment related toxicity.",Combination Drug Therapy,TREATS,Child
20223597,"Although the majority of children with acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy, the challenge remains to salvage patients with resistant disease and to reduce treatment related toxicity.",Disease,PROCESS_OF,Patients
20232432,CONCLUSION: These findings suggest an association between lower expression levels of the pro-apoptotic genes and a poor response to induction therapy at day 7 and prognosis in childhood ALL.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20232432,"PROCEDURE: The levels of mRNA expression of the apoptosis-related genes CASP3, CASP8, CASP9, FAS, and BCL2 were analyzed by quantitative real-time PCR in consecutive samples from 139 consecutive children with ALL at diagnosis treated by the Brazilian protocol (GBTLI-ALL 99).",mRNA Expression,PROCESS_OF,CONSECUTIVE SAMPLE
20232432,"PROCEDURE: The levels of mRNA expression of the apoptosis-related genes CASP3, CASP8, CASP9, FAS, and BCL2 were analyzed by quantitative real-time PCR in consecutive samples from 139 consecutive children with ALL at diagnosis treated by the Brazilian protocol (GBTLI-ALL 99).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20232432,The objective of the present study was to assess the expression profile of key apoptosis-related genes in terms of clinical and biological variables and of the survival of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20232432,"Low mRNA expression of the apoptosis-related genes CASP3, CASP8, and FAS is associated with low induction treatment response in childhood acute lymphoblastic leukemia (ALL).",Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20310003,Survivors of childhood acute lymphoblastic leukemia (ALL) treated with radiotherapy are at risk for impaired fertility.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
20310003,Sperm analysis of patients after successful treatment of childhood acute lymphoblastic leukemia with chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21802727,"METHODS: We collected recorded data and interviewed families of the children with ALL diagnosed between January 1997 and August 2007, who refused or abandoned treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21802727,"A report about treatment refusal and abandonment in children with acute lymphoblastic leukemia in China, 1997-2007.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22751908,"Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22751908,Induction chemotherapy is associated with increased thrombosis risk in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22751908,Induction chemotherapy is associated with increased thrombosis risk in children with acute lymphoblastic leukemia (ALL).,Pharmacotherapy,PREDISPOSES,Thrombosis
22751908,"Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia.",Anticoagulants,INTERACTS_WITH,Procoagulant
22751908,"Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia.",Pharmacotherapy,TREATS,Child
22751908,"Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23069254,"Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.",Exons,PART_OF,IL7R gene | IL7R
23069254,"Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.",B-cell childhood acute lymphoblastic leukemia,ISA,"Leukemia, B-Cell, Acute"
23069254,"Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.",Carcinoma of the Large Intestine,ISA,Malignant Neoplasms
23069254,"Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.",T-cell childhood acute lymphoblastic leukemia,ISA,Hematologic Neoplasms
23069254,"Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.",Carcinoma of the Large Intestine,COEXISTS_WITH,Neoplasm
23069254,"Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.",T-cell childhood acute lymphoblastic leukemia,ISA,Malignant Neoplasms
23069254,"Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.",T-cell childhood acute lymphoblastic leukemia,COEXISTS_WITH,Neoplasm
23069254,"Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.",Malignant neoplasm of lung,ISA,Malignant Neoplasms
23069254,"Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.",Hematologic Neoplasms,COEXISTS_WITH,Neoplasm
23069254,"Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.",Malignant neoplasm of lung,COEXISTS_WITH,Neoplasm
23069254,"Overall, we found 10 IL7R exon 6 mutations in seven hematologic malignancies (three childhood T-ALL [12%], one adult T-ALL [7%], two childhood precursor B-cell acute lymphoblastic leukemia (B-ALL) [2%] and one adult acute myelogenous leukemia (AML) [1%]) and three nonhematopoietic malignancies (one lung cancer [0.6%] and two colorectal cancer [0.5%]), but none in other tumors.",Malignant Neoplasms,COEXISTS_WITH,Neoplasm
23721155,"METHODS: We identified all children with acute lymphoblastic leukemia diagnosed at a single institution between January 2000 and June 2011, and linked them to a population-based cancer registry.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23721155,Validation of a registry-derived risk algorithm based on treatment protocol as a proxy for disease risk in childhood acute lymphoblastic leukemia.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21683798,"Our data indicate that long-term leukemia-free survival can be achieved in children with acute lymphoblastic leukemia in third remission using unrelated donor HCT, especially when the second relapse occurs late.",Cell Transplantation,ADMINISTERED_TO,Child
21683798,"Our data indicate that long-term leukemia-free survival can be achieved in children with acute lymphoblastic leukemia in third remission using unrelated donor HCT, especially when the second relapse occurs late.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22160836,"During remission induction chemotherapy for ALL, PRES may be caused by multiple drugs, such as L-asparaginase, vincristine, and corticosteroids, with different mechanisms of action.",Vincristine,CAUSES,Syndrome
22160836,"During remission induction chemotherapy for ALL, PRES may be caused by multiple drugs, such as L-asparaginase, vincristine, and corticosteroids, with different mechanisms of action.",ASPARAGINASE,CAUSES,Syndrome
22160836,"During remission induction chemotherapy for ALL, PRES may be caused by multiple drugs, such as L-asparaginase, vincristine, and corticosteroids, with different mechanisms of action.",Pharmaceutical Preparations,CAUSES,Syndrome
22160836,"During remission induction chemotherapy for ALL, PRES may be caused by multiple drugs, such as L-asparaginase, vincristine, and corticosteroids, with different mechanisms of action.",Adrenal Cortex Hormones,CAUSES,Syndrome
22160836,"During remission induction chemotherapy for ALL, PRES may be caused by multiple drugs, such as L-asparaginase, vincristine, and corticosteroids, with different mechanisms of action.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22246158,RALLE pilot: response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22246158,RALLE pilot: response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children.,Pilot,DIAGNOSES,"Leukemia, Lymphocytic, Acute"
22308840,Central hypothyroidism following chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22450738,Further research is needed to find explanations for the poorer survival of minority children with ALL and possible treatment implications.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22450738,"METHODS: Using data from the US National Cancer Institute's Surveillance, Epidemiology and End Results program from 1988 to 2008, we compared all natural-cause survival for children aged 19 years or under diagnosed with ALL using Cox proportional hazards models adjusted for age, diagnosis year, gender and disease immunophenotype.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22450738,Racial and ethnic disparities in survival of US children with acute lymphoblastic leukemia: evidence from the SEER database 1988-2008.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22662262,BACKGROUND: Relapses occur in about 20% of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22739150,"After induction chemotherapy in B-ALL, the expression of CD133-1 decreased significantly, but still higher than that in the normal control group.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22751908,"In this prospective study, we explored the effects of ALL and induction chemotherapy on the procoagulant, anticoagulant, and fibrinolytic systems in 20 children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22751908,"In this prospective study, we explored the effects of ALL and induction chemotherapy on the procoagulant, anticoagulant, and fibrinolytic systems in 20 children with ALL.",Anticoagulants,AFFECTS,"Leukemia, Lymphocytic, Acute"
23038194,"BACKGROUND: Over 80% of children with acute lymphatic leukaemia (ALL) survive, but many develop long-term effects after the therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23328642,"RESULTS: This study was performed in 170 children with ALL, 38 subjects with AML, and 30 healthy subjects.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23328642,"RESULTS: This study was performed in 170 children with ALL, 38 subjects with AML, and 30 healthy subjects.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
23683426,OBJECTIVE: To investigate thiopurine S-methyltransferase (TPMT) activity and gene promoter polymorphism to probe its significance of individual chemotherapy in acute lymphoblastic leukemia (ALL) children.,Pharmacotherapy,TREATS,Child
23683426,OBJECTIVE: To investigate thiopurine S-methyltransferase (TPMT) activity and gene promoter polymorphism to probe its significance of individual chemotherapy in acute lymphoblastic leukemia (ALL) children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23683426,OBJECTIVE: To investigate thiopurine S-methyltransferase (TPMT) activity and gene promoter polymorphism to probe its significance of individual chemotherapy in acute lymphoblastic leukemia (ALL) children.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23868820,We investigated the incidence of hyperglycemia during induction for childhood ALL in a retrospective cohort study of 144 patients treated on a single national protocol (UKALL2003) and explored its association with infection.,Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23868820,Hyperglycemia during induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) has been inconsistently associated with risk of infection.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23868820,Hyperglycemia during induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) has been inconsistently associated with risk of infection.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
23868820,The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL).,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23908358,PURPOSE: Corticosteroids induce apoptosis in the malignant lymphoid cells and are critical component of combination therapy for acute lymphoblastic leukemia (ALL).,Combined Modality Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23908358,PURPOSE: Corticosteroids induce apoptosis in the malignant lymphoid cells and are critical component of combination therapy for acute lymphoblastic leukemia (ALL).,Adrenal Cortex Hormones,CAUSES,Apoptosis
23908358,Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,Child
23908358,Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23908358,Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
20848637,"CONCLUSIONS: The negligible rate of fatal varicella infection in children with ALL, the risk that accompanies vaccination, and the necessity of withholding chemotherapy for vaccination appear to outweigh the potential benefit of varicella vaccination for children during treatment of ALL.",Pharmacotherapy,METHOD_OF,Vaccination
20848637,"CONCLUSIONS: The negligible rate of fatal varicella infection in children with ALL, the risk that accompanies vaccination, and the necessity of withholding chemotherapy for vaccination appear to outweigh the potential benefit of varicella vaccination for children during treatment of ALL.",Chickenpox,PROCESS_OF,Child
20848637,"RESULTS: We found that 20 of 35,128 children with ALL (0.057%; 95% confidence interval [CI], 0.037-0.088%) died of VZV infection.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20848637,BACKGROUND: The available guidelines for varicella vaccination of susceptible children with acute lymphoblastic leukemia (ALL) have become increasingly conservative.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20848637,"CONCLUSIONS: The negligible rate of fatal varicella infection in children with ALL, the risk that accompanies vaccination, and the necessity of withholding chemotherapy for vaccination appear to outweigh the potential benefit of varicella vaccination for children during treatment of ALL.",Vaccination,TREATS,"Leukemia, Lymphocytic, Acute"
20848637,The controversy of varicella vaccination in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
20848637,The controversy of varicella vaccination in children with acute lymphoblastic leukemia.,Varicella vaccination,TREATS,Child
20848637,"CONCLUSIONS: The negligible rate of fatal varicella infection in children with ALL, the risk that accompanies vaccination, and the necessity of withholding chemotherapy for vaccination appear to outweigh the potential benefit of varicella vaccination for children during treatment of ALL.",Varicella vaccination,TREATS,Child
20848637,The controversy of varicella vaccination in children with acute lymphoblastic leukemia.,Varicella vaccination,TREATS,"Leukemia, Lymphocytic, Acute"
20848637,"CONCLUSIONS: The negligible rate of fatal varicella infection in children with ALL, the risk that accompanies vaccination, and the necessity of withholding chemotherapy for vaccination appear to outweigh the potential benefit of varicella vaccination for children during treatment of ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21254378,The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study.,Remission Induction Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21813177,B-lineage acute lymphoblastic leukemia (B-ALL) is a common subtype of acute leukemia in children.,Acute leukemia,PROCESS_OF,Child
21813177,B-lineage acute lymphoblastic leukemia (B-ALL) is a common subtype of acute leukemia in children.,"Leukemia, Lymphocytic, Acute",ISA,Acute leukemia
21813177,B-lineage acute lymphoblastic leukemia (B-ALL) is a common subtype of acute leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22074251,Our aim was to evaluate the influence of MTX pathway polymorphisms on HD-MTX treatment outcome in children with ALL.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
22074251,The prediction of high-dose methotrexate (HD-MTX) toxicity is a key issue in the individualization of treatment in childhood acute lymphoblastic leukemia (ALL).,METHOTREXATE TOXICITY,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
22074251,Our study suggests an important role of polymorphisms and gene-gene interactions within the folate pathway in HD-MTX-related toxicity in childhood ALL.,METHOTREXATE TOXICITY,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
22074251,Our study suggests an important role of polymorphisms and gene-gene interactions within the folate pathway in HD-MTX-related toxicity in childhood ALL.,Folate,ASSOCIATED_WITH,METHOTREXATE TOXICITY
22074251,"In total, 167 children with ALL were genotyped for methylenetetrahydrofolate dehydrogenase (MTHFD1) 1958G > A, methylenetetrahydrofolate reductase (MTHFR) 677C > T and 1298A > C and thymidylate synthase (TYMS) 2R > 3R polymorphisms.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22074251,Our aim was to evaluate the influence of MTX pathway polymorphisms on HD-MTX treatment outcome in children with ALL.,Methotrexate,TREATS,Child
22074251,Our aim was to evaluate the influence of MTX pathway polymorphisms on HD-MTX treatment outcome in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22385687,"Glucocorticoids play an important role in the treatment of ALL, but they may suppress the hypothalamic-pituitary-adrenal (HPA) axis.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
23042281,"Additionally, we analyzed TAS in eight children with acute lymphoblastic leukemia (ALL) at diagnosis and during treatment after remission induction.",Remission Induction,PRECEDES,Therapeutic procedure
23042281,"Additionally, we analyzed TAS in eight children with acute lymphoblastic leukemia (ALL) at diagnosis and during treatment after remission induction.",Antioxidants,TREATS,Child
23042281,"Additionally, we analyzed TAS in eight children with acute lymphoblastic leukemia (ALL) at diagnosis and during treatment after remission induction.",Antioxidants,TREATS,"Leukemia, Lymphocytic, Acute"
23042281,"Additionally, we analyzed TAS in eight children with acute lymphoblastic leukemia (ALL) at diagnosis and during treatment after remission induction.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23114128,The antibody combination in regions of the two-parameter plots where the leukemic cells appeared were different from the normal cells was screened as the effective combination which was used to monitor MRD in the bone marrows of the T-ALL children after the inductive treatment.,Normal cell,LOCATION_OF,Antibodies
23114128,The antibody combination in regions of the two-parameter plots where the leukemic cells appeared were different from the normal cells was screened as the effective combination which was used to monitor MRD in the bone marrows of the T-ALL children after the inductive treatment.,Bone Marrow,LOCATION_OF,"Neoplasm, Residual"
23114128,The antibody combination in regions of the two-parameter plots where the leukemic cells appeared were different from the normal cells was screened as the effective combination which was used to monitor MRD in the bone marrows of the T-ALL children after the inductive treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23114128,"The purpose of this study was to establish a method for the monitoring of minimal residual disease (MRD) in bone marrow samples of the children with T acute lymphoid leukemia (T-ALL), and to evaluate its value in clinical application.",Bone marrow specimen,LOCATION_OF,"Neoplasm, Residual"
23114128,"The purpose of this study was to establish a method for the monitoring of minimal residual disease (MRD) in bone marrow samples of the children with T acute lymphoid leukemia (T-ALL), and to evaluate its value in clinical application.",Bone marrow specimen,PART_OF,Child
23114128,"The purpose of this study was to establish a method for the monitoring of minimal residual disease (MRD) in bone marrow samples of the children with T acute lymphoid leukemia (T-ALL), and to evaluate its value in clinical application.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23114128,The antibody combination in regions of the two-parameter plots where the leukemic cells appeared were different from the normal cells was screened as the effective combination which was used to monitor MRD in the bone marrows of the T-ALL children after the inductive treatment.,Bone Marrow,PART_OF,Child
23352628,"The overall temporal trend and seasonality of ALL were tested with Poisson regression models on 0-14-year-old ALL cases, and specifically on the B-cell precursor ALL (Bcp-ALL) cases.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
23793915,The aim of this report is to identify the potential benefits of unrelated CBT in high-risk childhood ALL with CNS relapse who has been treated on CNS-directed treatment strategies.,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23793915,Unrelated cord blood transplantation for central nervous system relapse in high-risk childhood acute lymphoblastic leukemia.,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23793915,"Eleven childhood ALL patients with CNS relapse who underwent unrelated CBT enrolled in our study between 2001 and 2011, and all of the patients had features associated with poor outcomes, such as high white blood cells at diagnosis, ph + chromosome, or a history of bone marrow relapse.",Transplantation,TREATS,Patients
23793915,"Eleven childhood ALL patients with CNS relapse who underwent unrelated CBT enrolled in our study between 2001 and 2011, and all of the patients had features associated with poor outcomes, such as high white blood cells at diagnosis, ph + chromosome, or a history of bone marrow relapse.",Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23793915,"Eleven childhood ALL patients with CNS relapse who underwent unrelated CBT enrolled in our study between 2001 and 2011, and all of the patients had features associated with poor outcomes, such as high white blood cells at diagnosis, ph + chromosome, or a history of bone marrow relapse.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
21254378,"BACKGROUND: Traumatic lumbar puncture with leukemic blasts (TLP+), which has been reported to occur 5-10%, in the previous studies, adversely affects the outcome of children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21828124,"As the bone marrow environment plays an important role in survival and chemotherapy resistance of leukemia cells by activating different signaling pathways, such as the VLA-4 and PI3K/Akt pathways, we studied the prognostic and biological impact of VLA-4 expression in leukemia cells from children with relapsed B-cell precursor acute lymphoblastic leukemia and its influence on the sensitivity of the leukemia cells to drugs.",Proto-Oncogene Proteins c-akt | AKT1,PRODUCES,Integrin alpha4beta1
21828124,"As the bone marrow environment plays an important role in survival and chemotherapy resistance of leukemia cells by activating different signaling pathways, such as the VLA-4 and PI3K/Akt pathways, we studied the prognostic and biological impact of VLA-4 expression in leukemia cells from children with relapsed B-cell precursor acute lymphoblastic leukemia and its influence on the sensitivity of the leukemia cells to drugs.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
21828124,"As the bone marrow environment plays an important role in survival and chemotherapy resistance of leukemia cells by activating different signaling pathways, such as the VLA-4 and PI3K/Akt pathways, we studied the prognostic and biological impact of VLA-4 expression in leukemia cells from children with relapsed B-cell precursor acute lymphoblastic leukemia and its influence on the sensitivity of the leukemia cells to drugs.",Pharmaceutical Preparations,AFFECTS,Leukemic Cell
21828124,CONCLUSIONS: Our results show that high VLA-4 expression is a marker of poor prognosis and a potential therapeutic target in children with relapsed acute lymphoblastic leukemia and confirm that cellular interactions and biological effects related to VLA-4 play a decisive role in the survival of leukemia cells and response to therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21828124,CONCLUSIONS: Our results show that high VLA-4 expression is a marker of poor prognosis and a potential therapeutic target in children with relapsed acute lymphoblastic leukemia and confirm that cellular interactions and biological effects related to VLA-4 play a decisive role in the survival of leukemia cells and response to therapy.,Prognosis bad,PROCESS_OF,Child
21996369,"CONCLUSION: Children with ALL are at risk of CNS morbidity, regardless of the mode of CNS-directed therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22021150,"Obesity affects 11-57% of children with acute lymphoblastic leukemia, probably due to increased energy intake and reduced energy expenditure secondary to reduced habitual activity caused by fatigue.",Fatigue,CAUSES,Obesity
22021150,"Obesity affects 11-57% of children with acute lymphoblastic leukemia, probably due to increased energy intake and reduced energy expenditure secondary to reduced habitual activity caused by fatigue.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22093874,"BACKGROUND: Glucocorticoids such as prednisolone and dexamethasone are critical drugs used in multi-agent chemotherapy protocols used to treat acute lymphoblastic leukemia (ALL), and response to glucocorticoids is highly predictive of outcome.",prednisolone,ISA,Glucocorticoids
22093874,"BACKGROUND: Glucocorticoids such as prednisolone and dexamethasone are critical drugs used in multi-agent chemotherapy protocols used to treat acute lymphoblastic leukemia (ALL), and response to glucocorticoids is highly predictive of outcome.",Dexamethasone,ISA,Pharmaceutical Preparations
22093874,"BACKGROUND: Glucocorticoids such as prednisolone and dexamethasone are critical drugs used in multi-agent chemotherapy protocols used to treat acute lymphoblastic leukemia (ALL), and response to glucocorticoids is highly predictive of outcome.",Dexamethasone,ISA,Glucocorticoids
22093874,Cells from a glucocorticoid-sensitive xenograft derived from a child with B-cell precursor ALL were inoculated into NOD/SCID mice.,Xenograft procedure,ADMINISTERED_TO,SCID Mice
22093874,Cells from a glucocorticoid-sensitive xenograft derived from a child with B-cell precursor ALL were inoculated into NOD/SCID mice.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
22093874,"BACKGROUND: Glucocorticoids such as prednisolone and dexamethasone are critical drugs used in multi-agent chemotherapy protocols used to treat acute lymphoblastic leukemia (ALL), and response to glucocorticoids is highly predictive of outcome.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
22093874,"BACKGROUND: Glucocorticoids such as prednisolone and dexamethasone are critical drugs used in multi-agent chemotherapy protocols used to treat acute lymphoblastic leukemia (ALL), and response to glucocorticoids is highly predictive of outcome.",prednisolone,ISA,Pharmaceutical Preparations
22568792,Sidney Farber and the treatment of childhood acute lymphoblastic leukemia with a chemotherapeutic agent.,Antineoplastic Agents,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22653976,Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.,bortezomib,TREATS,Lymphoma
22653976,Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22759733,The association between acute lymphoblastic leukemia in children and Helicobacter pylori as the marker for sanitation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22759733,"BACKGROUND: Greaves ""delayed infection"" hypothesis suggested that Acute Lymphoblastic Leukemia (ALL) in children is caused by a lack of exposure to infection in infancy, which may be due higher standards of sanitation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22759733,The association between acute lymphoblastic leukemia in children and Helicobacter pylori as the marker for sanitation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Helicobacter pylori
22865901,PURPOSE: Children with acute lymphoblastic leukemia (ALL) are at risk for impaired bone accrual.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23114164,Childhood acute lymphoblastic leukemia (C-ALL) is the most common pediatric cancer.,"Leukemia, Lymphocytic, Acute, L1",ISA,Malignant Childhood Neoplasm
23242576,CONCLUSION: Both MRD and karyotype are powerful determinants of outcome in childhood ALL.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23242576,METHODS: A retrospective review of 250 Irish children with ALL was carried out.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23351599,CONCLUSION: Adult survivors of childhood ALL treated with chemotherapeutic regimens of moderate intensity without cranial radiation therapy exhibit a modest loss in SDS for height at FH irrespective of GH status at the cessation of treatment.,Radiation therapy,TREATS,Height
23351599,CONCLUSION: Adult survivors of childhood ALL treated with chemotherapeutic regimens of moderate intensity without cranial radiation therapy exhibit a modest loss in SDS for height at FH irrespective of GH status at the cessation of treatment.,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23511488,Clinical relevance of the fusion transcripts distribution pattern in mexican children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23511488,"As presented here, this report gives an overview of the clinical implications of the fusion gene positivity in Mexican children with ALL in the context of traditional risk stratification variables.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23511488,"Multiplex RT-PCR assays were used to detect 4 commonest fusion transcripts in 261 Mexican children with B-cell precursor ALL aged 1 to 14 years old, comparing differences in the distribution of the patients between molecular subgroups to a common collection of clinical parameters.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
23940019,This study was conducted to establish processes for collaborative data collection and provide clinical characteristics and outcome of children with ALL in SA.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21319284,"BACKGROUND: Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for overweight, predisposing them to long-term morbidity.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
21854453,Trimethoprim-sulfamethoxazole (TMP/SMX) is used in children with acute lymphoblastic leukemia (ALL) to prevent Pneumocystis pneumonia (PCP).,Trimethoprim-Sulfamethoxazole Combination,TREATS,"Leukemia, Lymphocytic, Acute"
21854453,Trimethoprim-sulfamethoxazole (TMP/SMX) is used in children with acute lymphoblastic leukemia (ALL) to prevent Pneumocystis pneumonia (PCP).,Pneumonia,PROCESS_OF,Pneumocystis
21854453,Trimethoprim-sulfamethoxazole (TMP/SMX) is used in children with acute lymphoblastic leukemia (ALL) to prevent Pneumocystis pneumonia (PCP).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21854453,Trimethoprim-sulfamethoxazole (TMP/SMX) is used in children with acute lymphoblastic leukemia (ALL) to prevent Pneumocystis pneumonia (PCP).,Trimethoprim-Sulfamethoxazole Combination,TREATS,Child
22093422,[The protocol of minimal residual disease in childhood acute lymphoblastic leukemia].,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,palonosetron,PREVENTS,Vomiting
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,palonosetron,PREVENTS,Nausea
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,Vomiting,PROCESS_OF,Child
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,Nausea,PROCESS_OF,Child
22574072,"In this study, we evaluated changes in 3 parameters, namely, random blood glucose, body mass index (BMI), and Z score for BMI (Z-BMI), in children with ALL during chemotherapy and after completion of treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22574072,Evaluation of changes in random blood glucose and body mass index during and after completion of chemotherapy in children with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Child
22574072,Evaluation of changes in random blood glucose and body mass index during and after completion of chemotherapy in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22574072,Evaluation of changes in random blood glucose and body mass index during and after completion of chemotherapy in children with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22574072,"In this study, we evaluated changes in 3 parameters, namely, random blood glucose, body mass index (BMI), and Z score for BMI (Z-BMI), in children with ALL during chemotherapy and after completion of treatment.",Child,LOCATION_OF,Blood Glucose
22653976,"Thus, this combination of bortezomib with chemotherapy is active in B-precursor ALL, and prophylactic antibiotics may be useful in reducing mortality.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22971657,[Late sequelae of central nervous system prophylaxis in children with acute lymphoblastic leukemia: high doses of intravenous methotrexate versus radiotherapy of the central nervous system--review of literature].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22971657,[Late sequelae of central nervous system prophylaxis in children with acute lymphoblastic leukemia: high doses of intravenous methotrexate versus radiotherapy of the central nervous system--review of literature].,Methotrexate,compared_with,Radiation therapy
22971657,[Late sequelae of central nervous system prophylaxis in children with acute lymphoblastic leukemia: high doses of intravenous methotrexate versus radiotherapy of the central nervous system--review of literature].,Neuraxis,LOCATION_OF,Radiation therapy
22971657,[Late sequelae of central nervous system prophylaxis in children with acute lymphoblastic leukemia: high doses of intravenous methotrexate versus radiotherapy of the central nervous system--review of literature].,Sequela of disorder,PROCESS_OF,Child
22971657,Acute lymphoblastic leukemia is the most common malignancy in children.,Malignant Neoplasms,PROCESS_OF,Child
22971657,Acute lymphoblastic leukemia is the most common malignancy in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
22971657,Acute lymphoblastic leukemia is the most common malignancy in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23189085,"The efficacy of chemotherapy in pediatric acute lymphoblastic leukemia (ALL) patients has significantly increased in the last 20 years; as a result, the focus of research is slowly shifting from trying to increase survival rates to reduce chemotherapy-related toxicity.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23189085,Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.,Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23189085,"In this review we will discuss recent data on this field, with special focus on those polymorphisms that could be used in clinical practice to tailor chemotherapy for ALL in order to reduce the occurrence of serious adverse effects.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23189085,"The efficacy of chemotherapy in pediatric acute lymphoblastic leukemia (ALL) patients has significantly increased in the last 20 years; as a result, the focus of research is slowly shifting from trying to increase survival rates to reduce chemotherapy-related toxicity.",Pharmacotherapy,TREATS,Patients
23189085,"The efficacy of chemotherapy in pediatric acute lymphoblastic leukemia (ALL) patients has significantly increased in the last 20 years; as a result, the focus of research is slowly shifting from trying to increase survival rates to reduce chemotherapy-related toxicity.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
23227903,Prospective studies on clofarabine used during earlier phases of the disease may help to define how best this new drug can be exploited for childhood and adolescent ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
23274378,"Intrathecal and systemic methotrexate (MTX), as well as cranial radiation, are effective modalities to prevent central nervous system relapse in childhood acute lymphoblastic leukemia.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23799523,Children and adolescents with ALL are taller than expected at diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23799523,ALL children and adolescents were taller and black and Asian children shorter than white children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23799523,Children and adolescents with ALL are taller than expected at diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
23915977,"MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23934636,"In conclusion, hypercalcemia alone or combined with osteolytic lesions can be the only presenting symptom of ALL in children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23934636,"In conclusion, hypercalcemia alone or combined with osteolytic lesions can be the only presenting symptom of ALL in children.",Osteolytic lesion,COEXISTS_WITH,Hypercalcemia
21869842,"To evaluate whether outcomes for this drug-sensitive leukemia are improved by contemporary risk-directed therapy, we studied clinical features, response and adverse events of 168 children with newly diagnosed ETV6-RUNX1-positive ALL on St Jude Total Therapy studies XIIIA (N=36), XIIIB (N=38) and XV (N=94).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21869842,"Thus, the MRD-guided treatment schema including intensive asparaginase and high-dose methotrexate in the Total XV study produced significantly better outcomes than previous regimens and demonstrated that nearly all children with ETV6-RUNX1 ALL can be cured.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21869842,"To evaluate whether outcomes for this drug-sensitive leukemia are improved by contemporary risk-directed therapy, we studied clinical features, response and adverse events of 168 children with newly diagnosed ETV6-RUNX1-positive ALL on St Jude Total Therapy studies XIIIA (N=36), XIIIB (N=38) and XV (N=94).",Therapeutic procedure,TREATS,Adverse event
21869842,"To evaluate whether outcomes for this drug-sensitive leukemia are improved by contemporary risk-directed therapy, we studied clinical features, response and adverse events of 168 children with newly diagnosed ETV6-RUNX1-positive ALL on St Jude Total Therapy studies XIIIA (N=36), XIIIB (N=38) and XV (N=94).",Therapeutic procedure,TREATS,leukemia
22134717,"Particularly in children with atopic eczema, risk alleles for atopic disease were observed more often than in control subjects, and less often in children with ALL than in control subjects.",Atopy,PROCESS_OF,Child
22134717,"Particularly in children with atopic eczema, risk alleles for atopic disease were observed more often than in control subjects, and less often in children with ALL than in control subjects.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22134717,"The genotype distributions of two SNPs in the TLR6 gene, rs5743798 and rs6531666, differed significantly between children with ALL, children with atopic disease and control subjects.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22134717,"The genotype distributions of two SNPs in the TLR6 gene, rs5743798 and rs6531666, differed significantly between children with ALL, children with atopic disease and control subjects.",Single Nucleotide Polymorphism,COEXISTS_WITH,TLR6 gene | TLR6
22134717,"We studied 525 children, including 192 with childhood ALL, 149 with atopic disease and 184 healthy control subjects.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
22134717,"The genotype distributions of two SNPs in the TLR6 gene, rs5743798 and rs6531666, differed significantly between children with ALL, children with atopic disease and control subjects.",Atopy,PROCESS_OF,Child
22134717,"Particularly in children with atopic eczema, risk alleles for atopic disease were observed more often than in control subjects, and less often in children with ALL than in control subjects.","Dermatitis, Atopic",PROCESS_OF,Child
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,palonosetron,PREVENTS,Vomiting
22238187,"BACKGROUND: High dose methotrexate (HD-MTX), used in the treatment of children with acute lymphoblastic leukemia (ALL), is moderately emetogenic.",Methotrexate,TREATS,Child
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,palonosetron,PREVENTS,Nausea
22238187,"BACKGROUND: High dose methotrexate (HD-MTX), used in the treatment of children with acute lymphoblastic leukemia (ALL), is moderately emetogenic.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22238187,CONCLUSIONS: A single dose of palonosetron--without concomitant corticosteroid--was effective in preventing both acute and delayed phase CINV in majority of children with ALL treated with HD-MTX.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
22238187,"BACKGROUND: High dose methotrexate (HD-MTX), used in the treatment of children with acute lymphoblastic leukemia (ALL), is moderately emetogenic.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
22238187,CONCLUSIONS: A single dose of palonosetron--without concomitant corticosteroid--was effective in preventing both acute and delayed phase CINV in majority of children with ALL treated with HD-MTX.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,Vomiting,PROCESS_OF,Child
22238187,"The purpose of this study was to examine the effect of a single dose of palonosetron (5 ug/kg) for the prevention of chemotherapy-induced nausea and vomiting in children 18 years of age with ALL treated with HD-MTX, 5 g/m(2).",palonosetron,PREVENTS,Vomiting
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,Nausea,PROCESS_OF,Child
22238187,"The purpose of this study was to examine the effect of a single dose of palonosetron (5 ug/kg) for the prevention of chemotherapy-induced nausea and vomiting in children 18 years of age with ALL treated with HD-MTX, 5 g/m(2).",palonosetron,PREVENTS,Nausea
22238187,Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22238187,"The purpose of this study was to examine the effect of a single dose of palonosetron (5 ug/kg) for the prevention of chemotherapy-induced nausea and vomiting in children 18 years of age with ALL treated with HD-MTX, 5 g/m(2).",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
22459573,PATIENTS AND METHODS: Children with T-ALL aged 1-18 years treated in 37 institutions in Spain were enrolled in 4 consecutive trials from February-1989 to November-2009.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23444902,Acute lymphoblastic leukemia (ALL) is the most common malignancy in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
23444902,Acute lymphoblastic leukemia (ALL) is the most common malignancy in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23444902,Acute lymphoblastic leukemia (ALL) is the most common malignancy in children.,Malignant Neoplasms,PROCESS_OF,Child
23456849,"However, the impact of ALC relative to that of other prognostic factors on the outcome of children with acute lymphoblastic leukemia (ALL) treated in recent trials is unknown.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23528149,"Although, a slight male preponderance has been reported in childhood acute lymphoblastic leukemia (ALL) from several developed nations, several Indian studies suggest a skewed gender ratio in ALL.","Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
23607904,Central nervous system (CNS)-directed chemotherapy is delivered for the treatment of childhood acute lymphoblastic leukaemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23607904,"The present study aimed to compare the figurative language skills of seven children treated with CNS-directed chemotherapy for ALL before the age of 6 years (mean age at diagnosis 3 years 10 months) and a matched control group of children, using the Test of Language Competence-Expanded Edition (TLC-E) Figurative Language sub-test.",Pharmacotherapy,TREATS,Matched Groups
23607904,"The present study aimed to compare the figurative language skills of seven children treated with CNS-directed chemotherapy for ALL before the age of 6 years (mean age at diagnosis 3 years 10 months) and a matched control group of children, using the Test of Language Competence-Expanded Edition (TLC-E) Figurative Language sub-test.",Pharmacotherapy,TREATS,Child
23607904,"The present study aimed to compare the figurative language skills of seven children treated with CNS-directed chemotherapy for ALL before the age of 6 years (mean age at diagnosis 3 years 10 months) and a matched control group of children, using the Test of Language Competence-Expanded Edition (TLC-E) Figurative Language sub-test.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23621199,"CONCLUSIONS: The rate of being relapse-free in ALL children treated under the Thai national protocol at Srinagarind Hospital was better than with former protocols; however, it is still not as good as in developed countries.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23621199,"MATERIALS AND METHODS: A descriptive study was conducted in children aged between 0-15 years, newly diagnosed with ALL between March 2006 and March 2011 at Srinagarind Hospital, Department of Pediatrics, Faculty of Medicine, Khon Kaen University.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23621199,"MATERIALS AND METHODS: A descriptive study was conducted in children aged between 0-15 years, newly diagnosed with ALL between March 2006 and March 2011 at Srinagarind Hospital, Department of Pediatrics, Faculty of Medicine, Khon Kaen University.",Hospitals,LOCATION_OF,Clinical Research
23621199,BACKGROUND: The standard national protocol for treatment of acute lymphoblastic leukemia (ALL) in children was implemented in 2006.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22024548,RESULTS: In the 75 children with acute leukemia--54 with acute lymphoblastic leukemia (ALL) and 21 with acute myeloid leukemia (AML)--there were 10 episodes of typhlitis (4.5%) that developed during 221 periods of severe neutropenia.,Acute leukemia,PROCESS_OF,Child
22024548,RESULTS: In the 75 children with acute leukemia--54 with acute lymphoblastic leukemia (ALL) and 21 with acute myeloid leukemia (AML)--there were 10 episodes of typhlitis (4.5%) that developed during 221 periods of severe neutropenia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22024548,RESULTS: In the 75 children with acute leukemia--54 with acute lymphoblastic leukemia (ALL) and 21 with acute myeloid leukemia (AML)--there were 10 episodes of typhlitis (4.5%) that developed during 221 periods of severe neutropenia.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
22102553,Here we investigated whether ALC retained independent prognostic significance with respect to minimal residual disease (MRD) status in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22102553,Here we investigated whether ALC retained independent prognostic significance with respect to minimal residual disease (MRD) status in children with acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",PROCESS_OF,Child
22102553,Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
22238115,The incidence of TEL-AML1 in Iraqi ALL children appears to be similar to or slightly higher than those of Jordan (12%) and Kuwait (7%).,Child,LOCATION_OF,ETV6 gene | ETV6
22238115,The incidence of TEL-AML1 in Iraqi ALL children appears to be similar to or slightly higher than those of Jordan (12%) and Kuwait (7%).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22271707,Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country.,Methotrexate,ISA,Therapeutic procedure
22271707,Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22271707,Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22271707,Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country.,Therapeutic procedure,USES,Methotrexate
22448922,Patients with childhood relapsed and refractory mature B-cell non-Hodgkin lymphoma (B-NHL) and acute lymphoblastic leukemia (B-ALL) are rare and have a dismal prognosis.,"Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
22610685,CONCLUSION: Children with relapsed ALL of S1-S3 risk groups could be successfully treated with intensified treatment protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22610685,CONCLUSION: Children with relapsed ALL of S1-S3 risk groups could be successfully treated with intensified treatment protocol.,Treatment Protocols,TREATS,Child
22610685,CONCLUSION: Children with relapsed ALL of S1-S3 risk groups could be successfully treated with intensified treatment protocol.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
22915267,Hospitalisation for infection prior to diagnosis of acute lymphoblastic leukaemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23167807,BACKGROUND: Acute lymphoblastic leukaemia (ALL) patients treated with cranial radiotherapy (CRT) have an increased risk of GH deficiency (GHD).,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23167807,"CONCLUSIONS: Long-term ALL survivors treated with CRT have GHD and PRL insufficiency, and a high prevalence of lactation failure, but thyroid hormones remained normal.",Radiation therapy,TREATS,Long-Term Survivors
23167807,BACKGROUND: Acute lymphoblastic leukaemia (ALL) patients treated with cranial radiotherapy (CRT) have an increased risk of GH deficiency (GHD).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23167807,"CONCLUSIONS: Long-term ALL survivors treated with CRT have GHD and PRL insufficiency, and a high prevalence of lactation failure, but thyroid hormones remained normal.",Prolactin,TREATS,Long-Term Survivors
23167807,"CONCLUSIONS: Long-term ALL survivors treated with CRT have GHD and PRL insufficiency, and a high prevalence of lactation failure, but thyroid hormones remained normal.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23167807,"CONCLUSIONS: Long-term ALL survivors treated with CRT have GHD and PRL insufficiency, and a high prevalence of lactation failure, but thyroid hormones remained normal.",Prolactin,TREATS,"Leukemia, Lymphocytic, Acute"
23167807,"CONCLUSIONS: Long-term ALL survivors treated with CRT have GHD and PRL insufficiency, and a high prevalence of lactation failure, but thyroid hormones remained normal.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Long-Term Survivors
23167807,BACKGROUND: Acute lymphoblastic leukaemia (ALL) patients treated with cranial radiotherapy (CRT) have an increased risk of GH deficiency (GHD).,Radiation therapy,TREATS,Patients
23560011,"Herein, we report a boy who presented with right hemiparesis and anisocoria 1 year after the cessation of the chemotherapy protocol for acute lymphoblastic leukemia.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
23560011,"Herein, we report a boy who presented with right hemiparesis and anisocoria 1 year after the cessation of the chemotherapy protocol for acute lymphoblastic leukemia.",Anisocoria,PROCESS_OF,Boys
23560011,"Herein, we report a boy who presented with right hemiparesis and anisocoria 1 year after the cessation of the chemotherapy protocol for acute lymphoblastic leukemia.",Right hemiparesis,PROCESS_OF,Boys
23596103,"PURPOSE: Among children diagnosed with acute lymphoblastic leukemia (ALL) and given chemotherapy-only treatment, 40% to 70% of survivors experience neurocognitive impairment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23630183,Adenovirus pneumonia during induction therapy for childhood acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23630183,Adenovirus pneumonia during induction therapy for childhood acute lymphoblastic leukemia.,Pneumonia,PROCESS_OF,Adenoviruses
23705955,INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children.,Hematologic Neoplasms,PROCESS_OF,Child
23705955,INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
23705955,INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23906450,ALL- 2005 protocol was recommended as the regimen for older childhood ALL.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23906450,METHODS: The clinical data of 103 newly diagnosed ALL children aged 10 to 18 years old from five hospitals were enrolled in this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23906450,"OBJECTIVE: To retrospectively analyze the clinical characteristics and the treatment outcomes of older children with acute lymphoblastic leukemia (ALL), and to evaluate the multicenter cooperation regimen (ALL-2005).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23906450,[Analysis of multicenter efficacy of acute lymphoblastic leukemia in older children].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22102955,"We experienced a pediatric radiation-induced GBM patient which developed during the remission period of ALL, who were primarily treated with chemotherapeutic agents and brain radiation therapy for the prevention of central nervous system (CNS) relapse.",Radiation therapy,METHOD_OF,Prophylactic treatment
22102955,"We experienced a pediatric radiation-induced GBM patient which developed during the remission period of ALL, who were primarily treated with chemotherapeutic agents and brain radiation therapy for the prevention of central nervous system (CNS) relapse.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
22102955,"We experienced a pediatric radiation-induced GBM patient which developed during the remission period of ALL, who were primarily treated with chemotherapeutic agents and brain radiation therapy for the prevention of central nervous system (CNS) relapse.",Antineoplastic Agents,TREATS,"Leukemia, Lymphocytic, Acute"
22271901,CONCLUSIONS: Selective addition of Day 15 marrow response to conventional stratification criteria applied on ALL-BFM 95 (currently in use in several countries as regular chemotherapy protocol for childhood acute lymphoblastic leukemia) may significantly improve risk-adapted treatment delivery.,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22441210,Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22441210,Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.,Down Syndrome,PROCESS_OF,Child
22614971,Three-drug remission-induction therapy combined with MRD-based risk stratification to identify poor responders is an effective strategy for childhood ALL.,Remission Induction Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22614971,Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22915267,RESULTS: A total of 815 children were diagnosed with ALL during follow-up.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22997141,"PROCEDURE: We simultaneously detected IKZF1 gene deletions by multiplex ligation-dependent probe amplification and gene expression of IKZF1 isoforms in 206 children with BCR/ABL-negative ALL treated with ALL IC-BFM 2002 protocol, in which risk stratification was not based on minimal residual disease (MRD), and validated the results on a cohort of 189 patients treated with MRD-directed ALL-BFM 2000 protocol.",Gene Expression,PROCESS_OF,Child
22997141,"PROCEDURE: We simultaneously detected IKZF1 gene deletions by multiplex ligation-dependent probe amplification and gene expression of IKZF1 isoforms in 206 children with BCR/ABL-negative ALL treated with ALL IC-BFM 2002 protocol, in which risk stratification was not based on minimal residual disease (MRD), and validated the results on a cohort of 189 patients treated with MRD-directed ALL-BFM 2000 protocol.",Gene Deletion,AFFECTS,"Neoplasm, Residual"
22997141,"PROCEDURE: We simultaneously detected IKZF1 gene deletions by multiplex ligation-dependent probe amplification and gene expression of IKZF1 isoforms in 206 children with BCR/ABL-negative ALL treated with ALL IC-BFM 2002 protocol, in which risk stratification was not based on minimal residual disease (MRD), and validated the results on a cohort of 189 patients treated with MRD-directed ALL-BFM 2000 protocol.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23049407,"Acute lymphoblastic leukemia was successfully treated with standard chemotherapy, both children remaining in complete remission 16 and 17 months after their initial aplastic anemia diagnosis.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23056078,Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23056078,Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia.,gene polymorphism,PROCESS_OF,Child
23088710,A total number of 817 children with acute lymphoblastic leukemia (ALL) and 181 with acute myeloblastic leukemia (AML) were assessed for individualized tumor response testing (ITRT) profile as a prognostic factor in long-term follow-up.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
23088710,"In initial ALL, an impact on long-term response was shown in ITRT for 13 drugs, while in initial AML only for cytarabine.","Leukemia, Lymphocytic, Acute",COEXISTS_WITH,"Leukemia, Myelocytic, Acute"
23088710,A total number of 817 children with acute lymphoblastic leukemia (ALL) and 181 with acute myeloblastic leukemia (AML) were assessed for individualized tumor response testing (ITRT) profile as a prognostic factor in long-term follow-up.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23403504,Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia.,Prophylactic treatment,USES,Ciprofloxacin
23403504,Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia.,Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23407458,Children with acute lymphoblastic leukemia (ALL) and high minimal residual disease (MRD) levels after initial chemotherapy have a poor clinical outcome.,"Neoplasm, Residual",PROCESS_OF,Child
23407458,Children with acute lymphoblastic leukemia (ALL) and high minimal residual disease (MRD) levels after initial chemotherapy have a poor clinical outcome.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23407458,High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.,"Transplantation, Homologous",TREATS,"Leukemia, Lymphocytic, Acute, L1"
23407458,High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23750892,"Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23750892,"Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.",Pancreatitis,OCCURS_IN,Young adult
23750892,"Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.",Pancreatitis,OCCURS_IN,Child
23750892,"Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
23757107,Minimal residual disease (MRD) is a powerful predictor of the overall response to treatment in childhood acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23757107,Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23808872,Intensive multi-agent chemotherapy regimens and the introduction of risk-stratified therapy have substantially improved cure rates for children with acute lymphoblastic leukaemia (ALL).,Therapeutic procedure,TREATS,Child
23808872,Intensive multi-agent chemotherapy regimens and the introduction of risk-stratified therapy have substantially improved cure rates for children with acute lymphoblastic leukaemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23808872,Intensive multi-agent chemotherapy regimens and the introduction of risk-stratified therapy have substantially improved cure rates for children with acute lymphoblastic leukaemia (ALL).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
23056078,CONCLUSIONS: Polymorphisms associated with risk of ALL and clinical outcome may be potential biomarkers to predict clinical outcome and improve prognosis in childhood ALL.,"Leukemia, Lymphocytic, Acute",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23320002,The levels of such minimal residual disease (MRD) are now widely used as parameters for risk assignment in acute lymphoblastic leukemia (ALL) and increasingly so in acute myeloid leukemia (AML).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
23591360,"Recently, COG decided to treat children with T-cell ALL with separate protocols different from those for the precursor B-cell ALL, and the protocols of BFM for children with T-ALL have been the same as those of the precursor B-cell ALL.",Acute T Cell Leukemia,PROCESS_OF,Child
23591360,Relapses of ALL in children were more often in HR-ALL but also in very few non-HR-ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23591360,"Treatments with hybrid protocol, including both lymphoid- and myeloid-directed treatment elements, also contain HD-MTX and high dose Ara-C(HD-Ara-C), will further improve the outcome for infant ALL.",Ara-C,TREATS,"Leukemia, Lymphocytic, Acute"
23591360,"Recently, COG decided to treat children with T-cell ALL with separate protocols different from those for the precursor B-cell ALL, and the protocols of BFM for children with T-ALL have been the same as those of the precursor B-cell ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23591360,"Treatments with hybrid protocol, including both lymphoid- and myeloid-directed treatment elements, also contain HD-MTX and high dose Ara-C(HD-Ara-C), will further improve the outcome for infant ALL.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
23591360,"Recently, COG decided to treat children with T-cell ALL with separate protocols different from those for the precursor B-cell ALL, and the protocols of BFM for children with T-ALL have been the same as those of the precursor B-cell ALL.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
23591360,"Treatments with hybrid protocol, including both lymphoid- and myeloid-directed treatment elements, also contain HD-MTX and high dose Ara-C(HD-Ara-C), will further improve the outcome for infant ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
23591360,"Recently, COG decided to treat children with T-cell ALL with separate protocols different from those for the precursor B-cell ALL, and the protocols of BFM for children with T-ALL have been the same as those of the precursor B-cell ALL.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
23591360,"Infant ALL Interfant-99 study found that MLL rearrangement, age younger than 6 months, poor response to a prednisone prophase and high WBC count were strong independent predictive factors for poor prognosis in infants with ALL.",Prognosis bad,PROCESS_OF,Infant
23591360,"With more intensified chemotherapy , outcomes for children T-ALL were improved, approaching those for the precursor B-cell ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23591360,"Infant ALL Interfant-99 study found that MLL rearrangement, age younger than 6 months, poor response to a prednisone prophase and high WBC count were strong independent predictive factors for poor prognosis in infants with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
23591360,Children with T-ALL have had a worse outcome than with the precursor B-cell ALL previously.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23591360,Development of new agents targeted to leukemogenic pathways will promise to further improve the outcome of children ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23591360,Infants with ALL have a particularly high risk of treatment failure.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
23591360,Children with T-ALL have had a worse outcome than with the precursor B-cell ALL previously.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
23700050,During the last 6 years 73 previously untreated children and adolescents with acute lymphoblastic leukemia were enrolled on a non-randomized therapy protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
23700050,During the last 6 years 73 previously untreated children and adolescents with acute lymphoblastic leukemia were enrolled on a non-randomized therapy protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23700054,[Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].,"Neoplasm, Residual",PROCESS_OF,Child
23700054,[Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23700060,"The major findings derived from these ALL-BFM trials were as follows: 1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk ALL patients and eliminated in non-high-risk non-T-ALL patients, if it was replaced by high-dose and intrathecal methotrexate; 2) omission of delayed reintensification severely impaired outcome of low-risk patients; 3) 6 months less maintenance therapy caused an increase in systemic relapses; 4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; 5) condensed induction therapy resulted in a significant improvement of outcome; 6) the daunorubicin dose in induction could be safely reduced in low-risk patients; 7) intensification of consolidation/reintensification treatment led to considerable improvement of outcome in high-risk patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23700060,"The major findings derived from these ALL-BFM trials were as follows: 1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk ALL patients and eliminated in non-high-risk non-T-ALL patients, if it was replaced by high-dose and intrathecal methotrexate; 2) omission of delayed reintensification severely impaired outcome of low-risk patients; 3) 6 months less maintenance therapy caused an increase in systemic relapses; 4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; 5) condensed induction therapy resulted in a significant improvement of outcome; 6) the daunorubicin dose in induction could be safely reduced in low-risk patients; 7) intensification of consolidation/reintensification treatment led to considerable improvement of outcome in high-risk patients.",Induction,TREATS,Patients
23700060,"The major findings derived from these ALL-BFM trials were as follows: 1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk ALL patients and eliminated in non-high-risk non-T-ALL patients, if it was replaced by high-dose and intrathecal methotrexate; 2) omission of delayed reintensification severely impaired outcome of low-risk patients; 3) 6 months less maintenance therapy caused an increase in systemic relapses; 4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; 5) condensed induction therapy resulted in a significant improvement of outcome; 6) the daunorubicin dose in induction could be safely reduced in low-risk patients; 7) intensification of consolidation/reintensification treatment led to considerable improvement of outcome in high-risk patients.",Therapeutic procedure,TREATS,Patients
23700060,"The major findings derived from these ALL-BFM trials were as follows: 1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk ALL patients and eliminated in non-high-risk non-T-ALL patients, if it was replaced by high-dose and intrathecal methotrexate; 2) omission of delayed reintensification severely impaired outcome of low-risk patients; 3) 6 months less maintenance therapy caused an increase in systemic relapses; 4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; 5) condensed induction therapy resulted in a significant improvement of outcome; 6) the daunorubicin dose in induction could be safely reduced in low-risk patients; 7) intensification of consolidation/reintensification treatment led to considerable improvement of outcome in high-risk patients.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23700060,"The major findings derived from these ALL-BFM trials were as follows: 1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk ALL patients and eliminated in non-high-risk non-T-ALL patients, if it was replaced by high-dose and intrathecal methotrexate; 2) omission of delayed reintensification severely impaired outcome of low-risk patients; 3) 6 months less maintenance therapy caused an increase in systemic relapses; 4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; 5) condensed induction therapy resulted in a significant improvement of outcome; 6) the daunorubicin dose in induction could be safely reduced in low-risk patients; 7) intensification of consolidation/reintensification treatment led to considerable improvement of outcome in high-risk patients.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
23700062,ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22064329,Methotrexate (MTX) and 6-mercaptopurine (6MP) are the most commonly used drugs in the therapy of childhood acute lymphoblastic leukaemia (ALL).,6-Mercaptopurine,ISA,Pharmaceutical Preparations
22064329,"In this study, we investigated the level of basal and induced DNA damage as well as the effectiveness of DNA repair in lymphocytes of children with ALL at four time-points during therapy with MTX and 6MP.",Therapeutic procedure,USES,6-Mercaptopurine
22064329,"Finally, we compared the activity of base-excision repair (BER), involved in removal of both uracil and oxidized bases from DNA in lymphocytes of children with ALL and lymphocytes of healthy children.",Lymphocyte,PART_OF,Child
22064329,Methotrexate (MTX) and 6-mercaptopurine (6MP) are the most commonly used drugs in the therapy of childhood acute lymphoblastic leukaemia (ALL).,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22064329,"In this study, we investigated the level of basal and induced DNA damage as well as the effectiveness of DNA repair in lymphocytes of children with ALL at four time-points during therapy with MTX and 6MP.",Lymphocyte,PART_OF,Child
22064329,"Finally, we compared the activity of base-excision repair (BER), involved in removal of both uracil and oxidized bases from DNA in lymphocytes of children with ALL and lymphocytes of healthy children.",Lymphocyte,PART_OF,Child
22064329,Role of base-excision repair in the treatment of childhood acute lymphoblastic leukaemia with 6-mercaptopurine and high doses of methotrexate.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22064329,"In this study, we investigated the level of basal and induced DNA damage as well as the effectiveness of DNA repair in lymphocytes of children with ALL at four time-points during therapy with MTX and 6MP.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22064329,"Finally, we compared the activity of base-excision repair (BER), involved in removal of both uracil and oxidized bases from DNA in lymphocytes of children with ALL and lymphocytes of healthy children.",Lymphocyte,PART_OF,Child
22064329,Methotrexate (MTX) and 6-mercaptopurine (6MP) are the most commonly used drugs in the therapy of childhood acute lymphoblastic leukaemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22064329,"Finally, we compared the activity of base-excision repair (BER), involved in removal of both uracil and oxidized bases from DNA in lymphocytes of children with ALL and lymphocytes of healthy children.",Lymphocyte,PART_OF,Child
22064329,Methotrexate (MTX) and 6-mercaptopurine (6MP) are the most commonly used drugs in the therapy of childhood acute lymphoblastic leukaemia (ALL).,Methotrexate,ISA,Pharmaceutical Preparations
22064329,"Finally, we compared the activity of base-excision repair (BER), involved in removal of both uracil and oxidized bases from DNA in lymphocytes of children with ALL and lymphocytes of healthy children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22064329,Methotrexate (MTX) and 6-mercaptopurine (6MP) are the most commonly used drugs in the therapy of childhood acute lymphoblastic leukaemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22064329,"In this study, we investigated the level of basal and induced DNA damage as well as the effectiveness of DNA repair in lymphocytes of children with ALL at four time-points during therapy with MTX and 6MP.",Therapeutic procedure,USES,Methotrexate
22581001,Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.,Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22581001,Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.,Polymerase Chain Reaction,DIAGNOSES,"Neoplasm, Residual"
22581001,Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.,Flow Cytometry,DIAGNOSES,"Neoplasm, Residual"
22581001,"DESIGN AND METHODS: Polymerase chain reaction and flow cytometry were simultaneously applied for prospective minimal residual disease measurements at days 15, 33 and 78 of induction therapy on 3565 samples from 1547 children with acute lymphoblastic leukemia enrolled into the AIEOP-BFM ALL 2000 trial.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22581001,The aim of this study was to compare the performances of these two methodologies in the detection of minimal residual disease in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
22581001,The aim of this study was to compare the performances of these two methodologies in the detection of minimal residual disease in childhood acute lymphoblastic leukemia.,Two,ISA,Methodology
22872192,PURPOSE: To investigate the reliability of family history of cancer reported by parents of children with acute lymphoblastic leukemia (ALL) and parents of healthy control children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22881237,"With modern treatment regimens, survival in acute lymphoblastic leukaemia (ALL) approaches 90%.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
23162250,Pictorial essay: Acute neurological complications in children with acute lymphoblastic leukemia.,NEUROLOGIC COMPLICATION,PROCESS_OF,Child
23162250,Pictorial essay: Acute neurological complications in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23198157,The influence of genic polymorphisms involved in metabolism of chemotherapeutic agents as the methotrexate (MTX) has been studied mainly in acute lymphoblastic leukemia (ALL) of childhood.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
23198157,"Thus, we believe that patients with 80AA genotype presented a small reduction in MTX plasma level, suggesting that ALL children, carrying the 80AA genotype, showed a high toxicity to MTX (P < 0.0001).",Methotrexate measurement,DIAGNOSES,Toxic effect
23198157,"Thus, we believe that patients with 80AA genotype presented a small reduction in MTX plasma level, suggesting that ALL children, carrying the 80AA genotype, showed a high toxicity to MTX (P < 0.0001).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23323068,This study analyzed the incidence of central nervous system relapse and the risk factors for its occurrence in children and adolescents with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23323068,Incidence and risk factors for central nervous system relapse in children and adolescents with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
23323068,Incidence and risk factors for central nervous system relapse in children and adolescents with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23323068,This study analyzed the incidence of central nervous system relapse and the risk factors for its occurrence in children and adolescents with acute lymphoblastic leukemia.,Relapse,OCCURS_IN,Adolescent
23323068,This study analyzed the incidence of central nervous system relapse and the risk factors for its occurrence in children and adolescents with acute lymphoblastic leukemia.,Relapse,OCCURS_IN,Child
23323068,This study analyzed the incidence of central nervous system relapse and the risk factors for its occurrence in children and adolescents with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
23508829,Near haploidy (23-29 chromosomes) is a numerical cytogenetic aberration in childhood acute lymphoblastic leukemia (ALL) associated with particularly poor outcome.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23652803,Four hundred ninety-nine children with ALL from the ALL-BFM (Berlin-Frankfurt-Munster) 2000 trial who received 1996 courses of MTX at 5 g/m(2) were genotyped for 8 single nucleotide polymorphisms in 5 candidate genes of the MTX/folate pathway.,Single Nucleotide Polymorphism,COEXISTS_WITH,Candidate Disease Gene
23652803,"Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.",Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23652803,"Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.",Drug Kinetics,ASSOCIATED_WITH,Methotrexate
23652803,Four hundred ninety-nine children with ALL from the ALL-BFM (Berlin-Frankfurt-Munster) 2000 trial who received 1996 courses of MTX at 5 g/m(2) were genotyped for 8 single nucleotide polymorphisms in 5 candidate genes of the MTX/folate pathway.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23781853,"BACKGROUND: Being underweight or overweight and obesity at diagnosis may all worsen prognosis in childhood acute lymphoblastic leukaemia (ALL), although no studies have estimated the prevalence of an unhealthy weight status at diagnosis in large representative samples using contemporary definitions of weight status based on body mass index (BMI) for age.",Obesity,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21880630,"DESIGN AND METHODS: In this study, we employed real-time quantitative polymerase chain reaction analysis to examine minimal residual disease in 398 pairs of blood and bone marrow follow-up samples taken from 95 children with B-cell precursor acute lymphoblastic leukemia treated with the ALL IC-BFM 2002 protocol.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
21880630,"DESIGN AND METHODS: In this study, we employed real-time quantitative polymerase chain reaction analysis to examine minimal residual disease in 398 pairs of blood and bone marrow follow-up samples taken from 95 children with B-cell precursor acute lymphoblastic leukemia treated with the ALL IC-BFM 2002 protocol.",Berlin-Frankfort-Munster protocol,TREATS,"Leukemia, B-Cell, Acute"
22143821,"Meta-analyses of paternal smoking, including results from the Australian Study of Causes of Acute Lymphoblastic Leukemia in Children and those of previous studies, produced summary odds ratios of 1.15 (95% confidence interval: 1.06, 1.24) for any paternal smoking around the time of the child's conception and 1.44 (95% confidence interval: 1.24, 1.68) for smoking >=20 cigarettes per day at that time.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22143821,"Meta-analyses of paternal smoking, including results from the Australian Study of Causes of Acute Lymphoblastic Leukemia in Children and those of previous studies, produced summary odds ratios of 1.15 (95% confidence interval: 1.06, 1.24) for any paternal smoking around the time of the child's conception and 1.44 (95% confidence interval: 1.24, 1.68) for smoking >=20 cigarettes per day at that time.",Conception,PROCESS_OF,Child
22609262,"In the present review, the clinical significance of most chromosomal aberrations associated with pediatric ALL and AML as well as the current technology used for their identification is discussed.","Leukemia, Myelocytic, Acute",COEXISTS_WITH,Chromosome abnormality
22609262,"In the present review, the clinical significance of most chromosomal aberrations associated with pediatric ALL and AML as well as the current technology used for their identification is discussed.","Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,Chromosome abnormality
22713707,"METHODS: Guthrie cards from 50 children who later developed ALL and 100 matched controls were collected and analyzed by standard or real-time polymerase chain reaction for the presence of the VP1 region of KIPyV, WUPyV, and MCPyV, and the LT region for MCPyV.",Merkel Cells,LOCATION_OF,Polyomavirus
22713707,"METHODS: Guthrie cards from 50 children who later developed ALL and 100 matched controls were collected and analyzed by standard or real-time polymerase chain reaction for the presence of the VP1 region of KIPyV, WUPyV, and MCPyV, and the LT region for MCPyV.",Merkel Cells,LOCATION_OF,Polyomavirus
22713707,"RESULTS AND CONCLUSIONS: DNA from KIPyV, WUPyV, and MCPyV was not detected in neonatal blood samples from children with ALL or controls.",Blood specimen,LOCATION_OF,DNA
22713707,"KI, WU, and Merkel cell polyomavirus DNA was not detected in guthrie cards of children who later developed acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22713707,"RESULTS AND CONCLUSIONS: DNA from KIPyV, WUPyV, and MCPyV was not detected in neonatal blood samples from children with ALL or controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22713707,"KI, WU, and Merkel cell polyomavirus DNA was not detected in guthrie cards of children who later developed acute lymphoblastic leukemia.",DNA,PART_OF,Polyomavirus
22713707,"RESULTS AND CONCLUSIONS: DNA from KIPyV, WUPyV, and MCPyV was not detected in neonatal blood samples from children with ALL or controls.",Merkel Cells,LOCATION_OF,Polyomavirus
22713707,"RESULTS AND CONCLUSIONS: DNA from KIPyV, WUPyV, and MCPyV was not detected in neonatal blood samples from children with ALL or controls.",Blood specimen,PART_OF,"Infant, Newborn"
22713707,"METHODS: Guthrie cards from 50 children who later developed ALL and 100 matched controls were collected and analyzed by standard or real-time polymerase chain reaction for the presence of the VP1 region of KIPyV, WUPyV, and MCPyV, and the LT region for MCPyV.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22946019,We present a child with ALL that refer with multi bone fractures as a first manifestation of the disease.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23014359,Interleukin-1 receptor antagonist gene polymorphism increases susceptibility to septic shock in children with acute lymphoblastic leukemia.,Septic Shock,PROCESS_OF,Child
23014359,Interleukin-1 receptor antagonist gene polymorphism increases susceptibility to septic shock in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23056870,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23056870,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children.,Malignant Neoplasms,PROCESS_OF,Child
23056870,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
23089671,"In conclusion, MTHFR, C677T and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity in pediatric ALL.",Oxidoreductase,PREDISPOSES,METHOTREXATE TOXICITY
23089671,Methotrexate (MTX) is an important component of therapy used to treat childhood acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23089671,Methotrexate (MTX) is an important component of therapy used to treat childhood acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Therapeutic procedure
23089671,Methotrexate (MTX) is an important component of therapy used to treat childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23089671,"In conclusion, MTHFR, C677T and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity in pediatric ALL.",METHOTREXATE TOXICITY,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23508010,"In conclusion, this study has demonstrated in a large representative cohort of children with B-cell precursor acute lymphoblastic leukemia that the pattern of copy number abnormalities is highly variable according to the primary genetic abnormality.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
23559975,Vascular endothelial dysfunction after anthracyclines treatment in children with acute lymphoblastic leukemia.,Blood Vessels,LOCATION_OF,Endothelial dysfunction
23559975,PURPOSE: Anthracyclines have been utilized in the treatment of children with acute lymphoblastic leukemia (ALL).,Anthracycline Antibiotics,TREATS,Child
23559975,METHODS: We included 21 children with ALL who received anthracycline chemotherapy and 20 healthy children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23559975,Vascular endothelial dysfunction after anthracyclines treatment in children with acute lymphoblastic leukemia.,Anthracycline Antibiotics,ISA,Therapeutic procedure
23559975,PURPOSE: Anthracyclines have been utilized in the treatment of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23559975,METHODS: We included 21 children with ALL who received anthracycline chemotherapy and 20 healthy children.,Pharmacotherapy,ADMINISTERED_TO,Child
23559975,Vascular endothelial dysfunction after anthracyclines treatment in children with acute lymphoblastic leukemia.,Anthracycline Antibiotics,TREATS,"Leukemia, Lymphocytic, Acute"
23559975,PURPOSE: Anthracyclines have been utilized in the treatment of children with acute lymphoblastic leukemia (ALL).,Anthracycline Antibiotics,TREATS,"Leukemia, Lymphocytic, Acute"
23559975,METHODS: We included 21 children with ALL who received anthracycline chemotherapy and 20 healthy children.,Pharmacotherapy,ADMINISTERED_TO,Child
23559975,Vascular endothelial dysfunction after anthracyclines treatment in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23559975,This study was performed using brachial artery reactivity (BAR) to evaluate vascular endothelial function in ALL patients who were treated with anthracycline chemotherapy.,Pharmacotherapy,TREATS,Patients
23559975,Vascular endothelial dysfunction after anthracyclines treatment in children with acute lymphoblastic leukemia.,Anthracycline Antibiotics,TREATS,Child
23559975,This study was performed using brachial artery reactivity (BAR) to evaluate vascular endothelial function in ALL patients who were treated with anthracycline chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23559975,Vascular endothelial dysfunction after anthracyclines treatment in children with acute lymphoblastic leukemia.,Therapeutic procedure,USES,Anthracycline Antibiotics
23559975,This study was performed using brachial artery reactivity (BAR) to evaluate vascular endothelial function in ALL patients who were treated with anthracycline chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23559975,METHODS: We included 21 children with ALL who received anthracycline chemotherapy and 20 healthy children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23775832,CONCLUSIONS: Results from this pilot study suggest that adult survivors of ALL treated with dexamethasone are at increased risk for memory deficits and altered neural activity in specific brain regions and networks associated with memory function.,Brain region,LOCATION_OF,Memory impairment
23775832,"As glucocorticoids influence hippocampal function, we investigated memory networks in survivors of childhood ALL treated with dexamethasone or prednisone.",Glucocorticoids,TREATS,Survivors
23775832,"As glucocorticoids influence hippocampal function, we investigated memory networks in survivors of childhood ALL treated with dexamethasone or prednisone.",Prednisone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23775832,"As glucocorticoids influence hippocampal function, we investigated memory networks in survivors of childhood ALL treated with dexamethasone or prednisone.",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23775832,"BACKGROUND: Dexamethasone is used in acute lymphoblastic leukemia (ALL) treatment, though long-term impact on central nervous system (CNS) function is unclear.",Therapeutic procedure,AFFECTS,CNS function
23775832,"BACKGROUND: Dexamethasone is used in acute lymphoblastic leukemia (ALL) treatment, though long-term impact on central nervous system (CNS) function is unclear.",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
23775832,CONCLUSIONS: Results from this pilot study suggest that adult survivors of ALL treated with dexamethasone are at increased risk for memory deficits and altered neural activity in specific brain regions and networks associated with memory function.,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
21880524,The cross-sectional study was conducted in a cohort of 69 Caucasian children and adolescents (46 boys and 23 girls) aged 12.15 +/- 0.5yr diagnosed with ALL and screened up to 5 yr after cessation of the treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21880524,The cross-sectional study was conducted in a cohort of 69 Caucasian children and adolescents (46 boys and 23 girls) aged 12.15 +/- 0.5yr diagnosed with ALL and screened up to 5 yr after cessation of the treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.",osteosarcoma,PROCESS_OF,Child
22811513,"Separate analyses were done for children with ALL, medulloblastoma and neuroblastoma according to clinically relevant age thresholds.",medulloblastoma,PROCESS_OF,Child
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.",Hodgkin Disease,PROCESS_OF,Child
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.",Neuroblastoma,PROCESS_OF,Child
22811513,"Separate analyses were done for children with ALL, medulloblastoma and neuroblastoma according to clinically relevant age thresholds.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.",Nephroblastoma,PROCESS_OF,Child
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.",Ewings sarcoma,PROCESS_OF,Child
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.",medulloblastoma,PROCESS_OF,Child
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.",Hepatoblastoma,PROCESS_OF,Child
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.","Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.",Germ cell tumor,PROCESS_OF,Child
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
22811513,"PATIENTS AND METHODS: The population-based data were analysed for 25 853 children (66% of all registered childhood cancers) diagnosed in Britain during 1978-2005 with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma, non-Hodgkin lymphoma, medulloblastoma, neuroblastoma, Wilms tumour, hepatoblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and germ-cell tumours.",Rhabdomyosarcoma,PROCESS_OF,Child
22811513,"Separate analyses were done for children with ALL, medulloblastoma and neuroblastoma according to clinically relevant age thresholds.",Neuroblastoma,PROCESS_OF,Child
23014359,Genotype IL-1RN*2 is associated with the risk of development of septic shock in children with acute lymphoblastic leukemia.,Septic Shock,PROCESS_OF,Child
23014359,Genotype IL-1RN*2 is associated with the risk of development of septic shock in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23014359,METHODS: This cohort study was conducted in 57 consecutive children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23049293,CONCLUSIONS: Compliance to the therapeutic protocol by both doctors and patients should always be considered in the evaluation of therapeutic failure in acute lymphoblastic leukemia; strict adherence to treatment protocols contributes to better treatment results in acute lymphoblastic leukemia children.,Therapeutic procedure,TREATS,Child
23049293,CONCLUSIONS: Compliance to the therapeutic protocol by both doctors and patients should always be considered in the evaluation of therapeutic failure in acute lymphoblastic leukemia; strict adherence to treatment protocols contributes to better treatment results in acute lymphoblastic leukemia children.,Physicians,DIAGNOSES,"Leukemia, Lymphocytic, Acute"
23049293,CONCLUSIONS: Compliance to the therapeutic protocol by both doctors and patients should always be considered in the evaluation of therapeutic failure in acute lymphoblastic leukemia; strict adherence to treatment protocols contributes to better treatment results in acute lymphoblastic leukemia children.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
23049293,CONCLUSIONS: Compliance to the therapeutic protocol by both doctors and patients should always be considered in the evaluation of therapeutic failure in acute lymphoblastic leukemia; strict adherence to treatment protocols contributes to better treatment results in acute lymphoblastic leukemia children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23057204,[From disease's treatment to global care of the child with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23151340,A high resolution 244K array-based Comparative Genomic Hybridization (array-CGH) was used to study eleven ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL) patients.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
23151340,UNLABELLED: BACKGROUND: Acute lymphoblastic leukemia (ALL) is a heterogeneous form of hematological cancer consisting of various subtypes.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
23151340,Chromosomal Aberrations in ETV6/RUNX1-positive Childhood Acute Lymphoblastic Leukemia using 244K Oligonucleotide Array Comparative Genomic Hybridization.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23335239,Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.,Children's Oncology Group,LOCATION_OF,Clinical Trials
23335239,Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.,clofarabine,TREATS,"Leukemia, Lymphocytic, Acute"
23335239,Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.,Cytarabine,TREATS,"Leukemia, Lymphocytic, Acute"
23335239,"PROCEDURE: AAML0523 enrolled 21 children with ALL in second or third relapse, or those refractory to re-induction therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23335239,Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.,clofarabine,TREATS,Child
23335239,Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23335239,Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.,Cytarabine,TREATS,Child
23628024,[Expression of IGF-IR and IR in children with acute lymphoblastic leukemia].,Child,LOCATION_OF,Insulin Receptor | INSR
23628024,[Expression of IGF-IR and IR in children with acute lymphoblastic leukemia].,Child,LOCATION_OF,Insulin Receptor | INSR
23628024,[Expression of IGF-IR and IR in children with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23660772,METHODS: Fifty-three children with ALL treated according to the NOPHO-ALL 2000 protocol were included in the study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23660772,PURPOSE: Important drugs in the treatment of childhood acute lymphoblastic leukaemia (ALL) are 6-mercaptopurine (6-MP) and methotrexate (MTX).,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23660772,PURPOSE: Important drugs in the treatment of childhood acute lymphoblastic leukaemia (ALL) are 6-mercaptopurine (6-MP) and methotrexate (MTX).,6-Mercaptopurine,ISA,Pharmaceutical Preparations
23660772,"CONCLUSIONS: Our results show that TPMT genotyping should be performed in children with ALL, since 40 % of the children in our study who carried the wild-type TPMT gene were at risk of initial underdosing of 6-MP in cases where only TPMT enzyme activity was determined.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23660772,"CONCLUSIONS: Our results show that TPMT genotyping should be performed in children with ALL, since 40 % of the children in our study who carried the wild-type TPMT gene were at risk of initial underdosing of 6-MP in cases where only TPMT enzyme activity was determined.",Genotype determination,USES,Thiopurine S-Methyltransferase
23660772,"CONCLUSIONS: Our results show that TPMT genotyping should be performed in children with ALL, since 40 % of the children in our study who carried the wild-type TPMT gene were at risk of initial underdosing of 6-MP in cases where only TPMT enzyme activity was determined.",Methyltransferase Gene,PART_OF,Child
23666219,[The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].,Erwinia asparaginase,TREATS,Allergic Reaction
23666219,[The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].,ASPARAGINASE | ASPG,PART_OF,Escherichia coli
23666219,Asparaginase (ASNase) is one of the most important key drugs in the treatment of acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute"
23666219,Asparaginase (ASNase) is one of the most important key drugs in the treatment of acute lymphoblastic leukemia (ALL).,ASPARAGINASE | ASPG,ISA,Pharmaceutical Preparations
23666219,[The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
23666219,Asparaginase (ASNase) is one of the most important key drugs in the treatment of acute lymphoblastic leukemia (ALL).,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
23666219,[The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].,Allergic Reaction,PROCESS_OF,Patients
23666219,[The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].,Erwinia asparaginase,TREATS,Patients
23786458,"Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is a highly effective treatment, but at the same time causes significant suppression of the patient's immunity.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23786458,"Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is a highly effective treatment, but at the same time causes significant suppression of the patient's immunity.",Immunity,PROCESS_OF,Patients
23786458,"Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is a highly effective treatment, but at the same time causes significant suppression of the patient's immunity.",Pharmacotherapy,ISA,Therapeutic procedure
22137828,The aim of the present study was to review the oral health status in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22137828,"Oral inflammatory conditions including chelitis, gingivitis, herpetic gingivostomatitis, mucositis, oral candidiasis, periodontitis and ulcerations are common manifestations in children with ALL.",Ulcer,PROCESS_OF,Child
22137828,Oral health status in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22137828,"Oral inflammatory conditions including chelitis, gingivitis, herpetic gingivostomatitis, mucositis, oral candidiasis, periodontitis and ulcerations are common manifestations in children with ALL.",Periodontitis,PROCESS_OF,Child
22137828,"Oral inflammatory conditions including chelitis, gingivitis, herpetic gingivostomatitis, mucositis, oral candidiasis, periodontitis and ulcerations are common manifestations in children with ALL.",Gingivitis,PROCESS_OF,Child
22137828,RESULTS: Periodontal inflammatory conditions and oral mucositis were reported to be significantly higher in children with ALL as compared to healthy controls.,Oral Mucositis,PROCESS_OF,Child
22137828,"Oral inflammatory conditions including chelitis, gingivitis, herpetic gingivostomatitis, mucositis, oral candidiasis, periodontitis and ulcerations are common manifestations in children with ALL.",Cheilitis,PROCESS_OF,Child
22137828,RESULTS: Periodontal inflammatory conditions and oral mucositis were reported to be significantly higher in children with ALL as compared to healthy controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22137828,"Oral inflammatory conditions including chelitis, gingivitis, herpetic gingivostomatitis, mucositis, oral candidiasis, periodontitis and ulcerations are common manifestations in children with ALL.",Oral candidiasis,PROCESS_OF,Child
22137828,"Oral inflammatory conditions including chelitis, gingivitis, herpetic gingivostomatitis, mucositis, oral candidiasis, periodontitis and ulcerations are common manifestations in children with ALL.","Gingivostomatitis, Herpetic",PROCESS_OF,Child
22137828,"Oral inflammatory conditions including chelitis, gingivitis, herpetic gingivostomatitis, mucositis, oral candidiasis, periodontitis and ulcerations are common manifestations in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22137828,"Oral inflammatory conditions including chelitis, gingivitis, herpetic gingivostomatitis, mucositis, oral candidiasis, periodontitis and ulcerations are common manifestations in children with ALL.",Mucositis,PROCESS_OF,Child
22513795,Methotrexate (MTX) is commonly administered in high doses for treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22513795,Methotrexate (MTX) is commonly administered in high doses for treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Therapeutic procedure
22513795,The aim of this analysis was to study the influence of 2 common MTHFR polymorphisms (MTHFR 677C>T and 1298 A>C) on MTX toxicity in children with ALL.,METHOTREXATE TOXICITY,PROCESS_OF,Child
22513795,The aim of this analysis was to study the influence of 2 common MTHFR polymorphisms (MTHFR 677C>T and 1298 A>C) on MTX toxicity in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22734031,"CONCLUSION: Children with ALL have a high incidence of vertebral fractures after 12 months of chemotherapy, and the presence of vertebral fractures and reductions in spine BMD Z-scores at baseline are highly associated clinical features.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22734031,"CONCLUSION: Children with ALL have a high incidence of vertebral fractures after 12 months of chemotherapy, and the presence of vertebral fractures and reductions in spine BMD Z-scores at baseline are highly associated clinical features.",Spinal Fractures,PROCESS_OF,Child
22734031,PATIENT AND METHODS: We prospectively evaluated 155 children with ALL during the first 12 months of leukemia therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22842379,"Although, standard treatment protocol for ALL includes multimodality therapy, MTX is usually associated with neurotoxicity and affects periventricular deep white matter region.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
22887801,"PROCEDURE: In the present study, we explored episodic memory and its neuroimaging correlates in 10 adult survivors of childhood acute lymphoblastic leukemia (ALL) treated with cranial radiation therapy and both systemic and intrathecal chemotherapy and 10 controls matched for age and sex, using a subsequent memory paradigm after episodic encoding of visual scenes.",Intrathecal Chemotherapy,TREATS,Age
22887801,"PROCEDURE: In the present study, we explored episodic memory and its neuroimaging correlates in 10 adult survivors of childhood acute lymphoblastic leukemia (ALL) treated with cranial radiation therapy and both systemic and intrathecal chemotherapy and 10 controls matched for age and sex, using a subsequent memory paradigm after episodic encoding of visual scenes.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22948968,"BACKGROUND: The anthracyclines daunorubicin (DNR) and doxorubicin (DOX) are among the most important drugs in the treatment of childhood acute lymphoblastic leukemia, however there are conflicting in vitro data about the comparative efficacy and equivalent doses of both anthracyclines.",Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22948968,"BACKGROUND: The anthracyclines daunorubicin (DNR) and doxorubicin (DOX) are among the most important drugs in the treatment of childhood acute lymphoblastic leukemia, however there are conflicting in vitro data about the comparative efficacy and equivalent doses of both anthracyclines.",Doxorubicin,ISA,Pharmaceutical Preparations
22948968,"BACKGROUND: The anthracyclines daunorubicin (DNR) and doxorubicin (DOX) are among the most important drugs in the treatment of childhood acute lymphoblastic leukemia, however there are conflicting in vitro data about the comparative efficacy and equivalent doses of both anthracyclines.",Doxorubicin,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22948968,"BACKGROUND: The anthracyclines daunorubicin (DNR) and doxorubicin (DOX) are among the most important drugs in the treatment of childhood acute lymphoblastic leukemia, however there are conflicting in vitro data about the comparative efficacy and equivalent doses of both anthracyclines.",Daunorubicin,ISA,Pharmaceutical Preparations
22948968,"BACKGROUND: The anthracyclines daunorubicin (DNR) and doxorubicin (DOX) are among the most important drugs in the treatment of childhood acute lymphoblastic leukemia, however there are conflicting in vitro data about the comparative efficacy and equivalent doses of both anthracyclines.",Daunorubicin,ISA,Anthracycline Antibiotics
22948968,"BACKGROUND: The anthracyclines daunorubicin (DNR) and doxorubicin (DOX) are among the most important drugs in the treatment of childhood acute lymphoblastic leukemia, however there are conflicting in vitro data about the comparative efficacy and equivalent doses of both anthracyclines.",Daunorubicin,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22948968,PROCEDURE: Children with newly diagnosed B-Precursor ALL or T-ALL were eligible for the randomized comparison.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
22961784,"Therefore, increased asparagine synthesis by MSCs is of relevance for resistance to asparaginase of leukemic cells in vitro, but it is questionable whether this leads to asparaginase resistance in childhood ALL patients.",ASPARAGINASE | ASPG,TREATS,Patients
22961784,"Therefore, increased asparagine synthesis by MSCs is of relevance for resistance to asparaginase of leukemic cells in vitro, but it is questionable whether this leads to asparaginase resistance in childhood ALL patients.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
22961784,"Therefore, increased asparagine synthesis by MSCs is of relevance for resistance to asparaginase of leukemic cells in vitro, but it is questionable whether this leads to asparaginase resistance in childhood ALL patients.",ASPARAGINASE | ASPG,PART_OF,Leukemic Cell
22961784,"Therefore, increased asparagine synthesis by MSCs is of relevance for resistance to asparaginase of leukemic cells in vitro, but it is questionable whether this leads to asparaginase resistance in childhood ALL patients.",ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22976937,Cytomegalovirus retinitis as an adverse immunological effect of pulses of vincristine and dexamethasone in maintenance therapy for childhood acute lymphoblastic leukemia.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23066086,"Our findings suggested that TERT promoter rs2735940 polymorphism may affect the TERT activity, and rs2736100 may be associated with telomere function, and thus, it is a potential biomarker for genetic susceptibility to ALL in Chinese children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23066086,TERT polymorphisms modify the risk of acute lymphoblastic leukemia in Chinese children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23881645,"The purpose of our research was to assess the expression of myeloid and lymphoblastic antigens in children with ALL, and to determine the impact of surface antigens on early response to treatment.",Antigens,PART_OF,lymphoblast
23881645,"58 children [33 girls (56.9 %), 25 boys (43.2 %)] with ALL were studied.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23881645,"The purpose of our research was to assess the expression of myeloid and lymphoblastic antigens in children with ALL, and to determine the impact of surface antigens on early response to treatment.",Antigens,INTERACTS_WITH,Surface Antigens
23881645,"The purpose of our research was to assess the expression of myeloid and lymphoblastic antigens in children with ALL, and to determine the impact of surface antigens on early response to treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23937310,To investigate its value in the frontline treatment of ALL we applied clofarabine 5 * 40 mg/m(2) in combination with pegylated asparaginase (PEG-ASP) 1 * 2500 iu/m(2) in high risk ALL patients as a novel post-induction element in the German Co-operative Study Group for treatment of ALL (CoALL) trial 08-09.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23937310,To investigate its value in the frontline treatment of ALL we applied clofarabine 5 * 40 mg/m(2) in combination with pegylated asparaginase (PEG-ASP) 1 * 2500 iu/m(2) in high risk ALL patients as a novel post-induction element in the German Co-operative Study Group for treatment of ALL (CoALL) trial 08-09.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23937310,Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23937310,To investigate its value in the frontline treatment of ALL we applied clofarabine 5 * 40 mg/m(2) in combination with pegylated asparaginase (PEG-ASP) 1 * 2500 iu/m(2) in high risk ALL patients as a novel post-induction element in the German Co-operative Study Group for treatment of ALL (CoALL) trial 08-09.,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
21528407,Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21528407,Serum levels of sFas and sFasL were measured with an enzyme-linked immunosorbent assay in 48 patients with newly diagnosed childhood acute lymphoblastic leukemia and 38 healthy children.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
21528407,Serum levels of sFas and sFasL were measured with an enzyme-linked immunosorbent assay in 48 patients with newly diagnosed childhood acute lymphoblastic leukemia and 38 healthy children.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
21528407,We compared serum levels of sFas and sFasL in children with acute lymphoblastic leukemia and healthy children to determine the prognostic significance of these molecules.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21528407,Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia.,Child,LOCATION_OF,Tumor Necrosis Factor Ligand Superfamily Member 6
21528407,Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia.,Child,LOCATION_OF,FAS
21921043,"Using matched diagnosis/relapse bone marrow samples from children with relapsed B-precursor ALL, we evaluated gene expression, copy number abnormalities (CNAs), and DNA methylation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21921043,"Despite an increase in survival for children with acute lymphoblastic leukemia (ALL), the outcome after relapse is poor.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22137828,"Children with ALL have a reduced salivary flow rate, which makes them more susceptible to dental caries as compared to healthy children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22137828,Tooth morphological disorders including microdontia and enamel and dentin are common manifestations in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22137828,"Tooth morphological disorders including agenesis, microdontia, short roots and developmental defects in the enamel and dentin were more often observed in children with ALL as compared to healthy controls.",Tooth Diseases,PROCESS_OF,Child
22137828,CONCLUSION: Oral inflammatory conditions including mucositis and gingivitis are common in children with ALL as compared to healthy children.,Mucositis,PROCESS_OF,Child
22137828,"Tooth morphological disorders including agenesis, microdontia, short roots and developmental defects in the enamel and dentin were more often observed in children with ALL as compared to healthy controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22137828,CONCLUSION: Oral inflammatory conditions including mucositis and gingivitis are common in children with ALL as compared to healthy children.,Gingivitis,PROCESS_OF,Child
22137828,CONCLUSION: Oral inflammatory conditions including mucositis and gingivitis are common in children with ALL as compared to healthy children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22137828,"Malocclusion due to microdontia may also trigger temporomandibular joint disorders in children with ALL; however, this relationship needs further investigations.",Temporomandibular Joint Disorders,PROCESS_OF,Child
22137828,"Malocclusion due to microdontia may also trigger temporomandibular joint disorders in children with ALL; however, this relationship needs further investigations.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22137828,Tooth morphological disorders including microdontia and enamel and dentin are common manifestations in children with ALL.,Tooth Diseases,PROCESS_OF,Child
22838948,CONCLUSION: Gene-gene interaction between thiopurine and folate pathways inflate the 6-MP-mediated toxicity in Indian children with ALL illustrating the importance of ethnicity in the toxicity of 6-MP.,thiopurine,INTERACTS_WITH,6-Mercaptopurine
22838948,CONCLUSION: Gene-gene interaction between thiopurine and folate pathways inflate the 6-MP-mediated toxicity in Indian children with ALL illustrating the importance of ethnicity in the toxicity of 6-MP.,Folate,INTERACTS_WITH,6-Mercaptopurine
22838948,"MATERIALS & METHODS: Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5'-UTR 2R3R, TYMS 3'-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22838948,AIM: The rationale of this study was to explore the contribution of genetic variants of the folate pathway to toxicity of 6-mercaptopurine (6-MP)-mediated hematological toxicity in children with acute lymphoblastic leukemia (ALL) and to explore the interaction of these variants with TPMT and ITPA haplotypes using multifactor dimensionality reduction analysis.,Folate,PREDISPOSES,Toxic effect
22838948,AIM: The rationale of this study was to explore the contribution of genetic variants of the folate pathway to toxicity of 6-mercaptopurine (6-MP)-mediated hematological toxicity in children with acute lymphoblastic leukemia (ALL) and to explore the interaction of these variants with TPMT and ITPA haplotypes using multifactor dimensionality reduction analysis.,6-Mercaptopurine,INTERACTS_WITH,TPMT gene | TPMT
22838948,AIM: The rationale of this study was to explore the contribution of genetic variants of the folate pathway to toxicity of 6-mercaptopurine (6-MP)-mediated hematological toxicity in children with acute lymphoblastic leukemia (ALL) and to explore the interaction of these variants with TPMT and ITPA haplotypes using multifactor dimensionality reduction analysis.,Toxic effect,PROCESS_OF,Child
22838948,CONCLUSION: Gene-gene interaction between thiopurine and folate pathways inflate the 6-MP-mediated toxicity in Indian children with ALL illustrating the importance of ethnicity in the toxicity of 6-MP.,Toxic effect,PROCESS_OF,Child
22838948,AIM: The rationale of this study was to explore the contribution of genetic variants of the folate pathway to toxicity of 6-mercaptopurine (6-MP)-mediated hematological toxicity in children with acute lymphoblastic leukemia (ALL) and to explore the interaction of these variants with TPMT and ITPA haplotypes using multifactor dimensionality reduction analysis.,6-Mercaptopurine,INTERACTS_WITH,ITPA
22838948,CONCLUSION: Gene-gene interaction between thiopurine and folate pathways inflate the 6-MP-mediated toxicity in Indian children with ALL illustrating the importance of ethnicity in the toxicity of 6-MP.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22838948,AIM: The rationale of this study was to explore the contribution of genetic variants of the folate pathway to toxicity of 6-mercaptopurine (6-MP)-mediated hematological toxicity in children with acute lymphoblastic leukemia (ALL) and to explore the interaction of these variants with TPMT and ITPA haplotypes using multifactor dimensionality reduction analysis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22911020,Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia.,Cardiotoxicity,PROCESS_OF,Child
22911020,Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23166343,Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.,Doxorubicin,TREATS,Child
23166343,Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23166343,Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.,Doxorubicin,TREATS,"Leukemia, Lymphocytic, Acute"
23182223,Allergy and risk of acute lymphoblastic leukemia among children: a nationwide case control study in Greece.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23403311,Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23410194,We report two children with acute lymphoblastic leukemia and intestinal mucormycosis.,Mucormycosis,PROCESS_OF,Child
23410194,We report two children with acute lymphoblastic leukemia and intestinal mucormycosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23410194,We report two children with acute lymphoblastic leukemia and intestinal mucormycosis.,Intestines,LOCATION_OF,Mucormycosis
23585457,"A link between obesity and a childhood cancer has been identified: obese children diagnosed with high-risk acute lymphoblastic leukemia (ALL) had a 50% greater risk of relapse than their lean counterparts. l-asparaginase (ASNase) is a first-line therapy for ALL that breaks down asparagine and glutamine, exploiting the fact that ALL cells are more dependent on these amino acids than other cells.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23585457,"A link between obesity and a childhood cancer has been identified: obese children diagnosed with high-risk acute lymphoblastic leukemia (ALL) had a 50% greater risk of relapse than their lean counterparts. l-asparaginase (ASNase) is a first-line therapy for ALL that breaks down asparagine and glutamine, exploiting the fact that ALL cells are more dependent on these amino acids than other cells.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
23585457,"A link between obesity and a childhood cancer has been identified: obese children diagnosed with high-risk acute lymphoblastic leukemia (ALL) had a 50% greater risk of relapse than their lean counterparts. l-asparaginase (ASNase) is a first-line therapy for ALL that breaks down asparagine and glutamine, exploiting the fact that ALL cells are more dependent on these amino acids than other cells.",Amino Acids,STIMULATES,Glutamine
23585457,"A link between obesity and a childhood cancer has been identified: obese children diagnosed with high-risk acute lymphoblastic leukemia (ALL) had a 50% greater risk of relapse than their lean counterparts. l-asparaginase (ASNase) is a first-line therapy for ALL that breaks down asparagine and glutamine, exploiting the fact that ALL cells are more dependent on these amino acids than other cells.",Amino Acids,STIMULATES,Asparagine
23585457,"A link between obesity and a childhood cancer has been identified: obese children diagnosed with high-risk acute lymphoblastic leukemia (ALL) had a 50% greater risk of relapse than their lean counterparts. l-asparaginase (ASNase) is a first-line therapy for ALL that breaks down asparagine and glutamine, exploiting the fact that ALL cells are more dependent on these amino acids than other cells.",Obesity,PROCESS_OF,Child
23585457,"A link between obesity and a childhood cancer has been identified: obese children diagnosed with high-risk acute lymphoblastic leukemia (ALL) had a 50% greater risk of relapse than their lean counterparts. l-asparaginase (ASNase) is a first-line therapy for ALL that breaks down asparagine and glutamine, exploiting the fact that ALL cells are more dependent on these amino acids than other cells.",ASPARAGINASE,ISA,Therapeutic procedure
21495160,A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21555798,"PARTICIPANTS: 60 children with T-ALL and 139 with B- lineage ALL, and less than 15 years of age treated over 15 years.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
21555798,"OBJECTIVE: To assess the clinical features, prognostic factors and outcome of childhood T-ALL in comparison with B-lineage ALL, treated with a uniform treatment regimen (MCP 841).",Treatment Protocols,TREATS,"Leukemia, B-Cell, Acute"
22086750,Childhood acute lymphoblastic leukaemia is treated with long-term intensive chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22086750,Estimation of dynamic treatment strategies for maintenance therapy of children with acute lymphoblastic leukaemia: an application of history-adjusted marginal structural models.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22086750,Estimation of dynamic treatment strategies for maintenance therapy of children with acute lymphoblastic leukaemia: an application of history-adjusted marginal structural models.,Therapeutic procedure,METHOD_OF,Maintenance therapy
22160040,"Survival rates for children with acute lymphoblastic leukemia (ALL) have increased dramatically over the past 4 decades, with 5-year survival rates of > 90% in recent trials.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22434102,"To define this association, we compared HLA-DQB1 allele frequencies and allele carrier frequencies in a cohort of 135 adults and children with ALL with 150 controls, using polymerase chain reaction with sequence-specific primers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
22434102,"We suggest that DQ5 could be more strongly considered as an ALL susceptibility allele, and that this allele may underlie a pathogenic phenotype with a major role in the immunologic process involved in both adults and children with ALL.","Leukemia, Lymphocytic, Acute",AFFECTS,Child
22434102,"We suggest that DQ5 could be more strongly considered as an ALL susceptibility allele, and that this allele may underlie a pathogenic phenotype with a major role in the immunologic process involved in both adults and children with ALL.","Leukemia, Lymphocytic, Acute",AFFECTS,Adult
22434102,"We suggest that DQ5 could be more strongly considered as an ALL susceptibility allele, and that this allele may underlie a pathogenic phenotype with a major role in the immunologic process involved in both adults and children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22434102,"We suggest that DQ5 could be more strongly considered as an ALL susceptibility allele, and that this allele may underlie a pathogenic phenotype with a major role in the immunologic process involved in both adults and children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
22434102,"To define this association, we compared HLA-DQB1 allele frequencies and allele carrier frequencies in a cohort of 135 adults and children with ALL with 150 controls, using polymerase chain reaction with sequence-specific primers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22642244,"According to the results of quantitative RT-PCR, the levels of UBE2Q2 mRNA expression in the bone marrow cells of 11 out of the 20 children with ALL (55%) were significantly higher (> 2-47 fold) than those in blood cells of normal children.",Blood Cells,LOCATION_OF,UBE2Q2
22642244,"METHODS: Here, we have used quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to assess expression of the UBE2Q2 gene in bone marrow samples of 20 children with ALL.",Bone marrow specimen,PART_OF,Child
22642244,"METHODS: Here, we have used quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to assess expression of the UBE2Q2 gene in bone marrow samples of 20 children with ALL.",UBE2Q2,PART_OF,Bone marrow specimen
22642244,"METHODS: Here, we have used quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to assess expression of the UBE2Q2 gene in bone marrow samples of 20 children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22642244,"According to the results of quantitative RT-PCR, the levels of UBE2Q2 mRNA expression in the bone marrow cells of 11 out of the 20 children with ALL (55%) were significantly higher (> 2-47 fold) than those in blood cells of normal children.",Blood Cells,PART_OF,Child
22642244,"According to the results of quantitative RT-PCR, the levels of UBE2Q2 mRNA expression in the bone marrow cells of 11 out of the 20 children with ALL (55%) were significantly higher (> 2-47 fold) than those in blood cells of normal children.",Bone Marrow Cells,LOCATION_OF,UBE2Q2
22642244,"According to the results of quantitative RT-PCR, the levels of UBE2Q2 mRNA expression in the bone marrow cells of 11 out of the 20 children with ALL (55%) were significantly higher (> 2-47 fold) than those in blood cells of normal children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22846209,"Our aim was to estimate plasma levels of the endogenous nitric oxide formation inhibitor asymmetric dimethylarginine (ADMA), in long-term survivors of childhood acute lymphoblastic leukemia (ALL) treated with only chemotherapy.",Long-Term Survivors,LOCATION_OF,Nitric Oxide
22846209,"Our aim was to estimate plasma levels of the endogenous nitric oxide formation inhibitor asymmetric dimethylarginine (ADMA), in long-term survivors of childhood acute lymphoblastic leukemia (ALL) treated with only chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22964275,"In conclusion, the results of the present study suggest that CYP1A1 MspI polymorphism might be a risk factor for ALL, particularly childhood ALL.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
23138117,"CONCLUSIONS: St Jude Total 13A treatment protocols to treat childhood ALL can be successfully adapted, which suggests that such an approach may be useful in low socioeconomic regions; however, it should be noted that secondary leukemia can occur at a high rate.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23138117,"CONCLUSIONS: St Jude Total 13A treatment protocols to treat childhood ALL can be successfully adapted, which suggests that such an approach may be useful in low socioeconomic regions; however, it should be noted that secondary leukemia can occur at a high rate.",Treatment Protocols,USES,Maxillary left second premolar abutment
23211688,Children with acute lymphocytic leukemia who fail to enter remission have a poor prognosis.,Prognosis bad,PROCESS_OF,Child
23211688,Children with acute lymphocytic leukemia who fail to enter remission have a poor prognosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23211688,Chemotherapy for initial induction failures in childhood acute lymphoblastic leukemia: a Children's Oncology Group Study (POG 8764).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23211688,Chemotherapy for initial induction failures in childhood acute lymphoblastic leukemia: a Children's Oncology Group Study (POG 8764).,Children's Oncology Group,LOCATION_OF,Clinical Research
23211695,"PROCEDURES: Recently diagnosed adolescent ALL and lymphoma patients were recruited from 2 pediatric hematology and oncology clinics, and matched on age, race, and sex to healthy individuals in the community.",Lymphoma,PROCESS_OF,Patients
23211695,"PROCEDURES: Recently diagnosed adolescent ALL and lymphoma patients were recruited from 2 pediatric hematology and oncology clinics, and matched on age, race, and sex to healthy individuals in the community.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
23744583,"Results suggest long-term survivors of childhood ALL treated with CRT are at risk for progressive decline in verbal intellect, which may be driven by attention deficits.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23744583,"Survivors of childhood acute lymphoblastic leukemia (ALL) treated with cranial radiation therapy (CRT) are at risk for cognitive impairment, although whether impairment progresses with age into adulthood is unknown.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21495160,A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21555798,"PARTICIPANTS: 60 children with T-ALL and 139 with B- lineage ALL, and less than 15 years of age treated over 15 years.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
21555798,"OBJECTIVE: To assess the clinical features, prognostic factors and outcome of childhood T-ALL in comparison with B-lineage ALL, treated with a uniform treatment regimen (MCP 841).",Treatment Protocols,TREATS,"Leukemia, B-Cell, Acute"
22086750,Childhood acute lymphoblastic leukaemia is treated with long-term intensive chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22086750,Estimation of dynamic treatment strategies for maintenance therapy of children with acute lymphoblastic leukaemia: an application of history-adjusted marginal structural models.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22086750,Estimation of dynamic treatment strategies for maintenance therapy of children with acute lymphoblastic leukaemia: an application of history-adjusted marginal structural models.,Therapeutic procedure,METHOD_OF,Maintenance therapy
22160040,"Survival rates for children with acute lymphoblastic leukemia (ALL) have increased dramatically over the past 4 decades, with 5-year survival rates of > 90% in recent trials.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22434102,"To define this association, we compared HLA-DQB1 allele frequencies and allele carrier frequencies in a cohort of 135 adults and children with ALL with 150 controls, using polymerase chain reaction with sequence-specific primers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
22434102,"We suggest that DQ5 could be more strongly considered as an ALL susceptibility allele, and that this allele may underlie a pathogenic phenotype with a major role in the immunologic process involved in both adults and children with ALL.","Leukemia, Lymphocytic, Acute",AFFECTS,Child
22434102,"We suggest that DQ5 could be more strongly considered as an ALL susceptibility allele, and that this allele may underlie a pathogenic phenotype with a major role in the immunologic process involved in both adults and children with ALL.","Leukemia, Lymphocytic, Acute",AFFECTS,Adult
22434102,"We suggest that DQ5 could be more strongly considered as an ALL susceptibility allele, and that this allele may underlie a pathogenic phenotype with a major role in the immunologic process involved in both adults and children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22434102,"We suggest that DQ5 could be more strongly considered as an ALL susceptibility allele, and that this allele may underlie a pathogenic phenotype with a major role in the immunologic process involved in both adults and children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
22434102,"To define this association, we compared HLA-DQB1 allele frequencies and allele carrier frequencies in a cohort of 135 adults and children with ALL with 150 controls, using polymerase chain reaction with sequence-specific primers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22642244,"According to the results of quantitative RT-PCR, the levels of UBE2Q2 mRNA expression in the bone marrow cells of 11 out of the 20 children with ALL (55%) were significantly higher (> 2-47 fold) than those in blood cells of normal children.",Blood Cells,LOCATION_OF,UBE2Q2
22642244,"METHODS: Here, we have used quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to assess expression of the UBE2Q2 gene in bone marrow samples of 20 children with ALL.",Bone marrow specimen,PART_OF,Child
22642244,"METHODS: Here, we have used quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to assess expression of the UBE2Q2 gene in bone marrow samples of 20 children with ALL.",UBE2Q2,PART_OF,Bone marrow specimen
22642244,"METHODS: Here, we have used quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to assess expression of the UBE2Q2 gene in bone marrow samples of 20 children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22642244,"According to the results of quantitative RT-PCR, the levels of UBE2Q2 mRNA expression in the bone marrow cells of 11 out of the 20 children with ALL (55%) were significantly higher (> 2-47 fold) than those in blood cells of normal children.",Blood Cells,PART_OF,Child
22642244,"According to the results of quantitative RT-PCR, the levels of UBE2Q2 mRNA expression in the bone marrow cells of 11 out of the 20 children with ALL (55%) were significantly higher (> 2-47 fold) than those in blood cells of normal children.",Bone Marrow Cells,LOCATION_OF,UBE2Q2
22642244,"According to the results of quantitative RT-PCR, the levels of UBE2Q2 mRNA expression in the bone marrow cells of 11 out of the 20 children with ALL (55%) were significantly higher (> 2-47 fold) than those in blood cells of normal children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22846209,"Our aim was to estimate plasma levels of the endogenous nitric oxide formation inhibitor asymmetric dimethylarginine (ADMA), in long-term survivors of childhood acute lymphoblastic leukemia (ALL) treated with only chemotherapy.",Long-Term Survivors,LOCATION_OF,Nitric Oxide
22846209,"Our aim was to estimate plasma levels of the endogenous nitric oxide formation inhibitor asymmetric dimethylarginine (ADMA), in long-term survivors of childhood acute lymphoblastic leukemia (ALL) treated with only chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22964275,"In conclusion, the results of the present study suggest that CYP1A1 MspI polymorphism might be a risk factor for ALL, particularly childhood ALL.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
23138117,"CONCLUSIONS: St Jude Total 13A treatment protocols to treat childhood ALL can be successfully adapted, which suggests that such an approach may be useful in low socioeconomic regions; however, it should be noted that secondary leukemia can occur at a high rate.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23138117,"CONCLUSIONS: St Jude Total 13A treatment protocols to treat childhood ALL can be successfully adapted, which suggests that such an approach may be useful in low socioeconomic regions; however, it should be noted that secondary leukemia can occur at a high rate.",Treatment Protocols,USES,Maxillary left second premolar abutment
23211688,Children with acute lymphocytic leukemia who fail to enter remission have a poor prognosis.,Prognosis bad,PROCESS_OF,Child
23211688,Children with acute lymphocytic leukemia who fail to enter remission have a poor prognosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23211688,Chemotherapy for initial induction failures in childhood acute lymphoblastic leukemia: a Children's Oncology Group Study (POG 8764).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23211688,Chemotherapy for initial induction failures in childhood acute lymphoblastic leukemia: a Children's Oncology Group Study (POG 8764).,Children's Oncology Group,LOCATION_OF,Clinical Research
23211695,"PROCEDURES: Recently diagnosed adolescent ALL and lymphoma patients were recruited from 2 pediatric hematology and oncology clinics, and matched on age, race, and sex to healthy individuals in the community.",Lymphoma,PROCESS_OF,Patients
23211695,"PROCEDURES: Recently diagnosed adolescent ALL and lymphoma patients were recruited from 2 pediatric hematology and oncology clinics, and matched on age, race, and sex to healthy individuals in the community.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
23744583,"Results suggest long-term survivors of childhood ALL treated with CRT are at risk for progressive decline in verbal intellect, which may be driven by attention deficits.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23744583,"Survivors of childhood acute lymphoblastic leukemia (ALL) treated with cranial radiation therapy (CRT) are at risk for cognitive impairment, although whether impairment progresses with age into adulthood is unknown.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22373554,"The first patient, a 32-year-old female, who had several late effects caused by treatment for nephroblastoma; the second a 39-year-old female, who developed breast cancer after thoracic irradiation for metastatic nephroblastoma; the third a 45-year-old female diagnosed with a meningioma caused by cranial irradiation for acute lymphoblastic leukaemia.",Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute"
22373554,"The first patient, a 32-year-old female, who had several late effects caused by treatment for nephroblastoma; the second a 39-year-old female, who developed breast cancer after thoracic irradiation for metastatic nephroblastoma; the third a 45-year-old female diagnosed with a meningioma caused by cranial irradiation for acute lymphoblastic leukaemia.",Late effect of,PROCESS_OF,Patients
22373554,"The first patient, a 32-year-old female, who had several late effects caused by treatment for nephroblastoma; the second a 39-year-old female, who developed breast cancer after thoracic irradiation for metastatic nephroblastoma; the third a 45-year-old female diagnosed with a meningioma caused by cranial irradiation for acute lymphoblastic leukaemia.",Therapeutic procedure,CAUSES,Late effect of
22373554,"The first patient, a 32-year-old female, who had several late effects caused by treatment for nephroblastoma; the second a 39-year-old female, who developed breast cancer after thoracic irradiation for metastatic nephroblastoma; the third a 45-year-old female diagnosed with a meningioma caused by cranial irradiation for acute lymphoblastic leukaemia.",Radiation therapy,TREATS,stage IV Wilms' tumor
22373554,"The first patient, a 32-year-old female, who had several late effects caused by treatment for nephroblastoma; the second a 39-year-old female, who developed breast cancer after thoracic irradiation for metastatic nephroblastoma; the third a 45-year-old female diagnosed with a meningioma caused by cranial irradiation for acute lymphoblastic leukaemia.",Therapeutic procedure,TREATS,Nephroblastoma
22573402,Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia.,T-cell depletion,AFFECTS,Immunoregulation
22573402,Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia.,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22573402,These data suggest that in vivo T-cell depletion lowers GVHD without compromising LFS among children with acute lymphoblastic leukemia who are undergoing unrelated donor transplantation with myeloablative total body irradiation-based regimens.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22573402,These data suggest that in vivo T-cell depletion lowers GVHD without compromising LFS among children with acute lymphoblastic leukemia who are undergoing unrelated donor transplantation with myeloablative total body irradiation-based regimens.,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
22573402,"To determine whether in vivo T-cell depletion, which lowers GVHD, abrogates the antileukemic benefits of myeloablative total body irradiation-based conditioning and unrelated donor transplantation, in the present study, we analyzed 715 children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23098298,L-Asparaginase (ASNase) is important for the treatment of childhood acute lymphoblastic leukemia.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23098298,L-Asparaginase (ASNase) is important for the treatment of childhood acute lymphoblastic leukemia.,ASPARAGINASE,ISA,Therapeutic procedure
23134919,This prospective study was conducted to see the outcome of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
23134919,The result suggested that under nutrition has an influence on the out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,Malnutrition
23134919,This prospective study was conducted to see the outcome of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Malnutrition,PROCESS_OF,Child
23134919,The result suggested that under nutrition has an influence on the out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
23134919,Out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,Child
23134919,The result suggested that under nutrition has an influence on the out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Malnutrition,PROCESS_OF,Child
23134919,Out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23134919,This prospective study was conducted to see the outcome of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,Child
23134919,Out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
23134919,Out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,Malnutrition
23134919,This prospective study was conducted to see the outcome of induction of remission in undernourished children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23134919,The result suggested that under nutrition has an influence on the out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,Child
23134919,Out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Malnutrition,PROCESS_OF,Child
23134919,This prospective study was conducted to see the outcome of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,Malnutrition
23134919,The result suggested that under nutrition has an influence on the out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23154429,CONCLUSION: Our results suggest the possibility of white matter injury during the treatment for ALL with chemotherapy alone.,White Matter,LOCATION_OF,Injury
23154429,PURPOSE: Chemo- and radiotherapy used in acute lymphoblastic leukemia (ALL) can influence on brain functioning in the future.,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
23154429,PURPOSE: Chemo- and radiotherapy used in acute lymphoblastic leukemia (ALL) can influence on brain functioning in the future.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23154429,CONCLUSION: Our results suggest the possibility of white matter injury during the treatment for ALL with chemotherapy alone.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23222848,"We successfully replicated this latter observation in an independent cohort of 50 children with B-ALL, where we found an excess of rare PRDM9 alleles in aneuploid and infant B-ALL patients.","Leukemia, B-Cell, Acute",PROCESS_OF,Patients
23222848,"We successfully replicated this latter observation in an independent cohort of 50 children with B-ALL, where we found an excess of rare PRDM9 alleles in aneuploid and infant B-ALL patients.",PRDM9,ASSOCIATED_WITH,Aneuploidy
23222848,"We successfully replicated this latter observation in an independent cohort of 50 children with B-ALL, where we found an excess of rare PRDM9 alleles in aneuploid and infant B-ALL patients.","Leukemia, B-Cell, Acute",PROCESS_OF,Patients
23222848,"We successfully replicated this latter observation in an independent cohort of 50 children with B-ALL, where we found an excess of rare PRDM9 alleles in aneuploid and infant B-ALL patients.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
23239135,"Acute lymphoblastic leukemia (ALL) is the most common cancer in children, and efforts to understand its etiology has followed a paradigm that common genetic variation in the presence of modifiable environmental factors contribute to disease risk.",Malignant Neoplasms,PROCESS_OF,Child
23239135,"Acute lymphoblastic leukemia (ALL) is the most common cancer in children, and efforts to understand its etiology has followed a paradigm that common genetic variation in the presence of modifiable environmental factors contribute to disease risk.","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
23239135,"Acute lymphoblastic leukemia (ALL) is the most common cancer in children, and efforts to understand its etiology has followed a paradigm that common genetic variation in the presence of modifiable environmental factors contribute to disease risk.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23512250,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children and the incidence of ALL varies by ethnicity.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23512250,CONCLUSIONS: These findings indicate strong associations between inherited genetic variation and ALL susceptibility in children and shed new light on ALL molecular etiology in diverse ancestry.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23512250,"METHODS: We performed a multiethnic genome-wide association study in 1605 children with ALL and 6661 control subjects after adjusting for population structure, with validation in three replication series of 845 case subjects and 4316 control subjects.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23512250,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children and the incidence of ALL varies by ethnicity.,Malignant Neoplasms,PROCESS_OF,Child
23512250,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children and the incidence of ALL varies by ethnicity.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
23653000,Future studies may indicate a larger panel of genes involved in susceptibility of childhood ALL and other hematological neoplasias.,Hematologic Neoplasms,ISA,"Leukemia, Lymphocytic, Acute, L1"
23653000,Future studies may indicate a larger panel of genes involved in susceptibility of childhood ALL and other hematological neoplasias.,"Leukemia, Lymphocytic, Acute, L1",ISA,Hematologic Neoplasms
23653000,Future studies may indicate a larger panel of genes involved in susceptibility of childhood ALL and other hematological neoplasias.,Genes,ASSOCIATED_WITH,Hematologic Neoplasms
23653000,Future studies may indicate a larger panel of genes involved in susceptibility of childhood ALL and other hematological neoplasias.,Genes,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
23653000,Future studies may indicate a larger panel of genes involved in susceptibility of childhood ALL and other hematological neoplasias.,Genes,ASSOCIATED_WITH,Hematologic Neoplasms
23653000,Future studies may indicate a larger panel of genes involved in susceptibility of childhood ALL and other hematological neoplasias.,Genes,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
22174432,A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22592733,"Clinicians should consider prescribing glucocorticoid replacement therapy during periods of serious stress in the first weeks after cessation of glucocorticoid therapy for childhood ALL, to reduce the risk of life-threatening complications.",GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22592733,The exact occurrence and duration of HPA axis suppression after glucocorticoid therapy for childhood ALL are unclear.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22592733,"Clinicians should consider prescribing glucocorticoid replacement therapy during periods of serious stress in the first weeks after cessation of glucocorticoid therapy for childhood ALL, to reduce the risk of life-threatening complications.",Replacement therapy,PREVENTS,Complication
22592733,BACKGROUND: Glucocorticoids play a major role in the treatment of acute lymphoblastic leukaemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
22592733,"AUTHORS' CONCLUSIONS: Based on the available evidence, we conclude that adrenal insufficiency commonly occurs in the first days after cessation of glucocorticoid therapy for childhood ALL, but the exact duration is unclear.",GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22592733,Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22592733,The included studies demonstrated that adrenal insufficiency occurs in nearly all patients in the first days after cessation of glucocorticoid treatment for childhood ALL.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22592733,The included studies demonstrated that adrenal insufficiency occurs in nearly all patients in the first days after cessation of glucocorticoid treatment for childhood ALL.,Glucocorticoids,ISA,Therapeutic procedure
22592733,"SELECTION CRITERIA: All study designs, except case reports and patient series with fewer than 10 patients, examining the effect of glucocorticoid therapy for childhood ALL on the HPA axis function.",GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22592733,OBJECTIVES: To examine the occurrence and duration of HPA axis suppression after (each cycle of) glucocorticoid therapy for childhood ALL.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22812402,Differential protein analysis of lymphocytes between children with acute lymphoblastic leukemia and healthy children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22812402,"Samples of bone marrow lymphocytes from children with c-ALL and peripheral blood lymphocytes from healthy children were collected, and total proteins were extracted and separated from these samples followed by two-dimensional gel electrophoresis for comparative analysis.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
22812402,We identified differential proteins in lymphocytes between patients with childhood acute lymphoblastic leukemia (c-ALL) and healthy children.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
22812402,"Samples of bone marrow lymphocytes from children with c-ALL and peripheral blood lymphocytes from healthy children were collected, and total proteins were extracted and separated from these samples followed by two-dimensional gel electrophoresis for comparative analysis.",Lymphocyte,PART_OF,Bone Marrow
22812402,We identified differential proteins in lymphocytes between patients with childhood acute lymphoblastic leukemia (c-ALL) and healthy children.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
22812402,Differential protein analysis of lymphocytes between children with acute lymphoblastic leukemia and healthy children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22897724,We studied 140 bone marrow samples at diagnosis from children with acute lymphoblastic leukemia (ALL) treated according to the Brazilian Childhood Leukemia Treatment Group (GBTLI) ALL-99 protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23134919,The result suggested that under nutrition has an influence on the out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,Malnutrition
23134919,The result suggested that under nutrition has an influence on the out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
23134919,The result suggested that under nutrition has an influence on the out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Malnutrition,PROCESS_OF,Child
23134919,So appropriate measures are essential to improve nutritional status of children for successful management of ALL in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23134919,The result suggested that under nutrition has an influence on the out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,Induction,TREATS,Child
23134919,The result suggested that under nutrition has an influence on the out come of induction of remission in undernourished children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23589809,There is currently no protocol to evaluate the immunologic memory of patients who underwent chemotherapy for ALL or to revaccinate them after their treatment.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23589809,There is currently no protocol to evaluate the immunologic memory of patients who underwent chemotherapy for ALL or to revaccinate them after their treatment.,Pharmacotherapy,TREATS,Patients
23888320,This case-control study was performed on 75 children diagnosed with ALL and 115 age- and sex-matched children with no history of cancer of any type (as the control group).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23888320,This case-control study was performed on 75 children diagnosed with ALL and 115 age- and sex-matched children with no history of cancer of any type (as the control group).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23926015,OBJECTIVE: To assess whether polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene is associated with susceptibility to acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) in Chinese Han children.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
23926015,OBJECTIVE: To assess whether polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene is associated with susceptibility to acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) in Chinese Han children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21701492,"Although most of the B-ALL children take advantage from current therapeutic protocols, some patients relapse and need alternative therapies.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21933850,We explored whether cells reported as minimal residual disease by flow cytometry represent the malignant clone harboring clone-specific genomic markers (53 follow-up bone marrow samples from 28 children with B-cell precursor acute lymphoblastic leukemia).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
22121378,"Additional randomized studies are needed to confirm these benefits in larger populations of children with ALL, and in populations with cancer diagnoses other than ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22208990,"The one notable exception is Escherichia colil-asparaginase II (EcAII), which has been FDA-approved for the treatment of childhood acute lymphoblastic leukemia.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22376016,ALL-BFM 95 treatment in Turkish children with acute lymphoblastic leukemia--experience of a single center.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22376016,ALL-BFM 95 treatment in Turkish children with acute lymphoblastic leukemia--experience of a single center.,Therapeutic procedure,TREATS,Child
22376016,ALL-BFM 95 treatment in Turkish children with acute lymphoblastic leukemia--experience of a single center.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
22376016,The authors here report their 13 years' experience with original ALL-BFM (Berlin-Franfurt-Munster) 95 protocol in a cohort of 140 Turkish children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22376016,Little is known about the likelihood of curing children with high-dose chemotherapy regimens for treatment of childhood acute lymphoblastic leukemia (ALL) in Turkey.,Little's Disease,PROCESS_OF,Meleagris gallopavo
22376016,Little is known about the likelihood of curing children with high-dose chemotherapy regimens for treatment of childhood acute lymphoblastic leukemia (ALL) in Turkey.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22564489,Plasma NTproCNP and CNP were measured by radio-immunoassay in 12 children aged 2-9 years during induction and maintenance chemotherapy for children with ALL.,Plasma,LOCATION_OF,CNP
22564489,Here we have evaluated the relationship between linear bone growth during chemotherapy for ALL and bone derived C-type Natriuretic Peptide (CNP).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22564489,Plasma NTproCNP and CNP were measured by radio-immunoassay in 12 children aged 2-9 years during induction and maintenance chemotherapy for children with ALL.,Induction,TREATS,Child
22564489,"Impaired bone growth and mineralization, and osteonecrosis are significant and common long-term sequelae of chemotherapy for childhood acute lymphoblastic leukemia (ALL).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22564489,Plasma NTproCNP and CNP were measured by radio-immunoassay in 12 children aged 2-9 years during induction and maintenance chemotherapy for children with ALL.,Child,LOCATION_OF,"Natriuretic Peptide, C-Type"
22564489,"Impaired bone growth and mineralization, and osteonecrosis are significant and common long-term sequelae of chemotherapy for childhood acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
22564489,Plasma NTproCNP and CNP were measured by radio-immunoassay in 12 children aged 2-9 years during induction and maintenance chemotherapy for children with ALL.,Child,LOCATION_OF,CNP
22564489,C-type Natriuretic Peptide: a novel biomarker of steroid induced bone toxicity in children with acute lymphoblastic leukemia (ALL).,Toxic effect,PROCESS_OF,Child
22564489,Plasma NTproCNP and CNP were measured by radio-immunoassay in 12 children aged 2-9 years during induction and maintenance chemotherapy for children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22564489,C-type Natriuretic Peptide: a novel biomarker of steroid induced bone toxicity in children with acute lymphoblastic leukemia (ALL).,Steroids,CAUSES,Toxic effect
22564489,Plasma NTproCNP and CNP were measured by radio-immunoassay in 12 children aged 2-9 years during induction and maintenance chemotherapy for children with ALL.,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
22564489,C-type Natriuretic Peptide: a novel biomarker of steroid induced bone toxicity in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22856670,The purpose of this study was to explore associations between changes in cerebrospinal fluid (CSF) phospholipids and neurocognitive function in children undergoing chemotherapy for acute lymphoblastic leukemia.,Child,LOCATION_OF,Phospholipids
22856670,The purpose of this study was to explore associations between changes in cerebrospinal fluid (CSF) phospholipids and neurocognitive function in children undergoing chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Child
22856670,The purpose of this study was to explore associations between changes in cerebrospinal fluid (CSF) phospholipids and neurocognitive function in children undergoing chemotherapy for acute lymphoblastic leukemia.,Cerebrospinal Fluid,LOCATION_OF,Phospholipids
22856670,The purpose of this study was to explore associations between changes in cerebrospinal fluid (CSF) phospholipids and neurocognitive function in children undergoing chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22938053,Outcome of risk adapted therapy for relapsed/refractory acute lymphoblastic leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22938053,Outcome of risk adapted therapy for relapsed/refractory acute lymphoblastic leukemia in children.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
23453285,"In the current study, ALCs at the time of diagnosis (ALC-0), after 7 days of initial therapy (ALC-8) and at interim of the induction therapy (ALC-22) were examined in Chinese children with B-cell precursor (BCP) ALL and correlated with the level of minimal residual disease (MRD) at day 22 of induction therapy.",Neoadjuvant Therapy,TREATS,Child
23453285,"In the current study, ALCs at the time of diagnosis (ALC-0), after 7 days of initial therapy (ALC-8) and at interim of the induction therapy (ALC-22) were examined in Chinese children with B-cell precursor (BCP) ALL and correlated with the level of minimal residual disease (MRD) at day 22 of induction therapy.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
23453285,"In the current study, ALCs at the time of diagnosis (ALC-0), after 7 days of initial therapy (ALC-8) and at interim of the induction therapy (ALC-22) were examined in Chinese children with B-cell precursor (BCP) ALL and correlated with the level of minimal residual disease (MRD) at day 22 of induction therapy.",Neoadjuvant Therapy,TREATS,"Leukemia, B-Cell, Acute"
23608171,"In conclusion, ARID5B rs10821936 could serve as a potential biomarker for assessing the risk of childhood ALL in Chinese children.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
23650422,CONCLUSION: These results are consistent with our previous report of association between attention problems and MS in an independent cohort of long-term survivors of childhood ALL treated with chemotherapy only.,cohort,LOCATION_OF,5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
23650422,CONCLUSION: These results are consistent with our previous report of association between attention problems and MS in an independent cohort of long-term survivors of childhood ALL treated with chemotherapy only.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23887020,Raised expression of APRIL in Chinese children with acute lymphoblastic leukemia and its clinical implications.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23887020,Raised expression of APRIL in Chinese children with acute lymphoblastic leukemia and its clinical implications.,ANP32B gene | ANP32B,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
23887020,"Plasma samples from 20 untreated children with ALL, 23 children with ALL in remission, and 15 normal controls were assayed for APRIL plasma concentration by enzyme-linked immunosorbent assay.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23887020,"Plasma samples from 20 untreated children with ALL, 23 children with ALL in remission, and 15 normal controls were assayed for APRIL plasma concentration by enzyme-linked immunosorbent assay.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23887020,Raised expression of APRIL in Chinese children with acute lymphoblastic leukemia and its clinical implications.,ANP32B gene | ANP32B,PART_OF,Child
21643952,"In order to determine the influence of polymorphism in thymidylate synthase (TS 28-bp repeat) and methionine synthase (MS A2756G) genes on the susceptibility to acute lymphoblastic leukemia (ALL), 73 children with ALL and 128 age and sex matched unrelated healthy individuals from the Kermanshah Province of Iran were screened.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Individual
21643952,"In order to determine the influence of polymorphism in thymidylate synthase (TS 28-bp repeat) and methionine synthase (MS A2756G) genes on the susceptibility to acute lymphoblastic leukemia (ALL), 73 children with ALL and 128 age and sex matched unrelated healthy individuals from the Kermanshah Province of Iran were screened.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22058224,"DESIGN AND METHODS: Normal hematopoiesis during and after induction treatment (days 8, 15 and 33) was correlated with therapeutic outcome in a cohort of 256 children with acute lymphoblastic leukemia treated in one of three consecutive ALL-BFM trials at a single institute.",Normal hematopoiesis,PROCESS_OF,cohort
22058224,"DESIGN AND METHODS: Normal hematopoiesis during and after induction treatment (days 8, 15 and 33) was correlated with therapeutic outcome in a cohort of 256 children with acute lymphoblastic leukemia treated in one of three consecutive ALL-BFM trials at a single institute.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22058224,"DESIGN AND METHODS: Normal hematopoiesis during and after induction treatment (days 8, 15 and 33) was correlated with therapeutic outcome in a cohort of 256 children with acute lymphoblastic leukemia treated in one of three consecutive ALL-BFM trials at a single institute.",Institutes,LOCATION_OF,Clinical Trials
22058224,Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22169311,"The clinical data of 38 cases of newly diagnosed T-ALL from Jan 2005 to Aug 2010 were analyzed retrospectively, and 78 cases of B-ALL with intermediate and high risk were collected as control group, then the sensitive rate of patients to prednisone pretreatment, complete remission (CR) rate at day 33 after induction chemotherapy, relapse rate and 3-year event-free survival (EFS) were compared between T-ALL and B-ALL children.",Control Groups,INTERACTS_WITH,Patients
22169311,"The clinical data of 38 cases of newly diagnosed T-ALL from Jan 2005 to Aug 2010 were analyzed retrospectively, and 78 cases of B-ALL with intermediate and high risk were collected as control group, then the sensitive rate of patients to prednisone pretreatment, complete remission (CR) rate at day 33 after induction chemotherapy, relapse rate and 3-year event-free survival (EFS) were compared between T-ALL and B-ALL children.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
22496163,"Whereas the improvement in outcome for children with acute lymphoblastic leukemia has been gratifying, the poor outcome of patients who relapse warrants novel treatment approaches.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23165914,This study examined survival after relapse for children with ALL in Central America.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23225457,"AIM: The analysis of the prognostic impact of residual disease at day 15 of induction therapy, individual tumor response testing (ITRT) at diagnosis, initial factors and initial therapy response to the risk of relapse in children with precursor B-cell acute lymphoblastic leukemia (ALL).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
23225457,"AIM: The analysis of the prognostic impact of residual disease at day 15 of induction therapy, individual tumor response testing (ITRT) at diagnosis, initial factors and initial therapy response to the risk of relapse in children with precursor B-cell acute lymphoblastic leukemia (ALL).",Diagnosis,TREATS,Child
23225457,"AIM: The analysis of the prognostic impact of residual disease at day 15 of induction therapy, individual tumor response testing (ITRT) at diagnosis, initial factors and initial therapy response to the risk of relapse in children with precursor B-cell acute lymphoblastic leukemia (ALL).",Neoadjuvant Therapy,AFFECTS,Residual Tumor
23283630,"ALL patients treated with cranial radiotherapy (CRT) are at risk for growth hormone deficiency (GHD), but little is known about other pituitary insufficiencies, e.g.",Radiation therapy,TREATS,Patients
23283630,"ALL patients treated with cranial radiotherapy (CRT) are at risk for growth hormone deficiency (GHD), but little is known about other pituitary insufficiencies, e.g.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23283630,"ALL patients treated with cranial radiotherapy (CRT) are at risk for growth hormone deficiency (GHD), but little is known about other pituitary insufficiencies, e.g.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23346431,There are several case reports in the literature describing t(17;19) in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23346431,t(17;19) in Children with Acute Lymphocytic Leukemia: A Report of 3 Cases and a Review of the Literature.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23584394,Evaluation of memory impairment in aging adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiotherapy.,Memory impairment,PROCESS_OF,Survivors
23584394,Evaluation of memory impairment in aging adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiotherapy.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23619106,The aim of the study was to evaluate the rate of symptomatic VTEs in children with ALL and the predictive value of clinical and biological factors and routine monitoring of coagulation parameters in identifying children at a higher risk of this complication.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23619106,The aim of the study was to evaluate the rate of symptomatic VTEs in children with ALL and the predictive value of clinical and biological factors and routine monitoring of coagulation parameters in identifying children at a higher risk of this complication.,Thromboembolic event,PROCESS_OF,Child
23619106,Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23619106,Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience.,Screening procedure,TREATS,Blood Coagulation Disorders
23692373,She had received total body irradiation prior to her bone marrow transplant at age 6 years for relapsed acute lymphoblastic leukaemia.,Bone Marrow Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
23826583,Prognostic effect of blood transfusion in children with acute lymphoblastic leukemia.,Blood Transfusion,TREATS,Child
23826583,Prognostic effect of blood transfusion in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23826583,Prognostic effect of blood transfusion in children with acute lymphoblastic leukemia.,Blood Transfusion,TREATS,"Leukemia, Lymphocytic, Acute"
23826583,METHODS: We analyzed overall survival (OS) and event-free survival (EFS) in relation to leukocyte reduced and irradiated (LR/IRR) blood products transfused during the induction phase in 136 children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23826583,BACKGROUND: Most children with acute lymphoblastic leukemia (ALL) receive blood transfusions.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23826583,BACKGROUND: Most children with acute lymphoblastic leukemia (ALL) receive blood transfusions.,Blood Transfusion,ADMINISTERED_TO,Child
23887020,Real-time quantitative polymerase chain reaction was performed to determine the mRNA expression of APRIL and its receptors in blood mononuclear cells in 20 untreated ALL children and 15 normal controls.,MONONUCLEAR CELLS,PART_OF,Blood
23887020,Real-time quantitative polymerase chain reaction was performed to determine the mRNA expression of APRIL and its receptors in blood mononuclear cells in 20 untreated ALL children and 15 normal controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23887020,"Plasma samples from 20 untreated children with ALL, 23 children with ALL in remission, and 15 normal controls were assayed for APRIL plasma concentration by enzyme-linked immunosorbent assay.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23887020,These findings indicate that APRIL and BCMA are over expressed in untreated ALL children.,Child,LOCATION_OF,ANP32B gene | ANP32B
23887020,"Plasma samples from 20 untreated children with ALL, 23 children with ALL in remission, and 15 normal controls were assayed for APRIL plasma concentration by enzyme-linked immunosorbent assay.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23887020,Real-time quantitative polymerase chain reaction was performed to determine the mRNA expression of APRIL and its receptors in blood mononuclear cells in 20 untreated ALL children and 15 normal controls.,mRNA Expression,PROCESS_OF,Child
23887020,These findings indicate that APRIL and BCMA are over expressed in untreated ALL children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23887020,Real-time quantitative polymerase chain reaction was performed to determine the mRNA expression of APRIL and its receptors in blood mononuclear cells in 20 untreated ALL children and 15 normal controls.,MONONUCLEAR CELLS,LOCATION_OF,ANP32B gene | ANP32B
23887020,Real-time quantitative polymerase chain reaction was performed to determine the mRNA expression of APRIL and its receptors in blood mononuclear cells in 20 untreated ALL children and 15 normal controls.,MONONUCLEAR CELLS,LOCATION_OF,receptor
21972289,ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.,"Polymorphism, Genetic",AFFECTS,Activating Transcription Factors | PLAU
21972289,ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
21972289,ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21972289,Asparaginase is a standard and critical component in the therapy of childhood acute lymphoblastic leukemia.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21972289,Asparaginase is a standard and critical component in the therapy of childhood acute lymphoblastic leukemia.,ASPARAGINASE | ASPG,ISA,Therapeutic procedure
21972289,ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,Child
22260162,"From the present case series, the demonstrated in vitro resistance to chemotherapeutic agents may have a prognostic value in children with ALL before comprehensive minimal residual disease measurement is available.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22260162,"From the present case series, the demonstrated in vitro resistance to chemotherapeutic agents may have a prognostic value in children with ALL before comprehensive minimal residual disease measurement is available.",Antineoplastic Agents,TREATS,"Leukemia, Lymphocytic, Acute"
22260162,"From the present case series, the demonstrated in vitro resistance to chemotherapeutic agents may have a prognostic value in children with ALL before comprehensive minimal residual disease measurement is available.",Antineoplastic Agents,TREATS,Child
22699455,We conclude that IKZF1 and TP53 represent relevant prognostic factors that should be considered in future risk assessment of children with relapsed ALL to indicate treatment intensification or intervention.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22748822,Bone marrow samples from children with acute lymphoblastic leukemia were analyzed for the expression of RUNX1a/b/c isoforms.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22858075,Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22858075,Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.,carvedilol,PREVENTS,"Ventricular Dysfunction, Left"
22858075,BACKGROUND: Adriamycin (ADR) is a potent chemotherapeutic agent widely used in the treatment of childhood acute lymphoblastic leukemia (ALL); its clinical use is limited owing to its marked cardiotoxicity.,Antineoplastic Agents,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22858075,BACKGROUND: Adriamycin (ADR) is a potent chemotherapeutic agent widely used in the treatment of childhood acute lymphoblastic leukemia (ALL); its clinical use is limited owing to its marked cardiotoxicity.,Adriamycin,ISA,Antineoplastic Agents
22858075,BACKGROUND: Adriamycin (ADR) is a potent chemotherapeutic agent widely used in the treatment of childhood acute lymphoblastic leukemia (ALL); its clinical use is limited owing to its marked cardiotoxicity.,Adriamycin,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22858075,Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.,"Ventricular Dysfunction, Left",PROCESS_OF,Child
22895060,Bacterial L-asparaginase has been a universal component of therapies for childhood acute lymphoblastic leukemia since the 1970s.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22895060,Bacterial L-asparaginase has been a universal component of therapies for childhood acute lymphoblastic leukemia since the 1970s.,ASPARAGINASE | ASPG,ISA,Therapeutic procedure
22895060,Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.,ASPARAGINASE,PART_OF,Rhizobium etli
22895060,Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
22899827,"Although there is increasing evidence that immune dysregulation in children who develop acute lymphoblastic leukemia (ALL) is detectable from birth, debate about the role of infectious exposures in infancy continues.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22899827,Infectious illness in children subsequently diagnosed with acute lymphoblastic leukemia: modeling the trends from birth to diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22928913,"METHODS: Resting state eyes-closed magnetoencephalography (MEG) recordings were obtained from 14 ALL survivors treated with CT + CRT, 18 treated with CT alone and 35 controls.",Pharmacotherapy,TREATS,Survivors
22928913,"METHODS: Resting state eyes-closed magnetoencephalography (MEG) recordings were obtained from 14 ALL survivors treated with CT + CRT, 18 treated with CT alone and 35 controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
22928913,"METHODS: Resting state eyes-closed magnetoencephalography (MEG) recordings were obtained from 14 ALL survivors treated with CT + CRT, 18 treated with CT alone and 35 controls.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22994778,Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia.,Toxic effect,PROCESS_OF,Child
22994778,Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22994778,"In conclusion, the GGH -401CT and TT genotypes were found to increase the risk of severe leukopenia and thrombocytopenia after exposure to high dose MTX for childhood ALL therapy.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22994778,The study population comprised of 105 children with ALL who were treated according to the modified St Jude Total XV protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22994778,Methotrexate (MTX) is an important drug for the treatment of childhood acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22994778,Methotrexate (MTX) is an important drug for the treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Pharmaceutical Preparations
22994778,Methotrexate (MTX) is an important drug for the treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23074685,"The t(12;21)(p13;q22) occurs in 25% of cases of B-cell precursor ALL, it is rare in children less than 24 months and have been related to good prognosis.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
23321258,Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results.,Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23645689,"Between 1992 and 2008, 713 high hyperdiploid acute lymphoblastic leukemias in children aged 1-15 years were diagnosed and treated according to the Nordic Society for Pediatric Hematology and Oncology acute lymphoblastic leukemia 1992/2000 protocols.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21747412,We investigated the usefulness of the MTHFR genotype to increase the MTX dosage in the consolidation phase in 141 childhood ALL patients enrolled in the ALL/SHOP-2005 protocol.,MTHFR gene | MTHFR,STIMULATES,Methotrexate
21747412,We investigated the usefulness of the MTHFR genotype to increase the MTX dosage in the consolidation phase in 141 childhood ALL patients enrolled in the ALL/SHOP-2005 protocol.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
21747412,We investigated the usefulness of the MTHFR genotype to increase the MTX dosage in the consolidation phase in 141 childhood ALL patients enrolled in the ALL/SHOP-2005 protocol.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
21747412,We investigated the usefulness of the MTHFR genotype to increase the MTX dosage in the consolidation phase in 141 childhood ALL patients enrolled in the ALL/SHOP-2005 protocol.,Methotrexate,TREATS,Patients
22017305,METHODS: Seventy-two children with ALL and 109 age- and sex-matched healthy children from Western Iran were screened for MTHFR C677T and A1298C variants by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22017305,METHODS: Seventy-two children with ALL and 109 age- and sex-matched healthy children from Western Iran were screened for MTHFR C677T and A1298C variants by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22215096,Children with acute lymphoblastic leukemia (ALL) react very differently to chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22542578,"Childhood acute lymphoblastic leukemia (ALL) is treated with combined chemotherapy, including L-asparaginase (L-asp).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22897843,Ph-like acute lymphoblastic leukemia (ALL) is a novel subgroup of high-risk childhood ALL.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
22945774,Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
22945774,Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.,Flow Cytometry,DIAGNOSES,"Neoplasm, Residual"
23182707,"AIM: To assess markers of inflammatory activity, endothelial activation as well as monocyte heterogeneity in adult survivors of childhood acute lymphoblastic leukemia (ALL) who had been treated with chemotherapy without cranial irradiation.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23229439,"Our study is consistent with an environmental aetiology for acute lymphoblastic leukaemia in children associated with constant exposure to an, as yet unknown, environmental factor in small geographical areas.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23229439,The data set consisted of 134 children diagnosed with acute lymphoblastic leukaemia who were resident in part of Hungary during the period 1981-2000.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23355259,"The survival rates in childhood acute lymphoid leukemia (ALL) have improved dramatically; however, patients still suffer from a variety of drug-related toxicities.","Leukemia, Lymphocytic, Acute, L1",AFFECTS,Patients
23355259,"The survival rates in childhood acute lymphoid leukemia (ALL) have improved dramatically; however, patients still suffer from a variety of drug-related toxicities.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
23394310,Outcome of childhood acute Lymphoblastic leukemia in Egyptian children: a challenge for limited health resource countries.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
23459381,"Forty-five ALL patients (median age, 13.3 y) treated without cranial irradiation were compared with 34 ALL patients (12.0 y) treated with SCT and total body irradiation and 522 age-matched and sex-matched controls.",Stem cell transplant,TREATS,"Leukemia, Lymphocytic, Acute"
23459381,"Forty-five ALL patients (median age, 13.3 y) treated without cranial irradiation were compared with 34 ALL patients (12.0 y) treated with SCT and total body irradiation and 522 age-matched and sex-matched controls.",Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute"
23459381,"Forty-five ALL patients (median age, 13.3 y) treated without cranial irradiation were compared with 34 ALL patients (12.0 y) treated with SCT and total body irradiation and 522 age-matched and sex-matched controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23459381,"Forty-five ALL patients (median age, 13.3 y) treated without cranial irradiation were compared with 34 ALL patients (12.0 y) treated with SCT and total body irradiation and 522 age-matched and sex-matched controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23459381,"Forty-five ALL patients (median age, 13.3 y) treated without cranial irradiation were compared with 34 ALL patients (12.0 y) treated with SCT and total body irradiation and 522 age-matched and sex-matched controls.",Stem cell transplant,TREATS,Patients
23459381,"Forty-five ALL patients (median age, 13.3 y) treated without cranial irradiation were compared with 34 ALL patients (12.0 y) treated with SCT and total body irradiation and 522 age-matched and sex-matched controls.",Cranial Irradiation,compared_with,Stem cell transplant
23459381,"Forty-five ALL patients (median age, 13.3 y) treated without cranial irradiation were compared with 34 ALL patients (12.0 y) treated with SCT and total body irradiation and 522 age-matched and sex-matched controls.",Cranial Irradiation,TREATS,Patients
23612374,"Finally, as future treatment will be individualized on the basis of biological features, the pediatric hemato-oncologists need to be ready and prepared to tailor the ""right treatment"" to the ""right children"" with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23612374,"The application of standard diagnostic technologies such as a conventional karyotype and polymerase chain reaction methodologies, together with gene expression profiling and genome-wide analyses, allows us to genetically characterize almost 100% of children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23695017,Our objective was to investigate the associations between allergy history and the development of AL and acute lymphoblastic leukaemia (ALL) in children with Down syndrome (DS).,Acute leukemia,PROCESS_OF,Child
23695017,Our objective was to investigate the associations between allergy history and the development of AL and acute lymphoblastic leukaemia (ALL) in children with Down syndrome (DS).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23695017,Our objective was to investigate the associations between allergy history and the development of AL and acute lymphoblastic leukaemia (ALL) in children with Down syndrome (DS).,Down Syndrome,PROCESS_OF,Child
23865834,Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
23865834,Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23865834,Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients.,MTHFR gene | MTHFR,AFFECTS,Toxic effect
23936021,Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23936021,"Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute lymphoblastic leukemia.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23936021,"Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute lymphoblastic leukemia.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
21766297,BACKGROUND: Treatment regimens for childhood acute lymphoblastic leukemia (ALL) contain neurotoxic agents that may interfere with neuromuscular health.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22072526,"In this study, mutational screening of the linker-RING domains of CBL and CBLB was performed by denaturing high performance liquid chromatography in a cohort of diagnostic (n = 180) or relapse (n = 46) samples from children with acute lymphoblastic leukemia.",Screening procedure,TREATS,cohort
22072526,"In this study, mutational screening of the linker-RING domains of CBL and CBLB was performed by denaturing high performance liquid chromatography in a cohort of diagnostic (n = 180) or relapse (n = 46) samples from children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22404039,Genome-wide analysis of cytogenetic aberrations in ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
22433405,"In the 103 children with B-ALL, CD19 (90.3%), CD10 (83.5%) and CD20 (27.2%) were expressed as major antigens.",MS4A1 gene | MS4A1,PRODUCES,Antigens
22433405,OBJECTIVE: To study the immunophenotype and its relationship with clinical characteristics in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22433405,"In the 103 children with B-ALL, CD19 (90.3%), CD10 (83.5%) and CD20 (27.2%) were expressed as major antigens.",Neprilysin | MME,PRODUCES,Antigens
22433405,"In the 103 children with B-ALL, CD19 (90.3%), CD10 (83.5%) and CD20 (27.2%) were expressed as major antigens.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22433405,"RESULTS: In 139 ALL children, there were 103 cases (74.1%) of B-ALL, 24 cases (17.3%) of T-ALL, 12 cases of T/B biphenotypic (8.6% of T/BALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22433405,"METHODS: Bone marrow or blood samples (2-3 mL) with heparin anticoagulation from 139 children with ALL were obtained, and immunophenotypes were identified by flow cytometry.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22433405,"METHODS: Bone marrow or blood samples (2-3 mL) with heparin anticoagulation from 139 children with ALL were obtained, and immunophenotypes were identified by flow cytometry.",Flow Cytometry,METHOD_OF,Immunophenotyping
22433405,"METHODS: Bone marrow or blood samples (2-3 mL) with heparin anticoagulation from 139 children with ALL were obtained, and immunophenotypes were identified by flow cytometry.",anticoagulation,USES,Heparin
22555150,"To address the prognostic value of minimal residual disease (MRD) before unrelated cord blood transplantation (UCBT) in children with acute lymphoblastic leukemia (ALL), we analyzed 170 ALL children transplanted in complete remission (CR) after myeloablative conditioning regimen.","Neoplasm, Residual",PROCESS_OF,Child
22555150,"To address the prognostic value of minimal residual disease (MRD) before unrelated cord blood transplantation (UCBT) in children with acute lymphoblastic leukemia (ALL), we analyzed 170 ALL children transplanted in complete remission (CR) after myeloablative conditioning regimen.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22555150,"Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.",Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22555150,MRD assessment before UCBT for children with ALL in remission allows identifying patients at higher risk of relapse after transplantation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22555150,MRD assessment before UCBT for children with ALL in remission allows identifying patients at higher risk of relapse after transplantation.,Transplantation,TREATS,Child
22555150,MRD assessment before UCBT for children with ALL in remission allows identifying patients at higher risk of relapse after transplantation.,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
22555150,"To address the prognostic value of minimal residual disease (MRD) before unrelated cord blood transplantation (UCBT) in children with acute lymphoblastic leukemia (ALL), we analyzed 170 ALL children transplanted in complete remission (CR) after myeloablative conditioning regimen.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23266048,"RESULTS: Children with ALL were, on average, heavier than controls at all gestations, the disparity being driven by a deficit of low-birthweight at all gestations and an excess of high-birthweight at >/= 40 weeks.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23266048,"METHODS: Birthweight and gestational age on 4075 children with ALL and 12,065 controls were collected during the course of three studies conducted in the USA, the UK and Germany in the 1990s.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23430503,Asparaginase is a mainstay of treatment of childhood acute lymphoblastic leukemia.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23430503,Asparaginase is a mainstay of treatment of childhood acute lymphoblastic leukemia.,ASPARAGINASE,ISA,Therapeutic procedure
23430503,High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase.,Hyperammonemia,OCCURS_IN,Child
23430503,High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23725389,"Polymorphism of CYP1A1*2A, *2B and *4 alleles was examined in 186 Egyptian children with ALL and 200 normal individuals using polymerase chain reaction-single stranded conformation polymorphism (PCR-SSCP).","Polymorphism, Genetic",PROCESS_OF,Child
23725389,"Polymorphism of CYP1A1*2A, *2B and *4 alleles was examined in 186 Egyptian children with ALL and 200 normal individuals using polymerase chain reaction-single stranded conformation polymorphism (PCR-SSCP).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Individual
23725389,"Polymorphism of CYP1A1*2A, *2B and *4 alleles was examined in 186 Egyptian children with ALL and 200 normal individuals using polymerase chain reaction-single stranded conformation polymorphism (PCR-SSCP).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23725389,"Polymorphism of CYP1A1*2A, *2B and *4 alleles was examined in 186 Egyptian children with ALL and 200 normal individuals using polymerase chain reaction-single stranded conformation polymorphism (PCR-SSCP).","Polymorphism, Genetic",PROCESS_OF,Individual
23866268,"CONCLUSIONS: ZFX is over-expressed in children with B-ALL and its levels are higher in those with a poor prognosis than those with a good prognosis, which suggests that ZFX is important in the prognosis evaluation of B-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23866268,"Real-time PCR was used for detecting ZFX mRNA expression in the BMMCs of 82 children with newly-diagnosed B-ALL, 24 children with complete remission (CR) after induction therapy and 64 control children (fracture or congenital heart disease patients).",Bone Marrow Cells,LOCATION_OF,ZFX
23866268,"Real-time PCR was used for detecting ZFX mRNA expression in the BMMCs of 82 children with newly-diagnosed B-ALL, 24 children with complete remission (CR) after induction therapy and 64 control children (fracture or congenital heart disease patients).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23866268,"Real-time PCR was used for detecting ZFX mRNA expression in the BMMCs of 82 children with newly-diagnosed B-ALL, 24 children with complete remission (CR) after induction therapy and 64 control children (fracture or congenital heart disease patients).",Bone Marrow Cells,PART_OF,Child
23866268,"Real-time PCR was used for detecting ZFX mRNA expression in the BMMCs of 82 children with newly-diagnosed B-ALL, 24 children with complete remission (CR) after induction therapy and 64 control children (fracture or congenital heart disease patients).",Congenital heart disease,PROCESS_OF,Patients
23866268,"Real-time PCR was used for detecting ZFX mRNA expression in the BMMCs of 82 children with newly-diagnosed B-ALL, 24 children with complete remission (CR) after induction therapy and 64 control children (fracture or congenital heart disease patients).",Polymerase Chain Reaction,USES,ZFX
23866268,OBJECTIVE: To study the expression of zinc finger protein X-linked (ZFX) in bone marrow mononuclear cells (BMMCs) of children with B lineage acute lymphoblastic leukemia (B-ALL) and its relationship with prognosis.,Bone Marrow Cells,PART_OF,Child
23866268,"CONCLUSIONS: ZFX is over-expressed in children with B-ALL and its levels are higher in those with a poor prognosis than those with a good prognosis, which suggests that ZFX is important in the prognosis evaluation of B-ALL.",Child,LOCATION_OF,ZFX
23866268,OBJECTIVE: To study the expression of zinc finger protein X-linked (ZFX) in bone marrow mononuclear cells (BMMCs) of children with B lineage acute lymphoblastic leukemia (B-ALL) and its relationship with prognosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
21753739,We present a case of an adolescent female with advanced osteonecrosis of the proximal femur after chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
21973240,"To determine whether genetic variations in mTOR are associated with risk of acute lymphoblastic leukemia (ALL) in Chinese children, we genotyped two tag single nucleotide poymorphisms (SNPs) in mTOR (rs2536 and rs2295080) in a case-control study.",Sirolimus (substance),PREDISPOSES,"Leukemia, Lymphocytic, Acute"
21973240,"We observed that the variant genotype TC of mTOR rs2536 was associated with a significantly decreased risk of childhood ALL (adjusted odds ratio [OR] = 0.67, 95% confidence interval [CI] = 0.46-0.96), and the association was more pronounced in high-risk ALL and T-phenotype ALL groups.","Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
21973240,"We observed that the variant genotype TC of mTOR rs2536 was associated with a significantly decreased risk of childhood ALL (adjusted odds ratio [OR] = 0.67, 95% confidence interval [CI] = 0.46-0.96), and the association was more pronounced in high-risk ALL and T-phenotype ALL groups.","Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
21973240,"To determine whether genetic variations in mTOR are associated with risk of acute lymphoblastic leukemia (ALL) in Chinese children, we genotyped two tag single nucleotide poymorphisms (SNPs) in mTOR (rs2536 and rs2295080) in a case-control study.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22005784,"Eleven sibships were ALL-subtype concordant, being T-cell ALL (T-ALL) (N = 5, of a total of six sibships, where the first-born had T-ALL) or B-lineage ALL belonging to the same cytogenetic subset (N = 6), a finding that differs significantly from the expected chance distribution (kappa: 0.58; P < 0.0001).",Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
22005784,"It remains uncertain, whether siblings of children with ALL have an increased risk of developing ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22433405,"Of the 139 children with ALL, 32 cases (23.0%) showed myeloid antigen expression (My+ ALL) and the main expression antigens were CD13, CD33, CD14 and MPO.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22433405,"In the 12 children with B/T-ALL, T-lymphoid antigens included CD7 (50.0%) and CD5 (41.7%), while the B-lymphoid antigens included CD19 (50.0%) and CD10 (33.3%).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22433405,"In the 24 children with T-ALL, the major antigens were CD3 (79.2%), CD7 (66.7%) and CD5 (33.3%).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22433405,"The expression of CD10, CD34 and HLA-DR in the standard-risk, medium risk, high-risk ALL children was significantly different.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22433405,HLA-DR was expressed in 82 of the 139 ALL children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22433405,CD34-positive expression (15.6%) in My+ ALL children was significantly lower than in My-ALL children (24.3%).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22433405,CD34-positive expression (15.6%) in My+ ALL children was significantly lower than in My-ALL children (24.3%).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22494120,BACKGROUND: Failure of remission-induction therapy is a rare but highly adverse event in children and adolescents with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22494120,BACKGROUND: Failure of remission-induction therapy is a rare but highly adverse event in children and adolescents with acute lymphoblastic leukemia (ALL).,Adverse event,PROCESS_OF,Child
22522336,"Current chemotherapeutic regimens have been used to successfully treat many children with acute lymphoblastic leukemia (ALL), but have resulted in an increased risk of late central nervous system tumors, most commonly meningioma, particularly in patients who have received cranial irradiation.",meningioma,PROCESS_OF,Patients
22522336,"Current chemotherapeutic regimens have been used to successfully treat many children with acute lymphoblastic leukemia (ALL), but have resulted in an increased risk of late central nervous system tumors, most commonly meningioma, particularly in patients who have received cranial irradiation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22522336,"Current chemotherapeutic regimens have been used to successfully treat many children with acute lymphoblastic leukemia (ALL), but have resulted in an increased risk of late central nervous system tumors, most commonly meningioma, particularly in patients who have received cranial irradiation.",Cranial Irradiation,ADMINISTERED_TO,Patients
22522336,"Current chemotherapeutic regimens have been used to successfully treat many children with acute lymphoblastic leukemia (ALL), but have resulted in an increased risk of late central nervous system tumors, most commonly meningioma, particularly in patients who have received cranial irradiation.",meningioma,ISA,Central Nervous System Neoplasms
23257430,Two hundred and six children with B-ALL were enrolled in this study from Augest 2008 to September 2011 in our hospital.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
23257430,Two hundred and six children with B-ALL were enrolled in this study from Augest 2008 to September 2011 in our hospital.,Hospitals,LOCATION_OF,Clinical Research
23257430,This study was aimed to explore the clinical significance of monitoring level of minimal residual disease (MRD) at different time point in B-lineage childhood acute lymphoblastic leukemia (B-ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23257430,[Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
23262804,"In conclusion, ELF-MF exposure has no impact on the survival probability or risk of relapse in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23262804,"A previous US study reported poorer survival in children with acute lymphoblastic leukemia (ALL) exposed to extremely low-frequency magnetic fields (ELF-MF) above 0.3 muT, but based on small numbers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23215883,The present study aimed to investigate the influence of GST-M1 and GST-T1 deletions on clinical outcome of children with acute lymphoblastic leukemia treated according to the AIEOP-BFM ALL 2000 study protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24667111,Acute lymphoblastic leukemia (ALL) is the most common cancer in children and the main cause of morbidity among childhood blood disorders.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24667111,Acute lymphoblastic leukemia (ALL) is the most common cancer in children and the main cause of morbidity among childhood blood disorders.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
25203866,CONCLUSIONS: These results suggest that CPX-351 may be a promising chemotherapeutic to be utilized in the treatment of ALL and support its testing in pediatric patients with leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25203866,CONCLUSIONS: These results suggest that CPX-351 may be a promising chemotherapeutic to be utilized in the treatment of ALL and support its testing in pediatric patients with leukemia.,leukemia,PROCESS_OF,Patients
25261097,"These findings provide novel insights into the leukemogenesis of adult acute lymphoblastic leukemia, showing similarities to childhood disease in the pattern of deletions and the clonal relationship between diagnostic and relapse samples, but with the adult cases harboring additional aberrations that have not been described in pediatric acute lymphoblastic leukemia.",DELETION,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
25261097,"In contrast to acute lymphoblastic leukemia in children, adult cases of this disease are associated with a very poor prognosis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25261097,"In contrast to acute lymphoblastic leukemia in children, adult cases of this disease are associated with a very poor prognosis.",Prognosis bad,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
25261097,Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
25304613,The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25312094,Minimal residual disease (MRD) during early chemotherapy is a powerful predictor of relapse in acute lymphoblastic leukaemia (ALL) and is used in children to determine eligibility for allogeneic haematopoietic stem cell transplantation (HSCT) in first (CR1) or later complete remission (CR2/CR3).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
25312094,Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.,"Neoplasm, Residual",PROCESS_OF,Child
25312094,Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25344215,6-Mercaptopurine (6MP) is a well-known purine antimetabolite used to treat childhood acute lymphoblastic leukemia and other diseases.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25344215,6-Mercaptopurine (6MP) is a well-known purine antimetabolite used to treat childhood acute lymphoblastic leukemia and other diseases.,Antimetabolites,TREATS,Disease
25344215,6-Mercaptopurine (6MP) is a well-known purine antimetabolite used to treat childhood acute lymphoblastic leukemia and other diseases.,6-Mercaptopurine,TREATS,Disease
25344215,6-Mercaptopurine (6MP) is a well-known purine antimetabolite used to treat childhood acute lymphoblastic leukemia and other diseases.,"Leukemia, Lymphocytic, Acute, L1",ISA,Disease
25344215,6-Mercaptopurine (6MP) is a well-known purine antimetabolite used to treat childhood acute lymphoblastic leukemia and other diseases.,Disease,ISA,"Leukemia, Lymphocytic, Acute, L1"
25344215,6-Mercaptopurine (6MP) is a well-known purine antimetabolite used to treat childhood acute lymphoblastic leukemia and other diseases.,Antimetabolites,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25344215,6-Mercaptopurine (6MP) is a well-known purine antimetabolite used to treat childhood acute lymphoblastic leukemia and other diseases.,Antimetabolites,TREATS,Disease
25344215,6-Mercaptopurine (6MP) is a well-known purine antimetabolite used to treat childhood acute lymphoblastic leukemia and other diseases.,6-Mercaptopurine,ISA,Antimetabolites
25344215,6-Mercaptopurine (6MP) is a well-known purine antimetabolite used to treat childhood acute lymphoblastic leukemia and other diseases.,Antimetabolites,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25347948,"METHODS: Using linear mixed models, we explored myelo- and hepatotoxicity in relation to 6MP dosage and TPMT phenotype following 1,749 HD-MTX courses to 411 children with acute lymphoblastic leukemia on maintenance therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25347948,Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.,Methotrexate,TREATS,Childhood Leukemia
25360802,Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25360802,We present a child who experienced a severe and long-lasting neurotoxicity after the third intrathecal application of methotrexate with short sedation by nitrous oxide during induction therapy for acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
25360802,We present a child who experienced a severe and long-lasting neurotoxicity after the third intrathecal application of methotrexate with short sedation by nitrous oxide during induction therapy for acute lymphoblastic leukemia.,Sedation,PROCESS_OF,Child
25360802,Systemic and intrathecal methotrexate is widely used in treatment protocols for childhood acute lymphoblastic leukemia.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25360802,Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia.,Sedation,PROCESS_OF,Child
25407299,BACKGROUND: Obesity is a well documented problem associated with childhood acute lymphoblastic leukemia (ALL) with increasing body mass index often observed during therapy.,"Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,Obesity
25418987,PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.,Hypersensitivity,PROCESS_OF,Child
25418987,BACKGROUND: L-Asparaginase is an effective drug in the treatment of childhood acute lymphoblastic leukemia (ALL).,ASPARAGINASE,ISA,Pharmaceutical Preparations
25418987,BACKGROUND: L-Asparaginase is an effective drug in the treatment of childhood acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25418987,BACKGROUND: L-Asparaginase is an effective drug in the treatment of childhood acute lymphoblastic leukemia (ALL).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25418987,PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25544150,"There was evidence that mothers of children with acute lymphoblastic leukaemia (OR 1.36, 95% CI 1.14-1.63), medulloblastoma (OR 1.79, 95% CI 1.00-3.22) and Wilms tumour (OR 1.79; 95% CI 1.05-3.04) were more likely to have been prescribed iron when compared to mothers of controls.",Jan-36,PROCESS_OF,Child
25544150,"There was evidence that mothers of children with acute lymphoblastic leukaemia (OR 1.36, 95% CI 1.14-1.63), medulloblastoma (OR 1.79, 95% CI 1.00-3.22) and Wilms tumour (OR 1.79; 95% CI 1.05-3.04) were more likely to have been prescribed iron when compared to mothers of controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24273277,"CONCLUSION: In children with acute lymphoblastic leukemia, EBV and HCMV co-infection cause changes in the methylation levels of PTEN and hTERT.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24273641,"This review presents the traditional approaches to designing trials for children with ALL, as well as innovative approaches attempting to study the benefit of new treatments as reliably as possible for patient subsets with distinctive biological characteristics.",Therapeutic procedure,TREATS,Patients
24273641,"This review presents the traditional approaches to designing trials for children with ALL, as well as innovative approaches attempting to study the benefit of new treatments as reliably as possible for patient subsets with distinctive biological characteristics.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24273641,"Although outcomes for children with ALL have improved dramatically over the last 50 years, ALL remains the leading cause of childhood cancer death.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24565987,"The hypoplasia mesofacial, broad forehead, small nose, short columella, narrow ears, telethelia, Sydney crease (SC), Greek type feet and cafe-au-lait spots (CALS), had a 3 to 17 times higher frequency in children with ALL.",Small nose,PROCESS_OF,Child
24565987,"The hypoplasia mesofacial, broad forehead, small nose, short columella, narrow ears, telethelia, Sydney crease (SC), Greek type feet and cafe-au-lait spots (CALS), had a 3 to 17 times higher frequency in children with ALL.",Cafe-au-Lait Spots,PROCESS_OF,Child
24565987,"The hypoplasia mesofacial, broad forehead, small nose, short columella, narrow ears, telethelia, Sydney crease (SC), Greek type feet and cafe-au-lait spots (CALS), had a 3 to 17 times higher frequency in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24565987,"PATIENTS AND METHODS: In a hospital based case-control study, we studied 120 children with ALL (including standard and high risk) and 120 healthy children as a control group, matched for age and sex, seen in the Hospital Civil de Guadalajara Dr.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24806976,Significantly increased risk of childhood ALL was detected among children under 1 year of age residing in areas around birth with higher levels of mortality from influenza (Odds Ratio (OR) for trend was 1.05; 95%CI [1.01-1.09]; p = 0.012).,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
24806976,Our aim was to investigate the ecological association between death from infectious disease of the respiratory system and the risk of acute lymphoid leukaemia (ALL) in children aged less than 7 years.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24907114,EXPERIMENTAL DESIGN: We recently reported the results of an association study between ASNase pathway genes and event-free survival (EFS) in childhood patients with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24907114,EXPERIMENTAL DESIGN: We recently reported the results of an association study between ASNase pathway genes and event-free survival (EFS) in childhood patients with ALL.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
24907114,"PURPOSE: Asparaginase (ASNase) is a standard and critical component in the therapy of childhood acute lymphoblastic leukemia (ALL), but it is also associated with several toxicities.",ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24907114,"PURPOSE: Asparaginase (ASNase) is a standard and critical component in the therapy of childhood acute lymphoblastic leukemia (ALL), but it is also associated with several toxicities.",ASPARAGINASE | ASPG,ISA,Therapeutic procedure
24907114,Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.,Complication,PROCESS_OF,Child
24907114,Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24907114,EXPERIMENTAL DESIGN: We recently reported the results of an association study between ASNase pathway genes and event-free survival (EFS) in childhood patients with ALL.,ASPARAGINASE | ASPG,TREATS,Patients
25132503,Reduced beta-cell reserve and pancreatic volume in survivors of childhood acute lymphoblastic leukaemia treated with bone marrow transplantation and total body irradiation.,Bone Marrow Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25132503,Reduced beta-cell reserve and pancreatic volume in survivors of childhood acute lymphoblastic leukaemia treated with bone marrow transplantation and total body irradiation.,Whole-Body Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25222059,CD20 may lack prognostic value in children with BCP-ALL.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
25222059,CD20 may lack prognostic value in children with BCP-ALL.,Child,LOCATION_OF,MS4A1 gene | MS4A1
25222061,The Progression of Bone Mineral Density Abnormalities After Chemotherapy for Childhood Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25288392,We present a prospective multicentre cohort of 20 children with acute lymphoblastic leukaemia (ALL) and cerebral sinus venous thrombosis (CSVT).,Thrombosis of cerebral veins,PROCESS_OF,Child
25288392,We present a prospective multicentre cohort of 20 children with acute lymphoblastic leukaemia (ALL) and cerebral sinus venous thrombosis (CSVT).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25288392,We present a prospective multicentre cohort of 20 children with acute lymphoblastic leukaemia (ALL) and cerebral sinus venous thrombosis (CSVT).,Sinus,LOCATION_OF,Thrombosis of cerebral veins
25288392,Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25288392,Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology.,Thrombosis of cerebral veins,PROCESS_OF,Child
25288392,Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology.,Sinus,LOCATION_OF,Thrombosis of cerebral veins
25336436,"This review, focused on treatment of ALL and one of the therapeutic mainstays, 6-mercaptopurine, illustrates the importance of obesity as a modulating factor in dose individualisation.",6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
25336436,"In the last two decades, tremendous advances have been made in the treatment of acute lymphocytic leukaemia (ALL) in children with 5 year 'cure' rates in excess of 90%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25395472,"RESULTS: There was some evidence of a reduced risk of ALL among children who had, or whose father had, the MTRR 66GG genotype: ORs 0.60 [95% confidence interval (CI) 0.39-0.91] and 0.64 (95% CI, 0.40-1.03), respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,father
25395472,"RESULTS: There was some evidence of a reduced risk of ALL among children who had, or whose father had, the MTRR 66GG genotype: ORs 0.60 [95% confidence interval (CI) 0.39-0.91] and 0.64 (95% CI, 0.40-1.03), respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25522886,Relapse after transplantation is a major cause of treatment failure in paediatric acute lymphoblastic leukaemia (ALL).,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25545289,Detection of central nervous system involvement in childhood acute lymphoblastic leukemia by cytomorphology and flow cytometry of the cerebrospinal fluid.,Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23956352,Acute lymphoblastic leukemia (ALL) is the most prevalent and curable cancer among children and adolescents less than 15 years of age in the United States.,Malignant Neoplasms,PROCESS_OF,Adolescent
23956352,Acute lymphoblastic leukemia (ALL) is the most prevalent and curable cancer among children and adolescents less than 15 years of age in the United States.,Malignant Neoplasms,PROCESS_OF,Child
23956352,"This article reports changes in oxidative stress, measured by the biomarker F2-isoprostane (F2-IsoP), in the cerebrospinal fluid (CSF) in 47 children with ALL during the first 18 months of treatment.",Cerebrospinal Fluid,LOCATION_OF,F2-Isoprostanes
23956352,"This article reports changes in oxidative stress, measured by the biomarker F2-isoprostane (F2-IsoP), in the cerebrospinal fluid (CSF) in 47 children with ALL during the first 18 months of treatment.",Oxidative Stress,PROCESS_OF,Child
23956352,"This article reports changes in oxidative stress, measured by the biomarker F2-isoprostane (F2-IsoP), in the cerebrospinal fluid (CSF) in 47 children with ALL during the first 18 months of treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23956352,Acute lymphoblastic leukemia (ALL) is the most prevalent and curable cancer among children and adolescents less than 15 years of age in the United States.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
23956352,Acute lymphoblastic leukemia (ALL) is the most prevalent and curable cancer among children and adolescents less than 15 years of age in the United States.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24050555,"Methotrexate (MTX) is an effective treatment for childhood acute lymphoblastic leukemia (ALL) or Non-Hodgkin lymphoma (NHL); however, toxicity can arise with high doses MTX (HDMTX), especially in patients with delayed MTX elimination.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24050555,"Methotrexate (MTX) is an effective treatment for childhood acute lymphoblastic leukemia (ALL) or Non-Hodgkin lymphoma (NHL); however, toxicity can arise with high doses MTX (HDMTX), especially in patients with delayed MTX elimination.",Methotrexate,ISA,Therapeutic procedure
24050555,"Methotrexate (MTX) is an effective treatment for childhood acute lymphoblastic leukemia (ALL) or Non-Hodgkin lymphoma (NHL); however, toxicity can arise with high doses MTX (HDMTX), especially in patients with delayed MTX elimination.",Toxic effect,PROCESS_OF,Patients
24050555,"Methotrexate (MTX) is an effective treatment for childhood acute lymphoblastic leukemia (ALL) or Non-Hodgkin lymphoma (NHL); however, toxicity can arise with high doses MTX (HDMTX), especially in patients with delayed MTX elimination.",Methotrexate,TREATS,"Lymphoma, Non-Hodgkin's"
24565987,CALS and SC were confirmed as MPV in children with ALL.,Cafe-au-Lait Spots,PROCESS_OF,Child
24565987,CALS and SC were confirmed as MPV in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25060202,The reasons for such a positive effect are both better financial support for treatment of children with cancer in Lithuania and international collaboration with joining international treatment protocol for childhood ALL.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25065700,The effect of serum folate levels and methylenetetrahydrofolate reductase (MTHFR) genotype on complications and outcome of induction chemotherapy in 150 children with acute lymphoblastic leukemia (ALL) was studied.,Complication,PROCESS_OF,Child
25065700,The effect of serum folate levels and methylenetetrahydrofolate reductase (MTHFR) genotype on complications and outcome of induction chemotherapy in 150 children with acute lymphoblastic leukemia (ALL) was studied.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25065700,Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia.,Toxic effect,PROCESS_OF,Child
25065700,Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25072371,Hemiparesis in an Adolescent With Acute Lymphoblastic Leukemia: Everything Is Not Always What it Seems.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
25072371,Hemiparesis in an Adolescent With Acute Lymphoblastic Leukemia: Everything Is Not Always What it Seems.,Hemiparesis,PROCESS_OF,Adolescent
25242092,We screened for DNMT3A mutations in exon 23 and its adjacent intron regions in diagnostic samples of 201 children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25242092,"Thus, DNMT3A mutations can be found in a few children with ALL, and may have an adverse impact on prognosis.",Child,LOCATION_OF,DNMT3a | DNMT3A
25242092,"Thus, DNMT3A mutations can be found in a few children with ALL, and may have an adverse impact on prognosis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25243950,"The aim of this review is to describe the oral complications in children with acute lymphoblastic leukaemia and the methods of prevention and management before, during and after the cancer treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25243950,"The aim of this review is to describe the oral complications in children with acute lymphoblastic leukaemia and the methods of prevention and management before, during and after the cancer treatment.",Complication,PROCESS_OF,Child
25243950,Oral complications and dental care in children with acute lymphoblastic leukaemia.,Complication,PROCESS_OF,Child
25243950,Oral complications and dental care in children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25266680,We genotyped eight common single-nucleotide polymorphisms (SNPs) in the CYP3A4 and CYP3A5 genes in 511 children with ALL and investigated whether they influenced the survival of the patients.,Child,LOCATION_OF,CYP3A5 gene | CYP3A5
25266680,We genotyped eight common single-nucleotide polymorphisms (SNPs) in the CYP3A4 and CYP3A5 genes in 511 children with ALL and investigated whether they influenced the survival of the patients.,Child,LOCATION_OF,CYP3A4 gene | CYP3A4
25266680,We genotyped eight common single-nucleotide polymorphisms (SNPs) in the CYP3A4 and CYP3A5 genes in 511 children with ALL and investigated whether they influenced the survival of the patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25266680,We genotyped eight common single-nucleotide polymorphisms (SNPs) in the CYP3A4 and CYP3A5 genes in 511 children with ALL and investigated whether they influenced the survival of the patients.,Single Nucleotide Polymorphism,COEXISTS_WITH,CYP3A5 gene | CYP3A5
25266680,In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25266680,We genotyped eight common single-nucleotide polymorphisms (SNPs) in the CYP3A4 and CYP3A5 genes in 511 children with ALL and investigated whether they influenced the survival of the patients.,Single Nucleotide Polymorphism,COEXISTS_WITH,CYP3A4 gene | CYP3A4
25403995,"Further, we evaluated the frequency of therapeutic interruption during maintenance therapy in Japanese children with acute lymphoblastic leukemia (ALL).",Maintenance therapy,TREATS,Child
25403995,"Further, we evaluated the frequency of therapeutic interruption during maintenance therapy in Japanese children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25403995,"Further, we evaluated the frequency of therapeutic interruption during maintenance therapy in Japanese children with acute lymphoblastic leukemia (ALL).",Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute"
25403995,Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26835307,With current chemotherapy regimen favorable event free survival rates can be achieved for children and adolescents with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23960182,PURPOSE: CNS-directed chemotherapy (CT) and cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia or lymphoma have various neurotoxic properties.,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23960182,PURPOSE: CNS-directed chemotherapy (CT) and cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia or lymphoma have various neurotoxic properties.,Radiation therapy,TREATS,Lymphoma
23960182,PURPOSE: CNS-directed chemotherapy (CT) and cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia or lymphoma have various neurotoxic properties.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23960182,PURPOSE: CNS-directed chemotherapy (CT) and cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia or lymphoma have various neurotoxic properties.,Chemotherapy-Oncologic Procedure,TREATS,Lymphoma
23997116,Acute lymphoblastic leukemia (ALL) is the most common malignancy in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
23997116,Acute lymphoblastic leukemia (ALL) is the most common malignancy in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23997116,Acute lymphoblastic leukemia (ALL) is the most common malignancy in children.,Malignant Neoplasms,PROCESS_OF,Child
24050555,Atotal of 105 children with ALL and NHL were included in the study.,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
24050555,Atotal of 105 children with ALL and NHL were included in the study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24050555,The aim of this study was to examine the relationship between MTX elimination and renal function to identify parameters that may be useful for predicting delayed MTX elimination in Chinese children with ALL and NHL.,Renal function,PROCESS_OF,Child
24050555,The aim of this study was to examine the relationship between MTX elimination and renal function to identify parameters that may be useful for predicting delayed MTX elimination in Chinese children with ALL and NHL.,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
24050555,The aim of this study was to examine the relationship between MTX elimination and renal function to identify parameters that may be useful for predicting delayed MTX elimination in Chinese children with ALL and NHL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24195512,The aim of this study was to examine the relationship between MTX elimination and renal function to identify parameters that may be useful for predicting delayed MTX elimination in Chinese children with ALL and NHL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24195512,"Methotrexate (MTX) is an effective treatment for childhood acute lymphoblastic leukemia (ALL) or Non-Hodgkin lymphoma (NHL); however, toxicity can arise with high doses MTX (HDMTX), especially in patients with delayed MTX elimination.",Toxic effect,PROCESS_OF,Patients
24195512,"Methotrexate (MTX) is an effective treatment for childhood acute lymphoblastic leukemia (ALL) or Non-Hodgkin lymphoma (NHL); however, toxicity can arise with high doses MTX (HDMTX), especially in patients with delayed MTX elimination.",Methotrexate,TREATS,"Lymphoma, Non-Hodgkin's"
24195512,A total of 105 children with ALL and NHL were included in the study.,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
24195512,"Methotrexate (MTX) is an effective treatment for childhood acute lymphoblastic leukemia (ALL) or Non-Hodgkin lymphoma (NHL); however, toxicity can arise with high doses MTX (HDMTX), especially in patients with delayed MTX elimination.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24195512,A total of 105 children with ALL and NHL were included in the study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24195512,"Methotrexate (MTX) is an effective treatment for childhood acute lymphoblastic leukemia (ALL) or Non-Hodgkin lymphoma (NHL); however, toxicity can arise with high doses MTX (HDMTX), especially in patients with delayed MTX elimination.",Methotrexate,ISA,Therapeutic procedure
24195512,The aim of this study was to examine the relationship between MTX elimination and renal function to identify parameters that may be useful for predicting delayed MTX elimination in Chinese children with ALL and NHL.,Renal function,PROCESS_OF,Child
24195512,The aim of this study was to examine the relationship between MTX elimination and renal function to identify parameters that may be useful for predicting delayed MTX elimination in Chinese children with ALL and NHL.,"Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
25006282,"MATERIAL METHODS: Oral examinations was done in 33 children between the age group of 5-15 years with acute lymphoblastic leukemia (ALL) and acute myloblastic leukemia (AML), who were undergoing chemotherapy.",Pharmacotherapy,TREATS,Acute leukemia
25006282,"MATERIAL METHODS: Oral examinations was done in 33 children between the age group of 5-15 years with acute lymphoblastic leukemia (ALL) and acute myloblastic leukemia (AML), who were undergoing chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25006282,"MATERIAL METHODS: Oral examinations was done in 33 children between the age group of 5-15 years with acute lymphoblastic leukemia (ALL) and acute myloblastic leukemia (AML), who were undergoing chemotherapy.",Acute leukemia,PROCESS_OF,Child
25006282,"MATERIAL METHODS: Oral examinations was done in 33 children between the age group of 5-15 years with acute lymphoblastic leukemia (ALL) and acute myloblastic leukemia (AML), who were undergoing chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25099492,Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25099492,Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Caucasoid Race
25105254,BACKGROUND: Oxidative stress is a possible risk factor in the development of acute lymphoblastic leukemia (ALL) in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25105254,UGT1A1*28 polymorphism and acute lymphoblastic leukemia in children: a Danish case-control study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25105254,CONCLUSION: We found no association between the UGT1A1*28 genotypes and ALL in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25155938,"In the last few years, several pharmacogenetic studies have been performed to search for markers of outcome and toxicity in pediatric ALL.",Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
25253770,"We screened samples from children with B-lineage ALL entered into the ALL-REZ BFM 2002 clinical trial (www.clinicaltrials.gov, #NCT00114348) for somatic mutations activating the Ras pathway (KRAS, NRAS, FLT3, and PTPN11) and showed mutation to be highly prevalent (76 from 206).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25253770,"For most children who relapse with acute lymphoblastic leukemia (ALL), the prognosis is poor, and there is a need for novel therapies to improve outcome.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25391165,CONCLUSION: The national protocols for ALL showed benefit in the improvement of outcomes from treatment in childhood ALL.,"Leukemia, Lymphocytic, Acute",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
25521979,"Although the varied neurotoxicity of intrathecal (IT) chemotherapy for treatment of childhood acute leukemia is well known, most are related to transient post-puncture headache, drug-induced arachnoiditis, or leukoencephalopathy after methotrexate or cytarabine.",Methotrexate,TREATS,Childhood Leukemia
25521979,"Although the varied neurotoxicity of intrathecal (IT) chemotherapy for treatment of childhood acute leukemia is well known, most are related to transient post-puncture headache, drug-induced arachnoiditis, or leukoencephalopathy after methotrexate or cytarabine.",Cytarabine,TREATS,Childhood Leukemia
25527416,"According to individual-level composite SES indices, children from low SES suffered from nearly twofold higher death rates from ALL (pooled RR: 1.83, 95% confidence interval 1.00-3.34, based on four study arms); likewise, death RRs derived from an array of lower area-level SES indices ranged between 1.17 and 1.33 (based on 11 study arms).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23940529,For this we selected and genotyped 67 SNPs in 15 genes in the folate pathway in 543 children with ALL and 529 controls.,Folate,TREATS,Child
23940529,For this we selected and genotyped 67 SNPs in 15 genes in the folate pathway in 543 children with ALL and 529 controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23940529,For this we selected and genotyped 67 SNPs in 15 genes in the folate pathway in 543 children with ALL and 529 controls.,Genes,COEXISTS_WITH,Folate
23940529,For this we selected and genotyped 67 SNPs in 15 genes in the folate pathway in 543 children with ALL and 529 controls.,Single Nucleotide Polymorphism,COEXISTS_WITH,Genes
23940529,For this we selected and genotyped 67 SNPs in 15 genes in the folate pathway in 543 children with ALL and 529 controls.,Folate,TREATS,"Leukemia, Lymphocytic, Acute"
23960182,PURPOSE: CNS-directed chemotherapy (CT) and cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia or lymphoma have various neurotoxic properties.,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23960182,PURPOSE: CNS-directed chemotherapy (CT) and cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia or lymphoma have various neurotoxic properties.,Radiation therapy,TREATS,Lymphoma
23960182,PURPOSE: CNS-directed chemotherapy (CT) and cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia or lymphoma have various neurotoxic properties.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23960182,PURPOSE: CNS-directed chemotherapy (CT) and cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia or lymphoma have various neurotoxic properties.,Chemotherapy-Oncologic Procedure,TREATS,Lymphoma
23996088,"Acute lymphoblastic leukemia (ALL) is the major pediatric cancer diagnosed in economically developed countries with B-cell precursor (BCP)-ALL, accounting for approximately 70% of ALL.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
24052107,Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in childhood.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
24096378,A rare type of secondary cancer in a child with acute lymphoblastic leukemia: malignant fibrous histiocytoma.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24096378,"In this case, a 13 year-old-boy diagnosed as high-risk ALL was treated with chemotherapy and prophylactic cranial radiotherapy at a dose of 1800 cGy.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
24096378,"In this case, a 13 year-old-boy diagnosed as high-risk ALL was treated with chemotherapy and prophylactic cranial radiotherapy at a dose of 1800 cGy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24096378,A rare type of secondary cancer in a child with acute lymphoblastic leukemia: malignant fibrous histiocytoma.,Neoplasm Metastasis,PROCESS_OF,Child
24276040,Prognostic significance of being overweight and obese at diagnosis in children with acute lymphoblastic leukemia.,Overweight,PROCESS_OF,Child
24276040,Prognostic significance of being overweight and obese at diagnosis in children with acute lymphoblastic leukemia.,Obesity,PROCESS_OF,Child
24276040,Prognostic significance of being overweight and obese at diagnosis in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24291415,Hsa-miR-196a2 polymorphism increases the risk of acute lymphoblastic leukemia in Chinese children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24309613,We present a novel case of bilateral parotid enlargement along with bilateral palpable nephromegaly in a patient with newly diagnosed infant ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24309613,We present a novel case of bilateral parotid enlargement along with bilateral palpable nephromegaly in a patient with newly diagnosed infant ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
24309613,Bilateral parotid gland enlargement and palpable nephromegaly in infant acute lymphoblastic leukemia: case report and review of the literature.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
24369920,Overexpression of the MLL gene combined with 11q trisomy in a child with acute lymphoblastic leukemia.,Trisomy,PROCESS_OF,Child
24369920,Overexpression of the MLL gene combined with 11q trisomy in a child with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24393150,Berlin-Frankfurt-Munster (BFM) and Dana-Farber Cancer Institute (DFCI) consortia's treatment strategies for acute lymphoblastic leukaemia (ALL) in children are widely used.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24393150,Berlin-Frankfurt-Munster (BFM) and Dana-Farber Cancer Institute (DFCI) consortia's treatment strategies for acute lymphoblastic leukaemia (ALL) in children are widely used.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
24404132,"In the present study, we assessed the association between the ABCC2 -24C>T polymorphism and methotrexate (MTX) toxicities in childhood ALL patients treated with high-dose MTX.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24404132,A total of 112 Han Chinese ALL patients were treated with high-dose MTX according to the ALL-Berlin-Frankfurt-Muenster 2000 protocol.,Methotrexate,TREATS,Patients
24404132,"In the present study, we assessed the association between the ABCC2 -24C>T polymorphism and methotrexate (MTX) toxicities in childhood ALL patients treated with high-dose MTX.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
24404132,A total of 112 Han Chinese ALL patients were treated with high-dose MTX according to the ALL-Berlin-Frankfurt-Muenster 2000 protocol.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
24404132,Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.,Methotrexate,COEXISTS_WITH,ABCC2
24404132,A total of 112 Han Chinese ALL patients were treated with high-dose MTX according to the ALL-Berlin-Frankfurt-Muenster 2000 protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24404132,Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.,Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
24404132,"In the present study, we assessed the association between the ABCC2 -24C>T polymorphism and methotrexate (MTX) toxicities in childhood ALL patients treated with high-dose MTX.",Toxic effect,PROCESS_OF,Patients
24404132,"In the present study, we assessed the association between the ABCC2 -24C>T polymorphism and methotrexate (MTX) toxicities in childhood ALL patients treated with high-dose MTX.",Methotrexate,TREATS,Patients
24404132,"In the present study, we assessed the association between the ABCC2 -24C>T polymorphism and methotrexate (MTX) toxicities in childhood ALL patients treated with high-dose MTX.",Methotrexate,TREATS,Toxic effect
24428625,Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.,Pancreatitis,PROCESS_OF,Child
24428625,Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24428625,L-asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24428625,L-asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia (ALL).,ASPARAGINASE,ISA,Pharmaceutical Preparations
24428625,L-asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia (ALL).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25083816,A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25317319,"Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
25317319,"Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.",Therapeutic procedure,USES,ASPARAGINASE
25317319,"Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.",ASPARAGINASE,ISA,Therapeutic procedure
25317319,"Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
23953914,We analyzed methylation status of CpG sites upstream of CASP8AP2 gene in 86 children with ALL by bisulfite sequencing and quantitative PCR.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24087922,"Specifically, mothers with the minor allele of MTR rs1804742 and who delivered during the prefortification period were at a greater risk of having a child with ALL (OR = 1.54, 95% CI: 0.82-2.88), compared to those mothers who delivered during the postfortification period (OR = 0.81, 95% CI: 0.22-2.99, P for interaction = .03).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24136019,Steroid-induced osteonecrosis (ON) is a challenging complication encountered during modern chemotherapy for childhood acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24136019,Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.,Pharmacotherapy,TREATS,Child
24136019,Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24136019,Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.,Bone necrosis,PROCESS_OF,Child
24136019,Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.,Pharmacotherapy,TREATS,Bone necrosis
24276047,"A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24276047,"A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.",Pharmacotherapy,TREATS,Child
24276047,"A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24550419,PATIENTS AND METHODS: Prospective brain magnetic resonance imaging was performed at four time points for 369 children with ALL treated in a contemporary study that included five courses of high-dose MTX and 13 to 25 doses of triple intrathecal therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24550419,PATIENTS AND METHODS: Prospective brain magnetic resonance imaging was performed at four time points for 369 children with ALL treated in a contemporary study that included five courses of high-dose MTX and 13 to 25 doses of triple intrathecal therapy.,Brain,LOCATION_OF,Magnetic Resonance Imaging
24552501,"Acute lymphoblastic leukemia patients after being treated with methotrexate, have differences in methotrexate serum levels and toxic side effects.",Methotrexate,TREATS,Patients
24552501,"Acute lymphoblastic leukemia patients after being treated with methotrexate, have differences in methotrexate serum levels and toxic side effects.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
24552501,"Acute lymphoblastic leukemia patients after being treated with methotrexate, have differences in methotrexate serum levels and toxic side effects.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24552501,"Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia.",Adverse effects,PROCESS_OF,Child
24552501,"Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24744989,"Survival for children with relapsed ALL is poor, and the development and implementation of novel therapeutic strategies in pediatric ALL are critical to further advancements.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24822192,Glucocorticoids (GCs) have been used as therapeutic agents for children with acute lymphoblastic leukaemia (ALL) for over 50 years.,Therapeutic agent (substance),TREATS,Child
24822192,Glucocorticoids (GCs) have been used as therapeutic agents for children with acute lymphoblastic leukaemia (ALL) for over 50 years.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24822192,Glucocorticoids (GCs) have been used as therapeutic agents for children with acute lymphoblastic leukaemia (ALL) for over 50 years.,Glucocorticoids,ISA,Therapeutic agent (substance)
24822192,Glucocorticoids (GCs) have been used as therapeutic agents for children with acute lymphoblastic leukaemia (ALL) for over 50 years.,Therapeutic agent (substance),TREATS,"Leukemia, Lymphocytic, Acute"
24822192,Glucocorticoids (GCs) have been used as therapeutic agents for children with acute lymphoblastic leukaemia (ALL) for over 50 years.,Glucocorticoids,TREATS,Child
24863691,"A retrospective analysis of 343 children newly diagnosed with ALL (M/F 200/143, median age 6.8 years) was performed.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24904116,Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24969258,SAMPLE: 36 children (aged 3-14 years) newly diagnosed with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25084203,BACKGROUND: Vincristine (VCR) is a standard component in the treatment of childhood acute lymphoblastic leukemia (ALL).,Vincristine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25084203,BACKGROUND: Vincristine (VCR) is a standard component in the treatment of childhood acute lymphoblastic leukemia (ALL).,Vincristine,ISA,Therapeutic procedure
25084203,Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.,Vincristine,TREATS,Child
25084203,Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
25084203,Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.,Vincristine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25162442,"MATERIAL AND METHODS: Symptoms, signs and laboratory findings at the time of diagnosis were reviewed in a consecutive series of 100 children with ALL in order to determine the frequency of atypical features and to evaluate the Danish referral guideline.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25162442,INTRODUCTION: Acute lymphoblastic leukaemia (ALL) in children may have atypical presentations causing diagnostic delay.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25283637,9-O-acetylated sialic acids differentiating normal haematopoietic precursors from leukemic stem cells with high aldehyde dehydrogenase activity in children with acute lymphoblastic leukaemia.,Stem cells,LOCATION_OF,Sialic Acids
25283637,9-O-acetylated sialic acids differentiating normal haematopoietic precursors from leukemic stem cells with high aldehyde dehydrogenase activity in children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24116693,"All had acute lymphoblastic leukaemia, all had been treated by chemotherapy with or without CNS irradiation, and none had received haematopoietic stem cell transplantation.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
24116693,"All had acute lymphoblastic leukaemia, all had been treated by chemotherapy with or without CNS irradiation, and none had received haematopoietic stem cell transplantation.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25016259,"As a result of the increased frequency of TC, TT genotype and T allele at SNP-318, ALL children synthesized more CTLA-4 to deliver the inhibitive signal, and this lead to restraint of T cell activation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25016259,(2) The frequency of GG genotype and G allele in ALL children at SNP-CT60 position were significantly higher than controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25016259,"The frequency of TC, TT genotype and T allele in ALL children at SNP-318 position were statistically higher than controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25016259,To investigate the correlation between cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism and children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25210485,Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.,ASPARAGINASE,TREATS,Infant
25210485,Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
25210485,Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
25210485,Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
25210485,"Great improvements have been made in acute lymphoblastic leukemia (ALL) treatment in the past decades, especially due to the use of l-asparaginase (l-ASP).",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
25210485,Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.,ASPARAGINASE,TREATS,Patients
25287825,Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25287825,PATIENTS AND METHODS: We used RQ-PCR to detect MRD in 110 unselected patients treated in Italy in the International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000).,Treatment Protocols,TREATS,Child
25287825,PATIENTS AND METHODS: We used RQ-PCR to detect MRD in 110 unselected patients treated in Italy in the International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000).,"Neoplasm, Residual",PROCESS_OF,Patients
25287825,PATIENTS AND METHODS: We used RQ-PCR to detect MRD in 110 unselected patients treated in Italy in the International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000).,Polymerase Chain Reaction,DIAGNOSES,"Neoplasm, Residual"
25287825,PATIENTS AND METHODS: We used RQ-PCR to detect MRD in 110 unselected patients treated in Italy in the International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
25287825,PATIENTS AND METHODS: We used RQ-PCR to detect MRD in 110 unselected patients treated in Italy in the International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25287825,CONCLUSION: These findings provide further insights into the dynamic of MRD and the ongoing effort to define molecular relapse in childhood ALL.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
25287825,PATIENTS AND METHODS: We used RQ-PCR to detect MRD in 110 unselected patients treated in Italy in the International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000).,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
25287825,PATIENTS AND METHODS: We used RQ-PCR to detect MRD in 110 unselected patients treated in Italy in the International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000).,Treatment Protocols,TREATS,Adolescent
25360156,The coexistence of these two primary genetic aberrations within the same clone is very rare in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25486958,"There is great potential to combine immunotherapies to further improve overall cure rates in children, adolescents, and young adults with poor-risk ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
25486958,"There is great potential to combine immunotherapies to further improve overall cure rates in children, adolescents, and young adults with poor-risk ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25486958,"There is great potential to combine immunotherapies to further improve overall cure rates in children, adolescents, and young adults with poor-risk ALL.",Immunotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25486958,Children and adolescents with refractory/relapsed ALL continue to have a dismal prognosis with hematopoietic stem cell transplant being their most viable option for cure.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
25486958,"There is great potential to combine immunotherapies to further improve overall cure rates in children, adolescents, and young adults with poor-risk ALL.",Immunotherapy,TREATS,Adolescent
25486958,"There is great potential to combine immunotherapies to further improve overall cure rates in children, adolescents, and young adults with poor-risk ALL.",Immunotherapy,TREATS,Young adult
25486958,Children and adolescents with refractory/relapsed ALL continue to have a dismal prognosis with hematopoietic stem cell transplant being their most viable option for cure.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25486958,"There is great potential to combine immunotherapies to further improve overall cure rates in children, adolescents, and young adults with poor-risk ALL.",Immunotherapy,TREATS,Child
25486958,"Although the event-free survival for children and adolescents with acute lymphoblastic leukemia (ALL) has dramatically improved over the past half century, it has plateaued over the past decade.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25486958,"There is great potential to combine immunotherapies to further improve overall cure rates in children, adolescents, and young adults with poor-risk ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
24052438,The present study compared the gene expression pattern of some previously described genes at the time of diagnosis and after induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) in patients submitted to Brazilian Childhood Leukemia Treatment Group (GBTLI) ALL-99 Protocol.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24052438,The present study compared the gene expression pattern of some previously described genes at the time of diagnosis and after induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) in patients submitted to Brazilian Childhood Leukemia Treatment Group (GBTLI) ALL-99 Protocol.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
24239175,High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
24239175,High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia.,Adult,LOCATION_OF,CXCR4 gene | CXCR4
24239175,High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia.,Adult,LOCATION_OF,Integrin alpha4beta1
24255623,In this work the clinical and molecular cytogenetic evaluation by fluorescence in situ hybridization of a child with B-cell precursor acute lymphoblastic leukemia presenting the rare intrachromosomal amplification of chromosome 21 is described.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
24422724,Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24422728,No evidence for routine cerebrospinal fluid cytology in detecting asymptomatic central nervous system relapse in children with acute lymphoblastic leukaemia: 20 years' experience of a UK primary treatment centre.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24476575,METHODS: A case-control study was conducted among 98 children with ALL and 93 age- and sex- matched non-ALL controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24476575,BACKGROUND: The aim of this study was to investigate the relationship between the polymorphisms of the methylenetetrahytrofolate reductase (MTHFR) gene and susceptibility to childhood acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
24482072,CONCLUSION: Children with ALL are at risk of becoming overweight/obese early in treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24582913,"Less is known about the relationship between socio-economic determinants and survival from paediatric ALL, studied here for the first time in German children.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
24582913,"BACKGROUND: Sex, age, immunophenotype and white blood cell count at diagnosis are well accepted predictors of survival from acute lymphoblastic leukaemia (ALL) in children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24598854,Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia.,Bone necrosis,PROCESS_OF,Adolescent
24598854,Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia.,Bone necrosis,PROCESS_OF,Child
24598854,Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
24598854,Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24651962,"Despite the success recorded in the use of 6-MP in ALL, there is still lack of effect and life threatening toxicity in some patients due to variability in the pharmacokinetics of 6-MP.",Toxic effect,PROCESS_OF,Patients
24651962,"Despite the success recorded in the use of 6-MP in ALL, there is still lack of effect and life threatening toxicity in some patients due to variability in the pharmacokinetics of 6-MP.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24651962,"Despite the success recorded in the use of 6-MP in ALL, there is still lack of effect and life threatening toxicity in some patients due to variability in the pharmacokinetics of 6-MP.",6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
24651962,"Despite the success recorded in the use of 6-MP in ALL, there is still lack of effect and life threatening toxicity in some patients due to variability in the pharmacokinetics of 6-MP.",6-Mercaptopurine,TREATS,Toxic effect
24781017,"These findings demonstrate that with contemporary effective therapy that excludes cranial irradiation, approximately 6% of children with ALL may relapse after completion of treatment, and those who remain in remission at 4 years post treatment may be considered cured (that is, less than 1% chance of relapse).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24848770,RECENT FINDINGS: About 10% of childhood ALL and a higher percentage of adolescents and adults with ALLs are characterized by activation of cytokine receptors and signaling kinases.,BCR,STIMULATES,"Receptors, Cytokine"
24848770,RECENT FINDINGS: About 10% of childhood ALL and a higher percentage of adolescents and adults with ALLs are characterized by activation of cytokine receptors and signaling kinases.,BCR,STIMULATES,Phosphotransferases
24848770,RECENT FINDINGS: About 10% of childhood ALL and a higher percentage of adolescents and adults with ALLs are characterized by activation of cytokine receptors and signaling kinases.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
24848770,RECENT FINDINGS: About 10% of childhood ALL and a higher percentage of adolescents and adults with ALLs are characterized by activation of cytokine receptors and signaling kinases.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
25210485,"In summary, this review presents an overview on l-ASP data and focuses on cellular mechanisms underlying resistance and alternative therapies for the use of asparaginase in childhood ALL treatment.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25279465,"UNLABELLED: The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25403293,"MATERIAL AND METHODS: The study involved 96 children (63 boys and 33 girls), aged 3-12 years, with hematological malignancies (acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma).",Hematologic Neoplasms,PROCESS_OF,Child
25403293,"MATERIAL AND METHODS: The study involved 96 children (63 boys and 33 girls), aged 3-12 years, with hematological malignancies (acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma).","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
25403293,"MATERIAL AND METHODS: The study involved 96 children (63 boys and 33 girls), aged 3-12 years, with hematological malignancies (acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23991122,SNP association mapping across the extended major histocompatibility complex and risk of B-cell precursor acute lymphoblastic leukemia in children.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
24919644,MTHFR gene polymorphism in acute lymphoblastic leukemia among North Indian children: a case-control study and meta-analysis updated from 2011.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24919644,MTHFR gene polymorphism in acute lymphoblastic leukemia among North Indian children: a case-control study and meta-analysis updated from 2011.,MTHFR gene | MTHFR,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
24919644,MTHFR (677 and 1298) genotype of children with ALL and healthy adult controls were done by the PCR-restriction fragment length polymorphism (PCR-RFLP) method and were compared using various models of inheritance.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24919644,The present study examines this association in north Indian children with ALL and includes an updated meta-analysis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24940700,Pediatric acute lymphoblastic leukemia (ALL) is treated with combination chemotherapy including mercaptopurine (6MP) as an important component.,Combination Drug Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24940700,"Therefore, although a complex study of 6MP metabolism in ALL patients is feasible, it warrants more robust and strict data collection in order to be able to draw more reliable conclusions.",6-Mercaptopurine,TREATS,Patients
24940700,"Therefore, although a complex study of 6MP metabolism in ALL patients is feasible, it warrants more robust and strict data collection in order to be able to draw more reliable conclusions.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24940700,"Therefore, although a complex study of 6MP metabolism in ALL patients is feasible, it warrants more robust and strict data collection in order to be able to draw more reliable conclusions.",6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
24979081,PURPOSE: Children with acute lymphoblastic leukemia (ALL) are at increased risk of obesity and deconditioning from cancer therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24979081,Feasibility and initial effectiveness of home exercise during maintenance therapy for childhood acute lymphoblastic leukemia.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24979081,This pilot study assessed feasibility/initial efficacy of an exercise intervention for patients with ALL undergoing maintenance therapy.,Intervention regimes,TREATS,Patients
24979081,This pilot study assessed feasibility/initial efficacy of an exercise intervention for patients with ALL undergoing maintenance therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24979081,This pilot study assessed feasibility/initial efficacy of an exercise intervention for patients with ALL undergoing maintenance therapy.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute"
24979082,"Commentary on ""feasibility and initial effectiveness of home exercise during maintenance therapy for childhood acute lymphoblastic leukemia"".",Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25130190,PROCEDURE: A double-blind and controlled study was conducted in 136 children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25130190,Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.,Leukovorin rescue,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25130190,Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25136288,"BACKGROUND: Until now, the major prognostic factors for pediatric acute lymphoblastic leukemia (ALL), age, white blood cell count and chromosomal alterations are initially taken into account for the risk stratification of patients.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
25136288,Proteomic profile of pre - B2 lymphoblasts from children with acute lymphoblastic leukemia (ALL) in relation with the translocation (12; 21).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25136372,"Our results show that the TCM compounds adenosine triphosphate, manninotriose, raffinose, and stachyose could have potential to improve the side effects of MTX for ALL treatment.",Raffinose,AFFECTS,Adverse effects
25136372,Acute lymphoblastic leukemia (ALL) is a cancer that immature white blood cells continuously overproduce in the bone marrow.,Bone Marrow,LOCATION_OF,Malignant Neoplasms
25136372,Acute lymphoblastic leukemia (ALL) is a cancer that immature white blood cells continuously overproduce in the bone marrow.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
25136372,Acute lymphoblastic leukemia (ALL) is a cancer that immature white blood cells continuously overproduce in the bone marrow.,Bone Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
25136372,"Our results show that the TCM compounds adenosine triphosphate, manninotriose, raffinose, and stachyose could have potential to improve the side effects of MTX for ALL treatment.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
25136372,"Our results show that the TCM compounds adenosine triphosphate, manninotriose, raffinose, and stachyose could have potential to improve the side effects of MTX for ALL treatment.",manninotriose,AFFECTS,Adverse effects
25136372,"Our results show that the TCM compounds adenosine triphosphate, manninotriose, raffinose, and stachyose could have potential to improve the side effects of MTX for ALL treatment.",stachyose,AFFECTS,Adverse effects
25174644,"Improving treatment of children with acute lymphoblastic leukemia in developing countries through technology sharing, collaboration and partnerships.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25175168,PROCEDURE: We conducted a prospective cohort study of 159 children with average risk-ALL enrolled and treated on COG protocol AALL0331 at 31 selected sites.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25224311,"OBJECTIVES AND METHODS: We evaluated the feasibility and efficacy of T-cell-replete haploidentical peripheral blood stem cell transplantation (haplo-SCT) with low-dose anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate and prednisolone (PSL) in 14 paediatric patients with high-risk childhood acute leukaemia.",Childhood Leukemia,PROCESS_OF,Patients
25224311,"OBJECTIVES AND METHODS: We evaluated the feasibility and efficacy of T-cell-replete haploidentical peripheral blood stem cell transplantation (haplo-SCT) with low-dose anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate and prednisolone (PSL) in 14 paediatric patients with high-risk childhood acute leukaemia.",Human immunoglobulin,PART_OF,thymocyte
25224311,"OBJECTIVES AND METHODS: We evaluated the feasibility and efficacy of T-cell-replete haploidentical peripheral blood stem cell transplantation (haplo-SCT) with low-dose anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate and prednisolone (PSL) in 14 paediatric patients with high-risk childhood acute leukaemia.",Peripheral Stem Cell Transplantation,ISA,Stem cell transplant
25224311,"OBJECTIVES AND METHODS: We evaluated the feasibility and efficacy of T-cell-replete haploidentical peripheral blood stem cell transplantation (haplo-SCT) with low-dose anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate and prednisolone (PSL) in 14 paediatric patients with high-risk childhood acute leukaemia.",Tacrolimus,TREATS,Patients
25224311,"OBJECTIVES AND METHODS: We evaluated the feasibility and efficacy of T-cell-replete haploidentical peripheral blood stem cell transplantation (haplo-SCT) with low-dose anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate and prednisolone (PSL) in 14 paediatric patients with high-risk childhood acute leukaemia.",Tacrolimus,TREATS,Childhood Leukemia
25224311,"OBJECTIVES AND METHODS: We evaluated the feasibility and efficacy of T-cell-replete haploidentical peripheral blood stem cell transplantation (haplo-SCT) with low-dose anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate and prednisolone (PSL) in 14 paediatric patients with high-risk childhood acute leukaemia.",prednisolone,TREATS,Patients
25224311,"OBJECTIVES AND METHODS: We evaluated the feasibility and efficacy of T-cell-replete haploidentical peripheral blood stem cell transplantation (haplo-SCT) with low-dose anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate and prednisolone (PSL) in 14 paediatric patients with high-risk childhood acute leukaemia.",prednisolone,TREATS,Childhood Leukemia
25224311,"OBJECTIVES AND METHODS: We evaluated the feasibility and efficacy of T-cell-replete haploidentical peripheral blood stem cell transplantation (haplo-SCT) with low-dose anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate and prednisolone (PSL) in 14 paediatric patients with high-risk childhood acute leukaemia.",Methotrexate,TREATS,Patients
25224311,"OBJECTIVES AND METHODS: We evaluated the feasibility and efficacy of T-cell-replete haploidentical peripheral blood stem cell transplantation (haplo-SCT) with low-dose anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate and prednisolone (PSL) in 14 paediatric patients with high-risk childhood acute leukaemia.",Methotrexate,TREATS,Childhood Leukemia
25224311,"OBJECTIVES AND METHODS: We evaluated the feasibility and efficacy of T-cell-replete haploidentical peripheral blood stem cell transplantation (haplo-SCT) with low-dose anti-human thymocyte immunoglobulin (ATG), tacrolimus, methotrexate and prednisolone (PSL) in 14 paediatric patients with high-risk childhood acute leukaemia.",Peripheral Stem Cell Transplantation,USES,Human immunoglobulin
25286695,CONCLUSION: CD20 positivity was not found to be associated with worse prognosis of children with BCP-ALL.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
24243921,OBJECTIVE: The aim of this study was to assess serum soluble thrombomodulin and von Willebrand factor levels in children with acute lymphoblastic leukemia during acute phase of the disease to assess their potential prognostic value.,Child,LOCATION_OF,Thrombomodulin | THBD
24243921,OBJECTIVE: The aim of this study was to assess serum soluble thrombomodulin and von Willebrand factor levels in children with acute lymphoblastic leukemia during acute phase of the disease to assess their potential prognostic value.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24243921,Prognostic value of plasma levels of thrombomodulin and von Willebrand factor in Egyptian children with acute lymphoblastic leukemia.,Child,LOCATION_OF,VWF gene | VWF
24243921,Prognostic value of plasma levels of thrombomodulin and von Willebrand factor in Egyptian children with acute lymphoblastic leukemia.,Child,LOCATION_OF,Thrombomodulin | THBD
24243921,Prognostic value of plasma levels of thrombomodulin and von Willebrand factor in Egyptian children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24243921,"RESULTS: In children with acute lymphoblastic leukemia, there was a significant increase in soluble thrombomodulin, and von Willebrand factor levels during the acute phase of the disease.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24243921,OBJECTIVE: The aim of this study was to assess serum soluble thrombomodulin and von Willebrand factor levels in children with acute lymphoblastic leukemia during acute phase of the disease to assess their potential prognostic value.,Child,LOCATION_OF,VWF gene | VWF
24287213,Bone mineral density at diagnosis determines fracture rate in children with acute lymphoblastic leukemia treated according to the DCOG-ALL9 protocol.,Fracture,PROCESS_OF,Child
24287213,Bone mineral density at diagnosis determines fracture rate in children with acute lymphoblastic leukemia treated according to the DCOG-ALL9 protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24287213,"CONCLUSION: Low values of BMDLS at diagnosis and during treatment, rather than the treatment-related decline of BMDLS, determine the increased fracture risk of 17.8% in children with ALL.",Therapeutic procedure,TREATS,Child
24287213,"CONCLUSION: Low values of BMDLS at diagnosis and during treatment, rather than the treatment-related decline of BMDLS, determine the increased fracture risk of 17.8% in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24287213,"CONCLUSION: Low values of BMDLS at diagnosis and during treatment, rather than the treatment-related decline of BMDLS, determine the increased fracture risk of 17.8% in children with ALL.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
24287213,PURPOSE: To elucidate incidence and risk factors of bone mineral density and fracture risk in children with Acute Lymphoblastic Leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24424791,"BACKGROUND: In children, T-cell acute lymphoblastic leukemia (T-ALL) has inferior prognosis compared with B-cell precursor ALL.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
24473774,METHODS: A cohort study was performed of 159 children (aged 2 years-9.99 years) with SR-ALL who were enrolled on Children's Oncology Group protocol AALL0331 at 31 sites.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24473774,"BACKGROUND: The authors prospectively assessed anxiety, depression, and behavior in children with standard-risk acute lymphoblastic leukemia (SR-ALL) during the first year of therapy and identified associated risk factors.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24473774,"BACKGROUND: The authors prospectively assessed anxiety, depression, and behavior in children with standard-risk acute lymphoblastic leukemia (SR-ALL) during the first year of therapy and identified associated risk factors.",Behavior,PROCESS_OF,Child
24475044,"CONCLUSIONS: Survival for adults with ALL continues to be low compared with that for children, but a substantial increase in 5-year survival estimates was seen from 2002 to 2006 in both Germany and the US.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
24475044,"In contrast to childhood ALL, survival for adults with ALL is poor.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
24475044,Survival of adults with acute lymphoblastic leukemia in Germany and the United States.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
24702187,"Danish children (1-17 years) with ALL, treated according to the Nordic Society of Paediatric Haematology and Oncology ALL2008 protocol, standard and intermediate risk, were included.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24702187,Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.,ASPARAGINASE | ASPG,ISA,Therapeutic procedure
24702187,L-asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24702187,Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.,ASPARAGINASE | ASPG,TREATS,Child
24702187,L-asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia (ALL).,ASPARAGINASE,ISA,Pharmaceutical Preparations
24702187,L-asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia (ALL).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24702187,Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24702187,Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.,Therapeutic procedure,TREATS,Child
24702187,Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.,Therapeutic procedure,USES,ASPARAGINASE | ASPG
24702187,Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
24724064,"The estimated 3-year event free survival (EFS) and overall survival of ALL children with hyperleukocytosis were 75.0% and 81.2%, respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24724064,"RESULTS: Twenty (19.2%) of the 104 children with ALL had initial leukocyte counts of >100*10(9)/L, and 11 patients had a leukocyte count of >200*10(9)/L.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24724064,"RESULTS: Twenty (19.2%) of the 104 children with ALL had initial leukocyte counts of >100*10(9)/L, and 11 patients had a leukocyte count of >200*10(9)/L.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24724064,"METHODS: Between January 2001 and December 2010, 104 children with previously untreated ALL were enrolled at the Pusan National University Hospital.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24824603,Anticancer agent 6-mercaptopurine (6MP) has been in use since 1953 for the treatment of childhood acute lymphoblastic leukemia (ALL) and inflammatory bowel disease.,6-Mercaptopurine,ISA,Therapeutic procedure
24824603,Anticancer agent 6-mercaptopurine (6MP) has been in use since 1953 for the treatment of childhood acute lymphoblastic leukemia (ALL) and inflammatory bowel disease.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24824603,Anticancer agent 6-mercaptopurine (6MP) has been in use since 1953 for the treatment of childhood acute lymphoblastic leukemia (ALL) and inflammatory bowel disease.,6-Mercaptopurine,TREATS,Inflammatory Bowel Diseases
25098084,Immunoglobulin gene rearrangement in detection of minimal residual disease in acute lymphoblastic leukaemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
24145140,"Using quantitative real-time PCR, we evaluated 27 children with ALL at diagnosis and 15 children with normal bone marrow.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24145140,"Using quantitative real-time PCR, we evaluated 27 children with ALL at diagnosis and 15 children with normal bone marrow.",Bone Marrow,PART_OF,Child
24145140,"Using quantitative real-time PCR, we evaluated 27 children with ALL at diagnosis and 15 children with normal bone marrow.",Bone Marrow,PART_OF,Child
24145140,"Considering the direct and significant relationship between the increased expression of ABCA2, ABCA3, MDR1, and MRP1 genes and positive risk of MRD in children with ALL, evaluating the expression profile of these genes on diagnosis may identify high risk individuals and help plan a more efficient treatment strategy.","Neoplasm, Residual",PART_OF,Child
24145140,"Considering the direct and significant relationship between the increased expression of ABCA2, ABCA3, MDR1, and MRP1 genes and positive risk of MRD in children with ALL, evaluating the expression profile of these genes on diagnosis may identify high risk individuals and help plan a more efficient treatment strategy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24145140,"Using quantitative real-time PCR, we evaluated 27 children with ALL at diagnosis and 15 children with normal bone marrow.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24564228,RESULTS: Children with the IKZF1 SNP had an increased risk of developing MLL-germline ALL in white children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24564228,RESULTS: Children with the IKZF1 SNP had an increased risk of developing MLL-germline ALL in white children.,Single Nucleotide Polymorphism,PART_OF,Child
24568906,[Effect of Huangqi injection on short-term prognosis in children with acute lymphoblastic leukemia].,Injection procedure,TREATS,"Leukemia, Lymphocytic, Acute"
24568906,METHODS: A retrospective analysis was performed on the clinical data of 105 children newly diagnosed with ALL between January 2009 and December 2012.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24568906,[Effect of Huangqi injection on short-term prognosis in children with acute lymphoblastic leukemia].,Injection procedure,TREATS,Child
24568906,[Effect of Huangqi injection on short-term prognosis in children with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24727815,Dexamethasone could be more effective than prednisolone at similar anti-inflammatory doses in the treatment of childhood acute lymphoblastic leukemia.,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24727815,Dexamethasone could be more effective than prednisolone at similar anti-inflammatory doses in the treatment of childhood acute lymphoblastic leukemia.,Dexamethasone,higher_than,prednisolone
24727815,Dexamethasone could be more effective than prednisolone at similar anti-inflammatory doses in the treatment of childhood acute lymphoblastic leukemia.,Dexamethasone,compared_with,prednisolone
24727815,Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24727815,All newly diagnosed children and adolescents with acute lymphoblastic leukemia in the 58951 EORTC trial were randomized on prephase day 1 or day 8.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
24727815,All newly diagnosed children and adolescents with acute lymphoblastic leukemia in the 58951 EORTC trial were randomized on prephase day 1 or day 8.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24727815,Dexamethasone could be more effective than prednisolone at similar anti-inflammatory doses in the treatment of childhood acute lymphoblastic leukemia.,prednisolone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24949228,"In the pediatric population, B-acute lymphoblastic leukemia (B-ALL) is the most prevalent childhood hematological malignancy, as well as the leading cause of childhood cancer-related mortality.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
25102096,"GSTM1, GSTP1 and GSTT1 genotypes in 100 children with ALL and 300 healthy controls were compared.",Child,LOCATION_OF,GSTP1 gene | GSTP1
25102096,"GSTM1, GSTP1 and GSTT1 genotypes in 100 children with ALL and 300 healthy controls were compared.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25102096,Various studies on association of glutathione S-transferase (GST) polymorphisms and childhood acute lymphoblastic leukemia (ALL) have yielded conflicting results.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
25102096,Glutathione-S-transferase polymorphism and acute lymphoblastic leukemia (ALL) in north Indian children: a case-control study and meta-analysis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25102096,"GSTM1, GSTP1 and GSTT1 genotypes in 100 children with ALL and 300 healthy controls were compared.",Child,LOCATION_OF,GSTT1 gene | GSTT1
25102096,"GSTM1, GSTP1 and GSTT1 genotypes in 100 children with ALL and 300 healthy controls were compared.",Child,LOCATION_OF,GSTM1 gene | GSTM1
25224660,"Our objective was to determine the association between SES and event-free survival (EFS) among children with acute lymphoblastic leukemia (ALL) diagnosed in Ontario, Canada from 1995-2011 (N=1541) using Cox proportional hazards.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25254091,Acute lymphoblastic leukemia (ALL) is one of the most prevalent hematologic malignancies in children.,Hematologic Neoplasms,PROCESS_OF,Child
25254091,Acute lymphoblastic leukemia (ALL) is one of the most prevalent hematologic malignancies in children.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
25254091,Acute lymphoblastic leukemia (ALL) is one of the most prevalent hematologic malignancies in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25330012,These results suggested that muscle side effect monitoring might be helpful in the follow-up of children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25330012,"Muscle strength, motor performance, cardiac and muscle biomarkers in detection of muscle side effects during and after acute lymphoblastic leukemia treatment in children.",Motor Performance,PROCESS_OF,Child
25330012,"Muscle strength, motor performance, cardiac and muscle biomarkers in detection of muscle side effects during and after acute lymphoblastic leukemia treatment in children.",Detection,TREATS,"Leukemia, Lymphocytic, Acute"
24218069,"In conclusion, results of this study showed no contribution of Fas genotypes at positions -670 and -1377 to risk of ALL in children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24218069,In the present study the association between these polymorphisms and risk of the development of acute lymphoblastic leukemia (ALL) in children with ALL compared to cancer-free control subjects was examined by polymerase chain reaction- based restriction fragment length polymorphism.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24218069,In the present study the association between these polymorphisms and risk of the development of acute lymphoblastic leukemia (ALL) in children with ALL compared to cancer-free control subjects was examined by polymerase chain reaction- based restriction fragment length polymorphism.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24305505,Dramatic improvements in the cure rates and survival outcomes for children with ALL have been seen over the past several decades; currently the 5-year survival rate for childhood ALL is more than 80%.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24305505,Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
24305505,Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24305505,The authors will offer expert guidance to practicing oncologists on how to best incorporate newer treatment approaches into the care of children and adolescents with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
24305505,The authors will offer expert guidance to practicing oncologists on how to best incorporate newer treatment approaches into the care of children and adolescents with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24568906,"RESULTS: Of the 105 children with ALL, 99 had B-ALL, and 6 had T-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24568906,"RESULTS: Of the 105 children with ALL, 99 had B-ALL, and 6 had T-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24568906,CONCLUSIONS: Huangqi injection combined with chemotherapy has an enhanced anti-tumor effect and can improve the short-term prognosis and clinical outcome in children with ALL.,Pharmacotherapy,AFFECTS,Neoplasm
24568906,"RESULTS: Of the 105 children with ALL, 99 had B-ALL, and 6 had T-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24568906,CONCLUSIONS: Huangqi injection combined with chemotherapy has an enhanced anti-tumor effect and can improve the short-term prognosis and clinical outcome in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24568906,"On day 19 of remission induction therapy, the incidence of MRD>=10(-4) in the treatment group was significantly lower than that in the control group (69% vs 95%; P<0.05); among 80 children with B-ALL who achieved a CR (43 cases in the control group and 37 cases in the treatment group), the incidence of MRD>=10-4 was significantly lower in the treatment group than in the control group (27% vs 58%; P<0.05); in both circumstances above, the high- and low-risk cases in the treatment group had a significantly lower incidence of MRD>=10(-4) than the control group (P<0.05).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24568906,"On day 19 of remission induction therapy, the incidence of MRD>=10(-4) in the treatment group was significantly lower than that in the control group (69% vs 95%; P<0.05); among 80 children with B-ALL who achieved a CR (43 cases in the control group and 37 cases in the treatment group), the incidence of MRD>=10-4 was significantly lower in the treatment group than in the control group (27% vs 58%; P<0.05); in both circumstances above, the high- and low-risk cases in the treatment group had a significantly lower incidence of MRD>=10(-4) than the control group (P<0.05).","Neoplasm, Residual",PROCESS_OF,Control Groups
24568906,"On day 19 of remission induction therapy, the incidence of MRD>=10(-4) in the treatment group was significantly lower than that in the control group (69% vs 95%; P<0.05); among 80 children with B-ALL who achieved a CR (43 cases in the control group and 37 cases in the treatment group), the incidence of MRD>=10-4 was significantly lower in the treatment group than in the control group (27% vs 58%; P<0.05); in both circumstances above, the high- and low-risk cases in the treatment group had a significantly lower incidence of MRD>=10(-4) than the control group (P<0.05).","Neoplasm, Residual",PROCESS_OF,Control Groups
24568909,The chemotherapy agent L-asparaginase (L-asp) has been an important part of acute lymphoblastic leukemia therapy for over 30 years.,ASPARAGINASE,ISA,Therapeutic procedure
24568909,The chemotherapy agent L-asparaginase (L-asp) has been an important part of acute lymphoblastic leukemia therapy for over 30 years.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
24761390,"BACKGROUND: For the past 30 years, bacterial L-asparaginases have been used as therapeutic agents in the treatment of acute childhood lymphoblastic leukemia.",Therapeutic agent (substance),TREATS,"Leukemia, Lymphocytic, Acute"
24761390,"BACKGROUND: For the past 30 years, bacterial L-asparaginases have been used as therapeutic agents in the treatment of acute childhood lymphoblastic leukemia.",ASPARAGINASE | ASPG,ISA,Therapeutic agent (substance)
24761390,"BACKGROUND: For the past 30 years, bacterial L-asparaginases have been used as therapeutic agents in the treatment of acute childhood lymphoblastic leukemia.",ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
25087182,BACKGROUND: Asparaginase and steroids can cause hypertriglyceridaemia in children with acute lymphoblastic leukaemia (ALL).,Hypertriglyceridemia,PROCESS_OF,Child
25087182,BACKGROUND: Asparaginase and steroids can cause hypertriglyceridaemia in children with acute lymphoblastic leukaemia (ALL).,Steroids,CAUSES,Hypertriglyceridemia
25087182,BACKGROUND: Asparaginase and steroids can cause hypertriglyceridaemia in children with acute lymphoblastic leukaemia (ALL).,ASPARAGINASE,CAUSES,Hypertriglyceridemia
25087182,BACKGROUND: Asparaginase and steroids can cause hypertriglyceridaemia in children with acute lymphoblastic leukaemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25104793,"Glucocorticoids (e.g., dexamethasone) form a critical component of chemotherapy regimens for pediatric ALL, and the initial response to glucocorticoid therapy is a major prognostic factor, where resistance is predictive of poor outcome.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25250102,METHODS: Seventy-eight children with Acute Lymphoblastic Leukemia (ALL) have involved in this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25374219,PURPOSE: To investigate the impact of hyperglycemia during inductive treatment on the prognosis of acute lymphocytic leukemia (ALL) in children.,"Leukemia, Lymphocytic, Acute",AFFECTS,Hyperglycemia
25374219,PURPOSE: To investigate the impact of hyperglycemia during inductive treatment on the prognosis of acute lymphocytic leukemia (ALL) in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25374219,Impact of chemotherapy-related hyperglycemia on prognosis of child acute lymphocytic leukemia.,"Leukemia, Lymphocytic, Acute",AFFECTS,Hyperglycemia
25374219,Impact of chemotherapy-related hyperglycemia on prognosis of child acute lymphocytic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24076579,SUMMARY: A significant proportion of children with relapsed ALL are salvaged by risk-oriented therapies.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24076579,"With conventional therapies including HSCT, 40-50% of children with relapsed ALL can be rescued.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24076579,"PURPOSE OF REVIEW: To review and summarize the available evidence on factors predicting prognosis of children with relapsed acute lymphoblastic leukemia (ALL) and on the currently used treatment strategies, as well as on the most promising and innovative molecular or cellular therapies.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24330153,Host genome variations and risk of infections during induction treatment for childhood acute lymphoblastic leukaemia.,Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24395288,BACKGROUND: We sought to improve lumbar spine bone mineral density (LS-BMD) in long-term survivors of childhood acute lymphoblastic leukemia (ALL) using calcium and cholecalciferol supplementation.,Supplementation,ADMINISTERED_TO,Long-Term Survivors
24395288,BACKGROUND: We sought to improve lumbar spine bone mineral density (LS-BMD) in long-term survivors of childhood acute lymphoblastic leukemia (ALL) using calcium and cholecalciferol supplementation.,Supplementation,USES,Cholecalciferol
24395288,BACKGROUND: We sought to improve lumbar spine bone mineral density (LS-BMD) in long-term survivors of childhood acute lymphoblastic leukemia (ALL) using calcium and cholecalciferol supplementation.,Calcium,ADMINISTERED_TO,Long-Term Survivors
24395288,BACKGROUND: We sought to improve lumbar spine bone mineral density (LS-BMD) in long-term survivors of childhood acute lymphoblastic leukemia (ALL) using calcium and cholecalciferol supplementation.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
24608702,"Anxiety, depression, stress, and cortisol levels in mothers of children undergoing maintenance therapy for childhood acute lymphoblastic leukemia.",Stress,PROCESS_OF,Mothers
24608702,"Anxiety, depression, stress, and cortisol levels in mothers of children undergoing maintenance therapy for childhood acute lymphoblastic leukemia.",Maintenance therapy,TREATS,Child
24608702,Mothers of children with ALL experienced emotional symptoms many months after the initial diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24608702,Mothers of children with ALL experienced emotional symptoms many months after the initial diagnosis.,Symptoms,PROCESS_OF,Child
24608702,"Compared with mothers of healthy children, anxiety scores did not differ (P=.10), but depression scores were higher (P=.003) in mothers of children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24608702,"Anxiety, depression, stress, and cortisol levels in mothers of children undergoing maintenance therapy for childhood acute lymphoblastic leukemia.",Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24625531,"EMP1 silencing in six precursor-B ALL (BCP-ALL) and T-ALL cell lines induced apoptosis and cell-cycle arrest leading to 84.1+/-4.5% reduction in survival compared with non-silencing control transduced cells (non-silencing control short hairpin, shNSC) (P=0.014).",Silence,COEXISTS_WITH,"Leukemia, B-Cell, Acute"
24625531,"EMP1 silencing in six precursor-B ALL (BCP-ALL) and T-ALL cell lines induced apoptosis and cell-cycle arrest leading to 84.1+/-4.5% reduction in survival compared with non-silencing control transduced cells (non-silencing control short hairpin, shNSC) (P=0.014).","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
24625531,"EMP1 silencing in six precursor-B ALL (BCP-ALL) and T-ALL cell lines induced apoptosis and cell-cycle arrest leading to 84.1+/-4.5% reduction in survival compared with non-silencing control transduced cells (non-silencing control short hairpin, shNSC) (P=0.014).",Cell Cycle Arrest,AFFECTS,Cells
24625531,"EMP1 silencing in six precursor-B ALL (BCP-ALL) and T-ALL cell lines induced apoptosis and cell-cycle arrest leading to 84.1+/-4.5% reduction in survival compared with non-silencing control transduced cells (non-silencing control short hairpin, shNSC) (P=0.014).",Apoptosis,AFFECTS,Cells
24727996,"Ultimately, to improve the outcome for infants with ALL, key areas still to be addressed include identification and adaptation of novel prognostic markers and innovative therapies, establishing the role of hematopoietic stem cell transplantation in first complete remission, treatment strategies for relapsed/refractory disease and monitoring and timely intervention of late effects in survivors.",Late effect of,AFFECTS,Survivors
24727996,"Despite initial improvements in survival of infants with ALL since establishment of the first pediatric cooperative group ALL trials, the poor outcome has plateaued in recent years.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
24727996,Acute lymphoblastic leukemia (ALL) in infants has a significantly inferior outcome in comparison with older children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
24727996,The evolution of clinical trials for infant acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
24727996,"Ultimately, to improve the outcome for infants with ALL, key areas still to be addressed include identification and adaptation of novel prognostic markers and innovative therapies, establishing the role of hematopoietic stem cell transplantation in first complete remission, treatment strategies for relapsed/refractory disease and monitoring and timely intervention of late effects in survivors.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
24758291,METHODS: We quantified E2F3a expression at diagnosis in 148 children with ALL by real-time PCR.,Diagnosis,TREATS,Child
24758291,METHODS: We quantified E2F3a expression at diagnosis in 148 children with ALL by real-time PCR.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24758291,OBJECTIVES: To study E2F3a expression and its clinical significance in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24793957,IMPACT: Our findings implicate early life exposure to infections as protective factors for ALL in young children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24800034,"INTRODUCTION: Despite achievements in treating acute lymphoblastic leukemia (ALL) in children, its burden on the psychosocial status of patients is not well defined yet.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24800034,Emotional/Behavioral problems in children with acute lymphoblastic leukemia: a case-control study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24800034,Emotional/Behavioral problems in children with acute lymphoblastic leukemia: a case-control study.,Emotional problems,PROCESS_OF,Child
24800034,METHODS: We studied 100 children with ALL (aged 6-12 years) and 100 healthy sex/age peers as control group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25104793,"Fixed-ratio combination assays were performed against a broad panel of dexamethasone-resistant and -sensitive xenografts representative of BCP-ALL, T-cell ALL, and Mixed Lineage Leukemia-rearranged ALL, and synergy was observed in six of seven xenografts.",Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
23990388,Present work was carried out to study emotional and behavioral problems in children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23990388,Psychological morbidity in children undergoing chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23990388,Psychological morbidity in children undergoing chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Child
23990388,"Children with ALL scored higher on the conduct disorder, depression and physical illness with emotional problems.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23990388,Fourteen of 40 (35.0 %) children with ALL had a CPMS score of >=10 as against 11 of 50 (22.0 %) in the chronic disease group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23990388,"Children with ALL scored higher on the conduct disorder, depression and physical illness with emotional problems.",Emotional problems,PROCESS_OF,Child
23990388,Present work was carried out to study emotional and behavioral problems in children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy.,Emotional,PROCESS_OF,Child
23990388,Present work was carried out to study emotional and behavioral problems in children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24153013,We further integrated the miRNA-mRNA expression data of 37 children with BCP-ALL to identify candidate target genes for these three miRNAs.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
24153013,We further integrated the miRNA-mRNA expression data of 37 children with BCP-ALL to identify candidate target genes for these three miRNAs.,MicroRNAs,PART_OF,Child
24153013,We further integrated the miRNA-mRNA expression data of 37 children with BCP-ALL to identify candidate target genes for these three miRNAs.,MicroRNAs,ASSOCIATED_WITH,"Leukemia, B-Cell, Acute"
24158402,"METHODS: All children in the study had ALL or NHL, were in complete remission, and received HDMTX (3 or 5 g/m(2))+leucovorin.","Lymphoma, Non-Hodgkin's",PROCESS_OF,Child
24158402,"METHODS: All children in the study had ALL or NHL, were in complete remission, and received HDMTX (3 or 5 g/m(2))+leucovorin.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24158402,PURPOSE: Monitoring of plasma methotrexate (MTX) concentrations allows for therapeutic adjustments in treating childhood acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL) with high-dose MTX (HDMTX).,Methotrexate,TREATS,"Lymphoma, Non-Hodgkin's"
24158402,PURPOSE: Monitoring of plasma methotrexate (MTX) concentrations allows for therapeutic adjustments in treating childhood acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL) with high-dose MTX (HDMTX).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24308780,"In case of an immature ALL phenotype, ALDH activity might be an inherent characteristic of the whole leukemia and is not limited to a more immature subpopulation that could confer to resistance and increased MRD-levels during therapy.","Leukemia, Lymphocytic, Acute",ISA,leukemia
24344215,Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24474640,The aim of this study was to assess ASNS mRNA and protein expression in bone marrow cell populations of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24501014,METHODS: The authors analyzed the early response to TKIs during remission induction in children with Ph-positive ALL who were treated at St.,Remission Induction,TREATS,Child
24501014,METHODS: The authors analyzed the early response to TKIs during remission induction in children with Ph-positive ALL who were treated at St.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24501014,METHODS: The authors analyzed the early response to TKIs during remission induction in children with Ph-positive ALL who were treated at St.,Remission Induction,TREATS,"Leukemia, Lymphocytic, Acute"
24793952,"This loss occurs more often in children with ALL than in children with AML, solid tumors and Hodgkin disease.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24793952,"This loss occurs more often in children with ALL than in children with AML, solid tumors and Hodgkin disease.",Solid tumor,PROCESS_OF,Child
24793952,"This loss occurs more often in children with ALL than in children with AML, solid tumors and Hodgkin disease.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
24793952,"This loss occurs more often in children with ALL than in children with AML, solid tumors and Hodgkin disease.",Hodgkin Disease,PROCESS_OF,Child
24793952,"Whereas most studies to date focused on children with acute lymphoblastic leukemia (ALL), little data have been published on patients suffering from Hodgkin disease or from solid tumors.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24793952,"Whereas most studies to date focused on children with acute lymphoblastic leukemia (ALL), little data have been published on patients suffering from Hodgkin disease or from solid tumors.",Solid tumor,PROCESS_OF,Patients
24793952,"Whereas most studies to date focused on children with acute lymphoblastic leukemia (ALL), little data have been published on patients suffering from Hodgkin disease or from solid tumors.",Hodgkin Disease,PROCESS_OF,Patients
24910748,METHODS: This study used 63 peripheral blood and bone marrow (PB/BM) samples from children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24955371,Forty-three children with ALL and 14 age-matched healthy controls were included in the study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24955371,Forty-three children with ALL and 14 age-matched healthy controls were included in the study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Elderly
25422245,CONCLUSIONS: This study showed a relatively low prevalence of Philadelphia chromosome in Pakistani adults with ALL with an increase in frequency with age (p=0.003).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
25422245,BACKGROUND: The difference in prognosis of adult and childhood acute lymphoblastic leukemia (ALL) can be attributed largely to variation in cytogenetic abnormalities with age groups.,"Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,Chromosome abnormality
25422245,Frequency of chromosomal abnormalities in Pakistani adults with acute lymphoblastic leukemia.,Chromosome abnormality,PROCESS_OF,Adult
25422245,Frequency of chromosomal abnormalities in Pakistani adults with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
24183156,OBJECTIVES: To summarize the current knowledge about 1) cognitive changes associated with central nervous system-directed chemotherapy and cranial radiation among children with acute lymphoblastic leukemia and brain tumors and adult survivors; and 2) interventions designed to prevent or remediate the cognitive and academic problems associated with central nervous system-directed cancer treatment.,Therapeutic procedure,COEXISTS_WITH,Intervention regimes
24183156,OBJECTIVES: To summarize the current knowledge about 1) cognitive changes associated with central nervous system-directed chemotherapy and cranial radiation among children with acute lymphoblastic leukemia and brain tumors and adult survivors; and 2) interventions designed to prevent or remediate the cognitive and academic problems associated with central nervous system-directed cancer treatment.,Academic Problem,PROCESS_OF,Survivors
24183156,OBJECTIVES: To summarize the current knowledge about 1) cognitive changes associated with central nervous system-directed chemotherapy and cranial radiation among children with acute lymphoblastic leukemia and brain tumors and adult survivors; and 2) interventions designed to prevent or remediate the cognitive and academic problems associated with central nervous system-directed cancer treatment.,Brain Neoplasms,PROCESS_OF,Survivors
24183156,OBJECTIVES: To summarize the current knowledge about 1) cognitive changes associated with central nervous system-directed chemotherapy and cranial radiation among children with acute lymphoblastic leukemia and brain tumors and adult survivors; and 2) interventions designed to prevent or remediate the cognitive and academic problems associated with central nervous system-directed cancer treatment.,Brain Neoplasms,PROCESS_OF,Child
24183156,OBJECTIVES: To summarize the current knowledge about 1) cognitive changes associated with central nervous system-directed chemotherapy and cranial radiation among children with acute lymphoblastic leukemia and brain tumors and adult survivors; and 2) interventions designed to prevent or remediate the cognitive and academic problems associated with central nervous system-directed cancer treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
24183156,OBJECTIVES: To summarize the current knowledge about 1) cognitive changes associated with central nervous system-directed chemotherapy and cranial radiation among children with acute lymphoblastic leukemia and brain tumors and adult survivors; and 2) interventions designed to prevent or remediate the cognitive and academic problems associated with central nervous system-directed cancer treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24183156,OBJECTIVES: To summarize the current knowledge about 1) cognitive changes associated with central nervous system-directed chemotherapy and cranial radiation among children with acute lymphoblastic leukemia and brain tumors and adult survivors; and 2) interventions designed to prevent or remediate the cognitive and academic problems associated with central nervous system-directed cancer treatment.,Academic Problem,PROCESS_OF,Child
24232122,Promising data from recent clinical trials investigating VSLI in adults with ALL resulted in US Food and Drug Administration approval for use in patients with Philadelphia chromosome (t[9;22]/BCR-ABL1) (Ph)-negative (Ph-) disease.,vincristine sulfate liposomes,ISA,Injection procedure
24232122,Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.,Injection procedure,TREATS,"Leukemia, Lymphocytic, Acute"
24232122,Here we review the preclinical and clinical experience to date with VSLI for ALL.,Injection procedure,USES,vincristine sulfate liposomes
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,TREATS,"Leukemia, Lymphocytic, Acute"
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,TREATS,Hematologic Neoplasms
24232122,Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.,Injection procedure,USES,vincristine sulfate liposomes
24232122,Here we review the preclinical and clinical experience to date with VSLI for ALL.,vincristine sulfate liposomes,ISA,Injection procedure
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine sulfate liposomes,ISA,Injection procedure
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,TREATS,"Leukemia, Lymphocytic, Acute"
24232122,Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.,vincristine sulfate liposomes,ISA,Injection procedure
24232122,Here we review the preclinical and clinical experience to date with VSLI for ALL.,vincristine sulfate liposomes,TREATS,"Leukemia, Lymphocytic, Acute"
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",Hematologic Neoplasms,ISA,"Leukemia, Lymphocytic, Acute"
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",Injection procedure,USES,vincristine sulfate liposomes
24232122,Vincristine sulfate liposomal injection for acute lymphoblastic leukemia.,vincristine sulfate liposomes,TREATS,"Leukemia, Lymphocytic, Acute"
24232122,Promising data from recent clinical trials investigating VSLI in adults with ALL resulted in US Food and Drug Administration approval for use in patients with Philadelphia chromosome (t[9;22]/BCR-ABL1) (Ph)-negative (Ph-) disease.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,ISA,Injection procedure
24232122,Promising data from recent clinical trials investigating VSLI in adults with ALL resulted in US Food and Drug Administration approval for use in patients with Philadelphia chromosome (t[9;22]/BCR-ABL1) (Ph)-negative (Ph-) disease.,Philadelphia Chromosome,PART_OF,Patients
24232122,"VCR is particularly important for the treatment of acute lymphoblastic leukemia (ALL), a disease that accounts for approximately one-third of all childhood cancer diagnoses.",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,USES,vincristine sulfate liposomes
24232122,Promising data from recent clinical trials investigating VSLI in adults with ALL resulted in US Food and Drug Administration approval for use in patients with Philadelphia chromosome (t[9;22]/BCR-ABL1) (Ph)-negative (Ph-) disease.,Injection procedure,USES,vincristine sulfate liposomes
24232122,Promising data from recent clinical trials investigating VSLI in adults with ALL resulted in US Food and Drug Administration approval for use in patients with Philadelphia chromosome (t[9;22]/BCR-ABL1) (Ph)-negative (Ph-) disease.,vincristine sulfate liposomes,ADMINISTERED_TO,Adult
24232122,"VCR is particularly important for the treatment of acute lymphoblastic leukemia (ALL), a disease that accounts for approximately one-third of all childhood cancer diagnoses.",Vincristine,ISA,Therapeutic procedure
24232122,Here we review the preclinical and clinical experience to date with VSLI for ALL.,Injection procedure,TREATS,"Leukemia, Lymphocytic, Acute"
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,TREATS,Hematologic Neoplasms
24241962,High-dose methotrexate therapy (HD-MTX) has been well established for the treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Therapeutic procedure
24241962,High-dose methotrexate therapy (HD-MTX) has been well established for the treatment of childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24241962,High-dose methotrexate therapy (HD-MTX) has been well established for the treatment of childhood acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24241962,High-dose methotrexate therapy (HD-MTX) has been well established for the treatment of childhood acute lymphoblastic leukemia (ALL).,Therapeutic procedure,USES,Methotrexate
24267129,[Multi-center trial based on SCMC-ALL-2005 for children's acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24267134,"OBJECTIVE: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, while glucocorticoid (GC) is a critical component in multi-agent chemotherapy protocols currently used for the treatment of ALL.",Glucocorticoids,ISA,Chemotherapy-Oncologic Procedure
24267134,"OBJECTIVE: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, while glucocorticoid (GC) is a critical component in multi-agent chemotherapy protocols currently used for the treatment of ALL.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
24267134,"OBJECTIVE: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, while glucocorticoid (GC) is a critical component in multi-agent chemotherapy protocols currently used for the treatment of ALL.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
24370059,"What is more, the progress in the detection technique for minimal residual disease and pharmacogenomics help to estimate the sensitivity of chemotherapy and judge the prognosis, so as to provide the reliable objective foundation for the individualized therapy.In this review, the present states of individualized therapy in childhood acute lymphoblastic leukemia is discussed and summarized.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
24370059,"What is more, the progress in the detection technique for minimal residual disease and pharmacogenomics help to estimate the sensitivity of chemotherapy and judge the prognosis, so as to provide the reliable objective foundation for the individualized therapy.In this review, the present states of individualized therapy in childhood acute lymphoblastic leukemia is discussed and summarized.",Pharmacotherapy,METHOD_OF,Therapeutic procedure
24659638,These discoveries led to the development of efficient therapeutic regimens that greatly improved survival of children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24659638,Acute lymphoblastic leukemia (ALL) is the most common type of leukemia of childhood.,"Leukemia, Lymphocytic, Acute",ISA,leukemia
24762993,This study was aimed to compare the curative effect of BCH - 2003 protocol and CCLG - 2008 protocol for children with TEL-AML1 fusion gene positive childhood acute lymphoblastic leukemia (ALL) and to investigate the more suitable protocol for this subtype of childhood leukemia.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
24762993,"It is concluded that for children with TEL-AML1 fusion gene positive ALL, the induction of remission of BCH - 2003 protocol can decrease leukemic load more quickly than that of CCLG - 2008 protocol.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24762993,"The results showed that out of 204 children with TEL-AML1 fusion gene positive ALL, 134 and 70 patients were treated by BCH-2003 protocol and CCLG-2008 protocol respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24762993,"The results showed that out of 204 children with TEL-AML1 fusion gene positive ALL, 134 and 70 patients were treated by BCH-2003 protocol and CCLG-2008 protocol respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24762993,The clinical data for children with TEL-AML1 fusion gene positive ALL admitted from January 2003 to October 2010 in Hematology Center of Beijing Children's Hospital were collected.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24762995,"Four indexes were used to assess early response to treatment including response to prednisone on day 8 (D8-PR), percentage of lymphoblast in bone marrow on day 22 (D22-BM) and day 33 (D33-BM), the level of minimal residual disease (MRD) on day 33 (D33-MRD) by morphological and molecular biological method in 426 children with ALL.",Bone Marrow,LOCATION_OF,Prednisone
24762995,"Four indexes were used to assess early response to treatment including response to prednisone on day 8 (D8-PR), percentage of lymphoblast in bone marrow on day 22 (D22-BM) and day 33 (D33-BM), the level of minimal residual disease (MRD) on day 33 (D33-MRD) by morphological and molecular biological method in 426 children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24762995,"It is concluded that early response to treatment is an independent prognostic factor with important prognostic values, and it has important clinical guiding instructive significance for risk stratification in the treatment of children ALL.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
24762995,"It is concluded that early response to treatment is an independent prognostic factor with important prognostic values, and it has important clinical guiding instructive significance for risk stratification in the treatment of children ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24762995,"Four indexes were used to assess early response to treatment including response to prednisone on day 8 (D8-PR), percentage of lymphoblast in bone marrow on day 22 (D22-BM) and day 33 (D33-BM), the level of minimal residual disease (MRD) on day 33 (D33-MRD) by morphological and molecular biological method in 426 children with ALL.","Neoplasm, Residual",PROCESS_OF,Child
25150254,We prospectively studied the incidence and clinical course of hypertriglyceridemia and hypercholesterolemia during very prolonged use of asparaginase in relation to levels of asparaginase activity in children with acute lymphoblastic leukemia.,Hypertriglyceridemia,PROCESS_OF,Child
25150254,We prospectively studied the incidence and clinical course of hypertriglyceridemia and hypercholesterolemia during very prolonged use of asparaginase in relation to levels of asparaginase activity in children with acute lymphoblastic leukemia.,hypercholesterolemia,PROCESS_OF,Child
25150254,We prospectively studied the incidence and clinical course of hypertriglyceridemia and hypercholesterolemia during very prolonged use of asparaginase in relation to levels of asparaginase activity in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24019395,"CONCLUSIONS: Because of the methodologic strictness and high statistical power of the study, these results suggest that HTLV1 and MMTV-LV are not involved in the genesis of childhood ALL in Mexican children.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
24528220,Adolescents and adults with acute lymphoblastic leukemia/lymphoma (ALL) have better outcomes when treated using pediatric protocols compared with treatment using adult protocols.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
24528220,Adolescents and adults with acute lymphoblastic leukemia/lymphoma (ALL) have better outcomes when treated using pediatric protocols compared with treatment using adult protocols.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
24528220,Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol.,Lymphoma,PROCESS_OF,Adolescent
24528220,Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol.,Lymphoma,PROCESS_OF,Adult
24528220,Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
24528220,Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
24597986,"In conclusion, the RFC1 G80A polymorphism does not seem to be a good marker of MTX-related toxicity in pediatric ALL.",METHOTREXATE TOXICITY,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
24597986,The aim of this meta-analysis was to summarize all of these studies in order to clarify the correlation between the RFC1 G80A polymorphism and MTX toxicity in pediatric ALL.,METHOTREXATE TOXICITY,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
24597986,"We collected all studies that investigated the association of RFC1 G80A polymorphism and MTX toxicity in pediatric ALL, and found inconsistency among their results.",METHOTREXATE TOXICITY,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
24597986,"Abstract Methotrexate (MTX) is a key component of chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL), and enters the cell via active transport mediated by the reduced folate carrier (RFC1).",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24597986,"Abstract Methotrexate (MTX) is a key component of chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL), and enters the cell via active transport mediated by the reduced folate carrier (RFC1).",Methotrexate,ISA,Chemotherapy-Oncologic Procedure
24597986,"Abstract Methotrexate (MTX) is a key component of chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL), and enters the cell via active transport mediated by the reduced folate carrier (RFC1).",reduced folate carrier,INTERACTS_WITH,Methotrexate
24597986,"Abstract Methotrexate (MTX) is a key component of chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL), and enters the cell via active transport mediated by the reduced folate carrier (RFC1).",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24597986,Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.,METHOTREXATE TOXICITY,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
24805093,METHODS: Amoeboid neutrophils were examined in peripheral blood from 12 children with acute B-cell precursor lymphoblastic leukemia (BCP-ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24805093,METHODS: Amoeboid neutrophils were examined in peripheral blood from 12 children with acute B-cell precursor lymphoblastic leukemia (BCP-ALL).,B-Lymphocytes,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
24805093,BACKGROUND: We sometimes treat children with acute lymphoblastic leukemia in whom neutrophil function is impaired at diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24805093,BACKGROUND: We sometimes treat children with acute lymphoblastic leukemia in whom neutrophil function is impaired at diagnosis.,neutrophil,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
24998550,MATERIALS AND METHODS: This study was conducted on sixty patients with ALL and thirty children as controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24998550,MATERIALS AND METHODS: This study was conducted on sixty patients with ALL and thirty children as controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24998550,Correlation of inhibin and several antioxidants in children with acute lymphoblastic leukemia.,INHIBIN,TREATS,Child
24998550,Correlation of inhibin and several antioxidants in children with acute lymphoblastic leukemia.,Antioxidants,TREATS,Child
24998550,Correlation of inhibin and several antioxidants in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24998550,Correlation of inhibin and several antioxidants in children with acute lymphoblastic leukemia.,INHIBIN,TREATS,"Leukemia, Lymphocytic, Acute"
24998550,Correlation of inhibin and several antioxidants in children with acute lymphoblastic leukemia.,Antioxidants,TREATS,"Leukemia, Lymphocytic, Acute"
25125614,This study compares neurocognitive function and brain morphology in long-term adult survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy alone (n = 36) to those treated with cranial radiation therapy (n = 39) and to healthy control subjects (n = 23).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25125614,This study compares neurocognitive function and brain morphology in long-term adult survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy alone (n = 36) to those treated with cranial radiation therapy (n = 39) and to healthy control subjects (n = 23).,brain morphology,PROCESS_OF,Long-Term Survivors
25125614,This study compares neurocognitive function and brain morphology in long-term adult survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy alone (n = 36) to those treated with cranial radiation therapy (n = 39) and to healthy control subjects (n = 23).,Pharmacotherapy,compared_with,Radiation therapy
25125614,This study compares neurocognitive function and brain morphology in long-term adult survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy alone (n = 36) to those treated with cranial radiation therapy (n = 39) and to healthy control subjects (n = 23).,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25344183,OBJECTIVE: To study the long-term efficacy of CAMSBDH-ALL chemotherapy protocol for the treatment of childhood acute lymphoblastic leukemia (ALL).,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25344183,[Long-term efficacy of CAMSBDH-ALL chemotherapy protocol for the treatment of childhood acute lymphoblastic leukemia].,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23974192,"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.",BCR gene | BCR,NEG_PRODUCES,CRLF2
23974192,"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.",IKZF1,NEG_PRODUCES,CRLF2
23974192,"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
24025689,"BACKGROUND: Cytogenetic studies in Brazilian population about childhood acute lymphoblastic leukemia (ALL), the most common childhood malignancy, are scarce.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
24397596,Significance of CASP8AP2 and H2AFZ expression in survival and risk of relapse in children with acute lymphoblastic leukemia.,Child,LOCATION_OF,CASP8AP2
24397596,Significance of CASP8AP2 and H2AFZ expression in survival and risk of relapse in children with acute lymphoblastic leukemia.,Child,LOCATION_OF,H2AFZ
24397596,Significance of CASP8AP2 and H2AFZ expression in survival and risk of relapse in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24397596,We studied the expression of CASP8AP2 and H2AFZ associated with relapse and survival in bone marrow samples from newly diagnosed children with ALL.,Bone marrow specimen,LOCATION_OF,CASP8AP2
24397596,We studied the expression of CASP8AP2 and H2AFZ associated with relapse and survival in bone marrow samples from newly diagnosed children with ALL.,Bone marrow specimen,LOCATION_OF,H2AFZ
24397596,We studied the expression of CASP8AP2 and H2AFZ associated with relapse and survival in bone marrow samples from newly diagnosed children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24687836,PURPOSE: Previous studies regarding the influence of weight on event-free survival (EFS) and treatment-related toxicity (TRT) in childhood acute lymphoblastic leukemia (ALL) considered only weight at diagnosis.,Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
24774509,Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.,gene polymorphism,PROCESS_OF,Child
24774509,Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24774509,CONCLUSION: TMPT genotyping appears an important tool to further optimize 6-MP treatment design in Chilean patients with ALL.,6-Mercaptopurine,TREATS,Patients
24774509,CONCLUSION: TMPT genotyping appears an important tool to further optimize 6-MP treatment design in Chilean patients with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24774509,CONCLUSION: TMPT genotyping appears an important tool to further optimize 6-MP treatment design in Chilean patients with ALL.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
24774509,We determined the prevalence of the major genetic polymorphisms in 6-MP metabolizing enzymes in Chilean children with ALL.,"Polymorphism, Genetic",PROCESS_OF,Child
24774509,We determined the prevalence of the major genetic polymorphisms in 6-MP metabolizing enzymes in Chilean children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24998352,"Here, we aimed to identify proteins in BM plasma of children with ALL that may contribute to ALL aggressiveness and/or the microenvironment-mediated survival of ALL cells.",Plasma,PART_OF,Bone Marrow
24998352,"Here, we aimed to identify proteins in BM plasma of children with ALL that may contribute to ALL aggressiveness and/or the microenvironment-mediated survival of ALL cells.",Plasma,LOCATION_OF,Proteins
24998352,"Here, we aimed to identify proteins in BM plasma of children with ALL that may contribute to ALL aggressiveness and/or the microenvironment-mediated survival of ALL cells.",Proteins,AFFECTS,Cells
24998352,"Here, we aimed to identify proteins in BM plasma of children with ALL that may contribute to ALL aggressiveness and/or the microenvironment-mediated survival of ALL cells.",Proteins,PREDISPOSES,Aggressive behavior
24998352,"Here, we aimed to identify proteins in BM plasma of children with ALL that may contribute to ALL aggressiveness and/or the microenvironment-mediated survival of ALL cells.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24998352,"Here, we aimed to identify proteins in BM plasma of children with ALL that may contribute to ALL aggressiveness and/or the microenvironment-mediated survival of ALL cells.",Plasma,PART_OF,Child
25060657,"In this study, the rs4946936 polymorphism located in the 3'UTR of FOXO3a was selected to evaluate its relationship with a risk for ALL in Chinese children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25060657,"In this study, the rs4946936 polymorphism located in the 3'UTR of FOXO3a was selected to evaluate its relationship with a risk for ALL in Chinese children.",3' Untranslated Regions,PART_OF,FOXO3A gene | FOXO3
25190166,"CONCLUSION: The reassignment of risk group in low and median risk groups children with acute lymphoblastic leukemia by MRD did not increase the rate of serious infection but could reduce the relapse rate and mortality, and was beneficial to increase the patients' OS, EFS and DFS.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25309913,"EBV, HCMV, HHV6, and HHV7 screening in bone marrow samples from children with acute lymphoblastic leukemia.",Bone marrow specimen,LOCATION_OF,"Herpesvirus 6, Human"
25309913,"EBV, HCMV, HHV6, and HHV7 screening in bone marrow samples from children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25344183,METHODS: Three hundred and eighteen children who were newly diagnosed with ALL between January 1999 and December 2007 were enrolled in this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25349177,We analyzed MDF of end-induction bone marrow samples from a historical cohort of 198 children newly diagnosed with B-precursor ALL (BP-ALL) and treated with Children's Oncology Group induction regimens.,Bone marrow specimen,LOCATION_OF,milk-derived factor
25349177,We analyzed MDF of end-induction bone marrow samples from a historical cohort of 198 children newly diagnosed with B-precursor ALL (BP-ALL) and treated with Children's Oncology Group induction regimens.,cohort,LOCATION_OF,milk-derived factor
25349177,We analyzed MDF of end-induction bone marrow samples from a historical cohort of 198 children newly diagnosed with B-precursor ALL (BP-ALL) and treated with Children's Oncology Group induction regimens.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25349177,Obesity is associated with poorer event-free survival (EFS) in pediatric acute lymphoblastic leukemia (ALL).,Obesity,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
25349177,Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia.,leukemia,COEXISTS_WITH,Obesity
25349177,Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25349177,Obese children with newly diagnosed BP-ALL are at increased risk for positive end-induction MRD and poorer EFS.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25349177,Obese children with newly diagnosed BP-ALL are at increased risk for positive end-induction MRD and poorer EFS.,Obesity,PROCESS_OF,Child
26322196,CONCLUSION: Positive bias memory can explain low depression and lack of symptoms of post traumatic stress disorder in children with ALL.,"Stress Disorders, Post-Traumatic",PROCESS_OF,Child
26322196,CONCLUSION: Positive bias memory can explain low depression and lack of symptoms of post traumatic stress disorder in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26322196,"For this purpose, 78 children (33 girls and 45 boys aged 3 to 12 years) with pediatric acute lymphoblastic leukemia (ALL), and 89 healthy children (52 girls and 37 boys aged3 to 12 years) participated in this study.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
26322196,Cognitive Emotion Regulation in Children with Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24237708,"METHODS: In the present case-control study, 35 children with ALL and 48 healthy adult blood donors, all originating from the island of Crete (Greece), were screened for the presence of the RFC G80A polymorphism, using PCR/RFLP techniques.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24237708,The effect of RFC G80A polymorphism in Cretan children with acute lymphoblastic leukemia and its interaction with MTHFR C677T and A1298C polymorphisms.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24237708,"METHODS: In the present case-control study, 35 children with ALL and 48 healthy adult blood donors, all originating from the island of Crete (Greece), were screened for the presence of the RFC G80A polymorphism, using PCR/RFLP techniques.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Blood donor
24237708,"METHODS: In the present case-control study, 35 children with ALL and 48 healthy adult blood donors, all originating from the island of Crete (Greece), were screened for the presence of the RFC G80A polymorphism, using PCR/RFLP techniques.",Well adult,PROCESS_OF,Blood donor
24237708,"METHODS: In the present case-control study, 35 children with ALL and 48 healthy adult blood donors, all originating from the island of Crete (Greece), were screened for the presence of the RFC G80A polymorphism, using PCR/RFLP techniques.",Crete,ISA,Greece
24237708,INTRODUCTION: The association between the risk of acute lymphoblastic leukemia (ALL) in children and enzymes involved in the folate metabolism has been under investigation lately.,Enzymes,AFFECTS,folic acid metabolism
24237708,INTRODUCTION: The association between the risk of acute lymphoblastic leukemia (ALL) in children and enzymes involved in the folate metabolism has been under investigation lately.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24237708,The effect of RFC G80A polymorphism in Cretan children with acute lymphoblastic leukemia and its interaction with MTHFR C677T and A1298C polymorphisms.,gene polymorphism,AFFECTS,Child
24737427,SODD expression was high in the ALL children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25047756,OBJECTIVES: To determine the behavioural impact of chemotherapy in survivors of acute lymphoblastic leukaemia (ALL) treated with chemotherapy only and to identify treatment-related or sociodemography-related factors that might be associated with behavioural outcome.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25047756,OBJECTIVES: To determine the behavioural impact of chemotherapy in survivors of acute lymphoblastic leukaemia (ALL) treated with chemotherapy only and to identify treatment-related or sociodemography-related factors that might be associated with behavioural outcome.,Pharmacotherapy,TREATS,Survivors
25523574,METHODS: The clinical data of 183 children with newly-diagnosed acute B-ALL and who accepted MRD detection between October 2010 and March 2012 was retrospectively reviewed.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
25523574,"The result of MRD detection, as prednisone sensitivity and bone marrow morphology on the 15th day, is also a independent prognostic factor in children with B-ALL.",Detection,TREATS,Child
25523574,"The result of MRD detection, as prednisone sensitivity and bone marrow morphology on the 15th day, is also a independent prognostic factor in children with B-ALL.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
25523574,"The result of MRD detection, as prednisone sensitivity and bone marrow morphology on the 15th day, is also a independent prognostic factor in children with B-ALL.",Detection,TREATS,"Leukemia, B-Cell, Acute"
25523574,"The Cox's proportional hazards regression analysis showed that insensitive reaction for prednisone (RR=1.005, 95%CI: 0.864-1.170, P=0.032), bone marrow morphology that did not meet M1 on the 15th day (RR=6.454, 95%CI: 2.191-19.01, P=0.002) and MRD>=0.01% (RR=1.923, 95%CI: 0.750-4.933, P=0.043) were risk factors for relapse in children with B-ALL.","Neoplasm, Residual",PROCESS_OF,Child
25523574,"The Cox's proportional hazards regression analysis showed that insensitive reaction for prednisone (RR=1.005, 95%CI: 0.864-1.170, P=0.032), bone marrow morphology that did not meet M1 on the 15th day (RR=6.454, 95%CI: 2.191-19.01, P=0.002) and MRD>=0.01% (RR=1.923, 95%CI: 0.750-4.933, P=0.043) were risk factors for relapse in children with B-ALL.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
27997540,T cell ALL (T-ALL) represents about 15% of pediatric ALL cases and is considered a high-risk disease.,Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
27997540,BACKGROUND: Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the leading cause of cancer-related mortality in children.,Malignant Childhood Neoplasm,PROCESS_OF,Child
27997540,BACKGROUND: Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the leading cause of cancer-related mortality in children.,"Leukemia, Lymphocytic, Acute, L1",ISA,Malignant Childhood Neoplasm
27997540,BACKGROUND: Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the leading cause of cancer-related mortality in children.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
28000427,"Our analyses included frequencies and AAIR, together with age-specific incidence rates for all leukemias, acute lymphoblastic leukemia, and acute myeloid leukemia.","Leukemia, Lymphocytic, Acute",ISA,leukemia
28000427,"Our analyses included frequencies and AAIR, together with age-specific incidence rates for all leukemias, acute lymphoblastic leukemia, and acute myeloid leukemia.","Leukemia, Myelocytic, Acute",ISA,leukemia
28003275,"Remarkably, more than half of TP53 mutations in low-hypodiploid ALL in children are present in nontumor cells, indicating that low-hypodiploid ALL is a manifestation of Li-Fraumeni syndrome.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28003275,"Remarkably, more than half of TP53 mutations in low-hypodiploid ALL in children are present in nontumor cells, indicating that low-hypodiploid ALL is a manifestation of Li-Fraumeni syndrome.",TP53 gene | TP53,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
28003275,"Although alterations of TP53 are common in many tumors, they are infrequent in ALL, with the exception of two ALL subtypes associated with poor outcome: relapsed disease and ALL with hypodiploidy.",TP53 gene | TP53,ASSOCIATED_WITH,Neoplasm
28003275,"Although alterations of TP53 are common in many tumors, they are infrequent in ALL, with the exception of two ALL subtypes associated with poor outcome: relapsed disease and ALL with hypodiploidy.","Leukemia, Lymphocytic, Acute",ISA,Neoplasm
28003275,"Although alterations of TP53 are common in many tumors, they are infrequent in ALL, with the exception of two ALL subtypes associated with poor outcome: relapsed disease and ALL with hypodiploidy.",TP53 gene | TP53,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
28003275,Acute lymphoblastic leukemia (ALL) is an aggressive neoplasm of B- or T-lymphoid progenitors and is the commonest childhood tumor.,"Leukemia, Lymphocytic, Acute",ISA,Neoplasm
28004528,"In the Nordic Society of Paediatric Haematology and Oncology ALL-2008 treatment protocol, treatment stratification in B-lineage ALL is based on results of minimal residual disease (MRD) analysis with fluorescence-activated cell sorting (FACS).",Treatment Protocols,TREATS,"Leukemia, B-Cell, Acute"
28028966,"Bone marrow and blood samples were obtained from 30 children with newly-diagnosed ALL, who were seen at the Hematology-Oncology Service, Hospital para el Nino (HPN), Toluca, Mexico, from 20142015.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28028966,"In children with acute lymphoblastic leukemia (ALL), the activity of glycogen synthase kinase (GSK-3beta) has been associated with changes in the transcriptional activity and expression of nuclear factor kappa beta (NFKB) in the mononuclear cells of bone marrow.",MONONUCLEAR CELLS,PART_OF,Bone Marrow
28028966,"In children with acute lymphoblastic leukemia (ALL), the activity of glycogen synthase kinase (GSK-3beta) has been associated with changes in the transcriptional activity and expression of nuclear factor kappa beta (NFKB) in the mononuclear cells of bone marrow.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28028966,"In children with acute lymphoblastic leukemia (ALL), the activity of glycogen synthase kinase (GSK-3beta) has been associated with changes in the transcriptional activity and expression of nuclear factor kappa beta (NFKB) in the mononuclear cells of bone marrow.",MONONUCLEAR CELLS,LOCATION_OF,NF-kappa B
28028966,BACKGROUND: Acute lymphocytic leukemia (ALL) is the most common hematologic malignancy in early childhood.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
26773735,"CONCLUSIONS: Children with ALL experienced decreasing treatment-related anxiety, procedure-related anxiety, and pain during the first year of treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26773735,"CONCLUSIONS: Children with ALL experienced decreasing treatment-related anxiety, procedure-related anxiety, and pain during the first year of treatment.",Pain,PROCESS_OF,Child
26892073,The purpose of this case report was to examine the effectiveness of incorporating a play-based physical therapy (PT) intervention programme to improve functional mobility for an inpatient with relapsed ALL undergoing chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,inpatient
26892073,The purpose of this case report was to examine the effectiveness of incorporating a play-based physical therapy (PT) intervention programme to improve functional mobility for an inpatient with relapsed ALL undergoing chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26892073,The Effectiveness of Incorporating a Play-based Intervention to Improve Functional Mobility for a Child with Relapsed Acute Lymphoblastic Leukaemia: A Case Report.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26892073,DISCUSSION: This case report suggests that incorporating a play-based PT intervention programme could be physically tolerable and functionally beneficial for a young child with relapsed ALL undergoing inpatient chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young child
26892073,DISCUSSION: This case report suggests that incorporating a play-based PT intervention programme could be physically tolerable and functionally beneficial for a young child with relapsed ALL undergoing inpatient chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26892465,BACKGROUND: Acute lymphoblastic leukemia (ALL) is an aggressive malignant disorder of lymphoid progenitor cells in both children and adults.,Lymphoid Cells,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
26892465,"Although improvements in contemporary therapy and development of new treatment strategies have led to dramatic increases in the cure rate in children with ALL, the relapse rate remains high and the prognosis of relapsed childhood ALL is poor.",Therapeutic procedure,TREATS,Child
26892465,BACKGROUND: Acute lymphoblastic leukemia (ALL) is an aggressive malignant disorder of lymphoid progenitor cells in both children and adults.,"Leukemia, Lymphocytic, Acute",ISA,Disease
26892465,"Although improvements in contemporary therapy and development of new treatment strategies have led to dramatic increases in the cure rate in children with ALL, the relapse rate remains high and the prognosis of relapsed childhood ALL is poor.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26892465,BACKGROUND: Acute lymphoblastic leukemia (ALL) is an aggressive malignant disorder of lymphoid progenitor cells in both children and adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26892465,"Although improvements in contemporary therapy and development of new treatment strategies have led to dramatic increases in the cure rate in children with ALL, the relapse rate remains high and the prognosis of relapsed childhood ALL is poor.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
26892465,BACKGROUND: Acute lymphoblastic leukemia (ALL) is an aggressive malignant disorder of lymphoid progenitor cells in both children and adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
26892465,BACKGROUND: Acute lymphoblastic leukemia (ALL) is an aggressive malignant disorder of lymphoid progenitor cells in both children and adults.,Disease,PROCESS_OF,Child
26892465,BACKGROUND: Acute lymphoblastic leukemia (ALL) is an aggressive malignant disorder of lymphoid progenitor cells in both children and adults.,Disease,PROCESS_OF,Adult
26892465,BACKGROUND: Acute lymphoblastic leukemia (ALL) is an aggressive malignant disorder of lymphoid progenitor cells in both children and adults.,Lymphoid Cells,LOCATION_OF,Disease
27903646,"Through comprehensive whole transcriptome sequencing of 231 children with acute lymphoblastic leukemia (ALL), we identified 58 putative functional and predominant fusion genes in 54.1% of patients (n=125), 31 of which have not been reported previously.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27907849,"At >/=2years post-treatment, we examined the association of DHEAS with attention outcomes in 35 male and 34 female long-term survivors of childhood ALL (mean[standard deviation] age at evaluation 14.5[4.7] years; 7.5[1.9] years post-diagnosis) who were treated with only chemotherapy and without prophylactic cranial irradiation.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27907849,Association between dehydroepiandrosterone-sulfate and attention in long-term survivors of childhood acute lymphoblastic leukemia treated with only chemotherapy.,Dehydroepiandrosterone Sulfate,TREATS,Long-Term Survivors
27907849,Association between dehydroepiandrosterone-sulfate and attention in long-term survivors of childhood acute lymphoblastic leukemia treated with only chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27907849,"At >/=2years post-treatment, we examined the association of DHEAS with attention outcomes in 35 male and 34 female long-term survivors of childhood ALL (mean[standard deviation] age at evaluation 14.5[4.7] years; 7.5[1.9] years post-diagnosis) who were treated with only chemotherapy and without prophylactic cranial irradiation.",Prophylactic Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27922922,A Sleep Hygiene and Relaxation Intervention for Children With Acute Lymphoblastic Leukemia: A Pilot Randomized Controlled Trial.,Intervention regimes,TREATS,Child
27922922,No studies have tested these interventions to improve sleep and fatigue for children with acute lymphoblastic leukemia (ALL) in the home setting.,Intervention regimes,TREATS,Child
27922922,No studies have tested these interventions to improve sleep and fatigue for children with acute lymphoblastic leukemia (ALL) in the home setting.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27922922,A Sleep Hygiene and Relaxation Intervention for Children With Acute Lymphoblastic Leukemia: A Pilot Randomized Controlled Trial.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27966457,"In addition, MTHFR 1298 polymorphisms were protective against ALL and acute myeloid leukemia in European children, and in chronic myeloid leukemia in all adults worldwide and American adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
27966457,"In addition, MTHFR 1298 polymorphisms were protective against ALL and acute myeloid leukemia in European children, and in chronic myeloid leukemia in all adults worldwide and American adults.","Myeloid Leukemia, Chronic",PROCESS_OF,Child
27966457,"In addition, MTHFR 1298 polymorphisms were protective against ALL and acute myeloid leukemia in European children, and in chronic myeloid leukemia in all adults worldwide and American adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
27966457,"In addition, MTHFR 1298 polymorphisms were protective against ALL and acute myeloid leukemia in European children, and in chronic myeloid leukemia in all adults worldwide and American adults.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
27966457,"In addition, MTHFR 1298 polymorphisms were protective against ALL and acute myeloid leukemia in European children, and in chronic myeloid leukemia in all adults worldwide and American adults.","Leukemia, Myelocytic, Acute",PROCESS_OF,Adult
27966457,"In addition, MTHFR 1298 polymorphisms were protective against ALL and acute myeloid leukemia in European children, and in chronic myeloid leukemia in all adults worldwide and American adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27966457,"In addition, MTHFR 1298 polymorphisms were protective against ALL and acute myeloid leukemia in European children, and in chronic myeloid leukemia in all adults worldwide and American adults.","Leukemia, Myelocytic, Acute",PROCESS_OF,Adult
27966457,"The results revealed that, in European populations; childhood populations; children from Europe, East Asia, and America; and children with acute lymphocytic leukemia (ALL), MTHFR 677 polymorphisms (both TT and CT types together and individually) are protective, while CC wildtype was leukemogenic.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27966457,"The results revealed that, in European populations; childhood populations; children from Europe, East Asia, and America; and children with acute lymphocytic leukemia (ALL), MTHFR 677 polymorphisms (both TT and CT types together and individually) are protective, while CC wildtype was leukemogenic.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27966457,"In addition, MTHFR 1298 polymorphisms were protective against ALL and acute myeloid leukemia in European children, and in chronic myeloid leukemia in all adults worldwide and American adults.","Myeloid Leukemia, Chronic",PROCESS_OF,Adult
27966457,"In addition, MTHFR 1298 polymorphisms were protective against ALL and acute myeloid leukemia in European children, and in chronic myeloid leukemia in all adults worldwide and American adults.","Myeloid Leukemia, Chronic",PROCESS_OF,Adult
27979823,"We investigated infections at diagnosis and then assessed the timing of infection at birth in children with ALL and age, gender, and ethnicity matched controls to identify potential causal initiating infections.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27979823,"We investigated infections at diagnosis and then assessed the timing of infection at birth in children with ALL and age, gender, and ethnicity matched controls to identify potential causal initiating infections.",Birth,PROCESS_OF,Ethnic group
27979823,"We investigated infections at diagnosis and then assessed the timing of infection at birth in children with ALL and age, gender, and ethnicity matched controls to identify potential causal initiating infections.",Birth,PROCESS_OF,Child
27979823,This is the first study to suggest that congenital CMV infection is a risk factor for childhood ALL and is more prominent in Hispanic children.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
27979823,"We investigated infections at diagnosis and then assessed the timing of infection at birth in children with ALL and age, gender, and ethnicity matched controls to identify potential causal initiating infections.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Ethnic group
27980230,"Childhood acute lymphoblastic leukemia (cALL) is the most common pediatric cancer and, despite an 85% cure rate, still represents a major cause of disease-related death in children.",Cessation of life,PROCESS_OF,Child
27980230,"Childhood acute lymphoblastic leukemia (cALL) is the most common pediatric cancer and, despite an 85% cure rate, still represents a major cause of disease-related death in children.","Leukemia, Lymphocytic, Acute, L1",ISA,Malignant Childhood Neoplasm
26761625,"Changes in therapy according to decade included reduced rates of cranial radiotherapy for acute lymphoblastic leukemia (85% in the 1970s, 51% in the 1980s, and 19% in the 1990s), of abdominal radiotherapy for Wilms' tumor (78%, 53%, and 43%, respectively), of chest radiotherapy for Hodgkin's lymphoma (87%, 79%, and 61%, respectively), and of anthracycline exposure.",Breast radiotherapies,TREATS,Hodgkin Disease
26761625,"Changes in therapy according to decade included reduced rates of cranial radiotherapy for acute lymphoblastic leukemia (85% in the 1970s, 51% in the 1980s, and 19% in the 1990s), of abdominal radiotherapy for Wilms' tumor (78%, 53%, and 43%, respectively), of chest radiotherapy for Hodgkin's lymphoma (87%, 79%, and 61%, respectively), and of anthracycline exposure.",Radiation therapy,TREATS,Nephroblastoma
26761625,"Changes in therapy according to decade included reduced rates of cranial radiotherapy for acute lymphoblastic leukemia (85% in the 1970s, 51% in the 1980s, and 19% in the 1990s), of abdominal radiotherapy for Wilms' tumor (78%, 53%, and 43%, respectively), of chest radiotherapy for Hodgkin's lymphoma (87%, 79%, and 61%, respectively), and of anthracycline exposure.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
26794706,"We analyzed the frequency of early complications in children with ALL and AML presenting with white blood cell (WBC) count >100x10/L, and the type and frequency of complications related to leukapheresis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26794706,"We analyzed the frequency of early complications in children with ALL and AML presenting with white blood cell (WBC) count >100x10/L, and the type and frequency of complications related to leukapheresis.",Early complication,PROCESS_OF,Child
26794706,Hyperleukocytosis in children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) is associated with early morbidity and mortality.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
26794706,Hyperleukocytosis in children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) is associated with early morbidity and mortality.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26826739,"Allogeneic stem cell transplantations are indicated in high-risk subgroups of infant ALL (age below 6 months, high hyperleucocytosis >300.10(9)/L, MLL-rearrangement, initial poor prednisone response).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
26858334,PURPOSE: Survivors of childhood acute lymphoblastic leukemia (ALL) treated with CNS-directed chemotherapy are at risk for neurocognitive deficits.,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26858334,Age at diagnosis and patient sex may alter neurocognitive development in survivors of childhood ALL treated with chemotherapy-only protocols.,Diagnosis,TREATS,Survivors
26858334,Age at diagnosis and patient sex may alter neurocognitive development in survivors of childhood ALL treated with chemotherapy-only protocols.,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26878433,Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.,Allopurinol,TREATS,Child
26878433,Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.,Pancreatitis,PROCESS_OF,Child
26878433,Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26878433,Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.,Allopurinol,TREATS,Pancreatitis
26878433,Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.,Allopurinol,TREATS,"Leukemia, Lymphocytic, Acute"
26985820,BACKGROUND: Childhood acute lymphoblastic leukaemia (ALL) is the most common malignancy in children.,Malignant Neoplasms,PROCESS_OF,Child
26985820,BACKGROUND: Childhood acute lymphoblastic leukaemia (ALL) is the most common malignancy in children.,"Leukemia, Lymphocytic, Acute, L1",ISA,Malignant Neoplasms
26985820,BACKGROUND: Childhood acute lymphoblastic leukaemia (ALL) is the most common malignancy in children.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
27053012,Acute lymphoblastic leukemia (ALL) is the most commonly diagnosed malignancy in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
27053012,Acute lymphoblastic leukemia (ALL) is the most commonly diagnosed malignancy in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27053012,The results of the present study provided novel insights into the gene expression patterns in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27053012,"To improve current understanding of the underlying molecular mechanisms of ALL, the present study profiled genomewide digital gene expression (DGE) in a population of children with ALL in China.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27053012,Acute lymphoblastic leukemia (ALL) is the most commonly diagnosed malignancy in children.,Malignant Neoplasms,PROCESS_OF,Child
27063976,"BACKGROUND: Results from case-control studies have shown an increased risk of acute lymphoblastic leukaemia (ALL) in young children born by caesarean delivery, and prelabour caesarean delivery in particular; however, an association of method of delivery with childhood leukaemia subtypes has yet to be established.",Cesarean section (finding),PREDISPOSES,"Leukemia, Lymphocytic, Acute"
27063976,"We used multivariable logistic regression models, adjusted for child's birthweight, sex, age, ethnic origin, parental education, maternal age, and study, to estimate odds ratios (ORs) and 95% CIs for the risk of ALL and acute myeloid leukaemia (AML) in children aged 0-14 years at diagnosis.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
27063976,"BACKGROUND: Results from case-control studies have shown an increased risk of acute lymphoblastic leukaemia (ALL) in young children born by caesarean delivery, and prelabour caesarean delivery in particular; however, an association of method of delivery with childhood leukaemia subtypes has yet to be established.",Cesarean section (finding),PREDISPOSES,"Leukemia, Lymphocytic, Acute"
27063976,"We used multivariable logistic regression models, adjusted for child's birthweight, sex, age, ethnic origin, parental education, maternal age, and study, to estimate odds ratios (ORs) and 95% CIs for the risk of ALL and acute myeloid leukaemia (AML) in children aged 0-14 years at diagnosis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27063976,"BACKGROUND: Results from case-control studies have shown an increased risk of acute lymphoblastic leukaemia (ALL) in young children born by caesarean delivery, and prelabour caesarean delivery in particular; however, an association of method of delivery with childhood leukaemia subtypes has yet to be established.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27063976,"We used multivariable logistic regression models, adjusted for child's birthweight, sex, age, ethnic origin, parental education, maternal age, and study, to estimate odds ratios (ORs) and 95% CIs for the risk of ALL and acute myeloid leukaemia (AML) in children aged 0-14 years at diagnosis.",ORALIT,PREDISPOSES,"Leukemia, Myelocytic, Acute"
27063976,"We used multivariable logistic regression models, adjusted for child's birthweight, sex, age, ethnic origin, parental education, maternal age, and study, to estimate odds ratios (ORs) and 95% CIs for the risk of ALL and acute myeloid leukaemia (AML) in children aged 0-14 years at diagnosis.",ORALIT,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
27063976,"We used multivariable logistic regression models, adjusted for child's birthweight, sex, age, ethnic origin, parental education, maternal age, and study, to estimate odds ratios (ORs) and 95% CIs for the risk of ALL and acute myeloid leukaemia (AML) in children aged 0-14 years at diagnosis.",CISH,PREDISPOSES,"Leukemia, Myelocytic, Acute"
27063976,"We used multivariable logistic regression models, adjusted for child's birthweight, sex, age, ethnic origin, parental education, maternal age, and study, to estimate odds ratios (ORs) and 95% CIs for the risk of ALL and acute myeloid leukaemia (AML) in children aged 0-14 years at diagnosis.",CISH,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
27084898,We report a young man presenting with invasive breast cancer 19 years after receiving radiation therapy and bone marrow transplant for acute lymphocytic leukaemia in childhood.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
27084898,We report a young man presenting with invasive breast cancer 19 years after receiving radiation therapy and bone marrow transplant for acute lymphocytic leukaemia in childhood.,Bone Marrow Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
27094381,Influence Of Folate-Related Gene Polymorphisms On High-Dose Methotrexate-Related Toxicity And Prognosis In Turkish Children With Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27094381,"The aims of this study were to i) investigate the frequencies of polymorphisms in the genes for thymidilate synthase (TS), methionine synthase reductase (MTRR), and methylene tetrahydrofolate reductase (MTHFR) in Turkish children with ALL, and ii) assess for associations between these polymorphisms and HD-MTX-related toxicity and leukemia prognosis in this patient group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27094381,"OBJECTIVE: High-dose methotrexate (HD-MTX) is widely used in the consolidation phase of childhood acute lymphoblastic leukemia (ALL), but the roles that polymorphisms in folate-related genes (FRG) play in HD-MTX toxicity and prognosis in children with ALL are not well known.",Methotrexate,TREATS,Child
27094381,"OBJECTIVE: High-dose methotrexate (HD-MTX) is widely used in the consolidation phase of childhood acute lymphoblastic leukemia (ALL), but the roles that polymorphisms in folate-related genes (FRG) play in HD-MTX toxicity and prognosis in children with ALL are not well known.","Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,METHOTREXATE TOXICITY
27094381,"OBJECTIVE: High-dose methotrexate (HD-MTX) is widely used in the consolidation phase of childhood acute lymphoblastic leukemia (ALL), but the roles that polymorphisms in folate-related genes (FRG) play in HD-MTX toxicity and prognosis in children with ALL are not well known.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27094381,CONCLUSION: The frequencies of FRG polymorphisms in Turkish children with ALL are similar to those reported in other Caucasian populations.,gene polymorphism,PROCESS_OF,Child
27094381,"OBJECTIVE: High-dose methotrexate (HD-MTX) is widely used in the consolidation phase of childhood acute lymphoblastic leukemia (ALL), but the roles that polymorphisms in folate-related genes (FRG) play in HD-MTX toxicity and prognosis in children with ALL are not well known.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
27094381,CONCLUSION: The frequencies of FRG polymorphisms in Turkish children with ALL are similar to those reported in other Caucasian populations.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27094381,Influence Of Folate-Related Gene Polymorphisms On High-Dose Methotrexate-Related Toxicity And Prognosis In Turkish Children With Acute Lymphoblastic Leukemia.,METHOTREXATE TOXICITY,PROCESS_OF,Child
27094381,"The aims of this study were to i) investigate the frequencies of polymorphisms in the genes for thymidilate synthase (TS), methionine synthase reductase (MTRR), and methylene tetrahydrofolate reductase (MTHFR) in Turkish children with ALL, and ii) assess for associations between these polymorphisms and HD-MTX-related toxicity and leukemia prognosis in this patient group.","Polymorphism, Genetic",PROCESS_OF,Child
26790447,This case-control study was done on 110 children diagnosed with ALL and 120 healthy children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26790447,This case-control study was done on 110 children diagnosed with ALL and 120 healthy children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26824435,Taken together our data suggest that the hypothalamus is involved in the metabolic consequences after CRT in ALL survivors.,Radiation therapy,TREATS,Survivors
26824435,Taken together our data suggest that the hypothalamus is involved in the metabolic consequences after CRT in ALL survivors.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
26824435,Taken together our data suggest that the hypothalamus is involved in the metabolic consequences after CRT in ALL survivors.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
26824435,Metabolic complications are prevalent in individuals treated with cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia (ALL).,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26824435,Metabolic complications are prevalent in individuals treated with cranial radiotherapy (CRT) for childhood acute lymphoblastic leukemia (ALL).,Radiation therapy,TREATS,Individual
26825627,"We evaluated antithrombin III (ATIII), protein C, protein S, and D-dimer in 60 children with ALL compared with 30 healthy controls, and patients were followed up for 12 months for detection of thrombotic complications.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
26825627,"We evaluated antithrombin III (ATIII), protein C, protein S, and D-dimer in 60 children with ALL compared with 30 healthy controls, and patients were followed up for 12 months for detection of thrombotic complications.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26825627,"We evaluated antithrombin III (ATIII), protein C, protein S, and D-dimer in 60 children with ALL compared with 30 healthy controls, and patients were followed up for 12 months for detection of thrombotic complications.",Antithrombin III,TREATS,Patients
26825627,"We evaluated antithrombin III (ATIII), protein C, protein S, and D-dimer in 60 children with ALL compared with 30 healthy controls, and patients were followed up for 12 months for detection of thrombotic complications.",Antithrombin III,TREATS,Child
26825627,"We evaluated antithrombin III (ATIII), protein C, protein S, and D-dimer in 60 children with ALL compared with 30 healthy controls, and patients were followed up for 12 months for detection of thrombotic complications.",Antithrombin III,TREATS,"Leukemia, Lymphocytic, Acute"
26825627,ALL children during induction/consolidation phase of chemotherapy are at high risk of developing thromboembolism complications and the prophylactic use of anticoagulant should be considered.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26846409,"In conclusion, high expression levels of HOXA5 mRNA and protein in children with ALL indicate that HOXA5 is closely associated with childhood ALL.",Child,LOCATION_OF,Proteins
26846409,"In conclusion, high expression levels of HOXA5 mRNA and protein in children with ALL indicate that HOXA5 is closely associated with childhood ALL.",Child,LOCATION_OF,HOXA5
26846409,"In conclusion, high expression levels of HOXA5 mRNA and protein in children with ALL indicate that HOXA5 is closely associated with childhood ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26846409,"In conclusion, high expression levels of HOXA5 mRNA and protein in children with ALL indicate that HOXA5 is closely associated with childhood ALL.",HOXA5,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute, L1"
26856247,The top 100-ranked single-nucleotide polymorphisms (SNPs) were then carried forward replication in 59 children with acute lymphoblastic leukemia (ALL) exposed to large fixed doses of PD as part of their chemotherapeutic regimen.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26856247,The top 100-ranked single-nucleotide polymorphisms (SNPs) were then carried forward replication in 59 children with acute lymphoblastic leukemia (ALL) exposed to large fixed doses of PD as part of their chemotherapeutic regimen.,Child,LOCATION_OF,Single Nucleotide Polymorphism
26876989,"Although most children with acute lymphoblastic leukaemia (ALL) do not harbor germline mutations that strongly predispose them to development of this malignancy, large syndrome registries and detailed mapping of exomes or whole genomes of familial leukaemia kindreds have revealed that 3-5% of all childhood ALL cases are due to such germline mutations, but the figure may be higher.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26888258,Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.,Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26888258,"Induction therapy for childhood acute lymphoblastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileukemic potency, leading to fewer relapses and improved survival.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26888258,Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.,Dexamethasone,compared_with,Prednisone
27027340,"Although most children with ALL are cured, there is still a group of patients for which therapy fails owing to severe toxicities and drug resistance.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27028090,Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27028865,Here we analyzed the immunophenotypic profile of BM and peripheral blood (PB) maturing/matured neutrophils from 118 children with BCP-ALL and their relationship with the features of the disease.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
27038831,"These estimates were stronger among children with acute myeloid leukemia (AML) than acute lymphoid leukemia, with a positive association observed among urban children with AML (4th quartile odds ratio: 5.25, 95% confidence interval: 1.09, 25.26).","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
27038831,"These estimates were stronger among children with acute myeloid leukemia (AML) than acute lymphoid leukemia, with a positive association observed among urban children with AML (4th quartile odds ratio: 5.25, 95% confidence interval: 1.09, 25.26).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27038831,"These estimates were stronger among children with acute myeloid leukemia (AML) than acute lymphoid leukemia, with a positive association observed among urban children with AML (4th quartile odds ratio: 5.25, 95% confidence interval: 1.09, 25.26).","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
27080467,"RT-PCR and western blot analysis were used to examine the expression of the GABA synthetizing enzyme glutamic acid decarboxylase (GAD) isoforms (GAD65 and GAD67), and type-A GABA receptor (GABAAR) subunits [alpha(1-6), beta(1-3), gamma(1-3), delta, epsilon, theta, pi, and rho(1-3)] in bone marrow lymphocytes of 19 ALL children before chemotherapy.",Glutamate Decarboxylase,ISA,Enzymes
27080467,"RT-PCR and western blot analysis were used to examine the expression of the GABA synthetizing enzyme glutamic acid decarboxylase (GAD) isoforms (GAD65 and GAD67), and type-A GABA receptor (GABAAR) subunits [alpha(1-6), beta(1-3), gamma(1-3), delta, epsilon, theta, pi, and rho(1-3)] in bone marrow lymphocytes of 19 ALL children before chemotherapy.",Lymphocyte,PART_OF,Child
27080467,"Moreover, RT-PCR and western blot showed that GAD and several GABAAR subunits were significantly increased in ALL children as compared with the data of non-ALL children.",Myeloid Leukemia,PROCESS_OF,Child
27080467,"Therefore, the goal of this report was to examine if GABAergic signaling expression is altered in bone marrow lymphocytes of ALL children.",Lymphocyte,PART_OF,Child
27080467,"RT-PCR and western blot analysis were used to examine the expression of the GABA synthetizing enzyme glutamic acid decarboxylase (GAD) isoforms (GAD65 and GAD67), and type-A GABA receptor (GABAAR) subunits [alpha(1-6), beta(1-3), gamma(1-3), delta, epsilon, theta, pi, and rho(1-3)] in bone marrow lymphocytes of 19 ALL children before chemotherapy.",Lymphocyte,LOCATION_OF,GABA Receptor
27080467,"Moreover, RT-PCR and western blot showed that GAD and several GABAAR subunits were significantly increased in ALL children as compared with the data of non-ALL children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27080467,"Therefore, the goal of this report was to examine if GABAergic signaling expression is altered in bone marrow lymphocytes of ALL children.",Lymphocyte,PART_OF,Bone Marrow
27080467,"RT-PCR and western blot analysis were used to examine the expression of the GABA synthetizing enzyme glutamic acid decarboxylase (GAD) isoforms (GAD65 and GAD67), and type-A GABA receptor (GABAAR) subunits [alpha(1-6), beta(1-3), gamma(1-3), delta, epsilon, theta, pi, and rho(1-3)] in bone marrow lymphocytes of 19 ALL children before chemotherapy.",Lymphocyte,LOCATION_OF,GAD1
27080467,We found that GAD and GABAAR subunits were expressed in bone marrow lymphocytes of ALL children.,Lymphocyte,PART_OF,Child
27080467,"Therefore, the goal of this report was to examine if GABAergic signaling expression is altered in bone marrow lymphocytes of ALL children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27080467,Our present study reveals up-regulation of GABAergic signaling events in bone marrow lymphocytes in ALL children.,Transcriptional Activation,PROCESS_OF,Child
27080467,"RT-PCR and western blot analysis were used to examine the expression of the GABA synthetizing enzyme glutamic acid decarboxylase (GAD) isoforms (GAD65 and GAD67), and type-A GABA receptor (GABAAR) subunits [alpha(1-6), beta(1-3), gamma(1-3), delta, epsilon, theta, pi, and rho(1-3)] in bone marrow lymphocytes of 19 ALL children before chemotherapy.",Lymphocyte,LOCATION_OF,GAD1
27080467,We found that GAD and GABAAR subunits were expressed in bone marrow lymphocytes of ALL children.,Glutamate Decarboxylase,PART_OF,Lymphocyte
27080467,Our present study reveals up-regulation of GABAergic signaling events in bone marrow lymphocytes in ALL children.,Lymphocyte,PART_OF,Bone Marrow
27080467,"RT-PCR and western blot analysis were used to examine the expression of the GABA synthetizing enzyme glutamic acid decarboxylase (GAD) isoforms (GAD65 and GAD67), and type-A GABA receptor (GABAAR) subunits [alpha(1-6), beta(1-3), gamma(1-3), delta, epsilon, theta, pi, and rho(1-3)] in bone marrow lymphocytes of 19 ALL children before chemotherapy.",Lymphocyte,PART_OF,Bone Marrow
27080467,We found that GAD and GABAAR subunits were expressed in bone marrow lymphocytes of ALL children.,Lymphocyte,PART_OF,Bone Marrow
27080467,Our present study reveals up-regulation of GABAergic signaling events in bone marrow lymphocytes in ALL children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27080467,"RT-PCR and western blot analysis were used to examine the expression of the GABA synthetizing enzyme glutamic acid decarboxylase (GAD) isoforms (GAD65 and GAD67), and type-A GABA receptor (GABAAR) subunits [alpha(1-6), beta(1-3), gamma(1-3), delta, epsilon, theta, pi, and rho(1-3)] in bone marrow lymphocytes of 19 ALL children before chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27080467,We found that GAD and GABAAR subunits were expressed in bone marrow lymphocytes of ALL children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27080467,"Moreover, RT-PCR and western blot showed that GAD and several GABAAR subunits were significantly increased in ALL children as compared with the data of non-ALL children.",Child,LOCATION_OF,Glutamate Decarboxylase
26755523,PURPOSE: We sought to determine whether cranial radiotherapy (CRT) is necessary to prevent relapse in any subgroup of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26755523,Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.,Radiation therapy,TREATS,Child
26755523,Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26755523,Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
26755523,CONCLUSION: CRT does not have an impact on the risk of relapse in children with ALL treated on contemporary protocols.,Radiation therapy,TREATS,Child
26755523,Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
26755523,CONCLUSION: CRT does not have an impact on the risk of relapse in children with ALL treated on contemporary protocols.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26755523,CONCLUSION: CRT does not have an impact on the risk of relapse in children with ALL treated on contemporary protocols.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
26845034,"We studied the outcomes, including 1-year overall survival, complete remission, and quality of life, of 19 children with ALL who relapsed within the first year after their transplantation treated in the 5 participating centers between 2000 and 2011 Patients were distributed as follows: supportive care only (group A), outpatient treatment (mainly steroid and vincristine, group B), or intensive inpatient treatment (group C).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26845034,Relapses of acute lymphoblastic leukemia (ALL) early after hematopoietic stem cell transplantations in children are uncommon but associated with a very poor prognosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26845034,Keep in Mind Quality of Life: Outcome of a Ten-Year Series of Post-Transplantation Early Relapses in Childhood Acute Lymphoblastic Leukemia-A Report from the Grand Ouest Oncology Study Group for Children in France.,Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26845729,"METHODS: DNA samples obtained from 70 children with ALL and 152 age-matched controls (range, 1-15 years) were analyzed by real-time reverse transcription polymerase chain reaction (RT-qPCR) to detect MTHFR C677T and A1298C and TPMT*2 and TPMT*3A genotypes.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26845729,"Therefore, these genetic variants may lead to childhood acute lymphoblastic leukemia (ALL) susceptibility, in a Mexican population study.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
26855057,Our data suggest that children with Noonan syndrome are at higher risk to develop ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26855057,"Strikingly, all Noonan-associated ALL were B-cell precursor ALL, and high hyperdiploidy with more than 50 chromosomes was found in the leukemia cells of 13/17 (76%) patients with available genetics data.",Leukemic Cell,LOCATION_OF,"Leukemia, B-Cell, Acute"
26855057,"Strikingly, all Noonan-associated ALL were B-cell precursor ALL, and high hyperdiploidy with more than 50 chromosomes was found in the leukemia cells of 13/17 (76%) patients with available genetics data.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
26855057,Our data suggest that children with Noonan syndrome are at higher risk to develop ALL.,Noonan Syndrome,PART_OF,Child
26864366,CONCLUSION: Higher BMI at diagnosis is associated with poorer survival in children with pediatric ALL or AML.,Diagnosis,TREATS,Child
26864366,CONCLUSION: Higher BMI at diagnosis is associated with poorer survival in children with pediatric ALL or AML.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
26864366,CONCLUSION: Higher BMI at diagnosis is associated with poorer survival in children with pediatric ALL or AML.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
26864366,"In ALL, we observed poorer EFS in children with a higher BMI (RR: 1.35; 95% CI: 1.20, 1.51) than in those at a lower BMI.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26865705,Measurement of MRD from bone marrow at the end of induction chemotherapy (day 28) for childhood acute lymphoblastic leukaemia (ALL) can highlight a large group of patients (>40%) with an excellent (>90%) short-term event-free survival (EFS).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26865705,Measurement of MRD from bone marrow at the end of induction chemotherapy (day 28) for childhood acute lymphoblastic leukaemia (ALL) can highlight a large group of patients (>40%) with an excellent (>90%) short-term event-free survival (EFS).,Bone Marrow,LOCATION_OF,"Neoplasm, Residual"
26937602,"HRs of 1.62 (CI 0.85; 3.09) and 5.76 (CI 2.01; 16.51) were observed for the fourth or later born children with ALL (N = 41) and AML (N = 9), respectively.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
26937602,"HRs of 1.62 (CI 0.85; 3.09) and 5.76 (CI 2.01; 16.51) were observed for the fourth or later born children with ALL (N = 41) and AML (N = 9), respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27099644,BACKGROUND: Minimal residual disease (MRD) testing by higher performance techniques such as flow cytometry and polymerase chain reaction (PCR) can be used to detect the proportion of remaining leukemic cells in bone marrow or peripheral blood during and after the first phases of chemotherapy in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27099644,BACKGROUND: Minimal residual disease (MRD) testing by higher performance techniques such as flow cytometry and polymerase chain reaction (PCR) can be used to detect the proportion of remaining leukemic cells in bone marrow or peripheral blood during and after the first phases of chemotherapy in children with acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27099644,BACKGROUND: Minimal residual disease (MRD) testing by higher performance techniques such as flow cytometry and polymerase chain reaction (PCR) can be used to detect the proportion of remaining leukemic cells in bone marrow or peripheral blood during and after the first phases of chemotherapy in children with acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,Child
27100384,Hyperfractionated radiation therapy (HFX) for acute lymphoblastic leukemia (ALL) was randomized against conventionally fractionated radiation therapy (CFX) in the DFCI 87-01/91-01 trials attempting to minimize these effects.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
27110933,This study retrospectively reviewed all patients with B-cell ALL (B-ALL) from September 2005 to September 2010 to determine the benefit and cost of these procedures.,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
27110933,This study retrospectively reviewed all patients with B-cell ALL (B-ALL) from September 2005 to September 2010 to determine the benefit and cost of these procedures.,"Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
26729065,Dexamethasone is a key component in the treatment of childhood acute lymphoblastic leukaemia (ALL).,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26729065,Dexamethasone is a key component in the treatment of childhood acute lymphoblastic leukaemia (ALL).,Dexamethasone,ISA,Therapeutic procedure
26729065,Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26729065,Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.,Dexamethasone,ISA,Therapeutic procedure
26729065,Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.,Therapeutic procedure,USES,Dexamethasone
26729065,Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26740869,Prognostic Impact of WT-1 Gene Expression in Egyptian Children with Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26787046,"In a 3-year-old child with acute lymphoblastic leukemia (ALL), left leg weakness, hyperreflexia, and clonus were noted 4 days after her first dose of IT cytarabine during the induction phase of her chemotherapy.",Asthenia,PROCESS_OF,Child
26787046,"In a 3-year-old child with acute lymphoblastic leukemia (ALL), left leg weakness, hyperreflexia, and clonus were noted 4 days after her first dose of IT cytarabine during the induction phase of her chemotherapy.",Hyperreflexia,PROCESS_OF,Child
26787046,"In a 3-year-old child with acute lymphoblastic leukemia (ALL), left leg weakness, hyperreflexia, and clonus were noted 4 days after her first dose of IT cytarabine during the induction phase of her chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26787046,"In a 3-year-old child with acute lymphoblastic leukemia (ALL), left leg weakness, hyperreflexia, and clonus were noted 4 days after her first dose of IT cytarabine during the induction phase of her chemotherapy.",Clonus,PROCESS_OF,Child
26853405,The objective of this retrospective analysis was to evaluate the morbidity pattern and outcome of therapy in undernourished (UN) children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26853405,The objective of this retrospective analysis was to evaluate the morbidity pattern and outcome of therapy in undernourished (UN) children with acute lymphoblastic leukemia.,Malnutrition,PROCESS_OF,Child
26853405,The objective of this retrospective analysis was to evaluate the morbidity pattern and outcome of therapy in undernourished (UN) children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,Malnutrition
26853405,The objective of this retrospective analysis was to evaluate the morbidity pattern and outcome of therapy in undernourished (UN) children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
26853405,The objective of this retrospective analysis was to evaluate the morbidity pattern and outcome of therapy in undernourished (UN) children with acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,Child
26905118,MATERIALS AND METHODS: A retrospective analysis was performed from the records of children with ALL who were treated from January 2010 to December 2012.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26925793,"Our aim was to retrospectively evaluate disease characteristics and treatment outcomes of children with ALL enrolled in a single center into consecutive treatment protocols (ALL-BFM 90, ALL-BFM 95 and ALL IC-BFM 2002) between years 1990 and 2007 and comprehensively summarize diagnostic and therapeutic advances between protocols.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26925793,"Our aim was to retrospectively evaluate disease characteristics and treatment outcomes of children with ALL enrolled in a single center into consecutive treatment protocols (ALL-BFM 90, ALL-BFM 95 and ALL IC-BFM 2002) between years 1990 and 2007 and comprehensively summarize diagnostic and therapeutic advances between protocols.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26947147,METHODS: Gene expression data were obtained from public database for 26 children diagnosed with PBC ALL either sensitive or resistant to in vitro prednisolone treatment.,Therapeutic procedure,USES,prednisolone
26947147,METHODS: Gene expression data were obtained from public database for 26 children diagnosed with PBC ALL either sensitive or resistant to in vitro prednisolone treatment.,prednisolone,ISA,Therapeutic procedure
26947147,"Response to glucocorticoid (GC) treatment is out of the most important prognostic factors in childhood acute lymphoblastic leukemia (ALL), however, only few data are available connecting GC response and role of autophagy.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26947147,"Response to glucocorticoid (GC) treatment is out of the most important prognostic factors in childhood acute lymphoblastic leukemia (ALL), however, only few data are available connecting GC response and role of autophagy.",Glucocorticoids,ISA,Therapeutic procedure
26947147,"Response to glucocorticoid (GC) treatment is out of the most important prognostic factors in childhood acute lymphoblastic leukemia (ALL), however, only few data are available connecting GC response and role of autophagy.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26947147,METHODS: Gene expression data were obtained from public database for 26 children diagnosed with PBC ALL either sensitive or resistant to in vitro prednisolone treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27035574,"The SIR was significantly increased in child ALL (SIR 6.06), but not in adult ALL (SIR 1.16).",Sepsis Syndrome,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
27035574,"The SIR was significantly increased in child ALL (SIR 6.06), but not in adult ALL (SIR 1.16).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27035574,BACKGROUND: Acute lymphoblastic leukemia (ALL) is more common in children than in adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27035574,"CONCLUSIONS: When compared with the general population, child ALL shows a increased risk of developing SNs.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27036162,The antifolate methotrexate (MTX) is one of the pillars of acute lymphoblastic leukemia (ALL) treatment.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
27036162,The antifolate methotrexate (MTX) is one of the pillars of acute lymphoblastic leukemia (ALL) treatment.,Methotrexate,ISA,Therapeutic procedure
27036162,The antifolate methotrexate (MTX) is one of the pillars of acute lymphoblastic leukemia (ALL) treatment.,Methotrexate,ISA,Folic Acid Antagonists
27036162,Here we studied the association of FPGS splicing alterations with ex vivo MTX resistance as well as clinical response in 91 pediatric ALL patients.,Methotrexate,TREATS,Patients
27036162,The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27036162,Here we studied the association of FPGS splicing alterations with ex vivo MTX resistance as well as clinical response in 91 pediatric ALL patients.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27036162,Here we studied the association of FPGS splicing alterations with ex vivo MTX resistance as well as clinical response in 91 pediatric ALL patients.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
27099643,CONCLUSIONS: Minimal residual disease is an independent prognostic factor for relapse in childhood ALL.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
27099643,"Seven studies showed prognostic value of MRD measured at the end of induction therapy and two at the end of consolidation therapy in de novo ALL, one study in relapsed ALL after re-induction therapy, and three studies before hematopoietic stem cell transplant.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
27099643,This evidence review aimed to ascertain whether MRD is an independent prognostic factor for relapse and to assess the effect of MRD-directed treatment on patient-important outcomes in childhood ALL.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
25629981,Typing of MTHFR C677T and A1298C polymorphisms was done using restriction fragment length polymorphism (RFLP) for 100 children with ALL and 100 age- and sex-matched healthy controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26188848,"However, survival chances for infants with MLL-rearranged ALL do still not exceed 30-40%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
26188848,These observations led to the inclusion of cytarabine into the treatment regimens currently used for infants with ALL.,Treatment Protocols,TREATS,Infant
26188848,These observations led to the inclusion of cytarabine into the treatment regimens currently used for infants with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
26188848,These observations led to the inclusion of cytarabine into the treatment regimens currently used for infants with ALL.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
26188848,"MLL-rearranged acute lymphoblastic leukaemia (ALL) in infants is the most difficult-to-treat type of childhood ALL, displaying a chemotherapy-resistant phenotype, and unique histone modifications, gene expression signatures and DNA methylation patterns.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
26242828,"Our objective was to evaluate the ITPA 94C>A, IVS2+21A>C polymorphisms in patients with ALL treated with 6-MP and prediction of its clinical outcomes.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
26242828,"Our objective was to evaluate the ITPA 94C>A, IVS2+21A>C polymorphisms in patients with ALL treated with 6-MP and prediction of its clinical outcomes.",6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
26242828,"Our objective was to evaluate the ITPA 94C>A, IVS2+21A>C polymorphisms in patients with ALL treated with 6-MP and prediction of its clinical outcomes.",Mandibular left first premolar abutment,TREATS,"Leukemia, Lymphocytic, Acute"
26242828,"Our objective was to evaluate the ITPA 94C>A, IVS2+21A>C polymorphisms in patients with ALL treated with 6-MP and prediction of its clinical outcomes.",Mandibular left first premolar abutment,TREATS,Patients
26403224,These results indicate that the MIRLET7B-HMGA2-CDKN2A axis plays an important role in cell proliferation of leukaemic cells and could be a possible molecular target for the therapy of infant ALL with KMT2A-AFF1.,Molecular Target,AFFECTS,Cell Proliferation
26403224,These results indicate that the MIRLET7B-HMGA2-CDKN2A axis plays an important role in cell proliferation of leukaemic cells and could be a possible molecular target for the therapy of infant ALL with KMT2A-AFF1.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
26403224,Acute lymphoblastic leukaemia (ALL) in infants is an intractable cancer in childhood.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
26403224,Acute lymphoblastic leukaemia (ALL) in infants is an intractable cancer in childhood.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
26445634,"METHODS: In a case-control study, 33 of ALL survivors who were treated with chemotherapy (Group A), and 33 subjects who were treated with chemoplus cranial radiation (Group B) were compared against 33 matched age, sex, and pubertal stage of their healthy siblings (Group C).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Pharmacotherapy,TREATS,Late effect of
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Chemotherapy-Oncologic Procedure,TREATS,Survivors
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Pharmacotherapy,TREATS,Survivors
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Late effect of,PROCESS_OF,Survivors
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Chemotherapy-Oncologic Procedure,TREATS,Late effect of
26445634,"METHODS: In a case-control study, 33 of ALL survivors who were treated with chemotherapy (Group A), and 33 subjects who were treated with chemoplus cranial radiation (Group B) were compared against 33 matched age, sex, and pubertal stage of their healthy siblings (Group C).",Pharmacotherapy,TREATS,Survivors
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
26445634,"METHODS: In a case-control study, 33 of ALL survivors who were treated with chemotherapy (Group A), and 33 subjects who were treated with chemoplus cranial radiation (Group B) were compared against 33 matched age, sex, and pubertal stage of their healthy siblings (Group C).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
26913397,No significant difference was found in the median age at diagnosis between male and female children with B-NHL/B-ALL (P = 0.837).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26913397,[Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26914084,The successful non-invasive management of pulmonary thromboembolism in a child with acute lymphoblastic leukemia.,Pulmonary Thromboembolisms,PROCESS_OF,Child
26914084,The successful non-invasive management of pulmonary thromboembolism in a child with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26991355,Acute lymphoblastic leukemia (ALL) occurs with high frequency in childhood and is associated with high mortality in adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
27065575,"ALL is the most common hematologic malignancy in early childhood, and it reaches peak incidence between the ages of 2 and 3 years.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
27097569,RESULTS: Eighteen (21%) out of 86 children with B-ALL had PAX5 deletion.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27097569,CONCLUSIONS: PAX5 deletion is an independent risk factor for DFS in B-ALL children without reproducible chromosomal abnormalities.,Child,LOCATION_OF,PAX5 gene | PAX5
27097569,CONCLUSIONS: PAX5 deletion is an independent risk factor for DFS in B-ALL children without reproducible chromosomal abnormalities.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27097570,"CONCLUSIONS: HGs can be used to assess the treatment outcome and prognosis in children with B-ALL, and proliferation of HGs reflects the good effect of chemotherapy in such children.",Good effect,PROCESS_OF,Child
27097570,METHODS: A retrospective analysis was conducted for 196 children with newly-diagnosed B-ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27097570,"CONCLUSIONS: HGs can be used to assess the treatment outcome and prognosis in children with B-ALL, and proliferation of HGs reflects the good effect of chemotherapy in such children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25661341,"BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, though the etiology of the leukemia is poorly understood, both genetic and environmental factors appear to be involved.",Malignant Neoplasms,PROCESS_OF,Child
25661341,"BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, though the etiology of the leukemia is poorly understood, both genetic and environmental factors appear to be involved.","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
25661341,"BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, though the etiology of the leukemia is poorly understood, both genetic and environmental factors appear to be involved.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25661341,Previous studies investigating the association between MDR1 C3435T polymorphisms and risk of children with ALL reported controversial results.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25661341,"BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, though the etiology of the leukemia is poorly understood, both genetic and environmental factors appear to be involved.","Leukemia, Lymphocytic, Acute",CAUSES,leukemia
25692130,"The aims of this multicenter study were to determine the prevalence of the four most common gene rearrangements [ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, and MLL rearrangements] and to explore their relationship with mortality rates during the first year of treatment in ALL children from Mexico City.",Gene Rearrangement,PROCESS_OF,Child
25692130,"The aims of this multicenter study were to determine the prevalence of the four most common gene rearrangements [ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, and MLL rearrangements] and to explore their relationship with mortality rates during the first year of treatment in ALL children from Mexico City.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25726706,INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most prevalent malignancy among children and makes up 23% of total childhood cancers worldwide.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
25726706,INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most prevalent malignancy among children and makes up 23% of total childhood cancers worldwide.,Malignant Neoplasms,PROCESS_OF,Child
25726706,INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most prevalent malignancy among children and makes up 23% of total childhood cancers worldwide.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25804798,"In conclusion, NAT2 gene polymorphism(s) with slow acetylator phenotype is generally associated with the risk of development of ALL in children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25999454,"In particular, unbiased genome-wide association studies have identified germline variants strongly associated with the predisposition to ALL in children, providing novel insight into the mechanisms of leukemogenesis and evidence for complex interactions between inherited and acquired genetic variations in ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25999454,"In particular, unbiased genome-wide association studies have identified germline variants strongly associated with the predisposition to ALL in children, providing novel insight into the mechanisms of leukemogenesis and evidence for complex interactions between inherited and acquired genetic variations in ALL.",Leukemogenesis,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
26033531,Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.,Toxic effect,PROCESS_OF,Child
26033531,Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26044969,"Gender-specific differences in survival by clinical trial era in Yorkshire were assessed for children with acute lymphoid leukaemia (ALL) enrolled onto UKALLXI, ALL97/99 or UKALL2003 (n = 630; 1990-2011).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26188848,We conclude that clofarabine is an interesting candidate for further studies in MLL-rearranged ALL in infants.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
26188848,We conclude that clofarabine is an interesting candidate for further studies in MLL-rearranged ALL in infants.,clofarabine,TREATS,"Leukemia, Lymphocytic, Acute"
26329293,CONCLUSIONS: PTX potentiates blast apoptosis induced by PRD in children with ALL during steroid window phase.,Prednisone,TREATS,Child
26329293,CONCLUSIONS: PTX potentiates blast apoptosis induced by PRD in children with ALL during steroid window phase.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26329293,CONCLUSIONS: PTX potentiates blast apoptosis induced by PRD in children with ALL during steroid window phase.,Prednisone,TREATS,"Leukemia, Lymphocytic, Acute"
26329293,A clinical trial was developed to evaluate the effect of the addition of PTX to the induction steroid window phase in children with acute lymphoblastic leukemia (ALL).,Pentoxifylline,TREATS,Child
26329293,A clinical trial was developed to evaluate the effect of the addition of PTX to the induction steroid window phase in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26329293,A clinical trial was developed to evaluate the effect of the addition of PTX to the induction steroid window phase in children with acute lymphoblastic leukemia (ALL).,Pentoxifylline,TREATS,"Leukemia, Lymphocytic, Acute"
26329293,CONCLUSIONS: PTX potentiates blast apoptosis induced by PRD in children with ALL during steroid window phase.,Prednisone,CAUSES,Apoptosis
26455582,"More recently, response to treatment, which is evaluated by assessment of minimal residual disease (MRD), has been found to be clinically significant in relapsed ALL as well as in the initially diagnosed disease.",Assessment procedure,METHOD_OF,Therapeutic procedure
26455582,Acute lymphoblastic leukemia (ALL) is the most frequent cancer in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26455582,"More recently, response to treatment, which is evaluated by assessment of minimal residual disease (MRD), has been found to be clinically significant in relapsed ALL as well as in the initially diagnosed disease.","Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
26650335,"Knox tests were performed on geocoded residence at birth and diagnosis separately for leukaemia, acute lymphoid leukaemia (ALL), lymphomas, tumours of the central nervous system, neuroblastomas and soft tissue sarcomas.","Leukemia, Lymphocytic, Acute",ISA,leukemia
26705211,To assess the self-esteem of pediatric patients on chemotherapy for acute lymphoblastic leukemia (ALL) and psychological status of their parents.The psychological status of 178 children receiving chemotherapy for ALL and their parents was assessed using parenting stress index (PSI) to determine the degree of stress the parents are exposed to using parent's and child's domains.,Pharmacotherapy,TREATS,Psychiatric problem
26705211,To assess the self-esteem of pediatric patients on chemotherapy for acute lymphoblastic leukemia (ALL) and psychological status of their parents.The psychological status of 178 children receiving chemotherapy for ALL and their parents was assessed using parenting stress index (PSI) to determine the degree of stress the parents are exposed to using parent's and child's domains.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26705211,Chemotherapy for ALL has a significant impact on the psychological status of both patients and their parents with high prevalence of low self-esteem in children and high degree of stress in their parents.,Stress,PROCESS_OF,parent
26705211,Psychological Impact of Chemotherapy for Childhood Acute Lymphoblastic Leukemia on Patients and Their Parents.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26705211,Chemotherapy for ALL has a significant impact on the psychological status of both patients and their parents with high prevalence of low self-esteem in children and high degree of stress in their parents.,Psychiatric problem,PROCESS_OF,Child
26705211,Chemotherapy for ALL has a significant impact on the psychological status of both patients and their parents with high prevalence of low self-esteem in children and high degree of stress in their parents.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26705211,To assess the self-esteem of pediatric patients on chemotherapy for acute lymphoblastic leukemia (ALL) and psychological status of their parents.The psychological status of 178 children receiving chemotherapy for ALL and their parents was assessed using parenting stress index (PSI) to determine the degree of stress the parents are exposed to using parent's and child's domains.,Pharmacotherapy,ADMINISTERED_TO,Child
26705211,To assess the self-esteem of pediatric patients on chemotherapy for acute lymphoblastic leukemia (ALL) and psychological status of their parents.The psychological status of 178 children receiving chemotherapy for ALL and their parents was assessed using parenting stress index (PSI) to determine the degree of stress the parents are exposed to using parent's and child's domains.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26705449,Association of Serum Leptin Level with Obesity in Children with Acute Lymphoblastic Leukemia.,Serum,LOCATION_OF,Leptin | LEP
26705449,Association of Serum Leptin Level with Obesity in Children with Acute Lymphoblastic Leukemia.,Obesity,PROCESS_OF,Child
26705449,Association of Serum Leptin Level with Obesity in Children with Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25586065,"PROCEDURE: All children with ALL diagnosed 1995-2011 (N = 1,541) in Ontario, Canada were linked to population-based health administrative databases.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25586065,We aimed to construct and validate a diagnostic interval measure using health services data among children with acute lymphoblastic leukemia (ALL) in order to determine predictors of prolonged intervals and associations with event-free survival (EFS).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25781207,Basal cell carcinoma (BCC) is a rare secondary malignancy which may occur more often in children with acute lymphoblastic leukemia (ALL) who have previously received radiation therapy compared to to those who received no radiation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25781207,Basal cell carcinoma (BCC) is a rare secondary malignancy which may occur more often in children with acute lymphoblastic leukemia (ALL) who have previously received radiation therapy compared to to those who received no radiation.,Second Primary Cancers,OCCURS_IN,Child
25814529,"Elimination of CRT from ALL therapy has improved, but not eliminated, body-composition outcomes.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
25987655,Our objective was to use a genome-wide approach to identify loci associated with asparaginase hypersensitivity in children with ALL enrolled on St.,Hypersensitivity,PROCESS_OF,Child
25987655,Our objective was to use a genome-wide approach to identify loci associated with asparaginase hypersensitivity in children with ALL enrolled on St.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25987655,"Asparaginase is used to treat acute lymphoblastic leukemia (ALL); however, hypersensitivity reactions can lead to suboptimal asparaginase exposure.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
25987655,"RNA-seq data available from 65 SJCRH ALL tumor samples and 52 Yoruba HapMap samples showed that samples carrying the rs6021191 variant had higher NFATC2 expression compared with noncarriers (P = 1.1 x 10(-3) and 0.03, respectively).","Leukemia, Lymphocytic, Acute",ISA,Neoplasm
26022049,"In this issue of Blood, Ness et al report that, despite the omission of prophylactic cranial radiotherapy (CRT) in the treatment of acute lymphoblastic leukemia (ALL), adult survivors of childhood ALL remain at risk for impaired fitness, body composition, and energy balance.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
26022503,Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26022503,CONCLUSIONS: These findings emphasize the central role of MTX in ALL treatment thereby expanding our understanding of the molecular basis of clinical differences in treatment response between ALL individuals.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
26022503,CONCLUSIONS: These findings emphasize the central role of MTX in ALL treatment thereby expanding our understanding of the molecular basis of clinical differences in treatment response between ALL individuals.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Individual
26022503,"In addition, we assessed both the association of several MTX resistance-related parameters determined in vitro with treatment outcome as well as clinical characteristics of pediatric ALL patients treated with MTX-containing combination chemotherapy.",Combination Drug Therapy,TREATS,Patients
26022503,"In addition, we assessed both the association of several MTX resistance-related parameters determined in vitro with treatment outcome as well as clinical characteristics of pediatric ALL patients treated with MTX-containing combination chemotherapy.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
26022503,"In addition, we assessed both the association of several MTX resistance-related parameters determined in vitro with treatment outcome as well as clinical characteristics of pediatric ALL patients treated with MTX-containing combination chemotherapy.",Combination Drug Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26033531,rs116855232 is an important determinant of 6-MP myelotoxicity in Japanese children with ALL and may represent the most robust toxicity-related locus in Asians to date.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26369984,Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
26380954,Pri-miR-34b/c rs4938723 polymorphism contributes to acute lymphoblastic leukemia susceptibility in Chinese children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26528799,"MTHFR polymorphisms were assessed in 47 pediatric ALL patients, treated according to intensive chemotherapy for childhood ALL, ALL IC BFM 2009.",Patients,LOCATION_OF,Oxidoreductase
26528799,"MTHFR polymorphisms were assessed in 47 pediatric ALL patients, treated according to intensive chemotherapy for childhood ALL, ALL IC BFM 2009.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26528799,"MTHFR polymorphisms were assessed in 47 pediatric ALL patients, treated according to intensive chemotherapy for childhood ALL, ALL IC BFM 2009.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
26528799,Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.,METHOTREXATE TOXICITY,PROCESS_OF,Child
26528799,Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26549586,"BACKGROUND: l-asparaginase is a universal component of treatment for childhood acute lymphoblastic leukaemia, and is usually administered intramuscularly.",ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26549586,"BACKGROUND: l-asparaginase is a universal component of treatment for childhood acute lymphoblastic leukaemia, and is usually administered intramuscularly.",ASPARAGINASE | ASPG,ISA,Therapeutic procedure
26648836,"The purpose of the current study was to evaluate the cytogenetic findings in 1,057 children with acute lymphoblastic leukemia (ALL) referred to the cytogenetics laboratory at the Hospital de Pediatria Dr.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26648836,Cytogenetic and Molecular Findings in Children with Acute Lymphoblastic Leukemia: Experience of a Single Institution in Argentina.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26648836,"Finally, to the best of our knowledge, this is the first series of cytogenetic findings in children with ALL reported in Argentina.",Vitelliform dystrophy,PROCESS_OF,Child
26648836,"Finally, to the best of our knowledge, this is the first series of cytogenetic findings in children with ALL reported in Argentina.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25659406,B-precursor acute lymphoblastic leukaemia (BPL) is the most common form of cancer in children and adolescents.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
25659406,B-precursor acute lymphoblastic leukaemia (BPL) is the most common form of cancer in children and adolescents.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
25659406,B-precursor acute lymphoblastic leukaemia (BPL) is the most common form of cancer in children and adolescents.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25659406,B-precursor acute lymphoblastic leukaemia (BPL) is the most common form of cancer in children and adolescents.,Malignant Neoplasms,PROCESS_OF,Adolescent
25659406,B-precursor acute lymphoblastic leukaemia (BPL) is the most common form of cancer in children and adolescents.,Malignant Neoplasms,PROCESS_OF,Child
25746326,"In total, 121 children with ALL and 184 unrelated healthy controls of Slovenian origin were genotyped for 14 polymorphisms in seven genes of folate pathway, base excision repair and homologous recombination repair (TYMS, MTHFR, OGG1, XRCC1, NBN, RAD51, and XRCC3).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26108168,METHODS: Participants were recruited from two multicenter studies: sample 1 included 128 parents of a child diagnosed with acute lymphoblastic leukemia (ALL) (response rate 82 %) and sample 2 included 114 parents of a child diagnosed with cancer (response rate 74 %).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26108168,METHODS: Participants were recruited from two multicenter studies: sample 1 included 128 parents of a child diagnosed with acute lymphoblastic leukemia (ALL) (response rate 82 %) and sample 2 included 114 parents of a child diagnosed with cancer (response rate 74 %).,Malignant Neoplasms,PROCESS_OF,Child
26175952,"The most common cancer in children is acute lymphoblastic leukemia (ALL) and it had high cure rate, especially for B-precursor ALL.",Malignant Neoplasms,PROCESS_OF,Child
26175952,"The most common cancer in children is acute lymphoblastic leukemia (ALL) and it had high cure rate, especially for B-precursor ALL.","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
26175952,"The most common cancer in children is acute lymphoblastic leukemia (ALL) and it had high cure rate, especially for B-precursor ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26304874,"CONCLUSION: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.",Therapeutic procedure,TREATS,Child
26304874,"CONCLUSION: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
26304874,"CONCLUSION: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26304874,"CONCLUSION: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
26304874,PURPOSE: To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia (ALL) in children and adolescents.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26304874,PURPOSE: To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia (ALL) in children and adolescents.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
26304874,"CONCLUSION: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.",Therapeutic procedure,TREATS,Adolescent
26327566,Genetic alterations in glucocorticoid signaling pathway components are associated with adverse prognosis in children with relapsed ETV6/RUNX1-positive acute lymphoblastic leukemia.,Mutation,PROCESS_OF,Child
26327566,Genetic alterations in glucocorticoid signaling pathway components are associated with adverse prognosis in children with relapsed ETV6/RUNX1-positive acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26411491,We studied TPMT expression following 6-mercaptopurine and methotrexate administration in childhood acute lymphoblastic leukemia (ALL) patients and the pharmacogenomic potential of the VNTR architecture.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26411491,We studied TPMT expression following 6-mercaptopurine and methotrexate administration in childhood acute lymphoblastic leukemia (ALL) patients and the pharmacogenomic potential of the VNTR architecture.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
26411491,CONCLUSION: The TPMT promoter genetic variants need to be considered at the very beginning of the maintenance therapy for childhood ALL patients.,Maintenance therapy,TREATS,Patients
26411491,We studied TPMT expression following 6-mercaptopurine and methotrexate administration in childhood acute lymphoblastic leukemia (ALL) patients and the pharmacogenomic potential of the VNTR architecture.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26411491,CONCLUSION: The TPMT promoter genetic variants need to be considered at the very beginning of the maintenance therapy for childhood ALL patients.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26411491,TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner.,TPMT gene | TPMT,COEXISTS_WITH,TPMT
26411491,CONCLUSION: The TPMT promoter genetic variants need to be considered at the very beginning of the maintenance therapy for childhood ALL patients.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
26411491,TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner.,Maintenance therapy,TREATS,Patients
26411491,We studied TPMT expression following 6-mercaptopurine and methotrexate administration in childhood acute lymphoblastic leukemia (ALL) patients and the pharmacogenomic potential of the VNTR architecture.,Methotrexate,TREATS,Patients
26411491,TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26411491,We studied TPMT expression following 6-mercaptopurine and methotrexate administration in childhood acute lymphoblastic leukemia (ALL) patients and the pharmacogenomic potential of the VNTR architecture.,6-Mercaptopurine,TREATS,Patients
26411491,TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
26485054,BACKGROUND: Children with T-lineage acute lymphoblastic leukemia ALL (T-ALL) historically have had inferior outcomes compared with the children with precursor-B ALL (B-ALL).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
26485054,BACKGROUND: Children with T-lineage acute lymphoblastic leukemia ALL (T-ALL) historically have had inferior outcomes compared with the children with precursor-B ALL (B-ALL).,BCR,PART_OF,Child
26527286,"We identified a CDKN2A missense variant (rs3731249) with 2% allele frequency in controls that confers three-fold increased risk of ALL in children of European ancestry (OR, 2.99; P = 1.51 x 10(-9)) and Hispanic children (OR, 2.77; P = 3.78 x 10(-4)).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26527286,"We identified a CDKN2A missense variant (rs3731249) with 2% allele frequency in controls that confers three-fold increased risk of ALL in children of European ancestry (OR, 2.99; P = 1.51 x 10(-9)) and Hispanic children (OR, 2.77; P = 3.78 x 10(-4)).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26527318,We performed longitudinal whole-exome sequencing analysis in three adult patients with Ph- B-cell ALL (Ph- B-ALL) on samples collected from diagnosis to relapse after allo-HSCT.,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
26527318,We performed longitudinal whole-exome sequencing analysis in three adult patients with Ph- B-cell ALL (Ph- B-ALL) on samples collected from diagnosis to relapse after allo-HSCT.,"Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
26625771,Childhood acute lymphoblastic leukemia (ALL) is one of the most common hematologic malignancies which accounts for one fourth of all childhood cancer cases.,"Leukemia, Lymphocytic, Acute, L1",ISA,Hematologic Neoplasms
26703788,Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26703788,BACKGROUND: Discontinuation of E. coli l-asparaginase in patients with acute lymphoblastic leukemia (ALL) is unavoidable upon severe allergic reaction.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
26703788,BACKGROUND: Discontinuation of E. coli l-asparaginase in patients with acute lymphoblastic leukemia (ALL) is unavoidable upon severe allergic reaction.,ASPARAGINASE | ASPG,TREATS,Patients
26703788,BACKGROUND: Discontinuation of E. coli l-asparaginase in patients with acute lymphoblastic leukemia (ALL) is unavoidable upon severe allergic reaction.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
26703788,Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.,Allergic Reaction,PROCESS_OF,Child
25616285,METHODS: A total of 73 children who were diagnosed with ALL between March 2011 and March 2013 were included into this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25616285,OBJECTIVE: To investigate the influence of thymidylate synthase (TS) gene polymorphisms on high-dose methotrexate (HD-MTX)-related toxicities in childhood acute lymphoblastic leukemia (ALL).,METHOTREXATE TOXICITY,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
25616285,OBJECTIVE: To investigate the influence of thymidylate synthase (TS) gene polymorphisms on high-dose methotrexate (HD-MTX)-related toxicities in childhood acute lymphoblastic leukemia (ALL).,TYMS gene | TYMS,ASSOCIATED_WITH,METHOTREXATE TOXICITY
26107212,"MATERIALS AND METHODS: Between March 2006 and February 2008, 486 children with ALL from 12 institutions were enrolled in the Thai national protocols.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26107232,"MATERIALS AND METHODS: During May 1997 and December 2003, 134 children diagnosed with ALL were recruited from one hospital in Thailand.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26239197,"l-asparaginase (ASNase), a key component in the treatment of childhood acute lymphoblastic leukemia (ALL), hydrolyzes plasma asparagine and glutamine and thereby disturbs metabolic homeostasis of leukemic cells.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26239197,"l-asparaginase (ASNase), a key component in the treatment of childhood acute lymphoblastic leukemia (ALL), hydrolyzes plasma asparagine and glutamine and thereby disturbs metabolic homeostasis of leukemic cells.",Plasma,LOCATION_OF,Asparagine
26270775,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children and L-asparaginase is an essential component of the treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26270775,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children and L-asparaginase is an essential component of the treatment.,ASPARAGINASE,ISA,Therapeutic procedure
26270775,Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children With Acute Lymphoblastic Leukemia.,Pancreatitis,PROCESS_OF,Child
26270775,"METHODS: Children (aged 1.0-17.9 years) with childhood ALL treated at the University Hospital Rigshopitalet, Copenhagen, according to the standard or intermediate risk arms of the NOPHO ALL2008 protocol, with PEG-asparaginase of 2 or 6 week intervals, for 30 weeks had their pancreas monitored using serial ultrasound in order to detect early signs of inflammation.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
26270775,Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children With Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26270775,"METHODS: Children (aged 1.0-17.9 years) with childhood ALL treated at the University Hospital Rigshopitalet, Copenhagen, according to the standard or intermediate risk arms of the NOPHO ALL2008 protocol, with PEG-asparaginase of 2 or 6 week intervals, for 30 weeks had their pancreas monitored using serial ultrasound in order to detect early signs of inflammation.",pegaspargase,PART_OF,Upper arm
26270775,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children and L-asparaginase is an essential component of the treatment.,Malignant Neoplasms,PROCESS_OF,Child
26270775,BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common cancer in children and L-asparaginase is an essential component of the treatment.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
26271029,"This paper documents the process of developing an Android application (app) ""Care Assistant"" for family caregivers of children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26271029,Caring for children with ALL is an uncommon experience for parents without medical training.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26271029,"Developing ""Care Assistant"": A smartphone application to support caregivers of children with acute lymphoblastic leukaemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26271029,"The key informants and focus group members included: caregivers of children with ALL, cancer care physicians and nurses, and software engineers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26271029,"This paper documents the process of developing an Android application (app) ""Care Assistant"" for family caregivers of children with ALL.",Application procedure,TREATS,Family Caregivers
26282194,BACKGROUND: Glucocorticoids play a major role in the treatment of acute lymphoblastic leukaemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
26282194,Clinicians should consider prescribing glucocorticoid replacement therapy during periods of serious stress in the first weeks after cessation of glucocorticoid therapy for childhood ALL to reduce the risk of life-threatening complications.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26282194,Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26282194,Clinicians should consider prescribing glucocorticoid replacement therapy during periods of serious stress in the first weeks after cessation of glucocorticoid therapy for childhood ALL to reduce the risk of life-threatening complications.,Replacement therapy,PREVENTS,Complication
26282194,"AUTHORS' CONCLUSIONS: We concluded that adrenal insufficiency commonly occurs in the first days after cessation of glucocorticoid therapy for childhood ALL, but the exact duration is unclear.",GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26282194,The included studies demonstrated that adrenal insufficiency occurs in nearly all children in the first days after cessation of glucocorticoid treatment for childhood ALL.,Glucocorticoids,ISA,Therapeutic procedure
26282194,The included studies demonstrated that adrenal insufficiency occurs in nearly all children in the first days after cessation of glucocorticoid treatment for childhood ALL.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26282194,"SELECTION CRITERIA: All study designs, except case reports and patient series with fewer than 10 children, examining the effect of glucocorticoid therapy for childhood ALL on the HPA axis function.",GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26282194,OBJECTIVES: To examine the occurrence and duration of HPA axis suppression after (each cycle of) glucocorticoid therapy for childhood ALL.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26527286,"We identified a CDKN2A missense variant (rs3731249) with 2% allele frequency in controls that confers three-fold increased risk of ALL in children of European ancestry (OR, 2.99; P = 1.51 x 10(-9)) and Hispanic children (OR, 2.77; P = 3.78 x 10(-4)).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26527286,"We identified a CDKN2A missense variant (rs3731249) with 2% allele frequency in controls that confers three-fold increased risk of ALL in children of European ancestry (OR, 2.99; P = 1.51 x 10(-9)) and Hispanic children (OR, 2.77; P = 3.78 x 10(-4)).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25551271,"For children with precursor B (pre-B) acute lymphoblastic leukemia (ALL) with TCF3-PBX1 fusion gene, their prognosis has been a controversial topic.",PBX1 gene | PBX1,PART_OF,"Leukemia, B-Cell, Acute"
25551271,Clinical features and prognostic significance of TCF3-PBX1 fusion gene in Chinese children with acute lymphoblastic leukemia by using a modified ALL-BFM-95 protocol.,Child,LOCATION_OF,PBX1 gene | PBX1
25551271,Clinical features and prognostic significance of TCF3-PBX1 fusion gene in Chinese children with acute lymphoblastic leukemia by using a modified ALL-BFM-95 protocol.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25551271,"For children with precursor B (pre-B) acute lymphoblastic leukemia (ALL) with TCF3-PBX1 fusion gene, their prognosis has been a controversial topic.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
25603726,Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25603726,Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.,Therapeutic procedure,USES,ASPARAGINASE
25603726,Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.,ASPARAGINASE,ISA,Therapeutic procedure
25603726,Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25710658,OBJECTIVE: To identify genetic germline variants associated with the occurrence or severity of vincristine-induced peripheral neuropathy in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25710658,Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.,Peripheral Neuropathy,PROCESS_OF,Child
25710658,Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25710658,"CONCLUSIONS AND RELEVANCE: In this preliminary study of children with ALL, an inherited polymorphism in the promoter region of CEP72 was associated with increased risk and severity of vincristine-related peripheral neuropathy.",Promoter Regions (Genetics),PART_OF,CEP72
25710658,"CONCLUSIONS AND RELEVANCE: In this preliminary study of children with ALL, an inherited polymorphism in the promoter region of CEP72 was associated with increased risk and severity of vincristine-related peripheral neuropathy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25710658,OBJECTIVE: To identify genetic germline variants associated with the occurrence or severity of vincristine-induced peripheral neuropathy in children with ALL.,Peripheral Neuropathy,OCCURS_IN,Child
25755168,"In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL).","Receptors, Antigen",INTERACTS_WITH,CD19 gene | CD19
25755168,"In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
25755168,"In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL).","Leukemia, B-Cell, Acute",PROCESS_OF,Adult
25755168,"In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL).",Cells,LOCATION_OF,"Leukemia, B-Cell, Acute"
25755857,"OBJECTIVE: This study investigated the expression and prognostic significance of the CD95 death receptor and CD20, a B cell-lineage associated marker, along with CD34 and CD44 non-lineage associated molecules in Iranian children with acute lymphoblastic leukemia (ALL).",CD34 gene | CD34,PART_OF,Child
25755857,"OBJECTIVE: This study investigated the expression and prognostic significance of the CD95 death receptor and CD20, a B cell-lineage associated marker, along with CD34 and CD44 non-lineage associated molecules in Iranian children with acute lymphoblastic leukemia (ALL).",CD44 Antigens | CD44,PART_OF,Child
25755857,"OBJECTIVE: This study investigated the expression and prognostic significance of the CD95 death receptor and CD20, a B cell-lineage associated marker, along with CD34 and CD44 non-lineage associated molecules in Iranian children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25755857,"OBJECTIVE: This study investigated the expression and prognostic significance of the CD95 death receptor and CD20, a B cell-lineage associated marker, along with CD34 and CD44 non-lineage associated molecules in Iranian children with acute lymphoblastic leukemia (ALL).",CD34 gene | CD34,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
25755857,"OBJECTIVE: This study investigated the expression and prognostic significance of the CD95 death receptor and CD20, a B cell-lineage associated marker, along with CD34 and CD44 non-lineage associated molecules in Iranian children with acute lymphoblastic leukemia (ALL).",CD44 Antigens | CD44,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
25755857,METHODS: We performed immunophenotyping for expressions of the molecules in blood samples from children diagnosed with ALL by using a panel of monoclonal antibodies for flow cytometry analysis.,Immunophenotyping,USES,Monoclonal Antibodies
25755857,METHODS: We performed immunophenotyping for expressions of the molecules in blood samples from children diagnosed with ALL by using a panel of monoclonal antibodies for flow cytometry analysis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25776794,[Current treatment of acute lymphoblastic leukemia in adults].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
25919550,CONCLUSIONS: One-step multiplex RT-PCR may be another alternative for detection of common fusion transcripts in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25919550,CONCLUSIONS: One-step multiplex RT-PCR may be another alternative for detection of common fusion transcripts in children with ALL.,Detection,TREATS,"Leukemia, Lymphocytic, Acute"
25919550,"OBJECTIVE: To evaluate the efficiency of one-step multiplex RT-PCR for identifying four common fusion transcripts (TEL/AML1, E2A/PBX1, MLL/AF4 and BCR/ABL) in children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25919550,CONCLUSIONS: One-step multiplex RT-PCR may be another alternative for detection of common fusion transcripts in children with ALL.,Detection,TREATS,Child
25919550,CONCLUSIONS: One-step multiplex RT-PCR may be another alternative for detection of common fusion transcripts in children with ALL.,Reverse Transcriptase Polymerase Chain Reaction,METHOD_OF,Detection
25941002,"L-Asparaginase (ASNase) is a front-line chemotherapy for acute lymphoblastic leukemia (ALL), which acts by deaminating asparagine and glutamine.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25941002,"L-Asparaginase (ASNase) is a front-line chemotherapy for acute lymphoblastic leukemia (ALL), which acts by deaminating asparagine and glutamine.",ASPARAGINASE | ASPG,ISA,Pharmacotherapy
25941002,"L-Asparaginase (ASNase) is a front-line chemotherapy for acute lymphoblastic leukemia (ALL), which acts by deaminating asparagine and glutamine.",ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
25985447,BACKGROUND: The response to initial glucocorticoid (gc) treatment is a reliable stratification factor in childhood acute lymphoblastic leukemia (ALL) and may predict the response to multi-agent chemotherapy.,Glucocorticoids,ISA,Therapeutic procedure
25985447,BACKGROUND: The response to initial glucocorticoid (gc) treatment is a reliable stratification factor in childhood acute lymphoblastic leukemia (ALL) and may predict the response to multi-agent chemotherapy.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25985447,BACKGROUND: The response to initial glucocorticoid (gc) treatment is a reliable stratification factor in childhood acute lymphoblastic leukemia (ALL) and may predict the response to multi-agent chemotherapy.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26104880,Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26104880,"There is increasing evidence from genome-wide association studies for a strong inherited genetic basis of susceptibility to acute lymphoblastic leukaemia (ALL) in children, yet the effects of protein-coding variants on ALL risk have not been systematically evaluated.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26227851,"We compared the levels of chemokine receptors in marrow samples from 82 children with ALL at diagnosis versus 15 at relapses, and quantified the levels of chemokines in central system fluid (CSF) samples.",Child,LOCATION_OF,chemokine receptor
26227851,"We compared the levels of chemokine receptors in marrow samples from 82 children with ALL at diagnosis versus 15 at relapses, and quantified the levels of chemokines in central system fluid (CSF) samples.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26227851,"We compared the levels of chemokine receptors in marrow samples from 82 children with ALL at diagnosis versus 15 at relapses, and quantified the levels of chemokines in central system fluid (CSF) samples.",Fluid specimen,LOCATION_OF,chemokine receptor
26227851,"We compared the levels of chemokine receptors in marrow samples from 82 children with ALL at diagnosis versus 15 at relapses, and quantified the levels of chemokines in central system fluid (CSF) samples.",Marrow,LOCATION_OF,chemokine receptor
26547381,These novel findings suggest that an assortment of deleterious FPGS splicing alterations may constitute a mechanism of antifolate resistance in childhood ALL.,Folic Acid Antagonists,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25582575,"We studied 522 Danish children with ALL, 93% of all those eligible.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25603726,This article will briefly review asparaginase therapy in children with ALL and comprehensively analyze recent reports on the potential mechanisms of asparaginase resistance.,Therapeutic procedure,USES,ASPARAGINASE
25603726,This article will briefly review asparaginase therapy in children with ALL and comprehensively analyze recent reports on the potential mechanisms of asparaginase resistance.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
25603726,This article will briefly review asparaginase therapy in children with ALL and comprehensively analyze recent reports on the potential mechanisms of asparaginase resistance.,ASPARAGINASE,ISA,Therapeutic procedure
25603726,This article will briefly review asparaginase therapy in children with ALL and comprehensively analyze recent reports on the potential mechanisms of asparaginase resistance.,ASPARAGINASE,TREATS,Child
25603726,"Not only leukemic cells but also patients themselves may play a role in causing asparaginase resistance, which has been associated with unfavorable outcome in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25603726,"Not only leukemic cells but also patients themselves may play a role in causing asparaginase resistance, which has been associated with unfavorable outcome in children with ALL.",ASPARAGINASE,TREATS,Child
25603726,This article will briefly review asparaginase therapy in children with ALL and comprehensively analyze recent reports on the potential mechanisms of asparaginase resistance.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25603726,"Not only leukemic cells but also patients themselves may play a role in causing asparaginase resistance, which has been associated with unfavorable outcome in children with ALL.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
25603726,This article will briefly review asparaginase therapy in children with ALL and comprehensively analyze recent reports on the potential mechanisms of asparaginase resistance.,Therapeutic procedure,TREATS,Child
25789165,BACKGROUND: Acute Lymphoblastic Leukaemia (ALL) is the most common cancer in children.,Malignant Neoplasms,PROCESS_OF,Child
25789165,BACKGROUND: Acute Lymphoblastic Leukaemia (ALL) is the most common cancer in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
25789165,BACKGROUND: Acute Lymphoblastic Leukaemia (ALL) is the most common cancer in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25929116,This study investigated the perceptions and experiences of parents caring for newly diagnosed children with acute lymphoblastic leukemia (ALL) in relation to education given prior to the first discharge from hospital.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25929116,This study investigated the perceptions and experiences of parents caring for newly diagnosed children with acute lymphoblastic leukemia (ALL) in relation to education given prior to the first discharge from hospital.,Hospitals,LOCATION_OF,Clinical Research
25929116,Educatin given to parents of children newly diagnosed with acute lymphoblastic leukemia: the parent's perspective.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25929116,Understanding the family perspective is crucial to enabling clinicians to provide appropriate and informative education to children with ALL and their families.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Family
25929116,Understanding the family perspective is crucial to enabling clinicians to provide appropriate and informative education to children with ALL and their families.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25929116,"Using a grounded theory approach, 12 parents of children with ALL from a tertiary pediatric hematology and oncology setting in New Zealand were interviewed using a semi-structured interview technique.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25994910,In 2002-2007 children and adolescents with acute lymphoblastic leukemia were treated in an international randomized trial ALL-IC BFM 2002 in the Czech Republic.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
25994910,In 2002-2007 children and adolescents with acute lymphoblastic leukemia were treated in an international randomized trial ALL-IC BFM 2002 in the Czech Republic.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25994910,[The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26040247,The impact of etoposide (VP-16) plasma concentrations on the day of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on leukemia-free survival in children with acute lymphoblastic leukemia (ALL) was studied.,Hematopoietic Stem Cell Transplantation,TREATS,Child
26040247,The impact of etoposide (VP-16) plasma concentrations on the day of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on leukemia-free survival in children with acute lymphoblastic leukemia (ALL) was studied.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26040247,The impact of etoposide (VP-16) plasma concentrations on the day of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on leukemia-free survival in children with acute lymphoblastic leukemia (ALL) was studied.,VP-16,ISA,Etoposide
26040247,The impact of etoposide (VP-16) plasma concentrations on the day of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on leukemia-free survival in children with acute lymphoblastic leukemia (ALL) was studied.,Hematopoietic Stem Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
26237584,"The authors compared birth certificate data of 575 children diagnosed with ALL who were younger than 5 years and included in the Texas Cancer Registry, Texas Department of Health, between the years 1995 and 2003 with 11,379 controls matched by birth year.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26302283,CONCLUSIONS: Oxidative stress occurs following chemo-therapy for childhood ALL and is related to impaired fine motor skills and visual symptoms.,Chemotherapy-Oncologic Procedure,TREATS,Visual symptoms
26302283,"PURPOSE/OBJECTIVES: To examine associations among oxidative stress, fine and visual-motor abilities, and behavioral adjustment in children receiving chemotherapy for acute lymphoblastic leukemia (ALL).",motor ability,PROCESS_OF,Child
26302283,CONCLUSIONS: Oxidative stress occurs following chemo-therapy for childhood ALL and is related to impaired fine motor skills and visual symptoms.,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26302283,"PURPOSE/OBJECTIVES: To examine associations among oxidative stress, fine and visual-motor abilities, and behavioral adjustment in children receiving chemotherapy for acute lymphoblastic leukemia (ALL).",Pharmacotherapy,ADMINISTERED_TO,Child
26302283,CONCLUSIONS: Oxidative stress occurs following chemo-therapy for childhood ALL and is related to impaired fine motor skills and visual symptoms.,Chemotherapy-Oncologic Procedure,ISA,Therapeutic procedure
26302283,"FINDINGS: Children with ALL had below-average fine motor dexterity, visual processing speed, and visual-motor integration following the induction phase of ALL therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26302283,"FINDINGS: Children with ALL had below-average fine motor dexterity, visual processing speed, and visual-motor integration following the induction phase of ALL therapy.",Ability to perform general manipulative activities,PROCESS_OF,Child
26302283,SAMPLE: 89 children with ALL were followed from diagnosis to the end of chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26302283,CONCLUSIONS: Oxidative stress occurs following chemo-therapy for childhood ALL and is related to impaired fine motor skills and visual symptoms.,Oxidative Stress,AFFECTS,fine motor skills
26302283,"PURPOSE/OBJECTIVES: To examine associations among oxidative stress, fine and visual-motor abilities, and behavioral adjustment in children receiving chemotherapy for acute lymphoblastic leukemia (ALL).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26408741,AIM: To analyze the drug-resistance profile at first and subsequent relapse in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26700663,Acute lymphoblastic leukemia (ALL) is the major neoplasia type among children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25624441,PURPOSE: Mercaptopurine (MP) is the mainstay of curative therapy for acute lymphoblastic leukemia (ALL).,6-Mercaptopurine,ISA,Therapeutic procedure
25624441,Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.,Child,LOCATION_OF,NUDT15
25624441,Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25624441,We performed a genome-wide association study (GWAS) to identify comprehensively the genetic basis of MP intolerance in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25624441,PURPOSE: Mercaptopurine (MP) is the mainstay of curative therapy for acute lymphoblastic leukemia (ALL).,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
25687037,"OBJECTIVE: To study the methylation level in the promoter of caspase 8 associated protein 2 (CASP8AP2) gene between samples at diagnosis and in complete remission, and to investigate its relationship with clinical features and prognosis in children with acute lymphoblastic leukemia (ALL).",Diagnosis,TREATS,Child
25687037,"OBJECTIVE: To study the methylation level in the promoter of caspase 8 associated protein 2 (CASP8AP2) gene between samples at diagnosis and in complete remission, and to investigate its relationship with clinical features and prognosis in children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25687037,"METHODS: Diagnostic DNA samples from 109 newly diagnosed children with ALL admitted from August 2007 to March 2010, and 94 ALL children in CR (complete remission) among them were collected.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25687037,"METHODS: Diagnostic DNA samples from 109 newly diagnosed children with ALL admitted from August 2007 to March 2010, and 94 ALL children in CR (complete remission) among them were collected.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25687037,"METHODS: Diagnostic DNA samples from 109 newly diagnosed children with ALL admitted from August 2007 to March 2010, and 94 ALL children in CR (complete remission) among them were collected.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25939871,"Some genetic polymorphisms can predict treatment-related toxicity, and be used individually in dose modification of 6-mercaptopurine (6-MP) and methotrexate (MTX) in maintenance therapy for childhood acute lymphoblastic leukemia (ALL).",Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25962120,"Using whole-exome sequencing, we identified relapse-specific mutations in the phosphoribosyl pyrophosphate synthetase 1 gene (PRPS1), which encodes a rate-limiting purine biosynthesis enzyme, in 24/358 (6.7%) relapsed childhood B cell ALL (B-ALL) cases.",B-cell childhood acute lymphoblastic leukemia,ISA,"Leukemia, Lymphocytic, Acute"
25962120,Relapse is the leading cause of mortality in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26050202,"CONCLUSIONS: Given the lower incidence of ADRs between VCR and fluconazole compared with voriconazole or itraconazole, it is relatively safer to use fluconazole in ALL patients receiving VCR chemotherapy.",Vincristine,ADMINISTERED_TO,Patients
26050202,BACKGROUND: Vincristine (VCR) is a major chemotherapy drug for treatment of childhood acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26050202,"CONCLUSIONS: Given the lower incidence of ADRs between VCR and fluconazole compared with voriconazole or itraconazole, it is relatively safer to use fluconazole in ALL patients receiving VCR chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
26050202,BACKGROUND: Vincristine (VCR) is a major chemotherapy drug for treatment of childhood acute lymphoblastic leukemia (ALL).,Vincristine,ISA,Pharmaceutical Preparations
26050202,"CONCLUSIONS: Given the lower incidence of ADRs between VCR and fluconazole compared with voriconazole or itraconazole, it is relatively safer to use fluconazole in ALL patients receiving VCR chemotherapy.",Pharmacotherapy,USES,Vincristine
26050202,"CONCLUSIONS: Given the lower incidence of ADRs between VCR and fluconazole compared with voriconazole or itraconazole, it is relatively safer to use fluconazole in ALL patients receiving VCR chemotherapy.",Adverse drug effect,PROCESS_OF,Patients
26050202,BACKGROUND: Vincristine (VCR) is a major chemotherapy drug for treatment of childhood acute lymphoblastic leukemia (ALL).,Vincristine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26050202,"MATERIAL AND METHODS: A retrospective study was performed on 68 children with ALL (39 boys and 29 girls, median age: 5 years) who were treated with VCR chemotherapy (a total of 136 cases, including both induction and reinduction phases) from January 2012 to December 2013 in our hospital.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26050202,"CONCLUSIONS: Given the lower incidence of ADRs between VCR and fluconazole compared with voriconazole or itraconazole, it is relatively safer to use fluconazole in ALL patients receiving VCR chemotherapy.",Fluconazole,compared_with,voriconazole
26050202,Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia.,Adverse drug effect,PROCESS_OF,Child
26050202,"MATERIAL AND METHODS: A retrospective study was performed on 68 children with ALL (39 boys and 29 girls, median age: 5 years) who were treated with VCR chemotherapy (a total of 136 cases, including both induction and reinduction phases) from January 2012 to December 2013 in our hospital.",Vincristine,ISA,Pharmacotherapy
26050202,"MATERIAL AND METHODS: A retrospective study was performed on 68 children with ALL (39 boys and 29 girls, median age: 5 years) who were treated with VCR chemotherapy (a total of 136 cases, including both induction and reinduction phases) from January 2012 to December 2013 in our hospital.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26050202,"CONCLUSIONS: Given the lower incidence of ADRs between VCR and fluconazole compared with voriconazole or itraconazole, it is relatively safer to use fluconazole in ALL patients receiving VCR chemotherapy.",Pharmacotherapy,ADMINISTERED_TO,Patients
26050202,Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26050202,"MATERIAL AND METHODS: A retrospective study was performed on 68 children with ALL (39 boys and 29 girls, median age: 5 years) who were treated with VCR chemotherapy (a total of 136 cases, including both induction and reinduction phases) from January 2012 to December 2013 in our hospital.",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
26050202,"CONCLUSIONS: Given the lower incidence of ADRs between VCR and fluconazole compared with voriconazole or itraconazole, it is relatively safer to use fluconazole in ALL patients receiving VCR chemotherapy.",Vincristine,ISA,Pharmacotherapy
26050202,"MATERIAL AND METHODS: A retrospective study was performed on 68 children with ALL (39 boys and 29 girls, median age: 5 years) who were treated with VCR chemotherapy (a total of 136 cases, including both induction and reinduction phases) from January 2012 to December 2013 in our hospital.",Pharmacotherapy,USES,Vincristine
26050650,We performed a comprehensive analysis of the impact of IKZF1(del) in a large cohort of children (n=1223) with BCR-ABL1-negative BCP-ALL treated in the EORTC-CLG trial 58951.,cohort,LOCATION_OF,IKZF1
26050650,We performed a comprehensive analysis of the impact of IKZF1(del) in a large cohort of children (n=1223) with BCR-ABL1-negative BCP-ALL treated in the EORTC-CLG trial 58951.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26237075,"Although children with acute lymphoblastic leukemia (ALL) generally have a good outcome, some patients do relapse and survival following relapse is poor.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26312396,The present study assessed neuropsychological function in very long-term childhood ALL survivors treated with chemotherapy only.,Pharmacotherapy,TREATS,Long-Term Survivors
26312396,The present study assessed neuropsychological function in very long-term childhood ALL survivors treated with chemotherapy only.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Long-Term Survivors
26312396,The present study assessed neuropsychological function in very long-term childhood ALL survivors treated with chemotherapy only.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26312396,"CONCLUSIONS: Very long-term survivors of childhood ALL treated exclusively with chemotherapy showed no impairment in general intellectual ability, but significantly poorer performance in several neurocognitive domains than comparison peers.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25687037,CONCLUSION: The abnormal hypermethylation of the two CpG sites (at -1189 and -1176) of the promoter of the CASP8AP2 gene is possibly associated with leukemogenesis in childhood ALL.,Leukemogenesis,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
25687037,CONCLUSION: The abnormal hypermethylation of the two CpG sites (at -1189 and -1176) of the promoter of the CASP8AP2 gene is possibly associated with leukemogenesis in childhood ALL.,Leukemogenesis,AFFECTS,Hypermethylation
25687037,"METHODS: Diagnostic DNA samples from 109 newly diagnosed children with ALL admitted from August 2007 to March 2010, and 94 ALL children in CR (complete remission) among them were collected.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25687037,"METHODS: Diagnostic DNA samples from 109 newly diagnosed children with ALL admitted from August 2007 to March 2010, and 94 ALL children in CR (complete remission) among them were collected.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25687037,"METHODS: Diagnostic DNA samples from 109 newly diagnosed children with ALL admitted from August 2007 to March 2010, and 94 ALL children in CR (complete remission) among them were collected.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25698214,"BACKGROUND: Little is known about the relationship between family characteristics and survival from childhood acute lymphoblastic leukaemia (ALL), which we studied for the first time in German children.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
25788208,Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.,Methotrexate,ISA,Therapeutic procedure
25788208,Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.,6-Mercaptopurine,ISA,Therapeutic procedure
25788208,Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.,6-Mercaptopurine,USES,Methotrexate
25788208,High-dose methotrexate (HD-MTX) courses with concurrent oral low-dose MTX/6-mercaptopurine (6MP) for childhood acute lymphoblastic leukaemia (ALL) are often followed by neutro- and thrombocytopenia necessitating treatment interruptions.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25788208,Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25788208,Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.,6-Mercaptopurine,PREDISPOSES,Bone marrow toxicity
25788208,Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.,Therapeutic procedure,USES,Methotrexate
25798280,The present study aimed to determine the association between the HLA-DRB1 genotype and susceptibility to ALL in children and to assess the prognostic value of HLA-DRB1 alleles in these patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25809628,Therapeutic value of black seed oil in methotrexate hepatotoxicity in Egyptian children with acute lymphoblastic leukemia.,Hepatotoxicity,PROCESS_OF,Child
25809628,SUBJECTS AND METHODS: This study was conducted on 40 children with acute lymphoblastic leukemia' including 20 patients under methotrexate therapy and Black seeds 80 mg/kg/day for one week after each methotrexate dose [Group II] and 20 patients under methotrexate therapy and placebo [Group III].,Therapeutic procedure,USES,Methotrexate
25809628,Therapeutic value of black seed oil in methotrexate hepatotoxicity in Egyptian children with acute lymphoblastic leukemia.,Oils,ASSOCIATED_WITH,Hepatotoxicity
25809628,SUBJECTS AND METHODS: This study was conducted on 40 children with acute lymphoblastic leukemia' including 20 patients under methotrexate therapy and Black seeds 80 mg/kg/day for one week after each methotrexate dose [Group II] and 20 patients under methotrexate therapy and placebo [Group III].,Methotrexate,ISA,Therapeutic procedure
25809628,Therapeutic value of black seed oil in methotrexate hepatotoxicity in Egyptian children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25809628,SUBJECTS AND METHODS: This study was conducted on 40 children with acute lymphoblastic leukemia' including 20 patients under methotrexate therapy and Black seeds 80 mg/kg/day for one week after each methotrexate dose [Group II] and 20 patients under methotrexate therapy and placebo [Group III].,Methotrexate,ISA,Therapeutic procedure
25809628,AIM OF THE STUDY: To assess the therapeutic value of Black seed oil in 'methotrexate induced hepatotoxicity in Egyptian children with acute lymphoblastic leukemia'.,Hepatotoxicity,PROCESS_OF,Child
25809628,AIM OF THE STUDY: To assess the therapeutic value of Black seed oil in 'methotrexate induced hepatotoxicity in Egyptian children with acute lymphoblastic leukemia'.,Methotrexate,CAUSES,Hepatotoxicity
25809628,SUBJECTS AND METHODS: This study was conducted on 40 children with acute lymphoblastic leukemia' including 20 patients under methotrexate therapy and Black seeds 80 mg/kg/day for one week after each methotrexate dose [Group II] and 20 patients under methotrexate therapy and placebo [Group III].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25809628,AIM OF THE STUDY: To assess the therapeutic value of Black seed oil in 'methotrexate induced hepatotoxicity in Egyptian children with acute lymphoblastic leukemia'.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25809628,SUBJECTS AND METHODS: This study was conducted on 40 children with acute lymphoblastic leukemia' including 20 patients under methotrexate therapy and Black seeds 80 mg/kg/day for one week after each methotrexate dose [Group II] and 20 patients under methotrexate therapy and placebo [Group III].,Therapeutic procedure,USES,Methotrexate
26060305,Study of Posterior Reversible Encephalopathy Syndrome in Children With Acute Lymphoblastic Leukemia After Induction Chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26060305,Increasing occurrence of posterior reversible encephalopathy syndrome has been reported in children with acute lymphoblastic leukemia.,Syndrome,PROCESS_OF,Child
26060305,Increasing occurrence of posterior reversible encephalopathy syndrome has been reported in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26060305,Study of Posterior Reversible Encephalopathy Syndrome in Children With Acute Lymphoblastic Leukemia After Induction Chemotherapy.,Syndrome,PROCESS_OF,Child
26060508,"Due to limitations of comparative genomic hybridization, in terms of a routine application as first line-screening tests we evaluated the multiplex ligation-dependent probe amplification (MLPA) SALSA P327_A1 and P327_B1 probe sets for detecting chromosome 21 copy number alterations in Brazilian childhood BCP-ALL.",Chromosome abnormality,COEXISTS_WITH,B-cell childhood acute lymphoblastic leukemia
26060508,"Due to limitations of comparative genomic hybridization, in terms of a routine application as first line-screening tests we evaluated the multiplex ligation-dependent probe amplification (MLPA) SALSA P327_A1 and P327_B1 probe sets for detecting chromosome 21 copy number alterations in Brazilian childhood BCP-ALL.",Probes,TREATS,Chromosome abnormality
26171706,Pediatric acute lymphoblastic leukemia is the most common childhood cancer.,"Leukemia, Lymphocytic, Acute, L1",ISA,Malignant Childhood Neoplasm
26225654,"MATERIALS AND METHODS: The study concerned 50 children diagnosed with ALL (mean age, 8.55+/-2.54) compared to 40 healthy controls (mean age, 8.00+/-1.85).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26376459,Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
26376459,Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26376459,"In a single-arm, multicenter study, we evaluated nadir serum asparaginase activity (NSAA) and toxicity with intravenously administered asparaginase Erwinia chrysanthemi (IV-Erwinia) in children and adolescents with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma with hypersensitivity to E.coli-derived asparaginase.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26376459,"In a single-arm, multicenter study, we evaluated nadir serum asparaginase activity (NSAA) and toxicity with intravenously administered asparaginase Erwinia chrysanthemi (IV-Erwinia) in children and adolescents with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma with hypersensitivity to E.coli-derived asparaginase.",Toxic effect,PROCESS_OF,Child
26376459,Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.,Hypersensitivity,PROCESS_OF,Adolescent
26376459,Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.,Hypersensitivity,PROCESS_OF,Child
26524013,CD10(-) pro-B acute lymphoblastic leukemia (Pro - B-ALL) was predo-minant in infantile group (60%) with CD117 higher expression (40%).,"Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
26621337,"We characterized NK cells in 50 consecutive children with B-ALL at diagnosis, end induction and during maintenance therapy compared with age-matched controls.",Diagnosis,COEXISTS_WITH,Induction
26621337,"We characterized NK cells in 50 consecutive children with B-ALL at diagnosis, end induction and during maintenance therapy compared with age-matched controls.",Diagnosis,COEXISTS_WITH,Maintenance therapy
26621337,"We characterized NK cells in 50 consecutive children with B-ALL at diagnosis, end induction and during maintenance therapy compared with age-matched controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26711002,The t(12;21)(p13;q22) ETV6-RUNX1 gene fusion is one of the most common chromosomal translocation in childhood acute lymphoblastic leukemia (ALL).,Chromosomal translocation,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
25696852,These efforts are now being extended to ALL in adolescents and adults with the goal of fully defining the genetic landscape of ALL to further improve treatment outcomes in high-risk populations.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,High Risk Populations
25696852,These efforts are now being extended to ALL in adolescents and adults with the goal of fully defining the genetic landscape of ALL to further improve treatment outcomes in high-risk populations.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
25696852,These efforts are now being extended to ALL in adolescents and adults with the goal of fully defining the genetic landscape of ALL to further improve treatment outcomes in high-risk populations.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
25696852,The genomic landscape of acute lymphoblastic leukemia in children and young adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25696852,The genomic landscape of acute lymphoblastic leukemia in children and young adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
25808195,"RESULTS: The Study Population comprised 99 children with ALL diagnosed between 2007 and 2010, and the Historic Cohort comprised 181 children treated prior to the study interventions (1995-2004).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26124497,Minimal residual disease (MRD) is highly prognostic in pediatric B-precursor acute lymphoblastic leukemia (B-ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
26124497,Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
26137447,The study was conducted in 95 children with ALL and 190 healthy control subjects from the Turkish population.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26202931,Deletions in IKZF1 are found in ~15% of children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
26235006,"In conclusion, children with SR-ALL experience considerable impairment in HRQOL at the end of induction, but rapidly improve.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26321572,Acute lymphoblastic leukemia (ALL) is a malignant tumor common in children.,Malignant Neoplasms,PROCESS_OF,Child
26321572,Acute lymphoblastic leukemia (ALL) is a malignant tumor common in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
26321572,Acute lymphoblastic leukemia (ALL) is a malignant tumor common in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26321572,"In this study, we investigate the role of eight functional INDEL polymorphisms and influence of genetic ancestry to B-cell ALL susceptibility in children of Brazilian Amazon population, which has a high degree of inter-ethnic admixture.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
26376115,BACKGROUND: Current outcome of very early relapse of acute lymphoblastic leukemia (ALL) in children remains poor.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26449287,This study enrolled 123 children with de novo acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26449287,The early persistence of minimal residual disease (MRD) is considered a poor prognostic factor indicative of chemoresistance in acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
26501552,CONCLUSIONS: Children with ALL have higher levels of p15 CpG island methylation than a control group of children with ITP.,Inosine Triphosphate,PART_OF,Child
26501552,CONCLUSIONS: Children with ALL have higher levels of p15 CpG island methylation than a control group of children with ITP.,CpG Islands,PART_OF,CDKN2B gene | CDKN2B
26501552,"Among children with ALL, hypermethylation was associated with inferior EFS.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26501552,CONCLUSIONS: Children with ALL have higher levels of p15 CpG island methylation than a control group of children with ITP.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26522332,ETV6 variant function was characterised bioinformatically and correlated with clinical and demographic features in children with ALL.,Child,LOCATION_OF,ETS Variant Gene 6 Protein | ETV6
26522332,ETV6 variant function was characterised bioinformatically and correlated with clinical and demographic features in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26586463,Effective VCR/DEX pulse maintenance therapy in the KYCCSG ALL-02 protocol for pediatric acute lymphoblastic leukemia.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26698391,"L-asparaginase, an anti-leukaemic drug that has been approved for clinical use for many years in the treatment of childhood Acute Lymphoblastic Leukaemia (ALL), is obtained from bacterial origin (Escherichia coli and Erwinia carotovora).",Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26698391,"L-asparaginase, an anti-leukaemic drug that has been approved for clinical use for many years in the treatment of childhood Acute Lymphoblastic Leukaemia (ALL), is obtained from bacterial origin (Escherichia coli and Erwinia carotovora).","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
26698391,L-asparaginase as a critical component to combat Acute Lymphoblastic Leukaemia (ALL): A novel approach to target ALL.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
26710773,Detection of a specific gene rearrangement allows the identification of prognostically relevant subgroups in childhood B-ALL.,Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25696852,These efforts are now being extended to ALL in adolescents and adults with the goal of fully defining the genetic landscape of ALL to further improve treatment outcomes in high-risk populations.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,High Risk Populations
25696852,These efforts are now being extended to ALL in adolescents and adults with the goal of fully defining the genetic landscape of ALL to further improve treatment outcomes in high-risk populations.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
25696852,These efforts are now being extended to ALL in adolescents and adults with the goal of fully defining the genetic landscape of ALL to further improve treatment outcomes in high-risk populations.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
25761407,"Association of genetic variation in IKZF1, ARID5B, and CEBPE and surrogates for early-life infections with the risk of acute lymphoblastic leukemia in Hispanic children.",ARID5B,AFFECTS,Variation (Genetics)
25761407,"Association of genetic variation in IKZF1, ARID5B, and CEBPE and surrogates for early-life infections with the risk of acute lymphoblastic leukemia in Hispanic children.",IKZF1,AFFECTS,Variation (Genetics)
25761407,"Association of genetic variation in IKZF1, ARID5B, and CEBPE and surrogates for early-life infections with the risk of acute lymphoblastic leukemia in Hispanic children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25761407,"Association of genetic variation in IKZF1, ARID5B, and CEBPE and surrogates for early-life infections with the risk of acute lymphoblastic leukemia in Hispanic children.",Infection,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
25761407,"Association of genetic variation in IKZF1, ARID5B, and CEBPE and surrogates for early-life infections with the risk of acute lymphoblastic leukemia in Hispanic children.",CEBPE gene | CEBPE,AFFECTS,Variation (Genetics)
25948177,[Cytogenetic characteristics of 163 children with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25992345,OBJECTIVE: To study the clinical significance of TK-1 in children with ALL.,Child,LOCATION_OF,thymidine kinase 1
25992345,OBJECTIVE: To study the clinical significance of TK-1 in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25992345,Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia.,Child,LOCATION_OF,Thymidine Kinase
25992345,Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26100991,CONCLUSION: The frequency of T-ALL is higher in childhood as well as adult ALL in our population compared to the Western literature.,"Leukemia, Lymphocytic, Acute, L2",ISA,"Leukemia, Lymphocytic, Acute"
26101530,We undertook a retrospective review of children diagnosed with acute lymphoblastic leukemia (ALL) and treated with modern COG protocols (n = 80) to determine longitudinal changes in body mass index (BMI) and the prevalence of obesity compared with a healthy reference population.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26148325,"IMPLICATIONS FOR NURSING: Obesity/overweight prevention efforts are greatly needed in children with ALL, and efforts should occur before ALL treatment completion in preschool and school-age children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,School child
26148325,"IMPLICATIONS FOR NURSING: Obesity/overweight prevention efforts are greatly needed in children with ALL, and efforts should occur before ALL treatment completion in preschool and school-age children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26148325,"CONCLUSIONS: Important variations in rate and pattern of weight status trajectories exist by age group, demonstrating that children diagnosed with ALL during the preschool and school-age developmental years have the greatest vulnerability of developing obesity/overweight status.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26148325,"IMPLICATIONS FOR NURSING: Obesity/overweight prevention efforts are greatly needed in children with ALL, and efforts should occur before ALL treatment completion in preschool and school-age children.",Treatment completed,PREVENTS,Overweight
26159252,Interaction Between IGF1 Polymorphisms and the Risk of Acute Lymphoblastic Leukemia in Chinese Children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26202590,PATIENTS AND METHODS: We retrospectively analyzed the hospital reports of 323 children with de novo acute lymphoblastic leukemia from a 13-year period for acute neurological complications.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26266029,"The participants involved were an experimental group of 40 children with ALL and their mothers, and 30 healthy children as the control group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Mothers
26266029,"The participants involved were an experimental group of 40 children with ALL and their mothers, and 30 healthy children as the control group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26266029,"In this sense, the study focuses on coping strategies and locus of control in children with ALL during the treatment phase, and on their possible relation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26266029,"Both children with ALL and their mothers resorted to monitoring coping strategies with a statistically significant rate of occurrence (children: M=17.8, SD=3.8; mothers: M=10.48, SD=3.4).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Mothers
26266029,"Both children with ALL and their mothers resorted to monitoring coping strategies with a statistically significant rate of occurrence (children: M=17.8, SD=3.8; mothers: M=10.48, SD=3.4).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26287347,"METHODS: Eighty-seven children diagnosed with B-ALL between January 2014 and September 2014 were enrolled, and 20 hospitalized children who had no tumor or blood disease and had normal bone marrow cell morphology served as the control group.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26287347,"METHODS: Eighty-seven children diagnosed with B-ALL between January 2014 and September 2014 were enrolled, and 20 hospitalized children who had no tumor or blood disease and had normal bone marrow cell morphology served as the control group.",Neoplasm,PROCESS_OF,"Child, Hospitalized"
26287347,"METHODS: Eighty-seven children diagnosed with B-ALL between January 2014 and September 2014 were enrolled, and 20 hospitalized children who had no tumor or blood disease and had normal bone marrow cell morphology served as the control group.",Hematological Disease,PROCESS_OF,"Child, Hospitalized"
26405155,Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia.,Bone necrosis,PROCESS_OF,Child
26405155,Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26405155,"Osteonecrosis can, therefore, be considered a risk factor for low bone density in children with acute lymphoblastic leukemia.",Bone necrosis,PROCESS_OF,Child
26405155,"Osteonecrosis can, therefore, be considered a risk factor for low bone density in children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26426347,"CONCLUSION: Resilience factors may help to protect parents' mental health, especially mothers, when their child has survived acute lymphoblastic leukaemia and should be considered in a clinical setting.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26457881,Impact of therapy in a cohort of unselected children with Down Syndrome-associated Acute Lymphoblastic Leukaemia.,Therapeutic procedure,TREATS,cohort
26457881,Impact of therapy in a cohort of unselected children with Down Syndrome-associated Acute Lymphoblastic Leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26576011,"PURPOSE OF REVIEW: The prognosis for children with the most common childhood malignancy, acute lymphoblastic leukemia (ALL), has improved dramatically.",Malignant Neoplasms,PROCESS_OF,Child
26576011,"PURPOSE OF REVIEW: The prognosis for children with the most common childhood malignancy, acute lymphoblastic leukemia (ALL), has improved dramatically.","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
26576011,"PURPOSE OF REVIEW: The prognosis for children with the most common childhood malignancy, acute lymphoblastic leukemia (ALL), has improved dramatically.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26001791,Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
26001791,Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia.,Flow Cytometry,METHOD_OF,Polymerase Chain Reaction
26169300,"Further analysis of PBC-ALL in the young children suggested a better fit of models with a threshold, with the risk increasing above 100 J/cm(2), for which the SIR was 1.24 (95% CI 1.14-1.36) for a 25 J/cm(2) increase.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
26169300,"For each additional 25 J/cm(2), there was a significant increase in precursor B-cell acute lymphoblastic leukemia (PBC-ALL) in children aged less than 5 years (SIR 1.18; 95% CI 1.10-1.27).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
26265099,The levels of endotoxin and DAO were also measured in 4 different courses in 7 children with ALL.,Child,LOCATION_OF,Endotoxins
26265099,"CONCLUSION: By measuring the level of plasma endotoxin and DAO in children with ALL and during HDMTX chemotherapy, the results suggest that there is increased intestinal permeability.",Child,LOCATION_OF,Amine Oxidase (Copper-Containing)
26265099,The levels of endotoxin and DAO were also measured in 4 different courses in 7 children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26265099,"CONCLUSION: By measuring the level of plasma endotoxin and DAO in children with ALL and during HDMTX chemotherapy, the results suggest that there is increased intestinal permeability.",Child,LOCATION_OF,Endotoxins
26265099,"METHOD: Blood samples were collected from 30 normal children and 30 children with ALL at 1h, 24h, 44h and 68h after HDMTX.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26265099,"CONCLUSION: By measuring the level of plasma endotoxin and DAO in children with ALL and during HDMTX chemotherapy, the results suggest that there is increased intestinal permeability.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26265099,"METHOD: Blood samples were collected from 30 normal children and 30 children with ALL at 1h, 24h, 44h and 68h after HDMTX.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26265099,"CONCLUSION: By measuring the level of plasma endotoxin and DAO in children with ALL and during HDMTX chemotherapy, the results suggest that there is increased intestinal permeability.",high-dose chemotherapy,USES,Methotrexate
26265099,Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate.,Child,LOCATION_OF,Endotoxins
26265099,Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate.,Child,LOCATION_OF,Amine Oxidase (Copper-Containing)
26265099,"There was no significant difference found in the increased levels of endotoxin and DAO at 1h, 24h, 44h and 68h after HDMTX in 4 different courses of 7 children with ALL(P>0.05).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26265099,"CONCLUSION: By measuring the level of plasma endotoxin and DAO in children with ALL and during HDMTX chemotherapy, the results suggest that there is increased intestinal permeability.",Amine Oxidase (Copper-Containing),AUGMENTS,Permeability
26265099,Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26265099,The levels of endotoxin and DAO were also measured in 4 different courses in 7 children with ALL.,Child,LOCATION_OF,Amine Oxidase (Copper-Containing)
26265099,"CONCLUSION: By measuring the level of plasma endotoxin and DAO in children with ALL and during HDMTX chemotherapy, the results suggest that there is increased intestinal permeability.",Endotoxins,AUGMENTS,Permeability
26265099,Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
26287346,CONCLUSIONS: Application of imatinib significantly improves the clinical efficacy in children with Ph+ ALL and has good safety.,imatinib,TREATS,Child
26287346,CONCLUSIONS: Application of imatinib significantly improves the clinical efficacy in children with Ph+ ALL and has good safety.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26287346,CONCLUSIONS: Application of imatinib significantly improves the clinical efficacy in children with Ph+ ALL and has good safety.,imatinib,TREATS,"Leukemia, Lymphocytic, Acute"
26287346,"OBJECTIVE: To study the efficacy and safety of Chinese Childhood Leukemia Group ALL 2008 (CCLG-ALL2008) protocol combined with tyrosine kinase inhibitor (TKI, imatinib) for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26287346,"OBJECTIVE: To study the efficacy and safety of Chinese Childhood Leukemia Group ALL 2008 (CCLG-ALL2008) protocol combined with tyrosine kinase inhibitor (TKI, imatinib) for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in children.",Protein-tyrosine kinase inhibitor,TREATS,Philadelphia chromosome positive
26287347,"CONCLUSIONS: CD58 is over-expressed and stable in children with B-ALL, and it can be considered as an indicator for MRD detection in childhood B-ALL.",Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26287347,"CONCLUSIONS: CD58 is over-expressed and stable in children with B-ALL, and it can be considered as an indicator for MRD detection in childhood B-ALL.",Child,LOCATION_OF,CD58 gene | CD58
26287347,"CONCLUSIONS: CD58 is over-expressed and stable in children with B-ALL, and it can be considered as an indicator for MRD detection in childhood B-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26287347,"In the B-ALL children, the expression of CD58 on day 15 of induction chemotherapy (105+/-22) was not significantly different from that at diagnosis (107+/-26) (P>0.05).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26425336,CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
26425336,"Remarkably, 67-90% of children and adults with B-ALL treated with CD19 CAR T cells in these trials have achieved morphologic leukemia remission with many patients also in molecular remission.",T-Lymphocyte,PART_OF,Child
26425336,CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).,"Leukemia, B-Cell, Acute",PROCESS_OF,Adult
26425336,"Remarkably, 67-90% of children and adults with B-ALL treated with CD19 CAR T cells in these trials have achieved morphologic leukemia remission with many patients also in molecular remission.",T-Lymphocyte,PART_OF,Adult
26425336,CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).,Immunotherapy,TREATS,"Leukemia, B-Cell, Acute"
26425336,Investigative teams at several major cancer centers are currently conducting phase I clinical trials in children and/or adults with relapsed/refractory B-ALL to assess the safety and to identify the maximally tolerated dose of each group's CD19 CAR T-cell product.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
26425336,Relapsed and chemotherapy-refractory B-cell acute lymphoblastic leukemia (B-ALL) remain significant causes of cancer-associated morbidity and mortality for children and adults.,"Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
26425336,CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).,Immunotherapy,TREATS,Child
26425336,"Remarkably, 67-90% of children and adults with B-ALL treated with CD19 CAR T cells in these trials have achieved morphologic leukemia remission with many patients also in molecular remission.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26425336,CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).,Immunotherapy,TREATS,Adult
26425336,"Remarkably, 67-90% of children and adults with B-ALL treated with CD19 CAR T cells in these trials have achieved morphologic leukemia remission with many patients also in molecular remission.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
25589462,B cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common type of cancer in children.,Malignant Neoplasms,PROCESS_OF,Child
25589462,B cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common type of cancer in children.,"Leukemia, B-Cell, Acute",ISA,Malignant Neoplasms
25589462,B cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common type of cancer in children.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
25673168,"CONCLUSIONS: The current meta-analysis showed that there was association between CYP3A5 FNx01 3 polymorphism and the altered risk of ALL in children, especially in Caucasian populations.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25673168,"In subgroup analysis, the Z values of CYP3A5 FNx01 3 (heterozygous + homozygous) mutant and children with ALL in Asian and Caucasian populations were 1.34 and 2.51 with P = 0.18 and 0.01, respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25673168,"In subgroup analysis, the Z values of CYP3A5 FNx01 3 (heterozygous + homozygous) mutant and children with ALL in Asian and Caucasian populations were 1.34 and 2.51 with P = 0.18 and 0.01, respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Asians
25673448,BACKGROUND: Infections remain a major cause of therapy-associated morbidity and mortality in children with acute lymphoblastic leukemia (ALL).,Infection,PROCESS_OF,Child
25673448,BACKGROUND: Infections remain a major cause of therapy-associated morbidity and mortality in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25989709,"Childhood cancer (377 cases diagnosed prior to age 15 years) risk was analysed by type (all sites, leukaemia, acute lymphoblastic leukaemia, and non-leukaemia) and age at diagnosis.","Leukemia, Lymphocytic, Acute",ISA,leukemia
26001296,"Finally, common biological traits characterizing aggressive forms of ALL in both children and adults were found, including features of dormant hematopoietic stem cells, suggesting new therapeutic strategies.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26001296,"Finally, common biological traits characterizing aggressive forms of ALL in both children and adults were found, including features of dormant hematopoietic stem cells, suggesting new therapeutic strategies.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
26189108,20% of children suffering from high hyperdiploid acute lymphoblastic leukemia develop recurrent disease.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26211675,Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26211675,Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries.,"Complication, infection",PROCESS_OF,Child
26211675,"Children in LMIC with ALL, who are frequently underweight, are at increased risk of community-acquired pathogens, nosocomial multidrug-resistant pathogens and opportunistic microorganisms.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Opportunistic Infectious agent
26211675,"Children in LMIC with ALL, who are frequently underweight, are at increased risk of community-acquired pathogens, nosocomial multidrug-resistant pathogens and opportunistic microorganisms.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26211807,"In recent years, focus has been put on analyzing the genetic susceptibility in cancer and hematological malignancies, particularly in childhood acute lymphoblastic leukemia, using specific gene or (genome-wide association study) approach.",Hematologic Neoplasms,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
26211807,"In recent years, focus has been put on analyzing the genetic susceptibility in cancer and hematological malignancies, particularly in childhood acute lymphoblastic leukemia, using specific gene or (genome-wide association study) approach.",Malignant Neoplasms,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
26222068,The objective of this study was to determine the frequency of RAS mutations and the association between RAS mutations and other genetic aberrations in Arab Asian children with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
26222068,The objective of this study was to determine the frequency of RAS mutations and the association between RAS mutations and other genetic aberrations in Arab Asian children with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26308766,BACKGROUND: The objectives of this study were to assess the incidence of clinical allergy and end-induction antiasparaginase (anti-ASNase) antibodies in children with high-risk acute lymphoblastic leukemia treated with pegylated (PEG) Escherichia coli ASNase and to determine whether they carry any prognostic significance.,Hypersensitivity,PROCESS_OF,Child
26308766,BACKGROUND: The objectives of this study were to assess the incidence of clinical allergy and end-induction antiasparaginase (anti-ASNase) antibodies in children with high-risk acute lymphoblastic leukemia treated with pegylated (PEG) Escherichia coli ASNase and to determine whether they carry any prognostic significance.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26308766,BACKGROUND: The objectives of this study were to assess the incidence of clinical allergy and end-induction antiasparaginase (anti-ASNase) antibodies in children with high-risk acute lymphoblastic leukemia treated with pegylated (PEG) Escherichia coli ASNase and to determine whether they carry any prognostic significance.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
26308766,BACKGROUND: The objectives of this study were to assess the incidence of clinical allergy and end-induction antiasparaginase (anti-ASNase) antibodies in children with high-risk acute lymphoblastic leukemia treated with pegylated (PEG) Escherichia coli ASNase and to determine whether they carry any prognostic significance.,ASPARAGINASE,PART_OF,Escherichia coli
26308766,Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.,Allergic Reaction,PROCESS_OF,Child
26308766,Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26617896,CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia.,Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
26707629,Essentials Children with acute lymphoblastic leukemia (ALL) are at risk of thromboembolism (TE).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26707629,Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.,Thromboembolism,PROCESS_OF,Child
26707629,Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26707629,SUMMARY: Background Thromboembolism (TE) is a major toxicity in children with acute lymphoblastic leukemia (ALL) and may have a negative impact on ALL treatment.,Toxic effect,PROCESS_OF,Child
26707629,SUMMARY: Background Thromboembolism (TE) is a major toxicity in children with acute lymphoblastic leukemia (ALL) and may have a negative impact on ALL treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26707629,"This is a prospective evaluation of the incidence, risk factors and outcomes of TE in 1038 children with ALL.",Thromboembolism,OCCURS_IN,Child
26707629,"This is a prospective evaluation of the incidence, risk factors and outcomes of TE in 1038 children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26221900,"However, the threshold 70 WT1 copies/104 ABL copies post induction in childhood ALL did not show clinical significance for predicting prognosis (p=0.056).",Induction,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26221900,We detected WT1-RNA transcript level to estimate the diagnostic value of monitoring MRD in childhood acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,pediatric acute myeloblastic leukemia
26221900,We detected WT1-RNA transcript level to estimate the diagnostic value of monitoring MRD in childhood acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
26221900,But it did not show good enough to monitor MRD in childhood ALL.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
26509298,Acute lymphoblastic leukemia (ALL) is the most common cancer in children.,Malignant Neoplasms,PROCESS_OF,Child
26509298,Acute lymphoblastic leukemia (ALL) is the most common cancer in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
26509298,Acute lymphoblastic leukemia (ALL) is the most common cancer in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27527070,"RESULTS: Our study cohort consisted of 51 participants, made up of matched pediatric and adolescent patients with ALL and a healthy sibling.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Participant
27527070,"RESULTS: Our study cohort consisted of 51 participants, made up of matched pediatric and adolescent patients with ALL and a healthy sibling.","Leukemia, Lymphocytic, Acute",PROCESS_OF,sibling
27527070,"RESULTS: Our study cohort consisted of 51 participants, made up of matched pediatric and adolescent patients with ALL and a healthy sibling.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27527070,"RESULTS: Our study cohort consisted of 51 participants, made up of matched pediatric and adolescent patients with ALL and a healthy sibling.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
27527070,ALL accounts for about three out of four cases of childhood leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
27527070,Gastrointestinal microbial populations can distinguish pediatric and adolescent Acute Lymphoblastic Leukemia (ALL) at the time of disease diagnosis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
27529658,"BACKGROUND: Children of Hispanic ancestry have a higher incidence of acute lymphoblastic leukemia (ALL) compared with other ethnic groups, but to the authors' knowledge, the genetic basis for these racial disparities remain incompletely understood.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27536191,Concurrent hypopituitarism and leukemic retinopathy in a child with B-precursor acute lymphoblastic leukemia and isolated central nervous system relapse.,Leukaemic retinopathy,PROCESS_OF,Child
27536191,Concurrent hypopituitarism and leukemic retinopathy in a child with B-precursor acute lymphoblastic leukemia and isolated central nervous system relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27536191,Concurrent hypopituitarism and leukemic retinopathy in a child with B-precursor acute lymphoblastic leukemia and isolated central nervous system relapse.,Hypopituitarism,PROCESS_OF,Child
27544685,This study evaluated associations between environmental and parental factors and the risk for ALL in Egyptian children to gain insight into risk factors in this developing country.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27552439,The DNA virome of 95 children who later developed ALL was characterised from neonatal blood spots (NBS) using unbiased next-generation sequencing (NGS) and compared with the virome of 95 non-ALL controls.,Blood,LOCATION_OF,Exanthema
27552439,Virome characterisation from Guthrie cards in children who later developed acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27552439,CONCLUSIONS: Unbiased NGS was employed to search for DNA from potential infectious agents in neonatal samples of children who later developed ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27552439,The DNA virome of 95 children who later developed ALL was characterised from neonatal blood spots (NBS) using unbiased next-generation sequencing (NGS) and compared with the virome of 95 non-ALL controls.,Exanthema,AFFECTS,Myeloid Leukemia
27552439,The DNA virome of 95 children who later developed ALL was characterised from neonatal blood spots (NBS) using unbiased next-generation sequencing (NGS) and compared with the virome of 95 non-ALL controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27555087,"BACKGROUND: Each year approximately 200 children and adolescents are diagnosed with acute lymphoblastic leukemia (ALL) in the five Nordic countries, and 3% of these have central nervous system (CNS) involvement confirmed by leukemic cells in the cerebrospinal fluid (CSF) or neurological symptoms.",Neurologic Symptoms,PROCESS_OF,Child
27555087,"BACKGROUND: Each year approximately 200 children and adolescents are diagnosed with acute lymphoblastic leukemia (ALL) in the five Nordic countries, and 3% of these have central nervous system (CNS) involvement confirmed by leukemic cells in the cerebrospinal fluid (CSF) or neurological symptoms.",Neurologic Symptoms,PROCESS_OF,Adolescent
27555087,"BACKGROUND: Each year approximately 200 children and adolescents are diagnosed with acute lymphoblastic leukemia (ALL) in the five Nordic countries, and 3% of these have central nervous system (CNS) involvement confirmed by leukemic cells in the cerebrospinal fluid (CSF) or neurological symptoms.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
27555087,"BACKGROUND: Each year approximately 200 children and adolescents are diagnosed with acute lymphoblastic leukemia (ALL) in the five Nordic countries, and 3% of these have central nervous system (CNS) involvement confirmed by leukemic cells in the cerebrospinal fluid (CSF) or neurological symptoms.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27555294,"METHOD: Children (1.0-17.9 years) diagnosed with ALL, treated with asparaginase for 30 weeks, according to the NOPHO ALL2008 protocol at the University Hospital Rigshospitalet, Copenhagen, Denmark, were eligible.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27555294,Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27555294,"METHOD: Children (1.0-17.9 years) diagnosed with ALL, treated with asparaginase for 30 weeks, according to the NOPHO ALL2008 protocol at the University Hospital Rigshospitalet, Copenhagen, Denmark, were eligible.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
27555294,"BACKGROUND: l-Asparaginase is an important drug for treatment of childhood acute lymphoblastic leukemia (ALL), but is associated with serious toxicities, including pancreatitis and hypertriglyceridemia (HTG).",ASPARAGINASE,ASSOCIATED_WITH,Toxic effect
27555294,"BACKGROUND: l-Asparaginase is an important drug for treatment of childhood acute lymphoblastic leukemia (ALL), but is associated with serious toxicities, including pancreatitis and hypertriglyceridemia (HTG).",Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27555294,"BACKGROUND: l-Asparaginase is an important drug for treatment of childhood acute lymphoblastic leukemia (ALL), but is associated with serious toxicities, including pancreatitis and hypertriglyceridemia (HTG).",ASPARAGINASE,ISA,Pharmaceutical Preparations
27555294,"BACKGROUND: l-Asparaginase is an important drug for treatment of childhood acute lymphoblastic leukemia (ALL), but is associated with serious toxicities, including pancreatitis and hypertriglyceridemia (HTG).",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27555294,Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.,Hypertriglyceridemia,NEG_PREDISPOSES,Pancreatitis
27560110,Our results indicate that the clinical impact of MRD on treatment outcome in childhood ALL varies considerably according to leukemia subtype and time of measurement.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
27438018,The aim of this study was to identify key markers of minimal residual disease (MRD) in childhood Acute Lymphoblastic Leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
27438018,Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
27452984,PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy.,Toxic effect,PROCESS_OF,Child
27452984,"In this retrospective study including 305 paediatric ALL patients undergoing maintenance therapy, we systematically investigated the individual and combined effects of genetic variants of folate pathway enzymes, as well as of polymorphisms in PACSIN2 and ITPA, on drug-induced toxicities by applying a multi-analytical approach including logistic regression (LR), classification and regression tree (CART) and generalized multifactor dimensionality reduction (GMDR).",Maintenance therapy,TREATS,Patients
27452984,PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27452984,"In this retrospective study including 305 paediatric ALL patients undergoing maintenance therapy, we systematically investigated the individual and combined effects of genetic variants of folate pathway enzymes, as well as of polymorphisms in PACSIN2 and ITPA, on drug-induced toxicities by applying a multi-analytical approach including logistic regression (LR), classification and regression tree (CART) and generalized multifactor dimensionality reduction (GMDR).","Polymorphism, Genetic",AFFECTS,ITPA
27452984,"To our knowledge, this is the first study showing PACSIN2 genotype association with hematological toxicity in ALL patients undergoing maintenance therapy.",Toxic effect,PROCESS_OF,Patients
27452984,PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute"
27452984,"In this retrospective study including 305 paediatric ALL patients undergoing maintenance therapy, we systematically investigated the individual and combined effects of genetic variants of folate pathway enzymes, as well as of polymorphisms in PACSIN2 and ITPA, on drug-induced toxicities by applying a multi-analytical approach including logistic regression (LR), classification and regression tree (CART) and generalized multifactor dimensionality reduction (GMDR).","Polymorphism, Genetic",AFFECTS,PACSIN2
27452984,"To our knowledge, this is the first study showing PACSIN2 genotype association with hematological toxicity in ALL patients undergoing maintenance therapy.",Maintenance therapy,TREATS,Patients
27452984,PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy.,PACSIN2,ASSOCIATED_WITH,Toxic effect
27452984,"In this retrospective study including 305 paediatric ALL patients undergoing maintenance therapy, we systematically investigated the individual and combined effects of genetic variants of folate pathway enzymes, as well as of polymorphisms in PACSIN2 and ITPA, on drug-induced toxicities by applying a multi-analytical approach including logistic regression (LR), classification and regression tree (CART) and generalized multifactor dimensionality reduction (GMDR).",Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27452984,"To our knowledge, this is the first study showing PACSIN2 genotype association with hematological toxicity in ALL patients undergoing maintenance therapy.",Maintenance therapy,TREATS,Toxic effect
27452984,"In this retrospective study including 305 paediatric ALL patients undergoing maintenance therapy, we systematically investigated the individual and combined effects of genetic variants of folate pathway enzymes, as well as of polymorphisms in PACSIN2 and ITPA, on drug-induced toxicities by applying a multi-analytical approach including logistic regression (LR), classification and regression tree (CART) and generalized multifactor dimensionality reduction (GMDR).","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
27452984,"To our knowledge, this is the first study showing PACSIN2 genotype association with hematological toxicity in ALL patients undergoing maintenance therapy.",Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute"
27452984,"Adequate maintenance therapy for childhood acute lymphoblastic leukemia (ALL), with 6-mercaptopurine as an essential component, is necessary for retaining durable remission.",Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27452984,"To our knowledge, this is the first study showing PACSIN2 genotype association with hematological toxicity in ALL patients undergoing maintenance therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27472187,Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children that can be affected by maternal diet.,"Leukemia, Lymphocytic, Acute",ISA,leukemia
27472187,Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children that can be affected by maternal diet.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27472187,Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children that can be affected by maternal diet.,leukemia,PROCESS_OF,Child
27472187,Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children that can be affected by maternal diet.,Diet,AFFECTS,"Leukemia, Lymphocytic, Acute"
27476159,Long-Term Effect of Cranial Radiotherapy on Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia Survivors.,Radiation therapy,TREATS,Survivors
27476159,Long-Term Effect of Cranial Radiotherapy on Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia Survivors.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27476159,"The large group of ALL survivors treated with CRT in the 70-80-ties has now reached adulthood, and these survivors were treated mainly with 24 Gy, and the vast majority of these patients suffer from GHD.",Radiation therapy,TREATS,Survivors
27476159,Long-Term Effect of Cranial Radiotherapy on Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia Survivors.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Survivors
27476159,"The large group of ALL survivors treated with CRT in the 70-80-ties has now reached adulthood, and these survivors were treated mainly with 24 Gy, and the vast majority of these patients suffer from GHD.",Radiation therapy,TREATS,Survivors
27476159,"The large group of ALL survivors treated with CRT in the 70-80-ties has now reached adulthood, and these survivors were treated mainly with 24 Gy, and the vast majority of these patients suffer from GHD.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
27476159,"The large group of ALL survivors treated with CRT in the 70-80-ties has now reached adulthood, and these survivors were treated mainly with 24 Gy, and the vast majority of these patients suffer from GHD.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
27476159,"Deficiencies of one or more anterior pituitary hormones have been described following therapeutic CRT for primary brain tumors, nasopharyngeal tumors, and following prophylactic CRT for childhood acute lymphoblastic leukemia (ALL).",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27476159,"Deficiencies of one or more anterior pituitary hormones have been described following therapeutic CRT for primary brain tumors, nasopharyngeal tumors, and following prophylactic CRT for childhood acute lymphoblastic leukemia (ALL).","Pituitary Hormones, Anterior",TREATS,"Brain Tumor, Primary"
27489588,SUBJECTS AND METHODS: A total of 220 subjects including 100 children diagnosed with ALL and 120 healthy children participated in the case-control study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.",Pharmacotherapy,TREATS,Survivors
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Survivors
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.",Brain Metabolism,PROCESS_OF,Survivors
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.",Radiation therapy,TREATS,Survivors
27498739,"Acute leukemia, especially acute lymphoblastic leukemia, is the most common tumor in childhood.","Leukemia, Lymphocytic, Acute",ISA,Acute leukemia
27502091,"While the majority of children and adolescents with newly diagnosed childhood acute lymphoblastic leukemia (ALL) will be cured, as many as 20 % of patients will experience relapse.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Adolescent
27502091,"While the majority of children and adolescents with newly diagnosed childhood acute lymphoblastic leukemia (ALL) will be cured, as many as 20 % of patients will experience relapse.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
27513245,"Therefore, this study aimed to assess the relationship between socioeconomic status and rate as well as cause of abandoned treatment in children with ALL in the southeast of Iran.",Therapeutic procedure,TREATS,Child
27513245,"Therefore, this study aimed to assess the relationship between socioeconomic status and rate as well as cause of abandoned treatment in children with ALL in the southeast of Iran.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27513245,"Therefore, this study aimed to assess the relationship between socioeconomic status and rate as well as cause of abandoned treatment in children with ALL in the southeast of Iran.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
27526794,"The study was performed prospectively, in a cohort of 40 children with B-lineage ALL, adopting the protocol of the Brazilian Cooperative Group of the Treatment Childhood Leukemia (GBTLI-2009).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27527070,We assessed the GI microbiota composition in pediatric and adolescent patients with ALL during the course of chemotherapy by comparing stool samples taken before chemotherapy with stool samples collected at varying time points during the chemotherapeutic treatment.,Stool specimen,PART_OF,Patients
27527070,We assessed the GI microbiota composition in pediatric and adolescent patients with ALL during the course of chemotherapy by comparing stool samples taken before chemotherapy with stool samples collected at varying time points during the chemotherapeutic treatment.,Chemotherapy-Oncologic Procedure,ISA,Therapeutic procedure
27527070,We assessed the GI microbiota composition in pediatric and adolescent patients with ALL during the course of chemotherapy by comparing stool samples taken before chemotherapy with stool samples collected at varying time points during the chemotherapeutic treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
27527070,We assessed the GI microbiota composition in pediatric and adolescent patients with ALL during the course of chemotherapy by comparing stool samples taken before chemotherapy with stool samples collected at varying time points during the chemotherapeutic treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27527070,We assessed the GI microbiota composition in pediatric and adolescent patients with ALL during the course of chemotherapy by comparing stool samples taken before chemotherapy with stool samples collected at varying time points during the chemotherapeutic treatment.,Pharmacotherapy,ADMINISTERED_TO,Patients
27342632,BACKGROUND: Monitoring minimal residual disease (MRD) in B-lineage acute lymphoblastic leukemia (ALL) to assess treatment response is crucial for risk assignment.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
27345588,"This study evaluated associations between uric acid (UA), cardiovascular health, and neurocognitive function in adolescent and adult survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27345588,Uric Acid and Neurocognitive Function in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27362350,"Although dexamethasone is highly effective in the treatment of pediatric acute lymphoblastic leukemia (ALL), it can cause serious metabolic side effects.",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27362350,"Although dexamethasone is highly effective in the treatment of pediatric acute lymphoblastic leukemia (ALL), it can cause serious metabolic side effects.",Dexamethasone,ISA,Therapeutic procedure
27362350,Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone.,Dexamethasone,TREATS,Patients
27362350,Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
27362350,Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone.,Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27372260,"The current study demonstrates a significant association between the genotype GT and the polymorphic allele G424T, and introduces this SNP as a negative prognostic factor in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27372260,DNA samples were extracted from bone marrow slides of 129 children with ALL and 16 children with AML.,Bone Marrow,LOCATION_OF,DNA
27372260,DNA samples were extracted from bone marrow slides of 129 children with ALL and 16 children with AML.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27372260,DNA samples were extracted from bone marrow slides of 129 children with ALL and 16 children with AML.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27372260,DNA samples were extracted from bone marrow slides of 129 children with ALL and 16 children with AML.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
27372260,DNA samples were extracted from bone marrow slides of 129 children with ALL and 16 children with AML.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Child
27372260,"The current study demonstrates a significant association between the genotype GT and the polymorphic allele G424T, and introduces this SNP as a negative prognostic factor in children with ALL.",Child,LOCATION_OF,Single Nucleotide Polymorphism
27376478,BACKGROUND: Asparaginase is an important component of pediatric acute lymphoblastic leukemia (ALL) therapy.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27376478,BACKGROUND: Asparaginase is an important component of pediatric acute lymphoblastic leukemia (ALL) therapy.,ASPARAGINASE | ASPG,ISA,Therapeutic procedure
27382961,"Patient studies were performed by including 30 children with ALL at diagnosis, 3 children with bone marrow relapse, and 15 children with no symptoms of cancer.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27382961,"Patient studies were performed by including 30 children with ALL at diagnosis, 3 children with bone marrow relapse, and 15 children with no symptoms of cancer.",Symptoms,NEG_PROCESS_OF,Child
27382961,"Patient studies were performed by including 30 children with ALL at diagnosis, 3 children with bone marrow relapse, and 15 children with no symptoms of cancer.",Symptoms,NEG_PROCESS_OF,Child
27382961,"The current study was designed to investigate the in vitro and in vivo relationships between the expression levels of SORCIN: in tumor cell lines and children with ALL; its possible correlation with MDR1/P-glycoprotein (P-gp), a multidrug resistance-related gene; and response to therapy.","Cell Line, Tumor",LOCATION_OF,sorcin | SRI
27382961,"The current study was designed to investigate the in vitro and in vivo relationships between the expression levels of SORCIN: in tumor cell lines and children with ALL; its possible correlation with MDR1/P-glycoprotein (P-gp), a multidrug resistance-related gene; and response to therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27383875,AIM: To report the IM detected by 8-color FCM during the BFM-type remission induction in 24 consecutive MRD-positive samples of children with B-cell precursor ALL and the possible implications for MRD detection.,Remission Induction,TREATS,CONSECUTIVE SAMPLE
27383875,AIM: To report the IM detected by 8-color FCM during the BFM-type remission induction in 24 consecutive MRD-positive samples of children with B-cell precursor ALL and the possible implications for MRD detection.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
27383875,AIM: To report the IM detected by 8-color FCM during the BFM-type remission induction in 24 consecutive MRD-positive samples of children with B-cell precursor ALL and the possible implications for MRD detection.,Flow Cytometry,DIAGNOSES,"Neoplasm, Residual"
27392033,We describe EBV-LPD manifesting as facial lesions in two children with ALL in remission.,Lesion,PROCESS_OF,Child
27392033,We describe EBV-LPD manifesting as facial lesions in two children with ALL in remission.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27392277,Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia - a cohort study from the United Kingdom.,Cerebral arterial thrombosis,PROCESS_OF,Child
27392277,Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia - a cohort study from the United Kingdom.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
27392277,Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia - a cohort study from the United Kingdom.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27392277,Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia - a cohort study from the United Kingdom.,Cerebral arterial thrombosis,PROCESS_OF,Young adult
27401338,"The remission induction regimens were all based on VDLP (D) chemotherapy (VCR (Vincrisstine), DNR (Daunomycin), L-ASP (L-Asparagiase), Prednisolone and Dexamethasone).",Vincristine,ISA,Pharmacotherapy
27401338,METHODS: We enrolled 48 children who were newly diagnosed with ALL in our department during the period of 2013.1-2014.12.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27401338,BACKGROUND: We investigated the effects of glutamine (Gln)-enriched nutritional therapy during chemotherapy on the nutritional status and immune function of children with acute lymphoblastic leukemia (ALL).,Nutrition management,COEXISTS_WITH,Pharmacotherapy
27401338,BACKGROUND: We investigated the effects of glutamine (Gln)-enriched nutritional therapy during chemotherapy on the nutritional status and immune function of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27434379,"Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
27434379,"Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia.",XYY Karyotype,PROCESS_OF,Child
27437864,"PROCEDURES: We performed a multi-institutional, retrospective study including children with relapsed ALL treated with the R3 reinduction chemotherapy backbone block 1 across five pediatric centers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27437864,BACKGROUND: The UK ALLR3 (R3) regimen has been adopted to treat pediatric relapsed acute lymphoblastic leukemia (ALL) by many centers in the United States and has become a preferred therapeutic backbone for testing novel agents in clinical trials.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27277333,PBMCs were obtained from 50 pediatric patients diagnosed with ALL and from 20 children attending the ophthalmology and orthopedics services.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27277333,PBMCs were obtained from 50 pediatric patients diagnosed with ALL and from 20 children attending the ophthalmology and orthopedics services.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27281445,BACKGROUND: Glucocorticoids are probably the most important drugs in the treatment of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,ISA,Pharmaceutical Preparations
27281445,BACKGROUND: Glucocorticoids are probably the most important drugs in the treatment of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27281445,BACKGROUND: Glucocorticoids are probably the most important drugs in the treatment of childhood acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27283082,"However, progress has been slower for myeloid leukemia and certain subgroups like infant ALL, adolescent/young adult ALL, and relapsed ALL.","Leukemia, Lymphocytic, Acute, L2",ISA,"Leukemia, Lymphocytic, Acute"
27283082,"However, progress has been slower for myeloid leukemia and certain subgroups like infant ALL, adolescent/young adult ALL, and relapsed ALL.","Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Infant
27283082,"However, progress has been slower for myeloid leukemia and certain subgroups like infant ALL, adolescent/young adult ALL, and relapsed ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
27294727,"When analyzed separately, intake of supplements high in these nutrients was associated with a reduced risk of ALL in children of Hispanic women only.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27294727,"When analyzed separately, intake of supplements high in these nutrients was associated with a reduced risk of ALL in children of Hispanic women only.",Nutrients,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
27296238,Predicting trajectories of behavioral adjustment in children diagnosed with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27296238,"METHODS: In a multicenter longitudinal study, 108 parents of a child (response rate 80 %) diagnosed with ALL were assessed during induction treatment (T0), after induction/consolidation treatment (T1), and after end of treatment (T2).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27296949,Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and causes a high rate of mortality in affected adults.,Malignant Neoplasms,PROCESS_OF,Adult
27296949,Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and causes a high rate of mortality in affected adults.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
27296949,Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and causes a high rate of mortality in affected adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
27299279,"Although there are high survival rates for children with acute lymphoblastic leukaemia, their outcome is often counterbalanced by the burden of toxic effects.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27301866,"We conducted a population based case-control study to examine individual effects of benzene, 1,3-butadiene and polycyclic organic matter (POM) in ambient residential air on acute lymphocytic leukemia (ALL) diagnosed in children under age 5 years in Texas from 1995-2011.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27301866,"We conducted a population based case-control study to examine individual effects of benzene, 1,3-butadiene and polycyclic organic matter (POM) in ambient residential air on acute lymphocytic leukemia (ALL) diagnosed in children under age 5 years in Texas from 1995-2011.",Butadiene,INTERACTS_WITH,Benzene
27318855,OBJECTIVE: Children with acute lymphoblastic leukemia (ALL) are at elevated risk for nutrition-related morbidity both during and after therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27333926,"However, a few studies indirectly show that ED may appear in ALL children before treatment begins.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27333926,Elevated plasma ADMA contributes to development of endothelial dysfunction in children with acute lymphoblastic leukemia.,Endothelial dysfunction,PROCESS_OF,Child
27333926,DISCUSSION: This is the first demonstration that functionally assessed ED is present in ALL children at the diagnosis and results from elevated ADMA and parallel inflammatory ED.,Endothelial dysfunction,PROCESS_OF,Child
27333926,Elevated plasma ADMA contributes to development of endothelial dysfunction in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27333926,DISCUSSION: This is the first demonstration that functionally assessed ED is present in ALL children at the diagnosis and results from elevated ADMA and parallel inflammatory ED.,Endothelial dysfunction,PROCESS_OF,Child
27333926,Elevated plasma ADMA contributes to development of endothelial dysfunction in children with acute lymphoblastic leukemia.,Plasma,LOCATION_OF,"N,N-dimethylarginine"
27333926,DISCUSSION: This is the first demonstration that functionally assessed ED is present in ALL children at the diagnosis and results from elevated ADMA and parallel inflammatory ED.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27333926,PATIENTS/METHODS: Twenty-eight ALL children and 14 healthy age-matched control children were recruited.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27333926,"However, a few studies indirectly show that ED may appear in ALL children before treatment begins.",Endothelial dysfunction,PROCESS_OF,Child
27341996,Chromosomal aberrations in childhood acute lymphoblastic leukemia: 15-year single center experience.,Chromosome abnormality,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
27341996,"Our retrospective single center study of 86 children with ALL enrolled into three consecutive treatment protocols (ALL-BFM 90, ALL-BFM 95 and ALL IC-BFM 2002) between 1991 and 2007 demonstrates the importance of conventional cytogenetics and fluorescence in situ hybridization (FISH).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27341996,"Our retrospective single center study of 86 children with ALL enrolled into three consecutive treatment protocols (ALL-BFM 90, ALL-BFM 95 and ALL IC-BFM 2002) between 1991 and 2007 demonstrates the importance of conventional cytogenetics and fluorescence in situ hybridization (FISH).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27342632,CONCLUSIONS: It is possible to implement reliable measurements of MRD during remission induction therapy in childhood ALL despite limited resources.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
27342632,"METHODS: Fifty-nine samples from children with ALL, enrolled in the RE-LLA study at a pediatric oncology center in Recife (Brazil), were evaluated for MRD on day 19 and on day 26 of remission induction therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27151041,[Progress of Research on 6-Thioguanine versus 6-Mercaptopurine in childhood ALL].,Thioguanine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27151041,[Progress of Research on 6-Thioguanine versus 6-Mercaptopurine in childhood ALL].,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27151041,[Progress of Research on 6-Thioguanine versus 6-Mercaptopurine in childhood ALL].,Thioguanine,compared_with,6-Mercaptopurine
27158437,Acute lymphoblastic leukemia (ALL) is the most common cancer in children.,Malignant Neoplasms,PROCESS_OF,Child
27158437,Acute lymphoblastic leukemia (ALL) is the most common cancer in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
27158437,Acute lymphoblastic leukemia (ALL) is the most common cancer in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27158437,Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
27161966,We examined whether including a physiologic dose of hydrocortisone in dexamethasone treatment can reduce neuropsychologic and metabolic adverse effects in children with ALL.,Therapeutic procedure,USES,Dexamethasone
27161966,We examined whether including a physiologic dose of hydrocortisone in dexamethasone treatment can reduce neuropsychologic and metabolic adverse effects in children with ALL.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
27161966,We examined whether including a physiologic dose of hydrocortisone in dexamethasone treatment can reduce neuropsychologic and metabolic adverse effects in children with ALL.,Dexamethasone,ISA,Therapeutic procedure
27161966,We examined whether including a physiologic dose of hydrocortisone in dexamethasone treatment can reduce neuropsychologic and metabolic adverse effects in children with ALL.,Dexamethasone,TREATS,Child
27161966,"PURPOSE: Dexamethasone is a key component in the treatment of pediatric acute lymphoblastic leukemia (ALL), but can induce serious adverse effects.",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27161966,"PURPOSE: Dexamethasone is a key component in the treatment of pediatric acute lymphoblastic leukemia (ALL), but can induce serious adverse effects.",Dexamethasone,ISA,Therapeutic procedure
27161966,We examined whether including a physiologic dose of hydrocortisone in dexamethasone treatment can reduce neuropsychologic and metabolic adverse effects in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27161966,We examined whether including a physiologic dose of hydrocortisone in dexamethasone treatment can reduce neuropsychologic and metabolic adverse effects in children with ALL.,Therapeutic procedure,TREATS,Child
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Pharmacotherapy,TREATS,Blast Phase
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Pharmacotherapy,TREATS,Child
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.","Myeloid Leukemia, Chronic",PROCESS_OF,Patients
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Blast Phase,PROCESS_OF,Child
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Stem cell transplant,TREATS,"Myeloid Leukemia, Chronic"
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Stem cell transplant,TREATS,Patients
27168705,Effect of folate status and methylenetetrahydrofolate reductase genotypes on the complications and outcome of high dose methotrexate chemotherapy in north Indian children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27168705,Effect of folate status and methylenetetrahydrofolate reductase genotypes on the complications and outcome of high dose methotrexate chemotherapy in north Indian children with acute lymphoblastic leukemia.,high-dose chemotherapy,USES,Methotrexate
27168705,Effect of folate status and methylenetetrahydrofolate reductase genotypes on the complications and outcome of high dose methotrexate chemotherapy in north Indian children with acute lymphoblastic leukemia.,Complication,PROCESS_OF,Child
27169594,PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and young adults.,Malignant Neoplasms,PROCESS_OF,Young adult
27169594,PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and young adults.,Malignant Neoplasms,PROCESS_OF,Child
27169594,PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and young adults.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
27169594,PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and young adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
27169594,PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and young adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27177145,"Using state cancer registry data from Texas and Florida, we evaluated the impact of neighborhood-level poverty rate and race/ethnicity on OS for 4719 children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27177145,"With modern therapy, overall survival (OS) for children with acute lymphoblastic leukemia approaches 90%.",Therapeutic procedure,TREATS,Child
27177145,"With modern therapy, overall survival (OS) for children with acute lymphoblastic leukemia approaches 90%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27177145,"With modern therapy, overall survival (OS) for children with acute lymphoblastic leukemia approaches 90%.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
27187265,BACKGROUND: Hyperleukocytosis in children with acute lymphoblastic leukemia (ALL) has been associated with early morbidity and mortality.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27193222,Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age.,6-Mercaptopurine,TREATS,Child
27193222,Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27193222,Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
27193222,"Genotyping of NUDT15 could be a beneficial to estimate the tolerated dose of 6-MP for patients with childhood ALL, especially at a preschool age in Japan.",6-Mercaptopurine,TREATS,Patients
27193222,"Genotyping of NUDT15 could be a beneficial to estimate the tolerated dose of 6-MP for patients with childhood ALL, especially at a preschool age in Japan.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
27193222,"Genotyping of NUDT15 could be a beneficial to estimate the tolerated dose of 6-MP for patients with childhood ALL, especially at a preschool age in Japan.",6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27229005,"We analyzed cytogenetic data from 427 children with relapsed B-cell precursor ALL treated on the international trial, ALLR3.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
27233118,Neurocognitive sequelae are known to be induced by cranial radiotherapy and central-nervous-system-directed chemotherapy in childhood Acute Lymphoblastic Leukemia (ALL) and brain tumor patients.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27233118,Neurocognitive sequelae are known to be induced by cranial radiotherapy and central-nervous-system-directed chemotherapy in childhood Acute Lymphoblastic Leukemia (ALL) and brain tumor patients.,Pharmacotherapy,TREATS,Brain Neoplasms
27233118,Neurocognitive sequelae are known to be induced by cranial radiotherapy and central-nervous-system-directed chemotherapy in childhood Acute Lymphoblastic Leukemia (ALL) and brain tumor patients.,Brain Neoplasms,PROCESS_OF,Patients
27233118,Neurocognitive sequelae are known to be induced by cranial radiotherapy and central-nervous-system-directed chemotherapy in childhood Acute Lymphoblastic Leukemia (ALL) and brain tumor patients.,Radiation therapy,TREATS,Brain Neoplasms
27233118,Neurocognitive sequelae are known to be induced by cranial radiotherapy and central-nervous-system-directed chemotherapy in childhood Acute Lymphoblastic Leukemia (ALL) and brain tumor patients.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27269950,"CONCLUSION: Chemotherapy was substantially reduced safely in one-quarter of children with ALL who were selected on the basis of undetectable MRD levels, without jeopardizing the survival rate.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27269950,PURPOSE: Outcome of childhood acute lymphoblastic leukemia (ALL) improved greatly by intensifying chemotherapy for all patients.,Pharmacotherapy,TREATS,Patients
27269950,PURPOSE: Outcome of childhood acute lymphoblastic leukemia (ALL) improved greatly by intensifying chemotherapy for all patients.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25840770,"Incidence, risk factors, and treatment outcome of symptomatic osteonecrosis in Taiwanese children with acute lymphoblastic leukemia: a retrospective cohort study of 245 patients in a single institution.",Bone necrosis,OCCURS_IN,Child
25840770,"Incidence, risk factors, and treatment outcome of symptomatic osteonecrosis in Taiwanese children with acute lymphoblastic leukemia: a retrospective cohort study of 245 patients in a single institution.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25843568,We present a rare case of a child with acute lymphoblastic leukemia with a complex karyotype in which the classical t(9;11) (p22;q23) was cryptically relocated into a third chromosome in a balanced three-way translocation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25854371,"MATERIALS AND METHODS: To evaluate whether C3435T and C1236T MDR1 polymorphisms are associated with the occurrence and outcome of ALL, 208 children with ALL (median age 5.0 yr) and 101 healthy Thai children were studied by polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) assay.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25855413,Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome.,Toxic effect,PROCESS_OF,Child
25855413,Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25855413,Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome.,Gilbert Disease,PROCESS_OF,Child
25857254,"While CRT is often implicated in neurocognitive impairment in ALL survivors, there is a paucity of the literature that evaluates the persistence of neurocognitive deficits in long-term survivors of pediatric ALL who were treated with contemporary chemotherapy-only protocols.",Radiation therapy,TREATS,Survivors
25857254,"While CRT is often implicated in neurocognitive impairment in ALL survivors, there is a paucity of the literature that evaluates the persistence of neurocognitive deficits in long-term survivors of pediatric ALL who were treated with contemporary chemotherapy-only protocols.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25857254,"While CRT is often implicated in neurocognitive impairment in ALL survivors, there is a paucity of the literature that evaluates the persistence of neurocognitive deficits in long-term survivors of pediatric ALL who were treated with contemporary chemotherapy-only protocols.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
25857254,"While CRT is often implicated in neurocognitive impairment in ALL survivors, there is a paucity of the literature that evaluates the persistence of neurocognitive deficits in long-term survivors of pediatric ALL who were treated with contemporary chemotherapy-only protocols.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
25857254,The intensified administration of chemotherapeutic drugs has gradually replaced cranial radiation therapy (CRT) for the treatment of childhood acute lymphoblastic leukemia (ALL).,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25861237,Our study reveals a lower frequency of hyperdiploidy (5%) and a higher frequency of BCR-ABL gene fusion (20%) in childhood ALL.,Hyperploidy,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
25867866,Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25867866,Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
25867866,Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
25867866,Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,Child
25867866,Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,Adult
25876777,The prognosis of adults with ALL is not satisfactory and adult ALL remains a challenging disease.,"Leukemia, Lymphocytic, Acute, L2",ISA,Disease
25876777,The prognosis of adults with ALL is not satisfactory and adult ALL remains a challenging disease.,"Leukemia, Lymphocytic, Acute",ISA,Disease
25876777,The prognosis of adults with ALL is not satisfactory and adult ALL remains a challenging disease.,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Adult
25876777,The prognosis of adults with ALL is not satisfactory and adult ALL remains a challenging disease.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
25879337,MATERIALS AND METHODS: The study included 129 children with ALL in complete remission receiving 6-MP single daily oral dose in the evening.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25890837,Acute lymphoblastic leukemia is the most common malignancy in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25890837,Acute lymphoblastic leukemia is the most common malignancy in children.,Malignant Neoplasms,PROCESS_OF,Child
25890837,Acute lymphoblastic leukemia is the most common malignancy in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
25894846,"PROCEDURES: We analyzed 9,295 Californian children (3,251 Whites, 4,890 Hispanics, 796 Asians, and 358 Blacks) aged </= 19 years diagnosed with a first primary ALL during 1988-2011.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25894846,"BACKGROUND: Despite advances in treatment, survival from acute lymphoblastic leukemia (ALL) remains lower among non-White children than White children in the US.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25894846,"Racial/ethnic and socioeconomic disparities in survival among children with acute lymphoblastic leukemia in California, 1988-2011: A population-based observational study.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25896649,Analysis of bone marrow (BM) diagnostic samples derived from children with subsequent CNS-ALL revealed a significantly high expression of the NKG2D and NKp44 receptors.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27150991,"RESULTS: Out of 251 children with B-ALL, 77 cases were TEL-AML1(+) , 28 cases were E2A-PBX1(+) , 10 cases were MLL-AF4(+) , 11 cases were BCR-ABL(+) , the total positive rate was 50.2%, 82.5% showed IgH VH-JH rearrangement, 53.4% showed IgK rearrangement.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27150991,OBJECTIVE: To explore the application of combined detection of fusion gene and BIOMED-2 standardized immunoglobulin (Ig) gene rearrangement system in diagnosis and treatment of children with acute lymphoblastic leukemia (ALL).,Detection,COEXISTS_WITH,Diagnosis
27150991,OBJECTIVE: To explore the application of combined detection of fusion gene and BIOMED-2 standardized immunoglobulin (Ig) gene rearrangement system in diagnosis and treatment of children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27151041,Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children.,Malignant Neoplasms,PROCESS_OF,Child
27151041,Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
27151041,Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25824762,"Childhood acute lymphoblastic leukemia (ALL) is one of the most common hematologic malignancies, accounting for one fourth of all childhood cancer cases.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
25824762,"Childhood acute lymphoblastic leukemia (ALL) is one of the most common hematologic malignancies, accounting for one fourth of all childhood cancer cases.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
25833113,Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
25838646,"A retrospective analysis of case records of seven children with acute lymphoblastic leukemia and TLS, admitted to our Pediatric Oncology Unit of our Hospital between the period 2011 and 2013, was done.",Tumor Lysis Syndrome,PROCESS_OF,Child
25838646,"A retrospective analysis of case records of seven children with acute lymphoblastic leukemia and TLS, admitted to our Pediatric Oncology Unit of our Hospital between the period 2011 and 2013, was done.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25840770,"Considering the possible effect of ethnic difference on the clinical features of symptomatic ON in pediatric ALL, we retrospectively evaluated 245 children with ALL who were treated at Chang Gung Memorial Hospital, Linkou, between 2002 and 2011.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25840770,Osteonecrosis (ON) is a potentially disabling complication encountered in children who receive chemotherapy for acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25840770,Osteonecrosis (ON) is a potentially disabling complication encountered in children who receive chemotherapy for acute lymphoblastic leukemia (ALL).,Pharmacotherapy,ADMINISTERED_TO,Child
25840770,Osteonecrosis (ON) is a potentially disabling complication encountered in children who receive chemotherapy for acute lymphoblastic leukemia (ALL).,Complication,PROCESS_OF,Child
25840770,"Considering the possible effect of ethnic difference on the clinical features of symptomatic ON in pediatric ALL, we retrospectively evaluated 245 children with ALL who were treated at Chang Gung Memorial Hospital, Linkou, between 2002 and 2011.",Bone necrosis,AFFECTS,"Leukemia, Lymphocytic, Acute, L1"
27841777,Updates in the biology and therapy for infant acute lymphoblastic leukemia.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
27841777,Updates in the biology and therapy for infant acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
27858183,METHODS: 276 children with B-ALL were enrolled in the trial from April 1997 to March 2002 and were randomly assigned to receive a regimen including either THP (25 mg/m2 x 11) or DNR (30 mg/m2 x 11).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27858183,METHODS: 276 children with B-ALL were enrolled in the trial from April 1997 to March 2002 and were randomly assigned to receive a regimen including either THP (25 mg/m2 x 11) or DNR (30 mg/m2 x 11).,Treatment Protocols,ADMINISTERED_TO,Child
27862918,"We aimed to investigate the impact of a contemporary treatment protocol that omitted prophylactic cranial radiation and glucocorticoids from the maintenance phase on longitudinal BMI, height, and weight z-scores in children with ALL.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
27862918,"We aimed to investigate the impact of a contemporary treatment protocol that omitted prophylactic cranial radiation and glucocorticoids from the maintenance phase on longitudinal BMI, height, and weight z-scores in children with ALL.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
27862918,"We aimed to investigate the impact of a contemporary treatment protocol that omitted prophylactic cranial radiation and glucocorticoids from the maintenance phase on longitudinal BMI, height, and weight z-scores in children with ALL.",Treatment Protocols,TREATS,Child
27862918,"We aimed to investigate the impact of a contemporary treatment protocol that omitted prophylactic cranial radiation and glucocorticoids from the maintenance phase on longitudinal BMI, height, and weight z-scores in children with ALL.",Glucocorticoids,TREATS,Child
27862918,"We aimed to investigate the impact of a contemporary treatment protocol that omitted prophylactic cranial radiation and glucocorticoids from the maintenance phase on longitudinal BMI, height, and weight z-scores in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27870571,Purpose Philadelphia chromosome (Ph) -like acute lymphoblastic leukemia (ALL) is a high-risk subtype of childhood ALL characterized by kinase-activating alterations that are amenable to treatment with tyrosine kinase inhibitors.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
27870571,High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
27870571,Conclusion Ph-like ALL is a highly prevalent subtype of ALL in adults and is associated with poor outcome.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
27870571,"Results Patients with Ph-like ALL accounted for more than 20% of adults with ALL, including 27.9% of young adults (age 21 to 39 years), 20.4% of adults (age 40 to 59 years), and 24.0% of older adults (age 60 to 86 years).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
27870571,We sought to define the prevalence and genomic landscape of Ph-like ALL in adults and assess response to conventional chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
27870571,Purpose Philadelphia chromosome (Ph) -like acute lymphoblastic leukemia (ALL) is a high-risk subtype of childhood ALL characterized by kinase-activating alterations that are amenable to treatment with tyrosine kinase inhibitors.,Therapeutic procedure,USES,Protein-tyrosine kinase inhibitor
27870639,Acute lymphoblast leukemia (ALL) is characterized by overproduction of immature white blood cells in the bone marrow.,Bone Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
27885548,"PURPOSE: Children with acute lymphoblastic leukemia (ALL), the commonest form of cancer in this age group, suffer considerable morbidity during treatment, with the majority returning to good health soon after therapy has been completed, as reflected in health-related quality of life (HRQL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27886674,A total of 110 children with acute lymphoblastic leukemia (ALL) and 120 healthy children were recruited to participate in this study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27894077,"To evaluate the clinical significance of tyrosine kinase gene fusions in children with BCP-ALL, we studied the frequency of recently identified tyrosine kinase fusions, associated genetic features, and prognosis in a representative Dutch/German cohort.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
27416986,Acute lymphoblastic leukemia (ALL) in children exemplifies how multi-agent chemotherapy has improved the outcome for patients.,Pharmacotherapy,TREATS,Patients
27416986,Acute lymphoblastic leukemia (ALL) in children exemplifies how multi-agent chemotherapy has improved the outcome for patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27434294,"METHODS: BM or PB samples were collected from 57 children and adolescents with acute lymphoid leukemia (ALL), 14 children and adolescents with acute myeloid leukemia (AML), and 44 healthy individuals (HI) of the same age range.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
27434294,"METHODS: BM or PB samples were collected from 57 children and adolescents with acute lymphoid leukemia (ALL), 14 children and adolescents with acute myeloid leukemia (AML), and 44 healthy individuals (HI) of the same age range.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27600880,Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27600880,Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27742768,Osteonecrosis in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27742768,Osteonecrosis in children with acute lymphoblastic leukemia.,Bone necrosis,PROCESS_OF,Child
27798425,RECENT FINDINGS: Recent studies in children with acute lymphoblastic leukemia have conclusively demonstrated that nonadherence to oral antimetabolite therapy is associated with a significant increase in relapse risk.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27798425,RECENT FINDINGS: Recent studies in children with acute lymphoblastic leukemia have conclusively demonstrated that nonadherence to oral antimetabolite therapy is associated with a significant increase in relapse risk.,Therapeutic procedure,USES,Antimetabolites
27798425,RECENT FINDINGS: Recent studies in children with acute lymphoblastic leukemia have conclusively demonstrated that nonadherence to oral antimetabolite therapy is associated with a significant increase in relapse risk.,Antimetabolites,ISA,Therapeutic procedure
27800472,"Shorter Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia: The Experience of the Prospective, Randomized Brazilian GBTLI ALL-93 Protocol.",Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27804199,BACKGROUND: Approximately 30% of childhood acute lymphoblastic leukemia (ALL) cases are high hyperdiploid (HD).,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
27807957,"In children, leukaemias (34%) are prevalent, mostly acute lymphoblastic leukaemia (26%), followed by CNS tumours (18%); in adolescents, lymphomas (30%) are prevalent, mostly Hodgkin lymphomas (22%), followed by bone sarcomas (16%).","Leukemia, Lymphocytic, Acute",ISA,leukemia
27807957,"In children, leukaemias (34%) are prevalent, mostly acute lymphoblastic leukaemia (26%), followed by CNS tumours (18%); in adolescents, lymphomas (30%) are prevalent, mostly Hodgkin lymphomas (22%), followed by bone sarcomas (16%).",Hodgkin Disease,ISA,Lymphoma
27820126,"Detection of genetic alterations in B-ALL, such as CRLF2 rearrangements, may enhance patient risk stratification and therapy options in pediatric B-ALL.",Therapeutic procedure,TREATS,"Leukemia, B-Cell, Acute"
27820126,"Detection of genetic alterations in B-ALL, such as CRLF2 rearrangements, may enhance patient risk stratification and therapy options in pediatric B-ALL.",Detection,TREATS,"Leukemia, B-Cell, Acute"
27820126,"Detection of genetic alterations in B-ALL, such as CRLF2 rearrangements, may enhance patient risk stratification and therapy options in pediatric B-ALL.",Therapeutic procedure,TREATS,"Leukemia, B-Cell, Acute"
27820126,"Detection of genetic alterations in B-ALL, such as CRLF2 rearrangements, may enhance patient risk stratification and therapy options in pediatric B-ALL.",Detection,TREATS,"Leukemia, B-Cell, Acute"
27841777,SUMMARY: Advances in molecular profiling and integration of targeted therapy have the potential to reduce toxicity and improve survival for infants with ALL.,Advance,TREATS,"Leukemia, Lymphocytic, Acute"
27841777,PURPOSE OF REVIEW: The prognosis for infants less than 12 months of age who are diagnosed with acute lymphoblastic leukemia (ALL) remains poor despite overall advances in the treatment of childhood ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
27841777,Strategies to intensify therapy have not improved survival for infants with KMT2A-R ALL.,Therapeutic procedure,NEG_TREATS,"Leukemia, Lymphocytic, Acute"
27841777,Modern clinical trials are integrating molecularly targeted therapies into the treatment of infant ALL.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
27841777,PURPOSE OF REVIEW: The prognosis for infants less than 12 months of age who are diagnosed with acute lymphoblastic leukemia (ALL) remains poor despite overall advances in the treatment of childhood ALL.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
27841777,Recent molecular profiling studies have found that infant ALL with KMT2A-R is an epigenomic disease that lacks other somatic driver mutations.,Somatic mutation,PROCESS_OF,Drivers of Vehicles
27841777,Modern clinical trials are integrating molecularly targeted therapies into the treatment of infant ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
27841777,PURPOSE OF REVIEW: The prognosis for infants less than 12 months of age who are diagnosed with acute lymphoblastic leukemia (ALL) remains poor despite overall advances in the treatment of childhood ALL.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Infant
27841777,Recent molecular profiling studies have found that infant ALL with KMT2A-R is an epigenomic disease that lacks other somatic driver mutations.,"Leukemia, Lymphocytic, Acute",ISA,Disease
27841777,"In contrast, infant ALL without KMT2A-R is more similar to ALL of older children and survival has improved modestly with intensification of chemotherapy.","Leukemia, Lymphocytic, Acute",PART_OF,Child
27841777,SUMMARY: Advances in molecular profiling and integration of targeted therapy have the potential to reduce toxicity and improve survival for infants with ALL.,Advance,TREATS,Infant
27841777,Recent molecular profiling studies have found that infant ALL with KMT2A-R is an epigenomic disease that lacks other somatic driver mutations.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
27841777,"In contrast, infant ALL without KMT2A-R is more similar to ALL of older children and survival has improved modestly with intensification of chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
27841777,SUMMARY: Advances in molecular profiling and integration of targeted therapy have the potential to reduce toxicity and improve survival for infants with ALL.,Therapeutic procedure,PREVENTS,Toxic effect
27841777,"RECENT FINDINGS: Infant ALL can be divided into two major disease types, defined by the presence or absence of KMT2A (MLL) rearrangement (KMT2A-R).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
27841777,Strategies to intensify therapy have not improved survival for infants with KMT2A-R ALL.,Therapeutic procedure,NEG_TREATS,Infant
27841777,SUMMARY: Advances in molecular profiling and integration of targeted therapy have the potential to reduce toxicity and improve survival for infants with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
27841777,"In this review, we highlight the recent advances in the understanding of the pathogenesis of infant ALL and discuss opportunities for translating these findings into clinical trials.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
27841777,Strategies to intensify therapy have not improved survival for infants with KMT2A-R ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
26925710,Orbital involvement is considered to confer a poorer prognosis to children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26925710,Orbital Mass in a Child With Acute Lymphoblastic Leukemia: A Case Report and Review of the Literature.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26925710,Orbital Mass in a Child With Acute Lymphoblastic Leukemia: A Case Report and Review of the Literature.,ORBITAL MASS,PROCESS_OF,Child
27422759,METHODS: Children aged 5-18 years with newly diagnosed B-cell precursor ALL were included.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
27422759,Health-related quality of life in Japanese children with acute lymphoblastic leukemia during and after chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27447547,BACKGROUND: 6-Mercaptopurine (6MP) and methotrexate (MTX) based maintenance therapy is a critical phase of childhood acute lymphoblastic leukemia treatment.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27447547,BACKGROUND: 6-Mercaptopurine (6MP) and methotrexate (MTX) based maintenance therapy is a critical phase of childhood acute lymphoblastic leukemia treatment.,6-Mercaptopurine,ISA,Therapeutic procedure
27447547,BACKGROUND: 6-Mercaptopurine (6MP) and methotrexate (MTX) based maintenance therapy is a critical phase of childhood acute lymphoblastic leukemia treatment.,Methotrexate,ISA,Therapeutic procedure
27467375,"Survival for childhood acute lymphoblastic leukemia (ALL) has improved significantly, but these benefits may not be available to many children from low and middle income countries, where reasons for treatment failure may be unique to their environment.",treatment failure,ISA,Environment
27467375,"Survival for childhood acute lymphoblastic leukemia (ALL) has improved significantly, but these benefits may not be available to many children from low and middle income countries, where reasons for treatment failure may be unique to their environment.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
27494537,"METHODS: Latino (48%) and non-Latino (52%) children with acute lymphoblastic leukemia (ALL; n=670), acute myeloid leukemia (AML; n=104), and controls (n=1021) were enrolled in a study in California (2000-2008).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27569049,B-ALL is the most common type in pediatric ALL.,"Leukemia, Lymphocytic, Acute",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
27569049,B-ALL is the most common type in pediatric ALL.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
27600880,METHODS: A median of 22 (range 8-27) 6MP/MTX metabolite samples and 100 (range 25-130) blood counts during therapy and 10 (range 2-15) off therapy were collected in 50 children with ALL.,Therapeutic procedure,TREATS,Child
27600880,METHODS: A median of 22 (range 8-27) 6MP/MTX metabolite samples and 100 (range 25-130) blood counts during therapy and 10 (range 2-15) off therapy were collected in 50 children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27600880,METHODS: A median of 22 (range 8-27) 6MP/MTX metabolite samples and 100 (range 25-130) blood counts during therapy and 10 (range 2-15) off therapy were collected in 50 children with ALL.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
27600880,PURPOSE: Normal white blood cell counts (WBC) are unknown in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27647691,Study was applied in three hospitals in Ankara/Turkey with 91 children who were diagnosed and treated with ALL and with their family.,Hospitals,LOCATION_OF,Clinical Research
27647691,Study was applied in three hospitals in Ankara/Turkey with 91 children who were diagnosed and treated with ALL and with their family.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Family
27647691,Study was applied in three hospitals in Ankara/Turkey with 91 children who were diagnosed and treated with ALL and with their family.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27698447,"In the treatment of childhood acute lymphoblastic leukemia (ALL), excess shortening of maintenance therapy resulted in high relapse rate, as shown by our previous trial, TCCSG L92-13, in which maintenance therapy was terminated at 1 year from initiation of treatment.",Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27698447,Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27717083,"For reasons not yet understood, nearly all infants with acute lymphoblastic leukemia (ALL) are diagnosed with the B-cell type, with T-ALL in infancy representing a very rare exception.",Cells,PART_OF,Infant
27717083,"For reasons not yet understood, nearly all infants with acute lymphoblastic leukemia (ALL) are diagnosed with the B-cell type, with T-ALL in infancy representing a very rare exception.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
27717083,"For reasons not yet understood, nearly all infants with acute lymphoblastic leukemia (ALL) are diagnosed with the B-cell type, with T-ALL in infancy representing a very rare exception.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
27764235,A significant number of children with T-lineage acute lymphoblastic leukemia (T-ALL) fail to respond to therapy and experience early relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27778348,"The increase in incidence rates of childhood ALL appears to be driven by rising rates in older Hispanic children (10-14, and 15-19 years).","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
27778348,"Hispanic White children were more likely than non-Hispanic White, non-Hispanic Black or non-Hispanic Asian children to be diagnosed with acute lymphocytic leukemia (ALL) from 2009 to 2013.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27778348,"Hispanic White children were more likely than non-Hispanic White, non-Hispanic Black or non-Hispanic Asian children to be diagnosed with acute lymphocytic leukemia (ALL) from 2009 to 2013.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27422759,PedsQL Cancer Module (PedsQL-C) scores were also collected from children with ALL.,Malignant Neoplasms,PROCESS_OF,Modulus
27422759,"The Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL-J) were completed by children with ALL and their siblings, as well as by age- and sex-matched healthy controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,sibling
27422759,QOL of children with ALL differed with treatment phase.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27422759,"The Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL-J) were completed by children with ALL and their siblings, as well as by age- and sex-matched healthy controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27422759,"The off-treatment group had a large effect size only for physical functioning, and the social functioning score was even better in children with ALL than in matched controls.",Physical function,PROCESS_OF,Child
27422759,"The off-treatment group had a large effect size only for physical functioning, and the social functioning score was even better in children with ALL than in matched controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27422759,"RESULTS: QOL in children with ALL of the consolidation phase group was significantly decreased compared with that of healthy controls, except in the area of emotional functioning.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27422759,PedsQL Cancer Module (PedsQL-C) scores were also collected from children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27533339,"Due to the importance of the transport P-glycoprotein and methylenetetrahydrofolate reductase in the metabolism of chemotherapeutic agents, we analyzed the MDR1 rs1045642 and MTHFR rs1801133 polymorphisms and their associations with clinical outcomes in Mexican childhood ALL patients.",Antineoplastic Agents,TREATS,Patients
27533339,"Due to the importance of the transport P-glycoprotein and methylenetetrahydrofolate reductase in the metabolism of chemotherapeutic agents, we analyzed the MDR1 rs1045642 and MTHFR rs1801133 polymorphisms and their associations with clinical outcomes in Mexican childhood ALL patients.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
27533339,"Due to the importance of the transport P-glycoprotein and methylenetetrahydrofolate reductase in the metabolism of chemotherapeutic agents, we analyzed the MDR1 rs1045642 and MTHFR rs1801133 polymorphisms and their associations with clinical outcomes in Mexican childhood ALL patients.",Antineoplastic Agents,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27658980,"Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.",Leukoencephalopathy,PROCESS_OF,Survivors
27658980,"This study examines the associations between acute leukoencephalopathy and neurobehavioural, neurocognitive, and brain white matter imaging outcomes in long-term survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy without cranial radiation.",Leukoencephalopathy,PROCESS_OF,Long-Term Survivors
27658980,"Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27658980,"This study examines the associations between acute leukoencephalopathy and neurobehavioural, neurocognitive, and brain white matter imaging outcomes in long-term survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy without cranial radiation.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27658980,"BACKGROUND: Leukoencephalopathy is observed in some children undergoing chemotherapy for acute lymphoblastic leukaemia, although its effects on long-term outcomes is unknown.",Pharmacotherapy,TREATS,Child
27658980,"BACKGROUND: Leukoencephalopathy is observed in some children undergoing chemotherapy for acute lymphoblastic leukaemia, although its effects on long-term outcomes is unknown.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27658980,"METHODS: In this longitudinal analysis, we used data of children with acute lymphoblastic leukaemia at St Jude Children's Research Hospital (Memphis, TN, USA) who had been treated between June 1, 2000, and Oct 31, 2010.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27658980,"BACKGROUND: Leukoencephalopathy is observed in some children undergoing chemotherapy for acute lymphoblastic leukaemia, although its effects on long-term outcomes is unknown.",Leukoencephalopathy,PROCESS_OF,Child
27658980,"METHODS: In this longitudinal analysis, we used data of children with acute lymphoblastic leukaemia at St Jude Children's Research Hospital (Memphis, TN, USA) who had been treated between June 1, 2000, and Oct 31, 2010.","Hospitals, Pediatric",LOCATION_OF,Analysis
27658980,"BACKGROUND: Leukoencephalopathy is observed in some children undergoing chemotherapy for acute lymphoblastic leukaemia, although its effects on long-term outcomes is unknown.",Pharmacotherapy,TREATS,Leukoencephalopathy
27658980,"This study examines the associations between acute leukoencephalopathy and neurobehavioural, neurocognitive, and brain white matter imaging outcomes in long-term survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy without cranial radiation.",neurobehavior,PROCESS_OF,Long-Term Survivors
27694927,"To identify new susceptibility loci for the largest subtype of ALL, B-cell precursor ALL (BCP-ALL), we conducted a meta-analysis of two GWASs with imputation using 1000 Genomes and UK10K Project data as reference (totaling 1658 cases and 7224 controls).","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
27696656,"PROCEDURE: From 2002 to 2012, all newly diagnosed children with ALL in Taiwan were enrolled in Taiwan Pediatric Oncology Group ALL-2002 protocol.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27696656,BACKGROUND: Reinduction therapy has improved the outcomes in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27696656,BACKGROUND: Reinduction therapy has improved the outcomes in children with acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,Child
27696656,BACKGROUND: Reinduction therapy has improved the outcomes in children with acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
27696698,"Cognitive late-effects have been identified in patients treated with chemotherapy-only protocols for childhood acute lymphoblastic leukemia (ALL), yet the underlying neuropathology is not well understood.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27696698,"Cognitive late-effects have been identified in patients treated with chemotherapy-only protocols for childhood acute lymphoblastic leukemia (ALL), yet the underlying neuropathology is not well understood.",Late effect of,PROCESS_OF,Patients
27696698,"Cognitive late-effects have been identified in patients treated with chemotherapy-only protocols for childhood acute lymphoblastic leukemia (ALL), yet the underlying neuropathology is not well understood.",Chemotherapy-Oncologic Procedure,TREATS,Late effect of
27696698,"Cognitive late-effects have been identified in patients treated with chemotherapy-only protocols for childhood acute lymphoblastic leukemia (ALL), yet the underlying neuropathology is not well understood.",Chemotherapy-Oncologic Procedure,TREATS,Patients
27697278,"The aims of this study were to a) examine the feasibility, acceptability and satisfaction of a parenting intervention amongst parents of children with ALL and b) explore whether participation in a parenting intervention shows promise for improvements in child behavior.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27726029,CONCLUSIONS: The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
27742575,This underlines the importance of excellent MRD and chimerism monitoring after transplantation as the basis for IT to improve survival in childhood ALL.,Transplantation,METHOD_OF,Immunotherapy
27742575,"Patients with ALL who consecutively underwent transplantation in Frankfurt/Main, Germany between January 1, 2005 and July 1, 2014 were included in this retrospective study.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27742575,"Patients with ALL who consecutively underwent transplantation in Frankfurt/Main, Germany between January 1, 2005 and July 1, 2014 were included in this retrospective study.",Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
27742575,Monitoring of minimal residual disease (MRD) or chimerism may help guide pre-emptive immunotherapy (IT) with a view to preventing relapse in childhood acute lymphoblastic leukemia (ALL) after transplantation.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
27742575,This underlines the importance of excellent MRD and chimerism monitoring after transplantation as the basis for IT to improve survival in childhood ALL.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
27748030,The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27577869,CONCLUSIONS: This is the first report on the association of TPMT and NUDT15 polymorphisms with MP dose intolerance in Arab patients with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27577869,CONCLUSIONS: This is the first report on the association of TPMT and NUDT15 polymorphisms with MP dose intolerance in Arab patients with ALL.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
27577869,CONCLUSIONS: This is the first report on the association of TPMT and NUDT15 polymorphisms with MP dose intolerance in Arab patients with ALL.,6-Mercaptopurine,TREATS,Patients
27590521,We found an overall greater mutational burden and more driver mutations in T-cell ALL (T-ALL) patients compared to B-cell precursor ALL (BCP-ALL) patients.,Acute T Cell Leukemia,ISA,"Leukemia, Lymphocytic, Acute"
27590521,We found an overall greater mutational burden and more driver mutations in T-cell ALL (T-ALL) patients compared to B-cell precursor ALL (BCP-ALL) patients.,"Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
27613707,"RESULTS: We observed increased risks of acute lymphoblastic leukemia and Wilms' tumor in children of mothers with pre-pregnancy diabetes [odds ratio (OR) 95 % confidence interval (CI) 1.37 (1.11, 1.69); OR (95 % CI) 1.45 (0.97, 2.18), respectively].",Pregnancy in Diabetics,PROCESS_OF,Mothers
27613707,"RESULTS: We observed increased risks of acute lymphoblastic leukemia and Wilms' tumor in children of mothers with pre-pregnancy diabetes [odds ratio (OR) 95 % confidence interval (CI) 1.37 (1.11, 1.69); OR (95 % CI) 1.45 (0.97, 2.18), respectively].",Nephroblastoma,PROCESS_OF,Child
27613707,"RESULTS: We observed increased risks of acute lymphoblastic leukemia and Wilms' tumor in children of mothers with pre-pregnancy diabetes [odds ratio (OR) 95 % confidence interval (CI) 1.37 (1.11, 1.69); OR (95 % CI) 1.45 (0.97, 2.18), respectively].","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27632202,Relapsed/refractory acute lymphoblastic leukemia (ALL) is a leading cause of death by cancer in children.,Malignant Neoplasms,PROCESS_OF,Child
27632202,Relapsed/refractory acute lymphoblastic leukemia (ALL) is a leading cause of death by cancer in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
27632202,Relapsed/refractory acute lymphoblastic leukemia (ALL) is a leading cause of death by cancer in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27632202,Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27632202,Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy.,Therapeutic procedure,ADMINISTERED_TO,Child
27644650,CONCLUSIONS: Our findings provide the rst evidence that SNPs ARID5B- rs10821936 and IKZF1-rs4132601 are associated with decreased B-lineage ALL susceptibility in Indian children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27645371,"The present study, conducted on children with ALL whose treatment was abandoned, attempted to track all these children to ascertain the causes and outcome of therapy abandonment/refusal.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27645371,"Tracking children with acute lymphoblastic leukemia who abandoned therapy: Experience, challenges, parental perspectives, and impact of treatment subsidies and intensified counseling.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27648170,Unusual presentation of Erdheim-Chester disease in a child with acute lymphoblastic leukemia.,Erdheim-Chester Disease,PROCESS_OF,Child
27648170,Unusual presentation of Erdheim-Chester disease in a child with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27648206,Protective Role of Silymarin on Hepatic and Renal Toxicity Induced by MTX Based Chemotherapy in Children with Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27648206,Protective Role of Silymarin on Hepatic and Renal Toxicity Induced by MTX Based Chemotherapy in Children with Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27648206,Protective Role of Silymarin on Hepatic and Renal Toxicity Induced by MTX Based Chemotherapy in Children with Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,Child
27648206,Protective Role of Silymarin on Hepatic and Renal Toxicity Induced by MTX Based Chemotherapy in Children with Acute Lymphoblastic Leukemia.,Methotrexate,CAUSES,Toxic nephropathy
27655540,METHODS: The clinical data of 35 children who had newly-diagnosed ALL and achieved complete remission on day 33 of remission induction therapy were retrospectively reviewed.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27756164,"In order to investigate the prognostic impact of deletions and promoter methylation within 9p21, 641 children with newly diagnosed BCP-ALL using methylation specific multiplex ligation-dependent probe amplification (MS-MLPA) were investigated.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
27756164,"The inactivation of tumor suppressor genes located within 9p21 locus (CDKN2A, CDKN2B) occurs in up to 30% of children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), but its independent prognostic significance remains controversial.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
28628559,"Three out of five SNPs with a minor allele frequency more than 0.15 [CCR4-NOT transcription complex (CNOT4) rs3812265, miR-1206 rs2114358, miR-2053 rs10505168] were analyzed in 117 pediatric ALL patients treated with 5 g/m MTX (DCOG ALL-10).",Patients,LOCATION_OF,Single Nucleotide Polymorphism
28628559,"Three out of five SNPs with a minor allele frequency more than 0.15 [CCR4-NOT transcription complex (CNOT4) rs3812265, miR-1206 rs2114358, miR-2053 rs10505168] were analyzed in 117 pediatric ALL patients treated with 5 g/m MTX (DCOG ALL-10).",Methotrexate,TREATS,Patients
28628559,"Three out of five SNPs with a minor allele frequency more than 0.15 [CCR4-NOT transcription complex (CNOT4) rs3812265, miR-1206 rs2114358, miR-2053 rs10505168] were analyzed in 117 pediatric ALL patients treated with 5 g/m MTX (DCOG ALL-10).",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28628559,"Three out of five SNPs with a minor allele frequency more than 0.15 [CCR4-NOT transcription complex (CNOT4) rs3812265, miR-1206 rs2114358, miR-2053 rs10505168] were analyzed in 117 pediatric ALL patients treated with 5 g/m MTX (DCOG ALL-10).","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
28631637,An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
28641626,CONCLUSION: The MRD>/=10-2 at day 33 is a high risk factor for significant reduction of the 5-year EFS rate and the 5-year OS rate of children with B-ALL.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
28641626,METHODS: Three hundred and eighty cases of children's B-ALL from Augest 2008 to January 2013 in our hospital were enrolled in this study.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
28645022,"Furthermore, the estimates for children with acute myeloid leukemia (AML) were stronger than those with acute lymphoid leukemia, though not statistically significant.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
28645022,"Furthermore, the estimates for children with acute myeloid leukemia (AML) were stronger than those with acute lymphoid leukemia, though not statistically significant.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476194,"BACKGROUND AND AIMS: In high-income countries, treatment protocols for acute lymphoblastic leukemia (ALL) in children lead to a 5-year overall survival (OS) approaching 90%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476194,"BACKGROUND AND AIMS: In high-income countries, treatment protocols for acute lymphoblastic leukemia (ALL) in children lead to a 5-year overall survival (OS) approaching 90%.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
28476195,"METHODS: We included 670 children with ALL enrolled in a case-control study in California (1995-2013), including 50.6% Latinos.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476195,RESULTS: KRAS or NRAS mutations were detected in approximately 18% of children diagnosed with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476195,Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Latinos
28476195,Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476198,Copy Number Alterations Associated with Acute Lymphoblastic Leukemia in Mexican Children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28481918,"Therefore, the aim of this study was to determine whether the annotated risk variants in the CDKN2A/B locus affect the susceptibility of B cell precursor ALL (B-ALL) in our Spanish population and explore if other SNPs altering additional regulatory mechanisms could be also involved.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
28486976,DISCUSSION: This trial will be the first to assess efficacy and safety of thromboprophylaxis with LMWH during asparaginase treatment for ALL in children in a randomized design.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28486976,DISCUSSION: This trial will be the first to assess efficacy and safety of thromboprophylaxis with LMWH during asparaginase treatment for ALL in children in a randomized design.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
28486976,DISCUSSION: This trial will be the first to assess efficacy and safety of thromboprophylaxis with LMWH during asparaginase treatment for ALL in children in a randomized design.,Therapeutic procedure,USES,ASPARAGINASE
28486976,DISCUSSION: This trial will be the first to assess efficacy and safety of thromboprophylaxis with LMWH during asparaginase treatment for ALL in children in a randomized design.,ASPARAGINASE,ISA,Therapeutic procedure
28500740,Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28523449,Fifty-five children with BCP-ALL were included in the study.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
28525903,High-dose methotrexate (HDMTX) plays an important role in the treatment of acute lymphoblastic leukemia (ALL) although there is great inter-patient variability in the efficacy and toxicity of MTX.,Methotrexate,TREATS,Toxic effect
28525903,High-dose methotrexate (HDMTX) plays an important role in the treatment of acute lymphoblastic leukemia (ALL) although there is great inter-patient variability in the efficacy and toxicity of MTX.,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
28538500,Parental Perceptions of Obesity and Obesity Risk Associated With Childhood Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,Obesity
28538500,Parental Perceptions of Obesity and Obesity Risk Associated With Childhood Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute, L1",COEXISTS_WITH,Obesity
28545980,The primary aim of this exploratory investigation was to determine if there were changes in brain function of children with acute lymphoblastic leukemia before chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28550450,METHODS: ABCC4 G912T SNP was genotyped in 145 Iranian Philadelphia-negative (Ph-) children with ALL using modified tetra-primer ARMS PCR and evaluated for possible association with 3-year disease-free survival (3DFS).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28550450,ABCC4 functional SNP in the 3' splice acceptor site of exon 8 (G912T) is associated with unfavorable clinical outcome in children with acute lymphoblastic leukemia.,Unfavorable Clinical Outcome,PROCESS_OF,Child
28550450,ABCC4 functional SNP in the 3' splice acceptor site of exon 8 (G912T) is associated with unfavorable clinical outcome in children with acute lymphoblastic leukemia.,Single Nucleotide Polymorphism,COEXISTS_WITH,Splice Acceptor Site
28550450,ABCC4 functional SNP in the 3' splice acceptor site of exon 8 (G912T) is associated with unfavorable clinical outcome in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28552244,Recently attention in this area of research turned to another cause of AP - Asparaginase based drugs - which have been used quite successfully in treatments of childhood acute lymphoblastic leukaemia (ALL).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28580844,"The frequency, sites and outcome of relapsed ALL in children of northeast Mexico over a decade was documented.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28580844,METHODS: A retrospective analysis of 246 children belonging to a low-income group <16 years with de novo ALL during 2004-2015 was performed.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28598592,CONCLUSIONS: Hospitalizations for children with ALL were less expensive than in high-income countries but had a significant cost to low-income families and to the healthcare system.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28598592,CONCLUSIONS: Hospitalizations for children with ALL were less expensive than in high-income countries but had a significant cost to low-income families and to the healthcare system.,Hospitalization,TREATS,Child
28454370,"The mean levels of telomerase were 49.09+/-44.43 and 29.99+/-32.43 TPG units in children with ALL with and without CDKN2B methylation, respectively (P=0.041), therefore children with ALL exhibited significantly increased levels of telomerase.",Child,LOCATION_OF,Telomerase
28454370,"A total of 72 children with ALL and 12 children with immune thrombocytopenia (ITP) were subjected to bone marrow aspiration and methylation-specific polymerase chain reaction analysis, and modified telomeric repeat amplification protocol assay analyses, to evaluate CDKN2B methylation and telomerase activity, respectively.",Immune thrombocytopenia,PROCESS_OF,Child
28454370,"The mean levels of telomerase were 49.09+/-44.43 and 29.99+/-32.43 TPG units in children with ALL with and without CDKN2B methylation, respectively (P=0.041), therefore children with ALL exhibited significantly increased levels of telomerase.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28454370,"A total of 72 children with ALL and 12 children with immune thrombocytopenia (ITP) were subjected to bone marrow aspiration and methylation-specific polymerase chain reaction analysis, and modified telomeric repeat amplification protocol assay analyses, to evaluate CDKN2B methylation and telomerase activity, respectively.",Immune thrombocytopenia,PROCESS_OF,Child
28454370,"The mean levels of telomerase were 49.09+/-44.43 and 29.99+/-32.43 TPG units in children with ALL with and without CDKN2B methylation, respectively (P=0.041), therefore children with ALL exhibited significantly increased levels of telomerase.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28454370,The aim of the present study was to investigate the association between methylation of cyclin-dependent kinase inhibitor 2B (CDKN2B) CpG islands and telomerase activity in children with acute lymphoblastic leukemia (ALL).,telomerase activity,PROCESS_OF,Child
28454370,"Furthermore, the mean level of telomerase activity was 39.52+/-39.33 total product generated (TPG) units in children with ALL, which was significantly increased compared with 2.49+/-2.27 TPG units in the ITP controls (P=0.002).",telomerase activity,PROCESS_OF,Child
28454370,The aim of the present study was to investigate the association between methylation of cyclin-dependent kinase inhibitor 2B (CDKN2B) CpG islands and telomerase activity in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28454370,"The results of the present study demonstrated that, of these 72 children with ALL, 31 exhibited CDKN2B methylation at diagnosis (43.1%), whereas 41 exhibited no CDKN2B methylation (36.9%).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28454370,"Furthermore, the mean level of telomerase activity was 39.52+/-39.33 total product generated (TPG) units in children with ALL, which was significantly increased compared with 2.49+/-2.27 TPG units in the ITP controls (P=0.002).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28454370,"A total of 72 children with ALL and 12 children with immune thrombocytopenia (ITP) were subjected to bone marrow aspiration and methylation-specific polymerase chain reaction analysis, and modified telomeric repeat amplification protocol assay analyses, to evaluate CDKN2B methylation and telomerase activity, respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28454370,"The mean levels of telomerase were 49.09+/-44.43 and 29.99+/-32.43 TPG units in children with ALL with and without CDKN2B methylation, respectively (P=0.041), therefore children with ALL exhibited significantly increased levels of telomerase.",Child,LOCATION_OF,CDKN2B gene | CDKN2B
28454370,"A total of 72 children with ALL and 12 children with immune thrombocytopenia (ITP) were subjected to bone marrow aspiration and methylation-specific polymerase chain reaction analysis, and modified telomeric repeat amplification protocol assay analyses, to evaluate CDKN2B methylation and telomerase activity, respectively.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28475268,"BACKGROUND: Health-related quality of life (HRQoL) from diagnosis until end of treatment for children with acute lymphoblastic leukaemia was investigated, examining effects of age, gender, risk-stratified treatment regimen, and therapy intensity (one vs. two 'delayed intensifications' [DIs]).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28475268,"BACKGROUND: Health-related quality of life (HRQoL) from diagnosis until end of treatment for children with acute lymphoblastic leukaemia was investigated, examining effects of age, gender, risk-stratified treatment regimen, and therapy intensity (one vs. two 'delayed intensifications' [DIs]).",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
28475268,"BACKGROUND: Health-related quality of life (HRQoL) from diagnosis until end of treatment for children with acute lymphoblastic leukaemia was investigated, examining effects of age, gender, risk-stratified treatment regimen, and therapy intensity (one vs. two 'delayed intensifications' [DIs]).",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
28475268,"BACKGROUND: Health-related quality of life (HRQoL) from diagnosis until end of treatment for children with acute lymphoblastic leukaemia was investigated, examining effects of age, gender, risk-stratified treatment regimen, and therapy intensity (one vs. two 'delayed intensifications' [DIs]).",Therapeutic procedure,TREATS,Child
28475268,"BACKGROUND: Health-related quality of life (HRQoL) from diagnosis until end of treatment for children with acute lymphoblastic leukaemia was investigated, examining effects of age, gender, risk-stratified treatment regimen, and therapy intensity (one vs. two 'delayed intensifications' [DIs]).",Treatment Protocols,TREATS,Child
28475442,"In addition, less severe scarring was measured in children suffering from ALL compared with children suffering from other types of childhood cancer.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28475442,"In addition, less severe scarring was measured in children suffering from ALL compared with children suffering from other types of childhood cancer.",Cicatrix,PROCESS_OF,Child
28475442,"A higher total VSS score, resembling a worse scar, was assessed to the scars in the non-ALL group compared with the children with ALL (mean ALL: 0.91 (0-3) versus mean non-ALL: 2.50 (0-6), p=0.037).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28475442,"To evaluate the role of the immune system on scar severity and histology, the scars of children suffering from acute lymphoblastic leukaemia (ALL) were compared with the scars of children suffering from other types of childhood cancer.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476190,"The aim of the present study was to examine the contribution of ARID5B, CEBPE, and PIP4K2 risk alleles for the development of ALL in children from Mexico City and Yucatan, Mexico.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476192,"CONCLUSIONS: Our data support previous findings showing the relevance of PAX5, EBF1 and ZCCHC7 as potential biomarkers to identify a subgroup of ALL children in high risk to relapse.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476192,The aim of the study was to identify new potential biomarkers associated with very early relapse in Mexican ALL children through transcriptome analysis.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476192,Gene Expression Profiling of Acute Lymphoblastic Leukemia in Children with Very Early Relapse.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476194,We documented the results of treating children with ALL with two protocols in consecutive 5-year periods at a reference center in northeast Mexico.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476194,"BACKGROUND AND AIMS: In high-income countries, treatment protocols for acute lymphoblastic leukemia (ALL) in children lead to a 5-year overall survival (OS) approaching 90%.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476194,"BACKGROUND AND AIMS: In high-income countries, treatment protocols for acute lymphoblastic leukemia (ALL) in children lead to a 5-year overall survival (OS) approaching 90%.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
28476194,CONCLUSIONS: No improvement in survival rates of children with ALL from a low-income group living in a LMIC was achieved over a decade.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28476194,PATIENTS AND METHODS: Children </=16 years of age diagnosed with ALL treated with two protocols were studied.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28424165,"Glucocorticoids (GCs), including dexamethasone (dex), are a central component of combination chemotherapy for childhood B-cell precursor acute lymphoblastic leukemia (B-ALL).",Combination Drug Therapy,TREATS,B-cell childhood acute lymphoblastic leukemia
28424165,"Glucocorticoids (GCs), including dexamethasone (dex), are a central component of combination chemotherapy for childhood B-cell precursor acute lymphoblastic leukemia (B-ALL).",B-cell childhood acute lymphoblastic leukemia,ISA,"Leukemia, B-Cell, Acute"
28424165,Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
28431124,Background: It has been proposed that childhood vaccinations protect against acute lymphoblastic leukaemia (ALL) in children by modulation of future responses to common infections in childhood.,Vaccination,PREVENTS,"Leukemia, Lymphocytic, Acute"
28431124,Childhood vaccinations and risk of acute lymphoblastic leukaemia in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28431124,Results: Childhood ALL was diagnosed in 490 children during 10 829 194 person-years of follow-up.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
28431124,Background: It has been proposed that childhood vaccinations protect against acute lymphoblastic leukaemia (ALL) in children by modulation of future responses to common infections in childhood.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28440015,Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.,Therapeutic procedure,USES,ASPARAGINASE
28440015,"HTG is usually considered to be transient and benign in children with ALL, whereas low AT activity predisposes to thrombosis.",Hypertriglyceridemia,PROCESS_OF,Child
28440015,Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
28440015,"HTG is usually considered to be transient and benign in children with ALL, whereas low AT activity predisposes to thrombosis.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28440015,"PROCEDURE: We analyzed the laboratory and clinical data of children diagnosed with ALL at the Karolinska Hospital, Stockholm, Sweden, from July 2008 to December 2014.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28440015,Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.,ASPARAGINASE,ISA,Therapeutic procedure
28440015,BACKGROUND: Asparaginase (ASP) is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
28440015,"We investigated the incidence and significance of ASP-related HTG, defined as triglyceride values more than five times the upper normal limit, in children with ALL.",Hypertriglyceridemia,PROCESS_OF,Child
28440015,BACKGROUND: Asparaginase (ASP) is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL).,ASPARAGINASE,ISA,Therapeutic procedure
28440015,"Studies on the incidence and significance of HTG in children with ALL are scarce, and their findings have not always been congruent.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28440015,"We investigated the incidence and significance of ASP-related HTG, defined as triglyceride values more than five times the upper normal limit, in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28440015,Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28440015,"Studies on the incidence and significance of HTG in children with ALL are scarce, and their findings have not always been congruent.",Hypertriglyceridemia,PROCESS_OF,Child
28440015,Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.,ASPARAGINASE,TREATS,Child
28440015,"HTG is usually considered to be transient and benign in children with ALL, whereas low AT activity predisposes to thrombosis.",Antithrombins,PREDISPOSES,Thrombosis
28441264,"In this work, we analyzed the expression of CD19 isoforms in a cohort of 14 children with CD19 B-ALL and 6 nonleukemia donors.",CD19 gene | CD19,PART_OF,cohort
28441264,"In this work, we analyzed the expression of CD19 isoforms in a cohort of 14 children with CD19 B-ALL and 6 nonleukemia donors.","Leukemia, B-Cell, Acute",PROCESS_OF,Donor person
28441264,"In this work, we analyzed the expression of CD19 isoforms in a cohort of 14 children with CD19 B-ALL and 6 nonleukemia donors.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
28452038,"In conclusion, NGS is a promising tool for MRD detection with the potential to overcome most of the limitations of RQ-PCR and to become the new gold standard for MRD detection in ALL.",Polymerase Chain Reaction,DIAGNOSES,"Neoplasm, Residual"
28452038,Minimal residual disease (MRD) is the most important independent prognostic factor in acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
28452038,"In conclusion, NGS is a promising tool for MRD detection with the potential to overcome most of the limitations of RQ-PCR and to become the new gold standard for MRD detection in ALL.",Detection,TREATS,"Leukemia, Lymphocytic, Acute"
28452142,We examined these associations among survivors of childhood ALL treated with chemotherapy only.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28454370,A total of 22/31 children with ALL with methylated CDKN2B (71.0%) and 17/41 children with ALL with unmethylated CDKN2B (41.46%) exhibited increased telomerase activity (>15 TPG units).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28454370,A total of 22/31 children with ALL with methylated CDKN2B (71.0%) and 17/41 children with ALL with unmethylated CDKN2B (41.46%) exhibited increased telomerase activity (>15 TPG units).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28454370,A total of 22/31 children with ALL with methylated CDKN2B (71.0%) and 17/41 children with ALL with unmethylated CDKN2B (41.46%) exhibited increased telomerase activity (>15 TPG units).,CDKN2B gene | CDKN2B,PART_OF,"Leukemia, Lymphocytic, Acute"
28454370,A total of 22/31 children with ALL with methylated CDKN2B (71.0%) and 17/41 children with ALL with unmethylated CDKN2B (41.46%) exhibited increased telomerase activity (>15 TPG units).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28454370,A total of 22/31 children with ALL with methylated CDKN2B (71.0%) and 17/41 children with ALL with unmethylated CDKN2B (41.46%) exhibited increased telomerase activity (>15 TPG units).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28454370,A total of 22/31 children with ALL with methylated CDKN2B (71.0%) and 17/41 children with ALL with unmethylated CDKN2B (41.46%) exhibited increased telomerase activity (>15 TPG units).,CDKN2B gene | CDKN2B,PART_OF,"Leukemia, Lymphocytic, Acute"
28381164,The aim of this study was to investigate the association between ARID5B variants with acute lymphoblastic leukemia in Yemeni children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28381164,Association of ARID5B gene variants with acute lymphoblastic leukemia in Yemeni children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28392709,Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia (ALL).,Methotrexate,ISA,Therapeutic procedure
28392709,Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia (ALL).,Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28392709,"Therefore, MTHFR C677T and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity and/or outcome in pediatric ALL.",METHOTREXATE TOXICITY,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
28392709,Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia (ALL).,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28394186,"The presence of high level language deficits in older children who received CNS-directed ITC for ALL in early childhood is yet to be elucidated, with previous research suggesting that high level language deficits may appear later in ALL survivors' development at an age when these skills typically emerge.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
28394186,"The presence of high level language deficits in older children who received CNS-directed ITC for ALL in early childhood is yet to be elucidated, with previous research suggesting that high level language deficits may appear later in ALL survivors' development at an age when these skills typically emerge.",Pharmacotherapy,ADMINISTERED_TO,Child
28394186,"The presence of high level language deficits in older children who received CNS-directed ITC for ALL in early childhood is yet to be elucidated, with previous research suggesting that high level language deficits may appear later in ALL survivors' development at an age when these skills typically emerge.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28394186,"The presence of high level language deficits in older children who received CNS-directed ITC for ALL in early childhood is yet to be elucidated, with previous research suggesting that high level language deficits may appear later in ALL survivors' development at an age when these skills typically emerge.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
28395118,"During diagnostic immunophenotyping of 573 childhood B-cell precursor ALL (BCP-ALL), we identified eight cases with this immunophenotype among ""B-other ALL"" (BCP-ALL cases negative for routinely tested chromosomal/genetic aberrations).",B-cell childhood acute lymphoblastic leukemia,ISA,"Leukemia, Lymphocytic, Acute"
28401497,"Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28401497,"Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28401497,"In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL.",Pharmacotherapy,TREATS,Patients
28401497,Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Child
28401497,"In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL.",Neutropenia,CAUSES,"Complication, infection"
28401497,Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28401497,"In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
28401497,Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28401497,"In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28401497,"Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL.",Pharmacotherapy,TREATS,Child
28410228,"In order to identify new targets for ALL, we performed whole-exome sequencing on four adults with B-ALL and discovered a somatic JAK1 S646P mutation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Adrenal gland hypofunction,ISA,Endocrine System Diseases
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Hepatic Veno-Occlusive Disease,CAUSES,Hyperlipidemia
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Adrenal gland hypofunction,CAUSES,Hyperglycemia
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Endocrine System Diseases,CAUSES,Hyperglycemia
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Endocrine System Diseases,CAUSES,Adrenal gland hypofunction
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Hyperglycemia,ISA,Endocrine System Diseases
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Hepatic Veno-Occlusive Disease,CAUSES,Pancreatitis
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Hyperglycemia,CAUSES,Adrenal gland hypofunction
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Hepatic Veno-Occlusive Disease,CAUSES,Hypersensitivity
28414926,"Children with acute myeloid leukemia, infant acute lymphoblastic leukemia, hepatoblastoma, and malignant brain tumors had the highest risk of early death.",Hepatoblastoma,PROCESS_OF,Child
28414926,"Children with acute myeloid leukemia, infant acute lymphoblastic leukemia, hepatoblastoma, and malignant brain tumors had the highest risk of early death.",Malignant neoplasm of brain,PROCESS_OF,Child
28414926,"Children with acute myeloid leukemia, infant acute lymphoblastic leukemia, hepatoblastoma, and malignant brain tumors had the highest risk of early death.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
28414926,"Children with acute myeloid leukemia, infant acute lymphoblastic leukemia, hepatoblastoma, and malignant brain tumors had the highest risk of early death.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28414926,"Children with acute myeloid leukemia, infant acute lymphoblastic leukemia, hepatoblastoma, and malignant brain tumors had the highest risk of early death.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
28418010,Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.,6-Mercaptopurine,TREATS,Patients
28418010,Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
28418010,Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28419441,Flow cytometric detection of minimal residual disease (MRD) in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) requires immunophenotypic discrimination between residual leukaemic cells and B-cell precursors (BCPs) which regenerate during therapy intervals.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
28419441,Flow cytometric detection of minimal residual disease (MRD) in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) requires immunophenotypic discrimination between residual leukaemic cells and B-cell precursors (BCPs) which regenerate during therapy intervals.,"Neoplasm, Residual",PROCESS_OF,Child
28419441,Flow cytometric detection of minimal residual disease (MRD) in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) requires immunophenotypic discrimination between residual leukaemic cells and B-cell precursors (BCPs) which regenerate during therapy intervals.,Flow Cytometry,DIAGNOSES,"Neoplasm, Residual"
28419449,Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28422613,We determined the effect of these online conferences on the development and implementation of an innovative protocol for children with acute lymphoblastic leukemia (ALL) at IMIP.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28423235,"PROCEDURE: In children with ALL treated in Denmark according to the NOPHO ALL2008 protocol, we investigated the risk of SOS during methotrexate (MTX)/6-mercaptopurine (6MP) maintenance therapy that included PEG-asparaginase until week 33 (randomized to two- vs. six-week intervals), as well as alternating high-dose MTX or vincristine/dexamethasone pulses every four weeks.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28297628,"Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure rates exceeding 90% in children, it remains an important cause of morbidity and mortality in children and adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
28297628,"Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure rates exceeding 90% in children, it remains an important cause of morbidity and mortality in children and adults.",Malignant Childhood Neoplasm,PROCESS_OF,Child
28297628,The past decade has been marked by extraordinary advances into the genetic basis of leukemogenesis and treatment responsiveness in ALL.,Leukemogenesis,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
28297628,"Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure rates exceeding 90% in children, it remains an important cause of morbidity and mortality in children and adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28317081,RECENT FINDINGS: Multiple studies have examined the toxicities of the primary chemotherapeutic agents used to treat childhood ALL in relation to host genetic factors.,Antineoplastic Agents,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28317081,PURPOSE OF REVIEW: The aim of this review is to summarize the most recent and most robust pharmacogenetic predictors of treatment-related toxicity (TRT) in childhood acute lymphoblastic leukemia (ALL).,Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
28317081,Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.,Toxic effect,PROCESS_OF,Child
28317081,Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28319818,"CONCLUSIONS: The risk of ALL was elevated in young children with paternal occupational pesticide exposure during the perinatal period, using more detailed occupational information for exposure classification.",Paternal Exposure,PROCESS_OF,Child
28319818,"CONCLUSIONS: The risk of ALL was elevated in young children with paternal occupational pesticide exposure during the perinatal period, using more detailed occupational information for exposure classification.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28319818,METHODS: We assessed parental occupational pesticide exposure from the year before pregnancy to the child's third year of life for 669 children diagnosed with ALL and 1021 controls.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28321092,"Based on the initial diagnosis of BCP-ALL, induction chemotherapy for BCP-ALL was initiated.",Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
28321092,Refractory double-hit lymphoma/leukemia in childhood mimicking B-precursor acute lymphoblastic leukemia at initial presentation.,leukemia,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
28324281,Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
28324281,We sought to determine whether panels of antibodies combination are more suitable for detection of MRD in Childhood ALL.,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
28324281,We sought to determine whether panels of antibodies combination are more suitable for detection of MRD in Childhood ALL.,Detection,USES,Antibodies
28324281,Monitoring of minimal residual disease (MRD) is currently considered the most powerful predictor of outcome in acute lymphoblastic leukemia (ALL).,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
28326824,"In children with acute lymphoblastic leukemia with CNS involvement and with atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma, the serum and CSF OPN levels reflected tumor bulk and response to therapy, while in children with AT/RT and multisystem Langerhans cell histiocytosis with high-risk organs involvement, high OPN serum levels correlated with poorer survival.",Atypical teratoid/rhabdoid tumor,PROCESS_OF,Child
28326824,"In children with acute lymphoblastic leukemia with CNS involvement and with atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma, the serum and CSF OPN levels reflected tumor bulk and response to therapy, while in children with AT/RT and multisystem Langerhans cell histiocytosis with high-risk organs involvement, high OPN serum levels correlated with poorer survival.","Histiocytosis, Langerhans-Cell",PROCESS_OF,Child
28326824,"In children with acute lymphoblastic leukemia with CNS involvement and with atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma, the serum and CSF OPN levels reflected tumor bulk and response to therapy, while in children with AT/RT and multisystem Langerhans cell histiocytosis with high-risk organs involvement, high OPN serum levels correlated with poorer survival.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28326824,"In children with acute lymphoblastic leukemia with CNS involvement and with atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma, the serum and CSF OPN levels reflected tumor bulk and response to therapy, while in children with AT/RT and multisystem Langerhans cell histiocytosis with high-risk organs involvement, high OPN serum levels correlated with poorer survival.",Therapeutic procedure,TREATS,Atypical teratoid/rhabdoid tumor
28326824,"In children with acute lymphoblastic leukemia with CNS involvement and with atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma, the serum and CSF OPN levels reflected tumor bulk and response to therapy, while in children with AT/RT and multisystem Langerhans cell histiocytosis with high-risk organs involvement, high OPN serum levels correlated with poorer survival.",Atypical teratoid/rhabdoid tumor,PROCESS_OF,Child
28326824,"In children with acute lymphoblastic leukemia with CNS involvement and with atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma, the serum and CSF OPN levels reflected tumor bulk and response to therapy, while in children with AT/RT and multisystem Langerhans cell histiocytosis with high-risk organs involvement, high OPN serum levels correlated with poorer survival.",Therapeutic procedure,TREATS,"Histiocytosis, Langerhans-Cell"
28326824,"In children with acute lymphoblastic leukemia with CNS involvement and with atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma, the serum and CSF OPN levels reflected tumor bulk and response to therapy, while in children with AT/RT and multisystem Langerhans cell histiocytosis with high-risk organs involvement, high OPN serum levels correlated with poorer survival.",CNS metastases,PROCESS_OF,Child
28326824,"In children with acute lymphoblastic leukemia with CNS involvement and with atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma, the serum and CSF OPN levels reflected tumor bulk and response to therapy, while in children with AT/RT and multisystem Langerhans cell histiocytosis with high-risk organs involvement, high OPN serum levels correlated with poorer survival.",osteopontin,PART_OF,LAMC2
28326824,"In children with acute lymphoblastic leukemia with CNS involvement and with atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma, the serum and CSF OPN levels reflected tumor bulk and response to therapy, while in children with AT/RT and multisystem Langerhans cell histiocytosis with high-risk organs involvement, high OPN serum levels correlated with poorer survival.",medulloblastoma,PROCESS_OF,Child
28326824,"In children with acute lymphoblastic leukemia with CNS involvement and with atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma, the serum and CSF OPN levels reflected tumor bulk and response to therapy, while in children with AT/RT and multisystem Langerhans cell histiocytosis with high-risk organs involvement, high OPN serum levels correlated with poorer survival.",Therapeutic procedure,TREATS,Child
28339328,Purpose Children with acute lymphoblastic leukemia (ALL) are generally instructed to take mercaptopurine (6-MP) in the evening and without food or dairy products.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28339328,Purpose Children with acute lymphoblastic leukemia (ALL) are generally instructed to take mercaptopurine (6-MP) in the evening and without food or dairy products.,6-Mercaptopurine,ADMINISTERED_TO,Child
28339328,"Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.",Habits,PROCESS_OF,Child
28339328,"Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28339328,Future recommendations regarding 6-MP intake during maintenance therapy for childhood ALL should aim to simplify administration.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28339328,Methods Participants included 441 children with ALL receiving oral 6-MP for maintenance.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28381164,"In conclusion, our study has shown that ARID5B variants are associated with acute lymphoblastic leukemia in Yemeni children with several gender biases of ARID5B single nucleotide polymorphisms reported.",Sexism,PROCESS_OF,Child
28381164,"A total of 14 ARID5B gene single nucleotide polymorphisms (SNPs) were genotyped in 289 Yemeni children, of whom 136 had acute lymphoblastic leukemia and 153 were controls, using the nanofluidic Dynamic Array (Fluidigm 192.24 Dynamic Array).",Child,LOCATION_OF,Single Nucleotide Polymorphism
28381164,"A total of 14 ARID5B gene single nucleotide polymorphisms (SNPs) were genotyped in 289 Yemeni children, of whom 136 had acute lymphoblastic leukemia and 153 were controls, using the nanofluidic Dynamic Array (Fluidigm 192.24 Dynamic Array).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28381164,"In conclusion, our study has shown that ARID5B variants are associated with acute lymphoblastic leukemia in Yemeni children with several gender biases of ARID5B single nucleotide polymorphisms reported.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28381164,"In conclusion, our study has shown that ARID5B variants are associated with acute lymphoblastic leukemia in Yemeni children with several gender biases of ARID5B single nucleotide polymorphisms reported.",ARID5B,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
28139029,"BACKGROUND: Vincristine, an essential component of childhood acute lymphoblastic leukaemia (ALL) therapeutic protocols, is associated with dose-dependent neurotoxicity, but its long-term morbidity in treated children has not been clearly elucidated.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
28153823,We aimed to directly compare self-report to electronic monitoring (Medication Event Monitoring System [MEMS]) and identify predictors of overreporting in a cohort of 416 children with ALL in first remission over 4 study months (1344 patient-months for the cohort) during maintenance therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28153823,Adequate exposure to oral 6-mercaptopurine (6MP) during maintenance therapy for childhood acute lymphoblastic leukemia (ALL) is critical for sustaining durable remissions; accuracy of self-reported 6MP intake is unknown.,6-Mercaptopurine,TREATS,sustained remission
28153823,Adequate exposure to oral 6-mercaptopurine (6MP) during maintenance therapy for childhood acute lymphoblastic leukemia (ALL) is critical for sustaining durable remissions; accuracy of self-reported 6MP intake is unknown.,Maintenance therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28176509,"The principal outcome measure was the odds ratio (OR) with 95 % confidence interval (CI) for the risk of child ALL associated with GSTM1, GSTT1, GSTP1 Ile105Val.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28176509,"BACKGROUND: The association between glutathione-S-transferase polymorphisms (GSTM1, GSTT1 and GSTP1 Ile105Val) and risk of childhood acute lymphoblastic leukemia (ALL) remains controversial.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
28176509,"The principal outcome measure was the odds ratio (OR) with 95 % confidence interval (CI) for the risk of child ALL associated with GSTM1, GSTT1, GSTP1 Ile105Val.",GSTT1 gene | GSTT1,PREDISPOSES,"Leukemia, Lymphocytic, Acute"
28176509,"The principal outcome measure was the odds ratio (OR) with 95 % confidence interval (CI) for the risk of child ALL associated with GSTM1, GSTT1, GSTP1 Ile105Val.",GSTM1 gene | GSTM1,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
28179212,"Herein, investigation of the relationship between the N363S and BclI polymorphisms of the GC receptor gene (NR3C1) and the side effects of GCs during pediatric ALL therapy was aimed.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28179212,"Herein, investigation of the relationship between the N363S and BclI polymorphisms of the GC receptor gene (NR3C1) and the side effects of GCs during pediatric ALL therapy was aimed.",NR3C1 gene | NR3C1,ISA,Receptor Gene
28179212,OBJECTIVE: Glucocorticoids (GCs) are the key drugs for the treatment of pediatric acute lymphoblastic leukemia (ALL).,Glucocorticoids,ISA,Pharmaceutical Preparations
28179212,OBJECTIVE: Glucocorticoids (GCs) are the key drugs for the treatment of pediatric acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28179212,OBJECTIVE: Glucocorticoids (GCs) are the key drugs for the treatment of pediatric acute lymphoblastic leukemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28195091,AIMS: To study the effect of induction chemotherapy on coagulation parameters in pediatric ALL patients.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
28195091,AIMS: To study the effect of induction chemotherapy on coagulation parameters in pediatric ALL patients.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28195091,"CONTEXT: Thromboembolism in children with acute lymphoblastic leukemia (ALL) is most commonly reported after the initiation of antileukemic therapy, indicating a possible interaction of disease and therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28195091,"CONTEXT: Thromboembolism in children with acute lymphoblastic leukemia (ALL) is most commonly reported after the initiation of antileukemic therapy, indicating a possible interaction of disease and therapy.",Thromboembolism,PROCESS_OF,Child
28195091,AIMS: To study the effect of induction chemotherapy on coagulation parameters in pediatric ALL patients.,Pharmacotherapy,TREATS,Patients
28202116,METHODS: A retrospective analysis was performed for the clinical data of 130 children with newly-diagnosed childhood ALL.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
28202519,Our results suggest that prenatal and early-life tobacco smoke exposure increase the frequency of somatic deletions in children who develop ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28202519,Our results suggest that prenatal and early-life tobacco smoke exposure increase the frequency of somatic deletions in children who develop ALL.,Child,LOCATION_OF,Tobacco smoke
28244291,"In conclusion, a modified dose of idarubicin was effectively incorporated into the reinduction regimen for late marrow-relapsed ALL with a low toxic death rate.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
28244291,"Between 2006 and 2009, the trial accrued 44 patients, 1 to 21 years old with first marrow-relapsed ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
28244291,Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.,Idarubicin,TREATS,Child
28244291,Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28244291,Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.,Idarubicin,TREATS,"Leukemia, Lymphocytic, Acute"
28245377,[Prognostic Significance of Joint Detection of miR-210 and Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia].,Articular system,LOCATION_OF,Detection
28245377,[Prognostic Significance of Joint Detection of miR-210 and Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia].,"Neoplasm, Residual",COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
28250007,"In a multicenter prospective observational study, a total of 714 blood samples were collected from 51 children (age 1-17 years) with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28253825,METHODS: The expression of miR-21 was detected by real-time quantitative PCR in 75 children with de novo B-ALL as well as in 50 healthy controls.,Child,LOCATION_OF,MIRN21 gene | MIR21
28253825,METHODS: The expression of miR-21 was detected by real-time quantitative PCR in 75 children with de novo B-ALL as well as in 50 healthy controls.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
28258829,Mercaptopurine in childhood acute lymphoblastic leukaemia.,6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28295182,The addition of temsirolimus to UKALL R3 re-induction therapy resulted in excessive toxicity and was not tolerable in children with relapsed ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28295182,The addition of temsirolimus to UKALL R3 re-induction therapy resulted in excessive toxicity and was not tolerable in children with relapsed ALL.,Neoadjuvant Therapy,TREATS,Toxic effect
28295300,"The early-life immune environment has been implicated as a modulator of acute lymphoblastic leukemia (ALL) development in children, with infection being associated with significant changes in ALL risk.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28295300,"The early-life immune environment has been implicated as a modulator of acute lymphoblastic leukemia (ALL) development in children, with infection being associated with significant changes in ALL risk.",Immune,ISA,Environment
28050271,Most of the data concerning the possible instability of rearranged clonal TCR and IG genes during disease recurrence were obtained for ALL in children.,T-Cell Receptor | TRBV20OR9-2,TREATS,"Leukemia, Lymphocytic, Acute"
28050271,Most of the data concerning the possible instability of rearranged clonal TCR and IG genes during disease recurrence were obtained for ALL in children.,"Genes, Immunoglobulin",TREATS,"Leukemia, Lymphocytic, Acute"
28050271,Most of the data concerning the possible instability of rearranged clonal TCR and IG genes during disease recurrence were obtained for ALL in children.,T-Cell Receptor | TRBV20OR9-2,PART_OF,Clone
28050271,Most of the data concerning the possible instability of rearranged clonal TCR and IG genes during disease recurrence were obtained for ALL in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28060115,Hepatotoxicity During Maintenance Therapy and Prognosis in Children With Acute Lymphoblastic Leukemia.,Hepatotoxicity,PROCESS_OF,Child
28060115,Hepatotoxicity During Maintenance Therapy and Prognosis in Children With Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28063690,STUDY DESIGN: We retrospectively reviewed 158 children with precursor B-cell type ALL who were followed up for >2 years.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28069148,"Survivors of Acute Lymphoblastic Leukaemia (ALL), treated with cranial radiotherapy, are at a particularly high risk of having endocrine complications.",Complication,PROCESS_OF,Survivors
28069148,"Survivors of Acute Lymphoblastic Leukaemia (ALL), treated with cranial radiotherapy, are at a particularly high risk of having endocrine complications.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
28090653,We used a genome-wide association study to identify loci associated with elevated alanine transaminase (ALT) levels after induction therapy in children with ALL enrolled on St.,Neoadjuvant Therapy,TREATS,Child
28090653,We used a genome-wide association study to identify loci associated with elevated alanine transaminase (ALT) levels after induction therapy in children with ALL enrolled on St.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28090653,We used a genome-wide association study to identify loci associated with elevated alanine transaminase (ALT) levels after induction therapy in children with ALL enrolled on St.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
28094079,"The treatment of ALL involves multimodality therapy, and methotrexate (MTX) remains a mainstay of treatment.",Methotrexate,ISA,Therapeutic procedure
28094079,"The treatment of ALL involves multimodality therapy, and methotrexate (MTX) remains a mainstay of treatment.",Combined Modality Therapy,ISA,Therapeutic procedure
28094079,"The treatment of ALL involves multimodality therapy, and methotrexate (MTX) remains a mainstay of treatment.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
28094079,"The treatment of ALL involves multimodality therapy, and methotrexate (MTX) remains a mainstay of treatment.",Combined Modality Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
28116786,The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28774373,"Glucocorticoids are frequently used in the chemoradiotherapy regimen for ALL and can induce the apoptosis of ALL cells through several signaling pathways, but about 10% of ALL children have poor response to glucocorticoids.",Glucocorticoids,AUGMENTS,Apoptosis
28774373,"Glucocorticoids are frequently used in the chemoradiotherapy regimen for ALL and can induce the apoptosis of ALL cells through several signaling pathways, but about 10% of ALL children have poor response to glucocorticoids.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
28774373,"Glucocorticoids are frequently used in the chemoradiotherapy regimen for ALL and can induce the apoptosis of ALL cells through several signaling pathways, but about 10% of ALL children have poor response to glucocorticoids.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28774373,[Association between BIM gene and glucocorticoid resistance in children with acute lymphoblastic leukemia].,Glucocorticoids,TREATS,Child
28774373,[Association between BIM gene and glucocorticoid resistance in children with acute lymphoblastic leukemia].,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
28774373,[Association between BIM gene and glucocorticoid resistance in children with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28784991,"Monte Carlo cross-validation nested by 10-fold cross-validation was used to rank clinical variables on the randomly split training sets of 336 newly diagnosed ALL children, and a forward feature selection algorithm was employed to find the shortest list of most discriminatory variables.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28849107,The present study demonstrated that GATA4 was upregulated in children with acute lymphoblastic leukemia (ALL).,Child,LOCATION_OF,GATA4
28849107,The present study demonstrated that GATA4 was upregulated in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28940632,CONCLUSION: This study demonstrates increased risk of infant ALL in relation to young paternal age.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
29065105,"RESULTS: In our primary analysis of 12 496 children with ALL and 2 356 288 children without ALL from 38 studies, we found that any infection was not associated with ALL (odds ratio (OR)=1.10, 95% CI: 0.95-1.28).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29065105,"RESULTS: In our primary analysis of 12 496 children with ALL and 2 356 288 children without ALL from 38 studies, we found that any infection was not associated with ALL (odds ratio (OR)=1.10, 95% CI: 0.95-1.28).","Leukemia, Lymphocytic, Acute",NEG_AFFECTS,Child
29065105,"RESULTS: In our primary analysis of 12 496 children with ALL and 2 356 288 children without ALL from 38 studies, we found that any infection was not associated with ALL (odds ratio (OR)=1.10, 95% CI: 0.95-1.28).","Leukemia, Lymphocytic, Acute",NEG_AFFECTS,Child
29065105,METHODS: We included studies that assessed any infection in childhood prior to the diagnosis of ALL in children aged 0-19 years compared to children without cancer.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29065105,"RESULTS: In our primary analysis of 12 496 children with ALL and 2 356 288 children without ALL from 38 studies, we found that any infection was not associated with ALL (odds ratio (OR)=1.10, 95% CI: 0.95-1.28).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29085439,"Bisulfite sequencing polymerase chain reaction (BSP) was performed to determine the methylation density of cytosine-guanine pair islands in the promoter region of EPHB4, in bone marrow samples from 40 children with ALL.",Promoter Regions (Genetics),PART_OF,EPHB4
29085439,"Bisulfite sequencing polymerase chain reaction (BSP) was performed to determine the methylation density of cytosine-guanine pair islands in the promoter region of EPHB4, in bone marrow samples from 40 children with ALL.",Bone marrow specimen,LOCATION_OF,EPHB4
29085439,"Bisulfite sequencing polymerase chain reaction (BSP) was performed to determine the methylation density of cytosine-guanine pair islands in the promoter region of EPHB4, in bone marrow samples from 40 children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28710036,"A total of 41 children with ALL were screened for 10 SNPs in the SLC19A1, ABCB1, ABCC2, ABCC4 and ABCG2 transporter genes by means of direct sequencing.",Single Nucleotide Polymorphism,COEXISTS_WITH,ABCG2 gene | ABCG2
28710036,"A total of 41 children with ALL were screened for 10 SNPs in the SLC19A1, ABCB1, ABCC2, ABCC4 and ABCG2 transporter genes by means of direct sequencing.",Single Nucleotide Polymorphism,COEXISTS_WITH,ABCB1 gene | ABCB1
28710036,"A total of 41 children with ALL were screened for 10 SNPs in the SLC19A1, ABCB1, ABCC2, ABCC4 and ABCG2 transporter genes by means of direct sequencing.",Single Nucleotide Polymorphism,COEXISTS_WITH,SLC19A1
28710036,"A total of 41 children with ALL were screened for 10 SNPs in the SLC19A1, ABCB1, ABCC2, ABCC4 and ABCG2 transporter genes by means of direct sequencing.",Single Nucleotide Polymorphism,COEXISTS_WITH,ABCC2
28710036,"Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.","Polymorphism, Genetic",AFFECTS,Membrane Transport Proteins
28710036,"A total of 41 children with ALL were screened for 10 SNPs in the SLC19A1, ABCB1, ABCC2, ABCC4 and ABCG2 transporter genes by means of direct sequencing.",Single Nucleotide Polymorphism,COEXISTS_WITH,ABCC4
28710036,"Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28710036,"A total of 41 children with ALL were screened for 10 SNPs in the SLC19A1, ABCB1, ABCC2, ABCC4 and ABCG2 transporter genes by means of direct sequencing.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28859039,"There were 2 deaths, 1 in a child of Acute Lymphoblastic Leukemia on induction therapy and another in a child with anaplastic Wilms tumor.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28859039,"There were 2 deaths, 1 in a child of Acute Lymphoblastic Leukemia on induction therapy and another in a child with anaplastic Wilms tumor.",Death (finding),PROCESS_OF,Child
28859039,"There were 2 deaths, 1 in a child of Acute Lymphoblastic Leukemia on induction therapy and another in a child with anaplastic Wilms tumor.",Nephroblastoma,PROCESS_OF,Child
28991131,Recurrent Atypical Hemolytic Uremic Syndrome in Children With Acute Lymphoblastic Leukemia Undergoing Maintenance Chemotherapy.,Hemolytic-Uremic Syndrome,PROCESS_OF,Child
28991131,Recurrent Atypical Hemolytic Uremic Syndrome in Children With Acute Lymphoblastic Leukemia Undergoing Maintenance Chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29052781,Several retrospective studies in children with B cell precursor (BCP) acute lymphoblastic leukemia (ALL) provided clinical evidence that higher absolute lymphocyte counts (ALC) early into treatment significantly correlated with improved relapse-free and overall survival.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
29095311,BMIS did not differ between the children with ALL and those with no evidence of cancer.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29095311,"At the end of the first year of treatment, bone marrow iron store (BMIS) was evaluated in children with ALL and the relationship between iron store and minimal residual disease was investigated.",Therapeutic procedure,TREATS,Child
29095311,"At the end of the first year of treatment, bone marrow iron store (BMIS) was evaluated in children with ALL and the relationship between iron store and minimal residual disease was investigated.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29095311,"At the end of the first year of treatment, bone marrow iron store (BMIS) was evaluated in children with ALL and the relationship between iron store and minimal residual disease was investigated.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
29106702,"SELECTION CRITERIA: All study designs, except case reports and patient series with fewer than 10 children, examining effects of glucocorticoid therapy for childhood ALL on HPA axis function.",GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29106702,OBJECTIVES: To examine the occurrence and duration of HPA axis suppression after (each cycle of) glucocorticoid therapy for childhood ALL.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29106702,Clinicians may consider prescribing glucocorticoid replacement therapy during periods of serious stress in the first weeks after cessation of glucocorticoid therapy for childhood ALL to reduce the risk of life-threatening complications.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29106702,BACKGROUND: Glucocorticoids play a major role in the treatment of acute lymphoblastic leukaemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
29106702,Clinicians may consider prescribing glucocorticoid replacement therapy during periods of serious stress in the first weeks after cessation of glucocorticoid therapy for childhood ALL to reduce the risk of life-threatening complications.,Replacement therapy,PREVENTS,Complication
29106702,Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.,GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29106702,"AUTHORS' CONCLUSIONS: We concluded that adrenal insufficiency commonly occurs in the first days after cessation of glucocorticoid therapy for childhood ALL, but the exact duration is unclear.",GLUCOCORTICOID THERAPY,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29106702,Included studies demonstrated that adrenal insufficiency occurs in nearly all children during the first days after cessation of glucocorticoid treatment for childhood ALL.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29106702,Included studies demonstrated that adrenal insufficiency occurs in nearly all children during the first days after cessation of glucocorticoid treatment for childhood ALL.,Glucocorticoids,ISA,Therapeutic procedure
29148893,"Therefore, standard-risk patients of trial AIEOP-BFM ALL 2000 (Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With ALL) were investigated with the specific aim to reduce treatment intensity.",Combination Drug Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
29148893,"Purpose Delayed intensification (DI) is an integral part of treatment of childhood acute lymphoblastic leukemia (ALL), but it is associated with relevant toxicity.",Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
29148893,"Therefore, standard-risk patients of trial AIEOP-BFM ALL 2000 (Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With ALL) were investigated with the specific aim to reduce treatment intensity.",Combination Drug Therapy,TREATS,Patients
29148893,"Therefore, standard-risk patients of trial AIEOP-BFM ALL 2000 (Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With ALL) were investigated with the specific aim to reduce treatment intensity.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
29222263,"Thus, the need to reduce toxicity in pediatric ALL is becoming increasingly important.",Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
29222263,"The improvement in overall survival in children with acute lymphoblastic leukemia (ALL) over the last 5 decades has been considerable, with around 90% now surviving long term.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29266189,"BACKGROUND: Children, adolescents, and young adults with very high-risk (VHR) B acute lymphoblastic leukemia (B-ALL) have poor outcomes, and novel therapies are needed for this subgroup.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
29266189,"BACKGROUND: Children, adolescents, and young adults with very high-risk (VHR) B acute lymphoblastic leukemia (B-ALL) have poor outcomes, and novel therapies are needed for this subgroup.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
29266189,"BACKGROUND: Children, adolescents, and young adults with very high-risk (VHR) B acute lymphoblastic leukemia (B-ALL) have poor outcomes, and novel therapies are needed for this subgroup.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28751566,Asparaginase is an essential component of combination chemotherapy for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma.,Combination Drug Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28751566,Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.,Therapeutic procedure,TREATS,"Lymphoma, Non-Hodgkin's"
28751566,Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28751566,Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.,ASPARAGINASE | ASPG,ISA,Therapeutic procedure
28751566,Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.,ASPARAGINASE | ASPG,TREATS,"Lymphoma, Non-Hodgkin's"
28751566,Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28751566,Asparaginase is an essential component of combination chemotherapy for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma.,Combination Drug Therapy,TREATS,"Lymphoma, Non-Hodgkin's"
28770363,"BACKGROUND: In a previous nationwide ecological study based on 20 years of registration and 7,443 cases of acute lymphoblastic leukemia (ALL), we reported a positive association between residential solar ultraviolet (UV) light at diagnosis and childhood precursor B-cell acute lymphoblastic leukemia (PBC-ALL).",Sunlight,PROCESS_OF,Ultraviolet Rays
28770363,"BACKGROUND: In a previous nationwide ecological study based on 20 years of registration and 7,443 cases of acute lymphoblastic leukemia (ALL), we reported a positive association between residential solar ultraviolet (UV) light at diagnosis and childhood precursor B-cell acute lymphoblastic leukemia (PBC-ALL).",B-cell childhood acute lymphoblastic leukemia,ISA,"Leukemia, Lymphocytic, Acute"
28770363,"BACKGROUND: In a previous nationwide ecological study based on 20 years of registration and 7,443 cases of acute lymphoblastic leukemia (ALL), we reported a positive association between residential solar ultraviolet (UV) light at diagnosis and childhood precursor B-cell acute lymphoblastic leukemia (PBC-ALL).",Ultraviolet Rays,ISA,Sunlight
28844589,"AIM OF THE WORK: The aim of the study was to investigate the impact of drug metabolizing CYP1, GSTP1 and DNA repair (XRCC1) genes polymorphisms on the toxicity and response to chemotherapy in childhood ALL.",Toxic effect,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute, L1"
28844589,"AIM OF THE WORK: The aim of the study was to investigate the impact of drug metabolizing CYP1, GSTP1 and DNA repair (XRCC1) genes polymorphisms on the toxicity and response to chemotherapy in childhood ALL.",GSTP1 gene | GSTP1,INTERACTS_WITH,CYP1A1 gene | CYP1A1
28886882,"Acute lymphoblastic leukaemia (ALL) is the most common type of cancer in children, accounting for approximately 25% of childhood cancer cases.",Malignant Neoplasms,PROCESS_OF,Child
28886882,"Acute lymphoblastic leukaemia (ALL) is the most common type of cancer in children, accounting for approximately 25% of childhood cancer cases.","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
28886882,"Acute lymphoblastic leukaemia (ALL) is the most common type of cancer in children, accounting for approximately 25% of childhood cancer cases.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28945288,Thiopurines are part of a clinical regimen used for the treatment of autoimmune disorders and childhood acute lymphoblastic leukemia.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28945288,Thiopurines are part of a clinical regimen used for the treatment of autoimmune disorders and childhood acute lymphoblastic leukemia.,Treatment Protocols,TREATS,Autoimmune Diseases
28945288,Thiopurines are part of a clinical regimen used for the treatment of autoimmune disorders and childhood acute lymphoblastic leukemia.,thiopurine,ISA,Therapeutic procedure
29050116,Method: The clinical data from 330 ALL children who received 1 242 courses of HD-MTX therapies from September 2012 to November 2016 was collected.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29050116,Conclusion: Decreased renal toxicity and acceleration of MTX excretion may occur when childhood ALL with LR and IR were treated with the 4th revised regimen.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29050116,Method: The clinical data from 330 ALL children who received 1 242 courses of HD-MTX therapies from September 2012 to November 2016 was collected.,Therapeutic procedure,USES,Methotrexate
29050116,Method: The clinical data from 330 ALL children who received 1 242 courses of HD-MTX therapies from September 2012 to November 2016 was collected.,Methotrexate,ISA,Therapeutic procedure
29050695,Adults and children with Ph-like ALL harbor a diversity of alterations that all lead to activated kinase signaling.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29050695,Adults and children with Ph-like ALL harbor a diversity of alterations that all lead to activated kinase signaling.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
29052781,"To investigate this question, we implemented a prospective observational cohort study in 20 children with BCP ALL on day 29 (D29) of induction chemotherapy and immunophenotyped their lymphoid (T, B and natural killer cells) and myeloid (neutrophils, monocytes, dendritic cells) compartments.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
29070107,[Clinical Analysis of 7 Children with Mature B-cell Acute Lymphoblastic Leukemia].,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
29168384,Microbial asparaginase is an essential component of chemotherapy for the treatment of childhood acute lymphoblastic leukemia (cALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29168384,Microbial asparaginase is an essential component of chemotherapy for the treatment of childhood acute lymphoblastic leukemia (cALL).,ASPARAGINASE,PART_OF,microbial
29168384,Microbial asparaginase is an essential component of chemotherapy for the treatment of childhood acute lymphoblastic leukemia (cALL).,ASPARAGINASE,ISA,Pharmacotherapy
29168384,Microbial asparaginase is an essential component of chemotherapy for the treatment of childhood acute lymphoblastic leukemia (cALL).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29177615,Monosomy 7 is also a rare and unfavorable chromosomal abnormality in childhood BCP-ALL.,Monosomy 7,COEXISTS_WITH,B-cell childhood acute lymphoblastic leukemia
29177615,Monosomy 7 is also a rare and unfavorable chromosomal abnormality in childhood BCP-ALL.,Chromosome abnormality,COEXISTS_WITH,B-cell childhood acute lymphoblastic leukemia
29189508,Steroid-induced Hypertension During Induction Chemotherapy for Acute Lymphoblastic Leukemia in US Children's Hospitals.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29208883,Children with Acute lymphoblastic leukemia with hyperleukocytosis who are potential to develop tumor lysis syndrome were selected for the study in their initial presentation.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29208883,Children with Acute lymphoblastic leukemia with hyperleukocytosis who are potential to develop tumor lysis syndrome were selected for the study in their initial presentation.,Tumor Lysis Syndrome,PROCESS_OF,Child
29210328,DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29210328,DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.,Therapeutic procedure,TREATS,Child
29210328,DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Child
29210328,DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.,DNA,COEXISTS_WITH,DHFR gene | DHFR
29262887,OBJECTIVE: To study the clinical efficacy of amphotericin B and voriconazole in the treatment of invasive fungal infection in children with acute lymphoblastic leukemia(ALL) during chemotherapy.,Amphotericin B,TREATS,Mycoses
29262887,OBJECTIVE: To study the clinical efficacy of amphotericin B and voriconazole in the treatment of invasive fungal infection in children with acute lymphoblastic leukemia(ALL) during chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29262887,OBJECTIVE: To study the clinical efficacy of amphotericin B and voriconazole in the treatment of invasive fungal infection in children with acute lymphoblastic leukemia(ALL) during chemotherapy.,Mycoses,PROCESS_OF,Child
29262887,OBJECTIVE: To study the clinical efficacy of amphotericin B and voriconazole in the treatment of invasive fungal infection in children with acute lymphoblastic leukemia(ALL) during chemotherapy.,voriconazole,TREATS,Mycoses
29286560,"Modifying bone mineral density, physical function, and quality of life in children with acute lymphoblastic leukemia.",Physical function,PROCESS_OF,Child
29286560,"Modifying bone mineral density, physical function, and quality of life in children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28726435,"Though acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood age, it is a rare diagnosis in adults.",Malignant Neoplasms,PROCESS_OF,Adult
28726435,"Though acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood age, it is a rare diagnosis in adults.","Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
28726435,"Though acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood age, it is a rare diagnosis in adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
28766841,We retrospectively compared paired results of peripheral blood (PB) flow cytometric analysis and BM evaluation in 383 children with ALL diagnosed consecutively at a single center and found very high concordance of results between both tests.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28766841,Diagnostic procedures in children with acute lymphoblastic leukemia (ALL) are typically performed under general anesthesia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28766841,Diagnostic procedures in children with acute lymphoblastic leukemia (ALL) are typically performed under general anesthesia.,General Anesthesia,ADMINISTERED_TO,Child
28766841,Value of flow cytometric analysis of peripheral blood samples in children diagnosed with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28766851,The present study examines the prevalence and clinical implications of folate deficiency in north Indian children with ALL during the maintenance phase of treatment in view of prolonged antifolate treatment and high population prevalence of folate deficiency.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28766851,The present study examines the prevalence and clinical implications of folate deficiency in north Indian children with ALL during the maintenance phase of treatment in view of prolonged antifolate treatment and high population prevalence of folate deficiency.,Therapeutic procedure,USES,Folic Acid Antagonists
28766851,The present study examines the prevalence and clinical implications of folate deficiency in north Indian children with ALL during the maintenance phase of treatment in view of prolonged antifolate treatment and high population prevalence of folate deficiency.,Folic Acid Antagonists,ISA,Therapeutic procedure
28766851,The present study examines the prevalence and clinical implications of folate deficiency in north Indian children with ALL during the maintenance phase of treatment in view of prolonged antifolate treatment and high population prevalence of folate deficiency.,Folic Acid Deficiency,OCCURS_IN,Child
28766887,A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.,ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28766887,A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.,ASPARAGINASE | ASPG,ISA,Therapeutic procedure
28766887,A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.,Therapeutic procedure,USES,ASPARAGINASE | ASPG
28768142,"CONCLUSION: The IKZF1 SNPs, rs10235796 and rs6964969, and the CDKN2A SNP rs3731246 (previously unreported) could serve as risk markers for ALL susceptibility in Yemeni children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28768142,"No associations were found between the IKZF1 SNPs (rs11978267; rs7789635), DDC SNPs (rs3779084; rs880028; rs7809758), CDKN2A SNP (rs3731217), the CEBPE SNPs (rs2239633; rs12434881) and LMO1 SNPs (rs442264; rs3794012; rs4237770) with ALL in Yemeni children.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28843422,Acute lymphoblastic leukemia (ALL) is the most common cancer in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28843422,Acute lymphoblastic leukemia (ALL) is the most common cancer in children.,Malignant Neoplasms,PROCESS_OF,Child
28843422,Acute lymphoblastic leukemia (ALL) is the most common cancer in children.,"Leukemia, Lymphocytic, Acute",ISA,Malignant Neoplasms
28923207,Acute lymphoblastic leukemia (ALL) is a malignant hematological disease afflicting hematopoiesis in the bone marrow.,Bone Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
29058513,Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing.,Detection,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29070107,OBJECTIVE: To evaluate the efficacy of CCCG-BNHL-2015 protocol in treatment of children with mature B-cell acute lymphoblastic leukemia (mature B-ALL).,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
29112230,CONCLUSIONS: Many children with AR-ALL experience physical and emotional functioning impairment that begins early in treatment and persists.,Emotional,PROCESS_OF,Child
29112230,CONCLUSIONS: Many children with AR-ALL experience physical and emotional functioning impairment that begins early in treatment and persists.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29132472,Children with Ph-like ALL account for 15% of children with high-risk B-ALL.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
29250188,"In the present study, the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to determine miR-210 and CASP8AP2 expression in 91 children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29250188,The prognostic significance of microRNA (miR)-210 and the caspase 8-associated protein 2 (CASP8AP2) gene in children with acute lymphoblastic leukemia (ALL) has been validated and CASP8AP2 has been demonstrated as a target of miR-210.,Child,LOCATION_OF,MIRN210 gene | MIR210
29250188,The prognostic significance of microRNA (miR)-210 and the caspase 8-associated protein 2 (CASP8AP2) gene in children with acute lymphoblastic leukemia (ALL) has been validated and CASP8AP2 has been demonstrated as a target of miR-210.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29250188,"In the present study, the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to determine miR-210 and CASP8AP2 expression in 91 children with ALL.",reverse transcription polymerase chain reaction,PROCESS_OF,Child
29282361,"Osteonecrosis (ON) is corticosteroid-related complication, reported in children with acute lymphoblastic leukemia (ALL).",Complication,PROCESS_OF,Child
29282361,"Osteonecrosis (ON) is corticosteroid-related complication, reported in children with acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29282364,"To achieve this aim, we analyzed all the SNPs in miRNAs (minor allele frequency (MAF) >/= 0.01) which could regulate VCR-related genes in a large cohort of Spanish children with B-cell precursor ALL (B-ALL) homogeneously treated with LAL/SHOP protocols.",Single Nucleotide Polymorphism,COEXISTS_WITH,MicroRNAs
29282364,"To achieve this aim, we analyzed all the SNPs in miRNAs (minor allele frequency (MAF) >/= 0.01) which could regulate VCR-related genes in a large cohort of Spanish children with B-cell precursor ALL (B-ALL) homogeneously treated with LAL/SHOP protocols.","Leukemia, B-Cell, Acute",ISA,"Leukemia, Lymphocytic, Acute"
29282364,"Vincristine (VCR), an important component of childhood acute lymphoblastic leukemia (ALL) therapy, can cause sensory and motor neurotoxicity.",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29282364,"To achieve this aim, we analyzed all the SNPs in miRNAs (minor allele frequency (MAF) >/= 0.01) which could regulate VCR-related genes in a large cohort of Spanish children with B-cell precursor ALL (B-ALL) homogeneously treated with LAL/SHOP protocols.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
28671857,This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategies on neurocognitive functioning in children with high-risk B-lineage ALL.,Therapeutic procedure,TREATS,Child
28671857,This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategies on neurocognitive functioning in children with high-risk B-lineage ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28671857,This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategies on neurocognitive functioning in children with high-risk B-lineage ALL.,Therapeutic procedure,USES,Adrenal Cortex Hormones
28671857,This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategies on neurocognitive functioning in children with high-risk B-lineage ALL.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
28671857,This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategies on neurocognitive functioning in children with high-risk B-lineage ALL.,Adrenal Cortex Hormones,ISA,Therapeutic procedure
28671857,This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategies on neurocognitive functioning in children with high-risk B-lineage ALL.,Adrenal Cortex Hormones,TREATS,Child
28697165,"Patient group consisted of 115 patients (age, 1 to 17 y) with acute lymphoblastic leukemia and solid tumors, who were treated with vincristine consisting chemotherapy protocols.",Solid tumor,PROCESS_OF,Patients
28697165,"Patient group consisted of 115 patients (age, 1 to 17 y) with acute lymphoblastic leukemia and solid tumors, who were treated with vincristine consisting chemotherapy protocols.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
28697165,"Patient group consisted of 115 patients (age, 1 to 17 y) with acute lymphoblastic leukemia and solid tumors, who were treated with vincristine consisting chemotherapy protocols.",Vincristine,TREATS,Solid tumor
28697165,"Patient group consisted of 115 patients (age, 1 to 17 y) with acute lymphoblastic leukemia and solid tumors, who were treated with vincristine consisting chemotherapy protocols.",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
28698845,METHODS: The cytogenetic data from BCP-ALL children were reviewed.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
28744141,PURPOSE: The aim of this work was to study the correlation between the expressions of the ABCA2 and ABCA3 genes at the mRNA and protein levels in children with acute lymphoblastic leukemia (ALL) and the effects of this association on multidrug resistance (MDR).,Child,LOCATION_OF,ABCA3 gene | ABCA3
28744141,PURPOSE: The aim of this work was to study the correlation between the expressions of the ABCA2 and ABCA3 genes at the mRNA and protein levels in children with acute lymphoblastic leukemia (ALL) and the effects of this association on multidrug resistance (MDR).,Child,LOCATION_OF,ABCA2
28744141,PURPOSE: The aim of this work was to study the correlation between the expressions of the ABCA2 and ABCA3 genes at the mRNA and protein levels in children with acute lymphoblastic leukemia (ALL) and the effects of this association on multidrug resistance (MDR).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28744141,MATERIALS AND METHODS: Sixty-nine children with de novo ALL and 25 controls were enrolled in the study.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28761277,Bilateral parotidomegaly as an initial manifestation of acute lymphoblastic leukemia in a child: A case report and review of literature.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28983018,"A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative dose (MTCD) and evaluate safety, activity, pharmacokinetics, and immunogenicity of moxetumomab pasudotox in children, adolescents, and young adults with ALL (N = 55).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
28983018,"A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative dose (MTCD) and evaluate safety, activity, pharmacokinetics, and immunogenicity of moxetumomab pasudotox in children, adolescents, and young adults with ALL (N = 55).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28983018,"A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative dose (MTCD) and evaluate safety, activity, pharmacokinetics, and immunogenicity of moxetumomab pasudotox in children, adolescents, and young adults with ALL (N = 55).",Drug Kinetics,PROCESS_OF,Young adult
28983018,"A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative dose (MTCD) and evaluate safety, activity, pharmacokinetics, and immunogenicity of moxetumomab pasudotox in children, adolescents, and young adults with ALL (N = 55).",Drug Kinetics,PROCESS_OF,Adolescent
28983018,"A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative dose (MTCD) and evaluate safety, activity, pharmacokinetics, and immunogenicity of moxetumomab pasudotox in children, adolescents, and young adults with ALL (N = 55).",Drug Kinetics,PROCESS_OF,Child
28983018,"A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative dose (MTCD) and evaluate safety, activity, pharmacokinetics, and immunogenicity of moxetumomab pasudotox in children, adolescents, and young adults with ALL (N = 55).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
29234981,Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24755835,"Herein, we report a case of PM causing temporary quadriparesis in a 14-year-old girl undergoing induction therapy for acute lymphoblastic leukemia and we review the reported pediatric cases associated with induction therapy for hematologic malignancies.",Neoadjuvant Therapy,TREATS,Hematologic Neoplasms
24755835,"Herein, we report a case of PM causing temporary quadriparesis in a 14-year-old girl undergoing induction therapy for acute lymphoblastic leukemia and we review the reported pediatric cases associated with induction therapy for hematologic malignancies.",Neoadjuvant Therapy,TREATS,Girls
24755835,"Herein, we report a case of PM causing temporary quadriparesis in a 14-year-old girl undergoing induction therapy for acute lymphoblastic leukemia and we review the reported pediatric cases associated with induction therapy for hematologic malignancies.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
24755835,"Herein, we report a case of PM causing temporary quadriparesis in a 14-year-old girl undergoing induction therapy for acute lymphoblastic leukemia and we review the reported pediatric cases associated with induction therapy for hematologic malignancies.",Quadriparesis,PROCESS_OF,Girls
24755835,"Herein, we report a case of PM causing temporary quadriparesis in a 14-year-old girl undergoing induction therapy for acute lymphoblastic leukemia and we review the reported pediatric cases associated with induction therapy for hematologic malignancies.",Neoadjuvant Therapy,TREATS,Quadriparesis
24755835,Pyomyositis Causing Temporary Quadriparesis During Induction Therapy for Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
24932421,"Two haematological malignancies in a child with BS imply a fundamental role for BLM for normal haematopoiesis, in particular in the presence of genotoxic stress.",BLM gene | BLM,PART_OF,Child
24932421,"Two haematological malignancies in a child with BS imply a fundamental role for BLM for normal haematopoiesis, in particular in the presence of genotoxic stress.",Hematologic Neoplasms,PROCESS_OF,Child
24932421,"Two haematological malignancies in a child with BS imply a fundamental role for BLM for normal haematopoiesis, in particular in the presence of genotoxic stress.",BLM gene | BLM,ASSOCIATED_WITH,Hematologic Neoplasms
25089608,The patient recovered fully and completed chemotherapy for infant acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25089608,The patient recovered fully and completed chemotherapy for infant acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
25203866,CONCLUSIONS: These results suggest that CPX-351 may be a promising chemotherapeutic to be utilized in the treatment of ALL and support its testing in pediatric patients with leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25203866,CONCLUSIONS: These results suggest that CPX-351 may be a promising chemotherapeutic to be utilized in the treatment of ALL and support its testing in pediatric patients with leukemia.,leukemia,PROCESS_OF,Patients
25222055,"A 17-year-old boy was diagnosed with CMV retinitis 3 months after completion of chemotherapy for acute lymphoblastic leukemia, and his retinitis was assumed to be caused by a delayed immune reconstitution after chemotherapy.",Pharmacotherapy,TREATS,Retinitis
25222055,"A 17-year-old boy was diagnosed with CMV retinitis 3 months after completion of chemotherapy for acute lymphoblastic leukemia, and his retinitis was assumed to be caused by a delayed immune reconstitution after chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25222055,"However, CMV retinitis diagnosed after completion of chemotherapy for acute leukemia has not previously been reported.",Pharmacotherapy,TREATS,Acute leukemia
25222055,Cytomegalovirus retinitis diagnosed after completion of chemotherapy for acute lymphoblastic leukemia in an adolescent.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
25222055,Cytomegalovirus retinitis diagnosed after completion of chemotherapy for acute lymphoblastic leukemia in an adolescent.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25222061,The Progression of Bone Mineral Density Abnormalities After Chemotherapy for Childhood Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25272241,Double-unit cord blood (CB) grafts may improve engraftment and relapse risk in adults with haematological malignancies.,Graft acceptance,PROCESS_OF,Adult
25272241,Double-unit cord blood (CB) grafts may improve engraftment and relapse risk in adults with haematological malignancies.,Hematologic Neoplasms,PROCESS_OF,Adult
25293517,"Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China.",Pharmacotherapy,ADMINISTERED_TO,Patients
25293517,Neutropenic patients receiving induction chemotherapy for AML or MDS and those with previous IFI were at particular risk.,Pharmacotherapy,ADMINISTERED_TO,Patients
25293517,"Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China.",Pharmacotherapy,TREATS,Hematologic Neoplasms
25293517,Neutropenic patients receiving induction chemotherapy for AML or MDS and those with previous IFI were at particular risk.,Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
25293517,"Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China.",Mycoses,PROCESS_OF,Patients
25293517,Neutropenic patients receiving induction chemotherapy for AML or MDS and those with previous IFI were at particular risk.,Neutropenia,PROCESS_OF,Patients
25293517,"This stud y examined the epidemiology, risk factors, management, and outcome of invasive fungal infection (IFI) in patients receiving chemotherapy for hematological malignancy in China.",Pharmacotherapy,TREATS,Hematologic Neoplasms
25293517,"This stud y examined the epidemiology, risk factors, management, and outcome of invasive fungal infection (IFI) in patients receiving chemotherapy for hematological malignancy in China.",Mycoses,PROCESS_OF,Patients
25293517,"This stud y examined the epidemiology, risk factors, management, and outcome of invasive fungal infection (IFI) in patients receiving chemotherapy for hematological malignancy in China.",Pharmacotherapy,ADMINISTERED_TO,Patients
25360802,We present a child who experienced a severe and long-lasting neurotoxicity after the third intrathecal application of methotrexate with short sedation by nitrous oxide during induction therapy for acute lymphoblastic leukemia.,Sedation,PROCESS_OF,Child
25360802,We present a child who experienced a severe and long-lasting neurotoxicity after the third intrathecal application of methotrexate with short sedation by nitrous oxide during induction therapy for acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
25382151,"Despite the significant advances in modern chemotherapy, it remains challenging to treat adult patients with acute lymphoblastic leukaemia (ALL).",Pharmacotherapy,TREATS,Patients
25382151,"Despite the significant advances in modern chemotherapy, it remains challenging to treat adult patients with acute lymphoblastic leukaemia (ALL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
25382151,"Despite the significant advances in modern chemotherapy, it remains challenging to treat adult patients with acute lymphoblastic leukaemia (ALL).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25407157,Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.,Neoadjuvant Therapy,TREATS,Infant
25407157,Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Infant
25407157,Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
25440778,Disseminated Cunninghamella bertholletiae Infection During Induction Chemotherapy in a Girl with High-Risk Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,Girls
25440778,Disseminated Cunninghamella bertholletiae Infection During Induction Chemotherapy in a Girl with High-Risk Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Girls
25440778,Disseminated Cunninghamella bertholletiae Infection During Induction Chemotherapy in a Girl with High-Risk Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25445469,INTRODUCTION: Widespread use of tyrosine kinase inhibitors (TKIs) in combination with chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-SCT) has totally changed the existing treatment strategies for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL).,Hematopoietic Stem Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L2"
25445469,INTRODUCTION: Widespread use of tyrosine kinase inhibitors (TKIs) in combination with chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-SCT) has totally changed the existing treatment strategies for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
25548463,"We report here a very unusual case of a large pelvic lump which the patient herself could feel, that was probably an ovarian relapse of ALL, successfully treated with re-induction chemotherapy alone and achieved complete remission.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27034414,"Many of these authors continued their seminal contributions to developmental cancer therapy, and one (Donald Pinkel) would pioneer the successful ""total therapy"" for pediatric ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22307227,Our results show the therapeutic activity of LBH589 in combination with standard chemotherapy in pre-clinical models of ALL and suggest that this combination may be of clinical value in the treatment of patients with ALL.,Pharmacotherapy,TREATS,Patients
22307227,Our results show the therapeutic activity of LBH589 in combination with standard chemotherapy in pre-clinical models of ALL and suggest that this combination may be of clinical value in the treatment of patients with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
22307227,Our results show the therapeutic activity of LBH589 in combination with standard chemotherapy in pre-clinical models of ALL and suggest that this combination may be of clinical value in the treatment of patients with ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22358264,Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
22358264,Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON.,Pharmacotherapy,TREATS,Patients
22358264,Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22362744,T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy.,Acute T Cell Leukemia,ISA,Hematologic Neoplasms
22751908,"Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia.",Pharmacotherapy,TREATS,Child
22751908,"Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22751908,"Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22751908,"Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia.",Anticoagulants,INTERACTS_WITH,Procoagulant
23101060,The aims of this review were the: evaluation of studies on certain types of stem cell transplantation versus conventional chemotherapy in adults with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML); evaluation of studies on certain types of stem cell transplantation compared with each other in adults with ALL or AML.,Stem cell transplant,TREATS,"Leukemia, Lymphocytic, Acute, L2"
23101060,The aims of this review were the: evaluation of studies on certain types of stem cell transplantation versus conventional chemotherapy in adults with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML); evaluation of studies on certain types of stem cell transplantation compared with each other in adults with ALL or AML.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
23101060,The aims of this review were the: evaluation of studies on certain types of stem cell transplantation versus conventional chemotherapy in adults with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML); evaluation of studies on certain types of stem cell transplantation compared with each other in adults with ALL or AML.,Stem cell transplant,compared_with,Pharmacotherapy
23101060,The aims of this review were the: evaluation of studies on certain types of stem cell transplantation versus conventional chemotherapy in adults with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML); evaluation of studies on certain types of stem cell transplantation compared with each other in adults with ALL or AML.,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Adult
23101060,The aims of this review were the: evaluation of studies on certain types of stem cell transplantation versus conventional chemotherapy in adults with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML); evaluation of studies on certain types of stem cell transplantation compared with each other in adults with ALL or AML.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Adult
23101060,The aims of this review were the: evaluation of studies on certain types of stem cell transplantation versus conventional chemotherapy in adults with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML); evaluation of studies on certain types of stem cell transplantation compared with each other in adults with ALL or AML.,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Adult
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",Dexamethasone,TREATS,Patients
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",prednisolone,TREATS,"Leukemia, Lymphocytic, Acute"
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",Dexamethasone,TREATS,"Leukemia, Lymphocytic, Acute"
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",prednisolone,TREATS,Patients
23128824,"INTRODUCTION: Glucocorticoids, particularly prednisone/ prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells.",Glucocorticoids,TREATS,Patients
23146734,"CONCLUSIONS: The 24-hour blood concentration of MTX cannot be used to predict the incidence of adverse effects in MTX chemotherapy, but 48-hour blood concentration of MTX is helpful in this regard.",Methotrexate,PREDISPOSES,Adverse effects
23146734,"CONCLUSIONS: The 24-hour blood concentration of MTX cannot be used to predict the incidence of adverse effects in MTX chemotherapy, but 48-hour blood concentration of MTX is helpful in this regard.",Methotrexate,ISA,Pharmacotherapy
23146734,"CONCLUSIONS: The 24-hour blood concentration of MTX cannot be used to predict the incidence of adverse effects in MTX chemotherapy, but 48-hour blood concentration of MTX is helpful in this regard.",Pharmacotherapy,USES,Methotrexate
23906015,T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic malignancy with a poor prognosis.,Acute T Cell Leukemia,ISA,Hematologic Neoplasms
24612113,The purpose of this study was to investigate the longitudinal changes in anthropometric measures and serum albumin level during chemotherapy in patients with acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,Patients
24612113,The purpose of this study was to investigate the longitudinal changes in anthropometric measures and serum albumin level during chemotherapy in patients with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24612113,The purpose of this study was to investigate the longitudinal changes in anthropometric measures and serum albumin level during chemotherapy in patients with acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24844361,An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.,Pharmacotherapy,TREATS,Acute leukemia
24844361,An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.,imatinib,TREATS,Acute leukemia
24993745,"We also searched for subgroups of hematological malignancies, e.g. multiple myeloma, that are regarded as members of the acute or chronic types of leukemias.",Multiple Myeloma,ISA,Hematologic Neoplasms
24993745,"METHODS: We performed literature searches involving miR-29 family members and their relationship to individual hematological malignancies, namely acute myeloid leukemia (AML), chronic lymphoblastic leukemia (CLL) and chronic myeloid leukemia (CML).",Hematologic Neoplasms,PROCESS_OF,Individual
24993745,"METHODS: We performed literature searches involving miR-29 family members and their relationship to individual hematological malignancies, namely acute myeloid leukemia (AML), chronic lymphoblastic leukemia (CLL) and chronic myeloid leukemia (CML).","Leukemia, Myelocytic, Acute",ISA,Hematologic Neoplasms
24993745,"METHODS: We performed literature searches involving miR-29 family members and their relationship to individual hematological malignancies, namely acute myeloid leukemia (AML), chronic lymphoblastic leukemia (CLL) and chronic myeloid leukemia (CML).","Leukemia, Myelocytic, Acute",PROCESS_OF,Individual
25174022,"BACKGROUND: Non-Hodgkin lymphoma (NHL), the most common hematologic malignancy, consists of numerous subtypes.","Lymphoma, Non-Hodgkin's",ISA,Hematologic Neoplasms
25266680,In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25300567,"Among 400 AML patients, two cases of Ph+ AML (0.5%) were identified and treated with conventional chemotherapy with or without tyrosine kinase inhibitors (TKIs), followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT).",Protein-tyrosine kinase inhibitor,TREATS,"Leukemia, Myelocytic, Acute"
25300567,"Among 400 AML patients, two cases of Ph+ AML (0.5%) were identified and treated with conventional chemotherapy with or without tyrosine kinase inhibitors (TKIs), followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT).",Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
25300567,"Among 400 AML patients, two cases of Ph+ AML (0.5%) were identified and treated with conventional chemotherapy with or without tyrosine kinase inhibitors (TKIs), followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT).","Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
25321891,BACKGROUND: Glucocorticoids are essential in protocols of therapy of acute lymphoblastic leukemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
25321891,BACKGROUND: Glucocorticoids are essential in protocols of therapy of acute lymphoblastic leukemia (ALL).,Glucocorticoids,ISA,Therapeutic procedure
25338496,OBJECTIVE: To define the efficacy and safety of low-dose rasburicase in children from south India with hematologic malignancies.,Rasburicase,TREATS,Hematologic Neoplasms
25338496,OBJECTIVE: To define the efficacy and safety of low-dose rasburicase in children from south India with hematologic malignancies.,Rasburicase,TREATS,Child
25338496,OBJECTIVE: To define the efficacy and safety of low-dose rasburicase in children from south India with hematologic malignancies.,Hematologic Neoplasms,PROCESS_OF,Child
26842171,CONCLUSION: This study reports the outcome of high risk FN in patients with acute leukemia undergoing intensive chemotherapy.,Febrile neutropenia,PROCESS_OF,Patients
26842171,BACKGROUND: Outcome of febrile neutropenia (FN) in acute leukemia patients undergoing intensive chemotherapy from India is scanty.,Pharmacotherapy,TREATS,Acute leukemia
26842171,CONCLUSION: This study reports the outcome of high risk FN in patients with acute leukemia undergoing intensive chemotherapy.,Acute leukemia,PROCESS_OF,Patients
26842171,CONCLUSION: This study reports the outcome of high risk FN in patients with acute leukemia undergoing intensive chemotherapy.,Pharmacotherapy,TREATS,Acute leukemia
26842171,BACKGROUND: Outcome of febrile neutropenia (FN) in acute leukemia patients undergoing intensive chemotherapy from India is scanty.,Febrile neutropenia,PROCESS_OF,Patients
26842171,BACKGROUND: Outcome of febrile neutropenia (FN) in acute leukemia patients undergoing intensive chemotherapy from India is scanty.,Pharmacotherapy,TREATS,Patients
26842171,BACKGROUND: Outcome of febrile neutropenia (FN) in acute leukemia patients undergoing intensive chemotherapy from India is scanty.,Acute leukemia,PROCESS_OF,Patients
26842171,BACKGROUND: Outcome of febrile neutropenia (FN) in acute leukemia patients undergoing intensive chemotherapy from India is scanty.,Pharmacotherapy,TREATS,Febrile neutropenia
27007406,The heterogeneous hematologic malignancy acute lymphocytic leukemia (ALL) represents one of the more complicated cancers in adults.,Malignant Neoplasms,PROCESS_OF,Adult
27007406,The heterogeneous hematologic malignancy acute lymphocytic leukemia (ALL) represents one of the more complicated cancers in adults.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
22308840,Central hypothyroidism following chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",fludarabine,TREATS,Hematologic Neoplasms
22430085,"For less-fit patients with acute lymphoblastic leukemia and other hematologic malignancies frequently affecting the central nervous system, we designed a radiation-free regimen with fludarabine (25 mg/m2/day on days -6 to -4), carmustine (400 mg/m2 on day -6), and thiotepa (5 mg/kg twice daily on days -5 and -4), all of which readily penetrate the blood-brain barrier and have potent antileukemic and lymphotoxic activity.",Treatment Protocols,USES,fludarabine
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",fludarabine,TREATS,Hematologic Neoplasms
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",fludarabine,TREATS,"Leukemia, Lymphocytic, Acute"
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",Carmustine,TREATS,Hematologic Neoplasms
22430085,"For less-fit patients with acute lymphoblastic leukemia and other hematologic malignancies frequently affecting the central nervous system, we designed a radiation-free regimen with fludarabine (25 mg/m2/day on days -6 to -4), carmustine (400 mg/m2 on day -6), and thiotepa (5 mg/kg twice daily on days -5 and -4), all of which readily penetrate the blood-brain barrier and have potent antileukemic and lymphotoxic activity.",Hematologic Neoplasms,ISA,"Leukemia, Lymphocytic, Acute"
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",Thiotepa,TREATS,Hematologic Neoplasms
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",Carmustine,TREATS,"Leukemia, Lymphocytic, Acute"
22430085,"For less-fit patients with acute lymphoblastic leukemia and other hematologic malignancies frequently affecting the central nervous system, we designed a radiation-free regimen with fludarabine (25 mg/m2/day on days -6 to -4), carmustine (400 mg/m2 on day -6), and thiotepa (5 mg/kg twice daily on days -5 and -4), all of which readily penetrate the blood-brain barrier and have potent antileukemic and lymphotoxic activity.",Hematologic Neoplasms,PROCESS_OF,Patients
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",Thiotepa,TREATS,"Leukemia, Lymphocytic, Acute"
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",fludarabine,TREATS,"Leukemia, Lymphocytic, Acute"
22430085,"For less-fit patients with acute lymphoblastic leukemia and other hematologic malignancies frequently affecting the central nervous system, we designed a radiation-free regimen with fludarabine (25 mg/m2/day on days -6 to -4), carmustine (400 mg/m2 on day -6), and thiotepa (5 mg/kg twice daily on days -5 and -4), all of which readily penetrate the blood-brain barrier and have potent antileukemic and lymphotoxic activity.",Seizures,PROCESS_OF,Patients
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",Thiotepa,TREATS,Hematologic Neoplasms
22430085,"For less-fit patients with acute lymphoblastic leukemia and other hematologic malignancies frequently affecting the central nervous system, we designed a radiation-free regimen with fludarabine (25 mg/m2/day on days -6 to -4), carmustine (400 mg/m2 on day -6), and thiotepa (5 mg/kg twice daily on days -5 and -4), all of which readily penetrate the blood-brain barrier and have potent antileukemic and lymphotoxic activity.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",Carmustine,TREATS,Hematologic Neoplasms
22430085,"For less-fit patients with acute lymphoblastic leukemia and other hematologic malignancies frequently affecting the central nervous system, we designed a radiation-free regimen with fludarabine (25 mg/m2/day on days -6 to -4), carmustine (400 mg/m2 on day -6), and thiotepa (5 mg/kg twice daily on days -5 and -4), all of which readily penetrate the blood-brain barrier and have potent antileukemic and lymphotoxic activity.",Hematologic Neoplasms,PROCESS_OF,Patients
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",Thiotepa,TREATS,"Leukemia, Lymphocytic, Acute"
22430085,"For less-fit patients with acute lymphoblastic leukemia and other hematologic malignancies frequently affecting the central nervous system, we designed a radiation-free regimen with fludarabine (25 mg/m2/day on days -6 to -4), carmustine (400 mg/m2 on day -6), and thiotepa (5 mg/kg twice daily on days -5 and -4), all of which readily penetrate the blood-brain barrier and have potent antileukemic and lymphotoxic activity.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",Carmustine,TREATS,"Leukemia, Lymphocytic, Acute"
22430085,"For less-fit patients with acute lymphoblastic leukemia and other hematologic malignancies frequently affecting the central nervous system, we designed a radiation-free regimen with fludarabine (25 mg/m2/day on days -6 to -4), carmustine (400 mg/m2 on day -6), and thiotepa (5 mg/kg twice daily on days -5 and -4), all of which readily penetrate the blood-brain barrier and have potent antileukemic and lymphotoxic activity.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
22430085,"Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.",Hematologic Neoplasms,ISA,"Leukemia, Lymphocytic, Acute"
22739150,"After induction chemotherapy in B-ALL, the expression of CD133-1 decreased significantly, but still higher than that in the normal control group.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23077869,We present the case of a 47 years patient in medullar aplasia after induction chemotherapy for acute lymphoblastic leukemia that developed pulmonary infiltrates of parasitic origin.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23077869,We present the case of a 47 years patient in medullar aplasia after induction chemotherapy for acute lymphoblastic leukemia that developed pulmonary infiltrates of parasitic origin.,parasitic,ISA,Beginning
23146734,There are significant differences in 24- and 48-hour blood concentrations of MTX and the incidence of adverse effects between Uyghur and the Han children with ALL who receive MTX chemotherapy.,LobuloAlveolar Mouse MIN,PROCESS_OF,Child
23146734,There are significant differences in 24- and 48-hour blood concentrations of MTX and the incidence of adverse effects between Uyghur and the Han children with ALL who receive MTX chemotherapy.,Methotrexate,ISA,Pharmacotherapy
23146734,There are significant differences in 24- and 48-hour blood concentrations of MTX and the incidence of adverse effects between Uyghur and the Han children with ALL who receive MTX chemotherapy.,Methotrexate,ADMINISTERED_TO,Child
23146734,Monitoring of blood MTX concentration maybe significant for timely adjustment of MTX dosage and individualized MTX chemotherapy.,Methotrexate,ISA,Pharmacotherapy
23146734,There are significant differences in 24- and 48-hour blood concentrations of MTX and the incidence of adverse effects between Uyghur and the Han children with ALL who receive MTX chemotherapy.,Pharmacotherapy,USES,Methotrexate
23146734,Monitoring of blood MTX concentration maybe significant for timely adjustment of MTX dosage and individualized MTX chemotherapy.,Pharmacotherapy,USES,Methotrexate
23146734,There are significant differences in 24- and 48-hour blood concentrations of MTX and the incidence of adverse effects between Uyghur and the Han children with ALL who receive MTX chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23146734,There are significant differences in 24- and 48-hour blood concentrations of MTX and the incidence of adverse effects between Uyghur and the Han children with ALL who receive MTX chemotherapy.,Pharmacotherapy,ADMINISTERED_TO,Child
23377281,Acute lymphoblastic leukemia (ALL) is an aggressive hematological tumor resulting from the malignant transformation of lymphoid progenitors.,Malignant transformation,CAUSES,"Leukemia, Lymphocytic, Acute"
23377281,Acute lymphoblastic leukemia (ALL) is an aggressive hematological tumor resulting from the malignant transformation of lymphoid progenitors.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
23377281,Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23377281,These results support a prominent role for activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and chemotherapy resistance in ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23377281,These results support a prominent role for activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and chemotherapy resistance in ALL.,NT5C2,TREATS,"Leukemia, Lymphocytic, Acute"
23377281,These results support a prominent role for activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and chemotherapy resistance in ALL.,NT5C2,ASSOCIATED_WITH,Disease Progression
23377281,Acute lymphoblastic leukemia (ALL) is an aggressive hematological tumor resulting from the malignant transformation of lymphoid progenitors.,Malignant transformation,CAUSES,Hematologic Neoplasms
23445874,"Our study, not intended to evaluate whether transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete remission and high-risk features, shows that the allograft cured more than 60% of these patients; in the most recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.",Transplantation,compared_with,Pharmacotherapy
23445874,"Our study, not intended to evaluate whether transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete remission and high-risk features, shows that the allograft cured more than 60% of these patients; in the most recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.",Transplantation,TREATS,"Leukemia, Lymphocytic, Acute"
23445874,"Our study, not intended to evaluate whether transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete remission and high-risk features, shows that the allograft cured more than 60% of these patients; in the most recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23445874,"Our study, not intended to evaluate whether transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete remission and high-risk features, shows that the allograft cured more than 60% of these patients; in the most recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23445874,"Our study, not intended to evaluate whether transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete remission and high-risk features, shows that the allograft cured more than 60% of these patients; in the most recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.",Transplantation,TREATS,Child
23445874,"Our study, not intended to evaluate whether transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete remission and high-risk features, shows that the allograft cured more than 60% of these patients; in the most recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.",Pharmacotherapy,TREATS,Child
23445874,"Our study, not intended to evaluate whether transplantation is superior to chemotherapy for children with acute lymphoblastic leukemia in first complete remission and high-risk features, shows that the allograft cured more than 60% of these patients; in the most recent period, the outcome of recipients of grafts from matched family and unrelated donors was comparable.",Transplantation,higher_than,Pharmacotherapy
23664940,"We report here results in 100 adults, ages 18 to 69, with high-risk hematologic malignancy who received conditioning with fludarabine, carmustine, melphalan, and rabbit antithymocyte globulin (FBM-A).",Hematologic Neoplasms,PROCESS_OF,Adult
23664940,"We report here results in 100 adults, ages 18 to 69, with high-risk hematologic malignancy who received conditioning with fludarabine, carmustine, melphalan, and rabbit antithymocyte globulin (FBM-A).",Antithymoglobulin,PART_OF,Oryctolagus cuniculus
23683426,OBJECTIVE: To investigate thiopurine S-methyltransferase (TPMT) activity and gene promoter polymorphism to probe its significance of individual chemotherapy in acute lymphoblastic leukemia (ALL) children.,Pharmacotherapy,TREATS,Child
23683426,OBJECTIVE: To investigate thiopurine S-methyltransferase (TPMT) activity and gene promoter polymorphism to probe its significance of individual chemotherapy in acute lymphoblastic leukemia (ALL) children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23683426,OBJECTIVE: To investigate thiopurine S-methyltransferase (TPMT) activity and gene promoter polymorphism to probe its significance of individual chemotherapy in acute lymphoblastic leukemia (ALL) children.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23868820,The impact of hyperglycemia on risk of infection and early death during induction therapy for acute lymphoblastic leukemia (ALL).,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23868820,Hyperglycemia during induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) has been inconsistently associated with risk of infection.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23868820,Hyperglycemia during induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) has been inconsistently associated with risk of infection.,"Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
24518380,Myocardial infarction in a young man receiving chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25006282,"MATERIAL METHODS: Oral examinations was done in 33 children between the age group of 5-15 years with acute lymphoblastic leukemia (ALL) and acute myloblastic leukemia (AML), who were undergoing chemotherapy.",Acute leukemia,PROCESS_OF,Child
25006282,"MATERIAL METHODS: Oral examinations was done in 33 children between the age group of 5-15 years with acute lymphoblastic leukemia (ALL) and acute myloblastic leukemia (AML), who were undergoing chemotherapy.",Pharmacotherapy,TREATS,Acute leukemia
25006282,"MATERIAL METHODS: Oral examinations was done in 33 children between the age group of 5-15 years with acute lymphoblastic leukemia (ALL) and acute myloblastic leukemia (AML), who were undergoing chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25006282,"MATERIAL METHODS: Oral examinations was done in 33 children between the age group of 5-15 years with acute lymphoblastic leukemia (ALL) and acute myloblastic leukemia (AML), who were undergoing chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25080574,"Limiting use and reducing doses and volume of cranial irradiation while intensifying chemotherapy have improved survival and reduced the severity of cognitive dysfunction, especially in leukemia.",Pharmacotherapy,TREATS,leukemia
25430458,"All these children who accepted chemotherapy for ALL were divided into the control group (before chemotherapy), the infection group (after chemotherapy with infection), and the recovery group (the infection was controlled after 1 week).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22366875,"CONCLUSIONS: Paediatricians caring for children with haematological malignancies need to be aware of this cause of pseudohyperkalaemia so that unnecessary treatment, including the commencement of acute dialysis, is avoided.",Hematologic Neoplasms,PROCESS_OF,Child
22385687,"Glucocorticoids play an important role in the treatment of ALL, but they may suppress the hypothalamic-pituitary-adrenal (HPA) axis.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
22897203,Eruptive acral naevi following chemotherapy for acute lymphoblastic leukaemia follow typical acral dermoscopic patterns.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22898679,INTERPRETATION: Our results suggests that imatinib in conjunction with intensive chemotherapy is well tolerated and might be beneficial for treatment of children with Philadelphia-chromosome-positive ALL.,Pharmacotherapy,TREATS,Child
22898679,INTERPRETATION: Our results suggests that imatinib in conjunction with intensive chemotherapy is well tolerated and might be beneficial for treatment of children with Philadelphia-chromosome-positive ALL.,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Child
22898679,INTERPRETATION: Our results suggests that imatinib in conjunction with intensive chemotherapy is well tolerated and might be beneficial for treatment of children with Philadelphia-chromosome-positive ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
23067223,"Glucocorticoids (GCs) resistance is frequently encountered in children with acute lymphoblastic leukemia (ALL), especially in T-ALL, which usually results in failure of treatment.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23067223,"Glucocorticoids (GCs) resistance is frequently encountered in children with acute lymphoblastic leukemia (ALL), especially in T-ALL, which usually results in failure of treatment.",Glucocorticoids,TREATS,Child
23067223,"Glucocorticoids (GCs) resistance is frequently encountered in children with acute lymphoblastic leukemia (ALL), especially in T-ALL, which usually results in failure of treatment.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
23359302,"Delays in treatment for acute leukemia can adversely affect maternal prognosis, but chemotherapy during pregnancy may induce severe adverse effects on the fetus.",Therapeutic procedure,CAUSES,Adverse effects
23359302,"Delays in treatment for acute leukemia can adversely affect maternal prognosis, but chemotherapy during pregnancy may induce severe adverse effects on the fetus.",Pharmacotherapy,TREATS,Acute leukemia
23513505,T-cell acute lymphoblastic leukemia is a hematologic malignancy with propensity to involve extramedullary organs including the eyes.,Hematologic Neoplasms,AFFECTS,Organ
23513505,T-cell acute lymphoblastic leukemia is a hematologic malignancy with propensity to involve extramedullary organs including the eyes.,Acute T Cell Leukemia,ISA,Hematologic Neoplasms
23513505,T-cell acute lymphoblastic leukemia is a hematologic malignancy with propensity to involve extramedullary organs including the eyes.,Acute T Cell Leukemia,AFFECTS,Organ
23619116,"Notably, B. cereus bacteremia with concomitant cerebral abscess was associated with induction chemotherapy for acute leukemia in both children and adults (10 of 12 case reports).",Acute leukemia,PROCESS_OF,Child
23619116,"Here we report an 8-year-old boy undergoing induction therapy for acute lymphoblastic leukemia who developed multifocal B. cereus cerebral abscesses, highlighting the propensity for B. cereus to develop cerebral abscesses.",Neoadjuvant Therapy,TREATS,Cerebral Abscess
23619116,"Notably, B. cereus bacteremia with concomitant cerebral abscess was associated with induction chemotherapy for acute leukemia in both children and adults (10 of 12 case reports).",Acute leukemia,PROCESS_OF,Adult
23619116,"Notably, B. cereus bacteremia with concomitant cerebral abscess was associated with induction chemotherapy for acute leukemia in both children and adults (10 of 12 case reports).",Pharmacotherapy,TREATS,Acute leukemia
23619116,"Here we report an 8-year-old boy undergoing induction therapy for acute lymphoblastic leukemia who developed multifocal B. cereus cerebral abscesses, highlighting the propensity for B. cereus to develop cerebral abscesses.",Neoadjuvant Therapy,TREATS,Boys
23619116,"Here we report an 8-year-old boy undergoing induction therapy for acute lymphoblastic leukemia who developed multifocal B. cereus cerebral abscesses, highlighting the propensity for B. cereus to develop cerebral abscesses.",Cerebral Abscess,PROCESS_OF,Boys
23619116,"Here we report an 8-year-old boy undergoing induction therapy for acute lymphoblastic leukemia who developed multifocal B. cereus cerebral abscesses, highlighting the propensity for B. cereus to develop cerebral abscesses.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23619116,"Notably, B. cereus bacteremia with concomitant cerebral abscess was associated with induction chemotherapy for acute leukemia in both children and adults (10 of 12 case reports).",Pharmacotherapy,AFFECTS,Cerebral Abscess
23619116,"Here we report an 8-year-old boy undergoing induction therapy for acute lymphoblastic leukemia who developed multifocal B. cereus cerebral abscesses, highlighting the propensity for B. cereus to develop cerebral abscesses.",Cerebral Abscess,PROCESS_OF,Cereus
23689515,"Despite their initial efficient response to induction chemotherapy, relapse remains frequent in patients with T-cell acute lymphoblastic leukemia (T-ALL), an aggressive malignancy of immature T-cell progenitors.",Pharmacotherapy,TREATS,Patients
23689515,"Despite their initial efficient response to induction chemotherapy, relapse remains frequent in patients with T-cell acute lymphoblastic leukemia (T-ALL), an aggressive malignancy of immature T-cell progenitors.",Acute T Cell Leukemia,PROCESS_OF,Patients
23689515,"Despite their initial efficient response to induction chemotherapy, relapse remains frequent in patients with T-cell acute lymphoblastic leukemia (T-ALL), an aggressive malignancy of immature T-cell progenitors.",Pharmacotherapy,TREATS,Acute T Cell Leukemia
23762608,"Glucocorticoids are commonly used in the first-line treatment of hematological malignancies, such as acute lymphoblastic leukemia, due to the ability of these steroids to activate pro-apoptotic pathways in human lymphocytes.",Steroids,TREATS,Hematologic Neoplasms
23762608,"Glucocorticoids are commonly used in the first-line treatment of hematological malignancies, such as acute lymphoblastic leukemia, due to the ability of these steroids to activate pro-apoptotic pathways in human lymphocytes.",Lymphocyte,LOCATION_OF,Glucocorticoids
23762608,"Glucocorticoids are commonly used in the first-line treatment of hematological malignancies, such as acute lymphoblastic leukemia, due to the ability of these steroids to activate pro-apoptotic pathways in human lymphocytes.",Steroids,TREATS,"Leukemia, Lymphocytic, Acute"
23762608,"Glucocorticoids are commonly used in the first-line treatment of hematological malignancies, such as acute lymphoblastic leukemia, due to the ability of these steroids to activate pro-apoptotic pathways in human lymphocytes.",Lymphocyte,PART_OF,Human
23762608,"Glucocorticoids are commonly used in the first-line treatment of hematological malignancies, such as acute lymphoblastic leukemia, due to the ability of these steroids to activate pro-apoptotic pathways in human lymphocytes.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
23762608,"Glucocorticoids are commonly used in the first-line treatment of hematological malignancies, such as acute lymphoblastic leukemia, due to the ability of these steroids to activate pro-apoptotic pathways in human lymphocytes.",Glucocorticoids,ISA,Therapeutic procedure
24052107,Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in childhood.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
24891274,Decitabine and vorinostat followed by re-Induction chemotherapy was tolerable and demonstrated clinical benefit in relapsed patients with ALL.,Pharmacotherapy,TREATS,Patients
24891274,Decitabine and vorinostat followed by re-Induction chemotherapy was tolerable and demonstrated clinical benefit in relapsed patients with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24891274,Decitabine and vorinostat followed by re-Induction chemotherapy was tolerable and demonstrated clinical benefit in relapsed patients with ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24891274,We investigated the tolerability and efficacy of decitabine and vorinostat plus chemotherapy in relapse/refractory acute lymphoblastic leukemia (ALL).,5-aza-2'-deoxycytidine,TREATS,"Leukemia, Lymphocytic, Acute"
24891274,We investigated the tolerability and efficacy of decitabine and vorinostat plus chemotherapy in relapse/refractory acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24891274,A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25083816,A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25310465,Optimal chemotherapy for leukemia: a model-based strategy for individualized treatment.,Therapeutic procedure,USES,Study models
25310465,Optimal chemotherapy for leukemia: a model-based strategy for individualized treatment.,Pharmacotherapy,TREATS,leukemia
25313141,"B cell acute lymphoblastic leukemia (B-ALL) is the most common hematological malignancy diagnosed in children, and blockade of the abnormally activated PI3Kdelta displayed promising outcomes in B cell acute or chronic leukemias, but the mechanisms are not well understood.",Chronic leukemia (category),PROCESS_OF,Child
25313141,"B cell acute lymphoblastic leukemia (B-ALL) is the most common hematological malignancy diagnosed in children, and blockade of the abnormally activated PI3Kdelta displayed promising outcomes in B cell acute or chronic leukemias, but the mechanisms are not well understood.",Hematologic Neoplasms,PROCESS_OF,Child
25313141,"B cell acute lymphoblastic leukemia (B-ALL) is the most common hematological malignancy diagnosed in children, and blockade of the abnormally activated PI3Kdelta displayed promising outcomes in B cell acute or chronic leukemias, but the mechanisms are not well understood.","Leukemia, B-Cell, Acute",ISA,Chronic leukemia (category)
25313141,"B cell acute lymphoblastic leukemia (B-ALL) is the most common hematological malignancy diagnosed in children, and blockade of the abnormally activated PI3Kdelta displayed promising outcomes in B cell acute or chronic leukemias, but the mechanisms are not well understood.","Leukemia, B-Cell, Acute",ISA,Hematologic Neoplasms
25313141,"B cell acute lymphoblastic leukemia (B-ALL) is the most common hematological malignancy diagnosed in children, and blockade of the abnormally activated PI3Kdelta displayed promising outcomes in B cell acute or chronic leukemias, but the mechanisms are not well understood.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
25313141,"B cell acute lymphoblastic leukemia (B-ALL) is the most common hematological malignancy diagnosed in children, and blockade of the abnormally activated PI3Kdelta displayed promising outcomes in B cell acute or chronic leukemias, but the mechanisms are not well understood.",B-Lymphocytes,LOCATION_OF,"Leukemia, B-Cell, Acute"
25474988,BACKGROUND: Leukaemias are haematological malignancies characterized by unregulated clonal proliferation of haematopoietic cells.,leukemia,ISA,Hematologic Neoplasms
22574072,Evaluation of changes in random blood glucose and body mass index during and after completion of chemotherapy in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22574072,Evaluation of changes in random blood glucose and body mass index during and after completion of chemotherapy in children with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22574072,Evaluation of changes in random blood glucose and body mass index during and after completion of chemotherapy in children with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Child
22653976,Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.,bortezomib,TREATS,Lymphoma
22653976,Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22653976,"Thus, this combination of bortezomib with chemotherapy is active in B-precursor ALL, and prophylactic antibiotics may be useful in reducing mortality.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22899750,Abundant hepatic Gaucher-like cells following chemotherapy and bone marrow transplantation for hematologic malignancy: report of two cases.,Hepatic,LOCATION_OF,gaucher's
22899750,Large numbers of Gaucher-like cells were found in the livers at autopsy of 2 patients with hematologic malignancy treated with chemotherapy and bone marrow transplant.,Liver,LOCATION_OF,gaucher's
22899750,Large numbers of Gaucher-like cells were found in the livers at autopsy of 2 patients with hematologic malignancy treated with chemotherapy and bone marrow transplant.,Hematologic Neoplasms,PROCESS_OF,Patients
22899750,Large numbers of Gaucher-like cells were found in the livers at autopsy of 2 patients with hematologic malignancy treated with chemotherapy and bone marrow transplant.,Pharmacotherapy,TREATS,Hematologic Neoplasms
22899750,Large numbers of Gaucher-like cells were found in the livers at autopsy of 2 patients with hematologic malignancy treated with chemotherapy and bone marrow transplant.,Bone Marrow Transplantation,TREATS,Hematologic Neoplasms
22899750,Abundant hepatic Gaucher-like cells following chemotherapy and bone marrow transplantation for hematologic malignancy: report of two cases.,Pharmacotherapy,TREATS,Hematologic Neoplasms
22899750,Abundant hepatic Gaucher-like cells following chemotherapy and bone marrow transplantation for hematologic malignancy: report of two cases.,Bone Marrow Transplantation,TREATS,Hematologic Neoplasms
23189085,"In this review we will discuss recent data on this field, with special focus on those polymorphisms that could be used in clinical practice to tailor chemotherapy for ALL in order to reduce the occurrence of serious adverse effects.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23189085,"The efficacy of chemotherapy in pediatric acute lymphoblastic leukemia (ALL) patients has significantly increased in the last 20 years; as a result, the focus of research is slowly shifting from trying to increase survival rates to reduce chemotherapy-related toxicity.",Pharmacotherapy,TREATS,Patients
23189085,"The efficacy of chemotherapy in pediatric acute lymphoblastic leukemia (ALL) patients has significantly increased in the last 20 years; as a result, the focus of research is slowly shifting from trying to increase survival rates to reduce chemotherapy-related toxicity.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
23189085,"The efficacy of chemotherapy in pediatric acute lymphoblastic leukemia (ALL) patients has significantly increased in the last 20 years; as a result, the focus of research is slowly shifting from trying to increase survival rates to reduce chemotherapy-related toxicity.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23502666,Serum vascular endothelial growth factor-a levels during induction therapy in children with acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,Child
23502666,Serum vascular endothelial growth factor-a levels during induction therapy in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23502666,Serum vascular endothelial growth factor-a levels during induction therapy in children with acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23502666,Serum vascular endothelial growth factor-a levels during induction therapy in children with acute lymphoblastic leukemia.,Serum,LOCATION_OF,"VEGF protein, human | VEGFA"
23987587,"METHODS: We conducted a retrospective cohort study of 801 patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or acute lymphocytic leukemia (ALL) who underwent induction chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23987587,"METHODS: We conducted a retrospective cohort study of 801 patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or acute lymphocytic leukemia (ALL) who underwent induction chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
23987587,"METHODS: We conducted a retrospective cohort study of 801 patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or acute lymphocytic leukemia (ALL) who underwent induction chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23987587,"METHODS: We conducted a retrospective cohort study of 801 patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or acute lymphocytic leukemia (ALL) who underwent induction chemotherapy.","Leukemia, Myelocytic, Acute",ISA,Dysmyelopoietic Syndromes
23987587,BACKGROUND: Pneumonia is a major cause of death during induction chemotherapy for acute leukemia.,Pharmacotherapy,TREATS,Acute leukemia
23987587,"CONCLUSIONS: Pneumonia after induction chemotherapy for acute leukemia continues to be common, and it is the most important determinant of early mortality after induction chemotherapy.",Pharmacotherapy,TREATS,Acute leukemia
23987587,BACKGROUND: Pneumonia is a major cause of death during induction chemotherapy for acute leukemia.,Pneumonia,CAUSES,Cessation of life
23987587,"METHODS: We conducted a retrospective cohort study of 801 patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or acute lymphocytic leukemia (ALL) who underwent induction chemotherapy.","Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
24047855,OBJECTIVE: The aim of this study was to evaluate the oral health status of children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24047855,OBJECTIVE: The aim of this study was to evaluate the oral health status of children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24047855,Oral health status of children with acute lymphoblastic leukemia undergoing chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24047855,Oral health status of children with acute lymphoblastic leukemia undergoing chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24096378,"In this case, a 13 year-old-boy diagnosed as high-risk ALL was treated with chemotherapy and prophylactic cranial radiotherapy at a dose of 1800 cGy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24096378,"In this case, a 13 year-old-boy diagnosed as high-risk ALL was treated with chemotherapy and prophylactic cranial radiotherapy at a dose of 1800 cGy.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
24136019,Steroid-induced osteonecrosis (ON) is a challenging complication encountered during modern chemotherapy for childhood acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24136019,Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.,Pharmacotherapy,TREATS,Child
24136019,Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24136019,Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.,Bone necrosis,PROCESS_OF,Child
24136019,Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.,Pharmacotherapy,TREATS,Bone necrosis
24199811,We describe a case of isolated posterior fossa involvement of PRES which occurred during remission induction chemotherapy for T-cell acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Acute T Cell Leukemia
25386666,"SELECTION CRITERIA: We included RCTs comparing an aerobic physical exercise intervention, intending to improve the oxygen system, in addition to standard care with standard care only for adults suffering from haematological malignancies.",Hematologic Neoplasms,PROCESS_OF,Adult
25386666,"SELECTION CRITERIA: We included RCTs comparing an aerobic physical exercise intervention, intending to improve the oxygen system, in addition to standard care with standard care only for adults suffering from haematological malignancies.",Oxygen,TREATS,Hematologic Neoplasms
25386666,"OBJECTIVES: To evaluate the efficacy, safety and feasibility of aerobic physical exercise for adults suffering from haematological malignancies.",Exercise,TREATS,Adult
25386666,"OBJECTIVES: To evaluate the efficacy, safety and feasibility of aerobic physical exercise for adults suffering from haematological malignancies.",Hematologic Neoplasms,PROCESS_OF,Adult
25386666,"SELECTION CRITERIA: We included RCTs comparing an aerobic physical exercise intervention, intending to improve the oxygen system, in addition to standard care with standard care only for adults suffering from haematological malignancies.",Oxygen,TREATS,Adult
23456849,BACKGROUND: Absolute lymphocyte counts (ALC) during treatment have been associated with outcome in children and adults with hematologic malignancies.,Therapeutic procedure,TREATS,Child
23456849,BACKGROUND: Absolute lymphocyte counts (ALC) during treatment have been associated with outcome in children and adults with hematologic malignancies.,Therapeutic procedure,TREATS,Adult
23456849,BACKGROUND: Absolute lymphocyte counts (ALC) during treatment have been associated with outcome in children and adults with hematologic malignancies.,Hematologic Neoplasms,PROCESS_OF,Child
23456849,BACKGROUND: Absolute lymphocyte counts (ALC) during treatment have been associated with outcome in children and adults with hematologic malignancies.,Hematologic Neoplasms,PROCESS_OF,Adult
23456849,BACKGROUND: Absolute lymphocyte counts (ALC) during treatment have been associated with outcome in children and adults with hematologic malignancies.,Therapeutic procedure,TREATS,Hematologic Neoplasms
23556108,"While allogeneic hematopoietic cell transplantation (HCT) may offer the best chance of cure for patients suffering from aggressive hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, successful outcomes for the subgroup of patients with high-risk disease remain disappointing and lag behind those of lower-risk patients.","Leukemia, Myelocytic, Acute",ISA,Hematologic Neoplasms
23556108,"While allogeneic hematopoietic cell transplantation (HCT) may offer the best chance of cure for patients suffering from aggressive hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, successful outcomes for the subgroup of patients with high-risk disease remain disappointing and lag behind those of lower-risk patients.",Hematologic Neoplasms,PROCESS_OF,Patients
23556108,"While allogeneic hematopoietic cell transplantation (HCT) may offer the best chance of cure for patients suffering from aggressive hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, successful outcomes for the subgroup of patients with high-risk disease remain disappointing and lag behind those of lower-risk patients.","Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
23556108,"While allogeneic hematopoietic cell transplantation (HCT) may offer the best chance of cure for patients suffering from aggressive hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, successful outcomes for the subgroup of patients with high-risk disease remain disappointing and lag behind those of lower-risk patients.",Disease,PROCESS_OF,Patients
23556108,"While allogeneic hematopoietic cell transplantation (HCT) may offer the best chance of cure for patients suffering from aggressive hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, successful outcomes for the subgroup of patients with high-risk disease remain disappointing and lag behind those of lower-risk patients.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
23556108,"While allogeneic hematopoietic cell transplantation (HCT) may offer the best chance of cure for patients suffering from aggressive hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, successful outcomes for the subgroup of patients with high-risk disease remain disappointing and lag behind those of lower-risk patients.",Cell Transplantation,TREATS,Patients
23556108,"While allogeneic hematopoietic cell transplantation (HCT) may offer the best chance of cure for patients suffering from aggressive hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, successful outcomes for the subgroup of patients with high-risk disease remain disappointing and lag behind those of lower-risk patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23556108,"While allogeneic hematopoietic cell transplantation (HCT) may offer the best chance of cure for patients suffering from aggressive hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, successful outcomes for the subgroup of patients with high-risk disease remain disappointing and lag behind those of lower-risk patients.",Cell Transplantation,TREATS,Hematologic Neoplasms
23556108,"While allogeneic hematopoietic cell transplantation (HCT) may offer the best chance of cure for patients suffering from aggressive hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, successful outcomes for the subgroup of patients with high-risk disease remain disappointing and lag behind those of lower-risk patients.",Dysmyelopoietic Syndromes,ISA,Hematologic Neoplasms
23556108,"While allogeneic hematopoietic cell transplantation (HCT) may offer the best chance of cure for patients suffering from aggressive hematological malignancies such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, successful outcomes for the subgroup of patients with high-risk disease remain disappointing and lag behind those of lower-risk patients.",Dysmyelopoietic Syndromes,PROCESS_OF,Patients
23607904,"The present study aimed to compare the figurative language skills of seven children treated with CNS-directed chemotherapy for ALL before the age of 6 years (mean age at diagnosis 3 years 10 months) and a matched control group of children, using the Test of Language Competence-Expanded Edition (TLC-E) Figurative Language sub-test.",Pharmacotherapy,TREATS,Matched Groups
23607904,"The present study aimed to compare the figurative language skills of seven children treated with CNS-directed chemotherapy for ALL before the age of 6 years (mean age at diagnosis 3 years 10 months) and a matched control group of children, using the Test of Language Competence-Expanded Edition (TLC-E) Figurative Language sub-test.",Pharmacotherapy,TREATS,Child
23607904,"The present study aimed to compare the figurative language skills of seven children treated with CNS-directed chemotherapy for ALL before the age of 6 years (mean age at diagnosis 3 years 10 months) and a matched control group of children, using the Test of Language Competence-Expanded Edition (TLC-E) Figurative Language sub-test.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23607904,Central nervous system (CNS)-directed chemotherapy is delivered for the treatment of childhood acute lymphoblastic leukaemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23647709,We describe a 42-year-old woman with acute lymphoblastic leukemia who was treated with chemotherapy consisting of intrathecal MTX who developed a progressive myelopathy.,Spinal Cord Diseases,PROCESS_OF,Woman
23647709,We describe a 42-year-old woman with acute lymphoblastic leukemia who was treated with chemotherapy consisting of intrathecal MTX who developed a progressive myelopathy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Woman
23647709,We describe a 42-year-old woman with acute lymphoblastic leukemia who was treated with chemotherapy consisting of intrathecal MTX who developed a progressive myelopathy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23683872,CASE PRESENTATION: RHS had been clinically noted at the time of recovering of bone marrow function of a 64-year-old Japanese man who had chemotherapy for his acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23705955,INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children.,Hematologic Neoplasms,PROCESS_OF,Child
23705955,INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
23705955,INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23893073,This finding might indicate a negative effect of chemotherapy on neurological development in children with hematological malignancies.,Pharmacotherapy,TREATS,Child
23893073,This finding might indicate a negative effect of chemotherapy on neurological development in children with hematological malignancies.,Hematologic Neoplasms,PROCESS_OF,Child
23893073,This finding might indicate a negative effect of chemotherapy on neurological development in children with hematological malignancies.,Pharmacotherapy,TREATS,Hematologic Neoplasms
23893073,CONCLUSION: Chemotherapy in children with hematological malignancies predominantly affects the frontal WM.,Hematologic Neoplasms,PROCESS_OF,Child
23893073,CONCLUSION: Chemotherapy in children with hematological malignancies predominantly affects the frontal WM.,Pharmacotherapy,TREATS,Child
23893073,CONCLUSION: Chemotherapy in children with hematological malignancies predominantly affects the frontal WM.,Pharmacotherapy,TREATS,Hematologic Neoplasms
23893073,"INTRODUCTION: With reducing mortality in children with hematological malignancies, the survivors' quality of life regarding development of chronic neurological disturbances is important.",Hematologic Neoplasms,PROCESS_OF,Child
24154679,"Treatment with an anti-CTGF monoclonal antibody, FG-3019, significantly prolonged survival of mice injected with primary xenograft B-ALL cells when co-treated with conventional chemotherapy (vincristine, L-asparaginase and dexamethasone).",Therapeutic procedure,USES,"Antibodies, Anti-Idiotypic"
24154679,"Treatment with an anti-CTGF monoclonal antibody, FG-3019, significantly prolonged survival of mice injected with primary xenograft B-ALL cells when co-treated with conventional chemotherapy (vincristine, L-asparaginase and dexamethasone).",Vincristine,ISA,Pharmacotherapy
24154679,"Data suggest that CTGF represents a targetable molecular aberration in B-ALL, and blocking CTGF signaling in conjunction with administration of chemotherapy may represent a novel therapeutic approach for ALL patients.",Pharmacotherapy,TREATS,Patients
24154679,"Treatment with an anti-CTGF monoclonal antibody, FG-3019, significantly prolonged survival of mice injected with primary xenograft B-ALL cells when co-treated with conventional chemotherapy (vincristine, L-asparaginase and dexamethasone).",Dexamethasone,ISA,Pharmacotherapy
24154679,"Data suggest that CTGF represents a targetable molecular aberration in B-ALL, and blocking CTGF signaling in conjunction with administration of chemotherapy may represent a novel therapeutic approach for ALL patients.",CTGF gene | CTGF,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
24154679,"Data suggest that CTGF represents a targetable molecular aberration in B-ALL, and blocking CTGF signaling in conjunction with administration of chemotherapy may represent a novel therapeutic approach for ALL patients.",CTGF gene | CTGF,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
24154679,"Treatment with an anti-CTGF monoclonal antibody, FG-3019, significantly prolonged survival of mice injected with primary xenograft B-ALL cells when co-treated with conventional chemotherapy (vincristine, L-asparaginase and dexamethasone).",ASPARAGINASE,ISA,Pharmacotherapy
24154679,"Data suggest that CTGF represents a targetable molecular aberration in B-ALL, and blocking CTGF signaling in conjunction with administration of chemotherapy may represent a novel therapeutic approach for ALL patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24154679,"Data suggest that CTGF represents a targetable molecular aberration in B-ALL, and blocking CTGF signaling in conjunction with administration of chemotherapy may represent a novel therapeutic approach for ALL patients.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24154679,"Treatment with an anti-CTGF monoclonal antibody, FG-3019, significantly prolonged survival of mice injected with primary xenograft B-ALL cells when co-treated with conventional chemotherapy (vincristine, L-asparaginase and dexamethasone).",B-Lymphocytes,PART_OF,Mus
24575286,Evaluation of neuropathy during intensive vincristine chemotherapy for non-Hodgkin's lymphoma and Acute Lymphoblastic Leukemia.,Vincristine,TREATS,"Lymphoma, Non-Hodgkin's"
24575286,Evaluation of neuropathy during intensive vincristine chemotherapy for non-Hodgkin's lymphoma and Acute Lymphoblastic Leukemia.,Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
24575286,Evaluation of neuropathy during intensive vincristine chemotherapy for non-Hodgkin's lymphoma and Acute Lymphoblastic Leukemia.,Pharmacotherapy,USES,Vincristine
24575286,Evaluation of neuropathy during intensive vincristine chemotherapy for non-Hodgkin's lymphoma and Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Lymphoma, Non-Hodgkin's"
24575286,Evaluation of neuropathy during intensive vincristine chemotherapy for non-Hodgkin's lymphoma and Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24575286,Evaluation of neuropathy during intensive vincristine chemotherapy for non-Hodgkin's lymphoma and Acute Lymphoblastic Leukemia.,Vincristine,ISA,Pharmacotherapy
24657637,"Rearrangements of the genes encoding two nucleoporins, NUP98 and NUP214, have been implicated in the pathogenesis of several types of hematologic malignancies, particularly acute myeloid leukemia.",Pathogenesis,ASSOCIATED_WITH,Nuclear Pore Complex Proteins
24657637,"Rearrangements of the genes encoding two nucleoporins, NUP98 and NUP214, have been implicated in the pathogenesis of several types of hematologic malignancies, particularly acute myeloid leukemia.","Leukemia, Myelocytic, Acute",ISA,Hematologic Neoplasms
24657637,"Rearrangements of the genes encoding two nucleoporins, NUP98 and NUP214, have been implicated in the pathogenesis of several types of hematologic malignancies, particularly acute myeloid leukemia.",Genes,CAUSES,"Leukemia, Myelocytic, Acute"
24657637,"Rearrangements of the genes encoding two nucleoporins, NUP98 and NUP214, have been implicated in the pathogenesis of several types of hematologic malignancies, particularly acute myeloid leukemia.",Genes,CAUSES,Hematologic Neoplasms
24657637,"Rearrangements of the genes encoding two nucleoporins, NUP98 and NUP214, have been implicated in the pathogenesis of several types of hematologic malignancies, particularly acute myeloid leukemia.",Pathogenesis,ASSOCIATED_WITH,NUP98 gene | NUP98
24657637,"Rearrangements of the genes encoding two nucleoporins, NUP98 and NUP214, have been implicated in the pathogenesis of several types of hematologic malignancies, particularly acute myeloid leukemia.",Pathogenesis,ASSOCIATED_WITH,NUP214 gene | NUP214
22747869,FA transformed into acute lymphoblastic leukemia (ALL) is a rare phenomenon and one of the rarest haematological malignancies associated with this disorder.,Disease,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
22747869,Acute myeloid leukemia is the commonest haematological malignancy followed by myelodysplastic syndrome in children with FA.,Dysmyelopoietic Syndromes,PROCESS_OF,Child
22747869,Acute myeloid leukemia is the commonest haematological malignancy followed by myelodysplastic syndrome in children with FA.,Fanconi's Anemia,PROCESS_OF,Child
22747869,Acute myeloid leukemia is the commonest haematological malignancy followed by myelodysplastic syndrome in children with FA.,"Leukemia, Myelocytic, Acute",ISA,Hematologic Neoplasms
22747869,FA transformed into acute lymphoblastic leukemia (ALL) is a rare phenomenon and one of the rarest haematological malignancies associated with this disorder.,Disease,COEXISTS_WITH,Hematologic Neoplasms
22747869,FA transformed into acute lymphoblastic leukemia (ALL) is a rare phenomenon and one of the rarest haematological malignancies associated with this disorder.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
23049407,"Acute lymphoblastic leukemia was successfully treated with standard chemotherapy, both children remaining in complete remission 16 and 17 months after their initial aplastic anemia diagnosis.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23049435,Immunity against hepatitis B and measles vaccination after chemotherapy for acute lymphoblastic leukaemia in children: revaccination policy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23049435,Immunity against hepatitis B and measles vaccination after chemotherapy for acute lymphoblastic leukaemia in children: revaccination policy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23049435,Immunity against hepatitis B and measles vaccination after chemotherapy for acute lymphoblastic leukaemia in children: revaccination policy.,Pharmacotherapy,PRECEDES,Measles vaccination
23049455,"BACKGROUND: Our research goals were to assess the prevalence of malnutrition in children with cancer, observe malnutrition's effect on tolerance to chemotherapy, and establish malnutrition at onset as one of the prognostic factors in children with hematological malignancies.",Hematologic Neoplasms,PROCESS_OF,Child
23049455,Nutritional assessment of children with hematological malignancies and their subsequent tolerance to chemotherapy.,Hematologic Neoplasms,PROCESS_OF,Child
23049455,"BACKGROUND: Our research goals were to assess the prevalence of malnutrition in children with cancer, observe malnutrition's effect on tolerance to chemotherapy, and establish malnutrition at onset as one of the prognostic factors in children with hematological malignancies.",Malnutrition,OCCURS_IN,Child
23049455,"BACKGROUND: Our research goals were to assess the prevalence of malnutrition in children with cancer, observe malnutrition's effect on tolerance to chemotherapy, and establish malnutrition at onset as one of the prognostic factors in children with hematological malignancies.",Malignant Neoplasms,PROCESS_OF,Child
23369047,Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies.,Hematologic Neoplasms,PROCESS_OF,Child
23369047,Children with haematological malignancies and fever were enrolled prospectively.,Hematologic Neoplasms,PROCESS_OF,Child
23369047,Children with haematological malignancies and fever were enrolled prospectively.,Fever,PROCESS_OF,Child
23369047,Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies.,"ASPERGILLOSIS, INVASIVE",PROCESS_OF,Child
23369047,Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies.,Assay,DIAGNOSES,"ASPERGILLOSIS, INVASIVE"
23407458,High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.,"Transplantation, Homologous",TREATS,"Leukemia, Lymphocytic, Acute, L1"
23407458,High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23575054,Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23575054,Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.,Neoadjuvant Therapy,TREATS,Child
23575054,Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23609993,Motor functioning during and following treatment with chemotherapy for pediatric acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23630183,Adenovirus pneumonia during induction therapy for childhood acute lymphoblastic leukemia.,Pneumonia,PROCESS_OF,Adenoviruses
23630183,Adenovirus pneumonia during induction therapy for childhood acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23744127,Doxorubicin chemotherapy is effective and widely used to treat acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23744127,Doxorubicin chemotherapy is effective and widely used to treat acute lymphoblastic leukemia.,Pharmacotherapy,USES,Doxorubicin
23744127,Doxorubicin chemotherapy is effective and widely used to treat acute lymphoblastic leukemia.,Doxorubicin,ISA,Pharmacotherapy
23744127,Doxorubicin chemotherapy is effective and widely used to treat acute lymphoblastic leukemia.,Doxorubicin,TREATS,"Leukemia, Lymphocytic, Acute"
23893073,This finding might indicate a negative effect of chemotherapy on neurological development in children with hematological malignancies.,Pharmacotherapy,TREATS,Child
23893073,This finding might indicate a negative effect of chemotherapy on neurological development in children with hematological malignancies.,Hematologic Neoplasms,PROCESS_OF,Child
23893073,This finding might indicate a negative effect of chemotherapy on neurological development in children with hematological malignancies.,Pharmacotherapy,TREATS,Hematologic Neoplasms
23909089,Default rate was high and we found a strong association between cycles of chemotherapy given and survival in lymphoma patients.,Pharmacotherapy,TREATS,Patients
23909089,Default rate was high and we found a strong association between cycles of chemotherapy given and survival in lymphoma patients.,Lymphoma,PROCESS_OF,Patients
23909089,Default rate was high and we found a strong association between cycles of chemotherapy given and survival in lymphoma patients.,Pharmacotherapy,TREATS,Lymphoma
24116693,"All had acute lymphoblastic leukaemia, all had been treated by chemotherapy with or without CNS irradiation, and none had received haematopoietic stem cell transplantation.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
24116693,"All had acute lymphoblastic leukaemia, all had been treated by chemotherapy with or without CNS irradiation, and none had received haematopoietic stem cell transplantation.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24276047,"A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24276047,"A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24276047,"A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.",Pharmacotherapy,TREATS,Child
24932855,One patient developed PJP at 7 months following dasatinib in combination with chemotherapy for the treatment of acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25098829,E. coli-derived ASNase was approved in 1978 to be used as part of a multiagent chemotherapy to treat ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25482740,"Surveyed clinicians largely followed the current recommendations for prophylaxis in the setting of induction chemotherapy for acute myeloid leukaemia, as well as autologous and low-risk allogeneic haemopoietic stem cell transplantation (HSCT).",Hematopoietic Stem Cell Transplantation,TREATS,"Leukemia, Myelocytic, Acute"
25482740,"Surveyed clinicians largely followed the current recommendations for prophylaxis in the setting of induction chemotherapy for acute myeloid leukaemia, as well as autologous and low-risk allogeneic haemopoietic stem cell transplantation (HSCT).",Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
22762547,"This review summarizes and discusses current challenges in the treatment of patients with Ph+ ALL, such as selection of the appropriate induction therapy, minimization of transplant toxicity, correct use of TKIs after transplant, BCR-ABL monitoring, the study of mutations which confer resistance to TKIs and new drugs to overcome this resistance.",Neoadjuvant Therapy,TREATS,Patients
22762547,"This review summarizes and discusses current challenges in the treatment of patients with Ph+ ALL, such as selection of the appropriate induction therapy, minimization of transplant toxicity, correct use of TKIs after transplant, BCR-ABL monitoring, the study of mutations which confer resistance to TKIs and new drugs to overcome this resistance.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
22762547,"This review summarizes and discusses current challenges in the treatment of patients with Ph+ ALL, such as selection of the appropriate induction therapy, minimization of transplant toxicity, correct use of TKIs after transplant, BCR-ABL monitoring, the study of mutations which confer resistance to TKIs and new drugs to overcome this resistance.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
22841975,"Although the outcome of patients with acute lymphoblastic leukemia (ALL) has been improved continuously by chemotherapy and tyrosine kinase inhibitors, prognosis of patients with Philadelphia chromosome positive (Ph(+)) ALL still remains poor.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22841975,"Although the outcome of patients with acute lymphoblastic leukemia (ALL) has been improved continuously by chemotherapy and tyrosine kinase inhibitors, prognosis of patients with Philadelphia chromosome positive (Ph(+)) ALL still remains poor.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
22841975,"Although the outcome of patients with acute lymphoblastic leukemia (ALL) has been improved continuously by chemotherapy and tyrosine kinase inhibitors, prognosis of patients with Philadelphia chromosome positive (Ph(+)) ALL still remains poor.",Protein-tyrosine kinase inhibitor,TREATS,Patients
22841975,"Although the outcome of patients with acute lymphoblastic leukemia (ALL) has been improved continuously by chemotherapy and tyrosine kinase inhibitors, prognosis of patients with Philadelphia chromosome positive (Ph(+)) ALL still remains poor.",Pharmacotherapy,TREATS,Patients
22841975,"Although the outcome of patients with acute lymphoblastic leukemia (ALL) has been improved continuously by chemotherapy and tyrosine kinase inhibitors, prognosis of patients with Philadelphia chromosome positive (Ph(+)) ALL still remains poor.",Philadelphia chromosome positive,PROCESS_OF,Patients
22841975,"Although the outcome of patients with acute lymphoblastic leukemia (ALL) has been improved continuously by chemotherapy and tyrosine kinase inhibitors, prognosis of patients with Philadelphia chromosome positive (Ph(+)) ALL still remains poor.",Protein-tyrosine kinase inhibitor,TREATS,"Leukemia, Lymphocytic, Acute"
22975814,[Feasibility and safety of chemotherapy for acute lymphoblastic leukemia in adolescents and young adults: Interim analysis of JALSG ALL202-U].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
22975814,[Feasibility and safety of chemotherapy for acute lymphoblastic leukemia in adolescents and young adults: Interim analysis of JALSG ALL202-U].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
22975814,[Feasibility and safety of chemotherapy for acute lymphoblastic leukemia in adolescents and young adults: Interim analysis of JALSG ALL202-U].,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23047042,We report the case of a 7-year-old girl who developed massive cerebral sinovenous thrombosis on day 22 of induction therapy for high-risk acute lymphoblastic leukaemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23047042,We report the case of a 7-year-old girl who developed massive cerebral sinovenous thrombosis on day 22 of induction therapy for high-risk acute lymphoblastic leukaemia.,Cerebral arterial thrombosis,PROCESS_OF,Girls
23049440,Antibody responses to Hepatitis B and measles-mumps-rubella vaccines in children who received chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23049440,Antibody responses to Hepatitis B and measles-mumps-rubella vaccines in children who received chemotherapy for acute lymphoblastic leukemia.,Hepatitis B,PROCESS_OF,Child
23049440,Antibody responses to Hepatitis B and measles-mumps-rubella vaccines in children who received chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,ADMINISTERED_TO,Child
23225800,The aim of this study was to analyze the impact of lymphocyte recovery after allogeneic stem cell transplantation in children with hematologic malignancies.,Stem cell transplant,TREATS,Hematologic Neoplasms
23225800,The aim of this study was to analyze the impact of lymphocyte recovery after allogeneic stem cell transplantation in children with hematologic malignancies.,Stem cell transplant,TREATS,Child
23225800,The aim of this study was to analyze the impact of lymphocyte recovery after allogeneic stem cell transplantation in children with hematologic malignancies.,Hematologic Neoplasms,PROCESS_OF,Child
23519741,"CONCLUSIONS: Despite the limitations of this study, published reports and our results suggest that TMZ induces secondary hematological malignancies, particularly ALL, and might shorten the latency period when used in combination with other chemotherapeutic agents.",temozolomide,CAUSES,Hematologic Neoplasms
23519741,"CONCLUSIONS: Despite the limitations of this study, published reports and our results suggest that TMZ induces secondary hematological malignancies, particularly ALL, and might shorten the latency period when used in combination with other chemotherapeutic agents.",temozolomide,CAUSES,"Leukemia, Lymphocytic, Acute"
23519741,"CONCLUSIONS: Despite the limitations of this study, published reports and our results suggest that TMZ induces secondary hematological malignancies, particularly ALL, and might shorten the latency period when used in combination with other chemotherapeutic agents.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
23591360,"With more intensified chemotherapy , outcomes for children T-ALL were improved, approaching those for the precursor B-cell ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23813940,Response: chemotherapy versus allogeneic transplantation in adult patients with acute lymphoblastic leukemia in first remission--not a time for dogma.,"Transplantation, Homologous",TREATS,Patients
23813940,Response: chemotherapy versus allogeneic transplantation in adult patients with acute lymphoblastic leukemia in first remission--not a time for dogma.,Pharmacotherapy,TREATS,Patients
23813940,Response: chemotherapy versus allogeneic transplantation in adult patients with acute lymphoblastic leukemia in first remission--not a time for dogma.,Pharmacotherapy,compared_with,"Transplantation, Homologous"
23813940,Response: chemotherapy versus allogeneic transplantation in adult patients with acute lymphoblastic leukemia in first remission--not a time for dogma.,"Transplantation, Homologous",TREATS,"Leukemia, Lymphocytic, Acute"
23813940,Response: chemotherapy versus allogeneic transplantation in adult patients with acute lymphoblastic leukemia in first remission--not a time for dogma.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23813940,Response: chemotherapy versus allogeneic transplantation in adult patients with acute lymphoblastic leukemia in first remission--not a time for dogma.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24415457,CONCLUSIONS: Prophylaxis with ciprofloxacin and voriconazole or micafungin was found to reduce the rates of bloodstream infection and IFI in children with acute leukemia undergoing intensive chemotherapy.,voriconazole,TREATS,Child
24415457,"Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.",Pharmacotherapy,TREATS,Acute leukemia
24415457,"METHODS: Prophylaxis treatment was administered during intensive chemotherapy in children with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) from January 1, 2010 to December 31, 2012.",Pharmacotherapy,TREATS,Child
24415457,CONCLUSIONS: Prophylaxis with ciprofloxacin and voriconazole or micafungin was found to reduce the rates of bloodstream infection and IFI in children with acute leukemia undergoing intensive chemotherapy.,Prophylactic treatment,USES,voriconazole
24415457,"Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.",Infection,PROCESS_OF,Child
24415457,"METHODS: Prophylaxis treatment was administered during intensive chemotherapy in children with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) from January 1, 2010 to December 31, 2012.","Leukemia, Myelocytic, Acute",PROCESS_OF,Child
24415457,CONCLUSIONS: Prophylaxis with ciprofloxacin and voriconazole or micafungin was found to reduce the rates of bloodstream infection and IFI in children with acute leukemia undergoing intensive chemotherapy.,Prophylactic treatment,USES,Ciprofloxacin
24415457,"Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.",Prophylactic treatment,USES,micafungin
24415457,"METHODS: Prophylaxis treatment was administered during intensive chemotherapy in children with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) from January 1, 2010 to December 31, 2012.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24415457,CONCLUSIONS: Prophylaxis with ciprofloxacin and voriconazole or micafungin was found to reduce the rates of bloodstream infection and IFI in children with acute leukemia undergoing intensive chemotherapy.,Acute leukemia,PROCESS_OF,Child
24415457,"METHODS: Prophylaxis treatment was administered during intensive chemotherapy in children with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) from January 1, 2010 to December 31, 2012.",Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
24415457,CONCLUSIONS: Prophylaxis with ciprofloxacin and voriconazole or micafungin was found to reduce the rates of bloodstream infection and IFI in children with acute leukemia undergoing intensive chemotherapy.,Pharmacotherapy,TREATS,Acute leukemia
24415457,"METHODS: Prophylaxis treatment was administered during intensive chemotherapy in children with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) from January 1, 2010 to December 31, 2012.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24415457,CONCLUSIONS: Prophylaxis with ciprofloxacin and voriconazole or micafungin was found to reduce the rates of bloodstream infection and IFI in children with acute leukemia undergoing intensive chemotherapy.,micafungin,TREATS,Acute leukemia
24415457,CONCLUSIONS: Prophylaxis with ciprofloxacin and voriconazole or micafungin was found to reduce the rates of bloodstream infection and IFI in children with acute leukemia undergoing intensive chemotherapy.,micafungin,TREATS,Child
24415457,"Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.",Acute leukemia,PROCESS_OF,Child
24415457,CONCLUSIONS: Prophylaxis with ciprofloxacin and voriconazole or micafungin was found to reduce the rates of bloodstream infection and IFI in children with acute leukemia undergoing intensive chemotherapy.,voriconazole,TREATS,Acute leukemia
24604964,Successful outcome of mucormycosis in two children on induction therapy for acute lymphoblastic leukemia.,Mucormycosis,PROCESS_OF,Child
24604964,Successful outcome of mucormycosis in two children on induction therapy for acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
24716011,Neutropenic enterocolitis is one of the most common gastrointestinal complications seen in patients who are receiving chemotherapy for leukemia.,Pharmacotherapy,TREATS,leukemia
24716011,Neutropenic enterocolitis is one of the most common gastrointestinal complications seen in patients who are receiving chemotherapy for leukemia.,Gastrointestinal complication,PROCESS_OF,Patients
24937727,"CONCLUSIONS: Low-dose TMP-SMX with methotrexate chemotherapy appears to be standard for patients with acute lymphoblastic leukemia; however, other uses appear questionable, and clinicians should be cognizant of the risk for fatal interactions, especially when medications are prescribed by multiple providers.",Pharmacotherapy,TREATS,Patients
24937727,"CONCLUSIONS: Low-dose TMP-SMX with methotrexate chemotherapy appears to be standard for patients with acute lymphoblastic leukemia; however, other uses appear questionable, and clinicians should be cognizant of the risk for fatal interactions, especially when medications are prescribed by multiple providers.",Methotrexate,ISA,Pharmacotherapy
24937727,"CONCLUSIONS: Low-dose TMP-SMX with methotrexate chemotherapy appears to be standard for patients with acute lymphoblastic leukemia; however, other uses appear questionable, and clinicians should be cognizant of the risk for fatal interactions, especially when medications are prescribed by multiple providers.",Methotrexate,TREATS,Clinicians
24937727,"CONCLUSIONS: Low-dose TMP-SMX with methotrexate chemotherapy appears to be standard for patients with acute lymphoblastic leukemia; however, other uses appear questionable, and clinicians should be cognizant of the risk for fatal interactions, especially when medications are prescribed by multiple providers.",Methotrexate,TREATS,Patients
24937727,"CONCLUSIONS: Low-dose TMP-SMX with methotrexate chemotherapy appears to be standard for patients with acute lymphoblastic leukemia; however, other uses appear questionable, and clinicians should be cognizant of the risk for fatal interactions, especially when medications are prescribed by multiple providers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Clinicians
24937727,"CONCLUSIONS: Low-dose TMP-SMX with methotrexate chemotherapy appears to be standard for patients with acute lymphoblastic leukemia; however, other uses appear questionable, and clinicians should be cognizant of the risk for fatal interactions, especially when medications are prescribed by multiple providers.",Pharmacotherapy,USES,Methotrexate
24937727,"CONCLUSIONS: Low-dose TMP-SMX with methotrexate chemotherapy appears to be standard for patients with acute lymphoblastic leukemia; however, other uses appear questionable, and clinicians should be cognizant of the risk for fatal interactions, especially when medications are prescribed by multiple providers.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24937727,"CONCLUSIONS: Low-dose TMP-SMX with methotrexate chemotherapy appears to be standard for patients with acute lymphoblastic leukemia; however, other uses appear questionable, and clinicians should be cognizant of the risk for fatal interactions, especially when medications are prescribed by multiple providers.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24937727,"CONCLUSIONS: Low-dose TMP-SMX with methotrexate chemotherapy appears to be standard for patients with acute lymphoblastic leukemia; however, other uses appear questionable, and clinicians should be cognizant of the risk for fatal interactions, especially when medications are prescribed by multiple providers.",Pharmacotherapy,TREATS,Clinicians
25090024,"In contrast to CML and lung cancer, the BIM deletion did not predict for poorer clinical outcome in a retrospective analysis of 411 pediatric ALL patients who were uniformly treated with GCs and chemotherapy.",Pharmacotherapy,TREATS,Patients
25090024,"In contrast to CML and lung cancer, the BIM deletion did not predict for poorer clinical outcome in a retrospective analysis of 411 pediatric ALL patients who were uniformly treated with GCs and chemotherapy.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
25090024,"In contrast to CML and lung cancer, the BIM deletion did not predict for poorer clinical outcome in a retrospective analysis of 411 pediatric ALL patients who were uniformly treated with GCs and chemotherapy.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25090024,"In contrast to CML and lung cancer, the BIM deletion did not predict for poorer clinical outcome in a retrospective analysis of 411 pediatric ALL patients who were uniformly treated with GCs and chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25090024,"In contrast to CML and lung cancer, the BIM deletion did not predict for poorer clinical outcome in a retrospective analysis of 411 pediatric ALL patients who were uniformly treated with GCs and chemotherapy.",Glucocorticoids,TREATS,Patients
25321387,"Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy.",Pharmacotherapy,USES,Dexamethasone
25321387,"Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy.",Dexamethasone,ISA,Pharmacotherapy
25321387,"Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy.",Steroids,ADMINISTERED_TO,Patients
25321387,"Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy.",basal insulin,TREATS,Patients
22728618,"CONCLUSION: Following chemotherapy for ALL/NHL, cytopenia that is prolonged or not explainable on the basis of chemotherapy toxicity should be evaluated for CMV infection.",Pharmacotherapy,TREATS,"Lymphoma, Non-Hodgkin's"
22728618,Cytomegalovirus infection as a cause of cytopenia after chemotherapy for hematological malignancies.,Pharmacotherapy,TREATS,Hematologic Neoplasms
22728618,Cytomegalovirus infection as a cause of cytopenia after chemotherapy for hematological malignancies.,Cytomegalovirus Infections,CAUSES,Cytopenia
22949933,Two patients had a remote history of chemotherapy for hematological neoplasms (acute lymphoblastic leukemia and Hodgkin lymphoma respectively) and another had clear cell renal cell carcinoma and anaplastic pancreatic carcinoma diagnosed at autopsy without definable syndrome.,Pharmacotherapy,TREATS,Hematologic Neoplasms
22949933,Two patients had a remote history of chemotherapy for hematological neoplasms (acute lymphoblastic leukemia and Hodgkin lymphoma respectively) and another had clear cell renal cell carcinoma and anaplastic pancreatic carcinoma diagnosed at autopsy without definable syndrome.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
22949933,Two patients had a remote history of chemotherapy for hematological neoplasms (acute lymphoblastic leukemia and Hodgkin lymphoma respectively) and another had clear cell renal cell carcinoma and anaplastic pancreatic carcinoma diagnosed at autopsy without definable syndrome.,Hodgkin Disease,ISA,Hematologic Neoplasms
22949933,Two patients had a remote history of chemotherapy for hematological neoplasms (acute lymphoblastic leukemia and Hodgkin lymphoma respectively) and another had clear cell renal cell carcinoma and anaplastic pancreatic carcinoma diagnosed at autopsy without definable syndrome.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22949933,Two patients had a remote history of chemotherapy for hematological neoplasms (acute lymphoblastic leukemia and Hodgkin lymphoma respectively) and another had clear cell renal cell carcinoma and anaplastic pancreatic carcinoma diagnosed at autopsy without definable syndrome.,Pharmacotherapy,TREATS,Hodgkin Disease
22949933,Two patients had a remote history of chemotherapy for hematological neoplasms (acute lymphoblastic leukemia and Hodgkin lymphoma respectively) and another had clear cell renal cell carcinoma and anaplastic pancreatic carcinoma diagnosed at autopsy without definable syndrome.,Conventional (Clear Cell) Renal Cell Carcinoma,PROCESS_OF,Patients
22949933,Two patients had a remote history of chemotherapy for hematological neoplasms (acute lymphoblastic leukemia and Hodgkin lymphoma respectively) and another had clear cell renal cell carcinoma and anaplastic pancreatic carcinoma diagnosed at autopsy without definable syndrome.,Pancreatic carcinoma,PROCESS_OF,Patients
23547827,"Furthermore, we investigated whether accumulating mtDNA defects may then be a risk factor for cell transformation, in adult haematological malignancy (AHM).",Hematologic Neoplasms,PROCESS_OF,Adult
23547827,"Furthermore, we investigated whether accumulating mtDNA defects may then be a risk factor for cell transformation, in adult haematological malignancy (AHM).",cell transformation,COEXISTS_WITH,Hematologic Neoplasms
23559975,This study was performed using brachial artery reactivity (BAR) to evaluate vascular endothelial function in ALL patients who were treated with anthracycline chemotherapy.,Pharmacotherapy,TREATS,Patients
23559975,This study was performed using brachial artery reactivity (BAR) to evaluate vascular endothelial function in ALL patients who were treated with anthracycline chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23559975,This study was performed using brachial artery reactivity (BAR) to evaluate vascular endothelial function in ALL patients who were treated with anthracycline chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23832430,"We compared neuropsychological outcomes for patients treated on DFCI ALL Consortium Protocol 00-01, which included a randomized comparison of the two steroid preparations during post-induction therapy in children and adolescents with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
23832430,"We compared neuropsychological outcomes for patients treated on DFCI ALL Consortium Protocol 00-01, which included a randomized comparison of the two steroid preparations during post-induction therapy in children and adolescents with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23832430,"We compared neuropsychological outcomes for patients treated on DFCI ALL Consortium Protocol 00-01, which included a randomized comparison of the two steroid preparations during post-induction therapy in children and adolescents with ALL.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23832430,"We compared neuropsychological outcomes for patients treated on DFCI ALL Consortium Protocol 00-01, which included a randomized comparison of the two steroid preparations during post-induction therapy in children and adolescents with ALL.",Neoadjuvant Therapy,TREATS,Adolescent
23832430,"We compared neuropsychological outcomes for patients treated on DFCI ALL Consortium Protocol 00-01, which included a randomized comparison of the two steroid preparations during post-induction therapy in children and adolescents with ALL.",Neoadjuvant Therapy,TREATS,Child
23861246,"This strategy could reduce minimal residual disease and/or allow for chemotherapy dose reduction, thereby leading to improved event-free survival and reduced therapy-associated toxicity for patients with B-ALL.",Pharmacotherapy,TREATS,Patients
23861246,"This strategy could reduce minimal residual disease and/or allow for chemotherapy dose reduction, thereby leading to improved event-free survival and reduced therapy-associated toxicity for patients with B-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
23861246,"This strategy could reduce minimal residual disease and/or allow for chemotherapy dose reduction, thereby leading to improved event-free survival and reduced therapy-associated toxicity for patients with B-ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24052438,The present study compared the gene expression pattern of some previously described genes at the time of diagnosis and after induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) in patients submitted to Brazilian Childhood Leukemia Treatment Group (GBTLI) ALL-99 Protocol.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
24052438,The present study compared the gene expression pattern of some previously described genes at the time of diagnosis and after induction chemotherapy for childhood acute lymphoblastic leukemia (ALL) in patients submitted to Brazilian Childhood Leukemia Treatment Group (GBTLI) ALL-99 Protocol.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24365369,The lymphomas and leukemias are a heterogenous group of hematologic malignancies with protean manifestations.,leukemia,ISA,Hematologic Neoplasms
24365369,The lymphomas and leukemias are a heterogenous group of hematologic malignancies with protean manifestations.,Lymphoma,ISA,Hematologic Neoplasms
24598194,"During chemotherapy for hematologic malignancies, some patients with PRES reportedly develop paralytic ileus or tumor lysis syndrome.",Paralytic Ileus,PROCESS_OF,Patients
24598194,"During chemotherapy for hematologic malignancies, some patients with PRES reportedly develop paralytic ileus or tumor lysis syndrome.",Pharmacotherapy,TREATS,Hematologic Neoplasms
24598194,"After the immunophenotype of lymphocytes in her pleural effusion had been identified, she received CHOP therapy because her dyspnea worsened, and induction therapy for acute lymphoblastic leukemia was subsequently performed after confirmation of her diagnosis as T-LBL.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
24598194,"After the immunophenotype of lymphocytes in her pleural effusion had been identified, she received CHOP therapy because her dyspnea worsened, and induction therapy for acute lymphoblastic leukemia was subsequently performed after confirmation of her diagnosis as T-LBL.",Immunophenotyping,DIAGNOSES,Pleural effusion disorder
24598194,"After the immunophenotype of lymphocytes in her pleural effusion had been identified, she received CHOP therapy because her dyspnea worsened, and induction therapy for acute lymphoblastic leukemia was subsequently performed after confirmation of her diagnosis as T-LBL.",lymphoblast,LOCATION_OF,T-Cell Lymphoma
24598194,"During chemotherapy for hematologic malignancies, some patients with PRES reportedly develop paralytic ileus or tumor lysis syndrome.",Tumor Lysis Syndrome,PROCESS_OF,Patients
24598194,"After the immunophenotype of lymphocytes in her pleural effusion had been identified, she received CHOP therapy because her dyspnea worsened, and induction therapy for acute lymphoblastic leukemia was subsequently performed after confirmation of her diagnosis as T-LBL.",Therapeutic procedure,USES,DDIT3
24598194,"During chemotherapy for hematologic malignancies, some patients with PRES reportedly develop paralytic ileus or tumor lysis syndrome.",Syndrome,PROCESS_OF,Patients
24608079,Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25130816,This study was aimed to investigate the efficacy of Hyper-CVAD/MA regimen chemotherapy combined with haploidentical hematopoietic stem cell infusion for the treatment of lymphoblastic lymphoma/leukemia (LBL/ALL).,Pharmacotherapy,TREATS,leukemia
25130816,[Clinical analysis of lymphoblastic lymphoma/leukemia treated with Hyper-CVAD/MA regimen chemotherapy combined with haploidentical hematopoietic stem cell infusion].,Pharmacotherapy,TREATS,leukemia
25403293,The aim of this work was to identify clinical/dynamic and typological characteristics of mental disorders in children with hematological malignancies as well as the factors predisposing to these disorders.,Mental disorders,PROCESS_OF,Child
25403293,The aim of this work was to identify clinical/dynamic and typological characteristics of mental disorders in children with hematological malignancies as well as the factors predisposing to these disorders.,Hematologic Neoplasms,PROCESS_OF,Child
25403293,"MATERIAL AND METHODS: The study involved 96 children (63 boys and 33 girls), aged 3-12 years, with hematological malignancies (acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma).",Hematologic Neoplasms,PROCESS_OF,Child
25403293,"MATERIAL AND METHODS: The study involved 96 children (63 boys and 33 girls), aged 3-12 years, with hematological malignancies (acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma).","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
25403293,"MATERIAL AND METHODS: The study involved 96 children (63 boys and 33 girls), aged 3-12 years, with hematological malignancies (acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22550563,Hepatosplenic candidiasis (HSC) is a part of disseminated Candida infection that occurs most commonly in patients with hematologic malignancies treated with chemotherapy and requires protracted antifungal therapy.,Hematologic Neoplasms,PROCESS_OF,Patients
22550563,Hepatosplenic candidiasis (HSC) is a part of disseminated Candida infection that occurs most commonly in patients with hematologic malignancies treated with chemotherapy and requires protracted antifungal therapy.,Pharmacotherapy,TREATS,Hematologic Neoplasms
22550563,Hepatosplenic candidiasis (HSC) is a part of disseminated Candida infection that occurs most commonly in patients with hematologic malignancies treated with chemotherapy and requires protracted antifungal therapy.,Candidiasis,OCCURS_IN,Patients
22550563,Hepatosplenic candidiasis (HSC) is a part of disseminated Candida infection that occurs most commonly in patients with hematologic malignancies treated with chemotherapy and requires protracted antifungal therapy.,Hepatosplenic candidiasis,ISA,Candidiasis
22550563,Hepatosplenic candidiasis (HSC) is a part of disseminated Candida infection that occurs most commonly in patients with hematologic malignancies treated with chemotherapy and requires protracted antifungal therapy.,Hepatosplenic candidiasis,OCCURS_IN,Patients
22592050,Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.,Pharmacotherapy,TREATS,Patients
22592050,Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.,Acute leukemia,PROCESS_OF,Patients
22592050,Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.,Cell Transplantation,TREATS,Acute leukemia
22592050,Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.,Pharmacotherapy,TREATS,Acute leukemia
22734022,Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.,Children's Oncology Group,LOCATION_OF,Pilot Projects
22734022,Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.,Pharmacotherapy,TREATS,Acute T Cell Leukemia
23014520,Most patients with acute leukemia were treated with standard induction chemotherapy.,Acute leukemia,PROCESS_OF,Patients
23014520,Most patients with acute leukemia were treated with standard induction chemotherapy.,Pharmacotherapy,TREATS,Patients
23014520,Most patients with acute leukemia were treated with standard induction chemotherapy.,Pharmacotherapy,TREATS,Acute leukemia
23031157,"To see whether DNMT3A mutation occurs in other malignancies as well, we analyzed DNMT3A in 916 cancer tissues from 401 hematologic malignancies (AML, acute lymphoblastic leukemias (ALL), multiple myelomas and lymphomas) and 515 carcinomas (lung, breast, prostate, colorectal and gastric carcinomas) using a single-strand conformation polymorphism (SSCP) assay.",DNMT3a | DNMT3A,ASSOCIATED_WITH,Malignant Neoplasms
23031157,"To see whether DNMT3A mutation occurs in other malignancies as well, we analyzed DNMT3A in 916 cancer tissues from 401 hematologic malignancies (AML, acute lymphoblastic leukemias (ALL), multiple myelomas and lymphomas) and 515 carcinomas (lung, breast, prostate, colorectal and gastric carcinomas) using a single-strand conformation polymorphism (SSCP) assay.",Body tissue,PART_OF,Malignant Neoplasms
23031157,"To see whether DNMT3A mutation occurs in other malignancies as well, we analyzed DNMT3A in 916 cancer tissues from 401 hematologic malignancies (AML, acute lymphoblastic leukemias (ALL), multiple myelomas and lymphomas) and 515 carcinomas (lung, breast, prostate, colorectal and gastric carcinomas) using a single-strand conformation polymorphism (SSCP) assay.",Multiple Myeloma,ISA,Hematologic Neoplasms
23031157,"To see whether DNMT3A mutation occurs in other malignancies as well, we analyzed DNMT3A in 916 cancer tissues from 401 hematologic malignancies (AML, acute lymphoblastic leukemias (ALL), multiple myelomas and lymphomas) and 515 carcinomas (lung, breast, prostate, colorectal and gastric carcinomas) using a single-strand conformation polymorphism (SSCP) assay.",Lymphoma,ISA,Hematologic Neoplasms
23031157,"To see whether DNMT3A mutation occurs in other malignancies as well, we analyzed DNMT3A in 916 cancer tissues from 401 hematologic malignancies (AML, acute lymphoblastic leukemias (ALL), multiple myelomas and lymphomas) and 515 carcinomas (lung, breast, prostate, colorectal and gastric carcinomas) using a single-strand conformation polymorphism (SSCP) assay.","Leukemia, Myelocytic, Acute",ISA,Hematologic Neoplasms
23031157,"To see whether DNMT3A mutation occurs in other malignancies as well, we analyzed DNMT3A in 916 cancer tissues from 401 hematologic malignancies (AML, acute lymphoblastic leukemias (ALL), multiple myelomas and lymphomas) and 515 carcinomas (lung, breast, prostate, colorectal and gastric carcinomas) using a single-strand conformation polymorphism (SSCP) assay.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
23031157,"To see whether DNMT3A mutation occurs in other malignancies as well, we analyzed DNMT3A in 916 cancer tissues from 401 hematologic malignancies (AML, acute lymphoblastic leukemias (ALL), multiple myelomas and lymphomas) and 515 carcinomas (lung, breast, prostate, colorectal and gastric carcinomas) using a single-strand conformation polymorphism (SSCP) assay.",Body tissue,LOCATION_OF,DNMT3a | DNMT3A
23151340,UNLABELLED: BACKGROUND: Acute lymphoblastic leukemia (ALL) is a heterogeneous form of hematological cancer consisting of various subtypes.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
23255118,"Furthermore, primary leukemia cell cultures from T-ALL patients appeared to be equally sensitive to glucocorticoid dexamethasone and CpdA.",Dexamethasone,ISA,Glucocorticoids
23281776,"The purpose was to identify risk factors for bacteremia in febrile episodes occurring during chemotherapy for acute lymphoblastic leukemia (ALL) in children, and to develop a risk score permitting risk-adapted antibiotic therapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23281776,"The purpose was to identify risk factors for bacteremia in febrile episodes occurring during chemotherapy for acute lymphoblastic leukemia (ALL) in children, and to develop a risk score permitting risk-adapted antibiotic therapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23281776,"The purpose was to identify risk factors for bacteremia in febrile episodes occurring during chemotherapy for acute lymphoblastic leukemia (ALL) in children, and to develop a risk score permitting risk-adapted antibiotic therapy.",Bacteremia,COEXISTS_WITH,Fever
23281776,Prediction of bacteremia in children with febrile episodes during chemotherapy for acute lymphoblastic leukemia.,Fever,PREDISPOSES,Bacteremia
23281776,Prediction of bacteremia in children with febrile episodes during chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23281776,Prediction of bacteremia in children with febrile episodes during chemotherapy for acute lymphoblastic leukemia.,Bacteremia,PROCESS_OF,Child
23786458,"Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is a highly effective treatment, but at the same time causes significant suppression of the patient's immunity.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23786458,"Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is a highly effective treatment, but at the same time causes significant suppression of the patient's immunity.",Immunity,PROCESS_OF,Patients
23786458,"Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is a highly effective treatment, but at the same time causes significant suppression of the patient's immunity.",Pharmacotherapy,ISA,Therapeutic procedure
23883706,MATERIALS AND METHODS: Children with haematological malignancies and FN were enrolled prospectively.,Hematologic Neoplasms,PROCESS_OF,Child
23883706,MATERIALS AND METHODS: Children with haematological malignancies and FN were enrolled prospectively.,Febrile neutropenia,PROCESS_OF,Child
23887024,Treatment of relapsed precursor-B acute lymphoblastic leukemia with intensive chemotherapy: POG (Pediatric Oncology Group) study 9411 (SIMAL 9).,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
24696937,Long-term venous access catheters are very useful for administration of chemotherapy and other drug infusions in patients with haematological malignancies.,Pharmacotherapy,TREATS,Patients
24696937,Long-term venous access catheters are very useful for administration of chemotherapy and other drug infusions in patients with haematological malignancies.,Hematologic Neoplasms,PROCESS_OF,Patients
24696937,Long-term venous access catheters are very useful for administration of chemotherapy and other drug infusions in patients with haematological malignancies.,Pharmaceutical Preparations,TREATS,Hematologic Neoplasms
24696937,Long-term venous access catheters are very useful for administration of chemotherapy and other drug infusions in patients with haematological malignancies.,Pharmacotherapy,TREATS,Hematologic Neoplasms
24696937,Long-term venous access catheters are very useful for administration of chemotherapy and other drug infusions in patients with haematological malignancies.,Pharmaceutical Preparations,TREATS,Patients
24732057,"During chemotherapy for bilineal leukemia, a 6-month-old infant presented with a necrotizing skin and soft-tissue infection of the chest wall due to Rhizopus sp.",Soft Tissue Infections,PROCESS_OF,Infant
24732057,"During chemotherapy for bilineal leukemia, a 6-month-old infant presented with a necrotizing skin and soft-tissue infection of the chest wall due to Rhizopus sp.",Entire chest wall,LOCATION_OF,Soft Tissue Infections
24732057,"During chemotherapy for bilineal leukemia, a 6-month-old infant presented with a necrotizing skin and soft-tissue infection of the chest wall due to Rhizopus sp.",Pharmacotherapy,TREATS,leukemia
24732057,"During chemotherapy for bilineal leukemia, a 6-month-old infant presented with a necrotizing skin and soft-tissue infection of the chest wall due to Rhizopus sp.",Skin necrosis,PROCESS_OF,Infant
24828076,Intensified and central nervous system (CNS)-directed chemotherapy has improved outcomes for pediatric B cell acute lymphoblastic leukemia (B-ALL) but confers treatment-related morbidities.,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
24943696,"Search terms included corticosteroids, adrenal cortex hormones, steroid psychosis, substance-induced psychoses, glucocorticoids, dexamethasone, hydrocortisone, prednisone, adverse effects, mood disorders, mental disorders, psychosis, psychotic, psychoses, side effect, chemically induced, emotions, affective symptoms, toxicity, behavior, behavioral symptoms, infant, child, adolescent, pediatric, paediatric, neonatal, children, teen, and teenager.","Psychoses, Substance-Induced",ISA,Psychotic Disorders
24943696,"Search terms included corticosteroids, adrenal cortex hormones, steroid psychosis, substance-induced psychoses, glucocorticoids, dexamethasone, hydrocortisone, prednisone, adverse effects, mood disorders, mental disorders, psychosis, psychotic, psychoses, side effect, chemically induced, emotions, affective symptoms, toxicity, behavior, behavioral symptoms, infant, child, adolescent, pediatric, paediatric, neonatal, children, teen, and teenager.",Infant,ISA,Child
24943696,"Search terms included corticosteroids, adrenal cortex hormones, steroid psychosis, substance-induced psychoses, glucocorticoids, dexamethasone, hydrocortisone, prednisone, adverse effects, mood disorders, mental disorders, psychosis, psychotic, psychoses, side effect, chemically induced, emotions, affective symptoms, toxicity, behavior, behavioral symptoms, infant, child, adolescent, pediatric, paediatric, neonatal, children, teen, and teenager.",Dexamethasone,ISA,Glucocorticoids
24943696,"Search terms included corticosteroids, adrenal cortex hormones, steroid psychosis, substance-induced psychoses, glucocorticoids, dexamethasone, hydrocortisone, prednisone, adverse effects, mood disorders, mental disorders, psychosis, psychotic, psychoses, side effect, chemically induced, emotions, affective symptoms, toxicity, behavior, behavioral symptoms, infant, child, adolescent, pediatric, paediatric, neonatal, children, teen, and teenager.",Mood Disorders,ISA,Mental disorders
24943696,"Search terms included corticosteroids, adrenal cortex hormones, steroid psychosis, substance-induced psychoses, glucocorticoids, dexamethasone, hydrocortisone, prednisone, adverse effects, mood disorders, mental disorders, psychosis, psychotic, psychoses, side effect, chemically induced, emotions, affective symptoms, toxicity, behavior, behavioral symptoms, infant, child, adolescent, pediatric, paediatric, neonatal, children, teen, and teenager.",Psychotic Disorders,ISA,Mental disorders
25089609,"Children with hematologic malignancies may be challenged with life-threatening, invasive fungal infections by organisms that would otherwise have a low potential for virulence in healthy hosts.",Hematologic Neoplasms,PROCESS_OF,Child
25089609,"Children with hematologic malignancies may be challenged with life-threatening, invasive fungal infections by organisms that would otherwise have a low potential for virulence in healthy hosts.",Mycoses,PROCESS_OF,Child
22750733,Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias.,Pharmacotherapy,TREATS,Acute leukemia
22846209,"Our aim was to estimate plasma levels of the endogenous nitric oxide formation inhibitor asymmetric dimethylarginine (ADMA), in long-term survivors of childhood acute lymphoblastic leukemia (ALL) treated with only chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22846209,"Our aim was to estimate plasma levels of the endogenous nitric oxide formation inhibitor asymmetric dimethylarginine (ADMA), in long-term survivors of childhood acute lymphoblastic leukemia (ALL) treated with only chemotherapy.",Long-Term Survivors,LOCATION_OF,Nitric Oxide
22968660,B cell acute lymphoblastic leukemia (B-ALL) is an aggressive hematologic malignancy with limited treatment strategies.,"Leukemia, B-Cell, Acute",ISA,Hematologic Neoplasms
23099236,This study aimed to assess the physical activity levels of pediatric patients with acute leukemia undergoing chemotherapy.,Acute leukemia,PROCESS_OF,Patients
23099236,This study aimed to assess the physical activity levels of pediatric patients with acute leukemia undergoing chemotherapy.,Pharmacotherapy,TREATS,Acute leukemia
23099236,Physical activity of pediatric patients with acute leukemia undergoing induction or consolidation chemotherapy.,Acute leukemia,PROCESS_OF,Patients
23099236,Physical activity of pediatric patients with acute leukemia undergoing induction or consolidation chemotherapy.,Induction,TREATS,Acute leukemia
23099236,Physical activity of pediatric patients with acute leukemia undergoing induction or consolidation chemotherapy.,Pharmacotherapy,TREATS,Acute leukemia
23215773,"CONCLUSIONS: Symptomatic cavernous malformations of the brain may develop several years after chemotherapy and cranial radiation treatment for ALL, and the clinical course of these cavernous malformations may be more aggressive than that of the typical post-radiation lesions seen in other conditions.",Brain,LOCATION_OF,Congenital Abnormality
23215773,"CONCLUSIONS: Symptomatic cavernous malformations of the brain may develop several years after chemotherapy and cranial radiation treatment for ALL, and the clinical course of these cavernous malformations may be more aggressive than that of the typical post-radiation lesions seen in other conditions.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
23215773,"CONCLUSIONS: Symptomatic cavernous malformations of the brain may develop several years after chemotherapy and cranial radiation treatment for ALL, and the clinical course of these cavernous malformations may be more aggressive than that of the typical post-radiation lesions seen in other conditions.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23346799,"In case of lymphoma the biopsy for histopathologic and immunohistochemical evaluation is essential, allowing for diagnosis and appropriate chemotherapy, as far as there is different outline for the treatment of different lymphomas.",Pharmacotherapy,TREATS,Lymphoma
23346799,"In case of lymphoma the biopsy for histopathologic and immunohistochemical evaluation is essential, allowing for diagnosis and appropriate chemotherapy, as far as there is different outline for the treatment of different lymphomas.",Diagnosis,USES,Biopsy
23346799,"In case of lymphoma the biopsy for histopathologic and immunohistochemical evaluation is essential, allowing for diagnosis and appropriate chemotherapy, as far as there is different outline for the treatment of different lymphomas.",Pharmacotherapy,ISA,Therapeutic procedure
23399031,"RESULTS: We demonstrate the validity of the proposed method with simulations, and we illustrate its application to data from an observational study for the comparison of bone marrow transplantation and chemotherapy in the treatment of paediatric leukaemia.",Bone Marrow Transplantation,TREATS,leukemia
23399031,"RESULTS: We demonstrate the validity of the proposed method with simulations, and we illustrate its application to data from an observational study for the comparison of bone marrow transplantation and chemotherapy in the treatment of paediatric leukaemia.",Bone Marrow Transplantation,compared_with,Pharmacotherapy
23399031,"RESULTS: We demonstrate the validity of the proposed method with simulations, and we illustrate its application to data from an observational study for the comparison of bone marrow transplantation and chemotherapy in the treatment of paediatric leukaemia.",Pharmacotherapy,TREATS,leukemia
23578365,BACKGROUND: T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematologic malignancy.,Acute T Cell Leukemia,ISA,Hematologic Neoplasms
23781355,We report a 9-year-old boy with acute lymphoblastic leukemia (ALL) in high-risk group who suffered from left sided focal seizures and ipsilateral hemiparesis during his induction with Asparaginase chemotherapy.,Hemiparesis,PROCESS_OF,high-risk group
23781355,We report a 9-year-old boy with acute lymphoblastic leukemia (ALL) in high-risk group who suffered from left sided focal seizures and ipsilateral hemiparesis during his induction with Asparaginase chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,high-risk group
23781355,We report a 9-year-old boy with acute lymphoblastic leukemia (ALL) in high-risk group who suffered from left sided focal seizures and ipsilateral hemiparesis during his induction with Asparaginase chemotherapy.,Pharmacotherapy,USES,ASPARAGINASE
23781355,We report a 9-year-old boy with acute lymphoblastic leukemia (ALL) in high-risk group who suffered from left sided focal seizures and ipsilateral hemiparesis during his induction with Asparaginase chemotherapy.,ASPARAGINASE,ISA,Pharmacotherapy
23781355,"At one-year followup, he had complete response to chemotherapy for ALL, with residual mild left hemiparesis, and his MRI scans revealed recanalized venous sinuses.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23781355,We report a 9-year-old boy with acute lymphoblastic leukemia (ALL) in high-risk group who suffered from left sided focal seizures and ipsilateral hemiparesis during his induction with Asparaginase chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Boys
23781355,We report a 9-year-old boy with acute lymphoblastic leukemia (ALL) in high-risk group who suffered from left sided focal seizures and ipsilateral hemiparesis during his induction with Asparaginase chemotherapy.,"Seizures, Focal",PROCESS_OF,high-risk group
23970381,Excavation adjacent to Children's Medical Center Dallas (CMCD) April 2006-February 2007 provided an opportunity to determine if excavation adjacent to a hospital building is associated with increased risk of developing HAEMI in children receiving intensive chemotherapy for acute leukemia.,Pharmacotherapy,TREATS,Acute leukemia
23970381,Excavation adjacent to Children's Medical Center Dallas (CMCD) April 2006-February 2007 provided an opportunity to determine if excavation adjacent to a hospital building is associated with increased risk of developing HAEMI in children receiving intensive chemotherapy for acute leukemia.,Infection,PROCESS_OF,Child
23970381,Excavation adjacent to Children's Medical Center Dallas (CMCD) April 2006-February 2007 provided an opportunity to determine if excavation adjacent to a hospital building is associated with increased risk of developing HAEMI in children receiving intensive chemotherapy for acute leukemia.,Pharmacotherapy,ADMINISTERED_TO,Child
23970381,METHODS: Children who began receiving intensive chemotherapy for acute leukemia at CMCD from 2004 to 2008 were identified (n = 275).,Pharmacotherapy,ADMINISTERED_TO,Child
23970381,METHODS: Children who began receiving intensive chemotherapy for acute leukemia at CMCD from 2004 to 2008 were identified (n = 275).,Pharmacotherapy,TREATS,Acute leukemia
24568907,CONCLUSIONS: Huangqi injection may reduce bone marrow suppression caused by chemotherapy drugs and increase neutrophil count during remission induction chemotherapy to reduce the incidence and duration of infection in children with ALL.,Pharmaceutical Preparations,CAUSES,bone marrow suppression
24568907,CONCLUSIONS: Huangqi injection may reduce bone marrow suppression caused by chemotherapy drugs and increase neutrophil count during remission induction chemotherapy to reduce the incidence and duration of infection in children with ALL.,Injection procedure,PREVENTS,bone marrow suppression
24568907,CONCLUSIONS: Huangqi injection may reduce bone marrow suppression caused by chemotherapy drugs and increase neutrophil count during remission induction chemotherapy to reduce the incidence and duration of infection in children with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24568907,CONCLUSIONS: Huangqi injection may reduce bone marrow suppression caused by chemotherapy drugs and increase neutrophil count during remission induction chemotherapy to reduce the incidence and duration of infection in children with ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24568907,CONCLUSIONS: Huangqi injection may reduce bone marrow suppression caused by chemotherapy drugs and increase neutrophil count during remission induction chemotherapy to reduce the incidence and duration of infection in children with ALL.,Pharmacotherapy,TREATS,Child
24727815,Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24949228,"In the pediatric population, B-acute lymphoblastic leukemia (B-ALL) is the most prevalent childhood hematological malignancy, as well as the leading cause of childhood cancer-related mortality.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
25011520,Determinants of quality of life during induction therapy in pediatric acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25254091,Acute lymphoblastic leukemia (ALL) is one of the most prevalent hematologic malignancies in children.,Hematologic Neoplasms,PROCESS_OF,Child
25254091,Acute lymphoblastic leukemia (ALL) is one of the most prevalent hematologic malignancies in children.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
25254091,Acute lymphoblastic leukemia (ALL) is one of the most prevalent hematologic malignancies in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25332578,We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL.,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
25332578,We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL.,imatinib,TREATS,"Leukemia, Lymphocytic, Acute, L2"
25332578,We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
25332578,We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL.,imatinib,TREATS,Patients
25332578,We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL.,Pharmacotherapy,TREATS,Patients
22421815,BACKGROUND: The backbone of drug therapy used in acute lymphoblastic leukemia (ALL) in children includes 6-mercaptopurine (6-MP).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
22421815,BACKGROUND: The backbone of drug therapy used in acute lymphoblastic leukemia (ALL) in children includes 6-mercaptopurine (6-MP).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22564489,Here we have evaluated the relationship between linear bone growth during chemotherapy for ALL and bone derived C-type Natriuretic Peptide (CNP).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22564489,"Impaired bone growth and mineralization, and osteonecrosis are significant and common long-term sequelae of chemotherapy for childhood acute lymphoblastic leukemia (ALL).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22564489,"Impaired bone growth and mineralization, and osteonecrosis are significant and common long-term sequelae of chemotherapy for childhood acute lymphoblastic leukemia (ALL).","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
22728556,L-asp is currently used for treatment of a wide range of hematological malignancies such as ALL and NK/T-cell lymphoma.,ASPARAGINASE,TREATS,T-Cell Lymphoma
22728556,L-asp is currently used for treatment of a wide range of hematological malignancies such as ALL and NK/T-cell lymphoma.,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
22728556,[Fulminant hepatitis possibly caused by L-asparaginase during induction chemotherapy in a patient with acute lymphoblastic leukemia].,ASPARAGINASE,CAUSES,Hepatitis fulminant
22728556,L-asp is currently used for treatment of a wide range of hematological malignancies such as ALL and NK/T-cell lymphoma.,ASPARAGINASE,TREATS,Hematologic Neoplasms
22728556,[Fulminant hepatitis possibly caused by L-asparaginase during induction chemotherapy in a patient with acute lymphoblastic leukemia].,Pharmacotherapy,TREATS,Patients
22728556,L-asp is currently used for treatment of a wide range of hematological malignancies such as ALL and NK/T-cell lymphoma.,T-Cell Lymphoma,ISA,Hematologic Neoplasms
22728556,[Fulminant hepatitis possibly caused by L-asparaginase during induction chemotherapy in a patient with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
22728556,L-asp is currently used for treatment of a wide range of hematological malignancies such as ALL and NK/T-cell lymphoma.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
22728556,[Fulminant hepatitis possibly caused by L-asparaginase during induction chemotherapy in a patient with acute lymphoblastic leukemia].,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22728556,L-asp is currently used for treatment of a wide range of hematological malignancies such as ALL and NK/T-cell lymphoma.,ASPARAGINASE,ISA,Therapeutic procedure
23650422,CONCLUSION: These results are consistent with our previous report of association between attention problems and MS in an independent cohort of long-term survivors of childhood ALL treated with chemotherapy only.,cohort,LOCATION_OF,5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
23650422,CONCLUSION: These results are consistent with our previous report of association between attention problems and MS in an independent cohort of long-term survivors of childhood ALL treated with chemotherapy only.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23826578,BACKGROUND: Reduced bone mineral density (BMD) is a significant sequelae in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23826578,This study evaluated the safety and efficacy of pamidronate in children with low BMD during and after chemotherapy for ALL and NHL.,amidronate,TREATS,"Leukemia, Lymphocytic, Acute"
23826578,Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma.,amidronate,TREATS,Child
23826578,Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma.,Pharmacotherapy,TREATS,Child
23826578,BACKGROUND: Reduced bone mineral density (BMD) is a significant sequelae in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).,Sequela of disorder,PROCESS_OF,Child
23826578,This study evaluated the safety and efficacy of pamidronate in children with low BMD during and after chemotherapy for ALL and NHL.,Pharmacotherapy,TREATS,"Lymphoma, Non-Hodgkin's"
23826578,BACKGROUND: Reduced bone mineral density (BMD) is a significant sequelae in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).,Pharmacotherapy,ADMINISTERED_TO,Child
23826578,This study evaluated the safety and efficacy of pamidronate in children with low BMD during and after chemotherapy for ALL and NHL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23826578,Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma.,amidronate,TREATS,"Lymphoma, Non-Hodgkin's"
23826578,This study evaluated the safety and efficacy of pamidronate in children with low BMD during and after chemotherapy for ALL and NHL.,amidronate,TREATS,Child
23826578,Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma.,amidronate,TREATS,"Leukemia, Lymphocytic, Acute"
23826578,This study evaluated the safety and efficacy of pamidronate in children with low BMD during and after chemotherapy for ALL and NHL.,Pharmacotherapy,TREATS,Child
23826578,Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma.,Pharmacotherapy,TREATS,"Lymphoma, Non-Hodgkin's"
23826578,BACKGROUND: Reduced bone mineral density (BMD) is a significant sequelae in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).,Pharmacotherapy,TREATS,"Lymphoma, Non-Hodgkin's"
23826578,This study evaluated the safety and efficacy of pamidronate in children with low BMD during and after chemotherapy for ALL and NHL.,amidronate,TREATS,"Lymphoma, Non-Hodgkin's"
23826578,Efficacy of pamidronate in children with low bone mineral density during and after chemotherapy for acute lymphoblastic leukemia and non-Hodgkin lymphoma.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23990388,Present work was carried out to study emotional and behavioral problems in children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy.,Emotional,PROCESS_OF,Child
23990388,Present work was carried out to study emotional and behavioral problems in children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
23990388,Present work was carried out to study emotional and behavioral problems in children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23990388,Psychological morbidity in children undergoing chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23990388,Psychological morbidity in children undergoing chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Child
23998579,CALLG2008 Protocol is sequential chemotherapy for adult acute lymphoblastic leukemia (ALL) established by Collaborative Group of adults acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
24083543,"To date, there are no clinical practice exercise guidelines for patients with acute leukemia undergoing induction and consolidation chemotherapy.",Acute leukemia,PROCESS_OF,Patients
24083543,"To date, there are no clinical practice exercise guidelines for patients with acute leukemia undergoing induction and consolidation chemotherapy.",Induction,TREATS,Acute leukemia
24083543,"To date, there are no clinical practice exercise guidelines for patients with acute leukemia undergoing induction and consolidation chemotherapy.",Pharmacotherapy,TREATS,Acute leukemia
24344215,Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
24842350,A 39-year-old man received chemotherapy for Philadelphia-negative B cell ALL.,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
25030829,Sodium Bicarbonate Solution versus Chlorhexidine Mouthwash in Oral Care of Acute Leukemia Patients Undergoing Induction Chemotherapy: A Randomized Controlled Trial.,Acute leukemia,PROCESS_OF,Patients
25030829,Sodium Bicarbonate Solution versus Chlorhexidine Mouthwash in Oral Care of Acute Leukemia Patients Undergoing Induction Chemotherapy: A Randomized Controlled Trial.,Pharmacotherapy,TREATS,Acute leukemia
25030829,"CONCLUSION: As a result of this study, it was found that oral care by SB solution for acute leukemia patients undergoing chemotherapy was an effective intervention to improve oral health.",Pharmacotherapy,TREATS,Patients
25030829,"CONCLUSION: As a result of this study, it was found that oral care by SB solution for acute leukemia patients undergoing chemotherapy was an effective intervention to improve oral health.",Acute leukemia,PROCESS_OF,Patients
25030829,"CONCLUSION: As a result of this study, it was found that oral care by SB solution for acute leukemia patients undergoing chemotherapy was an effective intervention to improve oral health.",Pharmacotherapy,TREATS,Acute leukemia
25030829,Sodium Bicarbonate Solution versus Chlorhexidine Mouthwash in Oral Care of Acute Leukemia Patients Undergoing Induction Chemotherapy: A Randomized Controlled Trial.,Pharmacotherapy,TREATS,Patients
22346368,Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22346368,Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
22346368,Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Patients
22846425,"Treatment-related toxicity can be life-threatening and is the primary cause of interruption or discontinuation of chemotherapy for acute lymphoblastic leukemia (ALL), leading to an increased risk of relapse.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22928913,"METHODS: Resting state eyes-closed magnetoencephalography (MEG) recordings were obtained from 14 ALL survivors treated with CT + CRT, 18 treated with CT alone and 35 controls.",Pharmacotherapy,TREATS,Survivors
22928913,"METHODS: Resting state eyes-closed magnetoencephalography (MEG) recordings were obtained from 14 ALL survivors treated with CT + CRT, 18 treated with CT alone and 35 controls.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
22928913,"METHODS: Resting state eyes-closed magnetoencephalography (MEG) recordings were obtained from 14 ALL survivors treated with CT + CRT, 18 treated with CT alone and 35 controls.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22992064,"Further studies have confirmed activity of dasatinib as a single-agent, and combined with chemotherapy, for the treatment of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+-ALL).",Pharmacotherapy,TREATS,Patients
22992064,"Further studies have confirmed activity of dasatinib as a single-agent, and combined with chemotherapy, for the treatment of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+-ALL).","Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
22992064,"Further studies have confirmed activity of dasatinib as a single-agent, and combined with chemotherapy, for the treatment of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+-ALL).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
23006521,"Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010.",Antimicrobial susceptibility,PROCESS_OF,Adult
23006521,"Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010.",Hematologic Neoplasms,PROCESS_OF,Adult
23006521,"Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010.",Candidemia,PROCESS_OF,Adult
23071661,Findings from this study suggest that folinic acid supplementation during chronic methotrexate treatment can alleviate growth plate and metaphyseal damages and therefore may be potentially useful in paediatric patients who are at risk of skeletal growth suppression due to chronic methotrexate chemotherapy.,Methotrexate,ISA,Pharmacotherapy
23071661,Findings from this study suggest that folinic acid supplementation during chronic methotrexate treatment can alleviate growth plate and metaphyseal damages and therefore may be potentially useful in paediatric patients who are at risk of skeletal growth suppression due to chronic methotrexate chemotherapy.,Methotrexate,CAUSES,Growth retardation
23071661,Findings from this study suggest that folinic acid supplementation during chronic methotrexate treatment can alleviate growth plate and metaphyseal damages and therefore may be potentially useful in paediatric patients who are at risk of skeletal growth suppression due to chronic methotrexate chemotherapy.,Pharmacotherapy,USES,Methotrexate
23071661,Findings from this study suggest that folinic acid supplementation during chronic methotrexate treatment can alleviate growth plate and metaphyseal damages and therefore may be potentially useful in paediatric patients who are at risk of skeletal growth suppression due to chronic methotrexate chemotherapy.,METHOTREXATE TREATMENT,TREATS,Patients
23071661,Findings from this study suggest that folinic acid supplementation during chronic methotrexate treatment can alleviate growth plate and metaphyseal damages and therefore may be potentially useful in paediatric patients who are at risk of skeletal growth suppression due to chronic methotrexate chemotherapy.,Pharmacotherapy,CAUSES,Growth retardation
23071661,Findings from this study suggest that folinic acid supplementation during chronic methotrexate treatment can alleviate growth plate and metaphyseal damages and therefore may be potentially useful in paediatric patients who are at risk of skeletal growth suppression due to chronic methotrexate chemotherapy.,Supplementation,USES,Leucovorin
23145966,Continuous glucose monitoring: a valuable monitoring tool for management of hypoglycemia during chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23145966,Continuous glucose monitoring: a valuable monitoring tool for management of hypoglycemia during chemotherapy for acute lymphoblastic leukemia.,Management procedure,COEXISTS_WITH,Pharmacotherapy
23294096,"Therefore, the bone marrow microenvironment is a mediator of chemotherapy resistance in MLL-R ALL and targeting leukaemia-stroma interactions with CXCR4 inhibitors may prove useful in this high-risk subtype of paediatric ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23502765,These observations have potential implications for the design of immunotherapy treatment approaches for hematological malignancies and tumors based on the adoption of CAR effector cells.,Immunotherapy,ISA,Therapeutic procedure
23502765,These observations have potential implications for the design of immunotherapy treatment approaches for hematological malignancies and tumors based on the adoption of CAR effector cells.,Immunotherapy,TREATS,Hematologic Neoplasms
23502765,These observations have potential implications for the design of immunotherapy treatment approaches for hematological malignancies and tumors based on the adoption of CAR effector cells.,Immunotherapy,TREATS,Neoplasm
23502765,These observations have potential implications for the design of immunotherapy treatment approaches for hematological malignancies and tumors based on the adoption of CAR effector cells.,Therapeutic procedure,TREATS,Hematologic Neoplasms
23502765,These observations have potential implications for the design of immunotherapy treatment approaches for hematological malignancies and tumors based on the adoption of CAR effector cells.,Therapeutic procedure,TREATS,Neoplasm
23826578,CONCLUSION: Pamidronate appears to be safe and effective for the treatment of children with low BMD during and after chemotherapy for ALL and NHL.,Therapeutic procedure,TREATS,"Lymphoma, Non-Hodgkin's"
23826578,CONCLUSION: Pamidronate appears to be safe and effective for the treatment of children with low BMD during and after chemotherapy for ALL and NHL.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
23826578,CONCLUSION: Pamidronate appears to be safe and effective for the treatment of children with low BMD during and after chemotherapy for ALL and NHL.,Pharmacotherapy,TREATS,"Lymphoma, Non-Hodgkin's"
23826578,CONCLUSION: Pamidronate appears to be safe and effective for the treatment of children with low BMD during and after chemotherapy for ALL and NHL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
23826578,CONCLUSION: Pamidronate appears to be safe and effective for the treatment of children with low BMD during and after chemotherapy for ALL and NHL.,amidronate,TREATS,Child
24078372,We sought to compare directly the outcome of URD allo-HSCT and chemotherapy in patients with high-risk ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24078372,The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission.,Pharmacotherapy,TREATS,Patients
24078372,The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24078372,The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24078372,We sought to compare directly the outcome of URD allo-HSCT and chemotherapy in patients with high-risk ALL.,Pharmacotherapy,TREATS,Patients
24078372,We sought to compare directly the outcome of URD allo-HSCT and chemotherapy in patients with high-risk ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24267134,"OBJECTIVE: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, while glucocorticoid (GC) is a critical component in multi-agent chemotherapy protocols currently used for the treatment of ALL.",Glucocorticoids,ISA,Chemotherapy-Oncologic Procedure
24267134,"OBJECTIVE: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, while glucocorticoid (GC) is a critical component in multi-agent chemotherapy protocols currently used for the treatment of ALL.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
24267134,"OBJECTIVE: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, while glucocorticoid (GC) is a critical component in multi-agent chemotherapy protocols currently used for the treatment of ALL.",Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
24289042,"Patients were monitored for infection from initiation of AML treatment until recovery from the last cycle of chemotherapy, conditioning for hematopoietic stem cell transplantation, relapse, persistent disease or death (whichever occurred first).",Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
24878082,We analyzed the weekly results of nasal cultures and peripheral blood cultures in patients with leukemia undergoing chemotherapy.,leukemia,PROCESS_OF,Patients
24878082,We analyzed the weekly results of nasal cultures and peripheral blood cultures in patients with leukemia undergoing chemotherapy.,Pharmacotherapy,TREATS,leukemia
25132549,"T-cell acute lymphoblastic leukaemia (T-ALL) is a haematological malignancy with a dismal overall prognosis, including a relapse rate of up to 25%, mainly because of the lack of non-cytotoxic targeted therapy options.",Acute T Cell Leukemia,ISA,Hematologic Neoplasms
25222303,Children with hematologic malignancies are at an increased risk of invasive fungal infections and a greater risk has been seen with exposure to building construction.,Hematologic Neoplasms,PROCESS_OF,Child
25225619,CASE DESCRIPTION: We report the use of a stop-flow programmable shunt valve to maximize delivery of intraventricular chemotherapy in a child with acute lymphoblastic leukemia and disseminated intravascular coagulation who presented with spontaneous intracerebral and intraventricular hemorrhages.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25225619,CASE DESCRIPTION: We report the use of a stop-flow programmable shunt valve to maximize delivery of intraventricular chemotherapy in a child with acute lymphoblastic leukemia and disseminated intravascular coagulation who presented with spontaneous intracerebral and intraventricular hemorrhages.,Pharmacotherapy,TREATS,Disseminated Intravascular Coagulation
25225619,CASE DESCRIPTION: We report the use of a stop-flow programmable shunt valve to maximize delivery of intraventricular chemotherapy in a child with acute lymphoblastic leukemia and disseminated intravascular coagulation who presented with spontaneous intracerebral and intraventricular hemorrhages.,Pharmacotherapy,TREATS,Child
25225619,CASE DESCRIPTION: We report the use of a stop-flow programmable shunt valve to maximize delivery of intraventricular chemotherapy in a child with acute lymphoblastic leukemia and disseminated intravascular coagulation who presented with spontaneous intracerebral and intraventricular hemorrhages.,Ventricular hemorrhage,PROCESS_OF,Child
25225619,CASE DESCRIPTION: We report the use of a stop-flow programmable shunt valve to maximize delivery of intraventricular chemotherapy in a child with acute lymphoblastic leukemia and disseminated intravascular coagulation who presented with spontaneous intracerebral and intraventricular hemorrhages.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25225619,CASE DESCRIPTION: We report the use of a stop-flow programmable shunt valve to maximize delivery of intraventricular chemotherapy in a child with acute lymphoblastic leukemia and disseminated intravascular coagulation who presented with spontaneous intracerebral and intraventricular hemorrhages.,Disseminated Intravascular Coagulation,PROCESS_OF,Child
25225619,CASE DESCRIPTION: We report the use of a stop-flow programmable shunt valve to maximize delivery of intraventricular chemotherapy in a child with acute lymphoblastic leukemia and disseminated intravascular coagulation who presented with spontaneous intracerebral and intraventricular hemorrhages.,Pharmacotherapy,TREATS,Ventricular hemorrhage
25422204,Wilms' tumor gene (WT1) expression correlates with vascular epithelial growth factor (VEGF) in newly acute leukemia patients undergoing chemotherapy.,Acute leukemia,PROCESS_OF,Patients
25422204,Wilms' tumor gene (WT1) expression correlates with vascular epithelial growth factor (VEGF) in newly acute leukemia patients undergoing chemotherapy.,Pharmacotherapy,TREATS,Acute leukemia
25422204,Wilms' tumor gene (WT1) expression correlates with vascular epithelial growth factor (VEGF) in newly acute leukemia patients undergoing chemotherapy.,"Genes, Wilms Tumor",COEXISTS_WITH,vascular factor
25422204,Wilms' tumor gene (WT1) expression correlates with vascular epithelial growth factor (VEGF) in newly acute leukemia patients undergoing chemotherapy.,Patients,LOCATION_OF,vascular factor
25422204,Wilms' tumor gene (WT1) expression correlates with vascular epithelial growth factor (VEGF) in newly acute leukemia patients undergoing chemotherapy.,Pharmacotherapy,TREATS,Patients
22542578,"Childhood acute lymphoblastic leukemia (ALL) is treated with combined chemotherapy, including L-asparaginase (L-asp).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
22659796,Our data suggest that the choice of anti-diabetic pharmacotherapy during chemotherapy may influence clinical outcomes in ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22739263,Glucocorticoid (GC) steroid hormones are used to treat acute lymphoblastic leukemia (ALL) because of their pro-apoptotic effects in hematopoietic cells.,Steroid hormone,TREATS,"Leukemia, Lymphocytic, Acute"
22739263,Glucocorticoid (GC) steroid hormones are used to treat acute lymphoblastic leukemia (ALL) because of their pro-apoptotic effects in hematopoietic cells.,Glucocorticoids,ISA,Steroid hormone
22739263,Glucocorticoid (GC) steroid hormones are used to treat acute lymphoblastic leukemia (ALL) because of their pro-apoptotic effects in hematopoietic cells.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
22785211,Overcoming resistance to chemotherapy is the main therapeutic challenge in the treatment of acute lymphocytic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22785211,Overcoming resistance to chemotherapy is the main therapeutic challenge in the treatment of acute lymphocytic leukemia (ALL).,Pharmacotherapy,ISA,Therapeutic procedure
22829187,"Finally, Dex killed RS4;11 cells significantly more efficiently when cultured in lower glucose concentrations suggesting that modulation of glucose levels might influence the effectiveness of GC treatment in ALL.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
22829187,"Finally, Dex killed RS4;11 cells significantly more efficiently when cultured in lower glucose concentrations suggesting that modulation of glucose levels might influence the effectiveness of GC treatment in ALL.",Glucocorticoids,ISA,Therapeutic procedure
22829187,"Using liquid chromatography and mass spectrometry, we found that treatment of acute lymphoblastic leukemia (ALL) cells with the glucocorticoid (GC) dexamethasone (Dex) resulted in profound inhibition of glycolysis.",Dexamethasone,PART_OF,Cells
22829187,"Using liquid chromatography and mass spectrometry, we found that treatment of acute lymphoblastic leukemia (ALL) cells with the glucocorticoid (GC) dexamethasone (Dex) resulted in profound inhibition of glycolysis.",Dexamethasone,ISA,Glucocorticoids
23047478,"As key determinants of normal B-cell development, B-lineage transcription factors are frequently deregulated in hematological malignancies, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), and affected by either chromosomal translocations, gene deletions or point mutations.",TRANSCRIPTION FACTOR,ASSOCIATED_WITH,"Leukemia, B-Cell, Acute"
23047478,"As key determinants of normal B-cell development, B-lineage transcription factors are frequently deregulated in hematological malignancies, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), and affected by either chromosomal translocations, gene deletions or point mutations.","Leukemia, B-Cell, Acute",ISA,Hematologic Neoplasms
23047478,"As key determinants of normal B-cell development, B-lineage transcription factors are frequently deregulated in hematological malignancies, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), and affected by either chromosomal translocations, gene deletions or point mutations.",Chromosomal translocation,AFFECTS,"Leukemia, B-Cell, Acute"
23047478,"As key determinants of normal B-cell development, B-lineage transcription factors are frequently deregulated in hematological malignancies, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), and affected by either chromosomal translocations, gene deletions or point mutations.",TRANSCRIPTION FACTOR,ASSOCIATED_WITH,Hematologic Neoplasms
23227626,"This study was conducted to evaluate the response rate of induction chemotherapy in adult ALL patients in the Department of Haematology, Bangabandhu Sheikh Mujib Medical University, from January 2007 to December 2008.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
23227626,"This study was conducted to evaluate the response rate of induction chemotherapy in adult ALL patients in the Department of Haematology, Bangabandhu Sheikh Mujib Medical University, from January 2007 to December 2008.",Pharmacotherapy,TREATS,Patients
23227626,"This study was conducted to evaluate the response rate of induction chemotherapy in adult ALL patients in the Department of Haematology, Bangabandhu Sheikh Mujib Medical University, from January 2007 to December 2008.","Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",Injection procedure,USES,vincristine sulfate liposomes
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,ISA,Injection procedure
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,TREATS,Hematologic Neoplasms
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,USES,vincristine sulfate liposomes
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,TREATS,"Leukemia, Lymphocytic, Acute"
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine sulfate liposomes,ISA,Injection procedure
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,TREATS,Hematologic Neoplasms
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",Hematologic Neoplasms,ISA,"Leukemia, Lymphocytic, Acute"
24232122,"In the last decade, however, the discovery that liposomal encapsulation of chemotherapeutics can modulate the pharmacokinetic characteristics of a compound has stimulated much interest in liposomal VCR (vincristine sulfate liposomal injection [VSLI]) formulations for the treatment of ALL and other hematological malignancies.",vincristine liposomal,TREATS,"Leukemia, Lymphocytic, Acute"
24314630,Adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) may be treated either with ongoing systemic chemotherapy or with allogeneic hematopoietic cell transplantation (alloHCT).,Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L2"
24314630,Adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) may be treated either with ongoing systemic chemotherapy or with allogeneic hematopoietic cell transplantation (alloHCT).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
24324065,BACKGROUND: One of the major causes of failure in chemotherapy for patients with acute lymphoblastic leukemia (ALL) is the acquisition of multidrug resistance (MDR).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
24324065,BACKGROUND: One of the major causes of failure in chemotherapy for patients with acute lymphoblastic leukemia (ALL) is the acquisition of multidrug resistance (MDR).,Pharmacotherapy,TREATS,Patients
24324065,BACKGROUND: One of the major causes of failure in chemotherapy for patients with acute lymphoblastic leukemia (ALL) is the acquisition of multidrug resistance (MDR).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24325331,INTRODUCTION: Acute lymphoid leukemia (ALL) is the hematologic neoplasia most commonly diagnosed in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24325331,INTRODUCTION: Acute lymphoid leukemia (ALL) is the hematologic neoplasia most commonly diagnosed in children.,Hematologic Neoplasms,PROCESS_OF,Child
24325331,INTRODUCTION: Acute lymphoid leukemia (ALL) is the hematologic neoplasia most commonly diagnosed in children.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
24490021,"Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood and other organs.",Organ,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
24490021,"Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood and other organs.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
24490021,"Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood and other organs.",Bone Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
24490021,"Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood and other organs.",Organ,LOCATION_OF,Hematologic Neoplasms
24490021,"Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood and other organs.",Bone Marrow,LOCATION_OF,Hematologic Neoplasms
25125614,This study compares neurocognitive function and brain morphology in long-term adult survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy alone (n = 36) to those treated with cranial radiation therapy (n = 39) and to healthy control subjects (n = 23).,Pharmacotherapy,compared_with,Radiation therapy
25125614,This study compares neurocognitive function and brain morphology in long-term adult survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy alone (n = 36) to those treated with cranial radiation therapy (n = 39) and to healthy control subjects (n = 23).,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25125614,This study compares neurocognitive function and brain morphology in long-term adult survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy alone (n = 36) to those treated with cranial radiation therapy (n = 39) and to healthy control subjects (n = 23).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25125614,This study compares neurocognitive function and brain morphology in long-term adult survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy alone (n = 36) to those treated with cranial radiation therapy (n = 39) and to healthy control subjects (n = 23).,brain morphology,PROCESS_OF,Long-Term Survivors
25196579,Conventional chemotherapy for precursor B-cell (preB) acute lymphoblastic leukaemia (ALL) has limitations that could be overcome by targeted therapy.,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
25228846,Cytomegalovirus appendicitis with concurrent bacteremia after chemotherapy for acute leukemia.,Pharmacotherapy,TREATS,Acute leukemia
25228846,Cytomegalovirus appendicitis with concurrent bacteremia after chemotherapy for acute leukemia.,Appendicitis,PROCESS_OF,Cytomegalovirus
25303299,Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.,METHOTREXATE TOXICITY,PROCESS_OF,Adult
25303299,Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.,Hematologic Neoplasms,PROCESS_OF,Adult
25349177,Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25349177,Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia.,leukemia,COEXISTS_WITH,Obesity
25628832,"The aim of this study was to evaluate the response rate and prognostic factor of adult patients suffering from acute lymphoblastic leukemia, who were treated with chemotherapy in south east of Iran and demographic methods were used for this study.",Clinical Research,METHOD_OF,Demography
25628832,"The aim of this study was to evaluate the response rate and prognostic factor of adult patients suffering from acute lymphoblastic leukemia, who were treated with chemotherapy in south east of Iran and demographic methods were used for this study.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
25628832,"The aim of this study was to evaluate the response rate and prognostic factor of adult patients suffering from acute lymphoblastic leukemia, who were treated with chemotherapy in south east of Iran and demographic methods were used for this study.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
22818128,"OBJECTIVE: Invasive rhinocerebral fungal infections are a difficult and often fatal problem in children with hematologic malignancies, with increasing reports of rare pathogens.",Mycoses,PROCESS_OF,Child
22818128,"OBJECTIVE: Invasive rhinocerebral fungal infections are a difficult and often fatal problem in children with hematologic malignancies, with increasing reports of rare pathogens.",Hematologic Neoplasms,PROCESS_OF,Child
22845486,Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.,Hematologic Neoplasms,PROCESS_OF,Child
23165481,"Hematopoietic cell transplantation (HCT) and prolonged chemotherapy are standard postremission strategies for adult acute lymphoblastic leukemia in first complete remission, but the optimal strategy remains controversial.",Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L2"
23165481,"Hematopoietic cell transplantation (HCT) and prolonged chemotherapy are standard postremission strategies for adult acute lymphoblastic leukemia in first complete remission, but the optimal strategy remains controversial.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
23182707,"AIM: To assess markers of inflammatory activity, endothelial activation as well as monocyte heterogeneity in adult survivors of childhood acute lymphoblastic leukemia (ALL) who had been treated with chemotherapy without cranial irradiation.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
23307552,"Seven days after induction therapy for acute lymphoblastic leukemia, he was brought to the emergency department because of left eyelid swelling and was admitted to the hospital.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
23754844,"Because chemotherapy is the mainstay of AML treatment, it was hypothesized that standard cytotoxic chemotherapeutic agents induce dynamic changes in leukemia surface CXCR4 expression, and that chemotherapy-induced upregulation of CXCR4 represents a mechanism of acquired therapeutic resistance.",Antineoplastic Agents,COEXISTS_WITH,CXCR4 gene | CXCR4
23754844,"Because chemotherapy is the mainstay of AML treatment, it was hypothesized that standard cytotoxic chemotherapeutic agents induce dynamic changes in leukemia surface CXCR4 expression, and that chemotherapy-induced upregulation of CXCR4 represents a mechanism of acquired therapeutic resistance.",Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
23754844,"Because chemotherapy is the mainstay of AML treatment, it was hypothesized that standard cytotoxic chemotherapeutic agents induce dynamic changes in leukemia surface CXCR4 expression, and that chemotherapy-induced upregulation of CXCR4 represents a mechanism of acquired therapeutic resistance.",Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
23754844,"Because chemotherapy is the mainstay of AML treatment, it was hypothesized that standard cytotoxic chemotherapeutic agents induce dynamic changes in leukemia surface CXCR4 expression, and that chemotherapy-induced upregulation of CXCR4 represents a mechanism of acquired therapeutic resistance.",Pharmacotherapy,ISA,Therapeutic procedure
23754844,"Because chemotherapy is the mainstay of AML treatment, it was hypothesized that standard cytotoxic chemotherapeutic agents induce dynamic changes in leukemia surface CXCR4 expression, and that chemotherapy-induced upregulation of CXCR4 represents a mechanism of acquired therapeutic resistance.",Pharmacotherapy,ISA,Therapeutic procedure
24324529,"We conducted a retrospective audit of six patients with various haematological malignancies (two acute lymphoblastic leukaemia, one acute myeloid leukaemia, and three non-Hodgkin lymphoma); these patients were eligible to receive rasburicase, being at high risk of development of tumour lysis syndrome (TLS).",Hematologic Neoplasms,PROCESS_OF,Patients
24324529,"We conducted a retrospective audit of six patients with various haematological malignancies (two acute lymphoblastic leukaemia, one acute myeloid leukaemia, and three non-Hodgkin lymphoma); these patients were eligible to receive rasburicase, being at high risk of development of tumour lysis syndrome (TLS).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24324529,"We conducted a retrospective audit of six patients with various haematological malignancies (two acute lymphoblastic leukaemia, one acute myeloid leukaemia, and three non-Hodgkin lymphoma); these patients were eligible to receive rasburicase, being at high risk of development of tumour lysis syndrome (TLS).",Rasburicase,ADMINISTERED_TO,Patients
24324529,"We conducted a retrospective audit of six patients with various haematological malignancies (two acute lymphoblastic leukaemia, one acute myeloid leukaemia, and three non-Hodgkin lymphoma); these patients were eligible to receive rasburicase, being at high risk of development of tumour lysis syndrome (TLS).","Lymphoma, Non-Hodgkin's",ISA,Hematologic Neoplasms
24324529,"We conducted a retrospective audit of six patients with various haematological malignancies (two acute lymphoblastic leukaemia, one acute myeloid leukaemia, and three non-Hodgkin lymphoma); these patients were eligible to receive rasburicase, being at high risk of development of tumour lysis syndrome (TLS).","Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
24324529,"We conducted a retrospective audit of six patients with various haematological malignancies (two acute lymphoblastic leukaemia, one acute myeloid leukaemia, and three non-Hodgkin lymphoma); these patients were eligible to receive rasburicase, being at high risk of development of tumour lysis syndrome (TLS).","Leukemia, Myelocytic, Acute",ISA,Hematologic Neoplasms
24324529,"We conducted a retrospective audit of six patients with various haematological malignancies (two acute lymphoblastic leukaemia, one acute myeloid leukaemia, and three non-Hodgkin lymphoma); these patients were eligible to receive rasburicase, being at high risk of development of tumour lysis syndrome (TLS).","Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
24324529,"We conducted a retrospective audit of six patients with various haematological malignancies (two acute lymphoblastic leukaemia, one acute myeloid leukaemia, and three non-Hodgkin lymphoma); these patients were eligible to receive rasburicase, being at high risk of development of tumour lysis syndrome (TLS).","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
24443846,High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden.,Acute T Cell Leukemia,PROCESS_OF,Adult
24443846,High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden.,Pharmacotherapy,TREATS,Adult
24443846,High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden.,Pharmacotherapy,TREATS,Acute T Cell Leukemia
24454976,BACKGROUND: L-asparaginase (L-aspa) is an important component of chemotherapy in acute lymphoblastic leukemia (ALL).,ASPARAGINASE,ISA,Pharmacotherapy
24454976,BACKGROUND: L-asparaginase (L-aspa) is an important component of chemotherapy in acute lymphoblastic leukemia (ALL).,ASPARAGINASE,ASSOCIATED_WITH,"Leukemia, Lymphocytic, Acute"
24597985,Glucocorticoid (GC) resistance in children with acute lymphoblastic leukemia (ALL) usually resulted in the failure of treatment.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
24597985,Glucocorticoid (GC) resistance in children with acute lymphoblastic leukemia (ALL) usually resulted in the failure of treatment.,Glucocorticoids,TREATS,Child
24597985,Glucocorticoid (GC) resistance in children with acute lymphoblastic leukemia (ALL) usually resulted in the failure of treatment.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
24621157,We report a case of a Jehovah's Witness patient with acute lymphoblastic leukemia (ALL) who was successfully treated with non-myelosuppressive chemotherapy for both first and second remission and achieved complete remissions both times without transfusion of blood products.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
24621157,We report a case of a Jehovah's Witness patient with acute lymphoblastic leukemia (ALL) who was successfully treated with non-myelosuppressive chemotherapy for both first and second remission and achieved complete remissions both times without transfusion of blood products.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25047756,OBJECTIVES: To determine the behavioural impact of chemotherapy in survivors of acute lymphoblastic leukaemia (ALL) treated with chemotherapy only and to identify treatment-related or sociodemography-related factors that might be associated with behavioural outcome.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25047756,OBJECTIVES: To determine the behavioural impact of chemotherapy in survivors of acute lymphoblastic leukaemia (ALL) treated with chemotherapy only and to identify treatment-related or sociodemography-related factors that might be associated with behavioural outcome.,Pharmacotherapy,TREATS,Survivors
26850738,We aimed to extend this literature by examining the organization of the white matter connectome in young patients with a history of ALL treated with chemotherapy only.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26892073,DISCUSSION: This case report suggests that incorporating a play-based PT intervention programme could be physically tolerable and functionally beneficial for a young child with relapsed ALL undergoing inpatient chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young child
26892073,DISCUSSION: This case report suggests that incorporating a play-based PT intervention programme could be physically tolerable and functionally beneficial for a young child with relapsed ALL undergoing inpatient chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26892073,The purpose of this case report was to examine the effectiveness of incorporating a play-based physical therapy (PT) intervention programme to improve functional mobility for an inpatient with relapsed ALL undergoing chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,inpatient
26892073,The purpose of this case report was to examine the effectiveness of incorporating a play-based physical therapy (PT) intervention programme to improve functional mobility for an inpatient with relapsed ALL undergoing chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26892479,"We sought to determine the prevalence and clinical impact of these lesions in patients on CALGB 10001, a previously reported Phase II study of imatinib, chemotherapy, and hematopoietic cell transplant in adult Ph + ALL.",imatinib,TREATS,"Leukemia, Lymphocytic, Acute, L2"
26892479,"We sought to determine the prevalence and clinical impact of these lesions in patients on CALGB 10001, a previously reported Phase II study of imatinib, chemotherapy, and hematopoietic cell transplant in adult Ph + ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
26892479,"We sought to determine the prevalence and clinical impact of these lesions in patients on CALGB 10001, a previously reported Phase II study of imatinib, chemotherapy, and hematopoietic cell transplant in adult Ph + ALL.",imatinib,AFFECTS,Lesion
26892479,"We sought to determine the prevalence and clinical impact of these lesions in patients on CALGB 10001, a previously reported Phase II study of imatinib, chemotherapy, and hematopoietic cell transplant in adult Ph + ALL.",Lesion,PROCESS_OF,Patients
26892479,"We sought to determine the prevalence and clinical impact of these lesions in patients on CALGB 10001, a previously reported Phase II study of imatinib, chemotherapy, and hematopoietic cell transplant in adult Ph + ALL.",imatinib,ISA,Pharmacotherapy
26944678,"T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous group of hematological tumors composed of distinct subtypes that vary in their genetic abnormalities, gene expression signatures, and prognoses.",Acute T Cell Leukemia,ISA,Hematologic Neoplasms
26735150,"A 26-year-old patient with a history of chemotherapy for acute lymphoblastic leukemia presented with secondary amenorrhea and cyclic abdominal pain, and she was found to have vaginal stenosis due to adhesion of vaginal wall.",Secondary physiologic amenorrhea,COEXISTS_WITH,"Leukemia, Lymphocytic, Acute"
26735150,"A 26-year-old patient with a history of chemotherapy for acute lymphoblastic leukemia presented with secondary amenorrhea and cyclic abdominal pain, and she was found to have vaginal stenosis due to adhesion of vaginal wall.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26735150,"A 26-year-old patient with a history of chemotherapy for acute lymphoblastic leukemia presented with secondary amenorrhea and cyclic abdominal pain, and she was found to have vaginal stenosis due to adhesion of vaginal wall.",Vaginal wall,LOCATION_OF,Adhesions
26792372,Median time from diagnosis to the development of ON following chemotherapy for ALL was 1.15 years (range 0.25-2.12).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26793473,"Invasive disease occurs almost exclusively in immunocompromised hosts, particularly in neutropenic adults with hematological malignancies and uncommonly in children.",Disease,COEXISTS_WITH,Immunocompromised Host
26793473,"Invasive disease occurs almost exclusively in immunocompromised hosts, particularly in neutropenic adults with hematological malignancies and uncommonly in children.",Neutropenia,PROCESS_OF,Adult
26793473,"Invasive disease occurs almost exclusively in immunocompromised hosts, particularly in neutropenic adults with hematological malignancies and uncommonly in children.",Hematologic Neoplasms,PROCESS_OF,Adult
26834952,"In the coming years larger studies will better define the place of immunotherapy in the management of acute leukemias and lead to treatment approaches that combine conventional chemotherapy, immunotherapy and HSCT to achieve durable cures.",Hemopoietic stem cell transplant,TREATS,Acute leukemia
26834952,"In the coming years larger studies will better define the place of immunotherapy in the management of acute leukemias and lead to treatment approaches that combine conventional chemotherapy, immunotherapy and HSCT to achieve durable cures.",Immunotherapy,TREATS,Acute leukemia
26834952,"In the coming years larger studies will better define the place of immunotherapy in the management of acute leukemias and lead to treatment approaches that combine conventional chemotherapy, immunotherapy and HSCT to achieve durable cures.",Pharmacotherapy,TREATS,Acute leukemia
26865705,Measurement of MRD from bone marrow at the end of induction chemotherapy (day 28) for childhood acute lymphoblastic leukaemia (ALL) can highlight a large group of patients (>40%) with an excellent (>90%) short-term event-free survival (EFS).,Bone Marrow,LOCATION_OF,"Neoplasm, Residual"
26865705,Measurement of MRD from bone marrow at the end of induction chemotherapy (day 28) for childhood acute lymphoblastic leukaemia (ALL) can highlight a large group of patients (>40%) with an excellent (>90%) short-term event-free survival (EFS).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26888258,"Induction therapy for childhood acute lymphoblastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileukemic potency, leading to fewer relapses and improved survival.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26907650,Hypercalcemia is a rare complication of hematological malignancy in children.,Hematologic Neoplasms,PROCESS_OF,Child
26907653,Central Venous Catheters and Bloodstream Infection During Induction Therapy in Children With Acute Lymphoblastic Leukemia.,Neoadjuvant Therapy,TREATS,Child
26907653,It is concluded that the type of CVC inserted at diagnosis has no impact upon the risk of BSI in patients with ALL undergoing induction therapy.,Diagnosis,TREATS,Patients
26907653,Central Venous Catheters and Bloodstream Infection During Induction Therapy in Children With Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26907653,It is concluded that the type of CVC inserted at diagnosis has no impact upon the risk of BSI in patients with ALL undergoing induction therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
26907653,Central Venous Catheters and Bloodstream Infection During Induction Therapy in Children With Acute Lymphoblastic Leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
26907653,It is concluded that the type of CVC inserted at diagnosis has no impact upon the risk of BSI in patients with ALL undergoing induction therapy.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
26907653,The purpose of the study was to assess the risk of first-time bloodstream infection (BSI) according to type of central venous catheter (CVC) during induction therapy in children with acute lymphoblastic leukemia (ALL).,Neoadjuvant Therapy,TREATS,Child
26907653,The purpose of the study was to assess the risk of first-time bloodstream infection (BSI) according to type of central venous catheter (CVC) during induction therapy in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26907653,The purpose of the study was to assess the risk of first-time bloodstream infection (BSI) according to type of central venous catheter (CVC) during induction therapy in children with acute lymphoblastic leukemia (ALL).,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
26919107,Acute lymphoblastic leukemia (ALL) is a common hematological malignancy characterized by the uncontrolled proliferation of leukemia cells in children.,Hematologic Neoplasms,PROCESS_OF,Child
26919107,Acute lymphoblastic leukemia (ALL) is a common hematological malignancy characterized by the uncontrolled proliferation of leukemia cells in children.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
26919107,Acute lymphoblastic leukemia (ALL) is a common hematological malignancy characterized by the uncontrolled proliferation of leukemia cells in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26920889,"PURPOSE: To determine a safe and biologically active dose of quizartinib (AC220), a potent and selective class III receptor tyrosine kinase (RTK) FLT3 inhibitor, in combination with salvage chemotherapy in children with relapsed acute leukemia.",Pharmacotherapy,TREATS,Child
26920889,"PURPOSE: To determine a safe and biologically active dose of quizartinib (AC220), a potent and selective class III receptor tyrosine kinase (RTK) FLT3 inhibitor, in combination with salvage chemotherapy in children with relapsed acute leukemia.",Acute leukemia,PROCESS_OF,Child
26920889,"PURPOSE: To determine a safe and biologically active dose of quizartinib (AC220), a potent and selective class III receptor tyrosine kinase (RTK) FLT3 inhibitor, in combination with salvage chemotherapy in children with relapsed acute leukemia.",Pharmacotherapy,TREATS,Acute leukemia
26937602,"METHODS: All children born between 1973 and 2006 and diagnosed with a hematological malignancy before the age of 20 years (N = 1,819) were followed until 10 years from diagnosis.",Hematologic Neoplasms,PROCESS_OF,Child
26937602,"BACKGROUND: Due to diverse findings as to the role of family factors for childhood cancer survival even within Europe, we explored a nationwide, register-based cohort of Danish children with hematological malignancies.",Hematologic Neoplasms,PROCESS_OF,Child
26951627,PATIENTS AND METHODS: We assessed the minimal residual disease (MRD)-based effect and long-term outcome of first-line incorporation of dasatinib (100 mg once daily) into chemotherapy alternatively for adults with Ph-positive ALL.,Pharmacotherapy,TREATS,Adult
26951627,PATIENTS AND METHODS: We assessed the minimal residual disease (MRD)-based effect and long-term outcome of first-line incorporation of dasatinib (100 mg once daily) into chemotherapy alternatively for adults with Ph-positive ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
26951627,PATIENTS AND METHODS: We assessed the minimal residual disease (MRD)-based effect and long-term outcome of first-line incorporation of dasatinib (100 mg once daily) into chemotherapy alternatively for adults with Ph-positive ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26951627,BACKGROUND: The use of imatinib combined with chemotherapy has demonstrated improved outcome in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL).,Pharmacotherapy,TREATS,Adult
26951627,BACKGROUND: The use of imatinib combined with chemotherapy has demonstrated improved outcome in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL).,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Adult
26951627,BACKGROUND: The use of imatinib combined with chemotherapy has demonstrated improved outcome in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
27028090,Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27078747,"Following a high incidence of thrombotic episodes during induction therapy for ALL in our tertiary referral center, we prospectively instituted a protocol of AT replacement.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
27089960,CONCLUSION: Febrile neutropaenia continues to be of concern in ALL patients undergoing intensive chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27089960,CONCLUSION: Febrile neutropaenia continues to be of concern in ALL patients undergoing intensive chemotherapy.,Febrile neutropenia,PROCESS_OF,Patients
27089960,CONCLUSION: Febrile neutropaenia continues to be of concern in ALL patients undergoing intensive chemotherapy.,Pharmacotherapy,TREATS,Patients
27089960,CONCLUSION: Febrile neutropaenia continues to be of concern in ALL patients undergoing intensive chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27089960,CONCLUSION: Febrile neutropaenia continues to be of concern in ALL patients undergoing intensive chemotherapy.,Pharmacotherapy,TREATS,Febrile neutropenia
26221511,BACKGROUND: Chemotherapy plays a very important role in the treatment of leukemia but the resistance properties of the lymphoblasts limit the effect of chemotherapy.,Pharmacotherapy,TREATS,leukemia
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Chemotherapy-Oncologic Procedure,TREATS,Late effect of
26445634,"METHODS: In a case-control study, 33 of ALL survivors who were treated with chemotherapy (Group A), and 33 subjects who were treated with chemoplus cranial radiation (Group B) were compared against 33 matched age, sex, and pubertal stage of their healthy siblings (Group C).",Pharmacotherapy,TREATS,Survivors
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Chemotherapy-Oncologic Procedure,TREATS,"Leukemia, Lymphocytic, Acute"
26445634,"METHODS: In a case-control study, 33 of ALL survivors who were treated with chemotherapy (Group A), and 33 subjects who were treated with chemoplus cranial radiation (Group B) were compared against 33 matched age, sex, and pubertal stage of their healthy siblings (Group C).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
26445634,"METHODS: In a case-control study, 33 of ALL survivors who were treated with chemotherapy (Group A), and 33 subjects who were treated with chemoplus cranial radiation (Group B) were compared against 33 matched age, sex, and pubertal stage of their healthy siblings (Group C).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Pharmacotherapy,TREATS,Late effect of
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Chemotherapy-Oncologic Procedure,TREATS,Survivors
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Pharmacotherapy,TREATS,Survivors
26445634,We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.,Late effect of,PROCESS_OF,Survivors
26738796,"To evaluate the biology underlying these functional differences, we investigated T cell expansion potential and memory phenotype during chemotherapy in pediatric patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
26738796,"To evaluate the biology underlying these functional differences, we investigated T cell expansion potential and memory phenotype during chemotherapy in pediatric patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).",Pharmacotherapy,TREATS,"Lymphoma, Non-Hodgkin's"
26738796,"To evaluate the biology underlying these functional differences, we investigated T cell expansion potential and memory phenotype during chemotherapy in pediatric patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26738796,"To evaluate the biology underlying these functional differences, we investigated T cell expansion potential and memory phenotype during chemotherapy in pediatric patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).",Pharmacotherapy,TREATS,Patients
26738796,"To evaluate the biology underlying these functional differences, we investigated T cell expansion potential and memory phenotype during chemotherapy in pediatric patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).","Lymphoma, Non-Hodgkin's",PROCESS_OF,Patients
26800008,"We evaluated 272 adult patients with ALL and abnormal cytogenetics at baseline who were treated with frontline induction chemotherapy, achieved complete remission (CR) and had cytogenetic analysis performed at the time of CR.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
26800008,"We evaluated 272 adult patients with ALL and abnormal cytogenetics at baseline who were treated with frontline induction chemotherapy, achieved complete remission (CR) and had cytogenetic analysis performed at the time of CR.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26821066,T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy that preferentially affects children and adolescents.,Acute T Cell Leukemia,AFFECTS,Child
26821066,T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy that preferentially affects children and adolescents.,Hematologic Neoplasms,AFFECTS,Adolescent
26821066,T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy that preferentially affects children and adolescents.,Hematologic Neoplasms,AFFECTS,Child
26821066,T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy that preferentially affects children and adolescents.,Acute T Cell Leukemia,ISA,Hematologic Neoplasms
26821066,T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy that preferentially affects children and adolescents.,Acute T Cell Leukemia,AFFECTS,Adolescent
26851412,"While cumulative doses of osteotoxic chemotherapy for ALL have been reported to adversely impact bone density, the timing of onset of this effect as well as other changes to bone structure is not well characterized.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26914084,"The greater numbers of venous thromboembolism (VTE) are complications of underlying risk factors such as malignancies, chemotherapy (L-asparaginase), and central venous catheter.",ASPARAGINASE,ISA,Pharmacotherapy
26915519,"Among this age group, NHL was the most common HM.","Lymphoma, Non-Hodgkin's",ISA,Hematologic Neoplasms
26915519,"Non-Hodgkin's lymphoma (NHL) was the most common HM accounting for 29.7 % of all HM, followed by HL, MPN, multiple myelomas (MM), chronic lymphocytic leukemia (CLL), AML, MDS, acute lymphoblastic leukemia (ALL), and Waldenstrom macroglobulinemia (WM).","Lymphoma, Non-Hodgkin's",ISA,Hematologic Neoplasms
26937602,Kaplan-Meier curves and Cox proportional hazards models estimating hazard ratios (HR) and 95% confidence intervals (CI) were used to assess the impact of family characteristics on overall survival in children with hematological malignancies.,Hematologic Neoplasms,PROCESS_OF,Child
26947147,"Response to glucocorticoid (GC) treatment is out of the most important prognostic factors in childhood acute lymphoblastic leukemia (ALL), however, only few data are available connecting GC response and role of autophagy.",Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26947147,"Response to glucocorticoid (GC) treatment is out of the most important prognostic factors in childhood acute lymphoblastic leukemia (ALL), however, only few data are available connecting GC response and role of autophagy.",Glucocorticoids,ISA,Therapeutic procedure
26947147,"Response to glucocorticoid (GC) treatment is out of the most important prognostic factors in childhood acute lymphoblastic leukemia (ALL), however, only few data are available connecting GC response and role of autophagy.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26989914,"Although regimens for induction therapy in children with acute lymphoblastic leukemia (ALL) are similar across the United States, typical practice with regard to inpatient length of stay (LOS) varies by institution.",Neoadjuvant Therapy,TREATS,Child
26989914,"Although regimens for induction therapy in children with acute lymphoblastic leukemia (ALL) are similar across the United States, typical practice with regard to inpatient length of stay (LOS) varies by institution.",Treatment Protocols,METHOD_OF,Neoadjuvant Therapy
26989914,"Although regimens for induction therapy in children with acute lymphoblastic leukemia (ALL) are similar across the United States, typical practice with regard to inpatient length of stay (LOS) varies by institution.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
26989914,"Although regimens for induction therapy in children with acute lymphoblastic leukemia (ALL) are similar across the United States, typical practice with regard to inpatient length of stay (LOS) varies by institution.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27014503,"Here we report a case of PRES in an adult patient after chemotherapy (Escherichia coli L-asparaginase [L-ASP], daunorubicin, vincristine, and intrathecal methotrexate) for acute lymphoblastic leukemia.",Daunorubicin,ISA,Pharmacotherapy
27014503,"Here we report a case of PRES in an adult patient after chemotherapy (Escherichia coli L-asparaginase [L-ASP], daunorubicin, vincristine, and intrathecal methotrexate) for acute lymphoblastic leukemia.",Escherichia coli asparaginase,ISA,Pharmacotherapy
27014503,"Here we report a case of PRES in an adult patient after chemotherapy (Escherichia coli L-asparaginase [L-ASP], daunorubicin, vincristine, and intrathecal methotrexate) for acute lymphoblastic leukemia.",Daunorubicin,TREATS,"Leukemia, Lymphocytic, Acute"
27014503,"Here we report a case of PRES in an adult patient after chemotherapy (Escherichia coli L-asparaginase [L-ASP], daunorubicin, vincristine, and intrathecal methotrexate) for acute lymphoblastic leukemia.",Escherichia coli asparaginase,TREATS,"Leukemia, Lymphocytic, Acute"
27014503,Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy.,Pharmacotherapy,USES,ASPARAGINASE
27014503,"Here we report a case of PRES in an adult patient after chemotherapy (Escherichia coli L-asparaginase [L-ASP], daunorubicin, vincristine, and intrathecal methotrexate) for acute lymphoblastic leukemia.",Vincristine,ISA,Pharmacotherapy
27014503,Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy.,ASPARAGINASE,ISA,Pharmacotherapy
27014503,"Here we report a case of PRES in an adult patient after chemotherapy (Escherichia coli L-asparaginase [L-ASP], daunorubicin, vincristine, and intrathecal methotrexate) for acute lymphoblastic leukemia.",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
27014503,"Here we report a case of PRES in an adult patient after chemotherapy (Escherichia coli L-asparaginase [L-ASP], daunorubicin, vincristine, and intrathecal methotrexate) for acute lymphoblastic leukemia.",Methotrexate,ISA,Pharmacotherapy
27014503,"Here we report a case of PRES in an adult patient after chemotherapy (Escherichia coli L-asparaginase [L-ASP], daunorubicin, vincristine, and intrathecal methotrexate) for acute lymphoblastic leukemia.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27014503,"Here we report a case of PRES in an adult patient after chemotherapy (Escherichia coli L-asparaginase [L-ASP], daunorubicin, vincristine, and intrathecal methotrexate) for acute lymphoblastic leukemia.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
27014503,"Here we report a case of PRES in an adult patient after chemotherapy (Escherichia coli L-asparaginase [L-ASP], daunorubicin, vincristine, and intrathecal methotrexate) for acute lymphoblastic leukemia.",Syndrome,PROCESS_OF,Patients
27065575,"ALL is the most common hematologic malignancy in early childhood, and it reaches peak incidence between the ages of 2 and 3 years.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
27099644,BACKGROUND: Minimal residual disease (MRD) testing by higher performance techniques such as flow cytometry and polymerase chain reaction (PCR) can be used to detect the proportion of remaining leukemic cells in bone marrow or peripheral blood during and after the first phases of chemotherapy in children with acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,Child
27099644,BACKGROUND: Minimal residual disease (MRD) testing by higher performance techniques such as flow cytometry and polymerase chain reaction (PCR) can be used to detect the proportion of remaining leukemic cells in bone marrow or peripheral blood during and after the first phases of chemotherapy in children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27099644,BACKGROUND: Minimal residual disease (MRD) testing by higher performance techniques such as flow cytometry and polymerase chain reaction (PCR) can be used to detect the proportion of remaining leukemic cells in bone marrow or peripheral blood during and after the first phases of chemotherapy in children with acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27121472,Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.,Pharmacotherapy,TREATS,Patients
27121472,Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
27121472,Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
25768269,Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy characterized by proliferation of immature lymphoid cells throughout the bone marrow and peripheral blood.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
25781572,Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer and an important cause of morbidity from haematological malignancies in adults.,Hematologic Neoplasms,PROCESS_OF,Adult
26065651,Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
26076127,Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia.,Cell Transplantation,TREATS,Acute leukemia
26076127,Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia.,Pharmacotherapy,TREATS,Acute leukemia
26261894,This pediatric phase I/II study evaluated the toxicity profile and efficacy of B43-PAP immunotoxin in combination with standard induction chemotherapy in children and adolescents with relapsed CD19-positive B-lineage acute lymphoblastic leukemia (B-ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adolescent
26261894,Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.,Children's Oncology Group,LOCATION_OF,Feasibility Studies
26261894,Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
26261894,This pediatric phase I/II study evaluated the toxicity profile and efficacy of B43-PAP immunotoxin in combination with standard induction chemotherapy in children and adolescents with relapsed CD19-positive B-lineage acute lymphoblastic leukemia (B-ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26261894,This pediatric phase I/II study evaluated the toxicity profile and efficacy of B43-PAP immunotoxin in combination with standard induction chemotherapy in children and adolescents with relapsed CD19-positive B-lineage acute lymphoblastic leukemia (B-ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26261894,Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.,Pharmacotherapy,TREATS,Adolescent
26261894,Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.,Pharmacotherapy,TREATS,Child
26261894,This pediatric phase I/II study evaluated the toxicity profile and efficacy of B43-PAP immunotoxin in combination with standard induction chemotherapy in children and adolescents with relapsed CD19-positive B-lineage acute lymphoblastic leukemia (B-ALL).,Pharmacotherapy,TREATS,Adolescent
26261894,Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.,"Leukemia, B-Cell, Acute",PROCESS_OF,Adolescent
26261894,This pediatric phase I/II study evaluated the toxicity profile and efficacy of B43-PAP immunotoxin in combination with standard induction chemotherapy in children and adolescents with relapsed CD19-positive B-lineage acute lymphoblastic leukemia (B-ALL).,Pharmacotherapy,TREATS,Child
26261894,Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
26327632,"Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated with chemotherapy alone, and outcomes after allogeneic hematopoietic cell transplantation (HCT) is not well described.",Pharmacotherapy,TREATS,Child
26327632,"Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated with chemotherapy alone, and outcomes after allogeneic hematopoietic cell transplantation (HCT) is not well described.",Acute T Cell Leukemia,PROCESS_OF,Child
26327632,"Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated with chemotherapy alone, and outcomes after allogeneic hematopoietic cell transplantation (HCT) is not well described.",Pharmacotherapy,TREATS,Acute T Cell Leukemia
26360610,"POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26412181,"CONCLUSIONS: SOS should be considered in children who present with hepatomegaly, sudden weight gain, liver dysfunction and coagulation dysfunction after they have received chemotherapy for leukemia and hematopoietic stem cell transplantation.",Hematopoietic Stem Cell Transplantation,TREATS,leukemia
26412181,"CONCLUSIONS: SOS should be considered in children who present with hepatomegaly, sudden weight gain, liver dysfunction and coagulation dysfunction after they have received chemotherapy for leukemia and hematopoietic stem cell transplantation.",Pharmacotherapy,TREATS,leukemia
26412181,"CONCLUSIONS: SOS should be considered in children who present with hepatomegaly, sudden weight gain, liver dysfunction and coagulation dysfunction after they have received chemotherapy for leukemia and hematopoietic stem cell transplantation.",Hepatomegaly,PROCESS_OF,Child
26442676,BACKGROUND/PURPOSE: Acute leukemia is the most common pediatric hematological malignancy.,Acute leukemia,ISA,Hematologic Neoplasms
26442754,"METHODS: To elucidate the effects of CNS radio-chemotherapy on hippocampal plasticity and function in humans, we performed a longitudinal pilot study using 3T proton magnetic resonance spectroscopy ((1)H-MRS) and virtual water-maze-tests in 10 de-novo patients with acute lymphoblastic leukemia undergoing preventive whole brain radio-chemotherapy.",Magnetic Resonance Spectroscopy,USES,Protons
26442754,Preventive brain radio-chemotherapy alters plasticity associated metabolite profile in the hippocampus but seems to not affect spatial memory in young leukemia patients.,Pharmacotherapy,TREATS,Patients
26442754,Preventive brain radio-chemotherapy alters plasticity associated metabolite profile in the hippocampus but seems to not affect spatial memory in young leukemia patients.,leukemia,PROCESS_OF,Patients
26442754,"METHODS: To elucidate the effects of CNS radio-chemotherapy on hippocampal plasticity and function in humans, we performed a longitudinal pilot study using 3T proton magnetic resonance spectroscopy ((1)H-MRS) and virtual water-maze-tests in 10 de-novo patients with acute lymphoblastic leukemia undergoing preventive whole brain radio-chemotherapy.",Chemotherapy-Oncologic Procedure,TREATS,Human
26442754,Preventive brain radio-chemotherapy alters plasticity associated metabolite profile in the hippocampus but seems to not affect spatial memory in young leukemia patients.,Pharmacotherapy,TREATS,leukemia
26442754,"METHODS: To elucidate the effects of CNS radio-chemotherapy on hippocampal plasticity and function in humans, we performed a longitudinal pilot study using 3T proton magnetic resonance spectroscopy ((1)H-MRS) and virtual water-maze-tests in 10 de-novo patients with acute lymphoblastic leukemia undergoing preventive whole brain radio-chemotherapy.",Patients,LOCATION_OF,Mineralocorticoid Receptor | DEFA1 | MARS | MROS
26442754,"METHODS: To elucidate the effects of CNS radio-chemotherapy on hippocampal plasticity and function in humans, we performed a longitudinal pilot study using 3T proton magnetic resonance spectroscopy ((1)H-MRS) and virtual water-maze-tests in 10 de-novo patients with acute lymphoblastic leukemia undergoing preventive whole brain radio-chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
26442754,"METHODS: To elucidate the effects of CNS radio-chemotherapy on hippocampal plasticity and function in humans, we performed a longitudinal pilot study using 3T proton magnetic resonance spectroscopy ((1)H-MRS) and virtual water-maze-tests in 10 de-novo patients with acute lymphoblastic leukemia undergoing preventive whole brain radio-chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26445232,Further study is needed to establish a strategy to prevent HBV reactivation after chemotherapy in HBsAg negative patients with hematological malignancies.,Hepatitis B surface antigen negative,PROCESS_OF,Patients
26445232,Further study is needed to establish a strategy to prevent HBV reactivation after chemotherapy in HBsAg negative patients with hematological malignancies.,Pharmacotherapy,TREATS,Hepatitis B surface antigen negative
26445232,Further study is needed to establish a strategy to prevent HBV reactivation after chemotherapy in HBsAg negative patients with hematological malignancies.,Pharmacotherapy,TREATS,Hematologic Neoplasms
26445232,Further study is needed to establish a strategy to prevent HBV reactivation after chemotherapy in HBsAg negative patients with hematological malignancies.,Pharmacotherapy,TREATS,Patients
26445232,Further study is needed to establish a strategy to prevent HBV reactivation after chemotherapy in HBsAg negative patients with hematological malignancies.,Hematologic Neoplasms,PROCESS_OF,Patients
26528799,"MTHFR polymorphisms were assessed in 47 pediatric ALL patients, treated according to intensive chemotherapy for childhood ALL, ALL IC BFM 2009.",Patients,LOCATION_OF,Oxidoreductase
26528799,"MTHFR polymorphisms were assessed in 47 pediatric ALL patients, treated according to intensive chemotherapy for childhood ALL, ALL IC BFM 2009.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26528799,"MTHFR polymorphisms were assessed in 47 pediatric ALL patients, treated according to intensive chemotherapy for childhood ALL, ALL IC BFM 2009.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
26705211,Chemotherapy for ALL has a significant impact on the psychological status of both patients and their parents with high prevalence of low self-esteem in children and high degree of stress in their parents.,Psychiatric problem,PROCESS_OF,Child
26705211,Chemotherapy for ALL has a significant impact on the psychological status of both patients and their parents with high prevalence of low self-esteem in children and high degree of stress in their parents.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26705211,To assess the self-esteem of pediatric patients on chemotherapy for acute lymphoblastic leukemia (ALL) and psychological status of their parents.The psychological status of 178 children receiving chemotherapy for ALL and their parents was assessed using parenting stress index (PSI) to determine the degree of stress the parents are exposed to using parent's and child's domains.,Pharmacotherapy,ADMINISTERED_TO,Child
26705211,To assess the self-esteem of pediatric patients on chemotherapy for acute lymphoblastic leukemia (ALL) and psychological status of their parents.The psychological status of 178 children receiving chemotherapy for ALL and their parents was assessed using parenting stress index (PSI) to determine the degree of stress the parents are exposed to using parent's and child's domains.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26705211,To assess the self-esteem of pediatric patients on chemotherapy for acute lymphoblastic leukemia (ALL) and psychological status of their parents.The psychological status of 178 children receiving chemotherapy for ALL and their parents was assessed using parenting stress index (PSI) to determine the degree of stress the parents are exposed to using parent's and child's domains.,Pharmacotherapy,TREATS,Psychiatric problem
26705211,To assess the self-esteem of pediatric patients on chemotherapy for acute lymphoblastic leukemia (ALL) and psychological status of their parents.The psychological status of 178 children receiving chemotherapy for ALL and their parents was assessed using parenting stress index (PSI) to determine the degree of stress the parents are exposed to using parent's and child's domains.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26705211,Chemotherapy for ALL has a significant impact on the psychological status of both patients and their parents with high prevalence of low self-esteem in children and high degree of stress in their parents.,Stress,PROCESS_OF,parent
26705211,Psychological Impact of Chemotherapy for Childhood Acute Lymphoblastic Leukemia on Patients and Their Parents.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26717380,"The chemotherapy for ALL is associated with a profound secondary immune deficiency.We evaluated the number and phenotype of natural killer (NK) cells at diagnosis, after the intensive chemotherapy and following the completion of the entire treatment for patients with ALL.",Pharmacotherapy,TREATS,Patients
26717380,"The chemotherapy for ALL is associated with a profound secondary immune deficiency.We evaluated the number and phenotype of natural killer (NK) cells at diagnosis, after the intensive chemotherapy and following the completion of the entire treatment for patients with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
26717380,"The chemotherapy for ALL is associated with a profound secondary immune deficiency.We evaluated the number and phenotype of natural killer (NK) cells at diagnosis, after the intensive chemotherapy and following the completion of the entire treatment for patients with ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26717380,"The chemotherapy for ALL is associated with a profound secondary immune deficiency.We evaluated the number and phenotype of natural killer (NK) cells at diagnosis, after the intensive chemotherapy and following the completion of the entire treatment for patients with ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25688158,"One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia development and maintenance, and thus sensitive to small-molecule inhibitors that target epigenetic mechanisms.","Leukemia, B-Cell, Acute",ISA,leukemia
25688158,"One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia development and maintenance, and thus sensitive to small-molecule inhibitors that target epigenetic mechanisms.","Leukemia, B-Cell, Acute",ISA,Hematologic Neoplasms
25724525,This single-center phase I/II study was designed to test the safety and efficacy of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25724525,A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,Patients
25724525,A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
25724525,A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25755211,Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.,Pharmacotherapy,TREATS,Acute T Cell Leukemia
25941002,"L-Asparaginase (ASNase) is a front-line chemotherapy for acute lymphoblastic leukemia (ALL), which acts by deaminating asparagine and glutamine.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25941002,"L-Asparaginase (ASNase) is a front-line chemotherapy for acute lymphoblastic leukemia (ALL), which acts by deaminating asparagine and glutamine.",ASPARAGINASE | ASPG,ISA,Pharmacotherapy
25941002,"L-Asparaginase (ASNase) is a front-line chemotherapy for acute lymphoblastic leukemia (ALL), which acts by deaminating asparagine and glutamine.",ASPARAGINASE | ASPG,TREATS,"Leukemia, Lymphocytic, Acute"
25985238,Brain Abscesses Due to Aspergillus nidulans Infection During Induction Chemotherapy for Acute Lymphoblastic Leukemia.,Aspergillus infections,CAUSES,Brain Abscess
25985238,Brain Abscesses Due to Aspergillus nidulans Infection During Induction Chemotherapy for Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25985238,There are very few cases of invasive aspergillosis reported in children during induction chemotherapy for acute leukemia and A. nidulans is rare in the absence of chronic granulomatous disease.,Pharmacotherapy,TREATS,Acute leukemia
25985238,There are very few cases of invasive aspergillosis reported in children during induction chemotherapy for acute leukemia and A. nidulans is rare in the absence of chronic granulomatous disease.,"ASPERGILLOSIS, INVASIVE",PROCESS_OF,Child
25985238,We present the case of a 3-year-old boy who was diagnosed with cerebral abscesses due to Aspergillus nidulans infection on day 28 of induction chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25985238,We present the case of a 3-year-old boy who was diagnosed with cerebral abscesses due to Aspergillus nidulans infection on day 28 of induction chemotherapy for acute lymphoblastic leukemia.,Cerebral Abscess,PROCESS_OF,Boys
25985238,We present the case of a 3-year-old boy who was diagnosed with cerebral abscesses due to Aspergillus nidulans infection on day 28 of induction chemotherapy for acute lymphoblastic leukemia.,Aspergillus infections,CAUSES,Cerebral Abscess
25985447,BACKGROUND: The response to initial glucocorticoid (gc) treatment is a reliable stratification factor in childhood acute lymphoblastic leukemia (ALL) and may predict the response to multi-agent chemotherapy.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute, L1"
25985447,BACKGROUND: The response to initial glucocorticoid (gc) treatment is a reliable stratification factor in childhood acute lymphoblastic leukemia (ALL) and may predict the response to multi-agent chemotherapy.,Glucocorticoids,ISA,Therapeutic procedure
25985447,BACKGROUND: The response to initial glucocorticoid (gc) treatment is a reliable stratification factor in childhood acute lymphoblastic leukemia (ALL) and may predict the response to multi-agent chemotherapy.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26117012,OBJECTIVE: To explore the role of dynamic monitoring the karyotype changes for evaluation of chemotherapy efficacy in patients with acute leukemia.,Pharmacotherapy,TREATS,Acute leukemia
26117012,"CONCLUSION: For patients with AML, patients with t (15; 17) chromosomal abnormality can obtain better effect from chemotherapy, the clinical remission rate of ALL patients with normal karyotype is higher; the karyotype analysis has the important reference value for evaluating efficacy of chemotherapy in patients with leukemia.","Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
26117012,"CONCLUSION: For patients with AML, patients with t (15; 17) chromosomal abnormality can obtain better effect from chemotherapy, the clinical remission rate of ALL patients with normal karyotype is higher; the karyotype analysis has the important reference value for evaluating efficacy of chemotherapy in patients with leukemia.",Pharmacotherapy,TREATS,Patients
26117012,[Role of Dynamic Monitoring Chromosome Karyotypes for Evaluation of Chemotherapy Efficacy in Patients with Acute Leukemia].,Pharmacotherapy,TREATS,Patients
26117012,"CONCLUSION: For patients with AML, patients with t (15; 17) chromosomal abnormality can obtain better effect from chemotherapy, the clinical remission rate of ALL patients with normal karyotype is higher; the karyotype analysis has the important reference value for evaluating efficacy of chemotherapy in patients with leukemia.",leukemia,PROCESS_OF,Patients
26117012,[Role of Dynamic Monitoring Chromosome Karyotypes for Evaluation of Chemotherapy Efficacy in Patients with Acute Leukemia].,Acute leukemia,PROCESS_OF,Patients
26117012,"CONCLUSION: For patients with AML, patients with t (15; 17) chromosomal abnormality can obtain better effect from chemotherapy, the clinical remission rate of ALL patients with normal karyotype is higher; the karyotype analysis has the important reference value for evaluating efficacy of chemotherapy in patients with leukemia.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
26117012,[Role of Dynamic Monitoring Chromosome Karyotypes for Evaluation of Chemotherapy Efficacy in Patients with Acute Leukemia].,Pharmacotherapy,TREATS,Acute leukemia
26117012,"CONCLUSION: For patients with AML, patients with t (15; 17) chromosomal abnormality can obtain better effect from chemotherapy, the clinical remission rate of ALL patients with normal karyotype is higher; the karyotype analysis has the important reference value for evaluating efficacy of chemotherapy in patients with leukemia.",Pharmacotherapy,TREATS,leukemia
26117012,OBJECTIVE: To explore the role of dynamic monitoring the karyotype changes for evaluation of chemotherapy efficacy in patients with acute leukemia.,Pharmacotherapy,TREATS,Patients
26117012,OBJECTIVE: To explore the role of dynamic monitoring the karyotype changes for evaluation of chemotherapy efficacy in patients with acute leukemia.,Acute leukemia,PROCESS_OF,Patients
26239360,"Thus, Talpha1 may markedly promote the phenotypic and functional maturation of DCs, and may serve as a suitable immunomodulator of DCbased immunotherapy for treatment of hematological malignancies.",Immunotherapy,TREATS,Hematologic Neoplasms
26259760,Five of the six t-B-ALL patients had persistent leukemia following initiation of chemotherapy for secondary leukemia with survival ranging from 10 to 21 months.,leukemia,PROCESS_OF,Patients
26259760,Five of the six t-B-ALL patients had persistent leukemia following initiation of chemotherapy for secondary leukemia with survival ranging from 10 to 21 months.,Pharmacotherapy,TREATS,leukemia
26282194,The included studies demonstrated that adrenal insufficiency occurs in nearly all children in the first days after cessation of glucocorticoid treatment for childhood ALL.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26282194,The included studies demonstrated that adrenal insufficiency occurs in nearly all children in the first days after cessation of glucocorticoid treatment for childhood ALL.,Glucocorticoids,ISA,Therapeutic procedure
26282194,BACKGROUND: Glucocorticoids play a major role in the treatment of acute lymphoblastic leukaemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
26379166,A 3-year-old boy with disseminated Candida dubliniensis infection during induction chemotherapy for acute lymphoblastic leukemia deteriorated despite resolution of neutropenia and appropriate antifungal treatment.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
26379166,A 3-year-old boy with disseminated Candida dubliniensis infection during induction chemotherapy for acute lymphoblastic leukemia deteriorated despite resolution of neutropenia and appropriate antifungal treatment.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26431322,Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy characterized by highly proliferative immature lymphoid cells in the bone marrow and peripheral blood.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
26431322,Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy characterized by highly proliferative immature lymphoid cells in the bone marrow and peripheral blood.,Bone Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
26431322,Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy characterized by highly proliferative immature lymphoid cells in the bone marrow and peripheral blood.,Bone Marrow,LOCATION_OF,Hematologic Neoplasms
26547381,"However, drug resistance is a primary hindrance to curative chemotherapy in leukemia and its molecular mechanisms remain poorly understood.",Pharmacotherapy,TREATS,leukemia
26681571,Rechallenging With Intrathecal Methotrexate After Developing Subacute Neurotoxicity in Children With Hematologic Malignancies.,Methotrexate,TREATS,Hematologic Neoplasms
26681571,Rechallenging With Intrathecal Methotrexate After Developing Subacute Neurotoxicity in Children With Hematologic Malignancies.,Methotrexate,TREATS,Child
26681571,Rechallenging With Intrathecal Methotrexate After Developing Subacute Neurotoxicity in Children With Hematologic Malignancies.,Hematologic Neoplasms,PROCESS_OF,Child
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",ASPARAGINASE,TREATS,Patients
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",6-Mercaptopurine,TREATS,"Leukemia, Lymphocytic, Acute"
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",6-Mercaptopurine,TREATS,Patients
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",Protein-tyrosine kinase inhibitor,TREATS,"Leukemia, Lymphocytic, Acute"
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",Protein-tyrosine kinase inhibitor,TREATS,Patients
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",Vincristine,TREATS,Patients
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",Methotrexate,TREATS,"Leukemia, Lymphocytic, Acute"
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",Methotrexate,TREATS,Patients
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
25614322,"Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors.",Glucocorticoids,TREATS,Patients
25775418,It has also demonstrated favorable early results when combined with chemotherapy in older patients with ALL.,Pharmacotherapy,TREATS,Patients
25775418,It has also demonstrated favorable early results when combined with chemotherapy in older patients with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
25775418,It has also demonstrated favorable early results when combined with chemotherapy in older patients with ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25938942,"Glucocorticoids are universally used in the treatment of acute lymphoblastic leukemia (ALL), and resistance to glucocorticoids in leukemia cells confers poor prognosis.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
25938942,"Glucocorticoids are universally used in the treatment of acute lymphoblastic leukemia (ALL), and resistance to glucocorticoids in leukemia cells confers poor prognosis.",Glucocorticoids,ISA,Therapeutic procedure
25938942,"Glucocorticoids are universally used in the treatment of acute lymphoblastic leukemia (ALL), and resistance to glucocorticoids in leukemia cells confers poor prognosis.",Leukemic Cell,LOCATION_OF,Glucocorticoids
25962143,Bone Marrow Recovery by Morphometry during Induction Chemotherapy for Acute Lymphoblastic Leukemia in Children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25962143,Bone Marrow Recovery by Morphometry during Induction Chemotherapy for Acute Lymphoblastic Leukemia in Children.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26050202,"MATERIAL AND METHODS: A retrospective study was performed on 68 children with ALL (39 boys and 29 girls, median age: 5 years) who were treated with VCR chemotherapy (a total of 136 cases, including both induction and reinduction phases) from January 2012 to December 2013 in our hospital.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26050202,"MATERIAL AND METHODS: A retrospective study was performed on 68 children with ALL (39 boys and 29 girls, median age: 5 years) who were treated with VCR chemotherapy (a total of 136 cases, including both induction and reinduction phases) from January 2012 to December 2013 in our hospital.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26050202,"MATERIAL AND METHODS: A retrospective study was performed on 68 children with ALL (39 boys and 29 girls, median age: 5 years) who were treated with VCR chemotherapy (a total of 136 cases, including both induction and reinduction phases) from January 2012 to December 2013 in our hospital.",Vincristine,ISA,Pharmacotherapy
26050202,"MATERIAL AND METHODS: A retrospective study was performed on 68 children with ALL (39 boys and 29 girls, median age: 5 years) who were treated with VCR chemotherapy (a total of 136 cases, including both induction and reinduction phases) from January 2012 to December 2013 in our hospital.",Vincristine,TREATS,"Leukemia, Lymphocytic, Acute"
26050202,"MATERIAL AND METHODS: A retrospective study was performed on 68 children with ALL (39 boys and 29 girls, median age: 5 years) who were treated with VCR chemotherapy (a total of 136 cases, including both induction and reinduction phases) from January 2012 to December 2013 in our hospital.",Pharmacotherapy,USES,Vincristine
26061920,Nutritional Status and Induction Chemotherapy for Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26161258,"Due to the high intensity of chemotherapy in acute lymphoblastic leukemia (ALL), CSF as a crucial component of supportive care has played a significant role in the therapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26171196,An increasing incidence of hematological malignancies has been observed in children and adults worldwide over the last few decades.,Hematologic Neoplasms,PROCESS_OF,Child
26171196,An increasing incidence of hematological malignancies has been observed in children and adults worldwide over the last few decades.,Hematologic Neoplasms,PROCESS_OF,Adult
26183094,The paediatric haematology day hospital administers almost all types of chemotherapy used to treat acute lymphoblastic leukaemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26302283,"PURPOSE/OBJECTIVES: To examine associations among oxidative stress, fine and visual-motor abilities, and behavioral adjustment in children receiving chemotherapy for acute lymphoblastic leukemia (ALL).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26302283,"PURPOSE/OBJECTIVES: To examine associations among oxidative stress, fine and visual-motor abilities, and behavioral adjustment in children receiving chemotherapy for acute lymphoblastic leukemia (ALL).",motor ability,PROCESS_OF,Child
26302283,"PURPOSE/OBJECTIVES: To examine associations among oxidative stress, fine and visual-motor abilities, and behavioral adjustment in children receiving chemotherapy for acute lymphoblastic leukemia (ALL).",Pharmacotherapy,ADMINISTERED_TO,Child
26312396,"PROCEDURE: One-hundred and twelve adult ALL survivors, diagnosed 1970-2002 before age 16 and treated with chemotherapy only, and 100 comparison peers underwent neuropsychological tests covering processing speed, executive functions, working memory, and verbal learning and memory.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
26312396,"CONCLUSIONS: Very long-term survivors of childhood ALL treated exclusively with chemotherapy showed no impairment in general intellectual ability, but significantly poorer performance in several neurocognitive domains than comparison peers.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26312396,The present study assessed neuropsychological function in very long-term childhood ALL survivors treated with chemotherapy only.,Pharmacotherapy,TREATS,Long-Term Survivors
26312396,"PROCEDURE: One-hundred and twelve adult ALL survivors, diagnosed 1970-2002 before age 16 and treated with chemotherapy only, and 100 comparison peers underwent neuropsychological tests covering processing speed, executive functions, working memory, and verbal learning and memory.",Pharmacotherapy,TREATS,peer
26312396,The present study assessed neuropsychological function in very long-term childhood ALL survivors treated with chemotherapy only.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Long-Term Survivors
26312396,"PROCEDURE: One-hundred and twelve adult ALL survivors, diagnosed 1970-2002 before age 16 and treated with chemotherapy only, and 100 comparison peers underwent neuropsychological tests covering processing speed, executive functions, working memory, and verbal learning and memory.",Pharmacotherapy,TREATS,Survivors
26312396,The present study assessed neuropsychological function in very long-term childhood ALL survivors treated with chemotherapy only.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
26312396,"PROCEDURE: One-hundred and twelve adult ALL survivors, diagnosed 1970-2002 before age 16 and treated with chemotherapy only, and 100 comparison peers underwent neuropsychological tests covering processing speed, executive functions, working memory, and verbal learning and memory.",Neuropsychological Tests,ADMINISTERED_TO,peer
26312396,"PROCEDURE: One-hundred and twelve adult ALL survivors, diagnosed 1970-2002 before age 16 and treated with chemotherapy only, and 100 comparison peers underwent neuropsychological tests covering processing speed, executive functions, working memory, and verbal learning and memory.",Neuropsychological Tests,ADMINISTERED_TO,Survivors
26312396,"PROCEDURE: One-hundred and twelve adult ALL survivors, diagnosed 1970-2002 before age 16 and treated with chemotherapy only, and 100 comparison peers underwent neuropsychological tests covering processing speed, executive functions, working memory, and verbal learning and memory.","Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Survivors
26334102,These data support the development of clinical trials including AZD1775 in combination with conventional chemotherapy for acute leukemia.,Pharmacotherapy,TREATS,Acute leukemia
26376801,"Glucocorticoids are widely used to treat B acute lymphoblastic leukemia (B-ALL); however, the molecular mechanism underlying glucocorticoid response and resistance is unclear.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
26376890,PURPOSE: Acute lymphoblastic leukemia (ALL) is a rare hematological malignancy.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
26450951,One validation cohort included patients under treatment of acute lymphoblastic leukemia (ALL) and the second is patients receiving glucocorticoid treatment of various other indications.,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"
26450951,One validation cohort included patients under treatment of acute lymphoblastic leukemia (ALL) and the second is patients receiving glucocorticoid treatment of various other indications.,Glucocorticoids,ISA,Therapeutic procedure
26450951,One validation cohort included patients under treatment of acute lymphoblastic leukemia (ALL) and the second is patients receiving glucocorticoid treatment of various other indications.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
26588336,"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive hematologic malignancy primarily found in adults, often carrying a poor prognosis.",Hematologic Neoplasms,PROCESS_OF,Adult
26588336,"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive hematologic malignancy primarily found in adults, often carrying a poor prognosis.",Dendritic cell neoplasm,ISA,Hematologic Neoplasms
26588336,"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive hematologic malignancy primarily found in adults, often carrying a poor prognosis.",Dendritic cell neoplasm,PROCESS_OF,Adult
26644483,"Spontaneous tumor lysis syndrome is a rare initial presentation of hematologic malignancy in children that typically presents with complications of electrolyte derangement, specifically hyperkalemia, hyperphosphatemia, and hyperuricemia.",Hematologic Neoplasms,COEXISTS_WITH,Complication
26644483,"Spontaneous tumor lysis syndrome is a rare initial presentation of hematologic malignancy in children that typically presents with complications of electrolyte derangement, specifically hyperkalemia, hyperphosphatemia, and hyperuricemia.",Hematologic Neoplasms,PROCESS_OF,Child
26644483,"Spontaneous tumor lysis syndrome is a rare initial presentation of hematologic malignancy in children that typically presents with complications of electrolyte derangement, specifically hyperkalemia, hyperphosphatemia, and hyperuricemia.",Tumor Lysis Syndrome,ISA,Hematologic Neoplasms
26644483,"Spontaneous tumor lysis syndrome is a rare initial presentation of hematologic malignancy in children that typically presents with complications of electrolyte derangement, specifically hyperkalemia, hyperphosphatemia, and hyperuricemia.",Tumor Lysis Syndrome,PROCESS_OF,Child
26644483,"Spontaneous tumor lysis syndrome is a rare initial presentation of hematologic malignancy in children that typically presents with complications of electrolyte derangement, specifically hyperkalemia, hyperphosphatemia, and hyperuricemia.",Tumor Lysis Syndrome,COEXISTS_WITH,Complication
26711180,Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26711180,Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia.,Allografting,TREATS,"Leukemia, Lymphocytic, Acute"
23251470,Acute lymphoblastic leukemia (ALL) is the most common hematological cancer in children.,Hematologic Neoplasms,PROCESS_OF,Child
23251470,Acute lymphoblastic leukemia (ALL) is the most common hematological cancer in children.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
23251470,Acute lymphoblastic leukemia (ALL) is the most common hematological cancer in children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
25675295,"Deregulation of these particular transcriptional programs may result in a block in B-cell maturation, contributing to the development of hematological malignancies such as leukemia and lymphoma.",leukemia,ISA,Hematologic Neoplasms
25675295,"Deregulation of these particular transcriptional programs may result in a block in B-cell maturation, contributing to the development of hematological malignancies such as leukemia and lymphoma.",Lymphoma,ISA,Hematologic Neoplasms
25772933,Intra-thecal chemotherapy is a recognized therapy for hematological malignancies such as acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
25772933,Intra-thecal chemotherapy is a recognized therapy for hematological malignancies such as acute lymphoblastic leukemia (ALL).,Pharmacotherapy,ISA,Therapeutic procedure
25772933,Intra-thecal chemotherapy is a recognized therapy for hematological malignancies such as acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25772933,Intra-thecal chemotherapy is a recognized therapy for hematological malignancies such as acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,Hematologic Neoplasms
25796502,Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study.,Pharmacotherapy,TREATS,Patients
25796502,Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study.,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
25796502,Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study.,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
26136994,"The present study demonstrated that, in patients with a hematological malignancy (either AML or CML), the activation of numerous immune response-related molecules was inhibited.",Hematologic Neoplasms,PROCESS_OF,Patients
26136994,"The present study demonstrated that, in patients with a hematological malignancy (either AML or CML), the activation of numerous immune response-related molecules was inhibited.","Myeloid Leukemia, Chronic",ISA,Hematologic Neoplasms
26136994,"The present study demonstrated that, in patients with a hematological malignancy (either AML or CML), the activation of numerous immune response-related molecules was inhibited.","Myeloid Leukemia, Chronic",PROCESS_OF,Patients
26136994,"The present study demonstrated that, in patients with a hematological malignancy (either AML or CML), the activation of numerous immune response-related molecules was inhibited.","Leukemia, Myelocytic, Acute",ISA,Hematologic Neoplasms
26136994,"The present study demonstrated that, in patients with a hematological malignancy (either AML or CML), the activation of numerous immune response-related molecules was inhibited.","Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
26171196,An increasing incidence of hematological malignancies has been observed in children and adults worldwide over the last few decades.,Hematologic Neoplasms,PROCESS_OF,Child
26171196,An increasing incidence of hematological malignancies has been observed in children and adults worldwide over the last few decades.,Hematologic Neoplasms,PROCESS_OF,Adult
26189912,DNA topoisomerase II inhibitors e.g. doxorubicin and etoposide are currently used in the chemotherapy for acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26189912,DNA topoisomerase II inhibitors e.g. doxorubicin and etoposide are currently used in the chemotherapy for acute lymphoblastic leukemia (ALL).,Etoposide,ISA,Pharmacotherapy
26189912,DNA topoisomerase II inhibitors e.g. doxorubicin and etoposide are currently used in the chemotherapy for acute lymphoblastic leukemia (ALL).,Etoposide,TREATS,"Leukemia, Lymphocytic, Acute"
26189912,DNA topoisomerase II inhibitors e.g. doxorubicin and etoposide are currently used in the chemotherapy for acute lymphoblastic leukemia (ALL).,Doxorubicin,ISA,Pharmacotherapy
26189912,DNA topoisomerase II inhibitors e.g. doxorubicin and etoposide are currently used in the chemotherapy for acute lymphoblastic leukemia (ALL).,Doxorubicin,TREATS,"Leukemia, Lymphocytic, Acute"
26265699,Glucocorticoids are important therapy for acute lymphoblastic leukemia (ALL) and their major adverse effect is osteonecrosis.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
26265699,Glucocorticoids are important therapy for acute lymphoblastic leukemia (ALL) and their major adverse effect is osteonecrosis.,Glucocorticoids,ISA,Therapeutic procedure
26300018,Risk Factors for Hyperglycemia During Chemotherapy for Acute Lymphoblastic Leukemia Among Taiwanese Children.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
26300018,Risk Factors for Hyperglycemia During Chemotherapy for Acute Lymphoblastic Leukemia Among Taiwanese Children.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26308885,CONCLUSIONS: A combination of chemotherapy with dasatinib is effective in achieving long-term remission for patients with newly diagnosed Ph + ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
26308885,CONCLUSIONS: A combination of chemotherapy with dasatinib is effective in achieving long-term remission for patients with newly diagnosed Ph + ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26308885,CONCLUSIONS: A combination of chemotherapy with dasatinib is effective in achieving long-term remission for patients with newly diagnosed Ph + ALL.,Pharmacotherapy,TREATS,Patients
26331698,"L-asparaginase (L-ASNase) is an important branch of chemotherapy for acute lymphoblastic leukemia (ALL) and some types of non-Hodgkin's lymphoma, including natural killer (NK)-cell lymphoma.",ASPARAGINASE,AFFECTS,"Leukemia, Lymphocytic, Acute"
26331698,"L-asparaginase (L-ASNase) is an important branch of chemotherapy for acute lymphoblastic leukemia (ALL) and some types of non-Hodgkin's lymphoma, including natural killer (NK)-cell lymphoma.",Natural Killer Cells,LOCATION_OF,Lymphoma
26331698,"L-asparaginase (L-ASNase) is an important branch of chemotherapy for acute lymphoblastic leukemia (ALL) and some types of non-Hodgkin's lymphoma, including natural killer (NK)-cell lymphoma.",ASPARAGINASE,ISA,Pharmacotherapy
26352559,Impact of D-index and L-index on pulmonary infection in induction chemotherapy for acute lymphoblastic leukemia and lymphoblastic lymphoma.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26352559,"Discussion and conclusion In induction chemotherapy for ALL/LBL, c-D-index with a cutoff value of 5589 might have predictive value for the development of PI.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26352559,"We, retrospectively, investigated the impact of these indexes on pulmonary infection (PI) in induction chemotherapy for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).",Pharmacotherapy,TREATS,Large Cell Lymphoblastic Lymphoma
26352559,"We, retrospectively, investigated the impact of these indexes on pulmonary infection (PI) in induction chemotherapy for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26352559,Impact of D-index and L-index on pulmonary infection in induction chemotherapy for acute lymphoblastic leukemia and lymphoblastic lymphoma.,Pharmacotherapy,TREATS,Large Cell Lymphoblastic Lymphoma
26425338,Antibody-drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
26709559,This case report describes a patient with a history of bilateral avascular necrosis of the femoral head after chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25824762,"Childhood acute lymphoblastic leukemia (ALL) is one of the most common hematologic malignancies, accounting for one fourth of all childhood cancer cases.","Leukemia, Lymphocytic, Acute, L1",ISA,"Leukemia, Lymphocytic, Acute"
25824762,"Childhood acute lymphoblastic leukemia (ALL) is one of the most common hematologic malignancies, accounting for one fourth of all childhood cancer cases.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
25840770,Osteonecrosis (ON) is a potentially disabling complication encountered in children who receive chemotherapy for acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25840770,Osteonecrosis (ON) is a potentially disabling complication encountered in children who receive chemotherapy for acute lymphoblastic leukemia (ALL).,Pharmacotherapy,ADMINISTERED_TO,Child
25840770,Osteonecrosis (ON) is a potentially disabling complication encountered in children who receive chemotherapy for acute lymphoblastic leukemia (ALL).,Complication,PROCESS_OF,Child
25860236,"Acute lymphoblastic leukemia (ALL) following solid organ or hematologic malignancy (secondary ALL, s-ALL) is not well characterized.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
25862348,BACKGROUND: Pegaspargase (PEG-ASP) is essential chemotherapy for acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
25862348,BACKGROUND: Pegaspargase (PEG-ASP) is essential chemotherapy for acute lymphoblastic leukemia (ALL).,pegaspargase,ISA,Pharmacotherapy
25862348,BACKGROUND: Pegaspargase (PEG-ASP) is essential chemotherapy for acute lymphoblastic leukemia (ALL).,pegaspargase,TREATS,"Leukemia, Lymphocytic, Acute"
27547480,We report a case of bladder alveolar soft part sarcoma in an 18-year-old Thai male patient who had been treated with testicular radiation and systemic chemotherapy for acute lymphoblastic leukemia with testicular relapse.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27547480,We report a case of bladder alveolar soft part sarcoma in an 18-year-old Thai male patient who had been treated with testicular radiation and systemic chemotherapy for acute lymphoblastic leukemia with testicular relapse.,"Sarcoma, Alveolar Soft Part",PROCESS_OF,Patients
27547480,We report a case of bladder alveolar soft part sarcoma in an 18-year-old Thai male patient who had been treated with testicular radiation and systemic chemotherapy for acute lymphoblastic leukemia with testicular relapse.,"Sarcoma, Alveolar Soft Part",PART_OF,Bladder
27548616,"Adoptive immunotherapy infusing T cells with engineered specificity for CD19 expressed on B- cell malignancies is generating enthusiasm to extend this approach to other hematological malignancies, such as acute myelogenous leukemia (AML).","Leukemia, Myelocytic, Acute",ISA,Hematologic Neoplasms
27548616,"Adoptive immunotherapy infusing T cells with engineered specificity for CD19 expressed on B- cell malignancies is generating enthusiasm to extend this approach to other hematological malignancies, such as acute myelogenous leukemia (AML).",B-Lymphocytes,LOCATION_OF,Malignant Neoplasms
27561638,Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27561638,Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.,Treatment Protocols,TREATS,Young adult
27561638,Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.,Treatment Protocols,compared_with,Pharmacotherapy
27561638,Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Young adult
27561638,Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Young adult
27561638,Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.,Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
27571124,"Patients between 5 and 18 years receiving chemotherapy for acute lymphoblastic leukemia and with OM grade 1 or 2 were randomized in group A (treated with Mucosyte, 3 mouthwashes/d per 8 d) and group B (treated with placebo, ie, an inert water-based solution, 3 mouthwashes/d per 8 d).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27571124,"Patients between 5 and 18 years receiving chemotherapy for acute lymphoblastic leukemia and with OM grade 1 or 2 were randomized in group A (treated with Mucosyte, 3 mouthwashes/d per 8 d) and group B (treated with placebo, ie, an inert water-based solution, 3 mouthwashes/d per 8 d).",Pharmacotherapy,ADMINISTERED_TO,Patients
27907849,"At >/=2years post-treatment, we examined the association of DHEAS with attention outcomes in 35 male and 34 female long-term survivors of childhood ALL (mean[standard deviation] age at evaluation 14.5[4.7] years; 7.5[1.9] years post-diagnosis) who were treated with only chemotherapy and without prophylactic cranial irradiation.",Prophylactic Cranial Irradiation,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27907849,"At >/=2years post-treatment, we examined the association of DHEAS with attention outcomes in 35 male and 34 female long-term survivors of childhood ALL (mean[standard deviation] age at evaluation 14.5[4.7] years; 7.5[1.9] years post-diagnosis) who were treated with only chemotherapy and without prophylactic cranial irradiation.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27907849,Association between dehydroepiandrosterone-sulfate and attention in long-term survivors of childhood acute lymphoblastic leukemia treated with only chemotherapy.,Dehydroepiandrosterone Sulfate,TREATS,Long-Term Survivors
27907849,Association between dehydroepiandrosterone-sulfate and attention in long-term survivors of childhood acute lymphoblastic leukemia treated with only chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27913529,The success of combinatorial treatment of TKI with chemotherapy in the setting of Ph-positive ALL suggests that this approach may similarly improve outcomes for patients with Ph-like ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27913529,The success of combinatorial treatment of TKI with chemotherapy in the setting of Ph-positive ALL suggests that this approach may similarly improve outcomes for patients with Ph-like ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27913529,The success of combinatorial treatment of TKI with chemotherapy in the setting of Ph-positive ALL suggests that this approach may similarly improve outcomes for patients with Ph-like ALL.,Pharmacotherapy,TREATS,Patients
27913531,"Some progress has been made with delivering age-adapted, moderately intensive chemotherapy protocols for Ph/BCR-ABL-negative ALL and combinations of tyrosine kinase inhibitors with chemotherapy in Ph/BCR-ABL-positive ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27913531,"Some progress has been made with delivering age-adapted, moderately intensive chemotherapy protocols for Ph/BCR-ABL-negative ALL and combinations of tyrosine kinase inhibitors with chemotherapy in Ph/BCR-ABL-positive ALL.",DELIVER,TREATS,"Leukemia, Lymphocytic, Acute"
27913532,"With contemporary chemotherapy, outcomes for de novo T-ALL have steadily improved and now approach those observed in B-ALL, with approximately 85% 5-year event-free survival.",Pharmacotherapy,TREATS,Acute T Cell Leukemia
27930631,Immunotherapy has demonstrated significant potential for the treatment of patients with chemotherapy-resistant hematologic malignancies and solid tumors.,Solid tumor,PROCESS_OF,Patients
27930631,Immunotherapy has demonstrated significant potential for the treatment of patients with chemotherapy-resistant hematologic malignancies and solid tumors.,Immunotherapy,TREATS,Hematologic Neoplasms
27930631,Immunotherapy has demonstrated significant potential for the treatment of patients with chemotherapy-resistant hematologic malignancies and solid tumors.,Immunotherapy,TREATS,Solid tumor
27930631,Immunotherapy has demonstrated significant potential for the treatment of patients with chemotherapy-resistant hematologic malignancies and solid tumors.,Immunotherapy,TREATS,Patients
27930631,Immunotherapy has demonstrated significant potential for the treatment of patients with chemotherapy-resistant hematologic malignancies and solid tumors.,Hematologic Neoplasms,PROCESS_OF,Patients
27988194,Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
27997622,Dexamethasone Chemotherapy Does Not Disrupt Orexin Signaling.,Pharmacotherapy,USES,Dexamethasone
27997622,Dexamethasone Chemotherapy Does Not Disrupt Orexin Signaling.,Dexamethasone,ISA,Pharmacotherapy
28006851,Patients with Ph+ ALL who have +der(22)t(9;22) and/or -9/9p in the absence of HeH have relatively poor outcomes when treated with chemotherapy plus a TKI.,Pharmacotherapy,TREATS,Patients
28006851,Patients with Ph+ ALL who have +der(22)t(9;22) and/or -9/9p in the absence of HeH have relatively poor outcomes when treated with chemotherapy plus a TKI.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28006851,"In patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with chemotherapy plus a tyrosine kinase inhibitor (TKI), the prognostic impact of additional chromosomal abnormalities (ACAs) is not well-established.",Philadelphia chromosome positive,PROCESS_OF,Patients
28006851,"In patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with chemotherapy plus a tyrosine kinase inhibitor (TKI), the prognostic impact of additional chromosomal abnormalities (ACAs) is not well-established.",Protein-tyrosine kinase inhibitor,AFFECTS,Chromosome abnormality
28006851,"In patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with chemotherapy plus a tyrosine kinase inhibitor (TKI), the prognostic impact of additional chromosomal abnormalities (ACAs) is not well-established.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28006851,Patients with Ph+ ALL who have +der(22)t(9;22) and/or -9/9p in the absence of HeH have relatively poor outcomes when treated with chemotherapy plus a TKI.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
28012245,"We herein discuss four patients with DS with ALL and a history of AML who were treated with various chemotherapies, one of whom later received a bone marrow transplantation.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
28012245,"We herein discuss four patients with DS with ALL and a history of AML who were treated with various chemotherapies, one of whom later received a bone marrow transplantation.",Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
28012245,"We herein discuss four patients with DS with ALL and a history of AML who were treated with various chemotherapies, one of whom later received a bone marrow transplantation.",Bone Marrow Transplantation,ADMINISTERED_TO,Patients
28012245,"We herein discuss four patients with DS with ALL and a history of AML who were treated with various chemotherapies, one of whom later received a bone marrow transplantation.",Down Syndrome,PROCESS_OF,Patients
28028966,BACKGROUND: Acute lymphocytic leukemia (ALL) is the most common hematologic malignancy in early childhood.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
27345588,Uric Acid and Neurocognitive Function in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27354010,Our report highlights the importance of the early consideration of this life-threatening immune complication in patients who received chemotherapy for infantile ALL.,Complication,PROCESS_OF,Patients
27354010,Our report highlights the importance of the early consideration of this life-threatening immune complication in patients who received chemotherapy for infantile ALL.,Pharmacotherapy,ADMINISTERED_TO,Patients
27354010,"We describe five cases of children who completed chemotherapy for infantile acute lymphoblastic leukemia (ALL) and soon after were diagnosed with severe T-cell, non-HIV immunodeficiency, with varying B-cell and NK-cell depletion.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27354010,"We describe five cases of children who completed chemotherapy for infantile acute lymphoblastic leukemia (ALL) and soon after were diagnosed with severe T-cell, non-HIV immunodeficiency, with varying B-cell and NK-cell depletion.",T-Lymphocyte,PART_OF,Child
27354010,"We describe five cases of children who completed chemotherapy for infantile acute lymphoblastic leukemia (ALL) and soon after were diagnosed with severe T-cell, non-HIV immunodeficiency, with varying B-cell and NK-cell depletion.",Acquired Immunodeficiency Syndrome,ISA,Immunologic Deficiency Syndromes
27354010,Our report highlights the importance of the early consideration of this life-threatening immune complication in patients who received chemotherapy for infantile ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27399585,The objective of this study was to describe infections and identify risk factors of microbiologically documented infections at a sterile site in children with DS during chemotherapy for ALL.,Down Syndrome,PROCESS_OF,Child
27399585,The objective of this study was to describe infections and identify risk factors of microbiologically documented infections at a sterile site in children with DS during chemotherapy for ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27399585,The objective of this study was to describe infections and identify risk factors of microbiologically documented infections at a sterile site in children with DS during chemotherapy for ALL.,Infection,PROCESS_OF,Child
27408346,Acute lymphoblastic leukemia (ALL) is a haematological malignancy that can involve the central nervous system (CNS).,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
27408353,He was given testicular radiotherapy and systemic chemotherapy for relapsed ALL.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute"
27408353,He was given testicular radiotherapy and systemic chemotherapy for relapsed ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27431075,[The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia].,Pharmacotherapy,TREATS,Patients
27431075,[The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
27431075,[The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia].,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
27431075,OBJECTIVE: To investigate the prognostic significance of proportion of the blasts in bone marrow on day 14 (D14) during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia (Ph (-) ALL).,Pharmacotherapy,TREATS,Patients
27431075,OBJECTIVE: To investigate the prognostic significance of proportion of the blasts in bone marrow on day 14 (D14) during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia (Ph (-) ALL).,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
27431075,OBJECTIVE: To investigate the prognostic significance of proportion of the blasts in bone marrow on day 14 (D14) during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia (Ph (-) ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
27440950,Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs in children between 2 and 10 years of age.,Hematologic Neoplasms,OCCURS_IN,Child
27440950,Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs in children between 2 and 10 years of age.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
27440950,Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs in children between 2 and 10 years of age.,"Leukemia, Lymphocytic, Acute",OCCURS_IN,Child
27446573,"T-cell acute lymphoblastic leukemia (ALL) is an aggressive hematological malignancy, accounting for ~25% of all adult cases of ALL.",Acute T Cell Leukemia,ISA,Hematologic Neoplasms
27447436,"Initial clinical trials of this drug class focused on bortezomib, a reversible inhibitor of the 20S proteasome, with promising results for the treatment of adult hematologic malignancies, including multiple myeloma and non-Hodgkin lymphoma.",multicatalytic endopeptidase complex,TREATS,Hematologic Neoplasms
27447436,"Initial clinical trials of this drug class focused on bortezomib, a reversible inhibitor of the 20S proteasome, with promising results for the treatment of adult hematologic malignancies, including multiple myeloma and non-Hodgkin lymphoma.",bortezomib,INHIBITS,multicatalytic endopeptidase complex
27447436,"Initial clinical trials of this drug class focused on bortezomib, a reversible inhibitor of the 20S proteasome, with promising results for the treatment of adult hematologic malignancies, including multiple myeloma and non-Hodgkin lymphoma.",Hematologic Neoplasms,PROCESS_OF,Adult
27451956,T cell acute lymphoblastic leukaemia (T-ALL) is an aggressive haematological malignancy derived from early T cell progenitors.,Acute T Cell Leukemia,ISA,Hematologic Neoplasms
27461063,"TCF3-PBX1 BCP-ALL patients typically benefit from chemotherapy; however, many relapse and subsequently develop resistant disease with few effective treatment options.",Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
27461063,"TCF3-PBX1 BCP-ALL patients typically benefit from chemotherapy; however, many relapse and subsequently develop resistant disease with few effective treatment options.",Pharmacotherapy,TREATS,Patients
27461063,"TCF3-PBX1 BCP-ALL patients typically benefit from chemotherapy; however, many relapse and subsequently develop resistant disease with few effective treatment options.","Leukemia, B-Cell, Acute",PROCESS_OF,Patients
27489464,MATERIAL AND METHODS: Nighty-six children who received chemotherapy for acute lymphoblastic leukemia in our center between January 1995 and December 2010 were included in the study.,Pharmacotherapy,ADMINISTERED_TO,Child
27489464,MATERIAL AND METHODS: Nighty-six children who received chemotherapy for acute lymphoblastic leukemia in our center between January 1995 and December 2010 were included in the study.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27492792,We analyzed the predictive relevance of MRD levels before transplantation on the clinical outcome of Ph+ ALL patients treated with chemotherapy and imatinib in 2 consecutive prospective clinical trials.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27492792,We analyzed the predictive relevance of MRD levels before transplantation on the clinical outcome of Ph+ ALL patients treated with chemotherapy and imatinib in 2 consecutive prospective clinical trials.,imatinib,TREATS,Patients
27492792,We analyzed the predictive relevance of MRD levels before transplantation on the clinical outcome of Ph+ ALL patients treated with chemotherapy and imatinib in 2 consecutive prospective clinical trials.,Pharmacotherapy,TREATS,Patients
27492792,We analyzed the predictive relevance of MRD levels before transplantation on the clinical outcome of Ph+ ALL patients treated with chemotherapy and imatinib in 2 consecutive prospective clinical trials.,imatinib,TREATS,"Leukemia, Lymphocytic, Acute"
27492792,We analyzed the predictive relevance of MRD levels before transplantation on the clinical outcome of Ph+ ALL patients treated with chemotherapy and imatinib in 2 consecutive prospective clinical trials.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.",Brain Metabolism,PROCESS_OF,Survivors
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.",Radiation therapy,TREATS,Survivors
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.",Pharmacotherapy,TREATS,Survivors
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.",Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27498291,"The present study shows impaired brain metabolism detected by MRS, reduced brain volumes and neurocognitive impairment in childhood ALL survivors treated with cranial radiotherapy and chemotherapy, despite complete hormone substitution.","Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Survivors
27506924,"Although the response rates of chemotherapy in patients with acute T-lymphoblastic leukemia (T-ALL) have improved significantly, the outcome of these patients is still poor.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27506924,"Although the response rates of chemotherapy in patients with acute T-lymphoblastic leukemia (T-ALL) have improved significantly, the outcome of these patients is still poor.",Pharmacotherapy,TREATS,Patients
27506924,"Although the response rates of chemotherapy in patients with acute T-lymphoblastic leukemia (T-ALL) have improved significantly, the outcome of these patients is still poor.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27515250,"In the GIMEMA LAL 0904 protocol, adult Philadelphia positive acute lymphoblastic leukemia patients were treated with chemotherapy for induction and consolidation, followed by maintenance with imatinib.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
27515250,"A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
27515250,"In the GIMEMA LAL 0904 protocol, adult Philadelphia positive acute lymphoblastic leukemia patients were treated with chemotherapy for induction and consolidation, followed by maintenance with imatinib.",Pharmacotherapy,TREATS,Patients
27515250,"In the GIMEMA LAL 0904 protocol, adult Philadelphia positive acute lymphoblastic leukemia patients were treated with chemotherapy for induction and consolidation, followed by maintenance with imatinib.",Pharmacotherapy,METHOD_OF,Induction
27515250,"In the GIMEMA LAL 0904 protocol, adult Philadelphia positive acute lymphoblastic leukemia patients were treated with chemotherapy for induction and consolidation, followed by maintenance with imatinib.","Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
27527070,All children and adolescent acute leukemia patients will undergo chemotherapy as part of their treatment regimen.,Pharmacotherapy,TREATS,Patients
27527070,All children and adolescent acute leukemia patients will undergo chemotherapy as part of their treatment regimen.,Pharmacotherapy,TREATS,Child
27527070,All children and adolescent acute leukemia patients will undergo chemotherapy as part of their treatment regimen.,Acute leukemia,PROCESS_OF,Patients
27527070,All children and adolescent acute leukemia patients will undergo chemotherapy as part of their treatment regimen.,Pharmacotherapy,TREATS,Acute leukemia
27151000,"CONCLUSION: With higher response rate, lower drug toxicity and allergy incidence, the combined chemotherapy with PEG-Asp can replace the standard chemotherapy with L-Asp in the treatment of ALL and T-NHL.",Pharmacotherapy,TREATS,T-Cell Lymphoma
27151000,OBJECTIVE: To explore the effectiveness and safety of combined chemotherapy with pegasparaginase (PEG-Asp) for treatment of patients with acute lymphoblastic leukemia (ALL) and T cell non-Hodgkin's lymphoma (T-NHL) patients.,T-Cell Lymphoma,PROCESS_OF,Patients
27151000,"CONCLUSION: With higher response rate, lower drug toxicity and allergy incidence, the combined chemotherapy with PEG-Asp can replace the standard chemotherapy with L-Asp in the treatment of ALL and T-NHL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27151000,OBJECTIVE: To explore the effectiveness and safety of combined chemotherapy with pegasparaginase (PEG-Asp) for treatment of patients with acute lymphoblastic leukemia (ALL) and T cell non-Hodgkin's lymphoma (T-NHL) patients.,Pharmacotherapy,TREATS,T-Cell Lymphoma
27151000,"CONCLUSION: With higher response rate, lower drug toxicity and allergy incidence, the combined chemotherapy with PEG-Asp can replace the standard chemotherapy with L-Asp in the treatment of ALL and T-NHL.",Pharmacotherapy,USES,ASPARAGINASE
27151000,OBJECTIVE: To explore the effectiveness and safety of combined chemotherapy with pegasparaginase (PEG-Asp) for treatment of patients with acute lymphoblastic leukemia (ALL) and T cell non-Hodgkin's lymphoma (T-NHL) patients.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27151000,OBJECTIVE: To explore the effectiveness and safety of combined chemotherapy with pegasparaginase (PEG-Asp) for treatment of patients with acute lymphoblastic leukemia (ALL) and T cell non-Hodgkin's lymphoma (T-NHL) patients.,Pharmacotherapy,TREATS,Patients
27151000,[Comparison of the Effectiveness and Safety of Combined Chemotherapy with PEG-Asp for Treatment of ALL and T-NHL Patients].,Pharmacotherapy,TREATS,T-Cell Lymphoma
27151000,OBJECTIVE: To explore the effectiveness and safety of combined chemotherapy with pegasparaginase (PEG-Asp) for treatment of patients with acute lymphoblastic leukemia (ALL) and T cell non-Hodgkin's lymphoma (T-NHL) patients.,Pharmacotherapy,TREATS,Patients
27151000,[Comparison of the Effectiveness and Safety of Combined Chemotherapy with PEG-Asp for Treatment of ALL and T-NHL Patients].,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27151000,OBJECTIVE: To explore the effectiveness and safety of combined chemotherapy with pegasparaginase (PEG-Asp) for treatment of patients with acute lymphoblastic leukemia (ALL) and T cell non-Hodgkin's lymphoma (T-NHL) patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27151000,[Comparison of the Effectiveness and Safety of Combined Chemotherapy with PEG-Asp for Treatment of ALL and T-NHL Patients].,T-Cell Lymphoma,PROCESS_OF,Patients
27151000,OBJECTIVE: To explore the effectiveness and safety of combined chemotherapy with pegasparaginase (PEG-Asp) for treatment of patients with acute lymphoblastic leukemia (ALL) and T cell non-Hodgkin's lymphoma (T-NHL) patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27157479,"Acute Lymphoblastic Leukemia (ALL) is a common hematological malignancy in children, with a prognosis much worse in adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
27157479,"Acute Lymphoblastic Leukemia (ALL) is a common hematological malignancy in children, with a prognosis much worse in adults.",Hematologic Neoplasms,PROCESS_OF,Child
27157479,"Acute Lymphoblastic Leukemia (ALL) is a common hematological malignancy in children, with a prognosis much worse in adults.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
27157479,"Acute Lymphoblastic Leukemia (ALL) is a common hematological malignancy in children, with a prognosis much worse in adults.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Stem cell transplant,TREATS,Patients
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Pharmacotherapy,TREATS,Blast Phase
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Pharmacotherapy,TREATS,Child
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.","Myeloid Leukemia, Chronic",PROCESS_OF,Patients
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Blast Phase,PROCESS_OF,Child
27164534,"This distinction has significant potential therapeutic implications because most children with Ph ALL are now treated with chemotherapy plus a tyrosine kinase inhibitor, whereas allogeneic stem cell transplant is usually recommended for any patient with CML that presents in or later develops BC.",Stem cell transplant,TREATS,"Myeloid Leukemia, Chronic"
27225057,METHODS: We present a retrospective review of the medical records of two patients diagnosed with hematologic malignancies (acute myelogenous leukemia and multiple myeloma) with occurrence of relapse in the testicle.,Multiple Myeloma,ISA,Hematologic Neoplasms
27225057,METHODS: We present a retrospective review of the medical records of two patients diagnosed with hematologic malignancies (acute myelogenous leukemia and multiple myeloma) with occurrence of relapse in the testicle.,Hematologic Neoplasms,PROCESS_OF,Patients
27225057,METHODS: We present a retrospective review of the medical records of two patients diagnosed with hematologic malignancies (acute myelogenous leukemia and multiple myeloma) with occurrence of relapse in the testicle.,Multiple Myeloma,PROCESS_OF,Patients
27225057,METHODS: We present a retrospective review of the medical records of two patients diagnosed with hematologic malignancies (acute myelogenous leukemia and multiple myeloma) with occurrence of relapse in the testicle.,"Leukemia, Myelocytic, Acute",ISA,Hematologic Neoplasms
27225057,METHODS: We present a retrospective review of the medical records of two patients diagnosed with hematologic malignancies (acute myelogenous leukemia and multiple myeloma) with occurrence of relapse in the testicle.,"Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
27233118,Neurocognitive sequelae are known to be induced by cranial radiotherapy and central-nervous-system-directed chemotherapy in childhood Acute Lymphoblastic Leukemia (ALL) and brain tumor patients.,Radiation therapy,TREATS,Brain Neoplasms
27233118,Neurocognitive sequelae are known to be induced by cranial radiotherapy and central-nervous-system-directed chemotherapy in childhood Acute Lymphoblastic Leukemia (ALL) and brain tumor patients.,Radiation therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27233118,Neurocognitive sequelae are known to be induced by cranial radiotherapy and central-nervous-system-directed chemotherapy in childhood Acute Lymphoblastic Leukemia (ALL) and brain tumor patients.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27233118,Neurocognitive sequelae are known to be induced by cranial radiotherapy and central-nervous-system-directed chemotherapy in childhood Acute Lymphoblastic Leukemia (ALL) and brain tumor patients.,Pharmacotherapy,TREATS,Brain Neoplasms
27233118,Neurocognitive sequelae are known to be induced by cranial radiotherapy and central-nervous-system-directed chemotherapy in childhood Acute Lymphoblastic Leukemia (ALL) and brain tumor patients.,Brain Neoplasms,PROCESS_OF,Patients
27249738,"The deep complete responses seen with combination tyrosine kinase inhibitors (TKIs) and chemotherapy in Ph-positive ALL, and the reports of long-term survival among some patients not undergoing allogeneic stem cell transplant, has raised the question of whether there is a subset of patients who could be cured without this intervention.",In complete remission,PROCESS_OF,Patients
27249738,"The deep complete responses seen with combination tyrosine kinase inhibitors (TKIs) and chemotherapy in Ph-positive ALL, and the reports of long-term survival among some patients not undergoing allogeneic stem cell transplant, has raised the question of whether there is a subset of patients who could be cured without this intervention.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
27254421,CONCLUSIONS: According to our experience the standard chemotherapy for precursor lymphomas seems to be a beneficial treatment option for children with PTCL.,Pharmacotherapy,TREATS,Lymphoma
27254421,CONCLUSIONS: According to our experience the standard chemotherapy for precursor lymphomas seems to be a beneficial treatment option for children with PTCL.,"Lymphoma, T-Cell, Peripheral",PROCESS_OF,Child
27269950,PURPOSE: Outcome of childhood acute lymphoblastic leukemia (ALL) improved greatly by intensifying chemotherapy for all patients.,Pharmacotherapy,TREATS,Patients
27269950,PURPOSE: Outcome of childhood acute lymphoblastic leukemia (ALL) improved greatly by intensifying chemotherapy for all patients.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27281445,BACKGROUND: Glucocorticoids are probably the most important drugs in the treatment of childhood acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27281445,BACKGROUND: Glucocorticoids are probably the most important drugs in the treatment of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,ISA,Pharmaceutical Preparations
27281445,BACKGROUND: Glucocorticoids are probably the most important drugs in the treatment of childhood acute lymphoblastic leukemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27285991,The authors prospectively assessed all children on chemotherapy for ALL with prolonged febrile neutropenia (FN) for CMV disease over a 3-year period.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27285991,The authors prospectively assessed all children on chemotherapy for ALL with prolonged febrile neutropenia (FN) for CMV disease over a 3-year period.,Disease,PROCESS_OF,Cytomegalovirus
27285991,Viral infections are an underrecognized problem in children on standard chemotherapy for acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27285991,Viral infections are an underrecognized problem in children on standard chemotherapy for acute lymphoblastic leukemia (ALL).,Virus Diseases,PROCESS_OF,Child
27285991,The authors conclude that CMV is an important pathogen in children on standard chemotherapy for ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27285991,The authors conclude that CMV is an important pathogen in children on standard chemotherapy for ALL.,Cytomegalovirus,PROCESS_OF,Child
27285991,The authors prospectively assessed all children on chemotherapy for ALL with prolonged febrile neutropenia (FN) for CMV disease over a 3-year period.,Febrile neutropenia,PROCESS_OF,Child
27286322,BACKGROUND: Race-based survival in children and adolescents with hematologic malignancies has been a national challenge for decades.,Hematologic Neoplasms,PROCESS_OF,Adolescent
27286322,BACKGROUND: Race-based survival in children and adolescents with hematologic malignancies has been a national challenge for decades.,Hematologic Neoplasms,PROCESS_OF,Child
27313742,"However, a few weeks later, the patient developed irreversible paraplegia due to a complication of the intrathecal administration of chemotherapy (methotrexate and cytarabine arabinoside).",Complication,CAUSES,Paraplegia
27313742,"However, a few weeks later, the patient developed irreversible paraplegia due to a complication of the intrathecal administration of chemotherapy (methotrexate and cytarabine arabinoside).",Methotrexate,ISA,Pharmacotherapy
27313742,"However, a few weeks later, the patient developed irreversible paraplegia due to a complication of the intrathecal administration of chemotherapy (methotrexate and cytarabine arabinoside).",Cytarabine,ISA,Pharmacotherapy
27313742,"However, a few weeks later, the patient developed irreversible paraplegia due to a complication of the intrathecal administration of chemotherapy (methotrexate and cytarabine arabinoside).",Paraplegia,PROCESS_OF,Patients
27328933,": Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs.",Bone Marrow,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
27328933,": Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs.",Organ,LOCATION_OF,Hematologic Neoplasms
27328933,": Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs.",Bone Marrow,LOCATION_OF,Hematologic Neoplasms
27328933,": Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs.",Organ,LOCATION_OF,"Leukemia, Lymphocytic, Acute"
27328933,": Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
27345588,"This study evaluated associations between uric acid (UA), cardiovascular health, and neurocognitive function in adolescent and adult survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27160933,"AIM: The aim of this study was to assess the impact of the use of a fluoride toothpaste (Bioxtra(R) , Biopharm, Milan, Italy) with salivary enzymes, essential oils, proteins and colostrum extract versus a fluoride toothpaste without menthol on the oral hygiene grade and on the quality of life (QoL) of children with oral mucositis (OM) grade 1 or 2 receiving chemotherapy for Acute Lymphoblastic Leukaemia (ALL).",Menthol,TREATS,"Leukemia, Lymphocytic, Acute"
27160933,"AIM: The aim of this study was to assess the impact of the use of a fluoride toothpaste (Bioxtra(R) , Biopharm, Milan, Italy) with salivary enzymes, essential oils, proteins and colostrum extract versus a fluoride toothpaste without menthol on the oral hygiene grade and on the quality of life (QoL) of children with oral mucositis (OM) grade 1 or 2 receiving chemotherapy for Acute Lymphoblastic Leukaemia (ALL).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27160933,"AIM: The aim of this study was to assess the impact of the use of a fluoride toothpaste (Bioxtra(R) , Biopharm, Milan, Italy) with salivary enzymes, essential oils, proteins and colostrum extract versus a fluoride toothpaste without menthol on the oral hygiene grade and on the quality of life (QoL) of children with oral mucositis (OM) grade 1 or 2 receiving chemotherapy for Acute Lymphoblastic Leukaemia (ALL).",Proteins,compared_with,Fluorides Toothpaste
27161682,"CONCLUSIONS: It is concluded that both venous and arterial thrombosis occurs in around 10% of AML patients treated with intensive chemotherapy, which can be predicted by the presence of DIC, or individual DIC parameters at time of AML diagnosis.",Pharmacotherapy,TREATS,Individual
27161682,"CONCLUSIONS: It is concluded that both venous and arterial thrombosis occurs in around 10% of AML patients treated with intensive chemotherapy, which can be predicted by the presence of DIC, or individual DIC parameters at time of AML diagnosis.",Pharmacotherapy,TREATS,Patients
27161682,"CONCLUSIONS: It is concluded that both venous and arterial thrombosis occurs in around 10% of AML patients treated with intensive chemotherapy, which can be predicted by the presence of DIC, or individual DIC parameters at time of AML diagnosis.",Arterial thrombosis,COEXISTS_WITH,Disseminated Intravascular Coagulation
27161682,"CONCLUSIONS: It is concluded that both venous and arterial thrombosis occurs in around 10% of AML patients treated with intensive chemotherapy, which can be predicted by the presence of DIC, or individual DIC parameters at time of AML diagnosis.","Leukemia, Myelocytic, Acute",PROCESS_OF,Patients
27161682,"CONCLUSIONS: It is concluded that both venous and arterial thrombosis occurs in around 10% of AML patients treated with intensive chemotherapy, which can be predicted by the presence of DIC, or individual DIC parameters at time of AML diagnosis.",Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
27468137,We conducted an analysis of ECOG 2993/UKALLXII trial to study delays in postremission chemotherapy in adults with newly diagnosed ALL.,Pharmacotherapy,TREATS,Adult
27468137,We conducted an analysis of ECOG 2993/UKALLXII trial to study delays in postremission chemotherapy in adults with newly diagnosed ALL.,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Adult
27468137,We conducted an analysis of ECOG 2993/UKALLXII trial to study delays in postremission chemotherapy in adults with newly diagnosed ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
27468137,Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27749571,BACKGROUND: Although adenovirus (ADV) infection usually causes self-limiting respiratory disorders in immune competent children; severe and systemic ADV infection in children undergoing chemotherapy for leukemia has been continuously reported.,Adenovirus Infections,CAUSES,Respiration Disorders
27749571,BACKGROUND: Although adenovirus (ADV) infection usually causes self-limiting respiratory disorders in immune competent children; severe and systemic ADV infection in children undergoing chemotherapy for leukemia has been continuously reported.,Pharmacotherapy,TREATS,leukemia
27749571,BACKGROUND: Although adenovirus (ADV) infection usually causes self-limiting respiratory disorders in immune competent children; severe and systemic ADV infection in children undergoing chemotherapy for leukemia has been continuously reported.,Systemic infection,PROCESS_OF,Adenoviruses
27749571,BACKGROUND: Although adenovirus (ADV) infection usually causes self-limiting respiratory disorders in immune competent children; severe and systemic ADV infection in children undergoing chemotherapy for leukemia has been continuously reported.,Systemic infection,PROCESS_OF,Child
27749571,BACKGROUND: Although adenovirus (ADV) infection usually causes self-limiting respiratory disorders in immune competent children; severe and systemic ADV infection in children undergoing chemotherapy for leukemia has been continuously reported.,Pharmacotherapy,TREATS,Adenovirus Infections
27749571,BACKGROUND: Although adenovirus (ADV) infection usually causes self-limiting respiratory disorders in immune competent children; severe and systemic ADV infection in children undergoing chemotherapy for leukemia has been continuously reported.,Pharmacotherapy,TREATS,Systemic infection
27749571,BACKGROUND: Although adenovirus (ADV) infection usually causes self-limiting respiratory disorders in immune competent children; severe and systemic ADV infection in children undergoing chemotherapy for leukemia has been continuously reported.,Adenovirus Infections,PROCESS_OF,Child
27749571,BACKGROUND: Although adenovirus (ADV) infection usually causes self-limiting respiratory disorders in immune competent children; severe and systemic ADV infection in children undergoing chemotherapy for leukemia has been continuously reported.,Respiration Disorders,PROCESS_OF,Child
27749571,BACKGROUND: Although adenovirus (ADV) infection usually causes self-limiting respiratory disorders in immune competent children; severe and systemic ADV infection in children undergoing chemotherapy for leukemia has been continuously reported.,Systemic infection,CAUSES,Respiration Disorders
27749571,BACKGROUND: Although adenovirus (ADV) infection usually causes self-limiting respiratory disorders in immune competent children; severe and systemic ADV infection in children undergoing chemotherapy for leukemia has been continuously reported.,Pharmacotherapy,TREATS,Child
27749571,He had received reinduction chemotherapy for relapsed acute lymphoblastic leukemia under continuing antifungal therapy for previously diagnosed fungal pneumonia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27769550,Reversible Cerebral Vasoconstriction Syndrome during Chemotherapy for Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27771473,"However, in rare cases, malignancies have been described in patients with WBS, with hematologic cancer (mainly Burkitt Lymphoma and Acute Lymphoblastic Leukemia) as the most represented.",CDKN1C gene | CDKN1C,ASSOCIATED_WITH,Malignant Neoplasms
27771473,"However, in rare cases, malignancies have been described in patients with WBS, with hematologic cancer (mainly Burkitt Lymphoma and Acute Lymphoblastic Leukemia) as the most represented.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
27771473,"However, in rare cases, malignancies have been described in patients with WBS, with hematologic cancer (mainly Burkitt Lymphoma and Acute Lymphoblastic Leukemia) as the most represented.",Burkitt Lymphoma,ISA,Hematologic Neoplasms
27771473,"However, in rare cases, malignancies have been described in patients with WBS, with hematologic cancer (mainly Burkitt Lymphoma and Acute Lymphoblastic Leukemia) as the most represented.",CDKN1C gene | CDKN1C,PART_OF,Patients
27771473,"However, in rare cases, malignancies have been described in patients with WBS, with hematologic cancer (mainly Burkitt Lymphoma and Acute Lymphoblastic Leukemia) as the most represented.",Malignant Neoplasms,PROCESS_OF,Patients
27793951,"To evaluate quantitative changes in B, NK and T lymphocyte subsets in peripheral blood of children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy.",peripheral blood,PART_OF,Child
27793951,"To evaluate quantitative changes in B, NK and T lymphocyte subsets in peripheral blood of children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27793951,"To evaluate quantitative changes in B, NK and T lymphocyte subsets in peripheral blood of children with acute lymphoblastic leukemia (ALL) undergoing chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27793951,Immunomodulating action of chemotherapy in children with ALL results in reduction of proportion of senescent CD8+ T lymphocytes.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27793951,Immunomodulating action of chemotherapy in children with ALL results in reduction of proportion of senescent CD8+ T lymphocytes.,Pharmacotherapy,TREATS,Child
27793951,Immunomodulating action of chemotherapy in children with ALL results in reduction of proportion of senescent CD8+ T lymphocytes.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27795510,Outcomes of patients with acute lymphoblastic leukemia (ALL) have improved dramatically with conventional chemotherapy consisting of multiple agents.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27795510,Outcomes of patients with acute lymphoblastic leukemia (ALL) have improved dramatically with conventional chemotherapy consisting of multiple agents.,Pharmacotherapy,TREATS,Patients
27795510,Outcomes of patients with acute lymphoblastic leukemia (ALL) have improved dramatically with conventional chemotherapy consisting of multiple agents.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27798768,"PURPOSE: Despite vast improvements that have been made in the treatment of children with acute lymphoblastic leukemia (ALL), the majority of infant ALL patients (~80 %, < 1 year of age) that carry a chromosomal translocation involving the mixed lineage leukemia (MLL) gene shows a poor response to chemotherapeutic drugs, especially glucocorticoids (GCs), which are essential components of all current treatment regimens.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27798768,"PURPOSE: Despite vast improvements that have been made in the treatment of children with acute lymphoblastic leukemia (ALL), the majority of infant ALL patients (~80 %, < 1 year of age) that carry a chromosomal translocation involving the mixed lineage leukemia (MLL) gene shows a poor response to chemotherapeutic drugs, especially glucocorticoids (GCs), which are essential components of all current treatment regimens.",MLL gene | KMT2A,ASSOCIATED_WITH,Chromosomal translocation
27798768,"PURPOSE: Despite vast improvements that have been made in the treatment of children with acute lymphoblastic leukemia (ALL), the majority of infant ALL patients (~80 %, < 1 year of age) that carry a chromosomal translocation involving the mixed lineage leukemia (MLL) gene shows a poor response to chemotherapeutic drugs, especially glucocorticoids (GCs), which are essential components of all current treatment regimens.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
27798768,"PURPOSE: Despite vast improvements that have been made in the treatment of children with acute lymphoblastic leukemia (ALL), the majority of infant ALL patients (~80 %, < 1 year of age) that carry a chromosomal translocation involving the mixed lineage leukemia (MLL) gene shows a poor response to chemotherapeutic drugs, especially glucocorticoids (GCs), which are essential components of all current treatment regimens.",Glucocorticoids,ISA,Pharmaceutical Preparations
27798768,"PURPOSE: Despite vast improvements that have been made in the treatment of children with acute lymphoblastic leukemia (ALL), the majority of infant ALL patients (~80 %, < 1 year of age) that carry a chromosomal translocation involving the mixed lineage leukemia (MLL) gene shows a poor response to chemotherapeutic drugs, especially glucocorticoids (GCs), which are essential components of all current treatment regimens.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
27798768,"PURPOSE: Despite vast improvements that have been made in the treatment of children with acute lymphoblastic leukemia (ALL), the majority of infant ALL patients (~80 %, < 1 year of age) that carry a chromosomal translocation involving the mixed lineage leukemia (MLL) gene shows a poor response to chemotherapeutic drugs, especially glucocorticoids (GCs), which are essential components of all current treatment regimens.",Glucocorticoids,TREATS,Child
27801322,Objective: To explore the efficacy and prognostic factors of imatinib(IM)combined with chemotherapy for BCR-ABL gene positive acute lymphoblastic leukemia(ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27815226,OBJECTIVES: Invasive aspergillosis (IA) is an important cause of mortality and morbidity in children with hematological malignancies.,Hematologic Neoplasms,PROCESS_OF,Child
27815226,OBJECTIVES: Invasive aspergillosis (IA) is an important cause of mortality and morbidity in children with hematological malignancies.,"ASPERGILLOSIS, INVASIVE",PROCESS_OF,Child
27822099,"AIM OF DATABASE: The main aim of the Danish National Acute Leukemia Registry (DNLR) was to obtain information about the epidemiology of the hematologic cancers acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS).","Leukemia, Myelocytic, Acute",ISA,Hematologic Neoplasms
27862918,"We aimed to investigate the impact of a contemporary treatment protocol that omitted prophylactic cranial radiation and glucocorticoids from the maintenance phase on longitudinal BMI, height, and weight z-scores in children with ALL.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
27862918,"We aimed to investigate the impact of a contemporary treatment protocol that omitted prophylactic cranial radiation and glucocorticoids from the maintenance phase on longitudinal BMI, height, and weight z-scores in children with ALL.",Treatment Protocols,TREATS,Child
27862918,"We aimed to investigate the impact of a contemporary treatment protocol that omitted prophylactic cranial radiation and glucocorticoids from the maintenance phase on longitudinal BMI, height, and weight z-scores in children with ALL.",Glucocorticoids,TREATS,Child
27862918,"We aimed to investigate the impact of a contemporary treatment protocol that omitted prophylactic cranial radiation and glucocorticoids from the maintenance phase on longitudinal BMI, height, and weight z-scores in children with ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27862918,"We aimed to investigate the impact of a contemporary treatment protocol that omitted prophylactic cranial radiation and glucocorticoids from the maintenance phase on longitudinal BMI, height, and weight z-scores in children with ALL.",Treatment Protocols,TREATS,"Leukemia, Lymphocytic, Acute"
27869523,"INTRODUCTION: T-cell acute lymphoblastic leukemia (ALL) and lymphoma (LBL) are aggressive hematologic neoplasms that are treated with combination chemotherapy in the frontline, but have limited options in the relapsed or refractory setting.",Combination Drug Therapy,TREATS,Hematologic Neoplasms
27869523,"INTRODUCTION: T-cell acute lymphoblastic leukemia (ALL) and lymphoma (LBL) are aggressive hematologic neoplasms that are treated with combination chemotherapy in the frontline, but have limited options in the relapsed or refractory setting.",Lymphoma,ISA,Hematologic Neoplasms
27869523,"INTRODUCTION: T-cell acute lymphoblastic leukemia (ALL) and lymphoma (LBL) are aggressive hematologic neoplasms that are treated with combination chemotherapy in the frontline, but have limited options in the relapsed or refractory setting.",Acute T Cell Leukemia,ISA,Hematologic Neoplasms
27869523,"INTRODUCTION: T-cell acute lymphoblastic leukemia (ALL) and lymphoma (LBL) are aggressive hematologic neoplasms that are treated with combination chemotherapy in the frontline, but have limited options in the relapsed or refractory setting.",Combination Drug Therapy,TREATS,Lymphoma
27869523,"INTRODUCTION: T-cell acute lymphoblastic leukemia (ALL) and lymphoma (LBL) are aggressive hematologic neoplasms that are treated with combination chemotherapy in the frontline, but have limited options in the relapsed or refractory setting.",Combination Drug Therapy,TREATS,Acute T Cell Leukemia
27872496,T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a high incidence of relapse in pediatric ALL.,Acute T Cell Leukemia,ISA,Hematologic Neoplasms
27891349,Acute Leukemia is one of the common haematological malignancies encountered with varied clinical and haematological presentation.,Acute leukemia,ISA,Hematologic Neoplasms
27593934,"Starting from genome-wide gene-expression profiling to seek important NOTCH1 transcriptional targets, we identified DEP-domain containing mTOR-interacting protein (DEPTOR), which was previously shown to be important in multiple myeloma but remains functionally unclear in other hematological malignancies.",Multiple Myeloma,ISA,Hematologic Neoplasms
27593934,"Starting from genome-wide gene-expression profiling to seek important NOTCH1 transcriptional targets, we identified DEP-domain containing mTOR-interacting protein (DEPTOR), which was previously shown to be important in multiple myeloma but remains functionally unclear in other hematological malignancies.",FKBP12-rapamycin associated protein | MTOR,ASSOCIATED_WITH,Multiple Myeloma
27599414,A 10-year-old girl developed L-asparaginase (ASP)-associated pancreatitis during chemotherapy for acute lymphocytic leukemia.,Pancreatitis,PROCESS_OF,Girls
27599414,A 10-year-old girl developed L-asparaginase (ASP)-associated pancreatitis during chemotherapy for acute lymphocytic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27602765,T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with variable prognosis.,Acute T Cell Leukemia,ISA,Hematologic Neoplasms
27616461,Methotrexate (MTX) is a commonly used agent for chemotherapy in oncology and has been documented to cause lung injury in both patients with rheumatologic and oncologic diseases.,Lung,LOCATION_OF,Injury
27616461,Methotrexate (MTX) is a commonly used agent for chemotherapy in oncology and has been documented to cause lung injury in both patients with rheumatologic and oncologic diseases.,Pharmacotherapy,USES,Methotrexate
27616461,Methotrexate (MTX) is a commonly used agent for chemotherapy in oncology and has been documented to cause lung injury in both patients with rheumatologic and oncologic diseases.,Injury,PROCESS_OF,Patients
27616461,Methotrexate (MTX) is a commonly used agent for chemotherapy in oncology and has been documented to cause lung injury in both patients with rheumatologic and oncologic diseases.,Methotrexate,ISA,Pharmacotherapy
27634018,"The Wilms' tumor 1 (WT1) gene product is a tumor-associated antigen that is expressed in acute leukemia and other hematologic malignancies, with limited expression in normal tissues.",Proteins,PART_OF,Hematologic Neoplasms
27634018,"The Wilms' tumor 1 (WT1) gene product is a tumor-associated antigen that is expressed in acute leukemia and other hematologic malignancies, with limited expression in normal tissues.",Proteins,PART_OF,Acute leukemia
27634018,"The Wilms' tumor 1 (WT1) gene product is a tumor-associated antigen that is expressed in acute leukemia and other hematologic malignancies, with limited expression in normal tissues.",Proteins,PART_OF,Body tissue
27634018,"The Wilms' tumor 1 (WT1) gene product is a tumor-associated antigen that is expressed in acute leukemia and other hematologic malignancies, with limited expression in normal tissues.",Proteins,PART_OF,Hematologic Neoplasms
27634018,"The Wilms' tumor 1 (WT1) gene product is a tumor-associated antigen that is expressed in acute leukemia and other hematologic malignancies, with limited expression in normal tissues.",Proteins,PART_OF,Acute leukemia
27634018,"The Wilms' tumor 1 (WT1) gene product is a tumor-associated antigen that is expressed in acute leukemia and other hematologic malignancies, with limited expression in normal tissues.",Hematologic Neoplasms,ISA,Acute leukemia
27634018,"The Wilms' tumor 1 (WT1) gene product is a tumor-associated antigen that is expressed in acute leukemia and other hematologic malignancies, with limited expression in normal tissues.",Acute leukemia,ISA,Hematologic Neoplasms
27635203,OBJECTIVES: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignant tumor.,Acute T Cell Leukemia,ISA,Hematologic Neoplasms
27648206,Protective Role of Silymarin on Hepatic and Renal Toxicity Induced by MTX Based Chemotherapy in Children with Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,Child
27648206,Protective Role of Silymarin on Hepatic and Renal Toxicity Induced by MTX Based Chemotherapy in Children with Acute Lymphoblastic Leukemia.,Methotrexate,CAUSES,Toxic nephropathy
27648206,Protective Role of Silymarin on Hepatic and Renal Toxicity Induced by MTX Based Chemotherapy in Children with Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
27648206,Protective Role of Silymarin on Hepatic and Renal Toxicity Induced by MTX Based Chemotherapy in Children with Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27655514,"T-cell Acute Lymphoblastic Leukemia (T-cell ALL) is a rare haematological neoplasia, that affects children and less commonly adults.",Hematologic Neoplasms,AFFECTS,Child
27655514,"T-cell Acute Lymphoblastic Leukemia (T-cell ALL) is a rare haematological neoplasia, that affects children and less commonly adults.",Hematologic Neoplasms,AFFECTS,Adult
27655514,"T-cell Acute Lymphoblastic Leukemia (T-cell ALL) is a rare haematological neoplasia, that affects children and less commonly adults.",Acute T Cell Leukemia,ISA,Hematologic Neoplasms
27655514,"T-cell Acute Lymphoblastic Leukemia (T-cell ALL) is a rare haematological neoplasia, that affects children and less commonly adults.",Acute T Cell Leukemia,AFFECTS,Child
27655514,"T-cell Acute Lymphoblastic Leukemia (T-cell ALL) is a rare haematological neoplasia, that affects children and less commonly adults.",Acute T Cell Leukemia,AFFECTS,Adult
27658980,"Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27658980,"This study examines the associations between acute leukoencephalopathy and neurobehavioural, neurocognitive, and brain white matter imaging outcomes in long-term survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy without cranial radiation.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
27658980,"BACKGROUND: Leukoencephalopathy is observed in some children undergoing chemotherapy for acute lymphoblastic leukaemia, although its effects on long-term outcomes is unknown.",Pharmacotherapy,TREATS,Child
27658980,"BACKGROUND: Leukoencephalopathy is observed in some children undergoing chemotherapy for acute lymphoblastic leukaemia, although its effects on long-term outcomes is unknown.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27658980,"BACKGROUND: Leukoencephalopathy is observed in some children undergoing chemotherapy for acute lymphoblastic leukaemia, although its effects on long-term outcomes is unknown.",Leukoencephalopathy,PROCESS_OF,Child
27658980,"BACKGROUND: Leukoencephalopathy is observed in some children undergoing chemotherapy for acute lymphoblastic leukaemia, although its effects on long-term outcomes is unknown.",Pharmacotherapy,TREATS,Leukoencephalopathy
27658980,"This study examines the associations between acute leukoencephalopathy and neurobehavioural, neurocognitive, and brain white matter imaging outcomes in long-term survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy without cranial radiation.",neurobehavior,PROCESS_OF,Long-Term Survivors
27658980,"Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.",Leukoencephalopathy,PROCESS_OF,Survivors
27658980,"This study examines the associations between acute leukoencephalopathy and neurobehavioural, neurocognitive, and brain white matter imaging outcomes in long-term survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy without cranial radiation.",Leukoencephalopathy,PROCESS_OF,Long-Term Survivors
27708784,"The cure of patients with leukemias and other hematological malignancies after bone marrow transplantation (BMT) has been attributed in part to the ability of the donor immune cells, present in the graft, to recognize and eliminate neoplastic cells of the patient.",leukemia,PROCESS_OF,Patients
27708784,"The cure of patients with leukemias and other hematological malignancies after bone marrow transplantation (BMT) has been attributed in part to the ability of the donor immune cells, present in the graft, to recognize and eliminate neoplastic cells of the patient.",Neoplastic Cell,PART_OF,Patients
27708784,"The cure of patients with leukemias and other hematological malignancies after bone marrow transplantation (BMT) has been attributed in part to the ability of the donor immune cells, present in the graft, to recognize and eliminate neoplastic cells of the patient.",Hematologic Neoplasms,PROCESS_OF,Patients
27708784,"The cure of patients with leukemias and other hematological malignancies after bone marrow transplantation (BMT) has been attributed in part to the ability of the donor immune cells, present in the graft, to recognize and eliminate neoplastic cells of the patient.",leukemia,PROCESS_OF,Patients
27708784,"The cure of patients with leukemias and other hematological malignancies after bone marrow transplantation (BMT) has been attributed in part to the ability of the donor immune cells, present in the graft, to recognize and eliminate neoplastic cells of the patient.",Hematologic Neoplasms,ISA,leukemia
27708784,"The cure of patients with leukemias and other hematological malignancies after bone marrow transplantation (BMT) has been attributed in part to the ability of the donor immune cells, present in the graft, to recognize and eliminate neoplastic cells of the patient.",Hematologic Neoplasms,PROCESS_OF,Patients
27708784,"The cure of patients with leukemias and other hematological malignancies after bone marrow transplantation (BMT) has been attributed in part to the ability of the donor immune cells, present in the graft, to recognize and eliminate neoplastic cells of the patient.",leukemia,ISA,Hematologic Neoplasms
27718310,"CONCLUSIONS: After chemotherapy for ALL, most of the children were not protected against VPDs.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
27726029,CONCLUSIONS: The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
27749571,"CONCLUSION: ADV may cause severe infections not only in allogeneic hematopoietic cell transplant recipients, but also in patients undergoing chemotherapy for acute leukemia.",Pharmacotherapy,TREATS,Acute leukemia
27749571,"CONCLUSION: ADV may cause severe infections not only in allogeneic hematopoietic cell transplant recipients, but also in patients undergoing chemotherapy for acute leukemia.",Pharmacotherapy,TREATS,Patients
27749571,"CONCLUSION: ADV may cause severe infections not only in allogeneic hematopoietic cell transplant recipients, but also in patients undergoing chemotherapy for acute leukemia.",Adenoviruses,CAUSES,Infection
28631497,Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28632246,PURPOSE/OBJECTIVES: To assess change in specific cognitive processes during treatment with chemotherapy only among children with acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,Child
28632246,PURPOSE/OBJECTIVES: To assess change in specific cognitive processes during treatment with chemotherapy only among children with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28632246,PURPOSE/OBJECTIVES: To assess change in specific cognitive processes during treatment with chemotherapy only among children with acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28641623,"CONCLUSION: The CR rate after induction chemotherapy is high in adult ALL patients, but the OS rate is low.",Pharmacotherapy,TREATS,Patients
28641623,"CONCLUSION: The CR rate after induction chemotherapy is high in adult ALL patients, but the OS rate is low.","Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
28641623,"CONCLUSION: The CR rate after induction chemotherapy is high in adult ALL patients, but the OS rate is low.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
28654205,"Some of these targets may be used as predictive biomarkers for the development of novel targeted therapies, which depart significantly from conventional chemotherapy, the current mainstay for treatment of acute leukemias.",Pharmacotherapy,TREATS,Acute leukemia
28654466,We report a case of a 6-year-old male child who presented with a generalized papular eruption during chemotherapy for acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28654466,We report a case of a 6-year-old male child who presented with a generalized papular eruption during chemotherapy for acute lymphoblastic leukemia.,Papular eruption,PROCESS_OF,Child
28424165,Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
28444640,Diagnostic value of the dual-luciferase report assay for predicting response to glucocorticoid in children with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28444640,Diagnostic value of the dual-luciferase report assay for predicting response to glucocorticoid in children with acute lymphoblastic leukemia.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
28444640,Diagnostic value of the dual-luciferase report assay for predicting response to glucocorticoid in children with acute lymphoblastic leukemia.,Glucocorticoids,TREATS,Child
28452142,We examined these associations among survivors of childhood ALL treated with chemotherapy only.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28469534,CONCLUSIONS: Vitamin D potentially poses a risk of hyperphosphatemia in children undergoing induction chemotherapy for ALL.,Pharmacotherapy,TREATS,Hyperphosphatemia
28469534,"Because of the potential for renal injury during induction chemotherapy for ALL, Vitamin D supplementation's potential for increasing hyperphosphatemia could outweigh its suggested but unproven benefits.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28469534,CONCLUSIONS: Vitamin D potentially poses a risk of hyperphosphatemia in children undergoing induction chemotherapy for ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28469534,CONCLUSIONS: Vitamin D potentially poses a risk of hyperphosphatemia in children undergoing induction chemotherapy for ALL.,Hyperphosphatemia,PROCESS_OF,Child
28469534,CONCLUSIONS: Vitamin D potentially poses a risk of hyperphosphatemia in children undergoing induction chemotherapy for ALL.,Pharmacotherapy,TREATS,Child
28469959,Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy diagnosed in children and is a malignant disorder that originates from one single hematopoietic precursor committed to B- or T-cell lineage.,Hematologic Neoplasms,PROCESS_OF,Child
28469959,Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy diagnosed in children and is a malignant disorder that originates from one single hematopoietic precursor committed to B- or T-cell lineage.,Hematologic Neoplasms,ISA,Disease
28469959,Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy diagnosed in children and is a malignant disorder that originates from one single hematopoietic precursor committed to B- or T-cell lineage.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
28469959,Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy diagnosed in children and is a malignant disorder that originates from one single hematopoietic precursor committed to B- or T-cell lineage.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28479419,Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy in pediatric patients.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
28479419,Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy in pediatric patients.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
28479419,Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy in pediatric patients.,Hematologic Neoplasms,PROCESS_OF,Patients
28484265,"The combination of the GC dexamethasone and the JAK1/2 inhibitor ruxolitinib altered the balance between pro- and anti-apoptotic factors in samples with IL7-dependent GC resistance, but not in samples with IL7-independent GC resistance.",Janus kinase 1 | JAK1,STIMULATES,Glucocorticoids
28484265,"The combination of the GC dexamethasone and the JAK1/2 inhibitor ruxolitinib altered the balance between pro- and anti-apoptotic factors in samples with IL7-dependent GC resistance, but not in samples with IL7-independent GC resistance.",Dexamethasone,STIMULATES,Glucocorticoids
28484265,"The combination of the GC dexamethasone and the JAK1/2 inhibitor ruxolitinib altered the balance between pro- and anti-apoptotic factors in samples with IL7-dependent GC resistance, but not in samples with IL7-independent GC resistance.",Dexamethasone,ISA,Glucocorticoids
28510690,"Trichosporonosis is an emerging and often fatal opportunistic fungal infection in immunocompromised patients, particularly those with hematologic malignancy, but data in children are lacking.",Opportunistic Infections,COEXISTS_WITH,Immunocompromised Host
28510690,"Trichosporonosis is an emerging and often fatal opportunistic fungal infection in immunocompromised patients, particularly those with hematologic malignancy, but data in children are lacking.",Hematologic Neoplasms,PROCESS_OF,Child
28510690,"Trichosporonosis is an emerging and often fatal opportunistic fungal infection in immunocompromised patients, particularly those with hematologic malignancy, but data in children are lacking.",Trichosporonosis,COEXISTS_WITH,Immunocompromised Host
28548080,"In vitro treatment of haematological neoplasia (acute myeloid leukaemia-AML, acute lymphoblastic leukaemia-ALL and diffuse large B-cell lymphoma-DLBCL) with the lead compound CM-272, inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death.",Diffuse Large B Cell Lymphoma of the Mouse Hematologic System,ISA,Hematologic Neoplasms
28548080,"In vitro treatment of haematological neoplasia (acute myeloid leukaemia-AML, acute lymphoblastic leukaemia-ALL and diffuse large B-cell lymphoma-DLBCL) with the lead compound CM-272, inhibits cell proliferation and promotes apoptosis, inducing interferon-stimulated genes and immunogenic cell death.","Leukemia, Myelocytic, Acute",ISA,Hematologic Neoplasms
28566433,"Thus, ongoing clinical trials are testing mTOR inhibitors in combination with chemotherapy in B-ALL.",Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
28578002,The reported involvement of microRNAs (miRNAs) in drug resistance implied that deregulated miRNA expression might contribute to GC treatment response of ALL.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
28581459,The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28581459,The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
28582465,Glucocorticoids (GCs) and topoisomerase II inhibitors are used to treat acute lymphoblastic leukaemia (ALL) as they induce death in lymphoid cells through the glucocorticoid receptor (GR) and p53 respectively.,Topoisomerase-II Inhibitor,TREATS,"Leukemia, Lymphocytic, Acute"
28582465,Glucocorticoids (GCs) and topoisomerase II inhibitors are used to treat acute lymphoblastic leukaemia (ALL) as they induce death in lymphoid cells through the glucocorticoid receptor (GR) and p53 respectively.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
28584598,"OBJECTIVES: To evaluate the impact of myeloid antigen expression on complete remission (CR), event-free survival (EFS), and overall survival (OS) in patients with T-cell acute lymphoblastic leukemia (T-ALL) treated with intensive chemotherapy.",Acute T Cell Leukemia,PROCESS_OF,Patients
28584598,"OBJECTIVES: To evaluate the impact of myeloid antigen expression on complete remission (CR), event-free survival (EFS), and overall survival (OS) in patients with T-cell acute lymphoblastic leukemia (T-ALL) treated with intensive chemotherapy.",Pharmacotherapy,TREATS,Acute T Cell Leukemia
28605290,"We found that despite expected high levels of early bone marrow chemotherapy resistance (87%), the overall prognosis for adults with ETP-ALL treated using the GRAALL protocols was not inferior to that of the non-ETP-ALL group (5-year overall survival: ETP, 59.6%; 95% CI, 44.2% to 72.0% v non-ETP, 66.5%; 95% CI, 58.7% to 73.2%; P = 0.33) and that allogeneic stem-cell transplantation had a beneficial effect in a large proportion of patients with ETP-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
28605290,"We found that despite expected high levels of early bone marrow chemotherapy resistance (87%), the overall prognosis for adults with ETP-ALL treated using the GRAALL protocols was not inferior to that of the non-ETP-ALL group (5-year overall survival: ETP, 59.6%; 95% CI, 44.2% to 72.0% v non-ETP, 66.5%; 95% CI, 58.7% to 73.2%; P = 0.33) and that allogeneic stem-cell transplantation had a beneficial effect in a large proportion of patients with ETP-ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28605290,"We found that despite expected high levels of early bone marrow chemotherapy resistance (87%), the overall prognosis for adults with ETP-ALL treated using the GRAALL protocols was not inferior to that of the non-ETP-ALL group (5-year overall survival: ETP, 59.6%; 95% CI, 44.2% to 72.0% v non-ETP, 66.5%; 95% CI, 58.7% to 73.2%; P = 0.33) and that allogeneic stem-cell transplantation had a beneficial effect in a large proportion of patients with ETP-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
28605290,"We found that despite expected high levels of early bone marrow chemotherapy resistance (87%), the overall prognosis for adults with ETP-ALL treated using the GRAALL protocols was not inferior to that of the non-ETP-ALL group (5-year overall survival: ETP, 59.6%; 95% CI, 44.2% to 72.0% v non-ETP, 66.5%; 95% CI, 58.7% to 73.2%; P = 0.33) and that allogeneic stem-cell transplantation had a beneficial effect in a large proportion of patients with ETP-ALL.",Pharmacotherapy,TREATS,Adult
28608730,"First, is the introduction of tyrosine-kinase inhibitor coupled to chemotherapy for treatment of Philadelphia positive ALL opening new treatment possibilities for the recently identified subgroup of Ph-like ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
28622302,"Evaluation of coagulopathy before and during induction chemotherapy for acute lymphoblastic leukaemia, including assessment of global clotting tests.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28628558,"OBJECTIVES: Glucocorticoids such as dexamethasone have pleiotropic effects, including desired antileukemic, anti-inflammatory, or immunosuppressive effects, and undesired metabolic or toxic effects.",Dexamethasone,AFFECTS,pleiotropism
28628558,"OBJECTIVES: Glucocorticoids such as dexamethasone have pleiotropic effects, including desired antileukemic, anti-inflammatory, or immunosuppressive effects, and undesired metabolic or toxic effects.",Dexamethasone,ISA,Glucocorticoids
28280276,"T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy, and T-ALL patients are prone to early disease relapse and suffer from poor outcomes.",Acute T Cell Leukemia,ISA,Hematologic Neoplasms
28280276,"T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy, and T-ALL patients are prone to early disease relapse and suffer from poor outcomes.",Acute T Cell Leukemia,ISA,Hematologic Neoplasms
28280276,"T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy, and T-ALL patients are prone to early disease relapse and suffer from poor outcomes.",Acute T Cell Leukemia,PROCESS_OF,Patients
28287326,Delays or interruptions in chemotherapy due to toxicity such as neutropenia or severe infections are common in the treatment of pediatric acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28321092,"Based on the initial diagnosis of BCP-ALL, induction chemotherapy for BCP-ALL was initiated.",Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
28333402,"CONCLUSION: Co-administration of fluconazole during induction therapy for pediatric ALL does not significantly increase the risk for vincristine-associated toxicities; however, patients 10 years or older are at an increased risk for toxicity independent of fluconazole exposure.",Fluconazole,PREDISPOSES,Toxic effect
28333402,"CONCLUSION: Co-administration of fluconazole during induction therapy for pediatric ALL does not significantly increase the risk for vincristine-associated toxicities; however, patients 10 years or older are at an increased risk for toxicity independent of fluconazole exposure.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28333402,Vincristine toxicity with co-administration of fluconazole during induction therapy for pediatric acute lymphoblastic leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28333402,"Prophylaxis with fluconazole during induction therapy for pediatric ALL, if warranted, appears to be a safe clinical practice.",Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28333402,"Prophylaxis with fluconazole during induction therapy for pediatric ALL, if warranted, appears to be a safe clinical practice.",Prophylactic treatment,USES,Fluconazole
28384176,Covariate-adjusted analysis revealed decreasing relative risk (RR) of chemotherapy with increasing age for both ALL and AML (trend p <0.001).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28384176,INTRODUCTION: Identifying sociodemographic disparities in chemotherapy and hematopoietic cell transplantation (HCT) utilization for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) may improve survival for underserved populations.,Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
28384176,INTRODUCTION: Identifying sociodemographic disparities in chemotherapy and hematopoietic cell transplantation (HCT) utilization for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) may improve survival for underserved populations.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28384176,Lower nSES quintiles predicted lower chemotherapy and HCT utilization for both ALL and AML (trend p <0.001).,Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
28384176,Lower nSES quintiles predicted lower chemotherapy and HCT utilization for both ALL and AML (trend p <0.001).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28384176,Covariate-adjusted analysis revealed decreasing relative risk (RR) of chemotherapy with increasing age for both ALL and AML (trend p <0.001).,Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
28394186,"The presence of high level language deficits in older children who received CNS-directed ITC for ALL in early childhood is yet to be elucidated, with previous research suggesting that high level language deficits may appear later in ALL survivors' development at an age when these skills typically emerge.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
28394186,"The presence of high level language deficits in older children who received CNS-directed ITC for ALL in early childhood is yet to be elucidated, with previous research suggesting that high level language deficits may appear later in ALL survivors' development at an age when these skills typically emerge.",Pharmacotherapy,ADMINISTERED_TO,Child
28394186,"The presence of high level language deficits in older children who received CNS-directed ITC for ALL in early childhood is yet to be elucidated, with previous research suggesting that high level language deficits may appear later in ALL survivors' development at an age when these skills typically emerge.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28394186,"The presence of high level language deficits in older children who received CNS-directed ITC for ALL in early childhood is yet to be elucidated, with previous research suggesting that high level language deficits may appear later in ALL survivors' development at an age when these skills typically emerge.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Survivors
28401497,Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Child
28401497,"In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL.",Pharmacotherapy,TREATS,Patients
28401497,"In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL.",Neutropenia,CAUSES,"Complication, infection"
28401497,Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28401497,"In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
28401497,Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28401497,"In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28401497,"Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL.",Pharmacotherapy,TREATS,Child
28401497,"Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28401497,"Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28402038,Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Hepatic Veno-Occlusive Disease,CAUSES,Hyperlipidemia
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Adrenal gland hypofunction,CAUSES,Hyperglycemia
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Endocrine System Diseases,CAUSES,Hyperglycemia
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Endocrine System Diseases,CAUSES,Adrenal gland hypofunction
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Hyperglycemia,ISA,Endocrine System Diseases
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Hepatic Veno-Occlusive Disease,CAUSES,Pancreatitis
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Hyperglycemia,CAUSES,Adrenal gland hypofunction
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Hepatic Veno-Occlusive Disease,CAUSES,Hypersensitivity
28413626,"During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia.",Adrenal gland hypofunction,ISA,Endocrine System Diseases
28422191,The reported data suggest that induction therapy for acute lymphoblastic leukemia followed by allogeneic hematopoietic cell transplantation is more effective than induction therapy for acute myeloid leukemia or consolidation chemotherapy.,Neoadjuvant Therapy,TREATS,"Leukemia, Myelocytic, Acute"
28422191,The reported data suggest that induction therapy for acute lymphoblastic leukemia followed by allogeneic hematopoietic cell transplantation is more effective than induction therapy for acute myeloid leukemia or consolidation chemotherapy.,Cell Transplantation,TREATS,"Leukemia, Myelocytic, Acute"
28422191,The reported data suggest that induction therapy for acute lymphoblastic leukemia followed by allogeneic hematopoietic cell transplantation is more effective than induction therapy for acute myeloid leukemia or consolidation chemotherapy.,Cell Transplantation,higher_than,Neoadjuvant Therapy
28422191,The reported data suggest that induction therapy for acute lymphoblastic leukemia followed by allogeneic hematopoietic cell transplantation is more effective than induction therapy for acute myeloid leukemia or consolidation chemotherapy.,Cell Transplantation,compared_with,Neoadjuvant Therapy
28422191,The reported data suggest that induction therapy for acute lymphoblastic leukemia followed by allogeneic hematopoietic cell transplantation is more effective than induction therapy for acute myeloid leukemia or consolidation chemotherapy.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
28090653,We used a genome-wide association study to identify loci associated with elevated alanine transaminase (ALT) levels after induction therapy in children with ALL enrolled on St.,Neoadjuvant Therapy,TREATS,Child
28090653,We used a genome-wide association study to identify loci associated with elevated alanine transaminase (ALT) levels after induction therapy in children with ALL enrolled on St.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28090653,We used a genome-wide association study to identify loci associated with elevated alanine transaminase (ALT) levels after induction therapy in children with ALL enrolled on St.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
28101583,B-cell acute lymphoblastic leukemia (BALL) is an aggressive hematological malignancy and a leading cause of cancer-related mortality in children and young adults.,"Leukemia, B-Cell, Acute",ISA,Hematologic Neoplasms
28101583,B-cell acute lymphoblastic leukemia (BALL) is an aggressive hematological malignancy and a leading cause of cancer-related mortality in children and young adults.,"Leukemia, B-Cell, Acute",PROCESS_OF,Young adult
28101583,B-cell acute lymphoblastic leukemia (BALL) is an aggressive hematological malignancy and a leading cause of cancer-related mortality in children and young adults.,"Leukemia, B-Cell, Acute",PROCESS_OF,Child
28101583,B-cell acute lymphoblastic leukemia (BALL) is an aggressive hematological malignancy and a leading cause of cancer-related mortality in children and young adults.,Hematologic Neoplasms,PROCESS_OF,Young adult
28101583,B-cell acute lymphoblastic leukemia (BALL) is an aggressive hematological malignancy and a leading cause of cancer-related mortality in children and young adults.,Hematologic Neoplasms,PROCESS_OF,Child
28103625,We conducted a phase II trial of imatinib-combined chemotherapy for newly diagnosed BCR-ABL-positive ALL in adults.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
28103625,We conducted a phase II trial of imatinib-combined chemotherapy for newly diagnosed BCR-ABL-positive ALL in adults.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.",Glucocorticoids,TREATS,Rheumatoid Arthritis
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.",Glucocorticoids,TREATS,Autoimmune Diseases
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.",Autoimmune Diseases,ISA,"Leukemia, Lymphocytic, Acute"
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.",Glucocorticoids,TREATS,Asthma
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.",Rheumatoid Arthritis,ISA,Autoimmune Diseases
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.",Autoimmune Diseases,ISA,Rheumatoid Arthritis
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.",Glucocorticoids,TREATS,Rheumatoid Arthritis
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.","Leukemia, Lymphocytic, Acute",ISA,Autoimmune Diseases
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.",Glucocorticoids,TREATS,Nephrotic Syndrome
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.",Glucocorticoids,TREATS,Autoimmune Diseases
28112586,"Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
28115368,T-cell acute lymphoblastic leukemia (T-ALL) is a highly proliferative hematologic malignancy that results from the transformation of immature T-cell progenitors.,Acute T Cell Leukemia,ISA,Hematologic Neoplasms
28116786,The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28126143,PATIENTS AND METHODS: We have analyzed by multiplex ligation-dependent probe amplification the genetic material from bone marrow at diagnosis from 25 adult B-ALL patients treated with rituximab and specific chemotherapy.,Patients,LOCATION_OF,Genetic Materials
28126143,PATIENTS AND METHODS: We have analyzed by multiplex ligation-dependent probe amplification the genetic material from bone marrow at diagnosis from 25 adult B-ALL patients treated with rituximab and specific chemotherapy.,rituximab,TREATS,Patients
28126143,PATIENTS AND METHODS: We have analyzed by multiplex ligation-dependent probe amplification the genetic material from bone marrow at diagnosis from 25 adult B-ALL patients treated with rituximab and specific chemotherapy.,Pharmacotherapy,TREATS,Patients
28126143,PATIENTS AND METHODS: We have analyzed by multiplex ligation-dependent probe amplification the genetic material from bone marrow at diagnosis from 25 adult B-ALL patients treated with rituximab and specific chemotherapy.,rituximab,TREATS,"Leukemia, Lymphocytic, Acute, L2"
28126143,PATIENTS AND METHODS: We have analyzed by multiplex ligation-dependent probe amplification the genetic material from bone marrow at diagnosis from 25 adult B-ALL patients treated with rituximab and specific chemotherapy.,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
28126143,PATIENTS AND METHODS: We have analyzed by multiplex ligation-dependent probe amplification the genetic material from bone marrow at diagnosis from 25 adult B-ALL patients treated with rituximab and specific chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
28126143,PATIENTS AND METHODS: We have analyzed by multiplex ligation-dependent probe amplification the genetic material from bone marrow at diagnosis from 25 adult B-ALL patients treated with rituximab and specific chemotherapy.,Bone Marrow,LOCATION_OF,Genetic Materials
28151717,The combinations of LEE011 with the glucocorticoid dexamethasone or the mTOR inhibitor everolimus were tested in vivo and prolonged survival in three orthotopic mouse models of T-ALL.,Dexamethasone,TREATS,House mice
28151717,The combinations of LEE011 with the glucocorticoid dexamethasone or the mTOR inhibitor everolimus were tested in vivo and prolonged survival in three orthotopic mouse models of T-ALL.,Dexamethasone,ISA,Glucocorticoids
28151717,The combinations of LEE011 with the glucocorticoid dexamethasone or the mTOR inhibitor everolimus were tested in vivo and prolonged survival in three orthotopic mouse models of T-ALL.,everolimus,TREATS,House mice
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Patients,LOCATION_OF,Interleukin-17
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Acute leukemia,PROCESS_OF,Patients
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Acute leukemia,PROCESS_OF,Patients
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Patients,LOCATION_OF,Transforming Growth Factor beta
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Acute leukemia,PROCESS_OF,Patients
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Patients,LOCATION_OF,FOXP3
28167485,"In addition, compared with before chemotherapy, the levels of Th17 cells and CD4+ CD25+ Foxp3+ cells, and the serum levels of IL-17 and TGF-beta in acute leukemia patients all decreased significantly after 6 months of chemotherapy, and the difference was statistically significant (P<0.001).",Pharmacotherapy,compared_with,Transforming Growth Factor beta
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Acute leukemia,PROCESS_OF,Patients
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Pharmacotherapy,TREATS,Patients
28167485,"In addition, compared with before chemotherapy, the levels of Th17 cells and CD4+ CD25+ Foxp3+ cells, and the serum levels of IL-17 and TGF-beta in acute leukemia patients all decreased significantly after 6 months of chemotherapy, and the difference was statistically significant (P<0.001).",Pharmacotherapy,TREATS,Patients
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Pharmacotherapy,TREATS,Acute leukemia
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Patients,LOCATION_OF,Interleukin-17
28167485,"In addition, compared with before chemotherapy, the levels of Th17 cells and CD4+ CD25+ Foxp3+ cells, and the serum levels of IL-17 and TGF-beta in acute leukemia patients all decreased significantly after 6 months of chemotherapy, and the difference was statistically significant (P<0.001).",Acute leukemia,PROCESS_OF,Patients
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Patients,LOCATION_OF,Transforming Growth Factor beta
28167485,"In addition, compared with before chemotherapy, the levels of Th17 cells and CD4+ CD25+ Foxp3+ cells, and the serum levels of IL-17 and TGF-beta in acute leukemia patients all decreased significantly after 6 months of chemotherapy, and the difference was statistically significant (P<0.001).",Pharmacotherapy,TREATS,Acute leukemia
28167485,"In addition, we examined the levels of Th17 and CD4+ CD25+ Foxp3+ cells and associated factor levels in patients with remission after AL chemotherapy. the Th17 cells (CD3+ CD4+ IL-17+) in acute leukemia patients accounted for (1.51+/-0.27)%, which was significantly higher than that of control group (0.36+/-0.23)%, with statistical significance (t=20.51, P<0.001); the percentage of CD4+ CD25+ Foxp3+ cells in AL patients was (3.37+/-0.48)%, which was significantly higher than that of control group of (1.26+/-0.27)%, with statistical significance (t=24.23, P<0.001); the serum levels of IL-17 and TGF-beta in AL patients were (28.12+/-6.33) pg/ml and (38.41+/-8.44) pg/ml respectively, which were all significantly higher than that of control group of (14.41+/-6.21) pg/ml and (24.49+/-7.42) pg/ml, with statistical significance (t=7.83, P<0.001; t=7.83, P<0.001); the RORgammaT mRNA and Foxp3 mRNA levels in AL patients we",Patients,LOCATION_OF,FOXP3
28179212,OBJECTIVE: Glucocorticoids (GCs) are the key drugs for the treatment of pediatric acute lymphoblastic leukemia (ALL).,Pharmaceutical Preparations,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28179212,OBJECTIVE: Glucocorticoids (GCs) are the key drugs for the treatment of pediatric acute lymphoblastic leukemia (ALL).,Glucocorticoids,ISA,Pharmaceutical Preparations
28179212,OBJECTIVE: Glucocorticoids (GCs) are the key drugs for the treatment of pediatric acute lymphoblastic leukemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28179212,"Herein, investigation of the relationship between the N363S and BclI polymorphisms of the GC receptor gene (NR3C1) and the side effects of GCs during pediatric ALL therapy was aimed.",Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28179212,"Herein, investigation of the relationship between the N363S and BclI polymorphisms of the GC receptor gene (NR3C1) and the side effects of GCs during pediatric ALL therapy was aimed.",NR3C1 gene | NR3C1,ISA,Receptor Gene
28195091,AIMS: To study the effect of induction chemotherapy on coagulation parameters in pediatric ALL patients.,Pharmacotherapy,TREATS,Patients
28195091,AIMS: To study the effect of induction chemotherapy on coagulation parameters in pediatric ALL patients.,"Leukemia, Lymphocytic, Acute, L1",PROCESS_OF,Patients
28195091,AIMS: To study the effect of induction chemotherapy on coagulation parameters in pediatric ALL patients.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
28208868,Female Genital Tract (FGT) involvement with hematologic neoplasms is uncommon and the hematologic malignancies which involve the female genital organs are usually non-Hodgkin's lymphoma.,Hematologic Neoplasms,AFFECTS,Female genitalia
28208868,Female Genital Tract (FGT) involvement with hematologic neoplasms is uncommon and the hematologic malignancies which involve the female genital organs are usually non-Hodgkin's lymphoma.,Hematologic Neoplasms,AFFECTS,Female genitalia
28208868,Female Genital Tract (FGT) involvement with hematologic neoplasms is uncommon and the hematologic malignancies which involve the female genital organs are usually non-Hodgkin's lymphoma.,"Lymphoma, Non-Hodgkin's",ISA,Hematologic Neoplasms
28208868,Female Genital Tract (FGT) involvement with hematologic neoplasms is uncommon and the hematologic malignancies which involve the female genital organs are usually non-Hodgkin's lymphoma.,"Lymphoma, Non-Hodgkin's",ISA,Hematologic Neoplasms
28208868,Female Genital Tract (FGT) involvement with hematologic neoplasms is uncommon and the hematologic malignancies which involve the female genital organs are usually non-Hodgkin's lymphoma.,"Lymphoma, Non-Hodgkin's",AFFECTS,Female genitalia
28210842,"METHODS: Laboratory results were analyzed from patients undergoing either allogeneic or autologous HCT or induction chemotherapy for acute leukemia (n = 50 per group, n = 150 total).",Cell Transplantation,TREATS,Acute leukemia
28210842,"METHODS: Laboratory results were analyzed from patients undergoing either allogeneic or autologous HCT or induction chemotherapy for acute leukemia (n = 50 per group, n = 150 total).",Pharmacotherapy,TREATS,Acute leukemia
28245371,"After 1 course of standardized chemotherapy, the complete remission rates in adult and children's B-ALL patients with abnormal high expression of CD146 both were low as compared with adult and children's B-ALL without abnormal high expression of CD146 (P<0.05).",Pharmacotherapy,TREATS,Patients
28245371,"After 1 course of standardized chemotherapy, the complete remission rates in adult and children's B-ALL patients with abnormal high expression of CD146 both were low as compared with adult and children's B-ALL without abnormal high expression of CD146 (P<0.05).",Pharmacotherapy,TREATS,Adult
28245371,"After 1 course of standardized chemotherapy, the complete remission rates in adult and children's B-ALL patients with abnormal high expression of CD146 both were low as compared with adult and children's B-ALL without abnormal high expression of CD146 (P<0.05).","Leukemia, B-Cell, Acute",PROCESS_OF,Child
28245371,"After 1 course of standardized chemotherapy, the complete remission rates in adult and children's B-ALL patients with abnormal high expression of CD146 both were low as compared with adult and children's B-ALL without abnormal high expression of CD146 (P<0.05).","Leukemia, B-Cell, Acute",PROCESS_OF,Patients
28245371,"After 1 course of standardized chemotherapy, the complete remission rates in adult and children's B-ALL patients with abnormal high expression of CD146 both were low as compared with adult and children's B-ALL without abnormal high expression of CD146 (P<0.05).",Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
28249141,Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28063690,"Intensive evaluations for hematologic malignancies may be unnecessary in children who complain of limb pain without any definite cause, unless they also present with accompanying leukemic symptoms.",Entire limb,LOCATION_OF,Pain
28063690,"Intensive evaluations for hematologic malignancies may be unnecessary in children who complain of limb pain without any definite cause, unless they also present with accompanying leukemic symptoms.",Pain,COEXISTS_WITH,Symptoms
28063690,"Intensive evaluations for hematologic malignancies may be unnecessary in children who complain of limb pain without any definite cause, unless they also present with accompanying leukemic symptoms.",Hematologic Neoplasms,PROCESS_OF,Child
28085529,"We describe a neutropenic pediatric patient who developed AAC following chemotherapy for acute T-cell acute lymphoblastic leukemia (T-ALL), which was successfully managed with conservative treatment.",Acute cholecystitis without calculus,PROCESS_OF,Patients
28085529,"We describe a neutropenic pediatric patient who developed AAC following chemotherapy for acute T-cell acute lymphoblastic leukemia (T-ALL), which was successfully managed with conservative treatment.",Pharmacotherapy,TREATS,Acute T Cell Leukemia
28085529,"We describe a neutropenic pediatric patient who developed AAC following chemotherapy for acute T-cell acute lymphoblastic leukemia (T-ALL), which was successfully managed with conservative treatment.",Therapeutic procedure,TREATS,Acute T Cell Leukemia
28090487,Clinical characteristics and outcomes of varicella zoster virus infection in children with hematologic malignancies in the acyclovir era.,Varicella-zoster virus infection,PROCESS_OF,Child
28090487,Clinical characteristics and outcomes of varicella zoster virus infection in children with hematologic malignancies in the acyclovir era.,Hematologic Neoplasms,PROCESS_OF,Child
28731916,We here report the case of a 6.5-year-old girl who developed multiple central nervous system fungal abscesses possibly due to Aspergillus infection during induction therapy for acute lymphoblastic leukemia who has been successfully managed without compromising antileukemia therapy.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
28731916,We here report the case of a 6.5-year-old girl who developed multiple central nervous system fungal abscesses possibly due to Aspergillus infection during induction therapy for acute lymphoblastic leukemia who has been successfully managed without compromising antileukemia therapy.,Intracranial or intraspinal abscess NOS,PROCESS_OF,Girls
28731916,We here report the case of a 6.5-year-old girl who developed multiple central nervous system fungal abscesses possibly due to Aspergillus infection during induction therapy for acute lymphoblastic leukemia who has been successfully managed without compromising antileukemia therapy.,Aspergillus infections,CAUSES,Intracranial or intraspinal abscess NOS
28731917,"We established NTBI and oxidative stress determinants (OSD), iron parameters, high-sensitive C-reactive protein (hs-CRP) levels, liver tests, cumulative chemotherapeutic doses, and transfused blood in 36 children with acute leukemia throughout chemotherapy.",Acute leukemia,PROCESS_OF,Child
28731917,"We established NTBI and oxidative stress determinants (OSD), iron parameters, high-sensitive C-reactive protein (hs-CRP) levels, liver tests, cumulative chemotherapeutic doses, and transfused blood in 36 children with acute leukemia throughout chemotherapy.",Pharmacotherapy,TREATS,Acute leukemia
28731917,"We established NTBI and oxidative stress determinants (OSD), iron parameters, high-sensitive C-reactive protein (hs-CRP) levels, liver tests, cumulative chemotherapeutic doses, and transfused blood in 36 children with acute leukemia throughout chemotherapy.",Pharmacotherapy,TREATS,Child
28774373,[Association between BIM gene and glucocorticoid resistance in children with acute lymphoblastic leukemia].,Glucocorticoids,TREATS,Child
28774373,[Association between BIM gene and glucocorticoid resistance in children with acute lymphoblastic leukemia].,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28774373,[Association between BIM gene and glucocorticoid resistance in children with acute lymphoblastic leukemia].,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
28798774,ALL is the most common hematological malignancy in children.,Hematologic Neoplasms,PROCESS_OF,Child
28837377,Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Patients
28837377,Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
28837377,Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28859185,Conclusions and Relevance: The combination of inotuzumab with low-intensity mini-HCVD chemotherapy shows encouraging results in R/R ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28859185,Objective: To evaluate the efficacy and safety of inotuzumab ozogamicin plus low-intensity chemotherapy in patients with R/R ALL.,Pharmacotherapy,TREATS,Patients
28859185,Objective: To evaluate the efficacy and safety of inotuzumab ozogamicin plus low-intensity chemotherapy in patients with R/R ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
28859185,Objective: To evaluate the efficacy and safety of inotuzumab ozogamicin plus low-intensity chemotherapy in patients with R/R ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29034206,T-cell acute lymphoblastic leukemia (T-ALL) is a hematological malignancy characterized by the clonal proliferation of immature T-cell precursors.,Acute T Cell Leukemia,ISA,Hematologic Neoplasms
29034341,Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by abnormal proliferation and accumulation of lymphoblasts in the hematopoietic system.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
29106702,Included studies demonstrated that adrenal insufficiency occurs in nearly all children during the first days after cessation of glucocorticoid treatment for childhood ALL.,Glucocorticoids,ISA,Therapeutic procedure
29106702,BACKGROUND: Glucocorticoids play a major role in the treatment of acute lymphoblastic leukaemia (ALL).,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute"
29106702,Included studies demonstrated that adrenal insufficiency occurs in nearly all children during the first days after cessation of glucocorticoid treatment for childhood ALL.,Glucocorticoids,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29117236,We recently demonstrated the effectiveness of blocking CD49d with anti-functional antibodies or small molecule inhibitors as a rational targeted approach to the treatment of acute leukemia in combination with chemotherapy.,Pharmacotherapy,TREATS,Acute leukemia
29181701,Non-alcoholic steatohepatitis induced by induction chemotherapy for pediatric acute lymphoblastic leukemia.,Pharmacotherapy,CAUSES,"Steatohepatitis, non-alcoholic"
29181701,Non-alcoholic steatohepatitis induced by induction chemotherapy for pediatric acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29212227,"Treatments include glucocorticoids (GCs) such as dexamethasone (Dex) and prednisolone, which may be of value when used alongside cytotoxic anti-cancer drugs.",prednisolone,ISA,Glucocorticoids
29212227,"Treatments include glucocorticoids (GCs) such as dexamethasone (Dex) and prednisolone, which may be of value when used alongside cytotoxic anti-cancer drugs.",Dexamethasone,ISA,Glucocorticoids
29212227,"Treatments include glucocorticoids (GCs) such as dexamethasone (Dex) and prednisolone, which may be of value when used alongside cytotoxic anti-cancer drugs.",Therapeutic procedure,USES,Cytotoxic agent
29222892,BACKGROUND AND OBJECTIVES: To determine the effect of oral nutritional supplements (ONS) on children with acute lymphoblastic leukaemia undergoing remission-induction chemotherapy.,"Leukemia, Lymphocytic, Acute",AFFECTS,Child
29222892,BACKGROUND AND OBJECTIVES: To determine the effect of oral nutritional supplements (ONS) on children with acute lymphoblastic leukaemia undergoing remission-induction chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29256044,"Progress has been made with the development of age-adapted, moderately intensive chemotherapy protocols for Ph/BCR-ABL-negative ALL and combinations of tyrosine kinase inhibitors with chemotherapy in Ph/BCR-ABL-positive ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
29274118,"AALL0232 was a COG randomized phase III trial for children with acute lymphoblastic leukemia that found that dexamethasone (DEX) was a more effective glucocorticoid than prednisone (PRED) in patients younger than 10 years, but PRED was equally effective and less toxic in older patients.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
29274118,"AALL0232 was a COG randomized phase III trial for children with acute lymphoblastic leukemia that found that dexamethasone (DEX) was a more effective glucocorticoid than prednisone (PRED) in patients younger than 10 years, but PRED was equally effective and less toxic in older patients.",Prednisone,TREATS,Patients
29274118,"AALL0232 was a COG randomized phase III trial for children with acute lymphoblastic leukemia that found that dexamethasone (DEX) was a more effective glucocorticoid than prednisone (PRED) in patients younger than 10 years, but PRED was equally effective and less toxic in older patients.",Dexamethasone,ISA,Glucocorticoids
29274118,"AALL0232 was a COG randomized phase III trial for children with acute lymphoblastic leukemia that found that dexamethasone (DEX) was a more effective glucocorticoid than prednisone (PRED) in patients younger than 10 years, but PRED was equally effective and less toxic in older patients.",Prednisone,TREATS,Patients
28837377,The addition of the monoclonal antibody rituximab to standard chemotherapy has been shown to improve survival in adults with ALL.,rituximab,ISA,Monoclonal Antibodies
28837377,The addition of the monoclonal antibody rituximab to standard chemotherapy has been shown to improve survival in adults with ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28837377,The addition of the monoclonal antibody rituximab to standard chemotherapy has been shown to improve survival in adults with ALL.,Pharmacotherapy,TREATS,Adult
28837377,The addition of the monoclonal antibody rituximab to standard chemotherapy has been shown to improve survival in adults with ALL.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
28901791,Acute leukemia (AL) is the most common hematological malignancy requiring intensive care unit (ICU) management.,Acute leukemia,ISA,Hematologic Neoplasms
28947994,"We revealed the abnormal topological organization of the WM networks of ALL patients with chemotherapy, which may improve our understanding of the neural mechanism of chemotherapy in ALL from a WM topological organization level.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28947994,"We revealed the abnormal topological organization of the WM networks of ALL patients with chemotherapy, which may improve our understanding of the neural mechanism of chemotherapy in ALL from a WM topological organization level.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
28978582,Posterior reversible encephalopathy syndrome (PRES) is the most common neurological complication occurring in children undergoing induction chemotherapy for acute lymphoblastic leukaemia (ALL) but is increasingly recognised to occur in adults as well.,NEUROLOGIC COMPLICATION,OCCURS_IN,Child
28978582,Posterior reversible encephalopathy syndrome (PRES) is the most common neurological complication occurring in children undergoing induction chemotherapy for acute lymphoblastic leukaemia (ALL) but is increasingly recognised to occur in adults as well.,Syndrome,OCCURS_IN,Adult
28978582,Posterior reversible encephalopathy syndrome (PRES) is the most common neurological complication occurring in children undergoing induction chemotherapy for acute lymphoblastic leukaemia (ALL) but is increasingly recognised to occur in adults as well.,Pharmacotherapy,TREATS,Child
28978582,Posterior reversible encephalopathy syndrome (PRES) is the most common neurological complication occurring in children undergoing induction chemotherapy for acute lymphoblastic leukaemia (ALL) but is increasingly recognised to occur in adults as well.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28978840,"In Japan, nelarabine-combined chemotherapy has been tested in a phase II study in patients with newly diagnosed T-ALL.",Pharmacotherapy,TREATS,Patients
28978840,"In Japan, nelarabine-combined chemotherapy has been tested in a phase II study in patients with newly diagnosed T-ALL.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
28978840,"In Japan, nelarabine-combined chemotherapy has been tested in a phase II study in patients with newly diagnosed T-ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28978861,"In addition to optimizing appropriate chemotherapies for acute leukemia in AYAs, the development of novel therapy based on genomic analyses should be explored by close cooperation between pediatric hematologists/oncologists and adult hematologists.",Pharmacotherapy,TREATS,Acute leukemia
28990505,"The very distinct mechanisms of the anticancer activity of new immunotherapy approaches not only call for novel response criteria, but also might fundamental change treatment paradigms of certain types of hematologic malignancies in the near future.",Immunotherapy,TREATS,Hematologic Neoplasms
29020310,Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29020310,Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.,Prophylactic treatment,USES,Levofloxacin
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Immunotherapy,TREATS,"Leukemia, B-Cell, Acute"
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Immunotherapy,TREATS,"Leukemia, B-Cell, Acute"
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Pharmacotherapy,ISA,Therapeutic procedure
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Pharmacotherapy,ISA,Immunotherapy
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Therapeutic procedure,ISA,Pharmacotherapy
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Therapeutic procedure,ISA,Immunotherapy
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Therapeutic procedure,TREATS,"Leukemia, B-Cell, Acute"
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Immunotherapy,ISA,Therapeutic procedure
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Immunotherapy,ISA,Pharmacotherapy
29082835,"Ongoing trials in ALL incorporate blinatumomab in the first line therapy of BCP ALL in combination with chemotherapy, targeted therapies or other immunotherapies with the aim of increasing the depth of the remission and decreasing the probability of relapse.",Therapeutic procedure,TREATS,"Leukemia, B-Cell, Acute"
29095384,"We present the case of a 16-year-old boy who presented with fatigue, polyuria, and polydipsia while on chemotherapy for his relapsed acute lymphoblastic leukemia (ALL).",Polyuria,PROCESS_OF,Boys
29095384,The etiology for his hyperglycemia was most likely a result of oral glucocorticoid therapy combined with asparaginase therapy-both are a cornerstone of induction chemotherapy for ALL.,GLUCOCORTICOID THERAPY,CAUSES,Hyperglycemia
29095384,The etiology for his hyperglycemia was most likely a result of oral glucocorticoid therapy combined with asparaginase therapy-both are a cornerstone of induction chemotherapy for ALL.,Therapeutic procedure,USES,ASPARAGINASE
29095384,"We present the case of a 16-year-old boy who presented with fatigue, polyuria, and polydipsia while on chemotherapy for his relapsed acute lymphoblastic leukemia (ALL).",Fatigue,PROCESS_OF,Boys
29095384,The etiology for his hyperglycemia was most likely a result of oral glucocorticoid therapy combined with asparaginase therapy-both are a cornerstone of induction chemotherapy for ALL.,Pharmacotherapy,ISA,Therapeutic procedure
29095384,Hyperglycemic Hyperosmolar State During Induction Chemotherapy for Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29095384,The etiology for his hyperglycemia was most likely a result of oral glucocorticoid therapy combined with asparaginase therapy-both are a cornerstone of induction chemotherapy for ALL.,Pharmacotherapy,USES,ASPARAGINASE
29095384,The etiology for his hyperglycemia was most likely a result of oral glucocorticoid therapy combined with asparaginase therapy-both are a cornerstone of induction chemotherapy for ALL.,ASPARAGINASE,ISA,Therapeutic procedure
29095384,"We present the case of a 16-year-old boy who presented with fatigue, polyuria, and polydipsia while on chemotherapy for his relapsed acute lymphoblastic leukemia (ALL).",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29095384,"We present the case of a 16-year-old boy who presented with fatigue, polyuria, and polydipsia while on chemotherapy for his relapsed acute lymphoblastic leukemia (ALL).",Polydipsia,PROCESS_OF,Boys
29095384,The etiology for his hyperglycemia was most likely a result of oral glucocorticoid therapy combined with asparaginase therapy-both are a cornerstone of induction chemotherapy for ALL.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29168384,Microbial asparaginase is an essential component of chemotherapy for the treatment of childhood acute lymphoblastic leukemia (cALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29168384,Microbial asparaginase is an essential component of chemotherapy for the treatment of childhood acute lymphoblastic leukemia (cALL).,ASPARAGINASE,ISA,Pharmacotherapy
29168384,Microbial asparaginase is an essential component of chemotherapy for the treatment of childhood acute lymphoblastic leukemia (cALL).,ASPARAGINASE,PART_OF,microbial
29168384,Microbial asparaginase is an essential component of chemotherapy for the treatment of childhood acute lymphoblastic leukemia (cALL).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29189508,Steroid-induced Hypertension During Induction Chemotherapy for Acute Lymphoblastic Leukemia in US Children's Hospitals.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29200170,Terson Syndrome Before Induction Chemotherapy for Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29275139,We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1.,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
29275139,We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
29275139,We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1.,Pharmacotherapy,TREATS,Patients
29275139,We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1.,Cell Transplantation,TREATS,Patients
29275139,We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1.,Cell Transplantation,TREATS,"Leukemia, Lymphocytic, Acute, L2"
29285259,Patients with standard-risk adult acute lymphoblastic leukemia (ALL) treated with chemotherapy do not have satisfactory outcomes.,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
29285259,Patients with standard-risk adult acute lymphoblastic leukemia (ALL) treated with chemotherapy do not have satisfactory outcomes.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
29286562,Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study.,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
29286562,Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study.,Children's Oncology Group,LOCATION_OF,Clinical Research
28728499,We analyzed ammonium levels and acute central nervous complications in adult patients receiving chemotherapy for acute lymphoblastic leukemia with or without asparaginase (l-asp).,Pharmacotherapy,ADMINISTERED_TO,Patients
28728499,We analyzed ammonium levels and acute central nervous complications in adult patients receiving chemotherapy for acute lymphoblastic leukemia with or without asparaginase (l-asp).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28728499,We analyzed ammonium levels and acute central nervous complications in adult patients receiving chemotherapy for acute lymphoblastic leukemia with or without asparaginase (l-asp).,ASPARAGINASE,ADMINISTERED_TO,Patients
28728499,We analyzed ammonium levels and acute central nervous complications in adult patients receiving chemotherapy for acute lymphoblastic leukemia with or without asparaginase (l-asp).,ASPARAGINASE,TREATS,"Leukemia, Lymphocytic, Acute"
28728499,We analyzed ammonium levels and acute central nervous complications in adult patients receiving chemotherapy for acute lymphoblastic leukemia with or without asparaginase (l-asp).,Complication,PROCESS_OF,Patients
28748759,"Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children, characterized by an abnormal proliferation of immature lymphoid cells.",Hematologic Neoplasms,PROCESS_OF,Child
28748759,"Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children, characterized by an abnormal proliferation of immature lymphoid cells.","Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
28748759,"Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children, characterized by an abnormal proliferation of immature lymphoid cells.","Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28809761,"Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is the most common hematological malignancy in children, and the t(12;21)(p13;q22) occurs in approximately 25% of these cases, making it is the most prevalent chromosomal abnormality.",Hematologic Neoplasms,PROCESS_OF,Child
28809761,"Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is the most common hematological malignancy in children, and the t(12;21)(p13;q22) occurs in approximately 25% of these cases, making it is the most prevalent chromosomal abnormality.","Leukemia, B-Cell, Acute",ISA,Hematologic Neoplasms
28809761,"Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is the most common hematological malignancy in children, and the t(12;21)(p13;q22) occurs in approximately 25% of these cases, making it is the most prevalent chromosomal abnormality.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
28844708,"We summarize that upregulated tOPN can modulate HMs (leukemia, lymphoma and myeloma) progression, inducing cell adhesion, invasion, angiogenesis, cell differentiation and extramedullary and/or central nervous system infiltration.",SPP1,AFFECTS,leukemia
28844708,"We summarize that upregulated tOPN can modulate HMs (leukemia, lymphoma and myeloma) progression, inducing cell adhesion, invasion, angiogenesis, cell differentiation and extramedullary and/or central nervous system infiltration.",SPP1,AFFECTS,Hematologic Neoplasms
28844708,"We summarize that upregulated tOPN can modulate HMs (leukemia, lymphoma and myeloma) progression, inducing cell adhesion, invasion, angiogenesis, cell differentiation and extramedullary and/or central nervous system infiltration.",leukemia,ISA,Hematologic Neoplasms
28900336,Palatal perforation is an uncommon complication seen in children with acute lymphoblastic leukemia undergoing chemotherapy.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28900336,Palatal perforation is an uncommon complication seen in children with acute lymphoblastic leukemia undergoing chemotherapy.,Complication,PROCESS_OF,Child
28900336,Palatal perforation is an uncommon complication seen in children with acute lymphoblastic leukemia undergoing chemotherapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29018079,SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.,Pharmacotherapy,TREATS,leukemia
29020310,"Although long-term antibiotic-resistance monitoring is needed, these data support using targeted prophylaxis with levofloxacin in children undergoing induction chemotherapy for ALL.",Prophylactic treatment,USES,Levofloxacin
29020310,"Although long-term antibiotic-resistance monitoring is needed, these data support using targeted prophylaxis with levofloxacin in children undergoing induction chemotherapy for ALL.",Pharmacotherapy,TREATS,Child
29020310,Conclusions: This is the largest study to date of antibacterial prophylaxis during induction therapy for pediatric ALL and the first to include a broad-spectrum fluoroquinolone.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29020310,"Although long-term antibiotic-resistance monitoring is needed, these data support using targeted prophylaxis with levofloxacin in children undergoing induction chemotherapy for ALL.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29020310,"Although long-term antibiotic-resistance monitoring is needed, these data support using targeted prophylaxis with levofloxacin in children undergoing induction chemotherapy for ALL.",Levofloxacin,TREATS,Child
29046900,Addition of dasatinib to chemotherapy and HCT for younger patients with Ph+ ALL is feasible and warrants further testing.,Pharmacotherapy,TREATS,Patients
29046900,Addition of dasatinib to chemotherapy and HCT for younger patients with Ph+ ALL is feasible and warrants further testing.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
29046900,Addition of dasatinib to chemotherapy and HCT for younger patients with Ph+ ALL is feasible and warrants further testing.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29067094,Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and NUP214-ABL1 fusion: A case report.,Acute T Cell Leukemia,PROCESS_OF,Patients
29067094,Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and NUP214-ABL1 fusion: A case report.,Pharmacotherapy,TREATS,Patients
29067094,Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and NUP214-ABL1 fusion: A case report.,Pharmacotherapy,TREATS,Acute T Cell Leukemia
29101238,"We showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, are able to induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concentrations.",Dexamethasone,ISA,Glucocorticoids
29101238,"We showed that LCK inhibitors, such as dasatinib, bosutinib, nintedanib, and WH-4-023, are able to induce cell death in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC resistance, even at therapeutic drug concentrations.",Dexamethasone,PART_OF,T-Lymphocyte
29154447,Acute Lymphoblastic Leukemia (ALL) is an hematological malignancy characterized by the proliferation of early lymphoid precursors that replace normal hematopoietic cells of the bone marrow.,Normal cell,PART_OF,Bone Marrow
29154447,Acute Lymphoblastic Leukemia (ALL) is an hematological malignancy characterized by the proliferation of early lymphoid precursors that replace normal hematopoietic cells of the bone marrow.,"Leukemia, Lymphocytic, Acute",ISA,Hematologic Neoplasms
29218389,"Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT).",Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
29218389,"Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT).",Pharmacotherapy,TREATS,Hematologic Neoplasms
29218389,Our key recommendations are the following: prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS (AI).,Pharmacotherapy,TREATS,Dysmyelopoietic Syndromes
29218389,Our key recommendations are the following: prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS (AI).,Pharmacotherapy,TREATS,"Leukemia, Myelocytic, Acute"
29218389,"Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of allogeneic haematopoietic stem cell transplants (HSCT).",Pharmacotherapy,TREATS,Dysmyelopoietic Syndromes
29219891,We report on the case of a child with TTP associated with a human herpes virus type-6 infection occurring during chemotherapy for acute lymphoblastic leukemia who was effectively treated by fresh frozen plasma infusions and antiviral therapy.,"Purpura, Thrombotic Thrombocytopenic",PROCESS_OF,Child
29219891,We report on the case of a child with TTP associated with a human herpes virus type-6 infection occurring during chemotherapy for acute lymphoblastic leukemia who was effectively treated by fresh frozen plasma infusions and antiviral therapy.,Human herpesvirus 6 infection,COEXISTS_WITH,"Purpura, Thrombotic Thrombocytopenic"
29219891,We report on the case of a child with TTP associated with a human herpes virus type-6 infection occurring during chemotherapy for acute lymphoblastic leukemia who was effectively treated by fresh frozen plasma infusions and antiviral therapy.,Antiviral Therapy,TREATS,"Leukemia, Lymphocytic, Acute"
29219891,We report on the case of a child with TTP associated with a human herpes virus type-6 infection occurring during chemotherapy for acute lymphoblastic leukemia who was effectively treated by fresh frozen plasma infusions and antiviral therapy.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29259862,"She was planned for bronchial artery embolization and chemotherapy for ALL, but consent was not given and she left our institute against medical advice.","Embolization, Therapeutic",TREATS,"Leukemia, Lymphocytic, Acute"
29259862,"She was planned for bronchial artery embolization and chemotherapy for ALL, but consent was not given and she left our institute against medical advice.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29260426,The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,Adult
29260426,The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Adult
29260426,The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
29260426,The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29260426,The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.,Induction,TREATS,Adult
28666090,Several trials are now being conducted to evaluate the role of certain MoAbs in combination with chemotherapy in the treatment of B-cell ALL.,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
28670458,"He was diagnosed with acute lymphoblastic leukemia, and subsequently underwent chemotherapy.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
28698205,"Importantly, the combination of antibody CD19-DE and cytoreduction by chemotherapy (dexamethasone, vincristine, PEG-asparaginase) resulted in significantly improved survival rates in xenografted mice.",Pharmacotherapy,TREATS,Mus
28698205,"Importantly, the combination of antibody CD19-DE and cytoreduction by chemotherapy (dexamethasone, vincristine, PEG-asparaginase) resulted in significantly improved survival rates in xenografted mice.",Dexamethasone,ISA,Pharmacotherapy
28698205,"Thus, Fc-engineered CD19 antibodies may represent a promising treatment option for infants and children with MLL-rearranged BCP-ALL who have a poor outcome when treated with chemotherapy only.","Leukemia, B-Cell, Acute",PROCESS_OF,Infant
28698205,"Importantly, the combination of antibody CD19-DE and cytoreduction by chemotherapy (dexamethasone, vincristine, PEG-asparaginase) resulted in significantly improved survival rates in xenografted mice.",Dexamethasone,TREATS,Mus
28698205,"Thus, Fc-engineered CD19 antibodies may represent a promising treatment option for infants and children with MLL-rearranged BCP-ALL who have a poor outcome when treated with chemotherapy only.","Leukemia, B-Cell, Acute",PROCESS_OF,Child
28698205,"Thus, Fc-engineered CD19 antibodies may represent a promising treatment option for infants and children with MLL-rearranged BCP-ALL who have a poor outcome when treated with chemotherapy only.",Pharmacotherapy,TREATS,Infant
28698205,"Thus, Fc-engineered CD19 antibodies may represent a promising treatment option for infants and children with MLL-rearranged BCP-ALL who have a poor outcome when treated with chemotherapy only.",Pharmacotherapy,TREATS,Child
28698205,"Thus, Fc-engineered CD19 antibodies may represent a promising treatment option for infants and children with MLL-rearranged BCP-ALL who have a poor outcome when treated with chemotherapy only.",Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
28819740,"In the USA, a phase III trial evaluating inotuzumab ozogamicin in combination with frontline chemotherapy in adults with newly diagnosed B-cell ALL has recently been initiated and inotuzumab ozogamicin is under phase II evaluation in childhood CD22-positive B-cell ALL.",Inotuzumab Ozogamicin,ASSOCIATED_WITH,B-cell childhood acute lymphoblastic leukemia
28819740,"In the USA, a phase III trial evaluating inotuzumab ozogamicin in combination with frontline chemotherapy in adults with newly diagnosed B-cell ALL has recently been initiated and inotuzumab ozogamicin is under phase II evaluation in childhood CD22-positive B-cell ALL.",Inotuzumab Ozogamicin,ASSOCIATED_WITH,B-cell childhood acute lymphoblastic leukemia
28819740,"In the USA, a phase III trial evaluating inotuzumab ozogamicin in combination with frontline chemotherapy in adults with newly diagnosed B-cell ALL has recently been initiated and inotuzumab ozogamicin is under phase II evaluation in childhood CD22-positive B-cell ALL.","Leukemia, B-Cell, Acute",PROCESS_OF,Adult
28819740,"In the USA, a phase III trial evaluating inotuzumab ozogamicin in combination with frontline chemotherapy in adults with newly diagnosed B-cell ALL has recently been initiated and inotuzumab ozogamicin is under phase II evaluation in childhood CD22-positive B-cell ALL.",Pharmacotherapy,TREATS,Adult
28819740,"In the USA, a phase III trial evaluating inotuzumab ozogamicin in combination with frontline chemotherapy in adults with newly diagnosed B-cell ALL has recently been initiated and inotuzumab ozogamicin is under phase II evaluation in childhood CD22-positive B-cell ALL.",Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
28962960,A bone marrow biopsy was unequivocally diagnostic of B-cell acute lymphoblastic lymphoma followed by chemotherapy (methotrexate) and partial recovery was observed.,lymphoblast,LOCATION_OF,B-Cell Lymphomas
28962960,A bone marrow biopsy was unequivocally diagnostic of B-cell acute lymphoblastic lymphoma followed by chemotherapy (methotrexate) and partial recovery was observed.,Methotrexate,ISA,Pharmacotherapy
28972594,RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL).,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
28983018,Novel therapies are needed to overcome chemotherapy resistance for children with relapsed/refractory acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,Child
28983018,Novel therapies are needed to overcome chemotherapy resistance for children with relapsed/refractory acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Child
28983018,Novel therapies are needed to overcome chemotherapy resistance for children with relapsed/refractory acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29025266,"DATA SYNTHESIS: Conventional chemotherapy has been the mainstay in the treatment of ALL, producing cure rates of approximately 90% in pediatrics, but it remains suboptimal in adult patients.",Pharmacotherapy,ISA,Therapeutic procedure
29025266,"DATA SYNTHESIS: Conventional chemotherapy has been the mainstay in the treatment of ALL, producing cure rates of approximately 90% in pediatrics, but it remains suboptimal in adult patients.",Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29140934,BACKGROUND: Chronic disseminated candidiasis (CDC) is a severe invasive fungal infection principally observed during neutrophil recovery in patients with acute leukemia treated with intensive chemotherapy.,Chronic disseminated candidiasis,ISA,Mycoses
29140934,BACKGROUND: Chronic disseminated candidiasis (CDC) is a severe invasive fungal infection principally observed during neutrophil recovery in patients with acute leukemia treated with intensive chemotherapy.,Chronic disseminated candidiasis,PROCESS_OF,Patients
29140934,BACKGROUND: Chronic disseminated candidiasis (CDC) is a severe invasive fungal infection principally observed during neutrophil recovery in patients with acute leukemia treated with intensive chemotherapy.,Mycoses,PROCESS_OF,Patients
29140934,BACKGROUND: Chronic disseminated candidiasis (CDC) is a severe invasive fungal infection principally observed during neutrophil recovery in patients with acute leukemia treated with intensive chemotherapy.,Acute leukemia,PROCESS_OF,Patients
29140934,BACKGROUND: Chronic disseminated candidiasis (CDC) is a severe invasive fungal infection principally observed during neutrophil recovery in patients with acute leukemia treated with intensive chemotherapy.,Pharmacotherapy,TREATS,Acute leukemia
29161980,METHODS: The expression of CD200 and CD56 by blast cells was assessed by flow cytometry before the start of chemotherapy in 70 B-ALL patients.,Pharmacotherapy,TREATS,Patients
29161980,METHODS: The expression of CD200 and CD56 by blast cells was assessed by flow cytometry before the start of chemotherapy in 70 B-ALL patients.,"Leukemia, B-Cell, Acute",PROCESS_OF,Patients
29161980,METHODS: The expression of CD200 and CD56 by blast cells was assessed by flow cytometry before the start of chemotherapy in 70 B-ALL patients.,Pharmacotherapy,TREATS,"Leukemia, B-Cell, Acute"
29182564,This study aimed to identify damage to the oral cavity resulting from chemotherapy in pediatric patients with acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute"
29182564,This study aimed to identify damage to the oral cavity resulting from chemotherapy in pediatric patients with acute lymphoblastic leukemia (ALL).,Pharmacotherapy,TREATS,Patients
29182564,This study aimed to identify damage to the oral cavity resulting from chemotherapy in pediatric patients with acute lymphoblastic leukemia (ALL).,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
29234981,Muscle weakness is one of the most serious problems during chemotherapy for childhood hematological malignancies.,Pharmacotherapy,TREATS,Hematologic Neoplasms
29234981,Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance.,Neoadjuvant Therapy,TREATS,"Leukemia, Lymphocytic, Acute, L1"
29247779,Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,Patients
29247779,Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.,Stem cell transplant,compared_with,Protein-tyrosine kinase inhibitor
29247779,Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.,"Leukemia, Lymphocytic, Acute, L2",PROCESS_OF,Patients
29247779,Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.,Pharmacotherapy,TREATS,"Leukemia, Lymphocytic, Acute, L2"
29417201,NA,Therapeutic procedure,USES,RFP2 gene
29417201,NA,Therapeutic procedure,compared_with,Pharmacotherapy
29417201,NA,Induction,TREATS,"Leukemia, Lymphocytic, Acute"
29417201,NA,leukemia,PROCESS_OF,Patients
29417201,NA,"Leukemia, Lymphocytic, Acute",PROCESS_OF,Patients
29417201,NA,"Receptors, Antigen",AFFECTS,T-Lymphocyte
29417201,NA,Transplanted organ and tissue status,PROCESS_OF,Patients
29417201,NA,Therapeutic procedure,TREATS,"Leukemia, Lymphocytic, Acute"